Broad spectrum influenza virus vaccine

ABSTRACT

The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S.provisional application No. 62/471,771, filed Mar. 15, 2017, and U.S.provisional application No. 62/490,057, filed Apr. 26, 2017, each ofwhich is incorporated by reference herein in its entirety.

BACKGROUND

Influenza viruses are members of the orthomyxoviridae family, and areclassified into three distinct types (A, B, and C), based on antigenicdifferences between their nucleoprotein (NP) and matrix (M) protein. Theorthomyxoviruses are enveloped animal viruses of approximately 100 nm indiameter. The influenza virions consist of an internal ribonucleoproteincore (a helical nucleocapsid) containing a single-stranded RNA genome,and an outer lipoprotein envelope lined inside by a matrix protein (M1).The segmented genome of influenza A virus consists of eight molecules(seven for influenza C virus) of linear, negative polarity,single-stranded RNAs, which encode several polypeptides including: theRNA-directed RNA polymerase proteins (PB2, PB1 and PA) and nucleoprotein(NP), which form the nucleocapsid; the matrix proteins (M1, M2, which isalso a surface-exposed protein embedded in the virus membrane); twosurface glycoproteins, which project from the lipoprotein envelope:hemagglutinin (HA) and neuraminidase (NA); and nonstructural proteins(NS1 and NS2). Transcription and replication of the genome takes placein the nucleus and assembly takes place at the plasma membrane.

Hemagglutinin is the major envelope glycoprotein of influenza A and Bviruses, and hemagglutinin-esterase (HE) of influenza C viruses is aprotein homologous to HA. The rapid evolution of the HA protein of theinfluenza virus results in the constant emergence of new strains,rendering the adaptive immune response of the host only partiallyprotective to new infections. The biggest challenge for therapy andprophylaxis against influenza and other infections using traditionalvaccines is the limitation of vaccines in breadth, providing protectiononly against closely related subtypes. In addition, the length of timerequired to complete current standard influenza virus vaccine productionprocesses inhibits the rapid development and production of an adaptedvaccine in a pandemic situation.

Deoxyribonucleic acid (DNA) vaccination is one technique used tostimulate humoral and cellular immune responses to foreign antigens,such as influenza antigens. The direct injection of geneticallyengineered DNA (e.g., naked plasmid DNA) into a living host results in asmall number of its cells directly producing an antigen, resulting in aprotective immunological response. With this technique, however, comepotential problems, including the possibility of insertionalmutagenesis, which could lead to the activation of oncogenes or theinhibition of tumor suppressor genes.

SUMMARY

Provided herein is a ribonucleic acid (RNA) vaccine (or a composition oran immunogenic composition) that builds on the knowledge that RNA (e.g.,messenger RNA (mRNA)) can safely direct the body's cellular machinery toproduce nearly any protein of interest, from native proteins toantibodies and other entirely novel protein constructs that can havetherapeutic activity inside and outside of cells. The RNA vaccines ofthe present disclosure may be used to induce a balanced immune responseagainst influenza virus, comprising both cellular and humoral immunity,without risking the possibility of insertional mutagenesis, for example.

The RNA (e.g., mRNA) vaccines may be utilized in various settingsdepending on the prevalence of the infection or the degree or level ofunmet medical need. The RNA vaccines may be utilized to treat and/orprevent an influenza virus of various genotypes, strains, and isolates.The RNA vaccines typically have superior properties in that they producemuch larger antibody titers and produce responses earlier thancommercially available anti-viral therapeutic treatments. While notwishing to be bound by theory, it is believed that the RNA vaccines, asmRNA polynucleotides, are better designed to produce the appropriateprotein conformation upon translation as the RNA vaccines co-opt naturalcellular machinery. Unlike traditional vaccines, which are manufacturedex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA)vaccines are presented to the cellular system in a more native fashion.

There may be situations where persons are at risk for infection withmore than one strain of influenza virus. RNA (e.g., mRNA) therapeuticvaccines are particularly amenable to combination vaccination approachesdue to a number of factors including, but not limited to, speed ofmanufacture, ability to rapidly tailor vaccines to accommodate perceivedgeographical threat, and the like. Moreover, because the vaccinesutilize the human body to produce the antigenic protein, the vaccinesare amenable to the production of larger, more complex antigenicproteins, allowing for proper folding, surface expression, antigenpresentation, etc. in the human subject. To protect against more thanone strain of influenza, a combination vaccine can be administered thatincludes RNA (e.g., mRNA) encoding at least one antigenic polypeptideprotein (or antigenic portion thereof) of a first influenza virus ororganism and further includes RNA encoding at least one antigenicpolypeptide protein (or antigenic portion thereof) of a second influenzavirus or organism. RNA (e.g., mRNA) can be co-formulated, for example,in a single lipid nanoparticle (LNP) or can be formulated in separateLNPs for co-administration.

Some embodiments of the present disclosure provide influenza virus(influenza) vaccines (or compositions or immunogenic compositions) thatinclude at least one RNA polynucleotide having an open reading frameencoding at least one influenza antigenic polypeptide.

In some embodiments, the at least one antigenic polypeptide is one ofthe defined antigenic subdomains of HA, termed HA1, HA2, or acombination of HA1 and HA2, and at least one antigenic polypeptideselected from neuraminidase (NA), nucleoprotein (NP), matrix protein 1(M1), matrix protein 2 (M2), non-structural protein 1 (NS1) andnon-structural protein 2 (NS2).

In some embodiments, the at least one antigenic polypeptide is HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2,and at least one antigenic polypeptide selected from NA, NP, M1, M2, NS1and NS2.

In some embodiments, the at least one antigenic polypeptide is HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2and at least two antigenic polypeptides selected from NA, NP, M1, M2,NS1 and NS2.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenza virusprotein.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding multiple influenzavirus proteins.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one HA1, HA2, or a combination of both).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one HA1, HA2, or a combination of both, of any one of or acombination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10,H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least one otherRNA (e.g., mRNA) polynucleotide having an open reading frame encoding aprotein selected from a NP protein, a NA protein, a M1 protein, a M2protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one any one of or a combination of any or all of H1, H2, H3,H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/orH18) and at least two other RNAs (e.g., mRNAs) polynucleotides havingtwo open reading frames encoding two proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of any one of or a combination of any or all of H1, H2, H3,H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/orH18) and at least three other RNAs (e.g., mRNAs) polynucleotides havingthree open reading frames encoding three proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of any one of or a combination of any or all of H1, H2, H3,H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/orH18) and at least four other RNAs (e.g., mRNAs) polynucleotides havingfour open reading frames encoding four proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of any one of or a combination of any or all of H1, H2, H3,H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/orH18) and at least five other RNAs (e.g., mRNAs) polynucleotides havingfive open reading frames encoding five proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of any one of or a combination of any or all of H1, H2, H3,H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/orH18), a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1protein and a NS2 protein obtained from influenza virus.

Some embodiments of the present disclosure provide the following novelinfluenza virus polypeptide sequences: H1HA10-Foldon_ΔNgly1;H1HA10TM-PR8 (H1 A/Puerto Rico/8/34 HA); H1HA10-PR8-DS (H1 A/PuertoRico/8/34 HA; pH1HA10-Cal04-DS (H1 A/California/04/2009 HA); PandemicH1HA10 from California 04; pH1HA10-ferritin; HA10; Pandemic H1HA10 fromCalifornia 04; Pandemic H1HA10 from California 04 strain/without foldonand with K68C/R76C mutation for trimerization; H1HA10 from A/PuertoRico/8/34 strain, without foldon and with Y94D/N95L mutation fortrimerization; H1HA10 from A/Puerto Rico/8/34 strain, without foldon andwith K68C/R76C mutation for trimerization; H1N1 A/Viet Nam/850/2009;H3N2 A/Wisconsin/67/2005; H7N9 (A/Anhui/1/2013); H9N2 A/HongKong/1073/99; H10N8 A/JX346/2013.

Some embodiments of the present disclosure provide influenza virus(influenza) vaccines that include at least one RNA polynucleotide havingan open reading frame encoding at least one influenza antigenicpolypeptide. In some embodiments, an influenza vaccine comprises atleast one RNA (e.g., mRNA) polynucleotide having an open reading frameencoding at least one influenza antigenic polypeptide comprising amodified sequence that is at least 75% (e.g., any number between 75% and100%, inclusive, e.g., 70%, 80%, 85%, 90%, 95%, 99%, and 100%) identityto an amino acid sequence of the novel influenza virus sequencesdescribed above. The modified sequence can be at least 75% (e.g., anynumber between 75% and 100%, inclusive, e.g., 70%, 80%, 85%, 90%, 95%,99%, and 100%) identical to an amino acid sequence of the novelinfluenza virus sequences described above.

Some embodiments of the present disclosure provide an isolated nucleicacid comprising a sequence encoding the novel influenza viruspolypeptide sequences described above; an expression vector comprisingthe nucleic acid; and a host cell comprising the nucleic acid. Thepresent disclosure also provides a method of producing a polypeptide ofany of the novel influenza virus sequences described above. A method mayinclude culturing the host cell in a medium under conditions permittingnucleic acid expression of the novel influenza virus sequences describedabove, and purifying from the cultured cell or the medium of the cell anovel influenza virus polypeptide. The present disclosure also providesantibody molecules, including full length antibodies and antibodyderivatives, directed against the novel influenza virus sequences.

In some embodiments, an open reading frame of a RNA (e.g., mRNA) vaccineis codon-optimized. In some embodiments, at least one RNA polynucleotideencodes at least one antigenic polypeptide comprising an amino acidsequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479,or 543-565 (see also Tables 7-13 and 26) and is codon optimized mRNA.

In some embodiments, a RNA (e.g., mRNA) vaccine further comprising anadjuvant.

Tables 7-13 provide National Center for Biotechnology Information (NCBI)accession numbers of interest. It should be understood that the phrase“an amino acid sequence of Tables 7-13” refers to an amino acid sequenceidentified by one or more NCBI accession numbers listed in 7-13. Each ofthe amino acid sequences, and variants having greater than 95% identityor greater than 98% identity to each of the amino acid sequencesencompassed by the accession numbers of Tables 7-13 are included withinthe constructs (polynucleotides/polypeptides) of the present disclosure.

In some embodiments, at least one mRNA polynucleotide is encoded by anucleic acid comprising a sequence identified by any one of SEQ ID NO:447-457, 459, 461, 505-523, or 570-573 and having less than 80% identityto wild-type mRNA sequence. In some embodiments, at least one mRNApolynucleotide is encoded by a nucleic acid comprising a sequenceidentified by any one SEQ ID NO: 447-457, 459, 461, 505-523, or 570-573and having less than 75%, 85% or 95% identity to a wild-type mRNAsequence. In some embodiments, at least one mRNA polynucleotide isencoded by nucleic acid comprising a sequence identified by any one ofSEQ ID NO: 447-457, 459, 461, 505-523, or 570-573 and having less than50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80% or 78-80% identity towild-type mRNA sequence. In some embodiments, at least one mRNApolynucleotide is encoded by a nucleic acid comprising a sequenceidentified by any one of SEQ ID NO: 447-457, 459, 461, 505-523, or570-573 and having less than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%,75-85% or 80-85% identity to wild-type mRNA sequence. In someembodiments, at least one mRNA polynucleotide is encoded by a nucleicacid comprising a sequence identified by any one of SEQ ID NO: 447-457,459, 461, 505-523, or 570-573 and having less than 40-90%, 50-90%,60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90% identity to wild-typemRNA sequence.

In some embodiments, at least one mRNA polynucleotide comprises asequence identified by any one of SEQ ID NO: 491-503 or 566-569 and hasless than 80% identity to wild-type mRNA sequence. In some embodiments,at least one mRNA polynucleotide is encoded by a nucleic acid comprisinga sequence identified by any one SEQ ID NO: 491-503 or 566-569and hasless than 75%, 85% or 95% identity to a wild-type mRNA sequence. In someembodiments, at least one mRNA polynucleotide is encoded by nucleic acidcomprising a sequence identified by any one of SEQ ID NO: 491-503 or566-569and has less than 50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80%or 78-80% identity to wild-type mRNA sequence. In some embodiments, atleast one mRNA polynucleotide is encoded by a nucleic acid comprising asequence identified by any one of SEQ ID NO: 491-503 or 566-569and hasless than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%, 75-85% or 80-85%identity to wild-type mRNA sequence. In some embodiments, at least onemRNA polynucleotide is encoded by a nucleic acid comprising a sequenceidentified by any one of SEQ ID NO: 491-503 or 566-569and has less than40-90%, 50-90%, 60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90%identity to wild-type mRNA sequence.

In some embodiments, at least one RNA polynucleotide encodes at leastone antigenic polypeptide comprising an amino acid sequence identifiedby any one of SEQ ID NO: 1-444, 458, 460, 462-479, or 543-565 (see alsoTables 7-13 and 26) and having at least 80% (e.g., 85%, 90%, 95%, 98%,99%) identity to wild-type mRNA sequence, but does not include wild-typemRNA sequence.

In some embodiments, at least one RNA polynucleotide encodes at leastone antigenic polypeptide comprising an amino acid sequence identifiedby any one of SEQ ID NO: 1-444, 458, 460, 462-479, or 543-565 (see alsoTables 7-13 and 26) and has less than 95%, 90%, 85%, 80% or 75% identityto wild-type mRNA sequence. In some embodiments, at least one RNApolynucleotide encodes at least one antigenic polypeptide comprising anamino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460,462-479, or 543-565 (see also Tables 7-13 and 26) and has 30-80%,40-80%, 50-80%, 60-80%, 70-80%, 75-80% or 78-80%, 30-85%, 40-85%,50-805%, 60-85%, 70-85%, 75-85% or 78-85%, 30-90%, 40-90%, 50-90%,60-90%, 70-90%, 75-90%, 80-90% or 85-90% identity to wild-type mRNAsequence.

In some embodiments, at least one RNA polynucleotide encodes at leastone antigenic polypeptide having at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identity to an aminoacid sequence identified by any one of SEQ ID NO: 1-444, 458, 460,462-479, or 543-565 (see also Tables 7-13 and 26). In some embodiments,at least one RNA polynucleotide encodes at least one antigenicpolypeptide having 95%-99% identity to an amino acid sequence identifiedby any one of 1-444, 458, 460, 462-479, or 543-565 (see also Tables 7-13and 26).

In some embodiments, at least one RNA polynucleotide encodes at leastone antigenic polypeptide having at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identity to amino acidsequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479,or 543-565 (see also Tables 7-13 and 26) and having membrane fusionactivity. In some embodiments, at least one RNA polynucleotide encodesat least one antigenic polypeptide having 95%-99% identity to amino acidsequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479,or 543-565 (see also Tables 7-13 and 26) and having membrane fusionactivity.

In some embodiments, at least one RNA polynucleotide encodes at leastone influenza antigenic polypeptide that attaches to cell receptors.

In some embodiments, at least one RNA polynucleotide encodes at leastone influenza antigenic polypeptide that causes fusion of viral andcellular membranes.

In some embodiments, at least one RNA polynucleotide encodes at leastone influenza antigenic polypeptide that is responsible for binding ofthe virus to a cell being infected.

Some embodiments of the present disclosure provide a vaccine thatincludes at least one ribonucleic acid (RNA) (e.g., mRNA) polynucleotidehaving an open reading frame encoding at least one influenza antigenicpolypeptide, at least one 5′ terminal cap and at least one chemicalmodification, formulated within a lipid nanoparticle.

In some embodiments, a 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp.

In some embodiments, at least one chemical modification is selected frompseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine,2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine,2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine,2-thio-5-aza-uridine , 2-thio-dihydropseudouridine,2-thio-dihydrouridine, 2-thio-pseudouridine,4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine,4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine,dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In someembodiments, the chemical modification is in the 5-position of theuracil. In some embodiments, the chemical modification is aN1-methylpseudouridine. In some embodiments, the chemical modificationis a N1-ethylpseudouridine.

In some embodiments, a lipid nanoparticle comprises a cationic lipid, aPEG-modified lipid, a sterol and a non-cationic lipid. In someembodiments, a cationic lipid is an ionizable cationic lipid and thenon-cationic lipid is a neutral lipid, and the sterol is a cholesterol.In some embodiments, a cationic lipid is selected from the groupconsisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane(DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate(DLin-MC3-DMA), di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate,(12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine, andN,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine. In someembodiments, the cationic lipid is

In some embodiments, the cationic lipid is

In some embodiments, at least one cationic lipid selected from compoundsof Formula (I):

-   or a salt or isomer thereof, wherein:-   R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀    alkenyl, —R*YR″, —YR″, and —R″M′R′;-   R₂ and R₃ are independently selected from the group consisting of H,    C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is selected from the group consisting of a C₃₋₆ carbocycle,    —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆    alkyl, where Q is selected from a carbocycle, heterocycle, —OR,    —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,    —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,    —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂,    —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR,    —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,    —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and    —C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3,    4, and 5;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   R₈ is selected from the group consisting of C₃₋₆ carbocycle and    heterocycle;-   R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl,    —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₂₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

In some embodiments, a subset of compounds of Formula (I) includes thosein which when R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then(i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2.

In some embodiments, a subset of compounds of Formula (I) includes thosein which

-   R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀    alkenyl, —R*YR″, —YR″, and —R″M′R′;-   R₂ and R₃ are independently selected from the group consisting of H,    C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is selected from the group consisting of a C₃₋₆ carbocycle,    —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆    alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to    14-membered heteroaryl having one or more heteroatoms selected from    N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,    —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,    —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,    —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,    —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,    —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂,    —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and a 5- to 14-membered    heterocycloalkyl having one or more heteroatoms selected from N, O,    and S which is substituted with one or more substituents selected    from oxo (═O), OH, amino, mono- or di-alkylamino, and C₁₋₃ alkyl,    and each n is independently selected from 1, 2, 3, 4, and 5;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   R₈ is selected from the group consisting of C₃₋₆ carbocycle and    heterocycle;-   R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl,    —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₂₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′;

-   R₂ and R₃ are independently selected from the group consisting of H,    C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is selected from the group consisting of a C₃₋₆ carbocycle,    —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆    alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to    14-membered heterocycle having one or more heteroatoms selected from    N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,    —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,    —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,    —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,    —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,    —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,    —C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selected    from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered    heterocycle and (i) R₄ is —(CH₂)_(n)Q in which n is 1 or 2, or (ii)    R₄ is —(CH₂)_(n)CHQR in which n is 1, or (iii) R₄ is —CHQR, and    —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or 8- to    14-membered heterocycloalkyl;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   R₈ is selected from the group consisting of C₃₋₆ carbocycle and    heterocycle;-   R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl,    —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₂₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′;

-   R₂ and R₃ are independently selected from the group consisting of H,    C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is selected from the group consisting of a C₃₋₆ carbocycle,    —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆    alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to    14-membered heteroaryl having one or more heteroatoms selected from    N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,    —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,    —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,    —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,    —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,    —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,    —C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selected    from 1, 2, 3, 4, and 5;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   R₈ is selected from the group consisting of C₃₋₆ carbocycle and    heterocycle;-   R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl,    —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₂₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′;

-   R₂ and R₃ are independently selected from the group consisting of H,    C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR, where Q is —N(R)₂, and n is    selected from 3, 4, and 5;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₁₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′;

-   R₂ and R₃ are independently selected from the group consisting of    C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R₄ is selected from the group consisting of —(CH₂)_(n)Q,    —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is    selected from 1, 2, 3, 4, and 5;-   each R₅ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R₆ is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   M and M′ are independently selected from —C(O)O—, —OC(O)—,    —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,    —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a    heteroaryl group;-   R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃    alkenyl, and H;-   each R is independently selected from the group consisting of C₁₋₃    alkyl, C₂₋₃ alkenyl, and H;-   each R′ is independently selected from the group consisting of C₁₋₁₈    alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;-   each R″ is independently selected from the group consisting of C₃₋₁₄    alkyl and C₃₋₁₄ alkenyl;-   each R* is independently selected from the group consisting of C₁₋₁₂    alkyl and C₁₋₁₂ alkenyl;-   each Y is independently a C₃₋₆ carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (IA):

-   or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4,    and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄    is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,    —NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,    —NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,    heteroaryl or heterocycloalkyl; M and M′ are independently selected    from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl    group, and a heteroaryl group; and R₂ and R₃ are independently    selected from the group consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄    alkenyl.

Some embodiments of the present disclosure provide a vaccine thatincludes at least one RNA (e.g., mRNA) polynucleotide having an openreading frame encoding at least one influenza antigenic polypeptide,wherein at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) of the uracil inthe open reading frame have a chemical modification, optionally whereinthe vaccine is formulated in a lipid nanoparticle (e.g., a lipidnanoparticle comprises a cationic lipid, a PEG-modified lipid, a steroland a non-cationic lipid).

In some embodiments, 100% of the uracil in the open reading frame have achemical modification. In some embodiments, a chemical modification isin the 5-position of the uracil. In some embodiments, a chemicalmodification is a N1-methyl pseudouridine. In some embodiments, 100% ofthe uracil in the open reading frame have a N1-methyl pseudouridine inthe 5-position of the uracil.

In some embodiments, an open reading frame of a RNA (e.g., mRNA)polynucleotide encodes at least two influenza antigenic polypeptides. Insome embodiments, the open reading frame encodes at least five or atleast ten antigenic polypeptides. In some embodiments, the open readingframe encodes at least 100 antigenic polypeptides. In some embodiments,the open reading frame encodes 2-100 antigenic polypeptides.

In some embodiments, a vaccine comprises at least two RNA (e.g., mRNA)polynucleotides, each having an open reading frame encoding at least oneinfluenza antigenic polypeptide. In some embodiments, the vaccinecomprises at least five or at least ten RNA (e.g., mRNA)polynucleotides, each having an open reading frame encoding at least oneantigenic polypeptide. In some embodiments, the vaccine comprises atleast 100 RNA (e.g., mRNA) polynucleotides, each having an open readingframe encoding at least one antigenic polypeptide. In some embodiments,the vaccine comprises 2-100 RNA (e.g., mRNA) polynucleotides, eachhaving an open reading frame encoding at least one antigenicpolypeptide.

In some embodiments, at least one influenza antigenic polypeptide isfused to a signal peptide. In some embodiments, the signal peptide isselected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO:480); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQID NO: 481); Japanese encephalitis PRM signal sequence(MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 482), VSVg protein signal sequence(MKCLLYLAFLFIGVNCA; SEQ ID NO: 483) and Japanese encephalitis JEV signalsequence (MWLVSLAIVTACAGA; SEQ ID NO: 484).

In some embodiments, the signal peptide is fused to the N-terminus of atleast one antigenic polypeptide. In some embodiments, a signal peptideis fused to the C-terminus of at least one antigenic polypeptide.

In some embodiments, at least one influenza antigenic polypeptidecomprises a mutated N-linked glycosylation site.

Also provided herein is an influenza RNA (e.g., mRNA) vaccine of any oneof the foregoing paragraphs formulated in a nanoparticle (e.g., a lipidnanoparticle).

In some embodiments, the nanoparticle has a mean diameter of 50-200 nm.In some embodiments, the nanoparticle is a lipid nanoparticle. In someembodiments, the lipid nanoparticle comprises a cationic lipid, aPEG-modified lipid, a sterol and a non-cationic lipid. In someembodiments, the lipid nanoparticle comprises a molar ratio of about20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and25% non-cationic lipid. In some embodiments, the cationic lipid is anionizable cationic lipid and the non-cationic lipid is a neutral lipid,and the sterol is a cholesterol. In some embodiments, the cationic lipidis selected from 2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane(DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate(DLin-MC3-DMA), and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

In some embodiments, the nanoparticle has a polydispersity value of lessthan 0.4 (e.g., less than 0.3, 0.2 or 0.1).

In some embodiments, the nanoparticle has a net neutral charge at aneutral pH value.

In some embodiments, the RNA (e.g., mRNA) vaccine is multivalent.

Some embodiments of the present disclosure provide methods of inducingan antigen specific immune response in a subject, comprisingadministering to the subject any of the

RNA (e.g., mRNA) vaccine as provided herein in an amount effective toproduce an antigen-specific immune response. In some embodiments, theRNA (e.g., mRNA) vaccine is an influenza vaccine. In some embodiments,the RNA (e.g., mRNA) vaccine is a combination vaccine comprising acombination of influenza vaccines (a broad spectrum influenza vaccine).

In some embodiments, an antigen-specific immune response comprises a Tcell response or a B cell response.

In some embodiments, a method of producing an antigen-specific immuneresponse comprises administering to a subject a single dose (no boosterdose) of an influenza RNA (e.g., mRNA) vaccine of the presentdisclosure.

In some embodiments, a method further comprises administering to thesubject a second (booster) dose of an influenza RNA (e.g., mRNA)vaccine. Additional doses of an influenza RNA (e.g., mRNA) vaccine maybe administered.

In some embodiments, the subjects exhibit a seroconversion rate of atleast 80% (e.g., at least 85%, at least 90%, or at least 95%) followingthe first dose or the second (booster) dose of the vaccine.Seroconversion is the time period during which a specific antibodydevelops and becomes detectable in the blood. After seroconversion hasoccurred, a virus can be detected in blood tests for the antibody.During an infection or immunization, antigens enter the blood, and theimmune system begins to produce antibodies in response. Beforeseroconversion, the antigen itself may or may not be detectable, butantibodies are considered absent. During seroconversion, antibodies arepresent but not yet detectable. Any time after seroconversion, theantibodies can be detected in the blood, indicating a prior or currentinfection.

In some embodiments, an influenza RNA (e.g., mRNA) vaccine isadministered to a subject by intradermal injection, intramuscularinjection, or by intranasal administration. In some embodiments, aninfluenza RNA (e.g., mRNA) vaccine is administered to a subject byintramuscular injection.

Some embodiments, of the present disclosure provide methods of inducingan antigen specific immune response in a subject, includingadministering to a subject an influenza RNA (e.g., mRNA) vaccine in aneffective amount to produce an antigen specific immune response in asubject. Antigen-specific immune responses in a subject may bedetermined, in some embodiments, by assaying for antibody titer (fortiter of an antibody that binds to an influenza antigenic polypeptide)following administration to the subject of any of the influenza RNA(e.g., mRNA) vaccines of the present disclosure. In some embodiments,the anti-antigenic polypeptide antibody titer produced in the subject isincreased by at least 1 log relative to a control. In some embodiments,the anti-antigenic polypeptide antibody titer produced in the subject isincreased by 1-3 log relative to a control.

In some embodiments, the anti-antigenic polypeptide antibody titerproduced in a subject is increased at least 2 times relative to acontrol. In some embodiments, the anti-antigenic polypeptide antibodytiter produced in the subject is increased at least 5 times relative toa control. In some embodiments, the anti-antigenic polypeptide antibodytiter produced in the subject is increased at least 10 times relative toa control. In some embodiments, the anti-antigenic polypeptide antibodytiter produced in the subject is increased 2-10 times relative to acontrol.

In some embodiments, the control is an anti-antigenic polypeptideantibody titer produced in a subject who has not been administered a RNA(e.g., mRNA) vaccine of the present disclosure. In some embodiments, thecontrol is an anti-antigenic polypeptide antibody titer produced in asubject who has been administered a live attenuated or inactivatedinfluenza, or wherein the control is an anti-antigenic polypeptideantibody titer produced in a subject who has been administered arecombinant or purified influenza protein vaccine. In some embodiments,the control is an anti-antigenic polypeptide antibody titer produced ina subject who has been administered an influenza virus-like particle(VLP) vaccine (see, e.g., Cox RG et al., J Virol. 2014 June; 88(11):6368-6379).

A RNA (e.g., mRNA) vaccine of the present disclosure is administered toa subject in an effective amount (an amount effective to induce animmune response). In some embodiments, the effective amount is a doseequivalent to an at least 2-fold, at least 4-fold, at least 10-fold, atleast 100-fold, at least 1000-fold reduction in the standard of caredose of a recombinant influenza protein vaccine, wherein theanti-antigenic polypeptide antibody titer produced in the subject isequivalent to an anti-antigenic polypeptide antibody titer produced in acontrol subject administered the standard of care dose of a recombinantinfluenza protein vaccine, a purified influenza protein vaccine, a liveattenuated influenza vaccine, an inactivated influenza vaccine, or aninfluenza VLP vaccine. In some embodiments, the effective amount is adose equivalent to 2-1000-fold reduction in the standard of care dose ofa recombinant influenza protein vaccine, wherein the anti-antigenicpolypeptide antibody titer produced in the subject is equivalent to ananti-antigenic polypeptide antibody titer produced in a control subjectadministered the standard of care dose of a recombinant influenzaprotein vaccine, a purified influenza protein vaccine, a live attenuatedinfluenza vaccine, an inactivated influenza vaccine, or an influenza VLPvaccine.

In some embodiments, the control is an anti-antigenic polypeptideantibody titer produced in a subject who has been administered avirus-like particle (VLP) vaccine comprising structural proteins ofinfluenza.

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated in aneffective amount to produce an antigen specific immune response in asubject.

In some embodiments, the effective amount is a total dose of 25 μg to1000 μg, or 50 μg to 1000 μg. In some embodiments, the effective amountis a total dose of 100 μg. In some embodiments, the effective amount isa dose of 25 μg administered to the subject a total of two times. Insome embodiments, the effective amount is a dose of 100 μg administeredto the subject a total of two times. In some embodiments, the effectiveamount is a dose of 400 μg administered to the subject a total of twotimes. In some embodiments, the effective amount is a dose of 500 μgadministered to the subject a total of two times.

In some embodiments, the efficacy (or effectiveness) of a RNA (e.g.,mRNA) vaccine is greater than 60%. In some embodiments, the RNA (e.g.,mRNA) polynucleotide of the vaccine at least one Influenza antigenicpolypeptide.

Vaccine efficacy may be assessed using standard analyses (see, e.g.,Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). Forexample, vaccine efficacy may be measured by double-blind, randomized,clinical controlled trials. Vaccine efficacy may be expressed as aproportionate reduction in disease attack rate (AR) between theunvaccinated (ARU) and vaccinated (ARV) study cohorts and can becalculated from the relative risk (RR) of disease among the vaccinatedgroup with use of the following formulas:

Efficacy=(ARU−ARV)/ARU×100; and

Efficacy=(1−RR)×100.

Likewise, vaccine effectiveness may be assessed using standard analyses(see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1;201(11):1607-10). Vaccine effectiveness is an assessment of how avaccine (which may have already proven to have high vaccine efficacy)reduces disease in a population. This measure can assess the net balanceof benefits and adverse effects of a vaccination program, not just thevaccine itself, under natural field conditions rather than in acontrolled clinical trial. Vaccine effectiveness is proportional tovaccine efficacy (potency) but is also affected by how well targetgroups in the population are immunized, as well as by othernon-vaccine-related factors that influence the ‘real-world’ outcomes ofhospitalizations, ambulatory visits, or costs. For example, aretrospective case control analysis may be used, in which the rates ofvaccination among a set of infected cases and appropriate controls arecompared. Vaccine effectiveness may be expressed as a rate difference,with use of the odds ratio (OR) for developing infection despitevaccination:

Effectiveness=(1−OR)×100.

In some embodiments, the efficacy (or effectiveness) of a RNA (e.g.,mRNA) vaccine is at least 65%, at least 70%, at least 75%, at least 80%,at least 85%, or at least 90%.

In some embodiments, the vaccine immunizes the subject against Influenzafor up to 2 years. In some embodiments, the vaccine immunizes thesubject against Influenza for more than 2 years, more than 3 years, morethan 4 years, or for 5-10 years.

In some embodiments, the subject is about 5 years old or younger. Forexample, the subject may be between the ages of about 1 year and about 5years (e.g., about 1, 2, 3, 5 or 5 years), or between the ages of about6 months and about 1 year (e.g., about 6, 7, 8, 9, 10, 11 or 12 months).In some embodiments, the subject is about 12 months or younger (e.g.,12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 months or 1 month). In someembodiments, the subject is about 6 months or younger.

In some embodiments, the subject was born full term (e.g., about 37-42weeks). In some embodiments, the subject was born prematurely, forexample, at about 36 weeks of gestation or earlier (e.g., about 36, 35,34, 33, 32, 31, 30, 29, 28, 27, 26 or 25 weeks). For example, thesubject may have been born at about 32 weeks of gestation or earlier. Insome embodiments, the subject was born prematurely between about 32weeks and about 36 weeks of gestation. In such subjects, a RNA (e.g.,mRNA) vaccine may be administered later in life, for example, at the ageof about 6 months to about 5 years, or older.

In some embodiments, the subject is a young adult between the ages ofabout 20 years and about 50 years (e.g., about 20, 25, 30, 35, 40, 45 or50 years old).

In some embodiments, the subject is an elderly subject about 60 yearsold, about 70 years old, or older (e.g., about 60, 65, 70, 75, 80, 85 or90 years old).

In some embodiments, the subject has been exposed to influenza (e.g., C.trachomatis); the subject is infected with influenza (e.g., C.trachomatis); or subject is at risk of infection by influenza (e.g., C.trachomatis).

In some embodiments, the subject is immunocompromised (has an impairedimmune system, e.g., has an immune disorder or autoimmune disorder).

In some embodiments the nucleic acid vaccines described herein arechemically modified. In other embodiments the nucleic acid vaccines areunmodified.

Yet other aspects provide compositions for and methods of vaccinating asubject comprising administering to the subject a nucleic acid vaccinecomprising one or more RNA polynucleotides having an open reading frameencoding a first virus antigenic polypeptide, wherein the RNApolynucleotide does not include a stabilization element, and wherein anadjuvant is not coformulated or co-administered with the vaccine.

In other aspects the invention is a composition for or method ofvaccinating a subject comprising administering to the subject a nucleicacid vaccine comprising one or more RNA polynucleotides having an openreading frame encoding a first antigenic polypeptide wherein a dosage ofbetween 10 μg/kg and 400 μg/kg of the nucleic acid vaccine isadministered to the subject. In some embodiments the dosage of the RNApolynucleotide is 1-5 μg, 5-10 μg, 10-15 μg, 15-20 μg, 10-25 μg, 20-25μg, 20-50 μg, 30-50 μg, 40-50 μg, 40-60 μg, 60-80 μg, 60-100 μg, 50-100μg, 80-120 μg, 40-120 μg, 40-150 μg, 50-150 μg, 50-200 μg, 80-200 μg,100-200 μg, 120-250 μg, 150-250 μg, 180-280 μg, 200-300 μg, 50-300 μg,80-300 μg, 100-300 μg, 40-300 μg, 50-350 μg, 100-350 μg, 200-350 μg,300-350 μg, 320-400 μg, 40-380 μg, 40-100 μg, 100-400 μg, 200-400 μg, or300-400 μg per dose. In some embodiments, the nucleic acid vaccine isadministered to the subject by intradermal or intramuscular injection.In some embodiments, the nucleic acid vaccine is administered to thesubject on day zero. In some embodiments, a second dose of the nucleicacid vaccine is administered to the subject on day twenty one.

In some embodiments, a dosage of 25 micrograms of the RNA polynucleotideis included in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 100 micrograms of the RNA polynucleotideis included in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 50 micrograms of the RNA polynucleotide isincluded in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 75 micrograms of the RNA polynucleotide isincluded in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 150 micrograms of the RNA polynucleotideis included in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 400 micrograms of the RNA polynucleotideis included in the nucleic acid vaccine administered to the subject. Insome embodiments, a dosage of 200 micrograms of the RNA polynucleotideis included in the nucleic acid vaccine administered to the subject. Insome embodiments, the RNA polynucleotide accumulates at a 100 foldhigher level in the local lymph node in comparison with the distal lymphnode. In other embodiments the nucleic acid vaccine is chemicallymodified and in other embodiments the nucleic acid vaccine is notchemically modified.

Aspects of the invention provide a nucleic acid vaccine comprising oneor more RNA polynucleotides having an open reading frame encoding afirst antigenic polypeptide, wherein the RNA polynucleotide does notinclude a stabilization element, and a pharmaceutically acceptablecarrier or excipient, wherein an adjuvant is not included in thevaccine. In some embodiments, the stabilization element is a histonestem-loop. In some embodiments, the stabilization element is a nucleicacid sequence having increased GC content relative to wild typesequence.

Aspects of the invention provide nucleic acid vaccines comprising one ormore RNA polynucleotides having an open reading frame encoding a firstantigenic polypeptide, wherein the RNA polynucleotide is present in theformulation for in vivo administration to a host, which confers anantibody titer superior to the criterion for seroprotection for thefirst antigen for an acceptable percentage of human subjects. In someembodiments, the antibody titer produced by the mRNA vaccines of theinvention is a neutralizing antibody titer. In some embodiments theneutralizing antibody titer is greater than a protein vaccine. In otherembodiments the neutralizing antibody titer produced by the mRNAvaccines of the invention is greater than an adjuvanted protein vaccine.In yet other embodiments the neutralizing antibody titer produced by themRNA vaccines of the invention is 1,000-10,000, 1,200-10,000,1,400-10,000, 1,500-10,000, 1,000-5,000, 1,000-4,000, 1,800-10,000,2000-10,000, 2,000-5,000, 2,000-3,000, 2,000-4,000, 3,000-5,000,3,000-4,000, or 2,000-2,500. A neutralization titer is typicallyexpressed as the highest serum dilution required to achieve a 50%reduction in the number of plaques.

Also provided are nucleic acid vaccines comprising one or more RNApolynucleotides having an open reading frame encoding a first antigenicpolypeptide, wherein the RNA polynucleotide is present in a formulationfor in vivo administration to a host for eliciting a longer lasting highantibody titer than an antibody titer elicited by an mRNA vaccine havinga stabilizing element or formulated with an adjuvant and encoding thefirst antigenic polypeptide. In some embodiments, the RNA polynucleotideis formulated to produce a neutralizing antibodies within one week of asingle administration. In some embodiments, the adjuvant is selectedfrom a cationic peptide and an immunostimulatory nucleic acid. In someembodiments, the cationic peptide is protamine.

Aspects provide nucleic acid vaccines comprising one or more RNApolynucleotides having an open reading frame comprising at least onechemical modification or optionally no modified nucleotides, the openreading frame encoding a first antigenic polypeptide, wherein the RNApolynucleotide is present in the formulation for in vivo administrationto a host such that the level of antigen expression in the hostsignificantly exceeds a level of antigen expression produced by an mRNAvaccine having a stabilizing element or formulated with an adjuvant andencoding the first antigenic polypeptide.

Other aspects provide nucleic acid vaccines comprising one or more RNApolynucleotides having an open reading frame comprising at least onechemical modification or optionally no modified nucleotides, the openreading frame encoding a first antigenic polypeptide, wherein thevaccine has at least 10 fold less RNA polynucleotide than is requiredfor an unmodified mRNA vaccine to produce an equivalent antibody titer.In some embodiments, the RNA polynucleotide is present in a dosage of25-100 micrograms.

Aspects of the invention also provide a unit of use vaccine, comprisingbetween bug and 400 μg of one or more RNA polynucleotides having an openreading frame comprising at least one chemical modification oroptionally no modified nucleotides, the open reading frame encoding afirst antigenic polypeptide, and a pharmaceutically acceptable carrieror excipient, formulated for delivery to a human subject. In someembodiments, the vaccine further comprises a cationic lipidnanoparticle.

Aspects of the invention provide methods of creating, maintaining orrestoring antigenic memory to a virus strain in an individual orpopulation of individuals comprising administering to said individual orpopulation an antigenic memory booster nucleic acid vaccine comprising(a) at least one RNA polynucleotide, said polynucleotide comprising atleast one chemical modification or optionally no modified nucleotidesand two or more codon-optimized open reading frames, said open readingframes encoding a set of reference antigenic polypeptides, and (b)optionally a pharmaceutically acceptable carrier or excipient.

In some embodiments, the vaccine is administered to the individual via aroute selected from the group consisting of intramuscularadministration, intradermal administration and subcutaneousadministration. In some embodiments, the administering step comprisescontacting a muscle tissue of the subject with a device suitable forinjection of the composition. In some embodiments, the administeringstep comprises contacting a muscle tissue of the subject with a devicesuitable for injection of the composition in combination withelectroporation.

Aspects of the invention provide methods of vaccinating a subjectcomprising administering to the subject a single dosage of between 25μg/kg and 400 μg/kg of a nucleic acid vaccine comprising one or more RNApolynucleotides having an open reading frame encoding a first antigenicpolypeptide in an effective amount to vaccinate the subject.

Other aspects provide nucleic acid vaccines comprising one or more RNApolynucleotides having an open reading frame comprising at least onechemical modification, the open reading frame encoding a first antigenicpolypeptide, wherein the vaccine has at least 10 fold less RNApolynucleotide than is required for an unmodified mRNA vaccine toproduce an equivalent antibody titer. In some embodiments, the RNApolynucleotide is present in a dosage of 25-100 micrograms.

Other aspects provide nucleic acid vaccines comprising an LNP formulatedRNA polynucleotide having an open reading frame comprising no nucleotidemodifications (unmodified), the open reading frame encoding a firstantigenic polypeptide, wherein the vaccine has at least 10 fold less RNApolynucleotide than is required for an unmodified mRNA vaccine notformulated in a LNP to produce an equivalent antibody titer. In someembodiments, the RNA polynucleotide is present in a dosage of 25-100micrograms.

The data presented in the Examples demonstrate significant enhancedimmune responses using the formulations of the invention. Bothchemically modified and unmodified RNA vaccines are useful according tothe invention. Surprisingly, in contrast to prior art reports that itwas preferable to use chemically unmodified mRNA formulated in a carrierfor the production of vaccines, it is described herein that chemicallymodified mRNA-LNP vaccines required a much lower effective mRNA dosethan unmodified mRNA, i.e., tenfold less than unmodified mRNA whenformulated in carriers other than LNP. Both the chemically modified andunmodified RNA vaccines of the invention produce better immune responsesthan mRNA vaccines formulated in a different lipid carrier.

In other aspects the invention encompasses a method of treating anelderly subject age 60 years or older comprising administering to thesubject a nucleic acid vaccine comprising one or more RNApolynucleotides having an open reading frame encoding an virus antigenicpolypeptide in an effective amount to vaccinate the subject.

In other aspects the invention encompasses a method of treating a youngsubject age 17 years or younger comprising administering to the subjecta nucleic acid vaccine comprising one or more RNA polynucleotides havingan open reading frame encoding an virus antigenic polypeptide in aneffective amount to vaccinate the subject.

In other aspects the invention encompasses a method of treating an adultsubject comprising administering to the subject a nucleic acid vaccinecomprising one or more RNA polynucleotides having an open reading frameencoding an virus antigenic polypeptide in an effective amount tovaccinate the subject.

In some aspects the invention is a method of vaccinating a subject witha combination vaccine including at least two nucleic acid sequencesencoding antigens wherein the dosage for the vaccine is a combinedtherapeutic dosage wherein the dosage of each individual nucleic acidencoding an antigen is a sub therapeutic dosage. In some embodiments,the combined dosage is 25 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodiments,the combined dosage is 100 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodimentsthe combined dosage is 50 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodiments,the combined dosage is 75 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodiments,the combined dosage is 150 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodiments,the combined dosage is 400 micrograms of the RNA polynucleotide in thenucleic acid vaccine administered to the subject. In some embodiments,the sub therapeutic dosage of each individual nucleic acid encoding anantigen is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, or 20 micrograms. In other embodiments the nucleic acid vaccineis chemically modified and in other embodiments the nucleic acid vaccineis not nucleotide modified.

In some embodiments, the RNA polynucleotide is one of SEQ ID NO:447-457, 459, 461, 491-503, 524-542, or 566-569 and includes at leastone chemical modification. In other embodiments, the RNA polynucleotideis one of SEQ ID NO: 447-457, 459, 461, 491-503, 524-542, or 566-569 anddoes not include any nucleotide modifications, or is unmodified. In yetother embodiments the at least one RNA polynucleotide encodes anantigenic protein of any of SEQ ID NO: 1-444, 458, 460, 462-479,543-565, or 566-569 and includes at least one chemical modification. Inother embodiments the RNA polynucleotide encodes an antigenic protein ofany of SEQ ID NO: 1-444, 458, 460, 462-479,543-565, or 566-569 and doesnot include any nucleotide modifications, or is unmodified.

In preferred aspects, vaccines of the invention (e.g., LNP-encapsulatedmRNA vaccines) produce prophylactically- and/ortherapeutically-efficacious levels, concentrations and/or titers ofantigen-specific antibodies in the blood or serum of a vaccinatedsubject. As defined herein, the term antibody titer refers to the amountof antigen-specific antibody produces in s subject, e.g., a humansubject. In exemplary embodiments, antibody titer is expressed as theinverse of the greatest dilution (in a serial dilution) that still givesa positive result. In exemplary embodiments, antibody titer isdetermined or measured by enzyme-linked immunosorbent assay (ELISA). Inexemplary embodiments, antibody titer is determined or measured byneutralization assay, e.g., by microneutralization assay. In certainaspects, antibody titer measurement is expressed as a ratio, such as1:40, 1:100, etc.

In exemplary embodiments of the invention, an efficacious vaccineproduces an antibody titer of greater than 1:40, greater that 1:100,greater than 1:400, greater than 1:1000, greater than 1:2000, greaterthan 1:3000, greater than 1:4000, greater than 1:500, greater than1:6000, greater than 1:7500, greater than 1:10000. In exemplaryembodiments, the antibody titer is produced or reached by 10 daysfollowing vaccination, by 20 days following vaccination, by 30 daysfollowing vaccination, by 40 days following vaccination, or by 50 ormore days following vaccination. In exemplary embodiments, the titer isproduced or reached following a single dose of vaccine administered tothe subject. In other embodiments, the titer is produced or reachedfollowing multiple doses, e.g., following a first and a second dose(e.g., a booster dose).

In exemplary aspects of the invention, antigen-specific antibodies aremeasured in units of μg/ml or are measured in units of IU/L(International Units per liter) or mIU/ml (milli International Units perml). In exemplary embodiments of the invention, an efficacious vaccineproduces >0.5 μg/ml, >0.1 μg/ml, >0.2 μg/ml, >0.35 μg/ml, >0.5 μg/ml, >1μg/ml, >2 μg/ml, >5 μg/ml or >10 μg/ml. In exemplary embodiments of theinvention, an efficacious vaccine produces >10 mIU/ml, >20 mIU/ml, >50mIU/ml, >100 mIU/ml, >200 mIU/ml, >500 mIU/ml or >1000 mIU/ml. Inexemplary embodiments, the antibody level or concentration is producedor reached by 10 days following vaccination, by 20 days followingvaccination, by 30 days following vaccination, by 40 days followingvaccination, or by 50 or more days following vaccination. In exemplaryembodiments, the level or concentration is produced or reached followinga single dose of vaccine administered to the subject. In otherembodiments, the level or concentration is produced or reached followingmultiple doses, e.g., following a first and a second dose (e.g., abooster dose.) In exemplary embodiments, antibody level or concentrationis determined or measured by enzyme-linked immunosorbent assay (ELISA).In exemplary embodiments, antibody level or concentration is determinedor measured by neutralization assay, e.g., by microneutralization assay.

The details of various embodiments of the disclosure are set forth inthe description below. Other features, objects, and advantages of thedisclosure will be apparent from the description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages will beapparent from the following description of particular embodiments of theinvention, as illustrated in the accompanying drawings in which likereference characters refer to the same parts throughout the differentviews. The drawings are not necessarily to scale, emphasis instead beingplaced upon illustrating the principles of various embodiments of theinvention.

FIG. 1 shows data obtained from an ELISA, demonstrating that vaccinationwith RNA encoding HA stem protein sequences from different strainsinduces serum antibodies that bind to diverse panel of recombinant HA(rHA) proteins.

FIG. 2 shows data demonstrating that serum antibody titers obtained frommice vaccinated with a second set of mRNA vaccine antigens induces serumantibodies that bind to a diverse panel of recombinant HA (rHA)proteins.

FIG. 3 shows combining mRNAs encoding HA stem protein from an H1 strainwith mRNA encoding HA stem protein from an H3 strain did not result ininterference in the immune response to either HA.

FIGS. 4A-4B depict endpoint titers of the pooled serum from animalsvaccinated with the test vaccines. In FIG. 4A, the vaccines tested areshown on the x-axis and the binding to HA from each of the differentstrains of influenza is plotted as an endpoint titer. In FIG. 4B, thevaccines tested are shown on the x-axis, and the endpoint titer to NPprotein is plotted.

FIG. 5 shows an examination of functional antibody response through anassessment of the ability of serum to neutralize a panel ofHA-pseudotyped viruses.

FIG. 6 shows data plotted as fold induction (sampleluminescence/background luminescence) versus serum concentration.

FIG. 7 is a representation of cell-mediated immune responses followingmRNA vaccination. Splenocytes were harvested from vaccinated mice andstimulated with a pool of overlapping NP peptides. The % of CD4 or CD8 Tcells secreting one of the three cytokines (IFN-γ, IL-2, or TNF-α) isplotted.

FIG. 8 is a representation of cell-mediated immune responses followingmRNA vaccination. Splenocytes were harvested from vaccinated mice andstimulated with a pool of overlapping HA peptides. The % of CD4 or CD8 Tcells secreting one of the three cytokines (IFN-γ, IL-2, or TNF-α) isplotted.

FIG. 9 shows murine weight loss following challenge with a lethal doseof mouse-adapted H1N1 A/Puerto Rico/8/1934. The percentage of weightlost as compared to baseline was calculated for each animal and wasaveraged across the group. The group average was plotted over time indays. Error bars represent standard error of the mean. Efficacy of theNIHGen6HASS-foldon+NP combination vaccine was better than that of eitherthe NIHGen6HASS-foldon or NP mRNA vaccine alone.

FIG. 10 shows vaccine efficacy was similar at all vaccine doses, as wellas with all co-formulation and co-delivery methods assessed. Followingchallenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934,the percentage of weight lost as compared to baseline was calculated foreach animal and was averaged across the group. The group average wasplotted over time in days. Error bars represent standard error of themean.

FIG. 11A depicts the endpoint titers of the pooled serum from animalsvaccinated with the test vaccines. FIG. 11B shows efficacy of the testvaccines (NIHGen6HASS-foldon and NIHGen6HASS-TM2) is similar. Followingchallenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934,the percentage of group weight lost as compared to baseline wascalculated and plotted over time in days.

FIG. 12A shows that serum from mice immunized with mRNA encodingconsensus HA antigens from the H1 subtype was able to detectablyneutralize the PR8 luciferase virus. FIG. 12B shows that serum from miceimmunized with mRNA encoding H1 subtype consensus HA antigens with aferritin fusion sequence was able to detectably neutralize the PR8luciferase virus, except for the Merck_pH1 Con_ferritin mRNA, whileserum from mice vaccinated with an mRNA encoding the consensus H3antigen with a ferritin fusion sequence was not able to neutralize thePR8 luciferase virus.

FIGS. 13A-13B show murine weight loss following challenge with a lethaldose of mouse-adapted H1N1 A/Puerto Rico/8/1934. The percentage of groupweight lost as compared to baseline was calculated and plotted over timein days.

FIG. 14 shows the results of neutralization assays performed on a panelof pseudoviruses to assess the breadth of the serum-neutralizingactivity elicited by the consensus HA antigens.

FIG. 15A depicts the ELISA endpoint anti-HA antibody titers of thepooled serum from animals vaccinated with the test vaccines. FIG. 15Bshows murine survival (left) and weight loss (right) following challengewith a lethal dose of mouse-adapted B/Ann Arbor/1954. The percentage ofgroup survival and weight loss as compared to baseline was calculatedand plotted over time in days.

FIGS. 16A-16C show data depicting the NIHGen6HASS-foldon vaccine'srobust antibody response as measured by ELISA assay (plates coated withrecombinantly-expressed NIHGen6HASS-foldon [HA stem] or NP proteins).FIG. 16A shows titers to HA stem, over time, for four rhesus macaquespreviously vaccinated with FLUZONE® and boosted a single time withNIHGen6HASS-foldon mRNA vaccine. FIG. 16B depicts titers to HA stem,over time, from four rhesus macaques vaccinated at days 0, 28 and 56with the same NIHGen6HASS-foldon RNA vaccine. FIG. 16C illustratesantibody titers to NP, over time, for four rhesus macaques vaccinated atdays 0, 28 and 56 with the NP mRNA vaccine and shows that the vaccineelicited a robust antibody response to NP.

FIGS. 17A-17B show the results of ELISAs examining the presence ofantibody capable of binding to recombinant hemagglutinin (rHA) from awide variety of influenza strains. FIG. 17A shows the results of rhesusmacaques previously vaccinated with FLUZONE® and boosted a single timewith NIHGen6HASS-foldon mRNA vaccine, and FIG. 17B shows the results ofnaive rhesus macaques vaccinated at days 0, 28 and 56 with the sameNIHGen6HASS-foldon RNA vaccine.

FIG. 18 is a representation of cell-mediated immune responses followingmRNA vaccination. Peripheral blood mononuclear cells were harvested fromvaccinated macaques and stimulated with a pool of overlapping NPpeptides. The % of CD4 or CD8 T cells secreting one of the threecytokines (IFN-γ, IL-2, or TNF-α) is plotted.

FIG. 19 shows the results of hemagglutination inhibition (HAI) tests.Placebo subjects (targeted to be 25% of each cohort) are included. Thedata is shown per protocol, and excludes those that did not receive theday 22 injection.

FIG. 20 shows the HAI test kinetics per subject, including the placebosubjects (targeted to be 25% of each cohort).

FIG. 21 shows the results of microneutralization (MN) tests, includingplacebo subjects (targeted to be 25% of each cohort). The data shown isper protocol, and excludes those that did not receive a day 22injection.

FIG. 22 shows the MN test kinetics per subject, including the placebosubjects (targeted to be 25% of each cohort).

FIG. 23 is a graph depicting the very strong correlation between HAI andMN. The data includes placebo subjects (targeted to be 25% of eachcohort).

FIG. 24A shows murine survival following challenge with a lethal dose ofmouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934 (PR8) orH3 A/Hong Kong/1/1968 (HK68). FIG. 24B shows murine weight lossfollowing challenge with a lethal dose of mouse-adapted influenza virusstrain H1N1 A/Puerto Rico/8/1934 (PR8) or H3 A/Hong Kong/1/1968 (HK68).FIG. 24C shows murine survival following challenge with a lethal dose ofHK68 virus. FIG. 24D shows murine weight loss following challenge with alethal dose of HK68 virus. The percentage of group survival and weightloss as compared to baseline was calculated and plotted over time indays.

DETAILED DESCRIPTION

Embodiments of the present disclosure provide RNA (e.g., mRNA) vaccinesthat include polynucleotide encoding an influenza virus antigen.Influenza virus RNA vaccines, as provided herein may be used to induce abalanced immune response, comprising both cellular and humoral immunity,without many of the risks associated with DNA vaccination.

In some embodiments, the virus is a strain of Influenza A or Influenza Bor combinations thereof. In some embodiments, the strain of Influenza Aor Influenza B is associated with birds, pigs, horses, dogs, humans ornon-human primates. In some embodiments, the antigenic polypeptideencodes a hemagglutinin protein. In some embodiments, the hemagglutininprotein is H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14,H15, H16, H17, H18. In some embodiments, the hemagglutinin protein doesnot comprise a head domain. In some embodiments, the hemagglutininprotein comprises a portion of the head domain. In some embodiments, thehemagglutinin protein does not comprise a cytoplasmic domain. In someembodiments, the hemagglutinin protein comprises a portion of thecytoplasmic domain. In some embodiments, the truncated hemagglutininprotein comprises a portion of the transmembrane domain. In someembodiments, the amino acid sequence of the hemagglutinin proteincomprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99%identify with any of the amino acid sequences having an amino acidsequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479,or 543-561 (see also Tables 7-13 and 26). In some embodiments, the virusis selected from the group consisting of H1N1, H3N2, H7N9, and H10N8. Insome embodiments, the antigenic polypeptide is selected from thoseproteins having an amino acid sequences identified by any one of SEQ IDNO: 1-444, 458, 460, 462-479, or 543-561 (see also Tables 7-13 and 26).

Some embodiments provide influenza vaccines comprising one or more RNApolynucleotides having an open reading frame encoding a hemagglutininprotein and a pharmaceutically acceptable carrier or excipient,formulated within a cationic lipid nanoparticle. In some embodiments,the hemagglutinin protein is selected from H1, H7 and H10. In someembodiments, the RNA polynucleotide further encodes neuraminidaseprotein. In some embodiments, the hemagglutinin protein is derived froma strain of Influenza A virus or Influenza B virus or combinationsthereof. In some embodiments, the Influenza virus is selected from H1N1,H3N2, H7N9, and H10N8.

Some embodiments provide methods of preventing or treating influenzaviral infection comprising administering to a subject any of thevaccines described herein. In some embodiments, the antigen specificimmune response comprises a T cell response. In some embodiments, theantigen specific immune response comprises a B cell response. In someembodiments, the antigen specific immune response comprises both a Tcell response and a B cell response. In some embodiments, the method ofproducing an antigen specific immune response involves a singleadministration of the vaccine. In some embodiments, the vaccine isadministered to the subject by intradermal, intramuscular injection,subcutaneous injection, intranasal inoculation, or oral administration.

In some embodiments, the RNA (e.g., mRNA) polynucleotides or portionsthereof may encode one or more polypeptides of an influenza strain as anantigen. Such antigens include, but are not limited to, those antigensencoded by the polynucleotides or portions thereof of thepolynucleotides listed in the Tables presented herein. In the Tables,the GenBank Accession Number or GI Accession Number represents eitherthe complete or partial CDS of the encoded antigen. The RNA (e.g., mRNA)polynucleotides may comprise a region of any of the sequences listed inthe Tables or entire coding region of the mRNA listed. They may comprisehybrid or chimeric regions, or mimics or variants.

In the following embodiments, when referring to at least one RNA (e.g.,mRNA) polynucleotide having an open reading frame encoding for aspecific influenza virus protein, the polynucleotides may comprise acoding region of the specific influenza virus protein sequence or theentire coding region of the mRNA for that specific influenza virusprotein sequence.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one HA1, HA2, or a combination of both, of H1-H18).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one HA1, HA2, or a combination of both, of H1-H18) and at leastone protein selected from a NP protein, a NA protein, a M1 protein, a M2protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of H1-H18) and at least two proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of H1-H18) and at least three proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of H1-H18) and at least four proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of H1-H18) and at least five proteins selected from a NPprotein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (e.g.,at least one of H1-H18), a NP protein, a NA protein, a M1 protein, a M2protein, a NS1 protein, and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein and aNA protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein and aM1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein and aM2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein and aNS1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein and aNS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NPprotein and a NA protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NPprotein, and a M1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NPprotein, and a M2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NPprotein, and a NS1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NPprotein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NAprotein, and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NAprotein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NAprotein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NAprotein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a M1protein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a M1protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a M1protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a M2protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a M2protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein, a NS1protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, anda NA protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein and aM1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein and aM2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein and aNS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein and aNS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NPprotein, and a NA protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NPprotein, and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NPprotein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NPprotein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NPprotein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NAprotein, and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NAprotein, and a

M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NAprotein and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a NAprotein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a M1protein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a M1protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a M1protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a M2protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, a M2protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA1 protein, aNS1 protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),and a NA protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2)and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2)and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2)and a NS1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2)and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NP protein, and a NA protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NP protein, and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NP protein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NP protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NP protein and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NA protein, and a M1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NA protein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NA protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NA protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a M1 protein, and a M2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a M1 protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a M1 protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a M2 protein, and a NS1 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a H HA protein (HAor derivatives thereof comprising antigenic sequences from HA1 and/orHA2), a M2 protein, and a NS2 protein, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a HA protein (HA orderivatives thereof comprising antigenic sequences from HA1 and/or HA2),a NS1 protein, and a NS2 protein, obtained from influenza virus.

It should be understood that the present disclosure is not intended tobe limited by a particular strain of influenza virus. The strain ofinfluenza virus used, as provided herein, may be any strain of influenzavirus. Examples of preferred strains of influenza virus and preferredinfluenza antigens are provided in Tables 7-13 below.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H1/PuertoRico/8/1934.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H1/New Caledonia/20/1999.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H1/California/04/2009.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H5/Vietnam/1194/2004.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H2/Japan/305/1957.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a

NS2 protein, an immunogenic fragment of any of the foregoing influenzaantigens, a variant or homolog of any of the foregoing influenzaantigens, or any combination of two or more of the foregoing influenzaantigens, variants or homologs) obtained from H9/Hong Kong/1073/99.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H3/Aichi/2/1968.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H3/Brisbane/10/2007.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H7/Anhui/1/2013.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H10/Jiangxi-Donghu/346/2013.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H3/Wisconsin/67/2005.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaantigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, aM1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenicfragment of any of the foregoing influenza antigens, a variant orhomolog of any of the foregoing influenza antigens, or any combinationof two or more of the foregoing influenza antigens, variants orhomologs) obtained from H1/Vietnam/850/2009.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding influenza H7N9 HA1protein, ferritin and a dendritic cell targeting peptide (see, e.g., RenX et al. Emerg Infect Dis 2013; 19(11):1881-84; Steel J et al. mBio2010; 1(1):e00018-10; Kanekiyo M. et al. Nature 2013; 499:102-6, each ofwhich is incorporated herein by reference).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an avian influenzaH7 HA protein.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding influenza H7 HA1protein (see, e.g., Steel Jet al. mBio 2010; 1(1):e00018-10).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding influenza H7N9 HAIprotein and ferritin (see, e.g., Kanekiyo M. et al. Nature 2013;499:102-6).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenza H5N1protein. In some embodiments, the influenza H5N1 protein is from a humanstrain.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenza H1N1protein.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenzaprotein from an influenza A strain, such as human H1N1, H5N1, H9N2 orH3N2.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding an influenza H1N1HA having a nanoscaffold (see, e.g., Walker A et al. Sci Rep2011:1(5):1-8, incorporated herein by reference).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA)polynucleotide having an open reading frame encoding a glycosylatedinfluenza H1N1 HA (see, e.g., Chen J et al. PNAS USA 2014;111(7):2476-81, incorporated herein by reference).

An influenza vaccine may comprise, for example, at least one RNA (e.g.,mRNA) polynucleotide having an open reading frame encoding at least oneinfluenza HA2 stem antigen selected from the influenza HA2 stemantigens, provided herein, for example, those listed in Table 16,comprising an amino acid sequence identified by any one of SEQ ID NO:394-412.

The present disclosure also encompasses an influenza vaccine comprising,for example, at least one RNA (e.g., mRNA) polynucleotide having anucleic acid sequence selected from the influenza sequences listed inSEQ ID NO: 491-503 or 566-569 (see also: Mallajosyula V V et al., FrontImmunol. 2015 Jun 26; 6:329.; Mallajosyula V V et al., Proc Natl AcadSci USA. 2014 Jun. 24; 111(25):E2514-23.; Bommakanti G, et al., J Virol.2012 December; 86(24):13434-44; Bommakanti G et al., Proc Natl Acad SciUSA. 2010 Aug. 3; 107(31):13701-6 and Yassine et al., Nat Med. 2015 Sep;21(9):1065-70; Impagliazzo et al., Science, 2015 Sep 18; 349(6254)).

The entire contents of International Application No. PCT/US2015/027400,International Publication No. WO2015/164674A, is incorporated herein byreference.

In some embodiments the vaccines described herein are consensussequences. A “consensus sequence” as used herein refers to a polypeptidesequence based on analysis of an alignment of multiple subtypes of aparticular influenza antigen. mRNA sequences that encode a consensuspolypeptide sequence may be prepared and used to induce broad immunityagainst multiple subtypes or serotypes of a particular influenzaantigen.

The mRNA encoding influenza antigens provided herein can be arranged asa vaccine that causes seroconversion in vaccinated mammals and providescross-reactivity against a broad range of seasonal strains of influenzaand also pandemic strains of influenza. The seroconversion and broadcross-reactivity can be determined by measuring inhibiting titersagainst different hemagglutinin strains of influenza. Preferredcombinations include at least two antigens from each of the influenzaantigens described herein.

It has been discovered that the mRNA vaccines described herein aresuperior to current vaccines in several ways. First, the lipidnanoparticle (LNP) delivery is superior to other formulations includinga protamine base approach described in the literature and no additionaladjuvants are to be necessary. The use of LNPs enables the effectivedelivery of chemically modified or unmodified mRNA vaccines.Additionally it has been demonstrated herein that both modified andunmodified LNP formulated mRNA vaccines were superior to conventionalvaccines by a significant degree. In some embodiments the mRNA vaccinesof the invention are superior to conventional vaccines by a factor of atleast 10 fold, 20 fold, 40 fold, 50 fold, 100 fold, 500 fold or 1,000fold.

Although attempts have been made to produce functional RNA vaccines,including mRNA vaccines and self-replicating RNA vaccines, thetherapeutic efficacy of these RNA vaccines have not yet been fullyestablished. Quite surprisingly, the inventors have discovered,according to aspects of the invention a class of formulations fordelivering mRNA vaccines in vivo that results in significantly enhanced,and in many respects synergistic, immune responses including enhancedantigen generation and functional antibody production withneutralization capability. These results can be achieved even whensignificantly lower doses of the mRNA are administered in comparisonwith mRNA doses used in other classes of lipid based formulations. Theformulations of the invention have demonstrated significant unexpectedin vivo immune responses sufficient to establish the efficacy offunctional mRNA vaccines as prophylactic and therapeutic agents.Additionally, self-replicating RNA vaccines rely on viral replicationpathways to deliver enough RNA to a cell to produce an immunogenicresponse. The formulations of the invention do not require viralreplication to produce enough protein to result in a strong immuneresponse. Thus, the mRNA of the invention are not self-replicating RNAand do not include components necessary for viral replication.

The invention involves, in some aspects, the surprising finding thatlipid nanoparticle (LNP) formulations significantly enhance theeffectiveness of mRNA vaccines, including chemically modified andunmodified mRNA vaccines. The efficacy of mRNA vaccines formulated inLNP was examined in vivo using several distinct antigens. The resultspresented herein demonstrate the unexpected superior efficacy of themRNA vaccines formulated in LNP over other commercially availablevaccines.

In addition to providing an enhanced immune response, the formulationsof the invention generate a more rapid immune response with fewer dosesof antigen than other vaccines tested. The mRNA-LNP formulations of theinvention also produce quantitatively and qualitatively better immuneresponses than vaccines formulated in a different carriers.

The data described herein demonstrate that the formulations of theinvention produced significant unexpected improvements over existingantigen vaccines. Additionally, the mRNA-LNP formulations of theinvention are superior to other vaccines even when the dose of mRNA islower than other vaccines. mRNA encoding HA protein sequences such as HAstem sequences from different strains have been demonstrated to induceserum antibodies that bind to diverse panel of recombinant HA (rHA)proteins. The vaccine efficacy in mice was similar at all vaccine doses,as well as with all co-formulation and co-delivery methods assessed.

The LNP used in the studies described herein has been used previously todeliver siRNA in various animal models as well as in humans. In view ofthe observations made in association with the siRNA delivery of LNPformulations, the fact that LNP is useful in vaccines is quitesurprising. It has been observed that therapeutic delivery of siRNAformulated in LNP causes an undesirable inflammatory response associatedwith a transient IgM response, typically leading to a reduction inantigen production and a compromised immune response. In contrast to thefindings observed with siRNA, the LNP-mRNA formulations of the inventionare demonstrated herein to generate enhanced IgG levels, sufficient forprophylactic and therapeutic methods rather than transient IgMresponses.

Nucleic Acids/Polynucleotides

Influenza virus vaccines, as provided herein, comprise at least one (oneor more) ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having anopen reading frame encoding at least one Influenza antigenicpolypeptide. The term “nucleic acid” includes any compound and/orsubstance that comprises a polymer of nucleotides (nucleotide monomer).These polymers are referred to as polynucleotides. Thus, the terms“nucleic acid” and “polynucleotide” are used interchangeably.

Nucleic acids may be or may include, for example, ribonucleic acids(RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs),glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), lockednucleic acids (LNAs, including LNA having a β-D-ribo configuration,α-LNA having an α-L-ribo configuration (a diastereomer of LNA),2′-amino-LNA having a 2′-amino functionalization, and 2′-amino-α-LNAhaving a 2′-amino functionalization), ethylene nucleic acids (ENA),cyclohexenyl nucleic acids (CeNA) or chimeras or combinations thereof.

In some embodiments, polynucleotides of the present disclosure functionas messenger RNA (mRNA). “Messenger RNA” (mRNA) refers to anypolynucleotide that encodes a (at least one) polypeptide (anaturally-occurring, non-naturally-occurring, or modified polymer ofamino acids) and can be translated to produce the encoded polypeptide invitro, in vivo, in situ or ex vivo. The skilled artisan will appreciatethat, except where otherwise noted, polynucleotide sequences set forthin the instant application will recite “T”s in a representative DNAsequence but where the sequence represents RNA (e.g., mRNA), the “T”swould be substituted for “U”s. Thus, any of the RNA polynucleotidesencoded by a DNA identified by a particular sequence identificationnumber may also comprise the corresponding RNA (e.g., mRNA) sequenceencoded by the DNA, where each “T” of the DNA sequence is substitutedwith “U.”

It should be understood that the mRNA polynucleotides of the vaccines asprovided herein are synthetic molecules, i.e., they are notnaturally-occurring molecules. That is, the mRNA polynucleotides of thepresent disclosure are isolated mRNA polynucleotides. As is known in theart, “isolated polynucleotides” refer to polynucleotides that aresubstantially physically separated from other cellular material (e.g.,separated from cells and/or systems that produce the polynucleotides) orfrom other material that hinders their use in the vaccines of thepresent disclosure. Isolated polynucleotides are substantially pure inthat they have been substantially separated from the substances withwhich they may be associated in living or viral systems. Thus, mRNApolynucleotide vaccines are not associated with living or viral systems,such as cells or viruses. The mRNA polynucleotide vaccines do notinclude viral components (e.g., viral capsids, viral enzymes, or otherviral proteins, for example, those needed for viral-based replication),and the mRNA polynucleotide vaccines are not packaged within,encapsulated within, linked to, or otherwise associated with a virus orviral particle. In some embodiments, the mRNA vaccines comprise a lipidnanoparticle that consists of, or consists essentially of, one or moremRNA polynucleotides (e.g., mRNA polynucleotides encoding one or moreinfluenza antigen(s)).

The basic components of an mRNA molecule typically include at least onecoding region, a 5′ untranslated region (UTR), a 3′ UTR, a 5′ cap and apoly-A tail. Polynucleotides of the present disclosure may function asmRNA but can be distinguished from wild-type mRNA in their functionaland/or structural design features, which serve to overcome existingproblems of effective polypeptide expression using nucleic-acid basedtherapeutics. In some embodiments, the RNA is a mRNA having an openreading frame encoding at least one influenza virus antigen. In someembodiments, the RNA (e.g., mRNA) further comprises a (at least one) 5′UTR, 3′ UTR, a polyA tail and/or a 5′ cap.

In some embodiments, a RNA polynucleotide of an RNA (e.g., mRNA) vaccineencodes 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7,3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6,6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9 or 9-10 antigenicpolypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide ofan influenza vaccine encodes at least 10, 20, 30, 40, 50 , 60, 70, 80,90 or 100 antigenic polypeptides. In some embodiments, a RNA (e.g.,mRNA) polynucleotide of an influenza vaccine encodes at least 100 or atleast 200 antigenic polypeptides. In some embodiments, a RNApolynucleotide of an influenza vaccine encodes 1-10, 5-15, 10-20, 15-25,20-30, 25-35, 30-40, 35-45, 40-50, 1-50, 1-100, 2-50 or 2-100 antigenicpolypeptides.

Polynucleotides of the present disclosure, in some embodiments, arecodon optimized. Codon optimization methods are known in the art and maybe used as provided herein. Codon optimization, in some embodiments, maybe used to match codon frequencies in target and host organisms toensure proper folding; bias GC content to increase mRNA stability orreduce secondary structures; minimize tandem repeat codons or base runsthat may impair gene construction or expression; customizetranscriptional and translational control regions; insert or removeprotein trafficking sequences; remove/add post translation modificationsites in encoded protein (e.g. glycosylation sites); add, remove orshuffle protein domains; insert or delete restriction sites; modifyribosome binding sites and mRNA degradation sites; adjust translationalrates to allow the various domains of the protein to fold properly; orto reduce or eliminate problem secondary structures within thepolynucleotide. Codon optimization tools, algorithms and services areknown in the art—non-limiting examples include services from GeneArt(Life Technologies), DNA2.0 (Menlo Park Calif.) and/or proprietarymethods. In some embodiments, the open reading frame (ORF) sequence isoptimized using optimization algorithms.

In some embodiments, a codon optimized sequence shares less than 95%sequence identity, less than 90% sequence identity, less than 85%sequence identity, less than 80% sequence identity, or less than 75%sequence identity to a naturally-occurring or wild-type sequence (e.g.,a naturally-occurring or wild-type mRNA sequence encoding a polypeptideor protein of interest (e.g., an antigenic protein or antigenicpolypeptide)).

In some embodiments, a codon-optimized sequence shares between 65% and85% (e.g., between about 67% and about 85%, or between about 67% andabout 80%) sequence identity to a naturally-occurring sequence or awild-type sequence (e.g., a naturally-occurring or wild-type mRNAsequence encoding a polypeptide or protein of interest (e.g., anantigenic protein or polypeptide)). In some embodiments, acodon-optimized sequence shares between 65% and 75%, or about 80%sequence identity to a naturally-occurring sequence or wild-typesequence (e.g., a naturally-occurring or wild-type mRNA sequenceencoding a polypeptide or protein of interest (e.g., an antigenicprotein or polypeptide)).

In some embodiments a codon-optimized RNA (e.g., mRNA) may, forinstance, be one in which the levels of G/C are enhanced. TheG/C-content of nucleic acid molecules may influence the stability of theRNA. RNA having an increased amount of guanine (G) and/or cytosine (C)residues may be functionally more stable than nucleic acids containing alarge amount of adenine (A) and thymine (T) or uracil (U) nucleotides.WO2002/098443 discloses a pharmaceutical composition containing an mRNAstabilized by sequence modifications in the translated region. Due tothe degeneracy of the genetic code, the modifications work bysubstituting existing codons for those that promote greater RNAstability without changing the resulting amino acid. The approach islimited to coding regions of the RNA.

Antigens/Antigenic Polypeptides

In some embodiments, an antigenic polypeptide (e.g., at least oneInfluenza antigenic polypeptide) is longer than 25 amino acids andshorter than 50 amino acids. The term “antigenic polypeptides” and“antigenic proteins” includes immunogenic fragments and epitopes thereof(e.g., an immunogenic fragment capable of inducing an immune response toinfluenza). Polypeptides include gene products, naturally occurringpolypeptides, synthetic polypeptides, homologs, orthologs, paralogs,fragments and other equivalents, variants, and analogs of the foregoing.A polypeptide may be a single molecule or may be a multi-molecularcomplex such as a dimer, trimer or tetramer. Polypeptides may alsocomprise single chain polypeptides or multichain polypeptides, such asantibodies or insulin, and may be associated or linked to each other.Most commonly, disulfide linkages are found in multichain polypeptides.The term “polypeptide” may also apply to amino acid polymers in which atleast one amino acid residue is an artificial chemical analogue of acorresponding naturally-occurring amino acid.

A “polypeptide variant” is a molecule that differs in its amino acidsequence relative to a native sequence or a reference sequence. Aminoacid sequence variants may possess substitutions, deletions, insertions,or a combination of any two or three of the foregoing, at certainpositions within the amino acid sequence, as compared to a nativesequence or a reference sequence. Ordinarily, variants possess at least50% identity to a native sequence or a reference sequence. In someembodiments, variants share at least 80% identity or at least 90%identity with a native sequence or a reference sequence.

In some embodiments “variant mimics” are provided. A “variant mimic”contains at least one amino acid that would mimic an activated sequence.For example, glutamate may serve as a mimic for phosphoro-threonineand/or phosphoro-serine. Alternatively, variant mimics may result indeactivation or in an inactivated product containing the mimic. Forexample, phenylalanine may act as an inactivating substitution fortyrosine, or alanine may act as an inactivating substitution for serine.

“Orthologs” refers to genes in different species that evolved from acommon ancestral gene by speciation. Normally, orthologs retain the samefunction in the course of evolution. Identification of orthologs isimportant for reliable prediction of gene function in newly sequencedgenomes.

“Analogs” is meant to include polypeptide variants that differ by one ormore amino acid alterations, for example, substitutions, additions ordeletions of amino acid residues that still maintain one or more of theproperties of the parent or starting polypeptide.

The present disclosure provides several types of compositions that arepolynucleotide or polypeptide based, including variants and derivatives.These include, for example, substitutional, insertional, deletion andcovalent variants and derivatives. The term “derivative” is synonymouswith the term “variant” and generally refers to a molecule that has beenmodified and/or changed in any way relative to a reference molecule or astarting molecule.

As such, polynucleotides encoding peptides or polypeptides containingsubstitutions, insertions and/or additions, deletions and covalentmodifications with respect to reference sequences, in particular thepolypeptide sequences disclosed herein, are included within the scope ofthis disclosure. For example, sequence tags or amino acids, such as oneor more lysines, can be added to peptide sequences (e.g., at theN-terminal or C-terminal ends). Sequence tags can be used for peptidedetection, purification or localization. Lysines can be used to increasepeptide solubility or to allow for biotinylation. Alternatively, aminoacid residues located at the carboxy and amino terminal regions of theamino acid sequence of a peptide or protein may optionally be deletedproviding for truncated sequences. Certain amino acids (e.g., C-terminalresidues or N-terminal residues) alternatively may be deleted dependingon the use of the sequence, as for example, expression of the sequenceas part of a larger sequence that is soluble, or linked to a solidsupport.

“Substitutional variants” when referring to polypeptides are those thathave at least one amino acid residue in a native or starting sequenceremoved and a different amino acid inserted in its place at the sameposition. Substitutions may be single, where only one amino acid in themolecule has been substituted, or they may be multiple, where two ormore (e.g., 3, 4 or 5) amino acids have been substituted in the samemolecule.

As used herein the term “conservative amino acid substitution” refers tothe substitution of an amino acid that is normally present in thesequence with a different amino acid of similar size, charge, orpolarity. Examples of conservative substitutions include thesubstitution of a non-polar (hydrophobic) residue such as isoleucine,valine and leucine for another non-polar residue. Likewise, examples ofconservative substitutions include the substitution of one polar(hydrophilic) residue for another such as between arginine and lysine,between glutamine and asparagine, and between glycine and serine.Additionally, the substitution of a basic residue such as lysine,arginine or histidine for another, or the substitution of one acidicresidue such as aspartic acid or glutamic acid for another acidicresidue are additional examples of conservative substitutions. Examplesof non-conservative substitutions include the substitution of anon-polar (hydrophobic) amino acid residue such as isoleucine, valine,leucine, alanine, methionine for a polar (hydrophilic) residue such ascysteine, glutamine, glutamic acid or lysine and/or a polar residue fora non-polar residue.

“Features” when referring to polypeptide or polynucleotide are definedas distinct amino acid sequence-based or nucleotide-based components ofa molecule respectively. Features of the polypeptides encoded by thepolynucleotides include surface manifestations, local conformationalshape, folds, loops, half-loops, domains, half-domains, sites, terminiand any combination(s) thereof.

As used herein when referring to polypeptides the term “domain” refersto a motif of a polypeptide having one or more identifiable structuralor functional characteristics or properties (e.g., binding capacity,serving as a site for protein-protein interactions).

As used herein when referring to polypeptides the terms “site” as itpertains to amino acid based embodiments is used synonymously with“amino acid residue” and “amino acid side chain.” As used herein whenreferring to polynucleotides the terms “site” as it pertains tonucleotide based embodiments is used synonymously with “nucleotide.” Asite represents a position within a peptide or polypeptide orpolynucleotide that may be modified, manipulated, altered, derivatizedor varied within the polypeptide-based or polynucleotide-basedmolecules.

As used herein the terms “termini” or “terminus” when referring topolypeptides or polynucleotides refers to an extremity of a polypeptideor polynucleotide respectively. Such extremity is not limited only tothe first or final site of the polypeptide or polynucleotide but mayinclude additional amino acids or nucleotides in the terminal regions.Polypeptide-based molecules may be characterized as having both anN-terminus (terminated by an amino acid with a free amino group (NH2))and a C-terminus (terminated by an amino acid with a free carboxyl group(COOH)). Proteins are in some cases made up of multiple polypeptidechains brought together by disulfide bonds or by non-covalent forces(multimers, oligomers). These proteins have multiple N- and C-termini.Alternatively, the termini of the polypeptides may be modified such thatthey begin or end, as the case may be, with a non-polypeptide basedmoiety such as an organic conjugate.

As recognized by those skilled in the art, protein fragments, functionalprotein domains, and homologous proteins are also considered to bewithin the scope of polypeptides of interest. For example, providedherein is any protein fragment (meaning a polypeptide sequence at leastone amino acid residue shorter than a reference polypeptide sequence butotherwise identical) of a reference protein having a length of 10, 20,30, 40, 50, 60, 70, 80, 90, 100 or longer than 100 amino acids. Inanother example, any protein that includes a stretch of 20, 30, 40, 50,or 100 (contiguous) amino acids that are 40%, 50%, 60%, 70%, 80%, 90%,95%, or 100% identical to any of the sequences described herein can beutilized in accordance with the disclosure. In some embodiments, apolypeptide includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations asshown in any of the sequences provided herein or referenced herein. Inanother example, any protein that includes a stretch of 20, 30, 40, 50,or 100 amino acids that are greater than 80%, 90%, 95%, or 100%identical to any of the sequences described herein, wherein the proteinhas a stretch of 5, 10, 15, 20, 25, or 30 amino acids that are less than80%, 75%, 70%, 65% to 60% identical to any of the sequences describedherein can be utilized in accordance with the disclosure.

Polypeptide or polynucleotide molecules of the present disclosure mayshare a certain degree of sequence similarity or identity with thereference molecules (e.g., reference polypeptides or referencepolynucleotides), for example, with art-described molecules (e.g.,engineered or designed molecules or wild-type molecules). The term“identity,” as known in the art, refers to a relationship between thesequences of two or more polypeptides or polynucleotides, as determinedby comparing the sequences. In the art, identity also means the degreeof sequence relatedness between two sequences as determined by thenumber of matches between strings of two or more amino acid residues ornucleic acid residues. Identity measures the percent of identicalmatches between the smaller of two or more sequences with gap alignments(if any) addressed by a particular mathematical model or computerprogram (e.g.,“algorithms”). Identity of related peptides can be readilycalculated by known methods. “% identity” as it applies to polypeptideor polynucleotide sequences is defined as the percentage of residues(amino acid residues or nucleic acid residues) in the candidate aminoacid or nucleic acid sequence that are identical with the residues inthe amino acid sequence or nucleic acid sequence of a second sequenceafter aligning the sequences and introducing gaps, if necessary, toachieve the maximum percent identity. Methods and computer programs forthe alignment are well known in the art. Identity depends on acalculation of percent identity but may differ in value due to gaps andpenalties introduced in the calculation. Generally, variants of aparticular polynucleotide or polypeptide have at least 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% but less than 100% sequence identity to that particularreference polynucleotide or polypeptide as determined by sequencealignment programs and parameters described herein and known to thoseskilled in the art. Such tools for alignment include those of the BLASTsuite (Stephen F. Altschul, et al. (1997). “Gapped BLAST and PSI-BLAST:a new generation of protein database search programs,” Nucleic AcidsRes. 25:3389-3402). Another popular local alignment technique is basedon the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981)“Identification of common molecular subsequences.” J. Mol. Biol.147:195-197). A general global alignment technique based on dynamicprogramming is the Needleman-Wunsch algorithm (Needleman, S. B. &Wunsch, C. D. (1970) “A general method applicable to the search forsimilarities in the amino acid sequences of two proteins.” J. Mol. Biol.48:443-453). More recently, a Fast Optimal Global Sequence AlignmentAlgorithm (FOGSAA) was developed that purportedly produces globalalignment of nucleotide and protein sequences faster than other optimalglobal alignment methods, including the Needleman-Wunsch algorithm.Other tools are described herein, specifically in the definition of“identity” below.

As used herein, the term “homology” refers to the overall relatednessbetween polymeric molecules, e.g. between nucleic acid molecules (e.g.DNA molecules and/or RNA molecules) and/or between polypeptidemolecules. Polymeric molecules (e.g. nucleic acid molecules (e.g. DNAmolecules and/or RNA molecules) and/or polypeptide molecules) that sharea threshold level of similarity or identity determined by alignment ofmatching residues are termed homologous. Homology is a qualitative termthat describes a relationship between molecules and can be based uponthe quantitative similarity or identity. Similarity or identity is aquantitative term that defines the degree of sequence match between twocompared sequences. In some embodiments, polymeric molecules areconsidered to be “homologous” to one another if their sequences are atleast 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, or 99% identical or similar. The term “homologous” necessarilyrefers to a comparison between at least two sequences (polynucleotide orpolypeptide sequences). Two polynucleotide sequences are consideredhomologous if the polypeptides they encode are at least 50%, 60%, 70%,80%, 90%, 95%, or even 99% for at least one stretch of at least 20 aminoacids. In some embodiments, homologous polynucleotide sequences arecharacterized by the ability to encode a stretch of at least 4-5uniquely specified amino acids. For polynucleotide sequences less than60 nucleotides in length, homology is determined by the ability toencode a stretch of at least 4-5 uniquely specified amino acids. Twoprotein sequences are considered homologous if the proteins are at least50%, 60%, 70%, 80%, or 90% identical for at least one stretch of atleast 20 amino acids.

Homology implies that the compared sequences diverged in evolution froma common origin. The term “homolog” refers to a first amino acidsequence or nucleic acid sequence (e.g., gene (DNA or RNA) or proteinsequence) that is related to a second amino acid sequence or nucleicacid sequence by descent from a common ancestral sequence. The term“homolog” may apply to the relationship between genes and/or proteinsseparated by the event of speciation or to the relationship betweengenes and/or proteins separated by the event of genetic duplication.“Orthologs” are genes (or proteins) in different species that evolvedfrom a common ancestral gene (or protein) by speciation. Typically,orthologs retain the same function in the course of evolution.“Paralogs” are genes (or proteins) related by duplication within agenome. Orthologs retain the same function in the course of evolution,whereas paralogs evolve new functions, even if these are related to theoriginal one.

The term “identity” refers to the overall relatedness between polymericmolecules, for example, between polynucleotide molecules (e.g. DNAmolecules and/or RNA molecules) and/or between polypeptide molecules.Calculation of the percent identity of two polynucleic acid sequences,for example, can be performed by aligning the two sequences for optimalcomparison purposes (e.g., gaps can be introduced in one or both of afirst and a second nucleic acid sequences for optimal alignment andnon-identical sequences can be disregarded for comparison purposes). Incertain embodiments, the length of a sequence aligned for comparisonpurposes is at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%, or 100% of thelength of the reference sequence. The nucleotides at correspondingnucleotide positions are then compared. When a position in the firstsequence is occupied by the same nucleotide as the correspondingposition in the second sequence, then the molecules are identical atthat position. The percent identity between the two sequences is afunction of the number of identical positions shared by the sequences,taking into account the number of gaps, and the length of each gap,which needs to be introduced for optimal alignment of the two sequences.The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm. For example, the percent identity between two nucleic acidsequences can be determined using methods such as those described inComputational Molecular Biology, Lesk, A. M., ed., Oxford UniversityPress, New York, 1988; Biocomputing: Informatics and Genome Projects,Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis inMolecular Biology, von Heinje, G., Academic Press, 1987; ComputerAnalysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G.,eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer,Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991;each of which is incorporated herein by reference. For example, thepercent identity between two nucleic acid sequences can be determinedusing the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), whichhas been incorporated into the ALIGN program (version 2.0) using aPAM120 weight residue table, a gap length penalty of 12 and a gappenalty of 4. The percent identity between two nucleic acid sequencescan, alternatively, be determined using the GAP program in the GCGsoftware package using an NWSgapdna.CMP matrix. Methods commonlyemployed to determine percent identity between sequences include, butare not limited to those disclosed in Carillo, H., and Lipman, D., SIAMJ Applied Math., 48:1073 (1988); incorporated herein by reference.Techniques for determining identity are codified in publicly availablecomputer programs. Exemplary computer software to determine homologybetween two sequences include, but are not limited to, GCG programpackage, Devereux, J., et al., Nucleic Acids Research, 12, 387 (1984)),BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215,403 (1990)).

Multiprotein and Multicomponent Vaccines

The present disclosure encompasses influenza vaccines comprisingmultiple RNA (e.g., mRNA) polynucleotides, each encoding a singleantigenic polypeptide, as well as influenza vaccines comprising a singleRNA polynucleotide encoding more than one antigenic polypeptide (e.g.,as a fusion polypeptide). Thus, a vaccine composition comprising a RNA(e.g., mRNA) polynucleotide having an open reading frame encoding afirst antigenic polypeptide and a RNA (e.g., mRNA) polynucleotide havingan open reading frame encoding a second antigenic polypeptideencompasses (a) vaccines that comprise a first RNA polynucleotideencoding a first antigenic polypeptide and a second RNA polynucleotideencoding a second antigenic polypeptide, and (b) vaccines that comprisea single RNA polynucleotide encoding a first and second antigenicpolypeptide (e.g., as a fusion polypeptide). RNA (e.g., mRNA) vaccinesof the present disclosure, in some embodiments, comprise 2-10 (e.g., 2,3, 4, 5, 6, 7, 8, 9 or 10), or more, RNA polynucleotides having an openreading frame, each of which encodes a different antigenic polypeptide(or a single RNA polynucleotide encoding 2-10, or more, differentantigenic polypeptides). The antigenic polypeptides may be selected fromany of the influenza antigenic polypeptides described herein.

In some embodiments, a multicomponent vaccine comprises at least one RNA(e.g., mRNA) polynucleotide encoding at least one influenza antigenicpolypeptide fused to a signal peptide (e.g., SEQ ID NO: 488-490). Thesignal peptide may be fused at the N-terminus or the C-terminus of anantigenic polypeptide.

Signal Peptides

In some embodiments, antigenic polypeptides encoded by influenza RNA(e.g., mRNA) polynucleotides comprise a signal peptide. Signal peptides,comprising the N-terminal 15-60 amino acids of proteins, are typicallyneeded for the translocation across the membrane on the secretorypathway and, thus, universally control the entry of most proteins bothin eukaryotes and prokaryotes to the secretory pathway. Signal peptidesgenerally include three regions: an N-terminal region of differinglength, which usually comprises positively charged amino acids; ahydrophobic region; and a short carboxy-terminal peptide region. Ineukaryotes, the signal peptide of a nascent precursor protein(pre-protein) directs the ribosome to the rough endoplasmic reticulum(ER) membrane and initiates the transport of the growing peptide chainacross it for processing. ER processing produces mature proteins,wherein the signal peptide is cleaved from precursor proteins, typicallyby a ER-resident signal peptidase of the host cell, or they remainuncleaved and function as a membrane anchor. A signal peptide may alsofacilitate the targeting of the protein to the cell membrane. The signalpeptide, however, is not responsible for the final destination of themature protein. Secretory proteins devoid of additional address tags intheir sequence are by default secreted to the external environment.During recent years, a more advanced view of signal peptides hasevolved, showing that the functions and immunodominance of certainsignal peptides are much more versatile than previously anticipated.

Influenza vaccines of the present disclosure may comprise, for example,RNA (e.g., mRNA) polynucleotides encoding an artificial signal peptide,wherein the signal peptide coding sequence is operably linked to and isin frame with the coding sequence of the antigenic polypeptide. Thus,influenza vaccines of the present disclosure, in some embodiments,produce an antigenic polypeptide fused to a signal peptide. In someembodiments, a signal peptide is fused to the N-terminus of theantigenic polypeptide. In some embodiments, a signal peptide is fused tothe C-terminus of the antigenic polypeptide.

In some embodiments, the signal peptide fused to the antigenicpolypeptide is an artificial signal peptide. In some embodiments, anartificial signal peptide fused to the antigenic polypeptide encoded bythe RNA (e.g., mRNA) vaccine is obtained from an immunoglobulin protein,e.g., an IgE signal peptide or an IgG signal peptide. In someembodiments, a signal peptide fused to the antigenic polypeptide encodedby a RNA (e.g., mRNA) vaccine is an Ig heavy chain epsilon-1 signalpeptide (IgE HC SP) having the sequence of: MDWTWILFLVAAATRVHS; SEQ IDNO: 481. In some embodiments, a signal peptide fused to the antigenicpolypeptide encoded by the (e.g., mRNA) RNA (e.g., mRNA) vaccine is anIgGk chain V-III region HAH signal peptide (IgGk SP) having the sequenceof METPAQLLFLLLLWLPDTTG; SEQ ID NO: 480. In some embodiments, the signalpeptide is selected from: Japanese encephalitis PRM signal sequence(MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 482), VSVg protein signal sequence(MKCLLYLAFLFIGVNCA; SEQ ID NO: 483) and Japanese encephalitis JEV signalsequence (MWLVSLAIVTACAGA; SEQ ID NO: 484).

In some embodiments, the antigenic polypeptide encoded by a RNA (e.g.,mRNA) vaccine comprises an amino acid sequence identified by any one ofSEQ ID NO: 1-444, 458, 460, 462-479, or 543-565 (see also Tables 7-13and 26) fused to a signal peptide identified by any one of SEQ ID NO:480-484. The examples disclosed herein are not meant to be limiting andany signal peptide that is known in the art to facilitate targeting of aprotein to ER for processing and/or targeting of a protein to the cellmembrane may be used in accordance with the present disclosure.

A signal peptide may have a length of 15-60 amino acids. For example, asignal peptide may have a length of 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,or 60 amino acids. In some embodiments, a signal peptide has a length of20-60, 25-60, 30-60, 35-60, 40-60, 45-60, 50-60, 55-60, 15-55, 20-55,25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50,35-50, 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40,20-40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30,25-30, 15-25, 20-25, or 15-20 amino acids.

A signal peptide is typically cleaved from the nascent polypeptide atthe cleavage junction during ER processing. The mature antigenicpolypeptide produce by an influenza RNA (e.g., mRNA) vaccine of thepresent disclosure typically does not comprise a signal peptide.

Chemical Modifications

Influenza vaccines of the present disclosure, in some embodiments,comprise at least RNA (e.g. mRNA) polynucleotide having an open readingframe encoding at least one antigenic polypeptide that comprises atleast one chemical modification.

The terms “chemical modification” and “chemically modified” refer tomodification with respect to adenosine (A), guanosine (G), uridine (U),thymidine (T) or cytidine (C) ribonucleosides or deoxyribnucleosides inat least one of their position, pattern, percent or population.Generally, these terms do not refer to the ribonucleotide modificationsin naturally occurring 5′-terminal mRNA cap moieties. With respect to apolypeptide, the term “modification” refers to a modification relativeto the canonical set 20 amino acids. Polypeptides, as provided herein,are also considered “modified” of they contain amino acid substitutions,insertions or a combination of substitutions and insertions.

Polynucleotides (e.g., RNA polynucleotides, such as mRNApolynucleotides), in some embodiments, comprise various (more than one)different modifications. In some embodiments, a particular region of apolynucleotide contains one, two or more (optionally different)nucleoside or nucleotide modifications. In some embodiments, a modifiedRNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced toa cell or organism, exhibits reduced degradation in the cell ororganism, respectively, relative to an unmodified polynucleotide. Insome embodiments, a modified RNA polynucleotide (e.g., a modified mRNApolynucleotide), introduced into a cell or organism, may exhibit reducedimmunogenicity in the cell or organism, respectively (e.g., a reducedinnate response).

Modifications of polynucleotides include, without limitation, thosedescribed herein. Polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) may comprise modifications that arenaturally-occurring, non-naturally-occurring or the polynucleotide maycomprise a combination of naturally-occurring andnon-naturally-occurring modifications. Polynucleotides may include anyuseful modification, for example, of a sugar, a nucleobase, or aninternucleoside linkage (e.g., to a linking phosphate, to aphosphodiester linkage or to the phosphodiester backbone).

Polynucleotides (e.g., RNA polynucleotides, such as mRNApolynucleotides), in some embodiments, comprise non-natural modifiednucleotides that are introduced during synthesis or post-synthesis ofthe polynucleotides to achieve desired functions or properties. Themodifications may be present on an internucleotide linkages, purine orpyrimidine bases, or sugars. The modification may be introduced withchemical synthesis or with a polymerase enzyme at the terminal of achain or anywhere else in the chain. Any of the regions of apolynucleotide may be chemically modified.

The present disclosure provides for modified nucleosides and nucleotidesof a polynucleotide (e.g., RNA polynucleotides, such as mRNApolynucleotides). A “nucleoside” refers to a compound containing a sugarmolecule (e.g., a pentose or ribose) or a derivative thereof incombination with an organic base (e.g., a purine or pyrimidine) or aderivative thereof (also referred to herein as “nucleobase”). Anucleotide” refers to a nucleoside, including a phosphate group.Modified nucleotides may by synthesized by any useful method, such as,for example, chemically, enzymatically, or recombinantly, to include oneor more modified or non-natural nucleosides. Polynucleotides maycomprise a region or regions of linked nucleosides. Such regions mayhave variable backbone linkages. The linkages may be standardphosphodioester linkages, in which case the polynucleotides wouldcomprise regions of nucleotides.

Modified nucleotide base pairing encompasses not only the standardadenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs,but also base pairs formed between nucleotides and/or modifiednucleotides comprising non-standard or modified bases, wherein thearrangement of hydrogen bond donors and hydrogen bond acceptors permitshydrogen bonding between a non-standard base and a standard base orbetween two complementary non-standard base structures. One example ofsuch non-standard base pairing is the base pairing between the modifiednucleotide inosine and adenine, cytosine or uracil. Any combination ofbase/sugar or linker may be incorporated into polynucleotides of thepresent disclosure.

Modifications of polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) that are useful in the vaccines of the presentdisclosure include, but are not limited to the following:2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine;2-methylthio-N6-methyl adenosine; 2-methylthio-N6-threonylcarbamoyladenosine; N6-glycinylcarb amoyladenosine;N6-isopentenyladenosine; N6-methyl adenosine; N6-threonylcarbamoyladenosine; 1,2′-O-dimethyl adenosine; 1-methyladenosine;2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladenosine;2-methylthio-N6-hydroxynorvalyl carbamoyladenosine;2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate);Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine;N6,2′-O-dimethyladenosine; N6,2′-O-dimethyladenosine;N6,N6,2′-O-trimethyladenosine; N6,N6-dimethyladenosine;N6-acetyladenosine; N6-hydroxynorvalylcarbamoyladenosine;N6-methyl-N6-threonylcarbamoyladenosine; 2-methyladenosine;2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine;N1-methyl-adenosine; N6, N6 (dimethyl)adenine;N6-cis-hydroxy-isopentenyl-adenosine; α-thio-adenosine; 2(amino)adenine; 2 (aminopropyl)adenine; 2 (methylthio) N6 (isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine;2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine;2-(propyl)adenine; 2′-Amino-2′-deoxy-ATP; 2′-Azido-2′-deoxy-ATP;2′-Deoxy-2′-a-aminoadenosine TP; 2′-Deoxy-2′-a-azidoadenosine TP; 6(alkyl)adenine; 6 (methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine;7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8(amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine;8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine;8-(hydroxyl)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine;8-azido-adenosine; aza adenine; deaza adenine; N6 (methyl)adenine;N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine;1-Deazaadenosine TP; 2′Fluoro-N6-Bz-deoxyadenosine TP;2′-OMe-2-Amino-ATP; 2′O-methyl-N6-Bz-deoxyadenosine TP; 2′-a-Ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP; 2-Amino-ATP;2′-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP;2′-b-Ethynyladenosine TP; 2-Bromoadenosine TP;2′-b-Trifluoromethyladenosine TP; 2-Chloroadenosine TP;2′-Deoxy-2′,2′-difluoroadenosine TP; 2′-Deoxy-2′-a-mercaptoadenosine TP;2′-Deoxy-2′-a-thiomethoxyadenosine TP; 2′-Deoxy-2′-b-aminoadenosine TP;2′-Deoxy-2′-b-azidoadenosine TP; 2′-Deoxy-2′-b-bromoadenosine TP;2′-Deoxy-2′-b-chloroadenosine TP; 2′-Deoxy-2′-b-fluoroadenosine TP;2′-Deoxy-2′-b-iodoadenosine TP; 2′-Deoxy-2′-b-mercaptoadenosine TP;2′-Deoxy-2′-b-thiomethoxyadenosine TP; 2-Fluoroadenosine TP;2-Iodoadenosine TP; 2-Mercaptoadenosine TP; 2-methoxy-adenine;2-methylthio-adenine; 2-Trifluoromethyladenosine TP;3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloroadenosine TP;3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP;3-Deazaadenosine TP; 4′-Azidoadenosine TP; 4′-Carbocyclic adenosine TP;4′-Ethynyladenosine TP; 5′-Homo-adenosine TP; 8-Aza-ATP;8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-DeazaadenosineTP; 2-aminopurine; 7-deaza-2,6-diaminopurine;7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine;2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine;2-thiocytidine; 3-methylcytidine; 5-formyl cytidine;5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine;2′-O-methyl cytidine; 2′-O-methylcytidine; 5,2′-O-dimethylcytidine;5-formyl-2′-O-methylcytidine; Lysidine; N4,2′-O-dimethylcytidine;N4-acetyl-2′-O-methylcytidine; N4-methylcytidine;N4,N4-Dimethyl-2′-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine;Pseudo-iso-cytidine; pyrrolo-cytidine; a-thio-cytidine;2-(thio)cytosine; 2′-Amino-2′-deoxy-CTP; 2′-Azido-2′-deoxy-CTP;2′-Deoxy-2′-a-aminocytidine TP; 2′-Deoxy-2′-a-azidocytidine TP; 3(deaza) 5 (aza)cytosine; 3 (methyl)cytosine; 3-(alkyl)cytosine;3-(deaza) 5 (aza)cytosine; 3-(methyl)cytidine; 4,2′-O-dimethylcytidine;5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5(trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine;5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine;5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6-(azo)cytosine;6-aza-cytidine; aza cytosine; deaza cytosine; N4 (acetyl)cytosine;1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine;2-methoxy-5-methyl-cytidine; 2-methoxy-cytidine;2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine;4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine;4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine;5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine;Zebularine; (E)-5-(2-Bromo-vinyl)cytidine TP; 2,2′-anhydro-cytidine TPhydrochloride; 2′Fluor-N4-Bz-cytidine TP; 2′Fluoro-N4-Acetyl-cytidineTP; 2′-O-Methyl-N4-Acetyl-cytidine TP; 2′0-methyl-N4-Bz-cytidine TP;2′-a-Ethynylcytidine TP; 2′-a-Trifluoromethylcytidine TP;2′-b-Ethynylcytidine TP; 2′-b-Trifluoromethylcytidine TP;2′-Deoxy-2′,2′-difluorocytidine TP; 2′-Deoxy-2′-a-mercaptocytidine TP;2′-Deoxy-2′-a-thiomethoxycytidine TP; 2′-Deoxy-2′-b-aminocytidine TP;2′-Deoxy-2′-b-azidocytidine TP; 2′-Deoxy-2′-b-bromocytidine TP;2′-Deoxy-2′-b-chlorocytidine TP; 2′-Deoxy-2′-b-fluorocytidine TP;2′-Deoxy-2′-b-iodocytidine TP; 2′-Deoxy-2′-b-mercaptocytidine TP;2′-Deoxy-2′-b-thiomethoxycytidine TP; 2′-O-Methyl-5-(1-propynyl)cytidineTP; 3′-Ethynylcytidine TP; 4′-Azidocytidine TP; 4′-Carbocyclic cytidineTP; 4′-Ethynylcytidine TP; 5-(1-Propynyl)ara-cytidine TP;5-(2-Chloro-phenyl)-2-thiocytidine TP; 5-(4-Amino-phenyl)-2-thiocytidineTP; 5-Aminoallyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP;5-Ethynylcytidine TP; 5′-Homo-cytidine TP; 5-Methoxycytidine TP;5-Trifluoromethyl-Cytidine TP; N4-Amino-cytidine TP; N4-Benzoyl-cytidineTP; Pseudoisocytidine; 7-methylguanosine; N2,2′-O-dimethylguanosine;N2-methylguanosine; Wyosine; 1,2′-O-dimethylguanosine;1-methylguanosine; 2′-O-methylguanosine; 2′-O-ribosylguanosine(phosphate); 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate);7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine;Methylwyosine; N2,7-dimethylguanosine; N2,N2,2′-O-trimethylguanosine;N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine;N2,7,2′-O-trimethylguanosine; 6-thio-guanosine; 7-deaza-guanosine;8-oxo-guanosine; N1-methyl-guanosine; α-thio-guanosine; 2(propyl)guanine; 2-(alkyl)guanine; 2′-Amino-2′-deoxy-GTP;2′-Azido-2′-deoxy-GTP; 2′-Deoxy-2′-a-aminoguanosine TP;2′-Deoxy-2′-a-azidoguanosine TP; 6 (methyl)guanine; 6-(alkyl)guanine;6-(methyl)guanine; 6-methyl-guanosine; 7 (alkyl)guanine; 7(deaza)guanine; 7 (methyl)guanine; 7-(alkyl)guanine; 7-(deaza)guanine;7-(methyl)guanine; 8 (alkyl)guanine; 8 (alkynyl)guanine; 8(halo)guanine; 8 (thioalkyl)guanine; 8-(alkenyl)guanine;8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine;8-(hydroxyl)guanine; 8-(thioalkyl)guanine; 8-(thiol)guanine; azaguanine; deaza guanine; N (methyl)guanine; N-(methyl)guanine;1-methyl-6-thio-guanosine; 6-methoxy-guanosine;6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine;6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine;7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thio-guanosine;N2-methyl-6-thio-guanosine; 1-Me-GTP; 2′Fluoro-N2-isobutyl-guanosine TP;2′0-methyl-N2-isobutyl-guanosine TP; 2′-a-Ethynylguanosine TP;2′-a-Trifluoromethylguanosine TP; 2′-b-Ethynylguanosine TP;2′-b-Trifluoromethylguanosine TP; 2′-Deoxy-2′,2′-difluoroguanosine TP;2′-Deoxy-2′-a-mercaptoguanosine TP; 2′-Deoxy-2′-a-thiomethoxyguanosineTP; 2′-Deoxy-2′-b-aminoguanosine TP; 2′-Deoxy-2′-b-azidoguanosine TP;2′-Deoxy-2′-b-bromoguanosine TP; 2′-Deoxy-2′-b-chloroguanosine TP;2′-Deoxy-2′-b-fluoroguanosine TP; 2′-Deoxy-2′-b-iodoguanosine TP;2′-Deoxy-2′-b-mercaptoguanosine TP; 2′-Deoxy-2′-b-thiomethoxyguanosineTP; 4′-Azidoguanosine TP; 4′-Carbocyclic guanosine TP;4′-Ethynylguanosine TP; 5′-Homo-guanosine TP; 8-bromo-guanosine TP;9-Deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; Inosine;1,2′-O-dimethylinosine; 2′-O-methylinosine; 7-methylinosine;2′-O-methylinosine; Epoxyqueuosine; galactosyl-queuosine;Mannosylqueuosine; Queuosine; allyamino-thymidine; aza thymidine; deazathymidine; deoxy-thymidine; 2′-O-methyluridine; 2-thiouridine;3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine;5-methyluridine; 5-taurinomethyl-2-thiouridine; 5-taurinomethyluridine;Dihydrouridine; Pseudouridine; (3-(3-amino-3-carboxypropyl)uridine;1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine;1-methylpseduouridine; 1-methyl-pseudouridine; 2′-O-methyluridine;2′-O-methylpseudouridine; 2′-O-methyluridine; 2-thio-2′-O-methyluridine;3-(3-amino-3-carboxypropyl)uridine; 3,2′-O-dimethyluri dine;3-Methyl-pseudo-Uridine TP; 4-thiouridine;5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methylester; 5,2′-O-dimethyluridine; 5,6-dihydro-uridine;5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2′-O-methyluridine;5-carbamoylmethyluridine; 5-carboxyhydroxymethyluridine;5-carboxyhydroxymethyluridine methyl ester;5-carboxymethylaminomethyl-2′-O-methyluridine;5-carboxymethylaminomethyl-2-thiouridine;5-carboxymethylaminomethyl-2-thiouridine;5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine;5-Carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2′-O-methyluridine;5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine;5-methoxyuridine; 5-methyl-2-thiouridine;5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine;5-methylaminomethyluridine; 5-Methyldihydrouridine; 5-Oxyaceticacid-Uridine TP; 5-Oxyacetic acid-methyl ester-Uridine TP;N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyaceticacid methyl ester; 3-(3-Amino-3-carboxypropyl)-Uridine TP;5-(iso-Pentenylaminomethyl)-2-thiouridine TP;5-(iso-Pentenylaminomethyl)-2′-O-methyluridine TP;5-(iso-Pentenylaminomethyl)uridine TP; 5-propynyl uracil;α-thio-uridine; 1(aminoalkylamino-carbonylethylenyl)-2(thio)-pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-4 (thio)pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-pseudouracil; 1(aminocarbonylethylenyl)-2(thio)-pseudouracil; 1(aminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1(aminocarbonylethylenyl)-4 (thio)pseudouracil; 1(aminocarbonylethylenyl)-p seudouracil; 1 substituted2(thio)-pseudouracil; 1 substituted 2,4-(dithio)pseudouracil; 1substituted 4 (thio)pseudouracil; 1 substituted pseudouracil;1-(aminoalkylamino-carbonylethylenyl)-2-(thio)-pseudouracil;1-Methyl-3-(3-amino-3-carboxypropyl) pseudouridine TP;1-Methyl-3-(3-amino-3-carboxypropyl)pseudo-UTP; 1-Methyl-pseudo-UTP; 2(thio)pseudouracil; 2′ deoxy uridine; 2′ fluorouridine; 2-(thio)uracil;2,4-(dithio)psuedouracil; 2′ methyl, 2′ amino, 2′azido,2′fluro-guanosine; 2′-Amino-2′-deoxy-UTP; 2′-Azido-2′-deoxy-UTP;2′-Azido-deoxyuridine TP; 2′-O-methylpseudouridine; 2′ deoxy uridine; 2′fluorouridine; 2′-Deoxy-2′-a-aminouridine TP; 2′-Deoxy-2′-a-azidouridineTP; 2-methylpseudouridine; 3 (3 amino-3 carboxypropyl)uracil; 4(thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil;5 (1,3-diazole-1-alkyl)uracil; 5 (2-aminopropyl)uracil; 5(aminoalkyl)uracil; 5 (dimethylaminoalkyl)uracil; 5(guanidiniumalkyl)uracil; 5 (methoxycarbonylmethyl)-2-(thio)uracil; 5(methoxycarbonyl-methyl)uracil; 5 (methyl) 2 (thio)uracil; 5 (methyl)2,4 (dithio)uracil; 5 (methyl) 4 (thio)uracil; 5 (methylaminomethyl)-2(thio)uracil; 5 (methylaminomethyl)-2,4 (dithio)uracil; 5(methylaminomethyl)-4 (thio)uracil; 5 (propynyl)uracil; 5(trifluoromethyl)uracil; 5-(2-aminopropyl)uracil;5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4 (dithio)pseudouracil;5-(alkyl)-4 (thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil;5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil;5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil;5-(guanidiniumalkyl)uracil; 5-(halo)uracil;5-(1,3-diazole-1-alkyl)uracil; 5-(methoxy)uracil;5-(methoxycarbonylmethyl)-2-(thio)uracil;5-(methoxycarbonyl-methyl)uracil; 5-(methyl) 2(thio)uracil; 5-(methyl)2,4 (dithio)uracil; 5-(methyl) 4 (thio)uracil;5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4 (dithio)pseudouracil;5-(methyl)-4 (thio)pseudouracil; 5-(methyl)pseudouracil;5-(methylaminomethyl)-2 (thio)uracil;5-(methylaminomethyl)-2,4(dithio)uracil;5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil;5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine;5-iodo-uridine; 5-uracil; 6 (azo)uracil; 6-(azo)uracil; 6-aza-uridine;allyamino-uracil; aza uracil; deaza uracil; N3 (methyl)uracil;Pseudo-UTP-1-2-ethanoic acid; Pseudouracil; 4-Thio-pseudo-UTP;1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine;1-propynyl -uridine; 1-taurinomethyl-1-methyl -uridine; 1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine;2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine;2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine;2-thio-dihydropseudouridine; 2-thio-dihydrouridine;2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine;4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine;4-thio-pseudouridine; 5-aza-uridine; Dihydropseudouridine;(±)1-(2-Hydroxypropyl)pseudouridine TP;(2R)-1-(2-Hydroxypropyl)pseudouridine TP;(2S)-1-(2-Hydroxypropyl)pseudouridine TP;(E)-5-(2-Bromo-vinyl)ara-uridine TP; (E)-5-(2-Bromo-vinyl)uridine TP;(Z)-5-(2-Bromo-vinyl)ara-uridine TP; (Z)-5-(2-Bromo-vinyl)uridine TP;1-(2,2,2-Trifluoroethyl)-pseudo-UTP;1-(2,2,3,3,3-Pentafluoropropyl)pseudouridine TP;1-(2,2-Diethoxyethyl)pseudouridine TP;1-(2,4,6-Trimethylbenzyl)pseudouridine TP;1-(2,4,6-Trimethyl-benzyl)pseudo-UTP;1-(2,4,6-Trimethyl-phenyl)pseudo-UTP;1-(2-Amino-2-carboxyethyl)pseudo-UTP; 1-(2-Amino-ethyl)pseudo-UTP;1-(2-Hydroxyethyl)pseudouridine TP; 1-(2-Methoxyethyl)pseudouridine TP;1-(3 ,4-Bis-trifluoromethoxybenzyl)pseudouridine TP;1-(3,4-Dimethoxybenzyl)pseudouridine TP;1-(3-Amino-3-carboxypropyl)pseudo-UTP; 1-(3-Amino-propyl)pseudo-UTP;1-(3-Cyclopropyl-prop-2-ynyl)pseudouridine TP;1-(4-Amino-4-carboxybutyl)pseudo-UTP; 1-(4-Amino-benzyl)pseudo-UTP;1-(4-Amino-butyl)pseudo-UTP; 1-(4-Amino-phenyl)pseudo-UTP;1-(4-Azidobenzyl)pseudouridine TP; 1-(4-Bromobenzyl)pseudouridine TP;1-(4-Chlorobenzyl)pseudouridine TP; 1-(4-Fluorobenzyl)pseudouridine TP;1-(4-Iodobenzyl)pseudouridine TP;1-(4-Methanesulfonylbenzyl)pseudouridine TP;1-(4-Methoxybenzyl)pseudouridine TP; 1-(4-Methoxy-benzyl)pseudo-UTP;1-(4-Methoxy-phenyl)pseudo-UTP; 1-(4-Methylbenzyl)pseudouridine TP;1-(4-Methyl-benzyl)pseudo-UTP; 1-(4-Nitrobenzyl)pseudouridine TP;1-(4-Nitro-benzyl)pseudo-UTP; 1(4-Nitro-phenyl)pseudo-UTP;1-(4-Thiomethoxybenzyl)pseudouridine TP;1-(4-Trifluoromethoxybenzyl)pseudouridine TP;1-(4-Trifluoromethylbenzyl)pseudouridine TP;1-(5-Amino-pentyl)pseudo-UTP; 1-(6-Amino-hexyl)pseudo-UTP;1,6-Dimethyl-pseudo-UTP;1-[3-(2-{2-[2-(2-Aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridineTP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]-propionyl}pseudouridine TP;1-Acetylpseudouridine TP; 1-Alkyl-6-(1-propynyl)-pseudo-UTP;1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-Alkyl-6-allyl-pseudo-UTP;1-Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP;1-Alkyl-6-vinyl-pseudo-UTP; 1-Allylpseudouridine TP;1-Aminomethyl-pseudo-UTP; 1-Benzoylpseudouridine TP;1-Benzyloxymethylpseudouridine TP; 1-B enzyl-pseudo-UTP;1-Biotinyl-PEG2-pseudouridine TP; 1-Biotinylpseudouridine TP;1-Butyl-pseudo-UTP; 1-Cyanomethylpseudouridine TP;1-Cyclobutylmethyl-pseudo-UTP; 1-Cyclobutyl-pseudo-UTP;1-Cycloheptylmethyl-pseudo-UTP; 1-Cycloheptyl-pseudo-UTP;1-Cyclohexylmethyl-pseudo-UTP; 1-Cyclohexyl-pseudo-UTP;1-Cyclooctylmethyl-pseudo-UTP; 1-Cyclooctyl-pseudo-UTP;1-Cyclopentylmethyl-pseudo-UTP; 1-Cyclopentyl-pseudo-UTP;1-Cyclopropylmethyl-pseudo-UTP; 1-Cyclopropyl-pseudo-UTP;1-Ethyl-pseudo-UTP; 1-Hexyl-pseudo-UTP; 1-Homoallylpseudouridine TP;1-Hydroxymethylpseudouridine TP; 1-iso-propyl-pseudo-UTP;1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP;1-Me-alpha-thio-pseudo-UTP; 1-Methanesulfonylmethylpseudouridine TP;1-Methoxymethylpseudouridine TP;1-Methyl-6-(2,2,2-Trifluoroethyl)pseudo-UTP;1-Methyl-6-(4-morpholino)-pseudo-UTP;1-Methyl-6-(4-thiomorpholino)-pseudo-UTP; 1-Methyl-6-(substitutedphenyl)pseudo-UTP; 1-Methyl-6-amino-pseudo-UTP;1-Methyl-6-azido-pseudo-UTP; 1-Methyl-6-bromo-pseudo-UTP;1-Methyl-6-butyl-pseudo-UTP; 1-Methyl-6-chloro-pseudo-UTP;1-Methyl-6-cyano-pseudo-UTP; 1-Methyl-6-dimethylamino-pseudo-UTP;1-Methyl-6-ethoxy-pseudo-UTP; 1-Methyl-6-ethylcarboxylate-pseudo-UTP;1-Methyl-6-ethyl-pseudo-UTP; 1-Methyl-6-fluoro-pseudo-UTP;1-Methyl-6-formyl-pseudo-UTP; 1-Methyl-6-hydroxyamino-pseudo-UTP;1-Methyl-6-hydroxy-pseudo-UTP; 1-Methyl-6-iodo-pseudo-UTP;1-Methyl-6-iso-propyl-pseudo-UTP; 1-Methyl-6-methoxy-pseudo-UTP;1-Methyl-6-methylamino-pseudo-UTP; 1-Methyl-6-phenyl-pseudo-UTP;1-Methyl-6-propyl-pseudo-UTP; 1-Methyl-6-tert-butyl-pseudo-UTP;1-Methyl-6-trifluoromethoxy-pseudo-UTP;1-Methyl-6-trifluoromethyl-pseudo-UTP; 1-MorpholinomethylpseudouridineTP; 1-Pentyl-pseudo-UTP; 1-Phenyl-pseudo-UTP; 1-PivaloylpseudouridineTP; 1-Propargylpseudouridine TP; 1-Propyl-pseudo-UTP;1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-Butyl-pseudo-UTP;1-Thiomethoxymethylpseudouridine TP; 1-ThiomorpholinomethylpseudouridineTP; 1-Trifluoroacetylpseudouridine TP; 1-Trifluoromethyl-pseudo-UTP;1-Vinylpseudouridine TP; 2,2′-anhydro-uridine TP; 2′-bromo-deoxyuridineTP; 2′-F-5-Methyl-2′-deoxy-UTP; 2′-OMe-5-Me-UTP; 2′-OMe-pseudo-UTP;2′-a-Ethynyluridine TP; 2′-a-Trifluoromethyluridine TP;2′-b-Ethynyluridine TP; 2′-b-Trifluoromethyluridine TP;2′-Deoxy-2′,2′-difluorouridine TP; 2′-Deoxy-2′-a-mercaptouridine TP;2′-Deoxy-2′-a-thiomethoxyuridine TP; 2′-Deoxy-2′-b-aminouridine TP;2′-Deoxy-2′-b-azidouridine TP; 2′-Deoxy-2′-b-bromouridine TP;2′-Deoxy-2′-b-chlorouridine TP; 2′-Deoxy-2′-b-fluorouridine TP;2′-Deoxy-2′-b-iodouridine TP; 2′-Deoxy-2′-b-mercaptouridine TP;2′-Deoxy-2′-b-thiomethoxyuridine TP; 2-methoxy-4-thio-uridine;2-methoxyuridine; 2′-O-Methyl-5-(1-propynyl)uridine TP;3-Alkyl-pseudo-UTP; 4′-Azidouridine TP; 4′-Carbocyclic uridine TP;4′-Ethynyluridine TP; 5-(1-Propynyl)ara-uridine TP; 5-(2-Furanyl)uridineTP; 5-Cyanouridine TP; 5-Dimethylaminouridine TP; 5′-Homo-uridine TP;5-iodo-2′-fluoro-deoxyuridine TP; 5-Phenylethynyluridine TP;5-Trideuteromethyl-6-deuterouridine TP; 5-Trifluoromethyl-Uridine TP;5-Vinylarauridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP;6-(4-Morpholino)-pseudo-UTP; 6-(4-Thiomorpholino)-pseudo-UTP;6-(Substituted-Phenyl)-pseudo-UTP; 6-Amino-pseudo-UTP;6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP;6-Chloro-pseudo-UTP; 6-Cyano-pseudo-UTP; 6-Dimethylamino-pseudo-UTP;6-Ethoxy-pseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP;6-Fluoro-pseudo-UTP; 6-Formyl-pseudo-UTP; 6-Hydroxyamino-pseudo-UTP;6-Hydroxy-pseudo-UTP; 6-Iodo-pseudo-UTP; 6-iso-Propyl-pseudo-UTP;6-Methoxy-pseudo-UTP; 6-Methylamino-pseudo-UTP; 6-Methyl-pseudo-UTP;6-Phenyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP;6-tert-Butyl-pseudo-UTP; 6-Trifluoromethoxy-pseudo-UTP;6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudo-UTP; Pseudouridine1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1-(4-methylbenzoicacid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; PseudouridineTP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid;Pseudouridine TP1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionicacid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionicacid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}] propionic acid;Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP1-methylphosphonic acid diethyl ester; Pseudo-UTP-N1-3-propionic acid;Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid;Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid;Pseudo-UTP-N1-methyl-p-benzoic acid; Pseudo-UTP-N1-p-benzoic acid;Wybutosine; Hydroxywybutosine; Isowyosine; Peroxywybutosine;undermodified hydroxywybutosine; 4-demethylwyosine; 2,6-(diamino)purine;1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl:1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;1,3,5-(triaza)-2,6-(dioxa)-naphthalene; 2(amino)purine;2,4,5-(trimethyl)phenyl; 2′ methyl, 2′amino, 2′azido, 2′fluro-cytidine;2′ methyl, 2′amino, 2′azido, 2′fluro-adenine; 2′methyl, 2′amino,2′azido, 2′fluro-uridine; 2′-amino-2′-deoxyribose;2-amino-6-Chloro-purine; 2-aza-inosinyl; 2′-azido-2′-deoxyribose;2′fluoro-2′-deoxyribose; 2′-fluoro-modified bases; 2′-O-methyl-ribose;2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidine-3-yl;2-pyridinone; 3 nitropyrrole; 3-(methyl)-7-(propynyl)isocarbostyrilyl;3-(methyl)isocarbostyrilyl; 4-(fluoro)-6-(methyl)benzimidazole;4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5nitroindole; 5 substituted pyrimidines; 5-(methyl)isocarbostyrilyl;5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine;6-(methyl)-7-(aza)indolyl; 6-chloro-purine;6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl;7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(aza)indolyl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazinl-yl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl;7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(guanidiniumalkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(propynyl)isocarbostyrilyl; 7-(propynyl)isocarbostyrilyl,propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidizopyridinyl;Aminoindolyl; Anthracenyl;bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl;Isocarbostyrilyl; Isoguanisine; N2-substituted purines;N6-methyl-2-amino-purine; N6-substituted purines; N-alkylatedderivative; Napthalenyl; Nitrobenzimidazolyl; Nitroimidazolyl;Nitroindazolyl; Nitropyrazolyl; Nubularine; O6-substituted purines;O-alkylated derivative;ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Oxoformycin TP;para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;para-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Pentacenyl;Phenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl;pyridopyrimidin-3-yl; pyridopyrimidin-3-yl,2-oxo-7-amino-pyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-on-3-yl;Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Stilbenzyl; substituted1,2,4-triazoles; Tetracenyl; Tubercidine; Xanthine; Xanthosine-5′-TP;2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine;pyridin-4-one ribonucleoside; 2-Amino-riboside-TP; Formycin A TP;Formycin B TP; Pyrrolosine TP; 2′-OH-ara-adenosine TP;2′-OH-ara-cytidine TP; 2′-OH-ara-uridine TP; 2′-OH-ara-guanosine TP;5-(2-carbomethoxyvinyl)uridine TP; andN6-(19-Amino-pentaoxanonadecyl)adenosine TP.

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) include a combination of at least two (e.g., 2, 3,4 or more) of the aforementioned modified nucleobases.

In some embodiments, modified nucleobases in polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) are selected from thegroup consisting of pseudouridine (ψ), N1-methylpseudouridine (m¹ψ),2-thiouridine, N1-ethylpseudouridine, 4′-thiouridine, 5-methylcytosine,2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine,2-thio-5-aza-uridine , 2-thio-dihydropseudouridine,2-thio-dihydrouridine, 2-thio-pseudouridine,4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine,4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine,dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In someembodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNApolynucleotides) include a combination of at least two (e.g., 2, 3, 4 ormore) of the aforementioned modified nucleobases.

In some embodiments, modified nucleobases in polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) are selected from thegroup consisting of 1-methyl-pseudouridine (m¹ψ), 5-methoxy-uridine(mo⁵U), 5-methyl-cytidine (m⁵C), pseudouridine (ψ), α-thio-guanosine andα-thio-adenosine. In some embodiments, polynucleotides includes acombination of at least two (e.g., 2, 3, 4 or more) of theaforementioned modified nucleobases.

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) comprise pseudouridine (ψ) and 5-methyl-cytidine(m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides,such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ). Insome embodiments, polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ) and5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine(s²U). In some embodiments, polynucleotides (e.g., RNA polynucleotides,such as mRNA polynucleotides) comprise 2-thiouridine and5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) comprise methoxy-uridine(mo⁵U). In some embodiments, polynucleotides (e.g., RNA polynucleotides,such as mRNA polynucleotides) comprise 5-methoxy-uridine (mo⁵U) and5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) comprise 2′-O-methyluridine. In some embodiments polynucleotides (e.g., RNA polynucleotides,such as mRNA polynucleotides) comprise 2′-O-methyl uridine and5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNApolynucleotides, such as mRNA polynucleotides) compriseN6-methyl-adenosine (m⁶A). In some embodiments, polynucleotides (e.g.,RNA polynucleotides, such as mRNA polynucleotides) compriseN6-methyl-adenosine (m⁶A) and 5-methyl-cytidine (m⁵C).

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) are uniformly modified (e.g., fully modified,modified throughout the entire sequence) for a particular modification.For example, a polynucleotide can be uniformly modified with5-methyl-cytidine (m⁵C), meaning that all cytosine residues in the mRNAsequence are replaced with 5-methyl-cytidine (m⁵C). Similarly, apolynucleotide can be uniformly modified for any type of nucleosideresidue present in the sequence by replacement with a modified residuesuch as those set forth above.

Exemplary nucleobases and nucleosides having a modified cytosine includeN4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine(e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C),1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), and2-thio-5-methyl-cytidine.

In some embodiments, a modified nucleobase is a modified uridine.Exemplary nucleobases and In some embodiments, a modified nucleobase isa modified cytosine. nucleosides having a modified uridine include5-cyano uridine, and 4′-thio uridine.

In some embodiments, a modified nucleobase is a modified adenine.Exemplary nucleobases and nucleosides having a modified adenine include7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), andN6-methyl-adenosine (m6A).

In some embodiments, a modified nucleobase is a modified guanine.Exemplary nucleobases and nucleosides having a modified guanine includeinosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine(mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQO),7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G),1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.

The polynucleotides of the present disclosure may be partially or fullymodified along the entire length of the molecule. For example, one ormore or all or a given type of nucleotide (e.g., purine or pyrimidine,or any one or more or all of A, G, U, C) may be uniformly modified in apolynucleotide of the invention, or in a given predetermined sequenceregion thereof (e.g., in the mRNA including or excluding the polyAtail). In some embodiments, all nucleotides X in a polynucleotide of thepresent disclosure (or in a given sequence region thereof) are modifiednucleotides, wherein X may any one of nucleotides A, G, U, C, or any oneof the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C orA+G+C.

The polynucleotide may contain from about 1% to about 100% modifiednucleotides (either in relation to overall nucleotide content, or inrelation to one or more types of nucleotide, i.e., any one or more of A,G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1%to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%,from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10%to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%,from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%,from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%,from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%,from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%,from 90% to 100%, and from 95% to 100%). Any remaining percentage isaccounted for by the presence of unmodified A, G, U, or C.

The polynucleotides may contain at a minimum 1% and at maximum 100%modified nucleotides, or any intervening percentage, such as at least 5%modified nucleotides, at least 10% modified nucleotides, at least 25%modified nucleotides, at least 50% modified nucleotides, at least 80%modified nucleotides, or at least 90% modified nucleotides. For example,the polynucleotides may contain a modified pyrimidine such as a modifieduracil or cytosine. In some embodiments, at least 5%, at least 10%, atleast 25%, at least 50%, at least 80%, at least 90% or 100% of theuracil in the polynucleotide is replaced with a modified uracil (e.g., a5-substituted uracil). The modified uracil can be replaced by a compoundhaving a single unique structure, or can be replaced by a plurality ofcompounds having different structures (e.g., 2, 3, 4 or more uniquestructures). n some embodiments, at least 5%, at least 10%, at least25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine inthe polynucleotide is replaced with a modified cytosine (e.g., a5-substituted cytosine). The modified cytosine can be replaced by acompound having a single unique structure, or can be replaced by aplurality of compounds having different structures (e.g., 2, 3, 4 ormore unique structures).

Thus, in some embodiments, the RNA (e.g., mRNA) vaccines comprise a5′UTR element, an optionally codon optimized open reading frame, and a3′UTR element, a poly(A) sequence and/or a polyadenylation signalwherein the RNA is not chemically modified.

In some embodiments, the modified nucleobase is a modified uracil.Exemplary nucleobases and nucleosides having a modified uracil includepseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine,6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s²U),4-thio-uridine (s⁴U), 4-thio-pseudouridine, 2-thio-pseudouridine,5-hydroxy-uridine (ho⁵U), 5-aminoallyl-uridine, 5-halo-uridine (e.g.,5-iodo-uridineor 5-bromo-uridine), 3-methyl-uridine (m³U),5-methoxy-uridine (mo⁵U), uridine 5-oxyacetic acid (cmo⁵U), uridine5-oxyacetic acid methyl ester (mcmo⁵U), 5-carboxymethyl-uridine (cm⁵U),1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm⁵U),5-carboxyhydroxymethyl-uridine methyl ester (mchm⁵U),5-methoxycarbonylmethyl-uridine (mcm⁵U),5-methoxycarbonylmethyl-2-thio-uridine (mcm⁵s²U),5-aminomethyl-2-thio-uridine (nm⁵s²U), 5-methylaminomethyl-uridine(mnm⁵U), 5-methylaminomethyl-2-thio-uridine (mnm⁵s²U),5-methylaminomethyl-2-seleno-uridine (mnm⁵se²U),5-carbamoylmethyl-uridine (ncm⁵U), 5-carboxymethylaminomethyl-uridine(cmnm⁵U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm⁵s²U),5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine(τm⁵U), 1-taurinomethyl-pseudouridine,5-taurinomethyl-2-thio-uridine(τm⁵ s²U),1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m⁵U, i.e.,having the nucleobase deoxythymine), 1-methyl-pseudouridine (m¹ψ),5-methyl-2-thio-uridine (m⁵ s²U), 1-methyl-4-thio-pseudouridine (m¹s⁴ψ),4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m³ψ),2-thio-1-methyl-pseudouridine, 1-methyl -1-deaza-p seudouri dine,2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D),dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m⁵D),2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine,2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine,4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine,3-(3-amino-3-carboxypropyl)uridine (acp³U),1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ ψ),5-(isopentenylaminomethyl)uridine (inm⁵U),5-(isopentenylaminomethyl)-2-thio-uridine (inm⁵s²U), α-thio-uridine,2′-O-methyl-uridine (Um), 5,2′-O-dimethyl-uridine (m⁵Um),2′-O-methyl-pseudouridine (ψm), 2-thio-2′-O-methyl-uridine (s²Um),5-methoxycarbonylmethyl-2′-O-methyl-uridine (mcm⁵Um),5-carbamoylmethyl-2′-O-methyl-uridine (ncm⁵Um),5-carboxymethylaminomethyl-2′-O-methyl-uridine (cmnm⁵Um),3,2′-O-dimethyl-uridine (m³Um), and5-(isopentenylaminomethyl)-2′-O-methyl-uridine (inm⁵Um), 1-thio-uridine,deoxythymidine, 2′-F-ara-uridine, 2′-F-uridine, 2′-OH-ara-uridine,5-(2-carbomethoxyvinyl) uridine, and 5-[3-(1-E-propenylamino)]uridine.

In some embodiments, the modified nucleobase is a modified cytosine.Exemplary nucleobases and nucleosides having a modified cytosine include5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine(m³C), N4-acetyl-cytidine (ac⁴C), 5-formyl-cytidine (f⁵C),N4-methyl-cytidine (m⁴C), 5-methyl-cytidine (m⁵C), 5-halo-cytidine(e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm⁵C),1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine,2-thio-cytidine (s²C), 2-thio-5-methyl-cytidine,4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine,4-thio-1-methyl-1-deaza-pseudoisocytidine,1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine,5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine,2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine,4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine,lysidine (k₂C), α-thio-cytidine, 2′-O-methyl-cytidine (Cm),5,2′-O-dimethyl-cytidine (m⁵Cm), N4-acetyl-2′-O-methyl-cytidine (ac⁴Cm),N4,2′-O-dimethyl-cytidine (m⁴Cm), 5-formyl-2′-O-methyl-cytidine (f⁵Cm),N4,N4,2′-O-trimethyl-cytidine (m⁴ ₂Cm), 1-thio-cytidine,2′-F-ara-cytidine, 2′-F-cytidine, and 2′-OH-ara-cytidine.

In some embodiments, the modified nucleobase is a modified adenine.Exemplary nucleobases and nucleosides having a modified adenine include2-amino-purine, 2, 6-diaminopurine, 2-amino-6-halo-purine (e.g.,2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine),2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine,7-deaza-8-aza-adenine, 7-deaza-2-amino-purine,7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine,7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m¹A),2-methyl-adenine (m²A), N6-methyl-adenosine (m⁶A),2-methylthio-N6-methyl-adenosine (ms²m⁶A), N6-isopentenyl-adenosine(i⁶A), 2-methylthio-N6-isopentenyl-adenosine (ms²i⁶A),N6-(cis-hydroxyisopentenyl)adenosine (io⁶A),2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms²io⁶A),N6-glycinylcarbamoyl-adenosine (g⁶A), N6-threonylcarbamoyl-adenosine(t⁶A), N6-methyl-N6-threonylcarbamoyl-adenosine (m⁶t⁶A),2-methylthio-N6-threonylcarbamoyl-adenosine (ms²g⁶A),N6,N6-dimethyl-adenosine (m⁶ ₂A), N6-hydroxynorvalylcarbamoyl-adenosine(hn⁶A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms²hn⁶A),N6-acetyl-adenosine (ac⁶A), 7-methyl-adenine, 2-methylthio-adenine,2-methoxy-adenine, α-thio-adenosine, 2′-O-methyl-adenosine (Am),N6,2′-O-dimethyl-adenosine (m⁶Am), N6,N6,2′-O-trimethyl-adenosine (m⁶₂Am), 1,2′-O-dimethyl-adenosine (m′Am), 2′-O-ribosyladenosine(phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine,8-azido-adenosine, 2′-F-ara-adenosine, 2′-F-adenosine,2′-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

In some embodiments, the modified nucleobase is a modified guanine.Exemplary nucleobases and nucleosides having a modified guanine includeinosine (I), 1-methyl-inosine (m¹I), wyosine (imG), methylwyosine(mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW),peroxywybutosine (o₂yW), hydroxywybutosine (OhyW), undermodifiedhydroxywybutosine (OhyW*), 7-deaza-guanosine, queuosine (Q),epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine(manQ), 7-cyano-7-deaza-guanosine (preQ₀),7-aminomethyl-7-deaza-guanosine (preQ₁), archaeosine (G⁺),7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine,6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m⁷G),6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine,1-methyl-guanosine (m⁷G), N2-methyl-guanosine (m²G),N2,N2-dimethyl-guanosine (m² ₂G), N2,7-dimethyl-guanosine (m²′⁷G), N2,N2,7-dimethyl-guanosine 8-oxo-guanosine, 7-methyl-8-oxo-guanosine,1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine,N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2′-O-methyl-guanosine(Gm), N2-methyl-2′-O-methyl-guanosine (m²Gm),N2,N2-dimethyl-2′-O-methyl-guanosine (m² ₂Gm),1-methyl-2′-O-methyl-guanosine (m¹Gm),N2,7-dimethyl-2′-O-methyl-guanosine (m²′⁷Gm), 2′-O-methyl-inosine (Im),1,2′-O-dimethyl-inosine (m¹Im), 2′-O-ribosylguanosine (phosphate)(Gr(p)) , 1-thio-guanosine, 06-methyl-guanosine, 2′-F-ara-guanosine, and2′-F-guanosine.

In Vitro Transcription of RNA (e.g., mRNA)

Influenza virus vaccines of the present disclosure comprise at least oneRNA polynucleotide, such as a mRNA (e.g., modified mRNA). mRNA, forexample, is transcribed in vitro from template DNA, referred to as an“in vitro transcription template.” In some embodiments, an in vitrotranscription template encodes a 5′ untranslated (UTR) region, containsan open reading frame, and encodes a 3′ UTR and a polyA tail. Theparticular nucleic acid sequence composition and length of an in vitrotranscription template will depend on the mRNA encoded by the template.

A “5′ untranslated region” (5′UTR) refers to a region of an mRNA that isdirectly upstream (i.e., 5′) from the start codon (i.e., the first codonof an mRNA transcript translated by a ribosome) that does not encode apolypeptide.

A “3′ untranslated region” (3′UTR) refers to a region of an mRNA that isdirectly downstream (i.e., 3′) from the stop codon (i.e., the codon ofan mRNA transcript that signals a termination of translation) that doesnot encode a polypeptide.

An “open reading frame” is a continuous stretch of DNA or RNA beginningwith a start codon (e.g., methionine (ATG or AUG)), and ending with astop codon (e.g., TAA, TAG or TGA, or UAA, UAG or UGA) and typicallyencodes a polypeptide (e.g., protein).

A “polyA tail” is a region of mRNA that is downstream, e.g., directlydownstream (i.e., 3′), from the 3′ UTR that contains multiple,consecutive adenosine monophosphates. A polyA tail may contain 10 to 300adenosine monophosphates. For example, a polyA tail may contain 10, 20,30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180,190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosinemonophosphates. In some embodiments, a polyA tail contains 50 to 250adenosine monophosphates. In a relevant biological setting (e.g., incells, in vivo) the poly(A) tail functions to protect mRNA fromenzymatic degradation, e.g., in the cytoplasm, and aids in transcriptiontermination, export of the mRNA from the nucleus and translation.

In some embodiments, a polynucleotide includes 200 to 3,000 nucleotides.For example, a polynucleotide may include 200 to 500, 200 to 1000, 200to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to3000 nucleotides.

Flagellin Adjuvants

Flagellin is an approximately 500 amino acid monomeric protein thatpolymerizes to form the flagella associated with bacterial motion.Flagellin is expressed by a variety of flagellated bacteria (Salmonellatyphimurium for example) as well as non-flagellated bacteria (such asEscherichia coli). Sensing of flagellin by cells of the innate immunesystem (dendritic cells, macrophages, etc.) is mediated by the Toll-likereceptor 5 (TLRS) as well as by Nod-like receptors (NLRs) Ipaf andNaip5. TLRs and NLRs have been identified as playing a role in theactivation of innate immune response and adaptive immune response.

As such, flagellin provides an adjuvant effect in a vaccine.

The nucleotide and amino acid sequences encoding known flagellinpolypeptides are publicly available in the NCBI GenBank database. Theflagellin sequences from S. Typhimurium, H. Pylori, V. Cholera, S.marcesens, S. flexneri, T Pallidum, L. pneumophila, B. burgdorferei, C.difficile, R. meliloti, A. tumefaciens, R. lupini, B. clarridgeiae, P.Mirabilis, B. subtilus, L. monocytogenes, P. aeruginosa, and E. coli,among others are known.

A flagellin polypeptide, as used herein, refers to a full lengthflagellin protein, immunogenic fragments thereof, and peptides having atleast 50% sequence identify to a flagellin protein or immunogenicfragments thereof. Exemplary flagellin proteins include flagellin fromSalmonella typhi (UniPro Entry number: Q56086), Salmonella typhimurium(A0A0C9DG09), Salmonella enteritidis (A0A0C9BAB7), and Salmonellacholeraesuis (Q6V2X8), and proteins having an amino acid sequenceidentified by any one of SEQ ID NO 1-444, 458, 460, 462-479, or 543-565(see also Tables 7-13 and 26). In some embodiments, the flagellinpolypeptide has at least 60%, 70%, 75%, 80%, 90%, 95%, 97%, 98%, or 99%sequence identify to a flagellin protein or immunogenic fragmentsthereof.

In some embodiments, the flagellin polypeptide is an immunogenicfragment. An immunogenic fragment is a portion of a flagellin proteinthat provokes an immune response. In some embodiments, the immuneresponse is a TLR5 immune response. An example of an immunogenicfragment is a flagellin protein in which all or a portion of a hingeregion has been deleted or replaced with other amino acids. For example,an antigenic polypeptide may be inserted in the hinge region. Hingeregions are the hypervariable regions of a flagellin. Hinge regions of aflagellin are also referred to as “D3 domain or region, “propellerdomain or region,” “hypervariable domain or region” and “variable domainor region.” “At least a portion of a hinge region,” as used herein,refers to any part of the hinge region of the flagellin, or the entiretyof the hinge region. In other embodiments an immunogenic fragment offlagellin is a 20, 25, 30, 35, or 40 amino acid C-terminal fragment offlagellin.

The flagellin monomer is formed by domains D0 through D3. D0 and D1,which form the stem, are composed of tandem long alpha helices and arehighly conserved among different bacteria. The D1 domain includesseveral stretches of amino acids that are useful for TLR5 activation.The entire D1 domain or one or more of the active regions within thedomain are immunogenic fragments of flagellin. Examples of immunogenicregions within the D1 domain include residues 88-114 and residues411-431 (in Salmonella typhimurium FliC flagellin. Within the 13 aminoacids in the 88-100 region, at least 6 substitutions are permittedbetween Salmonella flagellin and other flagellins that still preserveTLR5 activation. Thus, immunogenic fragments of flagellin includeflagellin like sequences that activate TLR5 and contain a 13 amino acidmotif that is 53% or more identical to the Salmonella sequence in 88-100of FliC (LQRVRELAVQSAN; SEQ ID NO: 504).

In some embodiments, the RNA (e.g., mRNA) vaccine includes an RNA thatencodes a fusion protein of flagellin and one or more antigenicpolypeptides. A “fusion protein” as used herein, refers to a linking oftwo components of the construct. In some embodiments, a carboxy-terminusof the antigenic polypeptide is fused or linked to an amino terminus ofthe flagellin polypeptide. In other embodiments, an amino-terminus ofthe antigenic polypeptide is fused or linked to a carboxy-terminus ofthe flagellin polypeptide. The fusion protein may include, for example,one, two, three, four, five, six or more flagellin polypeptides linkedto one, two, three, four, five, six or more antigenic polypeptides. Whentwo or more flagellin polypeptides and/or two or more antigenicpolypeptides are linked such a construct may be referred to as a“multimer.”

Each of the components of a fusion protein may be directly linked to oneanother or they may be connected through a linker. For instance, thelinker may be an amino acid linker. The amino acid linker encoded for bythe RNA (e.g., mRNA) vaccine to link the components of the fusionprotein may include, for instance, at least one member selected from thegroup consisting of a lysine residue, a glutamic acid residue, a serineresidue and an arginine residue. In some embodiments the linker is 1-30,1-25, 1-25, 5-10, 5, 15, or 5-20 amino acids in length.

In other embodiments the RNA (e.g., mRNA) vaccine includes at least twoseparate RNA polynucleotides, one encoding one or more antigenicpolypeptides and the other encoding the flagellin polypeptide. The atleast two RNA polynucleotides may be co-formulated in a carrier such asa lipid nanoparticle.

Methods of Treatment

Provided herein are compositions (e.g., pharmaceutical compositions),methods, kits and reagents for prevention and/or treatment of influenzavirus in humans and other mammals. Influenza virus RNA vaccines can beused as therapeutic or prophylactic agents. They may be used in medicineto prevent and/or treat infectious disease. In exemplary aspects, theinfluenza virus RNA vaccines of the present disclosure are used toprovide prophylactic protection from influenza virus. Prophylacticprotection from influenza virus can be achieved following administrationof an influenza virus RNA vaccine of the present disclosure. Vaccinescan be administered once, twice, three times, four times or more. It ispossible, although less desirable, to administer the vaccine to aninfected individual to achieve a therapeutic response. Dosing may needto be adjusted accordingly.

In some embodiments, the influenza virus vaccines of the presentdisclosure can be used as a method of preventing an influenza virusinfection in a subject, the method comprising administering to saidsubject at least one influenza virus vaccine as provided herein. In someembodiments, the influenza virus vaccines of the present disclosure canbe used as a method of inhibiting a primary influenza virus infection ina subject, the method comprising administering to said subject at leastone influenza virus vaccine as provided herein. In some embodiments, theinfluenza virus vaccines of the present disclosure can be used as amethod of treating an influenza virus infection in a subject, the methodcomprising administering to said subject at least one influenza virusvaccine as provided herein. In some embodiments, the influenza virusvaccines of the present disclosure can be used as a method of reducingan incidence of influenza virus infection in a subject, the methodcomprising administering to said subject at least one influenza virusvaccine as provided herein. In come embodiments, the influenza virusvaccines of the present disclosure can be used as a method of inhibitingspread of influenza virus from a first subject infected with influenzavirus to a second subject not infected with influenza virus, the methodcomprising administering to at least one of said first subject sand saidsecond subject at least one influenza virus vaccine as provided herein.

A method of eliciting an immune response in a subject against aninfluenza virus is provided in aspects of the invention. The methodinvolves administering to the subject an influenza virus RNA vaccinecomprising at least one RNA polynucleotide having an open reading frameencoding at least one influenza virus antigenic polypeptide, therebyinducing in the subject an immune response specific to influenza virusantigenic polypeptide, wherein anti-antigenic polypeptide antibody titerin the subject is increased following vaccination relative toanti-antigenic polypeptide antibody titer in a subject vaccinated with aprophylactically effective dose of a traditional vaccine against theinfluenza virus. An “anti-antigenic polypeptide antibody” is a serumantibody the binds specifically to the antigenic polypeptide.

A prophylactically effective dose is a therapeutically effective dosethat prevents infection with the virus at a clinically acceptable level.In some embodiments the therapeutically effective dose is a dose listedin a package insert for the vaccine. A traditional vaccine, as usedherein, refers to a vaccine other than the mRNA vaccines of the presentdisclosure. For instance, a traditional vaccine includes, but is notlimited to, live microorganism vaccines, killed microorganism vaccines,subunit vaccines, protein antigen vaccines, DNA vaccines, VLP vaccines,etc. In exemplary embodiments, a traditional vaccine is a vaccine thathas achieved regulatory approval and/or is registered by a national drugregulatory body, for example the Food and Drug Administration (FDA) inthe United States or the European Medicines Agency (EMA).

In some embodiments the anti-antigenic polypeptide antibody titer in thesubject is increased 1 log to 10 log following vaccination relative toanti-antigenic polypeptide antibody titer in a subject vaccinated with aprophylactically effective dose of a traditional vaccine against theinfluenza virus.

In some embodiments the anti-antigenic polypeptide antibody titer in thesubject is increased 1 log, 2 log, 3 log, 5 log or 10 log followingvaccination relative to anti-antigenic polypeptide antibody titer in asubject vaccinated with a prophylactically effective dose of atraditional vaccine against influenza.

A method of eliciting an immune response in a subject against aninfluenza virus is provided in other aspects of the present disclosure.The method involves administering to the subject an influenza virus RNAvaccine comprising at least one RNA polynucleotide having an openreading frame encoding at least one influenza virus antigenicpolypeptide, thereby inducing in the subject an immune response specificto influenza virus antigenic polypeptide, wherein the immune response inthe subject is equivalent to an immune response in a subject vaccinatedwith a traditional vaccine against the influenza virus at 2 times to 100times the dosage level relative to the RNA vaccine.

In some embodiments, the immune response in the subject is equivalent toan immune response in a subject vaccinated with a traditional vaccine at2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the influenzavaccine.

In some embodiments the immune response in the subject is equivalent toan immune response in a subject vaccinated with a traditional vaccine at10-100 times, or 100-1000 times, the dosage level relative to theinfluenza vaccine.

In some embodiments the immune response is assessed by determining[protein] antibody titer in the subject.

Some embodiments provide a method of inducing an immune response in asubject by administering to the subject an influenza RNA (e.g., mRNA)vaccine comprising at least one RNA (e.g., mRNA) polynucleotide havingan open reading frame encoding at least one influenza antigenicpolypeptide, thereby inducing in the subject an immune response specificto the antigenic polypeptide, wherein the immune response in the subjectis induced 2 days to 10 weeks earlier relative to an immune responseinduced in a subject vaccinated with a prophylactically effective doseof a traditional vaccine against influenza. In some embodiments, theimmune response in the subject is induced in a subject vaccinated with aprophylactically effective dose of a traditional vaccine at 2 times to100 times the dosage level relative to the influenza RNA (e.g., mRNA)vaccine.

In some embodiments the immune response in the subject is equivalent toan immune response in a subject vaccinated with a traditional vaccine at2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the influenzaRNA (e.g., mRNA) vaccine.

In some embodiments, the immune response in the subject is induced 2days earlier, or 3 days earlier, relative to an immune response inducedin a subject vaccinated with a prophylactically effective dose of atraditional vaccine.

In some embodiments the immune response in the subject is induced 1week, 2 weeks, 3 weeks, 5 weeks, or 10 weeks earlier relative to animmune response induced in a subject vaccinated with a prophylacticallyeffective dose of a traditional vaccine.

Therapeutic and Prophylactic Compositions

Provided herein are compositions (e.g., pharmaceutical compositions),methods, kits and reagents for prevention, treatment or diagnosis ofinfluenza in humans and other mammals, for example. Influenza RNA (e.g.mRNA) vaccines can be used as therapeutic or prophylactic agents. Theymay be used in medicine to prevent and/or treat infectious disease. Insome embodiments, the respiratory RNA (e.g., mRNA) vaccines of thepresent disclosure are used fin the priming of immune effector cells,for example, to activate peripheral blood mononuclear cells (PBMCs) exvivo, which are then infused (re-infused) into a subject.

In some embodiments, influenza vaccine containing RNA (e.g., mRNA)polynucleotides as described herein can be administered to a subject(e.g., a mammalian subject, such as a human subject), and the RNA (e.g.,mRNA) polynucleotides are translated in vivo to produce an antigenicpolypeptide.

The influenza RNA (e.g., mRNA) vaccines may be induced for translationof a polypeptide (e.g., antigen or immunogen) in a cell, tissue ororganism. In some embodiments, such translation occurs in vivo, althoughsuch translation may occur ex vivo, in culture or in vitro. In someembodiments, the cell, tissue or organism is contacted with an effectiveamount of a composition containing an influenza RNA (e.g., mRNA) vaccinethat contains a polynucleotide that has at least one a translatableregion encoding an antigenic polypeptide.

An “effective amount” of an influenza RNA (e.g. mRNA) vaccine isprovided based, at least in part, on the target tissue, target celltype, means of administration, physical characteristics of thepolynucleotide (e.g., size, and extent of modified nucleosides) andother components of the vaccine, and other determinants. In general, aneffective amount of the influenza RNA (e.g., mRNA) vaccine compositionprovides an induced or boosted immune response as a function of antigenproduction in the cell, preferably more efficient than a compositioncontaining a corresponding unmodified polynucleotide encoding the sameantigen or a peptide antigen. Increased antigen production may bedemonstrated by increased cell transfection (the percentage of cellstransfected with the RNA, e.g., mRNA, vaccine), increased proteintranslation from the polynucleotide, decreased nucleic acid degradation(as demonstrated, for example, by increased duration of proteintranslation from a modified polynucleotide), or altered antigen specificimmune response of the host cell.

In some embodiments, RNA (e.g. mRNA) vaccines (including polynucleotidestheir encoded polypeptides) in accordance with the present disclosuremay be used for treatment of Influenza.

Influenza RNA (e.g. mRNA) vaccines may be administered prophylacticallyor therapeutically as part of an active immunization scheme to healthyindividuals or early in infection during the incubation phase or duringactive infection after onset of symptoms. In some embodiments, theamount of RNA (e.g., mRNA) vaccine of the present disclosure provided toa cell, a tissue or a subject may be an amount effective for immuneprophylaxis.

Influenza RNA (e.g. mRNA) vaccines may be administrated with otherprophylactic or therapeutic compounds. As a non-limiting example, aprophylactic or therapeutic compound may be an adjuvant or a booster. Asused herein, when referring to a prophylactic composition, such as avaccine, the term “booster” refers to an extra administration of theprophylactic (vaccine) composition. A booster (or booster vaccine) maybe given after an earlier administration of the prophylacticcomposition. The time of administration between the initialadministration of the prophylactic composition and the booster may be,but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15minutes, 20 minutes 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years,7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95years or more than 99 years. In some embodiments, the time ofadministration between the initial administration of the prophylacticcomposition and the booster may be, but is not limited to, 1 week, 2weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months or 1 year.

In some embodiments, influenza RNA (e.g. mRNA) vaccines may beadministered intramuscularly, intradermally, or intranasally, similarlyto the administration of inactivated vaccines known in the art. In someembodiments, influenza RNA (e.g. mRNA) vaccines are administeredintramuscularly.

Influenza RNA (e.g. mRNA) vaccines may be utilized in various settingsdepending on the prevalence of the infection or the degree or level ofunmet medical need. As a non-limiting example, the RNA (e.g., mRNA)vaccines may be utilized to treat and/or prevent a variety ofinfluenzas. RNA (e.g., mRNA) vaccines have superior properties in thatthey produce much larger antibody titers and produce responses earlythan commercially available anti-viral agents/compositions.

Provided herein are pharmaceutical compositions including influenza RNA(e.g. mRNA) vaccines and RNA (e.g. mRNA) vaccine compositions and/orcomplexes optionally in combination with one or more pharmaceuticallyacceptable excipients.

Influenza RNA (e.g. mRNA) vaccines may be formulated or administeredalone or in conjunction with one or more other components. For instance,Influenza RNA (e.g., mRNA) vaccines (vaccine compositions) may compriseother components including, but not limited to, adjuvants.

In some embodiments, influenza (e.g. mRNA) vaccines do not include anadjuvant (they are adjuvant free).

Influenza RNA (e.g. mRNA) vaccines may be formulated or administered incombination with one or more pharmaceutically-acceptable excipients. Insome embodiments, vaccine compositions comprise at least one additionalactive substances, such as, for example, a therapeutically-activesubstance, a prophylactically-active substance, or a combination ofboth. Vaccine compositions may be sterile, pyrogen-free or both sterileand pyrogen-free. General considerations in the formulation and/ormanufacture of pharmaceutical agents, such as vaccine compositions, maybe found, for example, in Remington: The Science and Practice ofPharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporatedherein by reference in its entirety).

In some embodiments, influenza RNA (e.g. mRNA) vaccines are administeredto humans, human patients or subjects. For the purposes of the presentdisclosure, the phrase “active ingredient” generally refers to the RNA(e.g., mRNA) vaccines or the polynucleotides contained therein, forexample, RNA polynucleotides (e.g., mRNA polynucleotides) encodingantigenic polypeptides.

Formulations of the influenza vaccine compositions described herein maybe prepared by any method known or hereafter developed in the art ofpharmacology. In general, such preparatory methods include the step ofbringing the active ingredient (e.g., mRNA polynucleotide) intoassociation with an excipient and/or one or more other accessoryingredients, and then, if necessary and/or desirable, dividing, shapingand/or packaging the product into a desired single- or multi-dose unit.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition in accordance with the disclosure will vary,depending upon the identity, size, and/or condition of the subjecttreated and further depending upon the route by which the composition isto be administered. By way of example, the composition may comprisebetween 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between5-80%, at least 80% (w/w) active ingredient.

Influenza RNA (e.g. mRNA) vaccines can be formulated using one or moreexcipients to: increase stability; increase cell transfection; permitthe sustained or delayed release (e.g., from a depot formulation); alterthe biodistribution (e.g., target to specific tissues or cell types);increase the translation of encoded protein in vivo; and/or alter therelease profile of encoded protein (antigen) in vivo. In addition totraditional excipients such as any and all solvents, dispersion media,diluents, or other liquid vehicles, dispersion or suspension aids,surface active agents, isotonic agents, thickening or emulsifyingagents, preservatives, excipients can include, without limitation,lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes,core-shell nanoparticles, peptides, proteins, cells transfected withinfluenza RNA (e.g. mRNA)vaccines (e.g., for transplantation into asubject), hyaluronidase, nanoparticle mimics and combinations thereof.

Stabilizing Elements

Naturally-occurring eukaryotic mRNA molecules have been found to containstabilizing elements, including, but not limited to untranslated regions(UTR) at their 5′-end (5′UTR) and/or at their 3′-end (3′UTR), inaddition to other structural features, such as a 5′-cap structure or a3′-poly(A) tail. Both the 5′UTR and the 3′UTR are typically transcribedfrom the genomic DNA and are elements of the premature mRNA.Characteristic structural features of mature mRNA, such as the 5′-capand the 3′-poly(A) tail are usually added to the transcribed (premature)mRNA during mRNA processing. The 3′-poly(A) tail is typically a stretchof adenine nucleotides added to the 3′-end of the transcribed mRNA. Itcan comprise up to about 400 adenine nucleotides. In some embodimentsthe length of the 3′-poly(A) tail may be an essential element withrespect to the stability of the individual mRNA.

In some embodiments the RNA (e.g., mRNA) vaccine may include one or morestabilizing elements. Stabilizing elements may include for instance ahistone stem-loop. A stem-loop binding protein (SLBP), a 32 kDa proteinhas been identified. It is associated with the histone stem-loop at the3′-end of the histone messages in both the nucleus and the cytoplasm.Its expression level is regulated by the cell cycle; it is peaks duringthe S-phase, when histone mRNA levels are also elevated. The protein hasbeen shown to be essential for efficient 3′-end processing of histonepre-mRNA by the U7 snRNP. SLBP continues to be associated with thestem-loop after processing, and then stimulates the translation ofmature histone mRNAs into histone proteins in the cytoplasm. The RNAbinding domain of SLBP is conserved through metazoa and protozoa; itsbinding to the histone stem-loop depends on the structure of the loop.The minimum binding site includes at least three nucleotides 5′ and twonucleotides 3′ relative to the stem-loop.

In some embodiments, the RNA (e.g., mRNA) vaccines include a codingregion, at least one histone stem-loop, and optionally, a poly(A)sequence or polyadenylation signal. The poly(A) sequence orpolyadenylation signal generally should enhance the expression level ofthe encoded protein. The encoded protein, in some embodiments, is not ahistone protein, a reporter protein (e.g. Luciferase, GFP, EGFP,β-Galactosidase, EGFP), or a marker or selection protein (e.g.alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyltransferase (GPT)).

In some embodiments, the combination of a poly(A) sequence orpolyadenylation signal and at least one histone stem-loop, even thoughboth represent alternative mechanisms in nature, acts synergistically toincrease the protein expression beyond the level observed with either ofthe individual elements. It has been found that the synergistic effectof the combination of poly(A) and at least one histone stem-loop doesnot depend on the order of the elements or the length of the poly(A)sequence.

In some embodiments, the RNA (e.g., mRNA) vaccine does not comprise ahistone downstream element (HDE). “Histone downstream element” (HDE)includes a purine-rich polynucleotide stretch of approximately 15 to 20nucleotides 3′ of naturally occurring stem-loops, representing thebinding site for the U7 snRNA, which is involved in processing ofhistone pre-mRNA into mature histone mRNA. Ideally, the inventivenucleic acid does not include an intron.

In some embodiments, the RNA (e.g., mRNA) vaccine may or may not containa enhancer and/or promoter sequence, which may be modified or unmodifiedor which may be activated or inactivated. In some embodiments, thehistone stem-loop is generally derived from histone genes, and includesan intramolecular base pairing of two neighbored partially or entirelyreverse complementary sequences separated by a spacer, including (e.g.,consisting of) a short sequence, which forms the loop of the structure.The unpaired loop region is typically unable to base pair with either ofthe stem loop elements. It occurs more often in RNA, as is a keycomponent of many RNA secondary structures, but may be present insingle-stranded DNA as well. Stability of the stem-loop structuregenerally depends on the length, number of mismatches or bulges, andbase composition of the paired region. In some embodiments, wobble basepairing (non-Watson-Crick base pairing) may result. In some embodiments,the at least one histone stem-loop sequence comprises a length of 15 to45 nucleotides.

In other embodiments the RNA (e.g., mRNA) vaccine may have one or moreAU-rich sequences removed. These sequences, sometimes referred to asAURES are destabilizing sequences found in the 3′UTR. The AURES may beremoved from the RNA (e.g., mRNA) vaccines. Alternatively the AURES mayremain in the RNA (e.g., mRNA) vaccine.

Nanoparticle Formulations

In some embodiments, influenza RNA (e.g. mRNA) vaccines are formulatedin a nanoparticle. In some embodiments, influenza RNA (e.g. mRNA)vaccines are formulated in a lipid nanoparticle. In some embodiments,influenza RNA (e.g. mRNA) vaccines are formulated in a lipid-polycationcomplex, referred to as a cationic lipid nanoparticle. As a non-limitingexample, the polycation may include a cationic peptide or a polypeptidesuch as, but not limited to, polylysine, polyornithine and/orpolyarginine. In some embodiments, influenza RNA (e.g., mRNA) vaccinesare formulated in a lipid nanoparticle that includes a non-cationiclipid such as, but not limited to, cholesterol or dioleoylphosphatidylethanolamine (DOPE).

A lipid nanoparticle formulation may be influenced by, but not limitedto, the selection of the cationic lipid component, the degree ofcationic lipid saturation, the nature of the PEGylation, ratio of allcomponents and biophysical parameters such as size. In one example bySemple et al. (Nature Biotech. 2010 28:172-176), the lipid nanoparticleformulation is composed of 57.1% cationic lipid, 7.1%dipalmitoylphosphatidylcholine, 34.3% cholesterol, and 1.4% PEG-c-DMA.As another example, changing the composition of the cationic lipid canmore effectively deliver siRNA to various antigen presenting cells(Basha et al. Mol Ther. 2011 19:2186-2200).

In some embodiments, lipid nanoparticle formulations may comprise 35 to45% cationic lipid, 40% to 50% cationic lipid, 50% to 60% cationic lipidand/or 55% to 65% cationic lipid. In some embodiments, the ratio oflipid to RNA (e.g., mRNA) in lipid nanoparticles maybe 5:1 to 20:1, 10:1to 25:1, 15:1 to 30:1 and/or at least 30:1.

In some embodiments, the ratio of PEG in the lipid nanoparticleformulations may be increased or decreased and/or the carbon chainlength of the PEG lipid may be modified from C14 to C18 to alter thepharmacokinetics and/or biodistribution of the lipid nanoparticleformulations. As a non-limiting example, lipid nanoparticle formulationsmay contain 0.5% to 3.0%, 1.0% to 3.5%, 1.5% to 4.0%, 2.0% to 4.5%, 2.5%to 5.0% and/or 3.0% to 6.0% of the lipid molar ratio of PEG-c-DOMG(R-3-[(ω-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine)(also referred to herein as PEG-DOMG) as compared to the cationic lipid,DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may bereplaced with a PEG lipid such as, but not limited to, PEG-DSG(1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG(1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG(1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationiclipid may be selected from any lipid known in the art such as, but notlimited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.

In some embodiments, an influenza RNA (e.g. mRNA) vaccine formulation isa nanoparticle that comprises at least one lipid. The lipid may beselected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5,C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG,PEGylated lipids and amino alcohol lipids. In some embodiments, thelipid may be a cationic lipid such as, but not limited to, DLin-DMA,DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids.The amino alcohol cationic lipid may be the lipids described in and/ormade by the methods described in U.S. Patent Publication No.US2013/0150625, herein incorporated by reference in its entirety. As anon-limiting example, the cationic lipid may be2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol(Compound 1 in US2013/0150625);2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol(Compound 2 in US2013/0150625);2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol(Compound 3 in US2013/0150625); and2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol(Compound 4 in US2013/0150625); or any pharmaceutically acceptable saltor stereoisomer thereof.

Lipid nanoparticle formulations typically comprise a lipid, inparticular, an ionizable cationic lipid, for example,2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), ordi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, and furthercomprise a neutral lipid, a sterol and a molecule capable of reducingparticle aggregation, for example a PEG or PEG-modified lipid.

In some embodiments, a lipid nanoparticle formulation consistsessentially of (i) at least one lipid selected from the group consistingof 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate; (ii) a neutrallipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g.,cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molarratio of 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol;0.5-15% PEG-lipid.

In some embodiments, a lipid nanoparticle formulation includes 25% to75% on a molar basis of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, e.g., 35 to 65%, 45to 65%, 60%, 57.5%, 50% or 40% on a molar basis.

In some embodiments, a lipid nanoparticle formulation includes 0.5% to15% on a molar basis of the neutral lipid, e.g., 3 to 12%, 5 to 10% or15%, 10%, or 7.5% on a molar basis. Examples of neutral lipids include,without limitation, DSPC, POPC, DPPC, DOPE and SM. In some embodiments,the formulation includes 5% to 50% on a molar basis of the sterol (e.g.,15 to 45%, 20 to 40%, 40%, 38.5%, 35%, or 31% on a molar basis. Anon-limiting example of a sterol is cholesterol. In some embodiments, alipid nanoparticle formulation includes 0.5% to 20% on a molar basis ofthe PEG or PEG-modified lipid (e.g., 0.5 to 10%, 0.5 to 5%, 1.5%, 0.5%,1.5%, 3.5%, or 5% on a molar basis. In some embodiments, a PEG or PEGmodified lipid comprises a PEG molecule of an average molecular weightof 2,000 Da. In some embodiments, a PEG or PEG modified lipid comprisesa PEG molecule of an average molecular weight of less than 2,000, forexample around 1,500 Da, around 1,000 Da, or around 500 Da. Non-limitingexamples of PEG-modified lipids include PEG-distearoyl glycerol(PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA(further discussed in Reyes et al. J. Controlled Release, 107, 276-287(2005) the contents of which are herein incorporated by reference intheir entirety).

In some embodiments, lipid nanoparticle formulations include 25-75% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 0.5-15% of theneutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 35-65% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 3-12% of theneutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 45-65% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 5-10% of theneutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 60% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 7.5% of the neutrallipid, 31% of the sterol, and 1.5% of the PEG or PEG-modified lipid on amolar basis.

In some embodiments, lipid nanoparticle formulations include 50% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 10% of the neutrallipid, 38.5% of the sterol, and 1.5% of the PEG or PEG-modified lipid ona molar basis.

In some embodiments, lipid nanoparticle formulations include 50% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 10% of the neutrallipid, 35% of the sterol, 4.5% or 5% of the PEG or PEG-modified lipid,and 0.5% of the targeting lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 40% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 15% of the neutrallipid, 40% of the sterol, and 5% of the PEG or PEG-modified lipid on amolar basis.

In some embodiments, lipid nanoparticle formulations include 57.2% of acationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 7.1% of the neutrallipid, 34.3% of the sterol, and 1.4% of the PEG or PEG-modified lipid ona molar basis.

In some embodiments, lipid nanoparticle formulations include 57.5% of acationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA isfurther discussed in Reyes et al. (J. Controlled Release, 107, 276-287(2005), the contents of which are herein incorporated by reference intheir entirety), 7.5% of the neutral lipid, 31.5% of the sterol, and3.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations consistsessentially of a lipid mixture in molar ratios of 20-70% cationic lipid:5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid. Insome embodiments, lipid nanoparticle formulations consists essentiallyof a lipid mixture in a molar ratio of 20-60% cationic lipid: 5-25%neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.

In some embodiments, the molar lipid ratio is 50/10/38.5/1.5 (mol %cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g.,PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationiclipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g.,PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol %cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g.,PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol %cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g.,PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid,e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or52/13/30/5 (mol % cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

Non-limiting examples of lipid nanoparticle compositions and methods ofmaking them are described, for example, in Semple et al. (2010) Nat.Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed.,51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578(the contents of each of which are incorporated herein by reference intheir entirety).

In some embodiments, lipid nanoparticle formulations may comprise acationic lipid, a PEG lipid and a structural lipid and optionallycomprise a non-cationic lipid. As a non-limiting example, a lipidnanoparticle may comprise 40-60% of cationic lipid, 5-15% of anon-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structurallipid. As another non-limiting example, the lipid nanoparticle maycomprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and38.5% structural lipid. As yet another non-limiting example, a lipidnanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid,2.5% PEG lipid and 32.5% structural lipid. In some embodiments, thecationic lipid may be any cationic lipid described herein such as, butnot limited to, DLin-KC2-DMA, DLin-MC3-DMA and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

In some embodiments, the lipid nanoparticle formulations describedherein may be 4 component lipid nanoparticles. The lipid nanoparticlemay comprise a cationic lipid, a non-cationic lipid, a PEG lipid and astructural lipid. As a non-limiting example, the lipid nanoparticle maycomprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2%of a PEG lipid and 30-50% of a structural lipid. As another non-limitingexample, the lipid nanoparticle may comprise 50% cationic lipid, 10%non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yetanother non-limiting example, the lipid nanoparticle may comprise 55%cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5%structural lipid. In some embodiments, the cationic lipid may be anycationic lipid described herein such as, but not limited to,DLin-KC2-DMA, DLin-MC3-DMA and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

In some embodiments, the lipid nanoparticle formulations describedherein may comprise a cationic lipid, a non-cationic lipid, a PEG lipidand a structural lipid. As a non-limiting example, the lipidnanoparticle comprise 50% of the cationic lipid DLin-KC2-DMA, 10% of thenon-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of thestructural lipid cholesterol. As a non-limiting example, the lipidnanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of thenon-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of thestructural lipid cholesterol. As a non-limiting example, the lipidnanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of thenon-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DMG and 38.5% of thestructural lipid cholesterol. As yet another non-limiting example, thelipid nanoparticle comprise 55% of the cationic lipiddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 10% of thenon-cationic lipid DSPC, 2.5% of the PEG lipid PEG-DMG and 32.5% of thestructural lipid cholesterol.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in a vaccinecomposition may vary, depending upon the identity, size, and/orcondition of the subject being treated and further depending upon theroute by which the composition is to be administered. For example, thecomposition may comprise between 0.1% and 99% (w/w) of the activeingredient. By way of example, the composition may comprise between 0.1%and 100%, e.g., between .5 and 50%, between 1-30%, between 5-80%, atleast 80% (w/w) active ingredient.

In some embodiments, the influenza RNA (e.g. mRNA) vaccine compositionmay comprise the polynucleotide described herein, formulated in a lipidnanoparticle comprising MC3, Cholesterol, DSPC and PEG2000-DMG, thebuffer trisodium citrate, sucrose and water for injection. As anon-limiting example, the composition comprises: 2.0 mg/mL of drugsubstance, 21.8 mg/mL of MC3, 10.1 mg/mL of cholesterol, 5.4 mg/mL ofDSPC, 2.7 mg/mL of PEG2000-DMG, 5.16 mg/mL of trisodium citrate, 71mg/mL of sucrose and 1.0 mL of water for injection.

In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has amean diameter of 10-500 nm, 20-400 nm, 30-300 nm, 40-200 nm. In someembodiments, a nanoparticle (e.g., a lipid nanoparticle) has a meandiameter of 50-150 nm, 50-200 nm, 80-100 nm or 80-200 nm.

Liposomes, Lipoplexes, and Lipid Nanoparticles

The RNA (e.g., mRNA) vaccines of the disclosure can be formulated usingone or more liposomes, lipoplexes, or lipid nanoparticles. In someembodiments, pharmaceutical compositions of RNA (e.g., mRNA) vaccinesinclude liposomes. Liposomes are artificially-prepared vesicles whichmay primarily be composed of a lipid bilayer and may be used as adelivery vehicle for the administration of nutrients and pharmaceuticalformulations. Liposomes can be of different sizes such as, but notlimited to, a multilamellar vesicle (MLV) which may be hundreds ofnanometers in diameter and may contain a series of concentric bilayersseparated by narrow aqueous compartments, a small unicellular vesicle(SUV) which may be smaller than 50 nm in diameter, and a largeunilamellar vesicle (LUV) which may be between 50 and 500 nm indiameter. Liposome design may include, but is not limited to, opsoninsor ligands in order to improve the attachment of liposomes to unhealthytissue or to activate events such as, but not limited to, endocytosis.Liposomes may contain a low or a high pH in order to improve thedelivery of the pharmaceutical formulations.

The formation of liposomes may depend on the physicochemicalcharacteristics such as, but not limited to, the pharmaceuticalformulation entrapped and the liposomal ingredients, the nature of themedium in which the lipid vesicles are dispersed, the effectiveconcentration of the entrapped substance and its potential toxicity, anyadditional processes involved during the application and/or delivery ofthe vesicles, the optimization size, polydispersity and the shelf-lifeof the vesicles for the intended application, and the batch-to-batchreproducibility and possibility of large-scale production of safe andefficient liposomal products.

In some embodiments, pharmaceutical compositions described herein mayinclude, without limitation, liposomes such as those formed from1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2liposomes from Marina Biotech (Bothell, Wash.),1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA),2,2-dilinoleyl-4-(2-dimethylaminoethyl)[1,3]-dioxolane (DLin-KC2-DMA),and MC3 (US20100324120; herein incorporated by reference in itsentirety) and liposomes which may deliver small molecule drugs such as,but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).

In some embodiments, pharmaceutical compositions described herein mayinclude, without limitation, liposomes such as those formed from thesynthesis of stabilized plasmid-lipid particles (SPLP) or stabilizednucleic acid lipid particle (SNALP) that have been previously describedand shown to be suitable for oligonucleotide delivery in vitro and invivo (see Wheeler et al. Gene Therapy. 1999 6:271-281; Zhang et al. GeneTherapy. 1999 6:1438-1447; Jeffs et al. Pharm Res. 2005 22:362-372;Morrissey et al., Nat Biotechnol. 2005 2:1002-1007; Zimmermann et al.,Nature. 2006 441:111-114; Heyes et al. J Contr Rel. 2005 107:276-287;Semple et al. Nature Biotech. 2010 28:172-176; Judge et al. J ClinInvest. 2009 119:661-673; deFougerolles Hum Gene Ther. 2008 19:125-132;U.S. Patent Publication No US20130122104; all of which are incorporatedherein in their entireties). The original manufacture method by Wheeleret al. was a detergent dialysis method, which was later improved byJeffs et al. and is referred to as the spontaneous vesicle formationmethod. The liposome formulations are composed of 3 to 4 lipidcomponents in addition to the polynucleotide. As an example a liposomecan contain, but is not limited to, 55% cholesterol, 20%disteroylphosphatidyl choline (DSPC), 10% PEG-S-DSG, and 15%1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), as described by Jeffset al. As another example, certain liposome formulations may contain,but are not limited to, 48% cholesterol, 20% DSPC, 2% PEG-c-DMA, and 30%cationic lipid, where the cationic lipid can be1,2-distearloxy-N,N-dimethylaminopropane (DSDMA), DODMA, DLin-DMA, or1,2-dilinolenyloxy-3-dimethylaminopropane (DLenDMA), as described byHeyes et al.

In some embodiments, liposome formulations may comprise from about 25.0%cholesterol to about 40.0% cholesterol, from about 30.0% cholesterol toabout 45.0% cholesterol, from about 35.0% cholesterol to about 50.0%cholesterol and/or from about 48.5% cholesterol to about 60%cholesterol. In some embodiments, formulations may comprise a percentageof cholesterol selected from the group consisting of 28.5%, 31.5%,33.5%, 36.5%, 37.0%, 38.5%, 39.0% and 43.5%. In some embodiments,formulations may comprise from about 5.0% to about 10.0% DSPC and/orfrom about 7.0% to about 15.0% DSPC.

In some embodiments, the RNA (e.g., mRNA) vaccine pharmaceuticalcompositions may be formulated in liposomes such as, but not limited to,DiLa2 liposomes (Marina Biotech, Bothell, Wash.), SMARTICLES® (MarinaBiotech, Bothell, Wash.), neutral DOPC(1,2-dioleoyl-sn-glycero-3-phosphocholine) based liposomes (e.g., siRNAdelivery for ovarian cancer (Landen et al. Cancer Biology & Therapy 20065(12)1708-1713); herein incorporated by reference in its entirety) andhyaluronan-coated liposomes (Quiet Therapeutics, Israel).

In some embodiments, the cationic lipid may be a low molecular weightcationic lipid such as those described in U.S. Patent Application No.2013/0090372, the contents of which are herein incorporated by referencein their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated ina lipid vesicle, which may have crosslinks between functionalized lipidbilayers.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated ina lipid-polycation complex. The formation of the lipid-polycationcomplex may be accomplished by methods known in the art and/or asdescribed in U.S. Pub. No. 2012/0178702, herein incorporated byreference in its entirety. As a non-limiting example, the polycation mayinclude a cationic peptide or a polypeptide such as, but not limited to,polylysine, polyornithine and/or polyarginine. In some embodiments, theRNA (e.g., mRNA) vaccines may be formulated in a lipid-polycationcomplex, which may further include a non-cationic lipid such as, but notlimited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).

In some embodiments, the ratio of PEG in the lipid nanoparticle (LNP)formulations may be increased or decreased and/or the carbon chainlength of the PEG lipid may be modified from C14 to C18 to alter thepharmacokinetics and/or biodistribution of the LNP formulations. As anon-limiting example, LNP formulations may contain from about 0.5% toabout 3.0%, from about 1.0% to about 3.5%, from about 1.5% to about4.0%, from about 2.0% to about 4.5%, from about 2.5% to about 5.0%and/or from about 3.0% to about 6.0% of the lipid molar ratio ofPEG-c-DOMG(R-3-[ω-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine)(also referred to herein as PEG-DOMG) as compared to the cationic lipid,DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may bereplaced with a PEG lipid such as, but not limited to, PEG-DSG(1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG(1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG(1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationiclipid may be selected from any lipid known in the art such as, but notlimited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated ina lipid nanoparticle.

In some embodiments, the RNA (e.g., mRNA) vaccine formulation comprisingthe polynucleotide is a nanoparticle which may comprise at least onelipid. The lipid may be selected from, but is not limited to, DLin-DMA,DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA,PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In anotheraspect, the lipid may be a cationic lipid such as, but not limited to,DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and aminoalcohol lipids. The amino alcohol cationic lipid may be the lipidsdescribed in and/or made by the methods described in U.S. PatentPublication No. US20130150625, herein incorporated by reference in itsentirety. As a non-limiting example, the cationic lipid may be2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol(Compound 1 in US2013/0150625);2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol(Compound 2 in US2013/0150625);2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol(Compound 3 in US2013/0150625); and2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol(Compound 4 in US2013/0150625); or any pharmaceutically acceptable saltor stereoisomer thereof.

Lipid nanoparticle formulations typically comprise a lipid, inparticular, an ionizable cationic lipid, for example,2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), ordi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, and furthercomprise a neutral lipid, a sterol and a molecule capable of reducingparticle aggregation, for example a PEG or PEG-modified lipid.

In some embodiments, the lipid nanoparticle formulation consistsessentially of (i) at least one lipid selected from the group consistingof 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate; (ii) a neutrallipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g.,cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molarratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55%sterol; 0.5-15% PEG-lipid.

In some embodiments, the formulation includes from about 25% to about75% on a molar basis of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, e.g., from about 35to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about50% or about 40% on a molar basis.

In some embodiments, the formulation includes from about 0.5% to about15% on a molar basis of the neutral lipid e.g., from about 3 to about12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% ona molar basis. Examples of neutral lipids include, but are not limitedto, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulationincludes from about 5% to about 50% on a molar basis of the sterol(e.g., about 15 to about 45%, about 20 to about 40%, about 40%, about38.5%, about 35%, or about 31% on a molar basis. An exemplary sterol ischolesterol. In some embodiments, the formulation includes from about0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid(e.g., about 0.5 to about 10%, about 0.5 to about 5%, about 1.5%, about0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis. In someembodiments, the PEG or PEG modified lipid comprises a PEG molecule ofan average molecular weight of 2,000 Da. In other embodiments, the PEGor PEG modified lipid comprises a PEG molecule of an average molecularweight of less than 2,000, for example around 1,500 Da, around 1,000 Da,or around 500 Da. Examples of PEG-modified lipids include, but are notlimited to, PEG-distearoyl glycerol (PEG-DMG) (also referred herein asPEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. J.Controlled Release, 107, 276-287 (2005) the contents of which are hereinincorporated by reference in their entirety).

In some embodiments, the formulations of the present disclosure include25-75% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 0.5-15% of theneutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include35-65% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 3-12% of theneutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include45-65% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, 5-10% of theneutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure includeabout 60% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 7.5% of theneutral lipid, about 31% of the sterol, and about 1.5% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure includeabout 50% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 10% of theneutral lipid, about 38.5% of the sterol, and about 1.5% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure includeabout 50% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 10% of theneutral lipid, about 35% of the sterol, about 4.5% or about 5% of thePEG or PEG-modified lipid, and about 0.5% of the targeting lipid on amolar basis.

In some embodiments, the formulations of the present disclosure includeabout 40% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 15% of theneutral lipid, about 40% of the sterol, and about 5% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure includeabout 57.2% of a cationic lipid selected from2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA),dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), anddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 7.1% of theneutral lipid, about 34.3% of the sterol, and about 1.4% of the PEG orPEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure includeabout 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA(PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release,107, 276-287 (2005), the contents of which are herein incorporated byreference in their entirety), about 7.5% of the neutral lipid, about31.5% of the sterol, and about 3.5% of the PEG or PEG-modified lipid ona molar basis.

In some embodiments, lipid nanoparticle formulation consists essentiallyof a lipid mixture in molar ratios of about 20-70% cationic lipid: 5-45%neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid; morepreferably in a molar ratio of about 20-60% cationic lipid: 5-25%neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.

In some embodiments, the molar lipid ratio is approximately50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG),57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g.,DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol %cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g.,PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationiclipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG),40/10/40/10 (mol % cationic lipid/neutral lipid, e.g.,DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10(mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid,e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutrallipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

Examples of lipid nanoparticle compositions and methods of making sameare described, for example, in Semple et al. (2010) Nat. Biotechnol.28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51:8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (thecontents of each of which are incorporated herein by reference in theirentirety).

In some embodiments, the lipid nanoparticle formulations describedherein may comprise a cationic lipid, a PEG lipid and a structural lipidand optionally comprise a non-cationic lipid. As a non-limiting example,the lipid nanoparticle may comprise about 40-60% of cationic lipid,about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about30-50% of a structural lipid. As another non-limiting example, the lipidnanoparticle may comprise about 50% cationic lipid, about 10%non-cationic lipid, about 1.5% PEG lipid and about 38.5% structurallipid. As yet another non-limiting example, the lipid nanoparticle maycomprise about 55% cationic lipid, about 10% non-cationic lipid, about2.5% PEG lipid and about 32.5% structural lipid. In some embodiments,the cationic lipid may be any cationic lipid described herein such as,but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

In some embodiments, the lipid nanoparticle formulations describedherein may be 4 component lipid nanoparticles. The lipid nanoparticlemay comprise a cationic lipid, a non-cationic lipid, a PEG lipid and astructural lipid. As a non-limiting example, the lipid nanoparticle maycomprise about 40-60% of cationic lipid, about 5-15% of a non-cationiclipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid.As another non-limiting example, the lipid nanoparticle may compriseabout 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEGlipid and about 38.5% structural lipid. As yet another non-limitingexample, the lipid nanoparticle may comprise about 55% cationic lipid,about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5%structural lipid. In some embodiments, the cationic lipid may be anycationic lipid described herein such as, but not limited to,DLin-KC2-DMA, DLin-MC3-DMA and di((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate.

In some embodiments, the lipid nanoparticle formulations describedherein may comprise a cationic lipid, a non-cationic lipid, a PEG lipidand a structural lipid. As a non-limiting example, the lipidnanoparticle comprise about 50% of the cationic lipid DLin-KC2-DMA,about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipidPEG-DOMG and about 38.5% of the structural lipid cholesterol. As anon-limiting example, the lipid nanoparticle comprise about 50% of thecationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC,about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structurallipid cholesterol. As a non-limiting example, the lipid nanoparticlecomprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of thenon-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DMG and about38.5% of the structural lipid cholesterol. As yet another non-limitingexample, the lipid nanoparticle comprise about 55% of the cationic lipiddi((Z)-non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate, about 10% of thenon-cationic lipid DSPC, about 2.5% of the PEG lipid PEG-DMG and about32.5% of the structural lipid cholesterol.

As a non-limiting example, the cationic lipid may be selected from(20Z,23Z)-N,N-dimethylnonacosa-20,23-dien-10-amine,(17Z,20Z)-N,N-dimemylhexacosa-17,20-dien-9-amine,(1Z,19Z)-N5N-dimethylpentacosa-1 6, 19-dien-8-amine,(13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5-amine,(12Z,15Z)-N,N-dimethylhenicosa-12,15-dien-4-amine,(14Z,17Z)-N,N-dimethyltricosa-14,17-dien-6-amine,(15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-7-amine,(18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-10-amine,(15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-5-amine,(14Z,17Z)-N,N-dimethyltricosa-14,17-dien-4-amine,(19Z,22Z)-N,N-dimeihyloctacosa-19,22-dien-9-amine, (18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-8-amine,(17Z,20Z)-N,N-dimethylhexacosa-17,20-dien-7-amine,(16Z,19Z)-N,N-dimethylpentacosa-16,19-dien-6-amine,(22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine, (21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine,(18Z)-N,N-dimetylheptacos-18-en-10-amine,(17Z)-N,N-dimethylhexacos-17-en-9-amine,(19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-7-amine,N,N-dimethylheptacosan-10-amine,(20Z,23Z)-N-ethyl-N-methylnonacosa-20,23-dien-10-amine,1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine,(20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethyleptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine,(17Z)-N,N-dimethylnonacos-17-en-10-amine,(24Z)-N,N-dimethyltritriacont-24-en-10-amine,(20Z)-N,N-dimethylnonacos-20-en-10-amine,(22Z)-N,N-dimethylhentriacont-22-en-10-amine,(16Z)-N,N-dimethylpentacos-16-en-8-amine,(12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine,(13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]eptadecan-8-amine,1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine,N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimethyl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcycIopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine,N,N-dimethyl-[(1R,2S)-2-undecyIcyclopropyl]tetradecan-5-amine,N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl} dodecan-1-amine,1-[(1R,2S)-2-hepty lcyclopropyl]-N,N-dimethyloctadecan-9-amine,1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine,R-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,S-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine,(2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine,(2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine;(2S)-N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine,(2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine,(2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine,1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,(2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]octyl}oxy)propan-2-amine,N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine and(11E,20Z,23Z)-N,N-dimethylnonacosa-11,20,2-trien-10-amine or apharmaceutically acceptable salt or stereoisomer thereof.

In some embodiments, the LNP formulations of the RNA (e.g., mRNA)vaccines may contain PEG-c-DOMG at 3% lipid molar ratio. In someembodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines maycontain PEG-c-DOMG at 1.5% lipid molar ratio.

In some embodiments, the pharmaceutical compositions of the RNA (e.g.,mRNA) vaccines may include at least one of the PEGylated lipidsdescribed in International Publication No. WO2012/099755, the contentsof which are herein incorporated by reference in their entirety. In someembodiments, the LNP formulation may contain PEG-DMG 2000(1,2-dimyristoyl-sn-glycero-3-phophoethanolamine-N-[methoxy(polyethyleneglycol)-2000). In some embodiments, the LNP formulation may containPEG-DMG 2000, a cationic lipid known in the art and at least one othercomponent. In some embodiments, the LNP formulation may contain PEG-DMG2000, a cationic lipid known in the art, DSPC and cholesterol. As anon-limiting example, the LNP formulation may contain PEG-DMG 2000,DLin-DMA, DSPC and cholesterol. As another non-limiting example the LNPformulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol ina molar ratio of 2:40:10:48 (see e.g., Geall et al., Nonviral deliveryof self-amplifying RNA (e.g., mRNA) vaccines, PNAS 2012; PMID: 22908294,the contents of each of which are herein incorporated by reference intheir entirety).

The lipid nanoparticles described herein may be made in a sterileenvironment.

In some embodiments, the LNP formulation may be formulated in ananoparticle such as a nucleic acid-lipid particle. As a non-limitingexample, the lipid particle may comprise one or more active agents ortherapeutic agents; one or more cationic lipids comprising from about 50mol % to about 85 mol % of the total lipid present in the particle; oneor more non-cationic lipids comprising from about 13 mol % to about 49.5mol % of the total lipid present in the particle; and one or moreconjugated lipids that inhibit aggregation of particles comprising fromabout 0.5 mol % to about 2 mol % of the total lipid present in theparticle.

The nanoparticle formulations may comprise a phosphate conjugate. Thephosphate conjugate may increase in vivo circulation times and/orincrease the targeted delivery of the nanoparticle. As a non-limitingexample, the phosphate conjugates may include a compound of any one ofthe formulas described in International Application No. WO2013/033438,the contents of which are herein incorporated by reference in itsentirety.

The nanoparticle formulation may comprise a polymer conjugate. Thepolymer conjugate may be a water soluble conjugate. The polymerconjugate may have a structure as described in U.S. Patent ApplicationNo. 2013/0059360, the contents of which are herein incorporated byreference in its entirety. In some embodiments, polymer conjugates withthe polynucleotides of the present disclosure may be made using themethods and/or segmented polymeric reagents described in U.S. PatentApplication No. 2013/0072709, the contents of which are hereinincorporated by reference in its entirety. In some embodiments, thepolymer conjugate may have pendant side groups comprising ring moietiessuch as, but not limited to, the polymer conjugates described in U.S.Patent Publication No. US2013/0196948, the contents which are hereinincorporated by reference in its entirety.

The nanoparticle formulations may comprise a conjugate to enhance thedelivery of nanoparticles of the present disclosure in a subject.Further, the conjugate may inhibit phagocytic clearance of thenanoparticles in a subject. In one aspect, the conjugate may be a “self”peptide designed from the human membrane protein CD47 (e.g., the “self”particles described by Rodriguez et al. (Science 2013 339, 971-975),herein incorporated by reference in its entirety). As shown by Rodriguezet al., the self peptides delayed macrophage-mediated clearance ofnanoparticles which enhanced delivery of the nanoparticles. In anotheraspect, the conjugate may be the membrane protein CD47 (e.g., seeRodriguez et al. Science 2013 339, 971-975, herein incorporated byreference in its entirety). Rodriguez et al. showed that, similarly to“self” peptides, CD47 can increase the circulating particle ratio in asubject as compared to scrambled peptides and PEG coated nanoparticles.

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure are formulated in nanoparticles which comprise a conjugate toenhance the delivery of the nanoparticles of the present disclosure in asubject. The conjugate may be the CD47 membrane or the conjugate may bederived from the CD47 membrane protein, such as the “self” peptidedescribed previously. In some embodiments, the nanoparticle may comprisePEG and a conjugate of CD47 or a derivative thereof. In someembodiments, the nanoparticle may comprise both the “self” peptidedescribed above and the membrane protein CD47.

In some embodiments, a “self” peptide and/or CD47 protein may beconjugated to a virus-like particle or pseudovirion, as described hereinfor delivery of the RNA (e.g., mRNA) vaccines of the present disclosure.

In some embodiments, RNA (e.g., mRNA) vaccine pharmaceuticalcompositions comprising the polynucleotides of the present disclosureand a conjugate that may have a degradable linkage. Non-limitingexamples of conjugates include an aromatic moiety comprising anionizable hydrogen atom, a spacer moiety, and a water-soluble polymer.As a non-limiting example, pharmaceutical compositions comprising aconjugate with a degradable linkage and methods for delivering suchpharmaceutical compositions are described in U.S. Patent Publication No.US2013/0184443, the contents of which are herein incorporated byreference in their entirety.

The nanoparticle formulations may be a carbohydrate nanoparticlecomprising a carbohydrate carrier and a RNA (e.g., mRNA) vaccine. As anon-limiting example, the carbohydrate carrier may include, but is notlimited to, an anhydride-modified phytoglycogen or glycogen-typematerial, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin,anhydride-modified phytoglycogen beta-dextrin. (See e.g., InternationalPublication No. WO2012/109121; the contents of which are hereinincorporated by reference in their entirety).

Nanoparticle formulations of the present disclosure may be coated with asurfactant or polymer in order to improve the delivery of the particle.In some embodiments, the nanoparticle may be coated with a hydrophiliccoating such as, but not limited to, PEG coatings and/or coatings thathave a neutral surface charge. The hydrophilic coatings may help todeliver nanoparticles with larger payloads such as, but not limited to,RNA (e.g., mRNA) vaccines within the central nervous system. As anon-limiting example nanoparticles comprising a hydrophilic coating andmethods of making such nanoparticles are described in U.S. PatentPublication No. US2013/0183244, the contents of which are hereinincorporated by reference in their entirety.

In some embodiments, the lipid nanoparticles of the present disclosuremay be hydrophilic polymer particles. Non-limiting examples ofhydrophilic polymer particles and methods of making hydrophilic polymerparticles are described in U.S. Patent Publication No. US2013/0210991,the contents of which are herein incorporated by reference in theirentirety.

In some embodiments, the lipid nanoparticles of the present disclosuremay be hydrophobic polymer particles.

Lipid nanoparticle formulations may be improved by replacing thecationic lipid with a biodegradable cationic lipid which is known as arapidly eliminated lipid nanoparticle (reLNP). Ionizable cationiclipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, andDLin-MC3-DMA, have been shown to accumulate in plasma and tissues overtime and may be a potential source of toxicity. The rapid metabolism ofthe rapidly eliminated lipids can improve the tolerability andtherapeutic index of the lipid nanoparticles by an order of magnitudefrom a 1 mg/kg dose to a 10 mg/kg dose in rat. Inclusion of anenzymatically degraded ester linkage can improve the degradation andmetabolism profile of the cationic component, while still maintainingthe activity of the reLNP formulation. The ester linkage can beinternally located within the lipid chain or it may be terminallylocated at the terminal end of the lipid chain. The internal esterlinkage may replace any carbon in the lipid chain.

In some embodiments, the internal ester linkage may be located on eitherside of the saturated carbon.

In some embodiments, an immune response may be elicited by delivering alipid nanoparticle which may include a nanospecies, a polymer and animmunogen. (U.S. Publication No. 2012/0189700 and InternationalPublication No. WO2012/099805; each of which is herein incorporated byreference in their entirety). The polymer may encapsulate thenanospecies or partially encapsulate the nanospecies. The immunogen maybe a recombinant protein, a modified RNA and/or a polynucleotidedescribed herein. In some embodiments, the lipid nanoparticle may beformulated for use in a vaccine such as, but not limited to, against apathogen.

Lipid nanoparticles may be engineered to alter the surface properties ofparticles so the lipid nanoparticles may penetrate the mucosal barrier.Mucus is located on mucosal tissue such as, but not limited to, oral(e.g., the buccal and esophageal membranes and tonsil tissue),ophthalmic, gastrointestinal (e.g., stomach, small intestine, largeintestine, colon, rectum), nasal, respiratory (e.g., nasal, pharyngeal,tracheal and bronchial membranes), genital (e.g., vaginal, cervical andurethral membranes). Nanoparticles larger than 10-200 nm which arepreferred for higher drug encapsulation efficiency and the ability toprovide the sustained delivery of a wide array of drugs have beenthought to be too large to rapidly diffuse through mucosal barriers.Mucus is continuously secreted, shed, discarded or digested and recycledso most of the trapped particles may be removed from the mucosa tissuewithin seconds or within a few hours. Large polymeric nanoparticles (200nm -500 nm in diameter) which have been coated densely with a lowmolecular weight polyethylene glycol (PEG) diffused through mucus only 4to 6-fold lower than the same particles diffusing in water (Lai et al.PNAS 2007 104:1482-487; Lai et al. Adv Drug Deliv Rev. 2009 61: 158-171;each of which is herein incorporated by reference in their entirety).The transport of nanoparticles may be determined using rates ofpermeation and/or fluorescent microscopy techniques including, but notlimited to, fluorescence recovery after photobleaching (FRAP) and highresolution multiple particle tracking (MPT). As a non-limiting example,compositions which can penetrate a mucosal barrier may be made asdescribed in U.S. Pat. No. 8,241,670 or International Patent PublicationNo. WO2013/110028, the contents of each of which are herein incorporatedby reference in its entirety.

The lipid nanoparticle engineered to penetrate mucus may comprise apolymeric material (i.e. a polymeric core) and/or a polymer-vitaminconjugate and/or a tri-block co-polymer. The polymeric material mayinclude, but is not limited to, polyamines, polyethers, polyamides,polyesters, polycarbamates, polyureas, polycarbonates, poly(styrenes),polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes,polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates,polyacrylonitriles, and polyarylates. The polymeric material may bebiodegradable and/or biocompatible. Non-limiting examples ofbiocompatible polymers are described in International Patent PublicationNo. WO2013/116804, the contents of which are herein incorporated byreference in their entirety. The polymeric material may additionally beirradiated. As a non-limiting example, the polymeric material may begamma irradiated (see e.g., International App. No. WO2012/082165, hereinincorporated by reference in its entirety). Non-limiting examples ofspecific polymers include poly(caprolactone) (PCL), ethylene vinylacetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid)(PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid)(PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide)(PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone),poly(D,L-lactide-co-caprolactone-co-glycolide),poly(D,L-lactide-co-PEO-co-D,L-lactide),poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacralate,polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA),polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids),polyanhydrides, polyorthoesters, poly(ester amides), polyamides,poly(ester ethers), polycarbonates, polyalkylenes such as polyethyleneand polypropylene, polyalkylene glycols such as poly(ethylene glycol)(PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such aspoly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinylethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halidessuch as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes,polystyrene (PS), polyurethanes, derivatized celluloses such as alkylcelluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters,nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose,polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA),poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate),poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate),poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate),poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropylacrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) andcopolymers and mixtures thereof, polydioxanone and its copolymers,polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene,poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid),poly(lactide-co-caprolactone), PEG-PLGA-PEG and trimethylene carbonate,polyvinylpyrrolidone. The lipid nanoparticle may be coated or associatedwith a co-polymer such as, but not limited to, a block co-polymer (suchas a branched polyether-polyamide block copolymer described inInternational Publication No. WO2013/012476, herein incorporated byreference in its entirety), and (poly(ethylene glycol))-(poly(propyleneoxide))-(poly(ethylene glycol)) triblock copolymer (see e.g., U.S.Publication 2012/0121718 and U.S. Publication 2010/0003337 and U.S. Pat.No. 8,263,665, the contents of each of which is herein incorporated byreference in their entirety). The co-polymer may be a polymer that isgenerally regarded as safe (GRAS) and the formation of the lipidnanoparticle may be in such a way that no new chemical entities arecreated. For example, the lipid nanoparticle may comprise poloxamerscoating PLGA nanoparticles without forming new chemical entities whichare still able to rapidly penetrate human mucus (Yang et al. Angew.Chem. Int. Ed. 2011 50:2597-2600; the contents of which are hereinincorporated by reference in their entirety). A non-limiting scalablemethod to produce nanoparticles which can penetrate human mucus isdescribed by Xu et al. (see, e.g., J Control Release 2013, 170:279-86;the contents of which are herein incorporated by reference in theirentirety).

The vitamin of the polymer-vitamin conjugate may be vitamin E. Thevitamin portion of the conjugate may be substituted with other suitablecomponents such as, but not limited to, vitamin A, vitamin E, othervitamins, cholesterol, a hydrophobic moiety, or a hydrophobic componentof other surfactants (e.g., sterol chains, fatty acids, hydrocarbonchains and alkylene oxide chains).

The lipid nanoparticle engineered to penetrate mucus may include surfacealtering agents such as, but not limited to, polynucleotides, anionicproteins (e.g., bovine serum albumin), surfactants (e.g., cationicsurfactants such as for example dimethyldioctadecyl-ammonium bromide),sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids,polymers (e.g., heparin, polyethylene glycol and poloxamer), mucolyticagents (e.g., N-acetylcysteine, mugwort, bromelain, papain,clerodendrum, acetylcysteine, bromhexine, carbocisteine, eprazinone,mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin,gel solin, thymosin β4 dornase alfa, neltenexine, erdosteine) andvarious DNases including rhDNase. The surface altering agent may beembedded or enmeshed in the particle's surface or disposed (e.g., bycoating, adsorption, covalent linkage, or other process) on the surfaceof the lipid nanoparticle. (see e.g., U.S. Publication 2010/0215580 andU.S. Publication 2008/0166414 and US2013/0164343; the contents of eachof which are herein incorporated by reference in their entirety).

In some embodiments, the mucus penetrating lipid nanoparticles maycomprise at least one polynucleotide described herein. Thepolynucleotide may be encapsulated in the lipid nanoparticle and/ordisposed on the surface of the particle. The polynucleotide may becovalently coupled to the lipid nanoparticle. Formulations of mucuspenetrating lipid nanoparticles may comprise a plurality ofnanoparticles. Further, the formulations may contain particles which mayinteract with the mucus and alter the structural and/or adhesiveproperties of the surrounding mucus to decrease mucoadhesion, which mayincrease the delivery of the mucus penetrating lipid nanoparticles tothe mucosal tissue.

In some embodiments, the mucus penetrating lipid nanoparticles may be ahypotonic formulation comprising a mucosal penetration enhancingcoating. The formulation may be hypotonic for the epithelium to which itis being delivered. Non-limiting examples of hypotonic formulations maybe found in International Patent Publication No. WO2013/110028, thecontents of which are herein incorporated by reference in theirentirety.

In some embodiments, in order to enhance the delivery through themucosal barrier the RNA (e.g., mRNA) vaccine formulation may comprise orbe a hypotonic solution. Hypotonic solutions were found to increase therate at which mucoinert particles such as, but not limited to,mucus-penetrating particles, were able to reach the vaginal epithelialsurface (see e.g., Ensign et al. Biomaterials 2013 34(28):6922-9, thecontents of which are herein incorporated by reference in theirentirety).

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as alipoplex, such as, without limitation, the ATUPLEX™ system, the DACCsystem, the DBTC system and other siRNA-lipoplex technology from SilenceTherapeutics (London, United Kingdom), STEMFECT™ from STEMGENT®(Cambridge, Mass.), and polyethylenimine (PEI) or protamine-basedtargeted and non-targeted delivery of nucleic acids (Aleku et al. CancerRes. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 201250:76-78; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al.,Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 201023:334-344; Kaufmann et al. Microvasc Res 2010 80:286-293Weide et al. JImmunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31:180-188;Pascolo Expert Opin. Biol. Ther. 4:1285-1294; Fotin-Mleczek et al., 2011J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005,23:709-717; Peer et al., Proc Natl Acad Sci U S A. 2007 6;104:4095-4100; deFougerolles Hum Gene Ther. 2008 19:125-132, thecontents of each of which are incorporated herein by reference in theirentirety).

In some embodiments, such formulations may also be constructed orcompositions altered such that they passively or actively are directedto different cell types in vivo, including but not limited tohepatocytes, immune cells, tumor cells, endothelial cells, antigenpresenting cells, and leukocytes (Akinc et al. Mol Ther. 201018:1357-1364; Song et al., Nat Biotechnol. 2005 23:709-717; Judge etal., J Clin Invest. 2009 119:661-673; Kaufmann et al., Microvasc Res2010 80:286-293; Santel et al., Gene Ther 2006 13:1222-1234; Santel etal., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther.2010 23:334-344; Basha et al., Mol. Ther. 2011 19:2186-2200; Fenske andCullis, Expert Opin Drug Deliv. 2008 5:25-44; Peer et al., Science. 2008319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, thecontents of each of which are incorporated herein by reference in theirentirety). One example of passive targeting of formulations to livercells includes the DLin-DMA, DLin-KC2-DMA and DLin-MC3-DMA-based lipidnanoparticle formulations, which have been shown to bind toapolipoprotein E and promote binding and uptake of these formulationsinto hepatocytes in vivo (Akinc et al. Mol Ther. 2010 18:1357-1364, thecontents of which are incorporated herein by reference in theirentirety). Formulations can also be selectively targeted throughexpression of different ligands on their surface as exemplified by, butnot limited by, folate, transferrin, N-acetylgalactosamine (GalNAc), andantibody targeted approaches (Kolhatkar et al., Curr Drug DiscovTechnol. 2011 8:197-206; Musacchio and Torchilin, Front Biosci. 201116:1388-1412; Yu et al., Mol Membr Biol. 2010 27:286-298; Patil et al.,Crit Rev Ther Drug Carrier Syst. 2008 25:1-61; Benoit et al.,Biomacromolecules. 2011 12:2708-2714; Zhao et al., Expert Opin DrugDeliv. 2008 5:309-319; Akinc etal., Mol Ther. 2010 18:1357-1364;Srinivasan etal., Methods Mol Biol. 2012 820:105-116; Ben-Arie et al.,Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release.20:63-68; Peer et al., Proc Natl Acad Sci U S A. 2007 104:4095-4100; Kimet al., Methods Mol Biol. 2011 721:339-353; Subramanya et al., Mol Ther.2010 18:2028-2037; Song et al., Nat Biotechnol. 2005 23:709-717; Peer etal., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 201118:1127-1133, the contents of each of which are incorporated herein byreference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as asolid lipid nanoparticle. A solid lipid nanoparticle (SLN) may bespherical with an average diameter between 10 to 1000 nm. SLN possess asolid lipid core matrix that can solubilize lipophilic molecules and maybe stabilized with surfactants and/or emulsifiers. In some embodiments,the lipid nanoparticle may be a self-assembly lipid-polymer nanoparticle(see Zhang et al., ACS Nano, 2008, 2 , pp 1696-1702; the contents ofwhich are herein incorporated by reference in their entirety). As anon-limiting example, the SLN may be the SLN described in InternationalPatent Publication No. WO2013/105101, the contents of which are hereinincorporated by reference in their entirety. As another non-limitingexample, the SLN may be made by the methods or processes described inInternational Patent Publication No. WO2013/105101, the contents ofwhich are herein incorporated by reference in their entirety.

Liposomes, lipoplexes, or lipid nanoparticles may be used to improve theefficacy of polynucleotides directed protein production as theseformulations may be able to increase cell transfection by the RNA (e.g.,mRNA) vaccine; and/or increase the translation of encoded protein. Onesuch example involves the use of lipid encapsulation to enable theeffective systemic delivery of polyplex plasmid DNA (Heyes et al., MolTher. 2007 15:713-720; the contents of which are incorporated herein byreference in their entirety). The liposomes, lipoplexes, or lipidnanoparticles may also be used to increase the stability of thepolynucleotide.

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure can be formulated for controlled release and/or targeteddelivery. As used herein, “controlled release” refers to apharmaceutical composition or compound release profile that conforms toa particular pattern of release to effect a therapeutic outcome. In someembodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into adelivery agent described herein and/or known in the art for controlledrelease and/or targeted delivery. As used herein, the term “encapsulate”means to enclose, surround or encase. As it relates to the formulationof the compounds of the disclosure, encapsulation may be substantial,complete or partial. The term “substantially encapsulated” means that atleast greater than 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9,99.9 or greater than 99.999% of the pharmaceutical composition orcompound of the disclosure may be enclosed, surrounded or encased withinthe delivery agent. “Partially encapsulation” means that less than 10,10, 20, 30, 40 50 or less of the pharmaceutical composition or compoundof the disclosure may be enclosed, surrounded or encased within thedelivery agent. Advantageously, encapsulation may be determined bymeasuring the escape or the activity of the pharmaceutical compositionor compound of the disclosure using fluorescence and/or electronmicrograph. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80,85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of thepharmaceutical composition or compound of the disclosure areencapsulated in the delivery agent.

In some embodiments, the controlled release formulation may include, butis not limited to, tri-block co-polymers. As a non-limiting example, theformulation may include two different types of tri-block co-polymers(International Pub. No. WO2012/131104 and WO2012/131106, the contents ofeach of which are incorporated herein by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulatedinto a lipid nanoparticle or a rapidly eliminated lipid nanoparticle andthe lipid nanoparticles or a rapidly eliminated lipid nanoparticle maythen be encapsulated into a polymer, hydrogel and/or surgical sealantdescribed herein and/or known in the art. As a non-limiting example, thepolymer, hydrogel or surgical sealant may be PLGA, ethylene vinylacetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics, Inc. Alachua,Fla.), HYLENEX® (Halozyme Therapeutics, San Diego Calif.), surgicalsealants such as fibrinogen polymers (Ethicon Inc. Cornelia, Ga.),TISSELL® (Baxter International, Inc. Deerfield, Ill.), PEG-basedsealants, and COSEAL® (Baxter International, Inc Deerfield, Ill.).

In some embodiments, the lipid nanoparticle may be encapsulated into anypolymer known in the art which may form a gel when injected into asubject. As another non-limiting example, the lipid nanoparticle may beencapsulated into a polymer matrix which may be biodegradable.

In some embodiments, the RNA (e.g., mRNA) vaccine formulation forcontrolled release and/or targeted delivery may also include at leastone controlled release coating. Controlled release coatings include, butare not limited to, OPADRY®, polyvinylpyrrolidone/vinyl acetatecopolymer, polyvinylpyrrolidone, hydroxypropyl methylcellulose,hydroxypropyl cellulose, hydroxyethyl cellulose, EUDRAGIT RL®, EUDRAGITRS® and cellulose derivatives such as ethylcellulose aqueous dispersions(AQUACOAT® and SURELEASE®).

In some embodiments, the RNA (e.g., mRNA) vaccine controlled releaseand/or targeted delivery formulation may comprise at least onedegradable polyester which may contain polycationic side chains.Degradeable polyesters include, but are not limited to, poly(serineester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester),and combinations thereof. In some embodiments, the degradable polyestersmay include a PEG conjugation to form a PEGylated polymer.

In some embodiments, the RNA (e.g., mRNA) vaccine controlled releaseand/or targeted delivery formulation comprising at least onepolynucleotide may comprise at least one PEG and/or PEG related polymerderivatives as described in U.S. Pat. No. 8,404,222, the contents ofwhich are incorporated herein by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine controlled releasedelivery formulation comprising at least one polynucleotide may be thecontrolled release polymer system described in US2013/0130348, thecontents of which are incorporated herein by reference in theirentirety.

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure may be encapsulated in a therapeutic nanoparticle, referredto herein as “therapeutic nanoparticle RNA (e.g., mRNA) vaccines.”Therapeutic nanoparticles may be formulated by methods described hereinand known in the art such as, but not limited to, International Pub Nos.WO2010/005740, WO2010/030763, WO2010/005721, WO2010/005723,WO2012/054923,

U.S. Publication Nos. US2011/0262491, US2010/0104645, US2010/0087337,US2010/0068285, US2011/0274759, US2010/0068286, US2012/0288541,US2013/0123351 and US2013/0230567 and U.S. Pat. Nos. 8,206,747,8,293,276, 8,318,208 and 8,318,211; the contents of each of which areherein incorporated by reference in their entirety. In some embodiments,therapeutic polymer nanoparticles may be identified by the methodsdescribed in US Pub No. US2012/0140790, the contents of which are hereinincorporated by reference in their entirety.

In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA)vaccine may be formulated for sustained release. As used herein,“sustained release” refers to a pharmaceutical composition or compoundthat conforms to a release rate over a specific period of time. Theperiod of time may include, but is not limited to, hours, days, weeks,months and years. As a non-limiting example, the sustained releasenanoparticle may comprise a polymer and a therapeutic agent such as, butnot limited to, the polynucleotides of the present disclosure (seeInternational Pub No. WO2010/075072 and US Pub No. US2010/0216804,US2011/0217377 and US2012/0201859, the contents of each of which areincorporated herein by reference in their entirety). In anothernon-limiting example, the sustained release formulation may compriseagents which permit persistent bioavailability such as, but not limitedto, crystals, macromolecular gels and/or particulate suspensions (seeU.S. Patent Publication No US2013/0150295, the contents of each of whichare incorporated herein by reference in their entirety).

In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA)vaccines may be formulated to be target specific. As a non-limitingexample, the therapeutic nanoparticles may include a corticosteroid (seeInternational Pub. No. WO2011/084518, the contents of which areincorporated herein by reference in their entirety). As a non-limitingexample, the therapeutic nanoparticles may be formulated innanoparticles described in International Pub No. WO2008/121949,WO2010/005726, WO2010/005725, WO2011/084521 and US Pub No.US2010/0069426, US2012/0004293 and US2010/0104655, the contents of eachof which are incorporated herein by reference in their entirety.

In some embodiments, the nanoparticles of the present disclosure maycomprise a polymeric matrix. As a non-limiting example, the nanoparticlemay comprise two or more polymers such as, but not limited to,polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids,polypropylfumerates, polycaprolactones, polyamides, polyacetals,polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinylalcohols, polyurethanes, polyphosphazenes, polyacrylates,polymethacrylates, polycyanoacrylates, polyureas, polystyrenes,polyamines, polylysine, poly(ethylene imine), poly(serine ester),poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) orcombinations thereof.

In some embodiments, the therapeutic nanoparticle comprises a diblockcopolymer. In some embodiments, the diblock copolymer may include PEG incombination with a polymer such as, but not limited to, polyethylenes,polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates,polycaprolactones, polyamides, polyacetals, polyethers, polyesters,poly(orthoesters), polycyanoacrylates, polyvinyl alcohols,polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates,polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine,poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine),poly(4-hydroxy-L-proline ester) or combinations thereof. In yet anotherembodiment, the diblock copolymer may be a high-X diblock copolymer suchas those described in International Patent Publication No.WO2013/120052, the contents of which are incorporated herein byreference in their entirety.

As a non-limiting example the therapeutic nanoparticle comprises aPLGA-PEG block copolymer (see U.S. Publication No. US2012/0004293 andU.S. Pat. No. 8,236,330, each of which is herein incorporated byreference in their entirety). In another non-limiting example, thetherapeutic nanoparticle is a stealth nanoparticle comprising a diblockcopolymer of PEG and PLA or PEG and PLGA (see U.S. Pat. No 8,246,968 andInternational Publication No. WO2012/166923, the contents of each ofwhich are herein incorporated by reference in their entirety). In yetanother non-limiting example, the therapeutic nanoparticle is a stealthnanoparticle or a target-specific stealth nanoparticle as described inU.S. Patent Publication No. US2013/0172406, the contents of which areherein incorporated by reference in their entirety.

In some embodiments, the therapeutic nanoparticle may comprise amultiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910and U.S. Patent Pub. No. US2013/0195987, the contents of each of whichare herein incorporated by reference in their entirety).

In yet another non-limiting example, the lipid nanoparticle comprisesthe block copolymer PEG-PLGA-PEG (see e.g., the thermosensitive hydrogel(PEG-PLGA-PEG) was used as a TGF-betal gene delivery vehicle in Lee etal. Thermosensitive Hydrogel as a TGF-β1 Gene Delivery Vehicle EnhancesDiabetic Wound Healing. Pharmaceutical Research, 2003 20(12): 1995-2000;as a controlled gene delivery system in Li et al. Controlled GeneDelivery System Based on Thermosensitive Biodegradable Hydrogel.Pharmaceutical Research 2003 20:884-888; and Chang et al., Non-ionicamphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene deliveryefficiency in rat skeletal muscle. J Controlled Release. 2007118:245-253, the contents of each of which are herein incorporated byreference in their entirety). The RNA (e.g., mRNA) vaccines of thepresent disclosure may be formulated in lipid nanoparticles comprisingthe PEG-PLGA-PEG block copolymer.

In some embodiments, the therapeutic nanoparticle may comprise amultiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910and U.S. Patent Pub. No. US2013/0195987, the contents of each of whichare herein incorporated by reference in their entirety).

In some embodiments, the block copolymers described herein may beincluded in a polyion complex comprising a non-polymeric micelle and theblock copolymer. (see e.g., U.S. Publication No. 2012/0076836, thecontents of which are herein incorporated by reference in theirentirety).

In some embodiments, the therapeutic nanoparticle may comprise at leastone acrylic polymer. Acrylic polymers include but are not limited to,acrylic acid, methacrylic acid, acrylic acid and methacrylic acidcopolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates,cyanoethyl methacrylate, amino alkyl methacrylate copolymer,poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates andcombinations thereof.

In some embodiments, the therapeutic nanoparticles may comprise at leastone poly(vinyl ester) polymer. The poly(vinyl ester) polymer may be acopolymer such as a random copolymer. As a non-limiting example, therandom copolymer may have a structure such as those described inInternational Application No. WO2013/032829 or U.S. Patent PublicationNo US2013/0121954, the contents of each of which are herein incorporatedby reference in their entirety. In some embodiments, the poly(vinylester) polymers may be conjugated to the polynucleotides describedherein.

In some embodiments, the therapeutic nanoparticle may comprise at leastone diblock copolymer. The diblock copolymer may be, but it not limitedto, a poly(lactic) acid-poly(ethylene)glycol copolymer (see, e.g.,International Patent Publication No. WO2013/044219, the contents ofwhich are herein incorporated by reference in their entirety). As anon-limiting example, the therapeutic nanoparticle may be used to treatcancer (see International publication No. WO2013/044219, the contents ofwhich are herein incorporated by reference in their entirety).

In some embodiments, the therapeutic nanoparticles may comprise at leastone cationic polymer described herein and/or known in the art.

In some embodiments, the therapeutic nanoparticles may comprise at leastone amine-containing polymer such as, but not limited to polylysine,polyethylene imine, poly(amidoamine) dendrimers, poly(beta-amino esters)(see, e.g., U.S. Pat. No. 8,287,849, the contents of which are hereinincorporated by reference in their entirety) and combinations thereof.

In some embodiments, the nanoparticles described herein may comprise anamine cationic lipid such as those described in International PatentApplication No. WO2013/059496, the contents of which are hereinincorporated by reference in their entirety. In some embodiments, thecationic lipids may have an amino-amine or an amino-amide moiety.

In some embodiments, the therapeutic nanoparticles may comprise at leastone degradable polyester which may contain polycationic side chains.Degradeable polyesters include, but are not limited to, poly(serineester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester),and combinations thereof. In some embodiments, the degradable polyestersmay include a PEG conjugation to form a PEGylated polymer.

In some embodiments, the synthetic nanocarriers may contain animmunostimulatory agent to enhance the immune response from delivery ofthe synthetic nanocarrier. As a non-limiting example, the syntheticnanocarrier may comprise a Th1 immunostimulatory agent, which mayenhance a Th1-based response of the immune system (see International PubNo. WO2010/123569 and U.S. Publication No. US2011/0223201, the contentsof each of which are herein incorporated by reference in theirentirety).

In some embodiments, the synthetic nanocarriers may be formulated fortargeted release. In some embodiments, the synthetic nanocarrier isformulated to release the polynucleotides at a specified pH and/or aftera desired time interval. As a non-limiting example, the syntheticnanoparticle may be formulated to release the RNA (e.g., mRNA) vaccinesafter 24 hours and/or at a pH of 4.5 (see International Publication Nos.WO2010/138193 and WO2010/138194 and US Pub Nos. US2011/0020388 andUS2011/0027217, each of which is herein incorporated by reference intheir entireties).

In some embodiments, the synthetic nanocarriers may be formulated forcontrolled and/or sustained release of the polynucleotides describedherein. As a non-limiting example, the synthetic nanocarriers forsustained release may be formulated by methods known in the art,described herein and/or as described in International Pub No.WO2010/138192 and US Pub No. 2010/0303850, each of which is hereinincorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated forcontrolled and/or sustained release wherein the formulation comprises atleast one polymer that is a crystalline side chain (CYSC) polymer. CYSCpolymers are described in U.S. Pat. No. 8,399,007, herein incorporatedby reference in its entirety.

In some embodiments, the synthetic nanocarrier may be formulated for useas a vaccine. In some embodiments, the synthetic nanocarrier mayencapsulate at least one polynucleotide which encode at least oneantigen. As a non-limiting example, the synthetic nanocarrier mayinclude at least one antigen and an excipient for a vaccine dosage form(see International Publication No. WO2011/150264 and U.S. PublicationNo. US2011/0293723, the contents of each of which are hereinincorporated by reference in their entirety). As another non-limitingexample, a vaccine dosage form may include at least two syntheticnanocarriers with the same or different antigens and an excipient (seeInternational Publication No. WO2011/150249 and U.S. Publication No.US2011/0293701, the contents of each of which are herein incorporated byreference in their entirety). The vaccine dosage form may be selected bymethods described herein, known in the art and/or described inInternational Publication No. WO2011/150258 and U.S. Publication No.US2012/0027806, the contents of each of which are herein incorporated byreference in their entirety).

In some embodiments, the synthetic nanocarrier may comprise at least onepolynucleotide which encodes at least one adjuvant. As non-limitingexample, the adjuvant may comprise dimethyldioctadecylammonium-bromide,dimethyldioctadecylammonium-chloride,dimethyldioctadecylammonium-phosphate ordimethyldioctadecylammonium-acetate (DDA) and an apolar fraction or partof said apolar fraction of a total lipid extract of a mycobacterium(see, e.g., U.S. Pat. No. 8,241,610, the content of which is hereinincorporated by reference in its entirety). In some embodiments, thesynthetic nanocarrier may comprise at least one polynucleotide and anadjuvant. As a non-limiting example, the synthetic nanocarriercomprising and adjuvant may be formulated by the methods described inInternational Publication No. WO2011/150240 and U.S. Publication No.US2011/0293700, the contents of each of which are herein incorporated byreference in their entirety.

In some embodiments, the synthetic nanocarrier may encapsulate at leastone polynucleotide that encodes a peptide, fragment or region from avirus. As a non-limiting example, the synthetic nanocarrier may include,but is not limited to, any of the nanocarriers described inInternational Publication No. WO2012/024621, WO2012/02629, WO2012/024632and U.S. Publication No. US2012/0064110, US2012/0058153 andUS2012/0058154, the contents of each of which are herein incorporated byreference in their entirety.

In some embodiments, the synthetic nanocarrier may be coupled to apolynucleotide which may be able to trigger a humoral and/or cytotoxic Tlymphocyte (CTL) response (see, e.g., International Publication No.WO2013/019669, the contents of which are herein incorporated byreference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccine may be encapsulatedin, linked to and/or associated with zwitterionic lipids. Non-limitingexamples of zwitterionic lipids and methods of using zwitterionic lipidsare described in U.S. Patent Publication No. US2013/0216607, thecontents of which are herein incorporated by reference in theirentirety. In some aspects, the zwitterionic lipids may be used in theliposomes and lipid nanoparticles described herein.

In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated incolloid nanocarriers as described in U.S. Patent Publication No.US2013/0197100, the contents of which are herein incorporated byreference in their entirety.

In some embodiments, the nanoparticle may be optimized for oraladministration. The nanoparticle may comprise at least one cationicbiopolymer such as, but not limited to, chitosan or a derivativethereof. As a non-limiting example, the nanoparticle may be formulatedby the methods described in U.S. Publication No. US2012/0282343, thecontents of which are herein incorporated by reference in theirentirety.

In some embodiments, LNPs comprise the lipid KL52 (an amino-lipiddisclosed in U.S. Application Publication No. 2012/0295832, the contentsof which are herein incorporated by reference in their entirety.Activity and/or safety (as measured by examining one or more of ALT/AST,white blood cell count and cytokine induction, for example) of LNPadministration may be improved by incorporation of such lipids. LNPscomprising KL52 may be administered intravenously and/or in one or moredoses. In some embodiments, administration of LNPs comprising KL52results in equal or improved mRNA and/or protein expression as comparedto LNPs comprising MC3.

In some embodiments, RNA (e.g., mRNA) vaccine may be delivered usingsmaller LNPs. Such particles may comprise a diameter from below 0.1 umup to 100 nm such as, but not limited to, less than 0.1 um, less than1.0 um, less than 5 um, less than 10 um, less than 15 um, less than 20um, less than 25 um, less than 30 um, less than 35 um, less than 40 um,less than 50 um, less than 55 um, less than 60 um, less than 65 um, lessthan 70 um, less than 75 um, less than 80 um, less than 85 um, less than90 um, less than 95 um, less than 100 um, less than 125 um, less than150 um, less than 175 um, less than 200 um, less than 225 um, less than250 um, less than 275 um, less than 300 um, less than 325 um, less than350 um, less than 375 um, less than 400 um, less than 425 um, less than450 um, less than 475 um, less than 500 um, less than 525 um, less than550 um, less than 575 um, less than 600 um, less than 625 um, less than650 um, less than 675 um, less than 700 um, less than 725 um, less than750 um, less than 775 um, less than 800 um, less than 825 um, less than850 um, less than 875 um, less than 900 um, less than 925 um, less than950 um, less than 975 um, or less than 1000 um.

In some embodiments, RNA (e.g., mRNA) vaccines may be delivered usingsmaller LNPs, which may comprise a diameter from about 1 nm to about 100nm, from about 1 nm to about 10 nm, about 1 nm to about 20 nm, fromabout 1 nm to about 30 nm, from about 1 nm to about 40 nm, from about 1nm to about 50 nm, from about 1 nm to about 60 nm, from about 1 nm toabout 70 nm, from about 1 nm to about 80 nm, from about 1 nm to about 90nm, from about 5 nm to about from 100 nm, from about 5 nm to about 10nm, about 5 nm to about 20 nm, from about 5 nm to about 30 nm, fromabout 5 nm to about 40 nm, from about 5 nm to about 50 nm, from about 5nm to about 60 nm, from about 5 nm to about 70 nm, from about 5 nm toabout 80 nm, from about 5 nm to about 90 nm, about 10 to about 50 nm,from about 20 to about 50 nm, from about 30 to about 50 nm, from about40 to about 50 nm, from about 20 to about 60 nm, from about 30 to about60 nm, from about 40 to about 60 nm, from about 20 to about 70 nm, fromabout 30 to about 70 nm, from about 40 to about 70 nm, from about 50 toabout 70 nm, from about 60 to about 70 nm, from about 20 to about 80 nm,from about 30 to about 80 nm, from about 40 to about 80 nm, from about50 to about 80 nm, from about 60 to about 80 nm, from about 20 to about90 nm, from about 30 to about 90 nm, from about 40 to about 90 nm, fromabout 50 to about 90 nm, from about 60 to about 90 nm and/or from about70 to about 90 nm.

In some embodiments, such LNPs are synthesized using methods comprisingmicrofluidic mixers. Examples of microfluidic mixers may include, butare not limited to, a slit interdigital micromixer including, but notlimited to those manufactured by Microinnova (Allerheiligen bei Wildon,Austria) and/or a staggered herringbone micromixer (SHM) (Zhigaltsev,I.V. et al., Bottom-up design and synthesis of limit size lipidnanoparticle systems with aqueous and triglyceride cores usingmillisecond microfluidic mixing have been published (Langmuir. 2012.28:3633-40; Belliveau, N.M. et al., Microfluidic synthesis of highlypotent limit-size lipid nanoparticles for in vivo delivery of siRNA.Molecular Therapy-Nucleic Acids. 2012. 1:e37; Chen, D. et al., Rapiddiscovery of potent siRNA-containing lipid nanoparticles enabled bycontrolled microfluidic formulation. J Am Chem Soc. 2012.134(16):6948-51, the contents of each of which are herein incorporatedby reference in their entirety). In some embodiments, methods of LNPgeneration comprising SHM, further comprise the mixing of at least twoinput streams wherein mixing occurs by microstructure-induced chaoticadvection (MICA). According to this method, fluid streams flow throughchannels present in a herringbone pattern causing rotational flow andfolding the fluids around each other. This method may also comprise asurface for fluid mixing wherein the surface changes orientations duringfluid cycling. Methods of generating LNPs using SHM include thosedisclosed in U.S. Application Publication Nos. 2004/0262223 and2012/0276209, the contents of each of which are herein incorporated byreference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine of the presentdisclosure may be formulated in lipid nanoparticles created using amicromixer such as, but not limited to, a Slit InterdigitalMicrostructured Mixer (SIMM-V2) or a Standard Slit Interdigital MicroMixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet (IJMM)from theInstitut fur Mikrotechnik Mainz GmbH, Mainz Germany).

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure may be formulated in lipid nanoparticles created usingmicrofluidic technology (see, e.g., Whitesides, George M. The Originsand the Future of Microfluidics. Nature, 2006 442: 368-373; and Abrahamet al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651; eachof which is herein incorporated by reference in its entirety). As anon-limiting example, controlled microfluidic formulation includes apassive method for mixing streams of steady pressure-driven flows inmicro channels at a low Reynolds number (see, e.g., Abraham et al.Chaotic Mixer for Microchannels. Science, 2002 295: 647-651, thecontents of which are herein incorporated by reference in theirentirety).

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure may be formulated in lipid nanoparticles created using amicromixer chip such as, but not limited to, those from HarvardApparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). Amicromixer chip can be used for rapid mixing of two or more fluidstreams with a split and recombine mechanism.

In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure maybe formulated for delivery using the drug encapsulating microspheresdescribed in International Patent Publication No. WO2013063468 or U.S.Pat. No. 8,440,614, the contents of each of which are hereinincorporated by reference in their entirety. The microspheres maycomprise a compound of the formula (I), (II), (III), (IV), (V) or (VI)as described in International Patent Publication No. WO2013/063468, thecontents of which are herein incorporated by reference in theirentirety. In some embodiments, the amino acid, peptide, polypeptide,lipids (APPL) are useful in delivering the RNA (e.g., mRNA) vaccines ofthe disclosure to cells (see International Patent Publication No.WO2013/063468, the contents of which are herein incorporated byreference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure maybe formulated in lipid nanoparticles having a diameter from about 10 toabout 100 nm such as, but not limited to, about 10 to about 20 nm, about10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm,about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 toabout 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about30 to about 60 nm, about 30 to about 70 nm, about 30 to about 80 nm,about 30 to about 90 nm, about 30 to about 100 nm, about 40 to about 50nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40 to about80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about 50 toabout 60 nm, about 50 to about 70 nm about 50 to about 80 nm, about 50to about 90 nm, about 50 to about 100 nm, about 60 to about 70 nm, about60 to about 80 nm, about 60 to about 90 nm, about 60 to about 100 nm,about 70 to about 80 nm, about 70 to about 90 nm, about 70 to about 100nm, about 80 to about 90 nm, about 80 to about 100 nm and/or about 90 toabout 100 nm.

In some embodiments, the lipid nanoparticles may have a diameter fromabout 10 to 500 nm.

In some embodiments, the lipid nanoparticle may have a diameter greaterthan 100 nm, greater than 150 nm, greater than 200 nm, greater than 250nm, greater than 300 nm, greater than 350 nm, greater than 400 nm,greater than 450 nm, greater than 500 nm, greater than 550 nm, greaterthan 600 nm, greater than 650 nm, greater than 700 nm, greater than 750nm, greater than 800 nm, greater than 850 nm, greater than 900 nm,greater than 950 nm or greater than 1000 nm.

In some embodiments, the lipid nanoparticle may be a limit size lipidnanoparticle described in International Patent Publication No.WO2013/059922, the contents of which are herein incorporated byreference in their entirety. The limit size lipid nanoparticle maycomprise a lipid bilayer surrounding an aqueous core or a hydrophobiccore; where the lipid bilayer may comprise a phospholipid such as, butnot limited to, diacylphosphatidylcholine, adiacylphosphatidylethanolamine, a ceramide, a sphingomyelin, adihydrosphingomyelin, a cephalin, a cerebroside, a C8-C20 fatty aciddiacylphophatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine(POPC). In some embodiments, the limit size lipid nanoparticle maycomprise a polyethylene glycol-lipid such as, but not limited to,DLPE-PEG, DMPE-PEG, DPPC-PEG and DSPE-PEG.

In some embodiments, the RNA (e.g., mRNA) vaccines may be delivered,localized and/or concentrated in a specific location using the deliverymethods described in International Patent Publication No. WO2013/063530,the contents of which are herein incorporated by reference in theirentirety. As a non-limiting example, a subject may be administered anempty polymeric particle prior to, simultaneously with or afterdelivering the RNA (e.g., mRNA) vaccines to the subject. The emptypolymeric particle undergoes a change in volume once in contact with thesubject and becomes lodged, embedded, immobilized or entrapped at aspecific location in the subject.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated inan active substance release system (see, e.g., U.S. Patent PublicationNo. US2013/0102545, the contents of which are herein incorporated byreference in their entirety). The active substance release system maycomprise 1) at least one nanoparticle bonded to an oligonucleotideinhibitor strand which is hybridized with a catalytically active nucleicacid and 2) a compound bonded to at least one substrate molecule bondedto a therapeutically active substance (e.g., polynucleotides describedherein), where the therapeutically active substance is released by thecleavage of the substrate molecule by the catalytically active nucleicacid.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated ina nanoparticle comprising an inner core comprising a non-cellularmaterial and an outer surface comprising a cellular membrane. Thecellular membrane may be derived from a cell or a membrane derived froma virus. As a non-limiting example, the nanoparticle may be made by themethods described in International Patent Publication No. WO2013/052167,the contents of which are herein incorporated by reference in theirentirety. As another non-limiting example, the nanoparticle described inInternational Patent Publication No. WO2013/052167, the contents ofwhich are herein incorporated by reference in their entirety, may beused to deliver the RNA (e.g., mRNA) vaccines described herein.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated inporous nanoparticle-supported lipid bilayers (protocells). Protocellsare described in International Patent Publication No. WO2013/056132, thecontents of which are herein incorporated by reference in theirentirety.

In some embodiments, the RNA (e.g., mRNA) vaccines described herein maybe formulated in polymeric nanoparticles as described in or made by themethods described in U.S. Pat. Nos. 8,420,123 and 8,518,963 and EuropeanPatent No. EP2073848B1, the contents of each of which are hereinincorporated by reference in their entirety. As a non-limiting example,the polymeric nanoparticle may have a high glass transition temperaturesuch as the nanoparticles described in or nanoparticles made by themethods described in U.S. Pat. No. 8,518,963, the contents of which areherein incorporated by reference in their entirety. As anothernon-limiting example, the polymer nanoparticle for oral and parenteralformulations may be made by the methods described in European Patent No.EP2073848B1, the contents of which are herein incorporated by referencein their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines described herein maybe formulated in nanoparticles used in imaging. The nanoparticles may beliposome nanoparticles such as those described in U.S. PatentPublication No US2013/0129636, herein incorporated by reference in itsentirety. As a non-limiting example, the liposome may comprisegadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N′-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-aceticacid and a neutral, fully saturated phospholipid component (see, e.g.,U.S. Patent Publication No US2013/0129636, the contents of which areherein incorporated by reference in their entirety).

In some embodiments, the nanoparticles which may be used in the presentdisclosure are formed by the methods described in U.S. PatentApplication No. US2013/0130348, the contents of which are hereinincorporated by reference in their entirety.

The nanoparticles of the present disclosure may further includenutrients such as, but not limited to, those which deficiencies can leadto health hazards from anemia to neural tube defects (see, e.g., thenanoparticles described in International Patent Publication NoWO2013/072929, the contents of which are herein incorporated byreference in their entirety). As a non-limiting example, the nutrientmay be iron in the form of ferrous, ferric salts or elemental iron,iodine, folic acid, vitamins or micronutrients.

In some embodiments, the RNA (e.g., mRNA) vaccines of the presentdisclosure may be formulated in a swellable nanoparticle. The swellablenanoparticle may be, but is not limited to, those described in U.S. Pat.No. 8,440,231, the contents of which are herein incorporated byreference in their entirety. As a non-limiting embodiment, the swellablenanoparticle may be used for delivery of the RNA (e.g., mRNA) vaccinesof the present disclosure to the pulmonary system (see, e.g., U.S. Pat.No. 8,440,231, the contents of which are herein incorporated byreference in their entirety).

The RNA (e.g., mRNA) vaccines of the present disclosure may beformulated in polyanhydride nanoparticles such as, but not limited to,those described in U.S. Pat. No. 8,449,916, the contents of which areherein incorporated by reference in their entirety.

The nanoparticles and microparticles of the present disclosure may begeometrically engineered to modulate macrophage and/or the immuneresponse. In some embodiments, the geometrically engineered particlesmay have varied shapes, sizes and/or surface charges in order toincorporated the polynucleotides of the present disclosure for targeteddelivery such as, but not limited to, pulmonary delivery (see, e.g.,International Publication No WO2013/082111, the contents of which areherein incorporated by reference in their entirety). Other physicalfeatures the geometrically engineering particles may have include, butare not limited to, fenestrations, angled arms, asymmetry and surfaceroughness, charge which can alter the interactions with cells andtissues. As a non-limiting example, nanoparticles of the presentdisclosure may be made by the methods described in InternationalPublication No WO2013/082111, the contents of which are hereinincorporated by reference in their entirety.

In some embodiments, the nanoparticles of the present disclosure may bewater soluble nanoparticles such as, but not limited to, those describedin International Publication No. WO2013/090601, the contents of whichare herein incorporated by reference in their entirety. Thenanoparticles may be inorganic nanoparticles which have a compact andzwitterionic ligand in order to exhibit good water solubility. Thenanoparticles may also have small hydrodynamic diameters (HD), stabilitywith respect to time, pH, and salinity and a low level of non-specificprotein binding.

In some embodiments the nanoparticles of the present disclosure may bedeveloped by the methods described in U.S. Patent Publication No.US2013/0172406, the contents of which are herein incorporated byreference in their entirety.

In some embodiments, the nanoparticles of the present disclosure arestealth nanoparticles or target-specific stealth nanoparticles such as,but not limited to, those described in U.S. Patent Publication No.US2013/0172406, the contents of which are herein incorporated byreference in their entirety. The nanoparticles of the present disclosuremay be made by the methods described in U.S. Patent Publication No.US2013/0172406, the contents of which are herein incorporated byreference in their entirety.

In some embodiments, the stealth or target-specific stealthnanoparticles may comprise a polymeric matrix. The polymeric matrix maycomprise two or more polymers such as, but not limited to,polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids,polypropylfumerates, polycaprolactones, polyamides, polyacetals,polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinylalcohols, polyurethanes, polyphosphazenes, polyacrylates,polymethacrylates, polycyanoacrylates, polyureas, polystyrenes,polyamines, polyesters, polyanhydrides, polyethers, polyurethanes,polymethacrylates, polyacrylates, polycyanoacrylates or combinationsthereof.

In some embodiments, the nanoparticle may be a nanoparticle-nucleic acidhybrid structure having a high density nucleic acid layer. As anon-limiting example, the nanoparticle-nucleic acid hybrid structure maymade by the methods described in U.S. Patent Publication No.US2013/0171646, the contents of which are herein incorporated byreference in their entirety. The nanoparticle may comprise a nucleicacid such as, but not limited to, polynucleotides described hereinand/or known in the art.

At least one of the nanoparticles of the present disclosure may beembedded in in the core a nanostructure or coated with a low densityporous 3-D structure or coating which is capable of carrying orassociating with at least one payload within or on the surface of thenanostructure. Non-limiting examples of the nanostructures comprising atleast one nanoparticle are described in International Patent PublicationNo. WO2013/123523, the contents of which are herein incorporated byreference in their entirety.

In some embodiments the RNA (e.g., mRNA) vaccine may be associated witha cationic or polycationic compounds, including protamine, nucleoline,spermine or spermidine, or other cationic peptides or proteins, such aspoly-L-lysine (PLL), polyarginine, basic polypeptides, cell penetratingpeptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV),Tat-derived peptides, Penetratin, VP²² derived or analog peptides,Pestivirus Ems, HSV, VP²² (Herpes simplex), MAP, KALA or proteintransduction domains (PTDs), PpT620, prolin-rich peptides, arginine-richpeptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers,Calcitonin peptide(s), Antennapedia-derived peptides (particularly fromDrosophila antennapedia), pAntp, pIsl, FGF, Lactoferrin, Transportan,Buforin-2, Bac715-24, SynB, SynB, pVEC, hCT-derived peptides, SAP,histones, cationic polysaccharides, for example chitosan, polybrene,cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g.DOTMA: [1-(2,3-sioleyloxy)propyl)]-N,N,N-trimethylammonium chloride,DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP,DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC,DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristooxypropyl dimethylhydroxyethyl ammonium bromide, DOTAP:dioleoyloxy-3-(trimethylammonio)propane, DC-6-14:O,O-ditetradecanoyl-N-.alpha.-trimethylammonioacetyl)diethanolaminechloride, CLIP 1:rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammoniumchloride, CLIP6:rac-[2(2,3-dihexadecyloxypropyloxymethyloxy)ethyl]-trimethylammonium,CLIPS:rac-[2(2,3-dihexadecyloxypropyloxysuccinyloxy)ethyl]-trimethylammo-nium,oligofectamine, or cationic or polycationic polymers, e.g. modifiedpolyaminoacids, such as beta-aminoacid-polymers or reversed polyamides,etc., modified polyethylenes, such as PVP(poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates,such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc.,modified amidoamines such as pAMAM (poly(amidoamine)), etc., modifiedpolybetaminoester (PBAE), such as diamine end modified 1,4 butanedioldiacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such aspolypropylamine dendrimers or pAMAM based dendrimers, etc.,polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine),etc., polyallylamine, sugar backbone based polymers, such ascyclodextrin based polymers, dextran based polymers, chitosan, etc.,silan backbone based polymers, such as PMOXA-PDMS copolymers, etc.,blockpolymers consisting of a combination of one or more cationic blocks(e.g. selected from a cationic polymer as mentioned above) and of one ormore hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole), etc.

In other embodiments the RNA (e.g., mRNA) vaccine is not associated witha cationic or polycationic compounds.

In some embodiments, a nanoparticle comprises compounds of Formula (I):

or a salt or isomer thereof, wherein:

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a carbocycle, heterocycle, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂,—OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR,—N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

In some embodiments, a subset of compounds of Formula (I) includes thosein which when R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then(i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2.

In some embodiments, another subset of compounds of Formula (I) includesthose in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheteroaryl having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and a 5- to14-membered heterocycloalkyl having one or more heteroatoms selectedfrom N, O, and S which is substituted with one or more substituentsselected from oxo (═O), OH, amino, mono- or di-alkylamino, and C₁₋₃alkyl, and each n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl; each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orisomers thereof.

In some embodiments, another subset of compounds of Formula (I) includesthose in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheterocycle having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉)N(R)₂, and eachn is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5-to 14-membered heterocycle and (i) R₄ is —(CH₂)_(n)Q in which n is 1 or2, or (ii) R₄ is —(CH₂)_(n)CHQR in which n is 1, or (iii) R₄ is —CHQR,and —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or 8- to14-membered heterocycloalkyl;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

In some embodiments, another subset of compounds of Formula (I) includesthose in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a

C₃₋₆ carbocycle, a 5- to 14-membered heteroaryl having one or moreheteroatoms selected from N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR,—OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,—C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selectedfrom 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

In some embodiments, another subset of compounds of Formula (I) includesthose in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR, where Q is —N(R)₂, and n isselected from 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H; each R is independently selected from the group consisting ofC₁₋₃ alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

In some embodiments, another subset of compounds of Formula (I) includesthose in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is selected from 1, 2, 3,4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H; each R is independently selected from the group consisting ofC₁₋₃ alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (IA):

or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄ isunsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,—NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroarylor heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and R₂ and R₃ are independently selected from thegroup consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (II):

or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and5; M₁ is a bond or M′; R₄ is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(nQ,)in which n is 2, 3, or 4, and Q is OH, —NHC(S)N(R)₂, —NHC(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂,—OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—,—S—S—, an aryl group, and a heteroaryl group; and R₂ and R₃ areindependently selected from the group consisting of H, C₁₋₁₄ alkyl, andC₂₋₁₄ alkenyl.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (IIa), (IIb), (IIc), or (IIe):

or a salt or isomer thereof, wherein R₄ is as described herein.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (IId):

or a salt or isomer thereof, wherein n is 2, 3, or 4; and m, R′, R″, andR₂ through R₆ are as described herein. For example, each of R₂ and R₃may be independently selected from the group consisting of C₅₋₁₄ alkyland C₅₋₁₄ alkenyl.

In some embodiments, the compound of Formula (I) is selected from thegroup consisting of:

In further embodiments, the compound of Formula (I) is selected from thegroup consisting of:

In some embodiments, the compound of Formula (I) is selected from thegroup consisting of:

and salts and isomers thereof.

In some embodiments, a nanoparticle comprises the following compound:

or salts and isomers thereof.

In some embodiments, the disclosure features a nanoparticle compositionincluding a lipid component comprising a compound as described herein(e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb),(IIc), (IId) or (IIe)).

In some embodiments, the disclosure features a pharmaceuticalcomposition comprising a nanoparticle composition according to thepreceding embodiments and a pharmaceutically acceptable carrier. Forexample, the pharmaceutical composition is refrigerated or frozen forstorage and/or shipment (e.g., being stored at a temperature of 4° C. orlower, such as a temperature between about −150° C. and about 0° C. orbetween about −80° C. and about −20° C. (e.g., about −5° C., −10° C.,−15° C., −20° C., −25° C., −30° C., −40° C., −50° C., −60° C., −70° C.,−80° C., −90° C., −130° C. or −150° C.). For example, the pharmaceuticalcomposition is a solution that is refrigerated for storage and/orshipment at, for example, about −20° C., −30° C., −40° C., −50° C., −60°C., −70° C., or −80° C.

In some embodiments, the disclosure provides a method of delivering atherapeutic and/or prophylactic (e.g., RNA, such as mRNA) to a cell(e.g., a mammalian cell). This method includes the step of administeringto a subject (e.g., a mammal, such as a human) a nanoparticlecomposition including (i) a lipid component including a phospholipid(such as a polyunsaturated lipid), a PEG lipid, a structural lipid, anda compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or(IIe) and (ii) a therapeutic and/or prophylactic, in which administeringinvolves contacting the cell with the nanoparticle composition, wherebythe therapeutic and/or prophylactic is delivered to the cell.

In some embodiments, the disclosure provides a method of producing apolypeptide of interest in a cell (e.g., a mammalian cell). The methodincludes the step of contacting the cell with a nanoparticle compositionincluding (i) a lipid component including a phospholipid (such as apolyunsaturated lipid), a PEG lipid, a structural lipid, and a compoundof Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii)an mRNA encoding the polypeptide of interest, whereby the mRNA iscapable of being translated in the cell to produce the polypeptide.

In some embodiments, the disclosure provides a method of treating adisease or disorder in a mammal (e.g., a human) in need thereof. Themethod includes the step of administering to the mammal atherapeutically effective amount of a nanoparticle composition including(i) a lipid component including a phospholipid (such as apolyunsaturated lipid), a PEG lipid, a structural lipid, and a compoundof Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii)a therapeutic and/or prophylactic (e.g., an mRNA). In some embodiments,the disease or disorder is characterized by dysfunctional or aberrantprotein or polypeptide activity. For example, the disease or disorder isselected from the group consisting of rare diseases, infectiousdiseases, cancer and proliferative diseases, genetic diseases (e.g.,cystic fibrosis), autoimmune diseases, diabetes, neurodegenerativediseases, cardio- and reno-vascular diseases, and metabolic diseases.

In some embodiments, the disclosure provides a method of delivering(e.g., specifically delivering) a therapeutic and/or prophylactic to amammalian organ (e.g., a liver, spleen, lung, or femur). This methodincludes the step of administering to a subject (e.g., a mammal) ananoparticle composition including (i) a lipid component including aphospholipid, a PEG lipid, a structural lipid, and a compound of Formula(I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) atherapeutic and/or prophylactic (e.g., an mRNA), in which administeringinvolves contacting the cell with the nanoparticle composition, wherebythe therapeutic and/or prophylactic is delivered to the target organ(e.g., a liver, spleen, lung, or femur).

In some embodiments, the disclosure features a method for the enhanceddelivery of a therapeutic and/or prophylactic (e.g., an mRNA) to atarget tissue (e.g., a liver, spleen, lung, or femur). This methodincludes administering to a subject (e.g., a mammal) a nanoparticlecomposition, the composition including (i) a lipid component including acompound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a structural lipid, and a PEG lipid; and (ii) atherapeutic and/or prophylactic, the administering including contactingthe target tissue with the nanoparticle composition, whereby thetherapeutic and/or prophylactic is delivered to the target tissue.

In some embodiments, the disclosure features a method of loweringimmunogenicity comprising introducing the nanoparticle composition ofthe disclosure into cells, wherein the nanoparticle composition reducesthe induction of the cellular immune response of the cells to thenanoparticle composition, as compared to the induction of the cellularimmune response in cells induced by a reference composition whichcomprises a reference lipid instead of a compound of Formula (I), (IA),(II), (IIa), (IIb), (IIc), (IId) or (IIe). For example, the cellularimmune response is an innate immune response, an adaptive immuneresponse, or both.

The disclosure also includes methods of synthesizing a compound ofFormula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and methodsof making a nanoparticle composition including a lipid componentcomprising the compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc),(IId) or (IIe).

Modes of Vaccine Administration

Influenza RNA (e.g. mRNA) vaccines may be administered by any routewhich results in a therapeutically effective outcome. These include, butare not limited, to intradermal, intramuscular, intranasal and/orsubcutaneous administration. The present disclosure provides methodscomprising administering RNA (e.g., mRNA) vaccines to a subject in needthereof. The exact amount required will vary from subject to subject,depending on the species, age, and general condition of the subject, theseverity of the disease, the particular composition, its mode ofadministration, its mode of activity, and the like. Influenza RNA (e.g.,mRNA) vaccines compositions are typically formulated in dosage unit formfor ease of administration and uniformity of dosage. It will beunderstood, however, that the total daily usage of RNA (e.g., mRNA)vaccine compositions may be decided by the attending physician withinthe scope of sound medical judgment. The specific therapeuticallyeffective, prophylactically effective, or appropriate imaging dose levelfor any particular patient will depend upon a variety of factorsincluding the disorder being treated and the severity of the disorder;the activity of the specific compound employed; the specific compositionemployed; the age, body weight, general health, sex and diet of thepatient; the time of administration, route of administration, and rateof excretion of the specific compound employed; the duration of thetreatment; drugs used in combination or coincidental with the specificcompound employed; and like factors well known in the medical arts.

In some embodiments, influenza disease RNA (e.g. mRNA) vaccinescompositions may be administered at dosage levels sufficient to deliver0.0001 mg/kg to 100 mg/kg, 0.001 mg/kg to 0.05 mg/kg, 0.005 mg/kg to0.05 mg/kg, 0.001 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5 mg/kg, 0.01mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.5 mg/kg to 30 mg/kg, 0.01mg/kg to 10 mg/kg, 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 25 mg/kg, ofsubject body weight per day, one or more times a day, per week, permonth, etc. to obtain the desired therapeutic, diagnostic, prophylactic,or imaging effect (see, e.g., the range of unit doses described inInternational Publication No WO2013/078199, the contents of which areherein incorporated by reference in their entirety). The desired dosagemay be delivered three times a day, two times a day, once a day, everyother day, every third day, every week, every two weeks, every threeweeks, every four weeks, every 2 months, every three months, every 6months, etc. In some embodiments, the desired dosage may be deliveredusing multiple administrations (e.g., two, three, four, five, six,seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or moreadministrations). When multiple administrations are employed, splitdosing regimens such as those described herein may be used. In exemplaryembodiments, influenza RNA (e.g., mRNA) vaccines compositions may beadministered at dosage levels sufficient to deliver 0.0005 mg/kg to 0.01mg/kg, e.g., about 0.0005 mg/kg to about 0.0075 mg/kg, e.g., about0.0005 mg/kg, about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg,about 0.004 mg/kg or about 0.005 mg/kg.

In some embodiments, influenza disease RNA (e.g., mRNA) vaccinecompositions may be administered once or twice (or more) at dosagelevels sufficient to deliver 0.025 mg/kg to 0.250 mg/kg, 0.025 mg/kg to0.500 mg/kg, 0.025 mg/kg to 0.750 mg/kg, or 0.025 mg/kg to 1.0 mg/kg.

In some embodiments, influenza disease RNA (e.g., mRNA) vaccinecompositions may be administered twice (e.g., Day 0 and Day 7, Day 0 andDay 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 andDay 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later,Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 yearslater, Day 0 and 5 years later, or Day 0 and 10 years later) at a totaldose of or at dosage levels sufficient to deliver a total dose of 0.0100mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg, 0.125 mg, 0.150 mg, 0.175mg, 0.200 mg, 0.225 mg, 0.250 mg, 0.275 mg, 0.300 mg, 0.325 mg, 0.350mg, 0.375 mg, 0.400 mg, 0.425 mg, 0.450 mg, 0.475 mg, 0.500 mg, 0.525mg, 0.550 mg, 0.575 mg, 0.600 mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700mg, 0.725 mg, 0.750 mg, 0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875mg, 0.900 mg, 0.925 mg, 0.950 mg, 0.975 mg, or 1.0 mg. Higher and lowerdosages and frequency of administration are encompassed by the presentdisclosure. For example, an influenza RNA (e.g., mRNA) vaccinecomposition may be administered three or four times.

In some embodiments, influenza RNA (e.g., mRNA) vaccine compositions maybe administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 monthslater, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0and 5 years later, or Day 0 and 10 years later) at a total dose of or atdosage levels sufficient to deliver a total dose of 0.010 mg, 0.025 mg,0.100 mg or 0.400 mg.

In some embodiments, the influenza RNA (e.g., mRNA) vaccine for use in amethod of vaccinating a subject is administered to the subject as asingle dosage of between 10 μg/kg and 400 μg/kg of the nucleic acidvaccine (in an effective amount to vaccinate the subject).

In some embodiments the RNA (e.g., mRNA) vaccine for use in a method ofvaccinating a subject is administered to the subject as a single dosageof between 10 μg and 400 μg of the nucleic acid vaccine (in an effectiveamount to vaccinate the subject). In some embodiments, an influenza RNA(e.g., mRNA) vaccine for use in a method of vaccinating a subject isadministered to the subject as a single dosage of 25-1000 μg. In someembodiments, an influenza RNA (e.g., mRNA) vaccine is administered tothe subject as a single dosage of 25, 50, 100, 150, 200, 250, 300, 350,400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 μg.For example, an influenza RNA (e.g., mRNA) vaccine may be administeredto a subject as a single dose of 25-100, 25-500, 50-100, 50-500,50-1000, 100-500, 100-1000, 250-500, 250-1000, or 500-1000 μg. In someembodiments, an influenza RNA (e.g., mRNA) vaccine for use in a methodof vaccinating a subject is administered to the subject as two dosages,the combination of which equals 25-1000 μg of the influenza RNA (e.g.,mRNA) vaccine.

An influenza RNA (e.g. mRNA) vaccine pharmaceutical compositiondescribed herein can be formulated into a dosage form described herein,such as an intranasal, intratracheal, or injectable (e.g., intravenous,intraocular, intravitreal, intramuscular, intradermal, intracardiac,intraperitoneal, intranasal and subcutaneous).

Influenza Virus RNA (e.g., mRNA) vaccine formulations and methods of use

Some aspects of the present disclosure provide formulations of theinfluenza RNA (e.g., mRNA) vaccine, wherein the RNA (e.g., mRNA) vaccineis formulated in an effective amount to produce an antigen specificimmune response in a subject (e.g., production of antibodies specific toan influenza antigenic polypeptide). “An effective amount” is a dose ofan RNA (e.g., mRNA) vaccine effective to produce an antigen-specificimmune response. Also provided herein are methods of inducing anantigen-specific immune response in a subject.

In some embodiments, the antigen-specific immune response ischaracterized by measuring an anti-influenza antigenic polypeptideantibody titer produced in a subject administered an influenza RNA(e.g., mRNA) vaccine as provided herein. An antibody titer is ameasurement of the amount of antibodies within a subject, for example,antibodies that are specific to a particular antigen (e.g., an influenzaantigenic polypeptide) or epitope of an antigen. Antibody titer istypically expressed as the inverse of the greatest dilution thatprovides a positive result. Enzyme-linked immunosorbent assay (ELISA) isa common assay for determining antibody titers, for example.

In some embodiments, an antibody titer is used to assess whether asubject has had an infection or to determine whether immunizations arerequired. In some embodiments, an antibody titer is used to determinethe strength of an autoimmune response, to determine whether a boosterimmunization is needed, to determine whether a previous vaccine waseffective, and to identify any recent or prior infections. In accordancewith the present disclosure, an antibody titer may be used to determinethe strength of an immune response induced in a subject by the influenzaRNA (e.g., mRNA) vaccine.

In some embodiments, an anti-influenza antigenic polypeptide antibodytiter produced in a subject is increased by at least 1 log relative to acontrol. For example, anti-antigenic polypeptide antibody titer producedin a subject may be increased by at least 1.5, at least 2, at least 2.5,or at least 3 log relative to a control. In some embodiments, theanti-antigenic polypeptide antibody titer produced in the subject isincreased by 1, 1.5, 2, 2.5 or 3 log relative to a control. In someembodiments, the anti-antigenic polypeptide antibody titer produced inthe subject is increased by 1-3 log relative to a control. For example,the anti-antigenic polypeptide antibody titer produced in a subject maybe increased by 1-1.5, 1-2, 1-2.5, 1-3, 1.5-2, 1.5-2.5, 1.5-3, 2-2.5,2-3, or 2.5-3 log relative to a control.

In some embodiments, the anti-influenza antigenic polypeptide antibodytiter produced in a subject is increased at least 2 times relative to acontrol. For example, the anti-antigenic polypeptide antibody titerproduced in a subject may be increased at least 3 times, at least 4times, at least 5 times, at least 6 times, at least 7 times, at least 8times, at least 9 times, or at least 10 times relative to a control. Insome embodiments, the anti-antigenic polypeptide antibody titer producedin the subject is increased 2, 3, 4, 5 ,6, 7, 8, 9, or 10 times relativeto a control. In some embodiments, the anti-antigenic polypeptideantibody titer produced in a subject is increased 2-10 times relative toa control. For example, the anti-antigenic polypeptide antibody titerproduced in a subject may be increased 2-10, 2-9, 2-8, 2-7, 2-6, 2-5,2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6,4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8,8-10, 8-9, or 9-10 times relative to a control.

A control, in some embodiments, is the anti-influenza antigenicpolypeptide antibody titer produced in a subject who has not beenadministered an influenza RNA (e.g., mRNA) vaccine of the presentdisclosure. In some embodiments, a control is an anti-influenzaantigenic polypeptide antibody titer produced in a subject who has beenadministered a live attenuated influenza vaccine. An attenuated vaccineis a vaccine produced by reducing the virulence of a viable (live). Anattenuated virus is altered in a manner that renders it harmless or lessvirulent relative to live, unmodified virus. In some embodiments, acontrol is an anti-influenza antigenic polypeptide antibody titerproduced in a subject administered inactivated influenza vaccine. Insome embodiments, a control is an anti-influenza antigenic polypeptideantibody titer produced in a subject administered a recombinant orpurified influenza protein vaccine. Recombinant protein vaccinestypically include protein antigens that either have been produced in aheterologous expression system (e.g., bacteria or yeast) or purifiedfrom large amounts of the pathogenic organism. In some embodiments, acontrol is an anti-influenza antigenic polypeptide antibody titerproduced in a subject who has been administered an influenza virus-likeparticle (VLP) vaccine.

In some embodiments, an effective amount of an influenza RNA (e.g.,mRNA) vaccine is a dose that is reduced compared to the standard of caredose of a recombinant influenza protein vaccine. A “standard of care,”as provided herein, refers to a medical or psychological treatmentguideline and can be general or specific. “Standard of care” specifiesappropriate treatment based on scientific evidence and collaborationbetween medical professionals involved in the treatment of a givencondition. It is the diagnostic and treatment process that aphysician/clinician should follow for a certain type of patient, illnessor clinical circumstance. A “standard of care dose,” as provided herein,refers to the dose of a recombinant or purified influenza proteinvaccine, or a live attenuated or inactivated influenza vaccine, that aphysician/clinician or other medical professional would administer to asubject to treat or prevent influenza, or a related condition, whilefollowing the standard of care guideline for treating or preventinginfluenza, or a related condition.

In some embodiments, the anti-influenza antigenic polypeptide antibodytiter produced in a subject administered an effective amount of aninfluenza RNA (e.g., mRNA) vaccine is equivalent to an anti-influenzaantigenic polypeptide antibody titer produced in a control subjectadministered a standard of care dose of a recombinant or purifiedinfluenza protein vaccine or a live attenuated or inactivated influenzavaccine.

In some embodiments, an effective amount of an influenza RNA (e.g.,mRNA) vaccine is a dose equivalent to an at least 2-fold reduction in astandard of care dose of a recombinant or purified influenza proteinvaccine. For example, an effective amount of an influenza RNA (e.g.,mRNA) vaccine may be a dose equivalent to an at least 3-fold, at least4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least8-fold, at least 9-fold, or at least 10-fold reduction in a standard ofcare dose of a recombinant or purified influenza protein vaccine. Insome embodiments, an effective amount of an influenza RNA (e.g., mRNA)vaccine is a dose equivalent to an at least at least 100-fold, at least500-fold, or at least 1000-fold reduction in a standard of care dose ofa recombinant or purified influenza protein vaccine. In someembodiments, an effective amount of an influenza RNA (e.g., mRNA)vaccine is a dose equivalent to a 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-,20-, 50-, 100-, 250-, 500-, or 1000-fold reduction in a standard of caredose of a recombinant or purified influenza protein vaccine. In someembodiments, the anti-influenza antigenic polypeptide antibody titerproduced in a subject administered an effective amount of an influenzaRNA (e.g., mRNA) vaccine is equivalent to an anti-influenza antigenicpolypeptide antibody titer produced in a control subject administeredthe standard of care dose of a recombinant or protein influenza proteinvaccine or a live attenuated or inactivated influenza vaccine. In someembodiments, an effective amount of an influenza RNA (e.g., mRNA)vaccine is a dose equivalent to a 2-fold to 1000-fold (e.g., 2-fold to100-fold, 10-fold to 1000-fold) reduction in the standard of care doseof a recombinant or purified influenza protein vaccine, wherein theanti-influenza antigenic polypeptide antibody titer produced in thesubject is equivalent to an anti-influenza antigenic polypeptideantibody titer produced in a control subject administered the standardof care dose of a recombinant or purified influenza protein vaccine or alive attenuated or inactivated influenza vaccine.

In some embodiments, the effective amount of an influenza RNA (e.g.,mRNA) vaccine is a dose equivalent to a 2 to 1000-, 2 to 900-, 2 to800-, 2 to 700-, 2 to 600-, 2 to 500-, 2 to 400-, 2 to 300-, 2 to 200-,2 to 100-, 2 to 90-, 2 to 80-, 2 to 70-, 2 to 60-, 2 to 50-, 2 to 40-, 2to 30-, 2 to 20-, 2 to 10-, 2 to 9-, 2 to 8-, 2 to 7-, 2 to 6-, 2 to 5-,2 to 4-, 2 to 3-, 3 to 1000-, 3 to 900-, 3 to 800-, 3 to 700-, 3 to600-, 3 to 500-, 3 to 400-, 3 to 3 to 00-, 3 to 200-, 3 to 100-, 3 to90-, 3 to 80-, 3 to 70-, 3 to 60-, 3 to 50-, 3 to 40-, 3 to 30-, 3 to20-, 3 to 10-, 3 to 9-, 3 to 8-, 3 to 7-, 3 to 6-, 3 to 5-, 3 to 4-, 4to 1000-, 4 to 900-, 4 to 800-, 4 to 700-, 4 to 600- , 4 to 500-, 4 to400-, 4 to 300-, 4 to 200-, 4 to 100-, 4 to 90-, 4 to 80-, 4 to 70-, 4to 60-, 4 to 50-, 4 to 40-, 4 to 30-, 4 to 20-, 4 to 10-, 4 to 9-, 4 to8-, 4 to 7-, 4 to 6-, 4 to 5-, 4 to 4-, 5 to 1000-, 5 to 900-, 5 to800-, 5 to 700-, 5 to 600-, 5 to 500-, 5 to 400-, 5 to 300-, 5 to 200-,5 to 100-, 5 to 90-, 5 to 80-, 5 to 70-, 5 to 60-, 5 to 50-, 5 to 40-, 5to 30-, 5 to 20-, 5 to 10-, 5 to 9- , 5 to 8-, 5 to 7-, 5 to 6-, 6 to1000-, 6 to 900-, 6 to 800-, 6 to 700-, 6 to 600-, 6 to 500-, 6 to 400-,6 to 300-, 6 to 200-, 6 to 100-, 6 to 90-, 6 to 80-, 6 to 70-, 6 to 60-,6 to 50-, 6 to 40-, 6 to 30-, 6 to 20-, 6 to 10-, 6 to 9-, 6 to 8-, 6 to7-, 7 to 1000-, 7 to 900-, 7 to 800-, 7 to 700-, 7 to 600-, 7 to 500-, 7to 400-, 7 to 300-, 7 to 200-, 7 to 100-, 7 to 90-, 7 to 80-, 7 to 70-,7 to 60-, 7 to 50-, 7 to 40-, 7 to 30-, 7 to 20-, 7 to 10-, 7 to 9-, 7to 8-, 8 to 1000-, 8 to 900-, 8 to 800-, 8 to 700-, 8 to 600-, 8 to500-, 8 to 400-, 8 to 300-, 8 to 200-, 8 to 100-, 8 to 90-, 8 to 80-, 8to 70-, 8 to 60-, 8 to 50-, 8 to 40-, 8 to 30-, 8 to 20-, 8 to 10-, 8 to9-, 9 to 1000-, 9 to 900-, 9 to 800-, 9 to 700-, 9 to 600-, 9 to 500-, 9to 400-, 9 to 300-, 9 to 200-, 9 to 100-, 9 to 90-, 9 to 80-, 9 to 70-,9 to 60-, 9 to 50-, 9 to 40-, 9 to 30-, 9 to 20-, 9 to 10-, 10 to 1000-,10 to 900-, 10 to 800-, 10 to 700-, 10 to 600-, 10 to 500-, 10 to 400-,10 to 300-, 10 to 200-, 10 to 100-, 10 to 90-, 10 to 80-, 10 to 70-, 10to 60-, 10 to 50-, 10 to 40-, 10 to 30-, 10 to 20-, 20 to 1000-, 20 to900-, 20 to 800-, 20 to 700-, 20 to 600-, 20 to 500-, 20 to 400-, 20 to300-, 20 to 200-, 20 to 100-, 20 to 90-, 20 to 80-, 20 to 70-, 20 to60-, 20 to 50-, 20 to 40-, 20 to 30-, 30 to 1000-, 30 to 900-, 30 to800-, 30 to 700-, 30 to 600-, 30 to 500-, 30 to 400-, 30 to 300-, 30 to200-, 30 to 100-, 30 to 90-, 30 to 80-, 30 to 70-, 30 to 60-, 30 to 50-,30 to 40-, 40 to 1000-, 40 to 900-, 40 to 800-, 40 to 700-, 40 to 600-,40 to 500-, 40 to 400-, 40 to 300-, 40 to 200-, 40 to 100-, 40 to 90-,40 to 80-, 40 to 70-, 40 to 60-, 40 to 50-, 50 to 1000-, 50 to 900-, 50to 800-, 50 to 700-, 50 to 600-, 50 to 500-, 50 to 400-, 50 to 300-, 50to 200-, 50 to 100-, 50 to 90-, 50 to 80-, 50 to 70-, 50 to 60-, 60 to1000-, 60 to 900-, 60 to 800-, 60 to 700-, 60 to 600-, 60 to 500-, 60 to400-, 60 to 300-, 60 to 200-, 60 to 100-, 60 to 90-, 60 to 80-, 60 to70-, 70 to 1000-, 70 to 900-, 70 to 800-, 70 to 700-, 70 to 600-, 70 to500-, 70 to 400-, 70 to 300-, 70 to 200-, 70 to 100-, 70 to 90-, 70 to80-, 80 to 1000-, 80 to 900-, 80 to 800-, 80 to 700-, 80 to 600-, 80 to500-, 80 to 400-, 80 to 300-, 80 to 200-, 80 to 100-, 80 to 90-, 90 to1000-, 90 to 900-, 90 to 800-, 90 to 700-, 90 to 600-, 90 to 500-, 90 to400-, 90 to 300-, 90 to 200-, 90 to 100-, 100 to 1000-, 100 to 900-, 100to 800-, 100 to 700-, 100 to 600-, 100 to 500-, 100 to 400-, 100 to300-, 100 to 200-, 200 to 1000-, 200 to 900-, 200 to 800-, 200 to 700-,200 to 600-, 200 to 500-, 200 to 400-, 200 to 300-, 300 to 1000-, 300 to900-, 300 to 800-, 300 to 700-, 300 to 600-, 300 to 500-, 300 to 400-,400 to 1000-, 400 to 900-, 400 to 800-, 400 to 700-, 400 to 600-, 400 to500-, 500 to 1000-, 500 to 900-, 500 to 800-, 500 to 700-, 500 to 600-,600 to 1000-, 600 to 900-, 600 to 800-, 600 to 700-, 700 to 1000-, 700to 900-, 700 to 800-, 800 to 1000-, 800 to 900-, or 900 to 1000-foldreduction in the standard of care dose of a recombinant influenzaprotein vaccine. In some embodiments, the anti-antigenic polypeptideantibody titer produced in the subj ect is equivalent to ananti-antigenic polypeptide antibody titer produced in a control subj ectadministered the standard of care dose of a recombinant or purifiedinfluenza protein vaccine or a live attenuated or inactivated influenzavaccine. In some embodiments, the effective amount is a dose equivalentto (or equivalent to an at least) 2-, 3-,4-,5-,6-, 7-, 8-, 9-, 10-, 20-,30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 110-, 120-, 130-, 140-, 150-,160-, 170-, 1280-, 190-, 200-, 210-, 220-, 230-, 240-, 250-, 260-, 270-,280-, 290-, 300-, 310-, 320-, 330-, 340-, 350-, 360-, 370-, 380-, 390-,400-, 410-, 420-, 430-, 440-, 450-, 4360-, 470-, 480-, 490-, 500-, 510-,520-, 530-, 540-, 550-, 560-, 5760-, 580-, 590-, 600-, 610-, 620-, 630-,640-, 650-, 660-, 670-, 680-, 690-, 700-, 710-, 720-, 730-, 740-, 750-,760-, 770-, 780-, 790-, 800-, 810-, 820--, 830-, 840-, 850-, 860-, 870-,880-, 890-, 900-, 910-, 920-, 930-, 940-, 950-, 960-, 970-, 980-, 990-,or 1000-fold reduction in the standard of care dose of a recombinantinfluenza protein vaccine. In some embodiments, an anti-antigenicpolypeptide antibody titer produced in the subject is equivalent to ananti-antigenic polypeptide antibody titer produced in a control subjectadministered the standard of care dose of a recombinant or purifiedinfluenza protein vaccine or a live attenuated or inactivated aninfluenza vaccine.

In some embodiments, the effective amount of an influenza RNA (e.g.,mRNA) vaccine is a total dose of 50-1000 In some embodiments, theeffective amount of an influenza RNA (e.g., mRNA) vaccine is a totaldose of 50-1000, 50-900, 50-800, 50-700, 50-600, 50-500, 50-400, 50-300,50-200, 50-100, 50-90, 50-80, 50-70, 50-60, 60-1000, 60-900, 60-800,60-700, 60-600, 60-500, 60-400, 60-300, 60-200, 60-100, 60-90, 60-80,60-70, 70-1000, 70-900, 70-800, 70-700, 70-600, 70-500, 70-400, 70-300,70-200, 70-100, 70-90, 70-80, 80-1000, 80-900, 80-800, 80-700, 80-600,80-500, 80-400, 80-300, 80-200, 80-100, 80-90, 90-1000, 90-900, 90-800,90-700, 90-600, 90-500, 90-400, 90-300, 90-200, 90-100, 100-1000,100-900, 100-800, 100-700, 100-600, 100-500, 100-400, 100-300, 100-200,200-1000, 200-900, 200-800, 200-700, 200-600, 200-500, 200-400, 200-300,300-1000, 300-900, 300-800, 300-700, 300-600, 300-500, 300-400,400-1000, 400-900, 400-800, 400-700, 400-600, 400-500, 500-1000,500-900, 500-800, 500-700, 500-600, 600-1000, 600-900, 600-900, 600-700,700-1000, 700-900, 700-800, 800-1000, 800-900, or 900-1000 pg. In someembodiments, the effective amount of an influenza RNA (e.g., mRNA)vaccine is a total dose of 50, 100, 150, 200, 250, 300, 350, 400, 450,500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 In someembodiments, the effective amount is a dose of 25-500 administered tothe subject a total of two times. In some embodiments, the effectiveamount of an influenza RNA (e.g., mRNA) vaccine is a dose of 25-500,25-400, 25-300, 25-200, 25-100, 25-50, 50-500, 50-400, 50-300, 50-200,50-100, 100-500, 100-400, 100-300, 100-200, 150-500, 150-400, 150-300,150-200, 200-500, 200-400, 200-300, 250-500, 250-400, 250-300, 300-500,300-400, 350-500, 350-400, 400-500 or 450-500 μg administered to thesubject a total of two times. In some embodiments, the effective amountof an influenza RNA (e.g., mRNA) vaccine is a total dose of 25, 50, 100,150, 200, 250, 300, 350, 400, 450, or 500 μg administered to the subjecta total of two times.

Additional Embodiments

-   1. An influenza virus vaccine or composition or immunogenic    composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a5′ terminal cap, an open reading frame encoding at least one influenzaantigenic polypeptide, and a 3′ polyA tail.

-   2. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide is encoded by a sequence identified by SEQ ID NO:    447-457, 459, 461, 505-523, or 570-573.-   3. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide comprises a sequence identified by SEQ ID NO:    491-503, 524-542, or 566-569.-   4. The vaccine of paragraph 1, wherein the at least one antigenic    polypeptide comprises a sequence identified by SEQ ID NO: 1-444,    458, 460, 462-479, or 543-565.-   5. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide is encoded by a sequence identified by SEQ ID NO:    457.-   6. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide comprises a sequence identified by SEQ ID NO: 501.-   7. The vaccine of paragraph 1, wherein the at least one antigenic    polypeptide comprises a sequence identified by SEQ ID NO: 458.-   8. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide is encoded by a sequence identified by SEQ ID NO:    459.-   9. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide comprises a sequence identified by SEQ ID NO: 502.-   10. The vaccine of paragraph 1, wherein the at least one antigenic    polypeptide comprises a sequence identified by SEQ ID NO: 460.-   11. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide is encoded by a sequence identified by SEQ ID NO:    461.-   12. The vaccine of paragraph 1, wherein the at least one mRNA    polynucleotide comprises a sequence identified by SEQ ID NO: 503.-   13. The vaccine of paragraph 1, wherein the at least one antigenic    polypeptide comprises a sequence identified by SEQ ID NO: 462.-   14. The vaccine of any one of paragraphs 1-13, wherein the 5′    terminal cap is or comprises 7mG(5′)ppp(5′)NlmpNp.-   15. The vaccine of any one of paragraphs 1-14, wherein 100% of the    uracil in the open reading frame is modified to include N1-methyl    pseudouridine at the 5-position of the uracil.-   16. The vaccine of any one of paragraphs 1-15, wherein the vaccine    is formulated in a lipid nanoparticle comprising: DLin-MC3-DMA;    cholesterol; 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC); and    polyethylene glycol (PEG)2000-DMG.-   17. The vaccine of paragraph 16, wherein the lipid nanoparticle    further comprises trisodium citrate buffer, sucrose and water.-   18. A influenza virus vaccine or composition or immunogenic    composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ IDNO: 501 and a 3′ polyA tail, wherein the uracil nucleotides of thesequence identified by SEQ ID NO: 501 are modified to include N1-methylpseudouridine at the 5-position of the uracil nucleotide.

-   19. A influenza virus vaccine, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ IDNO: 502 and a 3′ polyA tail, wherein the uracil nucleotides of thesequence identified by SEQ ID NO: 502 are modified to include N1-methylpseudouridine at the 5-position of the uracil nucleotide.

-   20. A influenza virus vaccine or composition or immunogenic    composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ IDNO: 503 and a 3′ polyA tail, wherein the uracil nucleotides of thesequence identified by SEQ ID NO: 503 are modified to include N1-methylpseudouridine at the 5-position of the uracil nucleotide.

-   21. The vaccine of any one of paragraphs 18-20 formulated in a lipid    nanoparticle comprising DLin-MC3-DMA, cholesterol, 1,2-Di stearoyl    -sn-glycero-3-phosphocholine (DSPC), and polyethylene glycol    (PEG)2000-DMG.-   22. The vaccine of any one of paragraphs 1-21 formulated in a lipid    nanoparticle comprising at least one cationic lipid selected from    compounds of Formula (I):

-   or a salt or isomer thereof, wherein:-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of H,    C1-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is selected from the group consisting of a C3-6 carbocycle,    (CH2)nQ, (CH2)nCHQR, CHQR, CQ(R)2, and unsubstituted C1-6 alkyl,    where Q is selected from a carbocycle, heterocycle, —OR,    —O(CH2)nN(R)2, C(O)OR, —OC(O)R, CX3, CX2H, CXH2, CN, N(R)2,    C(O)N(R)2, N(R)C(O)R, N(R)S(O)2R, N(R)C(O)N(R)2, N(R)C(S)N(R)2,    N(R)R8, O(CH2)nOR, N(R)C(═NR9)N(R)2, N(R)C(═CHR9)N(R)2, OC(O)N(R)2,    N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)2R, N(OR)C(O)OR, N(OR)C(O)N(R)2,    N(OR)C(S)N(R)2, N(OR)C(═NR9)N(R)2, N(OR)C(═CHR9)N(R)2, C(═NR9)N(R)2,    C(═NR9)R, C(O)N(R)OR, and —C(R)N(R)2C(O)OR, and each n is    independently selected from 1, 2, 3, 4, and 5;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, S,    an aryl group, and a heteroaryl group;-   R7 is selected from the group consisting of C1-3 alkyl, C2-3    alkenyl, and H;-   R8 is selected from the group consisting of C3-6 carbocycle and    heterocycle;-   R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl,    —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and    heterocycle; each R is independently selected from the group    consisting of C1-3 alkyl, C2-3 alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C2-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.-   23. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which when R4 is (CH2)nQ, (CH2)nCHQR,    —CHQR, or CQ(R)2, then (i) Q is not N(R)2 when n is 1, 2, 3, 4 or 5,    or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1    or2.-   24. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of H,    C1-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is selected from the group consisting of a C3-6 carbocycle,    (CH2)nQ, (CH2)nCHQR, CHQR, CQ(R)2, and unsubstituted C1-6 alkyl,    where Q is selected from a C3-6 carbocycle, a 5- to 14-membered    heteroaryl having one or more heteroatoms selected from N, O, and S,    —OR, —O(CH2)nN(R)2, C(O)OR, —OC(O)R, CX3, CX2H, CXH2, CN, C(O)N(R)2,    N(R)C(O)R, N(R)S(O)2R, N(R)C(O)N(R)2, N(R)C(S)N(R)2, CRN(R)2C(O)OR,    N(R)R8, O(CH2)nOR, N(R)C(═NR9)N(R)2, N(R)C(═CHR9)N(R)2, OC(O)N(R)2,    N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)2R, N(OR)C(O)OR, N(OR)C(O)N(R)2,    N(OR)C(S)N(R)2, N(OR)C(═NR9)N(R)2, N(OR)C(═CHR9)N(R)2, C(═NR9)N(R)2,    C(═NR9)R, C(O)N(R)OR, and a 5- to 14-membered heterocycloalkyl    having one or more heteroatoms selected from N, O, and S which is    substituted with one or more substituents selected from oxo (═O),    OH, amino, mono- or di-alkylamino, and C1-3 alkyl, and each n is    independently selected from 1, 2, 3, 4, and 5;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, S,    an aryl group, and a heteroaryl group; R7 is selected from the group    consisting of C1-3 alkyl, C2-3 alkenyl, and H;-   R8 is selected from the group consisting of C3-6 carbocycle and    heterocycle;-   R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl,    —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C2-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.-   25. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of H,    C1-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is selected from the group consisting of a C3-6 carbocycle,    (CH2)nQ, (CH2)nCHQR, CHQR, CQ(R)2, and unsubstituted C1-6 alkyl,    where Q is selected from a C3-6 carbocycle, a 5- to 14-membered    heterocycle having one or more heteroatoms selected from N, O, and    S, —OR, —O(CH2)nN(R)2, C(O)OR, —OC(O)R, CX3, CX2H, CXH2, CN,    C(O)N(R)2, N(R)C(O)R, N(R)S(O)2R, N(R)C(O)N(R)2, N(R)C(S)N(R)2,    CRN(R)2C(O)OR, N(R)R8, O(CH2)nOR, N(R)C(═NR9)N(R)2,    N(R)C(═CHR9)N(R)2, OC(O)N(R)2, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)2R,    N(OR)C(O)OR, N(OR)C(O)N(R)2, N(OR)C(S)N(R)2, N(OR)C(═NR9)N(R)2,    N(OR)C(═CHR9)N(R)2, C(═NR9)R, C(O)N(R)OR, and C(═NR9)N(R)2, and each    n is independently selected from 1, 2, 3, 4, and 5; and when Q is a    5- to 14-membered heterocycle and (i) R4 is (CH2)nQ in which n is 1    or 2, or (ii) R4 is (CH2)nCHQR in which n is 1, or (iii) R4 is CHQR,    and CQ(R)2, then Q is either a 5- to 14-membered heteroaryl or 8- to    14-membered heterocycloalkyl;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, S,    an aryl group, and a heteroaryl group;-   R7 is selected from the group consisting of C1-3 alkyl, C2-3    alkenyl, and H;-   R8 is selected from the group consisting of C3-6 carbocycle and    heterocycle;-   R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl,    —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and    heterocycle; each R is independently selected from the group    consisting of C1-3 alkyl, C2-3 alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C2-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.-   26. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of H,    C1-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is selected from the group consisting of a C3-6 carbocycle,    (CH2)nQ, (CH2)nCHQR, CHQR, CQ(R)2, and unsubstituted C1-6 alkyl,    where Q is selected from a C3-6 carbocycle, a 5- to 14-membered    heteroaryl having one or more heteroatoms selected from N, O, and S,    —OR, —O(CH2)nN(R)2, C(O)OR, —OC(O)R, CX3, CX2H, CXH2, CN, C(O)N(R)2,    N(R)C(O)R, N(R)S(O)2R, N(R)C(O)N(R)2, N(R)C(S)N(R)2, CRN(R)2C(O)OR,    N(R)R8, O(CH2)nOR, N(R)C(═NR9)N(R)2, N(R)C(═CHR9)N(R)2, OC(O)N(R)2,    N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)2R, N(OR)C(O)OR, N(OR)C(O)N(R)2,    N(OR)C(S)N(R)2, N(OR)C(═NR9)N(R)2, N(OR)C(═CHR9)N(R)2, C(═NR9)R,    C(O)N(R)OR, and C(═NR9)N(R)2, and each n is independently selected    from 1, 2, 3, 4, and 5;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, SS,    an aryl group, and a heteroaryl group;-   R7 is selected from the group consisting of C1-3 alkyl, C2-3    alkenyl, and H;-   R8 is selected from the group consisting of C3-6 carbocycle and    heterocycle;-   R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl,    —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and    heterocycle;-   each R is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C2-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.-   27. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of H,    C2-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is (CH2)nQ or (CH2)nCHQR, where Q is N(R)2, and n is selected    from 3, 4, and 5;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, SS,    an aryl group, and a heteroaryl group; R7 is selected from the group    consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R is    independently selected from the group consisting of C1-3 alkyl, C2-3    alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C1-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.-   28. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those in which-   R1 is selected from the group consisting of C5-30 alkyl, C5-20    alkenyl, R*YR″, YR″, and R″M′R′;-   R2 and R3 are independently selected from the group consisting of    C1-14 alkyl, C2-14 alkenyl, R*YR″, YR″, and R*OR″, or R2 and R3,    together with the atom to which they are attached, form a    heterocycle or carbocycle;-   R4 is selected from the group consisting of (CH2)nQ, (CH2)nCHQR,    CHQR, and CQ(R)2, where Q is N(R)2, and n is selected from 1, 2, 3,    4, and 5;-   each R5 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R6 is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   M and M′ are independently selected from C(O)O, OC(O), C(O)N(R′),    N(R′)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR')O, S(O)2, SS,    an aryl group, and a heteroaryl group;-   R7 is selected from the group consisting of C1-3 alkyl, C2-3    alkenyl, and H;-   each R is independently selected from the group consisting of C1-3    alkyl, C2-3 alkenyl, and H;-   each R′ is independently selected from the group consisting of C1-18    alkyl, C2-18 alkenyl, R*YR″, YR″, and H;-   each R″ is independently selected from the group consisting of C3-14    alkyl and C3-14 alkenyl;-   each R* is independently selected from the group consisting of C1-12    alkyl and C1-12 alkenyl;-   each Y is independently a C3-6 carbocycle;-   each X is independently selected from the group consisting of F, Cl,    Br, and I; and-   m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,-   or salts or isomers thereof.-   29. The vaccine of paragraph 22, wherein a subset of compounds of    Formula (I) includes those of Formula (IA):

or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M′; R4 isunsubstituted C1-3 alkyl, or (CH2)nQ, in which Q is OH, NHC(S)N(R)2,NHC(O)N(R)2, N(R)C(O)R, N(R)S(O)2R, N(R)R8, NHC(═NR9)N(R)2,NHC(═CHR9)N(R)2, —OC(O)N(R)2, N(R)C(O)OR, heteroaryl orheterocycloalkyl; M and M′ are independently selected from C(O)O, OC(O),C(O)N(R′), P(O)(OR')O, SS, an aryl group, and a heteroaryl group; and R2and R3 are independently selected from the group consisting of H, C1-14alkyl, and C2-14 alkenyl.

This invention is not limited in its application to the details ofconstruction and the arrangement of components set forth in thefollowing description or illustrated in the drawings. The invention iscapable of other embodiments and of being practiced or of being carriedout in various ways. Also, the phraseology and terminology used hereinis for the purpose of description and should not be regarded aslimiting. The use of “including,” “comprising,” or “having,”“containing,” “involving,” and variations thereof herein, is meant toencompass the items listed thereafter and equivalents thereof as well asadditional items.

EXAMPLES Example 1: Manufacture of Polynucleotides

According to the present disclosure, the manufacture of polynucleotidesand/or parts or regions thereof may be accomplished utilizing themethods taught in International Publication WO2014/152027, entitled“Manufacturing Methods for Production of RNA Transcripts,” the contentsof which is incorporated herein by reference in its entirety.

Purification methods may include those taught in InternationalPublication WO2014/152030 and International Publication WO2014/152031,each of which is incorporated herein by reference in its entirety.

Detection and characterization methods of the polynucleotides may beperformed as taught in International Publication WO2014/144039, which isincorporated herein by reference in its entirety.

Characterization of the polynucleotides of the disclosure may beaccomplished using polynucleotide mapping, reverse transcriptasesequencing, charge distribution analysis, detection of RNA impurities,or any combination of two or more of the foregoing. “Characterizing”comprises determining the RNA transcript sequence, determining thepurity of the RNA transcript, or determining the charge heterogeneity ofthe RNA transcript, for example. Such methods are taught in, forexample, International Publication WO2014/144711 and InternationalPublication WO2014/144767, the content of each of which is incorporatedherein by reference in its entirety.

Example 2: Chimeric Polynucleotide Synthesis

According to the present disclosure, two regions or parts of a chimericpolynucleotide may be joined or ligated using triphosphate chemistry. Afirst region or part of 100 nucleotides or less is chemicallysynthesized with a 5′ monophosphate and terminal 3′desOH or blocked OH,for example. If the region is longer than 80 nucleotides, it may besynthesized as two strands for ligation.

If the first region or part is synthesized as a non-positionallymodified region or part using in vitro transcription (IVT), conversionthe 5′monophosphate with subsequent capping of the 3′ terminus mayfollow.

Monophosphate protecting groups may be selected from any of those knownin the art.

The second region or part of the chimeric polynucleotide may besynthesized using either chemical synthesis or IVT methods. IVT methodsmay include an RNA polymerase that can utilize a primer with a modifiedcap. Alternatively, a cap of up to 130 nucleotides may be chemicallysynthesized and coupled to the IVT region or part.

For ligation methods, ligation with DNA T4 ligase, followed by treatmentwith DNase should readily avoid concatenation.

The entire chimeric polynucleotide need not be manufactured with aphosphate-sugar backbone. If one of the regions or parts encodes apolypeptide, then such region or part may comprise a phosphate-sugarbackbone.

Ligation is then performed using any known click chemistry, orthoclickchemistry, solulink, or other bioconjugate chemistries known to those inthe art.

Synthetic route

The chimeric polynucleotide may be made using a series of startingsegments. Such segments include:

(a) a capped and protected 5′ segment comprising a normal 3′OH (SEG. 1)

(b) a 5′ triphosphate segment, which may include the coding region of apolypeptide and a normal 3′OH (SEG. 2)

(c) a 5′ monophosphate segment for the 3′ end of the chimericpolynucleotide (e.g., the tail) comprising cordycepin or no 3′OH (SEG.3)

After synthesis (chemical or IVT), segment 3 (SEG. 3) may be treatedwith cordycepin and then with pyrophosphatase to create the 5′monophosphate.

Segment 2 (SEG. 2) may then be ligated to SEG. 3 using RNA ligase. Theligated polynucleotide is then purified and treated with pyrophosphataseto cleave the diphosphate. The treated SEG.2-SEG. 3 construct may thenbe purified and SEG. 1 is ligated to the 5′ terminus. A furtherpurification step of the chimeric polynucleotide may be performed.

Where the chimeric polynucleotide encodes a polypeptide, the ligated orjoined segments may be represented as: 5′UTR (SEG. 1), open readingframe or ORF (SEG. 2) and 3′UTR+PolyA (SEG. 3).

The yields of each step may be as much as 90-95%.

Example 3: PCR for cDNA Production

PCR procedures for the preparation of cDNA may be performed using 2×KAPA HIFI™ HotStart ReadyMix by Kapa Biosystems (Woburn, Mass). Thissystem includes 2× KAPA ReadyMix 12.5 μl; Forward Primer (10 μM) 0.75μl; Reverse Primer (10 μM) 0.75 μl; Template cDNA 100 ng; and dH₂0diluted to 25.0 μl. The reaction conditions may be at 95° C. for 5 min.The reaction may be performed for 25 cycles of 98° C. for 20 sec, then58° C. for 15 sec, then 72° C. for 45 sec, then 72° C. for 5 min, then4° C. to termination.

The reaction may be cleaned up using Invitrogen's PURELINK™ PCR MicroKit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 μg).Larger reactions may require a cleanup using a product with a largercapacity. Following the cleanup, the cDNA may be quantified using theNANODROP™ and analyzed by agarose gel electrophoresis to confirm thatthe cDNA is the expected size. The cDNA may then be submitted forsequencing analysis before proceeding to the in vitro transcriptionreaction.

Example 4: In vitro Transcription (IVT)

The in vitro transcription reaction generates RNA polynucleotides. Suchpolynucleotides may comprise a region or part of the polynucleotides ofthe disclosure, including chemically modified RNA (e.g., mRNA)polynucleotides. The chemically modified RNA polynucleotides can beuniformly modified polynucleotides. The in vitro transcription reactionutilizes a custom mix of nucleotide triphosphates (NTPs). The NTPs maycomprise chemically modified NTPs, or a mix of natural and chemicallymodified NTPs, or natural NTPs.

A typical in vitro transcription reaction includes the following:

1) Template cDNA 1.0 μg 2) 10x transcription buffer 2.0 μl (400 mMTris-HCl pH 8.0, 190 mM MgCl₂, 50 mM DTT, 10 mM Spermidine) 3) CustomNTPs (25 mM each) 0.2 μl 4) RNase Inhibitor 20 U 5) T7 RNA polymerase3000 U 6) dH₂0 up to 20.0 μl. and 7) Incubation at 37° C. for 3 hr-5hrs.

The crude IVT mix may be stored at 4° C. overnight for cleanup the nextday. 1 U of RNase-free DNase may then be used to digest the originaltemplate. After 15 minutes of incubation at 37° C., the mRNA may bepurified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following themanufacturer's instructions. This kit can purify up to 500 μg of RNA.Following the cleanup, the RNA polynucleotide may be quantified usingthe NANODROP^(TM) and analyzed by agarose gel electrophoresis to confirmthe RNA polynucleotide is the proper size and that no degradation of theRNA has occurred.

Example 5: Enzymatic Capping

Capping of a RNA polynucleotide is performed as follows where themixture includes: IVT RNA 60 μg-180 μg and dH₂0 up to 72 μl. The mixtureis incubated at 65° C. for 5 minutes to denature RNA, and then istransferred immediately to ice.

The protocol then involves the mixing of 10× Capping Buffer (0.5 MTris-HCl (pH 8.0), 60 mM KCl, 12.5 mM MgCl₂) (10.0 μl); 20 mM GTP (5.0μl); 20 mM S-Adenosyl Methionine (2.5 μl); RNase Inhibitor (100 U);2′-O-Methyltransferase (400 U); Vaccinia capping enzyme (Guanylyltransferase) (40 U); dH₂0 (Up to 28 μl); and incubation at 37° C. for 30minutes for 60 μg RNA or up to 2 hours for 180 μs of RNA.

The RNA polynucleotide may then be purified using Ambion's MEGACLEAR™Kit (Austin, Tex.) following the manufacturer's instructions. Followingthe cleanup, the RNA may be quantified using the NANODROP™(ThermoFisher, Waltham, Mass.) and analyzed by agarose gelelectrophoresis to confirm the RNA polynucleotide is the proper size andthat no degradation of the RNA has occurred. The RNA polynucleotideproduct may also be sequenced by running a reverse-transcription-PCR togenerate the cDNA for sequencing.

Example 6: PolyA Tailing Reaction

Without a poly-T in the cDNA, a poly-A tailing reaction must beperformed before cleaning the final product. This is done by mixingcapped IVT RNA (100 μl); RNase Inhibitor (20 U); 10× Tailing Buffer (0.5M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl₂) (12.0 μl); 20 mM ATP (6.0μl); Poly-A Polymerase (20 U); dH₂O up to 123.5 μl and incubation at 37°C. for 30 min. If the poly-A tail is already in the transcript, then thetailing reaction may be skipped and proceed directly to cleanup withAmbion's MEGACLEAR™ kit (Austin, Tex.) (up to 500 μg). Poly-A Polymerasemay be a recombinant enzyme expressed in yeast.

It should be understood that the processivity or integrity of the polyAtailing reaction may not always result in an exact size polyA tail.Hence, polyA tails of approximately between 40-200 nucleotides, e.g.,about 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100,101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 150-165, 155, 156,157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope ofthe present disclosure.

Example 7: Natural 5′ Caps and 5′ Cap Analogues

5′-capping of polynucleotides may be completed concomitantly during thein vitro-transcription reaction using the following chemical RNA capanalogs to generate the 5′-guanosine cap structure according tomanufacturer protocols: 3′-O-Me-m7G(5′)ppp(5′) G [the ARCA cap];G(5)ppp(5′)A; G(5′)ppp(5′)G; m7G(5′)ppp(5′)A; m7G(5′)ppp(5′)G (NewEngland BioLabs, Ipswich, Mass.). 5′-capping of modified RNA may becompleted post-transcriptionally using a Vaccinia Virus Capping Enzymeto generate the “Cap 0” structure:

m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). Cap 1 structuremay be generated using both Vaccinia Virus Capping Enzyme and a 2′-Omethyl-transferase to generate: m7G(5′)ppp(5′)G-2′-O-methyl. Cap 2structure may be generated from the Cap 1 structure followed by the2′-O-methylation of the 5′-antepenultimate nucleotide using a 2′-Omethyl-transferase. Cap 3 structure may be generated from the Cap 2structure followed by the 2′-O-methylation of the 5′-preantepenultimatenucleotide using a 2′-O methyl-transferase. Enzymes are preferablyderived from a recombinant source.

When transfected into mammalian cells, the modified mRNAs have astability of between 12-18 hours or more than 18 hours, e.g., 24, 36,48, 60, 72 or greater than 72 hours.

Example 8: Capping Assays Protein Expression Assay

Polynucleotides (e.g., mRNA) encoding a polypeptide, containing any ofthe caps taught herein, can be transfected into cells at equalconcentrations. The amount of protein secreted into the culture mediumcan be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection.Synthetic polynucleotides that secrete higher levels of protein into themedium correspond to a synthetic polynucleotide with a highertranslationally-competent cap structure.

Purity Analysis Synthesis

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing anyof the caps taught herein can be compared for purity using denaturingAgarose-Urea gel electrophoresis or HPLC analysis. RNA polynucleotideswith a single, consolidated band by electrophoresis correspond to thehigher purity product compared to polynucleotides with multiple bands orstreaking bands. Chemically modified RNA polynucleotides with a singleHPLC peak also correspond to a higher purity product. The cappingreaction with a higher efficiency provides a more pure polynucleotidepopulation.

Cytokine Analysis

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing anyof the caps taught herein can be transfected into cells at multipleconcentrations. The amount of pro-inflammatory cytokines, such asTNF-alpha and IFN-beta, secreted into the culture medium can be assayedby ELISA at 6, 12, 24 and/or 36 hours post-transfection. RNApolynucleotides resulting in the secretion of higher levels ofpro-inflammatory cytokines into the medium correspond to apolynucleotides containing an immune-activating cap structure.

Capping Reaction Efficiency

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing anyof the caps taught herein can be analyzed for capping reactionefficiency by LC-MS after nuclease treatment. Nuclease treatment ofcapped polynucleotides yield a mixture of free nucleotides and thecapped 5′-5-triphosphate cap structure detectable by LC-MS. The amountof capped product on the LC-MS spectra can be expressed as a percent oftotal polynucleotide from the reaction and correspond to cappingreaction efficiency. The cap structure with a higher capping reactionefficiency has a higher amount of capped product by LC-MS.

Example 9: Agarose Gel Electrophoresis of Modified RNA or RT PCRProducts

Individual RNA polynucleotides (200-400 ng in a 20 μl volume) or reversetranscribed PCR products (200-400 ng) may be loaded into a well on anon-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, CA) and run for12-15 minutes, according to the manufacturer protocol.

Example 10: NANODROP™ Modified RNA Quantification and UV Spectral Data

Chemically modified RNA polynucleotides in TE buffer (1 μl) are used forNANODROP™ UV absorbance readings to quantitate the yield of eachpolynucleotide from an chemical synthesis or in vitro transcriptionreaction.

Example 11: Formulation of Modified mRNA Using Lipidoids

RNA (e.g., mRNA) polynucleotides may be formulated for in vitroexperiments by mixing the polynucleotides with the lipidoid at a setratio prior to addition to cells. In vivo formulation may require theaddition of extra ingredients to facilitate circulation throughout thebody. To test the ability of these lipidoids to form particles suitablefor in vivo work, a standard formulation process used for siRNA-lipidoidformulations may be used as a starting point. After formation of theparticle, polynucleotide is added and allowed to integrate with thecomplex. The encapsulation efficiency is determined using a standard dyeexclusion assays.

Example 12: Mouse Immunogenicity Studies Comparison of HA Stem Antigens

In this example, assays were carried out to evaluate the immune responseto influenza virus vaccine antigens delivered using an mRNA/LNP platformin comparison to protein antigens. The instant study was designed totest the immunogenicity in mice of candidate influenza virus vaccinescomprising an mRNA polynucleotide encoding HA stem protein obtained fromdifferent strains of influenza virus. Animals tested were 6-8 week oldfemale BALB/c mice obtained from Charles River Laboratories. Testvaccines included the following mRNAs formulated in MC3 LNP: stem ofH1/Puerto Rico/8/1934 (based on Mallajosyula V et al. PNAS 2014 Jun. 24;111(25):E2514-23), stem of H1/New Caledonia/20/1999 (based onMallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem ofH1/California/04/2009 (based on Mallajosyula Vet al. PNAS 2014 Jun. 24;111(25):E2514-23), stem of H5/Vietnam/1194/2004 (based on Mallajosyula Vet al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem ofH10/Jiangxi-Donghu/346/2013, and full-length H10/Jiangxi-Donghu/346/2013.

Protein vaccines tested in this study included the pH1HA10-Foldonprotein, as described in Mallajosyula et al. Proc Natl Acad Sci USA.2014; 111(25):E2514-23. Additional controls included MC3 (control foreffects of LNP) and PR8 influenza virus.

Mice were immunized intramuscularly with a total volume of 100 μL ofeach test vaccine, which was administered in a 50 μL immunization toeach quadricep, except for administration of the PR8 influenza viruscontrol which was delivered intranasally in a volume of 20 μL while theanimals were sedated with a mixture of Ketamine and Xylazine. The groupnumbers for each test vaccine along with the vaccine dose are outlinedin the table below:

TABLE 1 RNA Test Vaccines Group # Antigen dose formulation 1H10/Jiangxi- 10 μg MC3 Donghu/346/2013 full-length RNA 2 H10N8A/JX346/2013 stem 10 μg MC3 RNA 3 H1N1 A/Puerto Rico/8/1934 10 μg MC3stem RNA 4 H1N1 A/New 10 μg MC3 Caledonia/20/99 stem RNA 5 H1N1A/Califomia/04/2009 10 μg MC3 stem RNA 6 H5N1 A/Vietnam/1203/2004 10 μgMC3 stem RNA 7 pH1HA10-Foldon protein 20 μg CpG 7909 8 MC3  0 μg MC3 90.1 LD90 PR8 virus 0.1 LD90 NoneMice were immunized with two doses of the various influenza virus RNAvaccine formulations at weeks 0 and 3, and serum was collected two weeksafter immunization with the second dose.

To test the sera for the presence of antibodies capable of binding tohemagglutinin (HA) from a wide variety of influenza strains, ELISAplates were coated with 100 ng of the following recombinant HAs obtainedfrom Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99), cat#11683-V08H; Influenza A H3N2 (A/Aichi/2/1968), cat #11707-V08H;Influenza A H1N1 (A/California/04/2009) cat #11055-V08H; Influenza AH1N1 (A/Puerto Rico/8/34) cat #11684-V08H; Influenza A H3N2(A/Brisbane/10/2007), cat #11056-V08H; Influenza A H2N2(A/Japan/305/1957) cat #11088-V08H; Influenza A H7N9 (A/Anhui/1/2013)cat #40103-V08H; Influenza H5N1 (A/Vietnam/1194/2004) cat #11062-V08H1;Influenza H9N2 (A/Hong Kong/1073/99) cat #11229-V08H and Influenza AH10N8 (A/Jiangxi-Donghu/346/2013) cat #40359-V08B. After coating, theplates were washed, blocked with Phosphate Buffered Saline with 0.05%Tween-20 (PBST)+3% milk, and 100 μL of control antibodies or sera fromimmunized mice (diluted in PBST+3% milk) were added to the top well ofeach plate and serially diluted. Plates were sealed and incubated atroom temperature for 2 hours. Plates were washed, and goat anti-mouseIgG (H+L)-HRP conjugate (Novex, diluted 1:2000 in PBST/3% milk) wasadded to each well containing mouse sera. Plates were incubated at roomtemperature for 1 hr, washed, and incubated with TMB substrate (ThermoScientific). The color was allowed to develop for 10 minutes and thenquenched with 100 μL of 2N sulfuric acid. The plates were read at 450 nMon a microplate reader. Endpoint titers (2.5-fold above background) werecalculated.

In FIG. 1, the vaccines tested are shown on the y-axis and the endpointtiter to HA from each of the different strains of influenza are plotted.HAs from group 1 (H1, H2, H5, H9) strains of influenza are indicated byfilled circles while HAs from group 2 (H3, H7, H10) strains of influenzaare indicated by open circles. FIG. 1 illustrates that mRNA basedvaccines encoding HA-based antigens that are encapsulated in the MC3lipid nanoparticle induced high antibody binding titers to HA. FIG. 1also illustrates that mRNA vaccines designed to express a portion of thestem domain from different H1N1 or H5N1 strains of influenza elicitedhigh antibody titers that were capable of binding all strains of group 1HA tested as well as several group 2 strains. FIG. 1 also illustratesthat mRNA vaccines designed to express a portion of the H1N1A/California/04/2009 stem domain induced higher titers than a proteinvaccine of the same stem domain.

In another mouse immunogenicity study, the immune response to additionalinfluenza virus vaccine antigens delivered using an mRNA/LNP platformwas evaluated. The purpose of this study was to evaluate the ability ofa second set of mRNA vaccine antigens to elicit cross-protective immuneresponses in the mouse and to assess the potential for mRNA vaccinesencoding influenza HA antigens to be co-dosed. Animals tested were 6-8week old female BALB/c mice obtained from Charles River Laboratories.Test vaccines included the following mRNAs formulated in MC3 LNP: H1HA6(based on Bommakanti G et al. J Virol. 2012 Dec; 86(24):13434-44); H3HA6(based on Bommakanti G et al. PNAS 2010 Aug. 3; 107(31):13701-6);H1HA10-Foldon delta Ngly; eH1HA (ectodomain of HA from H1N1 A/PuertoRico/8/34); eH1HA_native signal seq (eH1HA with its native signalsequence); H3N2 A/Wisconsin/67/2005 stem; H3N2 A/Hong Kong/1/1968 stem(based on Mallajosyula V et al. Front Immunol. 2015 Jun. 26; 6:329);H7N9 A/Anhui/1/2013 stem; H1N1 A/California/04/2009 stem RNA (based onMallajosyula Vet al. PNAS 2014 Jun. 24; 111(25):E2514-23); and H1N1A/Puerto Rico/8/1934 stem RNA (based on Mallajosyula V et al. PNAS 2014Jun 24; 111(25):E2514-23).

Controls included: MC3 (control for effects of LNP); Naïve (unvaccinatedanimals); and vaccination with H1N1 A/PR/8/34 and H3N2 A/HK/1/68influenza viruses (positive controls).

Mice were immunized intramuscularly with a total volume of 100 μL ofeach test vaccine, which was administered in a 50 μL immunization toeach quadricep, except for administration of the H1N1 A/PR/8/34 and H3N2A/HK/1/68 virus influenza virus controls which were deliveredintranasally in a volume of 20 μL while the animals were sedated with amixture of Ketamine and Xylazine. The group numbers for each testvaccine along with the vaccine dose are outlined in the table below:

TABLE 2 Test Vaccines For- Antigen mula- Volume, Group # Antigen dosetion Route 1 H1HA6 RNA 10 μg MC3 100 μl, i.m. 2 H3HA6 RNA 10 μg MC3 100μl, i.m. 3 H1HA10-Foldon_delta Ngly 10 μg MC3 100 μl, i.m. 4 eH1HA 10 μgMC3 100 μl, i.m. 5 eH1HA_native signal seq 10 μg MC3 100 μl, i.m. 6 H3N2A/Wisconsin/67/2005 10 μg MC3 100 μl, i.m. stem RNA 7 H3N2 A/HongKong/1/1968 10 μg MC3 100 μl, i.m. stem RNA 8 H7N9 A/Anhui/1/2013 stem10 μg MC3 100 μl, i.m. RNA 9 H1N1 A/Puerto Rico/8/1934 10 μg MC3 100 μl,i.m. stem RNA AND H3N2 A/Wisconsin/67/2005 stem RNA (RNAs mixed prior toformulation) 10 H1N1 A/Puerto Rico/8/1934 10 μg MC3 100 μl, i.m. stemRNA AND H3N2 A/Wisconsin/67/2005 stem RNA (RNAs formulated and thenmixed 11 H1N1 A/California/04/2009 10 μg MC3 100 μl, i.m. stem RNA 12H1N1 A/Puerto Rico/8/1934 10 μg MC3 100 μl, i.m. stem RNA 13 MC3  0 μgMC3 100 μl, i.m. 14 Naïve  0 μg None None 15 H3N2 A/HK/1/68 virus 0.1LD90 None  20 μl, i.n. 16 H1N1 A/PR/8/34 virus 0.1 LD90 None  20 μl,i.n.

Animals were immunized on the study start day and then again three weeksafter the initial immunization. Sera were collected from the animals twoweeks after the second dose. To test the sera for the presence ofantibodies capable of binding to hemagglutinin (HA) from a wide varietyof influenza strains, ELISA plates were coated with 100 ng of thefollowing recombinant HAs obtained from Sino Biological Inc.: InfluenzaA H1N1 (A/New Caledonia/20/99), cat #11683-V08H; Influenza A H3N2(A/Aichi/2/1968), cat #11707-V08H; Influenza A H1N1(A/California/04/2009) cat #11055-V08H; Influenza A H1N1 (A/PuertoRico/8/34) cat #11684-V08H; Influenza A H3N2 (A/Brisbane/10/2007), cat#11056-V08H; Influenza A H2N2 (A/Japan/305/1957) cat #11088-V08H;Influenza A H7N9 (A/Anhui/1/2013) cat #40103-V08H and Influenza A H3N2(A/Moscow/10/99) cat #40154-V08. The ELISA assay was performed andendpoint titers were calculated as described above. FIGS. 2 and 3 showthe endpoint anti-HA antibody titers following the second immunizationwith the test vaccines. The vaccines tested are shown on the x-axis andthe binding to HA from each of the different strains of influenza isplotted. All mRNA vaccines encoding HA stem were immunogenic andelicited a robust antibody response recognizing HA from a diverse set ofinfluenza A virus strains. The H1HA6, eH1HA, andeH1HA_native-signal-sequence mRNAs elicited the highest overall bindingtiters across the panel of group 1 HAs, while the H3HA6 RNA elicited thehighest overall binding titers across group 2 Has (FIG. 2).Immunogenicity of combinations of stem mRNA vaccines was also tested. Inthis study, individual mRNAs were mixed prior to formulation with LNP(Group 9, co-form) or individual mRNAs were formulated with LNP prior tomixing (Group 10, mix-form). As shown in FIG. 3, combining H1 and H3stem-based mRNAs did not result in interference in the immune responseto either antigen, regardless of the method of formulation.

Example 13: Mouse Efficacy Studies

Influenza A challenge #1

This study was designed to test the immunogenicity and efficacy in miceof candidate influenza virus vaccines. Animals tested were 6-8 week oldfemale BALB/c mice obtained from Charles River Laboratories. Testvaccines included the following mRNAs formulated in MC3 LNP:NIHGen6HASS-foldon mRNA (based on Yassine et al. Nat. Med. 2015September; 21(9):1065-70), an mRNA encoding the nucleoprotein NP from anH3N2 strain, or one of several combinations of NIHGen6HASS-foldon and NPmRNAs. Several methods of vaccine antigen co-delivery were testedincluding: mixing individual mRNAs prior to formulation with LNP(co-form), formulation of individual mRNAs prior to mixing (mix indLNPs), and formulating mRNAs individually and injecting distal sites(opposite legs) (ind LNPs remote). Control animals were vaccinated withan RNA encoding the ectodomain of the HA from H1N1 A/Puerto Rico/8/1934(eH1HA, positive control) or empty MC3 LNP (to control for effects ofthe LNP) or were not vaccinated (naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with atotal volume of 100 μL of each test vaccine, which was administered in a50 μL immunization to each quadricep. Candidate influenza virus vaccinesevaluated in this study were described above and are outlined in thetable below. Sera were collected from all animals two weeks after thesecond dose. At week 6, spleens were harvested from a subset of theanimals (n=4). The remaining animals (n=6) were challenged intranasallywhile sedated with a mixture of Ketamine and Xylazine with a lethal doseof mouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934.Mortality was recorded and individual mouse weight was assessed dailyfor 20 days post-infection.

TABLE 3 Test Vaccines Group Antigen Formu- Volume, # Antigen dose lationRoute 1 NIHGen6HASS-foldon 10 μg  MC3 100 μl, i.m. RNA 2NIHGen6HASS-foldon 5 μg MC3 100 μl, i.m. RNA 3 NIHGen6HASS-foldon 2 μgMC3 100 μl, i.m. RNA 4 NP RNA 5 μg MC3 100 μl, i.m. 5 NIHGen6HASS-foldon5 μg of each MC3 100 μl, i.m. RNA + NP RNA RNA mixed, then formulated 6NIHGen6HASS-foldon 5 μg of each MC3 100 μl, i.m. RNA + NP RNA RNAformulated, then mixed 7 NIHGen6HASS-foldon 5 μg of each MC3 100 μl,i.m. RNA + NP RNA RNA formulated and injected into separate legs 8NIHGen6HASS-foldon 5 μg of NP + MC3 100 μl, i.m. RNA + NP RNA 2 μg ofNIHGen6HASS-foldon RNA mixed, then formulated 9 eH1HA RNA 10 μg  MC3 100μl, i.m. 10 MC3 0 μg MC3 100 μl, i.m. 11 Naïve 0 μg None None

To test the sera for the presence of antibodies capable of binding tohemagglutinin (HA) from a wide variety of influenza strains ornucleoprotein (NP), ELISA plates were coated with 100 ng of thefollowing recombinant proteins obtained from Sino Biological Inc.:Influenza A H1N1 (A/New Caledonia/20/99) HA, cat #11683-V08H; InfluenzaA H3N2 (A/Aichi/2/1968) HA, cat #11707-V08H; Influenza A H1N1(A/California/04/2009) HA, cat # 11055-V08H; Influenza A H1N1 (A/PuertoRico/8/34) HA, cat #11684-V08H; Influenza A H1N1 (A/Brisbane/59/2007)HA, cat #11052-V08H; Influenza A H2N2 (A/Japan/305/1957) HA, cat#11088-V08H; Influenza A H7N9 (A/Anhui/1/2013) HA, cat #40103-V08H,Influenza A H3N2 (A/Moscow/10/99) HA, cat #40154-V08 and Influenza AH3N2 (A/Aichi/2/1968) Nucleoprotein cat #40207-V08B. The ELISA assay wasperformed and endpoint titers were calculated as described above. FIG. 4depicts the endpoint titers of the pooled serum from animals vaccinatedwith the test vaccines. The vaccines tested are shown on the x-axis ofFIG. 4A and the binding to HA from each of the different strains ofinfluenza is plotted. The NIHGen6HASS-foldon mRNA vaccine elicited hightiters of antibodies that bound all H1, H2 and H7 HAs tested. Combiningthe NIHGen6HASS-foldon mRNA with one that encodes NP did not negativelyaffect the observed anti-HA response, regardless of the method of mRNAco-formulation or co-delivery. In serum collected from identical groupsfrom a separate study, a robust antibody response to NP protein was alsodetected in serum from animals vaccinated with NP mRNA containingvaccines, either NP alone or co-formulated with NIHGen6HASS-foldonmRNA(FIG. 4B).

To probe the functional antibody response, the ability of serum toneutralize a panel of HA-pseudotyped viruses was assessed (FIG. 5).Briefly, 293 cells were co-transfected with a replication-defectiveretroviral vector containing a firefly luciferase gene, an expressionvector encoding a human airway serine protease, and expression vectorsencoding influenza hemagglutinin (HA) and neuraminidase (NA) proteins.The resultant pseudoviruses were harvested from the culture supernatant,filtered, and titered. Serial dilutions of serum were incubated in 96well plates at 37° C. for one hour with pseudovirus stocks(30,000-300,000 relative light units per well) before 293 cells wereadded to each well. The cultures were incubated at 37° C. for 72 hours,luciferase substrate and cell lysing reagents were added, and relativelight units (RLU) were measured on a luminometer. Neutralization titersare expressed as the reciprocal of the serum dilution that inhibited 50%of pseudovirus infection (IC50).

For each sample tested (listed along the x-axis), each bar representsthe IC50 for neutralization of a different virus pseudotype. While theserum from naïve or NP RNA vaccinated mice was unable to inhibitpseudovirus infection, the serum from mice vaccinated with 10 μg or 5μgof NIHGen6HASS-foldon mRNA or with a combination of NIHGen6HASS-foldonand NP mRNAs neutralized, to a similar extent, all H1 and H5 viruspseudotypes tested.

The ability of NIHGen6HASS-foldon antisera to mediate antibody-dependentcell cytotoxicity (ADCC) surrogate activity in vitro was also assessed.Briefly, serially titrated mouse serum samples were incubated with A549cells stably expressing HA from H1N1 A/Puerto Rico/8/1934 on the cellsurface. Subsequently, ADCC Bioassay Effector cells (Promega, mouseFcgRIV NFAT-Luc effector cells) were added to the serum/target cellmixture. Approximately 6 hours later, Bio-glo reagent (Promega) wasadded to sample wells and luminescence was measured. Data was plotted asfold induction (sample luminescence/background luminescence) versusserum concentration (FIG. 6). When incubated with the appropriate targetcells, serum from NIHGen6HASS-foldon mRNA vaccinated mice was able tostimulate the surrogate ADCC effector cell line, suggesting that thevaccine may induce antibodies capable of mediating in vivo ADCCactivity.

Three weeks after the administration of the second vaccine dose, spleenswere harvested from a subset of animals in each group and splenocytesfrom animals in the same group were pooled. Splenic lymphocytes werestimulated with a pool of HA or NP peptides, and IFN-γ, IL-2 or TNF-αproduction was measured by intracellular staining and flow cytometry.FIG. 7 is a representation of responses following stimulation with apool of NP peptides, and FIG. 8 is a representation of responsesfollowing stimulation with a pool of H1 HA peptides. Followingvaccination with NP mRNA, either in the presence or absence ofNIHGen6HASS-foldon mRNA, antigen-specific CD4 and CD8 T cells were foundin the spleen. Following vaccination with NIHGen6HASS-foldon RNA ordelivery of NIHGen6HASS-foldon and NP RNAs to distal injections sites(dist. site), only HA-specific CD4 cells were observed. However, whenNIHGen6HASS-foldon and NP RNAs were co-administered to the sameinjection site (co-form, mix), an HA-specific CD8 T cell response wasdetected.

Following lethal challenge with mouse-adapted H1N1 A/Puerto Rico/8/1934,all naïve animals succumbed to infection by day 12 post-infection (FIG.9). In contrast, all animals vaccinated with NIHGen6HASS-foldon mRNA, NPmRNA, any combination of NIHGen6HASS-foldon and NP mRNAs, or eH1HA mRNAsurvived the challenge. As seen in FIG. 9, although there was nomortality, mice that were vaccinated with an H3N2 NP mRNA and challengedwith H1N1 virus lost a significant amount (˜15%) of weight prior torecovery. Those vaccinated with NIHGen6HASS-foldon RNA also lost ˜5%body weight. In contrast, mice vaccinated with a combination ofNIHGen6HASS-foldon and NP mRNAs appeared to be completely protected fromlethal influenza virus challenge, similar to those vaccinated with mRNAexpressing an HA antigen homologous to that of the challenge virus(eH1HA). Vaccine efficacy was similar at all vaccine doses, as well aswith all co-formulation and co-delivery methods assessed (FIG. 10).

Influenza A challenge #2

This study was designed to test the immunogenicity and efficacy in miceof candidate influenza virus vaccines. Animals tested were 6-8 week oldfemale BALB/c mice obtained from Charles River Laboratories. Testvaccines included the following mRNAs formulated in MC3 LNP:NIHGen6HASS-foldon mRNA (based on Yassine et al. Nat. Med. 2015September; 21(9):1065-70) and NIHGen6HASS-TM2 mRNA. Control animals werevaccinated with an mRNA encoding the ectodomain of the HA from H1N1A/Puerto Rico/8/1934 (eH1HA, positive control) or were not vaccinated(naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with atotal volume of 100 μL of each test vaccine, which was administered in a50 μL immunization to each quadricep. Candidate influenza virus vaccinesevaluated in this study were described above and outlined in the tablebelow. Sera were collected from all animals two weeks after the seconddose. At week 6, all animals were challenged intranasally while sedatedwith a mixture of Ketamine and Xylazine with a lethal dose ofmouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934.Mortality was recorded and group mouse weight was assessed daily for 20days post-infection.

TABLE 4 Test Vaccines Group Antigen Formu- Volume, # Antigen dose lationRoute 1 NIHGen6HASS-foldon 5 μg MC3 100 μl, i.m. RNA 2NIHGen6HASS-foldon- 5 μg MC3 100 μl, i.m. TM2 RNA 3 eH1HA RNA 10 μg  MC3100 μl, i.m. 4 Naïve 0 μg None None

To test the sera for the presence of antibody capable of binding tohemagglutinin (HA) from a wide variety of influenza strains, ELISAplates were coated with 100 ng of the following recombinant HAs obtainedfrom Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99), cat#11683-V08H; Influenza A H3N2 (A/Aichi/2/1968), cat #11707-V08H;Influenza A H1N1 (A/California/04/2009) cat #11055-V08H; Influenza AH1N1 (A/Puerto Rico/8/34) cat #11684-V08H; Influenza A H1N1(A/Brisbane/59/2007), cat #11052-V08H; Influenza A H2N2(A/Japan/305/1957) cat #11088-V08H; Influenza A H7N9 (A/Anhui/1/2013)cat #40103-V08H and Influenza A H3N2 (A/Moscow/10/99) cat #40154-V08.The ELISA assay was performed and endpoint titers were calculated asdescribed above. FIG. 11A depicts the endpoint titers of the pooledserum from animals vaccinated with the test vaccines. The vaccinestested are shown on the x-axis and the binding to HA from each of thedifferent strains of influenza is plotted. The NIHGen6HASS-foldon mRNAvaccine elicited high titers of antibodies that bound all H1, H2 and H7HAs tested. The binding titers from NIHGen6HASS-TM2 mRNA vaccinated micewere reduced as compared to those from NIHGen6HASS-foldon mRNAvaccinated mice.

Following lethal challenge with mouse-adapted H1N1 A/Puerto Rico/8/1934,all naive animals succumbed to infection by day 16 post-infection (FIG.11B). In contrast, all animals vaccinated with NIHGen6HASS-foldon mRNA,NIHGen6HASS-TM2 mRNA, or eH1HA RNA survived the challenge. As shown inFIG. 11B, the efficacy of the NIHGen6HASS-TM2 vaccine was equivalent tothat of the NIHGen6HASS-foldon vaccine.

Influenza A challenge #3

In this example, two animal studies and assays were carried out toevaluate the immune response to influenza virus consensus hemagglutinin(HA) vaccine antigens delivered using an mRNA/LNP platform. The purposeof these studies was to evaluate the ability of consensus HA mRNAvaccine antigens to elicit cross-protective immune responses in themouse.

To generate consensus HA sequences, 2415 influenza A serotype H1 HAsequences were obtained from the NIAID Influenza Research Database (IRD)(Squires et al., Influenza Other Respir Viruses. 2012 November; 6(6):404-416.) through the web site at http://www.fludb.org. After removal ofduplicate sequences and lab strains, 2385 entries remained, including1735 H1 sequences from pandemic H1N1 strains (pH1N1) and 650 fromseasonal H1N1 strains (sH1N1). Pandemic and seasonal H1 sequences wereseparately aligned and a consensus sequence was generated for each groupusing the Matlab 9.0 Bioinformatics toolbox (MathWorks, Natick, Mass.).Sequence profiles were generated for both groups separately using amodified Seq2Logo program (Thomsen et al., Nucleic Acids Res. 2012 Jul;40 (Web Server issue):W281-7).

Animals tested were 6-8 week old female BALB/c mice obtained fromCharles River Laboratories. Test vaccines included the following mRNAsformulated in MC3 LNP: ConH1 and ConH3 (based on Webby et al., PLoS One.2015 Oct 15; 10(10):e0140702.); Cobra_P1 and Cobra_X3 (based on Carteret al., J Virol. 2016 Apr 14; 90(9):4720-34); MRK_pH1_Con andMRK_sH1_Con (pandemic and seasonal consensus sequences described above);and each of the above mentioned six antigens with a ferritin fusionsequence for potential particle formation.

Controls included: MC3 (control for effects of LNP); Naïve (unvaccinatedanimals); and vaccination with eH1HA RNA, which encode the ectodomain ofHA from strain H1N1 A/PR/8/34 (positive control for the viruschallenge).

At week 0 and week 3, animals were immunized intramuscularly (IM) with atotal volume of 100 μL of each test vaccine, which was administered in a50 μL immunization to each quadricep. Candidate influenza virus vaccinesevaluated in this study were described above and are outlined in thetable below. Sera were collected from all animals two weeks after thesecond dose (week 5). At week 6, the animals were challengedintranasally while sedated with a mixture of Ketamine and Xylazine witha lethal dose of mouse-adapted influenza virus strain H1N1 A/PuertoRico/8/1934 (PR8). Mortality was recorded and group weight was assesseddaily for 20 days post-infection.

TABLE 5 Test Vaccines Group Antigen Formu- Volume, # Antigen dose lationRoute 1 Con_H1 RNA 10 μg MC3 100 μl, i.m. 2 Con_H3 RNA 10 μg MC3 100 μl,i.m. 3 Merck_pH1_Con RNA 10 μg MC3 100 μl, i.m. 4 Merck_sH1_Con RNA 10μg MC3 100 μl, i.m. 5 Cobra_P1 RNA 10 μg MC3 100 μl, i.m. 6 Cobra_X3 RNA10 μg MC3 100 μl, i.m. 7 ConH1_ferritin RNA 10 μg MC3 100 μl, i.m. 8ConH3_ferritin RNA 10 μg MC3 100 μl, i.m. 9 Merck_pH1_Con_ferritin 10 μgMC3 100 μl, i.m. RNA 10 Merck_sH1_Con_ferritin 10 μg MC3 100 μl, i.m.RNA 11 Cobra_P1_ferritin RNA 10 μg MC3 100 μl, i.m. 12 Cobra_X3_ferritinRNA 10 μg MC3 100 μl, i.m. 13 eH1HA 10 μg MC3 100 μl, i.m. 14 MC3  0 μgMC3 100 μl, i.m. 15 Naïve  0 μg None None

To test the ability of the serum antibodies to neutralize the challengevirus strain, a microneutralization assay using a modified PR8 viruswith a Gaussia luciferase reporter gene (Pan et al., Nat Commun. 2013;4:2369) was performed. Briefly, PR8 luciferase virus was diluted invirus diluent with TPCK-treated trypsin. Serum samples were diluted 1:10and then serially diluted 3-fold in 96-well cell culture plates. 50 μLof each diluted serum sample and an equal volume of diluted virus weremixed in the well and incubated at 37° C. with 5% CO₂ for 1 hr before100 μL of MDCK cells at 1.5×10{circumflex over ( )}5 cells/mL wereadded. Plates were then incubated at 37° C. with 5% CO₂ for 72 hrs.Luminescence signal was read with a Gaussia Luciferase Glow Assay Kit(Pierce) on an EnVision reader (Perkin Elmer). As shown in FIG. 12A,serum from mice immunized with mRNA encoding consensus HA antigens fromthe H1 subtype was able to detectably neutralize the PR8 luciferasevirus, even though the HA sequences of these antigens were 8-19%different from that of the PR8 strain. The HA sequence-matched antigen(eH1HA) elicited a much higher serum neutralizing antibody responseagainst this virus. Serum from mice vaccinated with RNA encoding theconsensus H3 antigen (ConH3), in contrast, was not able to neutralizethe PR8 luciferase virus, suggesting that the consensus sequences fromdifferent subtypes (H1 and H3, for example) may not cross-react.Similarly, serum from mice immunized with mRNA encoding H1 subtypeconsensus HA antigens with a ferritin fusion sequence was able todetectably neutralize the PR8 luciferase virus, except for the MerckpH1Conferritin mRNA, while serum from mice vaccinated with an mRNA encodingthe consensus H3 antigen with a ferritin fusion sequence was not able toneutralize the PR8 luciferase virus (FIG. 12B). Consistent with theserum neutralization data, mice immunized with the consensus H1 HAantigens (with or without ferritin fusion) survived the lethal PR8 viruschallenge and showed no weight loss, except for theMerck_pH1_Con_ferritin mRNA group, while mice in the ConH3, naive andLNP only control groups rapidly lost weight upon challenge (FIG. 13).Mice immunized with Merck_pH1_Con_ferritin mRNA survived the lethal PR8virus challenge and showed 5-10% weight loss, suggesting that partialprotection may be mediated by mechanism(s) other than virusneutralization.

To assess the breadth of the serum neutralizing activity elicited by theconsensus HA antigens, neutralization assays were performed on a panelof pseudoviruses as described above (FIG. 14). As expected, serum frommice immunized with influenza virus H1N1 A/Puerto Rico/8/1934 (fromstudies described in Example 12) was only able to neutralize a matchedpseudovirus strain (PR8). In contrast, serum from mice immunized withthe consensus H1 HA antigens, as well as the eH1HA antigen, were able toneutralize a panel of diverse group 1 pseudoviruses, including strainsfrom subtypes H1 and H5, but not a strain from group 2 (subtype H3).Consistently, serum from mice immunized with the consensus H3 HA antigenwas able to neutralize a strain from group 2 (subtype H3) but not any ofthe group 1 pseudoviruses.

Influenza B challenge

This study was designed to test the immunogenicity and efficacy in miceof candidate influenza virus vaccines. Animals tested were 6-8 week oldfemale BALB/c mice obtained from Charles River Laboratories. Testvaccines included the following mRNAs formulated in MC3 LNP:B/Phuket/3073/2013 sHA (soluble HA), B/Phuket/3073/2013 mHA (full-lengthHA with membrane anchor), B/Brisbane/60/2008 sHA, B/Victoria/02/1987sHA, B/Victoria/02/1987 mHA, B/Yamagata/16/1988 mHA, or BHA10 (HA stemdesign). Control animals were vaccinated with a nonlethal dose ofmouse-adapted B/Ann Arbor/1954 (positive control) or empty MC3 LNP (tocontrol for effects of the LNP) or were not vaccinated (naive).

At week 0 and week 3, animals were immunized intramuscularly (IM) with atotal volume of 100 μL of each test vaccine, which was administered in a50 μL immunization to each quadricep. Candidate influenza virus vaccinesevaluated in this study were described above and are outlined in thetable below. Sera were collected from all animals two weeks after thesecond dose. At week 6, all animals (n=10 per group) were challengedintranasally while sedated with a mixture of Ketamine and Xylazine witha lethal dose of mouse-adapted influenza virus strain B/Ann Arbor/1954.Mortality was recorded and group mouse weight was assessed daily for 20days post-infection.

Each of the sequences described herein encompasses a chemically modifiedsequence or an unmodified sequence which includes no nucleotidemodifications.

TABLE 6 Test Vaccines Group Antigen Formu- Volume, # Antigen dose lationRoute 1 B/Phuket/3073/2013 10 μg MC3 100 μl, i.m. sHA RNA 2B/Phuket/3073/2013 10 μg MC3 100 μl, i.m. mHA RNA 3 B/Brisbane/60/200810 μg MC3 100 μl, i.m. sHA RNA 4 B/Victoria/02/1987 10 μg MC3 100 μl,i.m. sHA RNA 5 B/Victoria/02/1987 10 μg MC3 100 μl, i.m. mHA RNA 6B/Yamagata/16/1988 10 μg MC3 100 μl, i.m. mHA RNA 7 BHA10 RNA 10 μg MC3100 μl, i.m. 8 MC3  0 μg MC3 100 μl, i.m. 9 Naive  0 μg None 100 μl,i.m. 10 B/Ann Arbor/1954 0.1 LD90 None 20 μl, i.n.

FIG. 15A depicts the ELISA endpoint anti-HA antibody titers of thepooled serum from animals vaccinated with the test vaccines. Thevaccines tested are shown on the x-axis and the binding to HA from eachof the different strains of influenza is plotted. All vaccines tested,except for those derived from B/Phuket/3073/2013 were immunogenic, andserum antibody bound to HA from both B/Yamagata/16/1988 (Yamagatalineage) and B/Florida/4/2006 (Victoria lineage).

Following lethal challenge with mouse-adapted B/Ann Arbor/1954, 90% ofMC3-vaccinated and naive animals succumbed to infection by day 16post-infection (FIG. 15B). The B/Phuket/3073/2013 sHA and mHA mRNAvaccines showed no efficacy against lethal challenge, and the BHA10 stemmRNA vaccine protected only half of the animals. All other vaccinestested protected mice completely from mortality (FIG. 15B), but only theB/Yamagata/16/1988 mHA RNA vaccine was able to prevent lethality andweight loss in animals challenged with a heterologous virus strain (FIG.15B).

Example 14: Non-Human Primate Immunogenicity

This study was designed to test the immunogenicity in rhesus macaques ofcandidate influenza virus vaccines. Test vaccines included the followingmRNAs formulated in MC3 LNP: NIHGen6HASS-foldon mRNA (based on Yassineet al. Nat. Med. 2015 September; 21(9):1065-70) and NP mRNA encoding NPprotein from an H3N2 influenza strain.

Animals in Group 1 had been previously vaccinated with seasonalinactivated influenza vaccine (FLUZONE®) and were boostedintramuscularly (IM) at day 0 with 300 μg of NIHGen6HASS-foldon mRNA.Animals in Groups 2 and 3 were influenza naïve at the study start andwere vaccinated at days 0, 28 and 56 with 300 μg of NIHGen6HASS-foldonmRNA or 300 μg of NP mRNA, respectively. Serum was collected from allanimals prior to the study start (day -8) as well as at days 14, 28, 42,56, 70, 84, 112, 140 and 168.

The NIHGen6HASS-foldon vaccine elicited a robust antibody response asmeasured by ELISA assay (plates coated with recombinantly-expressedNIHGen6HASS-foldon [HA stem] or NP proteins), and the data is depictedin FIG. 16. FIG. 16A shows titers to HA stem, over time, for four rhesusmacaques previously vaccinated with FLUZONE® and boosted a single timewith NIHGen6HASS-foldon mRNA vaccine. FIG. 16B depicts titers to HAstem, over time, from four rhesus macaques vaccinated at days 0, 28 and56 with the same NIHGen6HASS-foldon RNA vaccine. The NIHGen6HASS-foldonRNA vaccine was able to boost anti-HA stem antibody binding titers inanimal previously vaccinated with inactivated influenza vaccine as wellas elicited a robust response in naïve animals. In both groups, HA stemtiters remained elevated over baseline to at least study day 168. FIG.16C illustrates antibody titers to NP, over time, for four rhesusmacaques vaccinated at days 0, 28 and 56 with the NP mRNA vaccine andshows that the vaccine elicited a robust antibody response to NP.

To test the Group 1 and 2 sera for the presence of antibody capable ofbinding to hemagglutinin (HA) from a wide variety of influenza strains,ELISA plates were coated with recombinant HAs from a diverse set ofinfluenza strains as described above. EC10 titers were calculated as thereciprocal of the serum dilution that reached 10% of the maximal signal.For animals in Group 1 (FIG. 17A), a single dose of NIHGen6HASS-foldonvaccine boosted titers to H1 HAs ˜40-60 fold, and titers peakedapproximately 28 days post-vaccination. Titers decreased from days28-70, but day 70 titers were still ˜10-30-fold above the titersmeasured prior to vaccination. The NIHGen6HASS-foldon mRNA vaccine didnot boost titers to HAs from H3 or H7 influenza strains. For animals inGroup 2 (FIG. 17B), antibody titers to H1 and H2 HAs rose after eachdose of NIHGen6HASS-foldon mRNA vaccine, and titers appeared to risemost dramatically after dose 2.

In addition to robust antibody responses, the NP mRNA vaccine alsoelicited cell-mediated immunity in rhesus. On study day 0, 42, 70 and140, PBMCs were collected from Group 3 NP mRNA vaccinated rhesusmacaques. Lymphocytes were stimulated with a pool of NP peptides, andIFN-γ, IL-2 or TNF-α production were measured by intracellular stainingand flow cytometry. FIG. 18 is a representation of responses followingNP peptide pool stimulation. Following vaccination with NP mRNA,antigen-specific CD4 and CD8 T cells were found in the peripheral blood,and these cells were maintained above baseline to at least study day140.

Example 15: H7N9 Immunogenicity Studies

The instant study was designed to test H7N9 immunogenicity.Intramuscular immunizations of 25 μM were administered on days 1 and 22to 40 animals, and blood was collected on days 1, 8, 22, and 43.Hemagglutination inhibition (HAI) and microneutralization tests wereconducted using the blood samples.

The HAI test showed a geometric mean titer (GMT) of 45 for all of theanimals, including the placebo group. The GMT of the responders only was116 (FIG. 19). The HAI kinetics for each individual subject are given inFIG. 20.

The microneutralization (MN) test showed a geometric mean titer (GMT) of36 for all of the animals, including the placebo group. The GMT of theresponders only was 84 (FIG. 21). The MN test kinetics for each subjectare given in FIG. 22.

HAI and MN showed a very strong correlation (FIG. 23). Only one subjecthad a protective titer in one assay , but not in the other. Also, 10subjects had no detectable HAI or MN titer at Day 43.

Example 16: Mouse Immunogenicity Studies

This study was designed to test the immunogenicity and efficacy in miceof candidate influenza virus vaccines. Animals tested were 6-8 week oldfemale BALB/c mice obtained from Charles River Laboratories. Testvaccines included the following mRNAs formulated in a cationic LNP:MRK_H1 cot_all, MRK_H3 cot_all, MRK_H3 con_all, MRK_H3_Consensus A andMRK_H3_Consensus B. Control animals were vaccinated with an mRNAencoding the HA from H1N1 A/Puerto Rico/8/1934 (FLHA_PR8, positivecontrol for PR8 infection), vaccinated with empty LNP, infected with anonlethal dose of mouse-adapted H3 A/Hong Kong/1/1968, or were notvaccinated (naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with atotal volume of 100 mL of each test vaccine, which was administered in a50 mL immunization to each quadricep. Candidate influenza virus vaccinesevaluated in this study were described above and outlined in the tablebelow. Sera were collected from all animals two weeks after the seconddose. At week 6, all animals were challenged intranasally while sedatedwith a mixture of Ketamine and Xylazine with a lethal dose ofmouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934 (PR8) orH3 A/Hong Kong/1/1968 (HK68). Mortality was recorded and group mouseweight was assessed daily for 20 days post-infection.

TABLE A Group Antigen Formu- Volume, # Antigen dose lation Route 1FLHA_PR8 RNA  5 ug LNP 100 ul, i.m. (SEQ ID NO: 541) 2 MRK_H1_cot_allRNA 10 ug LNP 100 ul, i.m. (SEQ ID NO: 530) 3 MRK_H3_cot_all RNA 10 ugLNP 100 ul, i.m. (SEQ ID NO: 534) 4 MRK_H3_con_all RNA 10 ug LNP 100 ul,i.m. (SEQ ID NO: 533) 5 MRK_H3_Consensus A 10 ug LNP 100 ul, i.m. RNA(SEQ ID NO: 531) 6 MRK_H3 _Consensus B 10 ug LNP 100 ul, i.m. RNA (SEQID NO: 532) 7 Empty LNP  0 ug LNP 100 ul, i.m. 8 Mouse-adapted H3 0.1LD90 None 20 ul, i.n. A/Hong Kong/1/1968 virus 9 Naïve  0 ug None None

To assess the breadth of the serum activity elicited by the antigens,hemagglutination inhibition assays (HAI) were performed using a panel ofH1N1 and H3N2 influenza viruses (Tables B and C. Briefly, serum sampleswere treated with receptor destroying enzyme (RDE) for 18-20 hrs at 37°C. before inactivation at 56° C. for 35-45 min. RDE-treated sera wasthen serially diluted in a 96 well plate and mixed with 4hemagglutinating units of virus. An equal volume of 0.5% turkey redblood cells was added to each well, and plates were incubated at roomtemperature for 30 min. The highest dilution with no visibleagglutination was assigned as the serum titer. While the MRK_H1 cot_allmRNA vaccine elicited titers to only two viruses in the H1 HAI panel(Table B), the MRK_H3 cot_all, MRKH3con_all, MRK_H3_Consensus A andMRK_H3_Consensus B mRNAs induced high HAI titers to multiple H3 strainsisolated between 1997 and 2014 (Table C).

Although mice immunized with MRKH1cot all mRNA did not have detectableHAI titers to the PR8 virus, they were partially protected from lethalchallenge with PR8 virus. In contrast to naïve or LNP vaccinated mice,all MRK_H1 cot_all mRNA immunized mice survived challenge (FIG. 24A),though they lost, on average, approximately 10% of their body weightpost-infection (FIG. 24B). Similarly, mice vaccinated with any of the H3COT or consensus mRNAs tested survived challenge with a lethal dose ofHK68 virus (FIG. 24C) but lost between 10 and 15% or their body weightpost-infection (FIG. 24D).

TABLE B A/Puerto A/Fort/Monmouth/ A/New A/Brazil/ A/Singapore/ A/Texas/Vaccine Rico/8/1934 1/1947 Jersey/10/1976 11/1978 6/1986 36/1991 MRK H1cot all <10 <10 2,560 <10 <10 <10 Naive <10 <10 <10 <10 <10 <10A/Beijing/ A/New A/Solomon A/Brisbane/ A/California/ Vaccine 262/1995Caledonia/20/1999 Islands/3/2006 59/2007 07/2009 — MRK H1 cot all <10<10 <10 <10 10,240 — Naive <10 <10 <10 <10 <10 —

TABLE C A/HongKong/ A/Philippines/ A/Sydney/ A/Texas/ A/Switzerland/A/HongKong/ Vaccine 1/1968 1982 5/1997 50/2012 9715293/2013 4801/2014H3_cot_all <10 <10 <10 40,960 20,480 10,240 MRK_H3_con_all <10 <10 <1040,960 10,240 10,240 MRK_H3_ConA <10 <10 10,240 640 320 20 MRK_H3_ConB<10 <10 <10 40,960 10,240 10,240 Naive <10 <10 <10 <10 <10 <10

TABLE 7 Influenza H1N1 Antigens GenBank/GI Strain/Protein LengthAccession No. Influenza A virus (A/Bayern/7/95(H1N1)) NA 1,459 bpAJ518104.1 gene for neuraminidase, genomic RNA linear mRNA GI: 31096418Influenza A virus (A/Brazil/11/1978(X- 1,072 bp X86654.1 71)(H1N1)) mRNAfor hemagglutinin HA1, escape linear mRNA GI: 995549 variant 1 InfluenzaA virus (A/Brazil/11/1978(X- 1,072 bp X86655.1 71)(H1N1)) mRNA forhemagglutinin HA1, escape linear mRNA GI: 995550 variant 2 Influenza Avirus (A/Brazil/11/1978(X- 1,072 bp X86656.1 71)(H1N1)) mRNA forhemagglutinin HA1, escape linear mRNA GI: 995551 variant 3 Influenza Avirus (A/Brazil/11/1978(X- 1,072 bp X86657.1 71)(H1N1)) mRNA forhemagglutinin HA1, escape linear mRNA GI: 995552 variant 4 Influenza Avirus 1,220 bp AF116575.1 (A/Brevig_Mission/1/18(H1N1)) hemagglutininlinear mRNA GI: 4325017 (HA) mRNA, partial cds Influenza A virus 1,410bp AF250356.2 (A/Brevig_Mission/1/18(H1N1)) neuraminidase linear mRNAGI: 13260556 (NA) gene, complete cds Influenza A virus (A/Brevig 1,497bp AY744935.1 Mission/1/1918(H1N1)) nucleoprotein (np) linear mRNA GI:55273940 mRNA, complete cds Influenza A virus (A/Brevig 2,280 bpDQ208309.1 Mission/1/1918(H1N1)) polymerase PB2 (PB2) linear mRNA GI:76786704 mRNA, complete cds Influenza A virus (A/Brevig 2,274 bpDQ208310.1 Mission/1/1918(H1N1)) polymerase PB1 (PB1) linear mRNA GI:76786706 mRNA, complete cds Influenza A virus (A/Brevig 2,151 bpDQ208311.1 Mission/1/1918(H1N1)) polymerase PA (PA) linear mRNA GI:76786708 mRNA, complete cds Influenza A virus 366 bp M73975.1(A/camel/Mongolia/1982(H1N1)) hemagglutinin linear mRNA GI: 324242 mRNA,partial cds Influenza A virus 460 bp M73978.1(A/camel/Mongolia/1982(H1N1)) matrix protein linear mRNA GI: 324402mRNA, partial cds Influenza A virus 310 bp M73976.1(A/camel/Mongolia/1982(H1N1)) neuraminidase linear mRNA GI: 324579 (NA)mRNA, partial cds Influenza A Virus A/camel/Mongolia/82 NS1 273 bpM73977.1 protein mRNA, partial cds linear mRNA GI: 324768 Influenza Avirus 227 bp M73974.1 (A/camel/Mongolia/1982(H1N1)) PA polymerase linearmRNA GI: 324931 mRNA, partial cds Influenza A virus 531 bp M73973.1(A/camel/Mongolia/1982(H1N1)) PB1 protein linear mRNA GI: 324971 mRNA,partial cds Influenza A Virus (A/camel/Mongolia/82(H1N1)) 379 bpM73972.1 polymerase 2 (P2) mRNA, partial cds linear mRNA GI: 324993Influenza A virus (A/chicken/Hong 1,169 bp U46782.1 Kong/14/1976(H1N1))hemagglutinin precursor linear mRNA GI: 1912328 (HA) mRNA, partial cdsInfluenza A virus (A/Chonnam/07/2002(H1N1)) 1,452 bp AY297141.1neuraminidase (NA) mRNA, complete cds linear mRNA GI: 31871990 InfluenzaA virus (A/Chonnam/07/2002(H1N1)) 1,137 bp AY297154.1 hemagglutinin (HA)mRNA, partial cds linear mRNA GI: 32140347 Influenza A virus(A/Chonnam/18/2002(H1N1)) 1,458 bp AY297143.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31871994 Influenza A virus(A/Chonnam/18/2002(H1N1)) 1,176 bp AY297156.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140355 Influenza A virus(A/Chonnam/19/2002(H1N1)) 1,458 bp AY310410.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872389 Influenza A virus(A/Chonnam/19/2002(H1N1)) 1,167 bp AY299502.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140392 Influenza A virus(A/Chonnam/51/2002(H1N1)) 1,443 bp AY310412.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31873090 Influenza A virus(A/Chonnam/51/2002(H1N1)) 1,161 bp AY299498.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140384 Influenza A virus(A/Chungbuk/50/2002(H1N1)) 1,425 bp AY297150.1 neuraminidase (NA) mRNA,partial cds linear mRNA GI: 31872010 Influenza A virus(A/Chungbuk/50/2002(H1N1)) 1,161 bp AY299506.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140400 Influenza A virus(A/Denmark/40/2000(H1N1)) 1,458 bp AJ518095.1 NA gene for neuraminidase,genomic RNA linear mRNA GI: 31096400 Influenza A virus(A/Denver/1/57(H1N1)) 379 bp AF305216.1 neuraminidase mRNA, partial cdslinear mRNA GI: 10732818 Influenza A virus (A/Denver/1/57(H1N1)) 442 bpAF305217.1 matrix protein gene, partial cds linear mRNA GI: 10732820Influenza A virus (A/Denver/1/57(H1N1)) 215 bp AF305218.1 hemagglutiningene, partial cds linear mRNA GI: 10732822 Influenza A virus 981 bpU47309.1 (A/duck/Australia/749/80(H1N1)) hemagglutinin linear mRNA GI:1912348 precursor (HA) mRNA, partial cds Influenza A virus 1,777 bpAF091312.1 (A/duck/Australia/749/80(H1N1)) segment 4 linear mRNA GI:4585166 hemagglutinin precursor (HA) mRNA, complete cds Influenza Avirus (A/duck/Bavaria/1/77 1,777 bp AF091313.1 (H1N1)) segment 4hemagglutinin precursor linear mRNA GI: 4585168 (HA) mRNA, complete cdsInfluenza A virus (A/duck/Bavaria/2/77(H1N1)) 981 bp U47308.1hemagglutinin precursor (HA) mRNA, partial linear mRNA GI: 1912346 cdsInfluenza A virus (A/duck/Eastern 1,458 bp EU429749.1China/103/2003(H1N1)) segment 6 neuraminidase linear mRNA GI: 167859463(NA) mRNA, complete cds Influenza A virus (A/duck/Eastern 1,461 bpEU429751.1 China/152/2003(H1N1)) segment 6 neuraminidase linear mRNA GI:167859467 (NA) mRNA, complete cds Influenza A virus (A/Duck/Ohio/118C/931,410 bp AF250361.2 (H1N1)) neuraminidase (NA) gene, complete cds linearmRNA GI: 13260576 Influenza A virus (A/Duck/Ohio/175/86 (H1N1)) 1,410 bpAF250358.2 neuraminidase (NA) gene, complete cds linear mRNA GI:13260565 Influenza A virus (A/Duck/Ohio/194/86 (H1N1)) 1,410 bpAF250360.2 neuraminidase (NA) gene, complete cds linear mRNA GI:13260573 Influenza A virus (A/Duck/Ohio/30/86 (H1N1)) 1,410 bpAF250359.2 neuraminidase (NA) gene, complete cds linear mRNA GI:13260570 Influenza A virus strain 1,460 bp AJ006954.1A/Fiji/15899/83(H1N1) mRNA for neuraminidase linear mRNA GI: 4210707Influenza A Virus (A/Fiji/15899/83(H1N1)) 2,341 bp AJ564805.1 mRNA forPB2 protein linear mRNA GI: 31442134 Influenza A Virus(A/Fiji/15899/83(H1N1)) 2,113 bp AJ564807.1 partial mRNA for PB1 proteinlinear mRNA GI: 31442138 Influenza A virus (A/FM/1/47 (H1N1)) 1,395 bpAF250357.2 neuraminidase (NA) gene, complete cds linear mRNA GI:13260561 Influenza A virus (A/goose/Hong 1,091 bp U46021.1Kong/8/1976(H1N1)) hemagglutinin precursor linear mRNA GI: 1912326 (HA)mRNA, partial cds Influenza A virus (A/goose/Hong 261 bp U48284.1Kong/8/1976(H1N1)) polymerase (PB1) mRNA, linear mRNA GI: 1912372partial cds Influenza A virus (A/goose/Hong 1,395 bp U49093.1Kong/8/1976(H1N1)) nucleoprotein (NP) mRNA, linear mRNA GI: 1912384partial cds Influenza A virus 1,775 bp EU382986.1(A/Guangzhou/1561/2006(H1N1)) segment 4 linear mRNA GI: 170762603hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462 bpEU382993.1 (A/Guangzhou/1561/2006(H1N1)) segment 6 linear mRNA GI:170762617 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382987.1 (A/Guangzhou/1684/2006(H1N1)) segment 4 linear mRNA GI:170762605 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462bp EU382994.1 (A/Guangzhou/1684/2006(H1N1)) segment 6 linear mRNA GI:170762619 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382981.1 (A/Guangzhou/483/2006(H1N1)) segment 4 linear mRNA GI:170762593 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462bp EU382988.1 (A/Guangzhou/483/2006(H1N1)) segment 6 linear mRNA GI:170762607 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382982.1 (A/Guangzhou/506/2006(H1N1)) segment 4 linear mRNA GI:170762595 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,461bp EU382989.1 (A/Guangzhou/506/2006(H1N1)) segment 6 linear mRNA GI:170762609 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382983.1 (A/Guangzhou/555/2006(H1N1)) segment 4 linear mRNA GI:170762597 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462bp EU382990.1 (A/Guangzhou/555/2006(H1N1)) segment 6 linear mRNA GI:170762611 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382984.1 (A/Guangzhou/657/2006(H1N1)) segment 4 linear mRNA GI:170762599 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462bp EU382991.1 (A/Guangzhou/657/2006(H1N1)) segment 6 linear mRNA GI:170762613 neuraminidase (NA) mRNA, complete cds Influenza A virus 1,775bp EU382985.1 (A/Guangzhou/665/2006(H1N1)) segment 4 linear mRNA GI:170762601 hemagglutinin (HA) mRNA, complete cds Influenza A virus 1,462bp EU382992.1 (A/Guangzhou/665/2006(H1N1)) segment 6 linear mRNA GI:170762615 neuraminidase (NA) mRNA, complete cds Influenza A virus(A/Gwangju/55/2002(H1N1)) 1,431 bp AY297151.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872012 Influenza A virus(A/Gwangju/55/2002(H1N1)) 1,179 bp AY299507.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140402 Influenza A virus(A/Gwangju/57/2002(H1N1)) 1,446 bp AY297152.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872014 Influenza A virus(A/Gwangju/57/2002(H1N1)) 1,167 bp AY299508.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140404 Influenza A virus(A/Gwangju/58/2002(H1N1)) 1,434 bp AY297153.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872016 Influenza A virus(A/Gwangju/58/2002(H1N1)) 1,176 bp AY299509.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140406 Influenza A virus(A/Gwangju/90/2002(H1N1)) 1,446 bp AY297147.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872002 Influenza A virus(A/Gwangju/90/2002(H1N1)) 1,164 bp AY299499.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140386 Influenza A virus (A/Hong 1,403 bpAJ518101.1 Kong/437/2002(H1N1)) partial NA gene for linear mRNA GI:31096412 neuraminidase, genomic RNA Influenza A virus (A/Hong 1,352 bpAJ518102.1 Kong/747/2001(H1N1)) partial NA gene for linear mRNA GI:31096414 neuraminidase, genomic RNA Influenza A virus(A/London/1/1918(H1N1)) 563 bp AY184805.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32395285 Influenza A virus(A/London/1/1919(H1N1)) 563 bp AY184806.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32395287 Influenza A virus(A/Loygang/4/1957(H1N1)) 1,565 bp M76604.1 nucleoprotein mRNA, completecds linear mRNA GI: 324255 Influenza A virus (A/Lyon/651/2001(H1N1))1,318 bp AJ518103.1 partial NA gene for neuraminidase, genomic linearmRNA GI: 31096416 RNA Influenza A virus (A/mallard/Alberta/119/98 947 bpAY664487.1 (H1N1)) nonfunctional matrix protein mRNA, linear mRNA GI:51011891 partial sequence Influenza A virus 981 bp U47310.1(A/duck/Alberta/35/76(H1N1)) hemagglutinin linear mRNA GI: 1912350precursor (HA) mRNA, partial cds Influenza A virus 1,777 bp AF091309.1(A/duck/Alberta/35/76(H1N1)) segment 4 linear mRNA GI: 4585160hemagglutinin precursor (HA) mRNA, complete cds Influenza A virus 1,410bp AF250362.2 (A/duck/Alberta/35/76(H1N1)) neuraminidase linear mRNA GI:13260579 (NA) gene, complete cds Influenza A virus 981 bp U47307.1(A/mallard/Tennessee/11464/85 (H1N1)) linear mRNA GI: 1912344hemagglutinin precursor (HA) mRNA, partial cds Influenza A virus 1,777bp AF091311.1 (A/mallard/Tennessee/11464/85 (H1N1)) segment linear mRNAGI: 4585164 4 hemagglutinin precursor (HA) mRNA, complete cds InfluenzaA virus (A/New 294 bp HQ008884.1 Caledonia/20/1999(H1N1)) segment 7matrix linear mRNA GI: 302566794 protein 2 (M2) mRNA, complete cdsInfluenza A virus (A/New Jersey/4/1976(H1N1)) 1,565 bp M76605.1nucleoprotein mRNA, complete cds linear mRNA GI: 324581 Influenza Avirus (A/New Jersey/8/1976(H1N1)) 1,565 bp M76606.1 nucleoprotein mRNA,complete cds linear mRNA GI: 324583 Influenza A virus(A/New_York/1/18(H1N1)) 1,220 bp AF116576.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 4325019 Influenza A virus(A/Ohio/3523/1988(H1N1)) 1,565 bp M76602.1 nucleoprotein mRNA, completecds linear mRNA GI: 324889 Influenza A virus (A/Pusan/22/2002(H1N1))1,455 bp AY310411.1 neuraminidase (NA) mRNA, complete cds linear mRNAGI: 31872391 Influenza A virus (A/Pusan/22/2002(H1N1)) 1,149 bpAY299503.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI: 32140394Influenza A virus (A/Pusan/23/2002(H1N1)) 1,440 bp AY297144.1neuraminidase (NA) mRNA, complete cds linear mRNA GI: 31871996 InfluenzaA virus (A/Pusan/23/2002(H1N1)) 1,158 bp AY297157.1 hemagglutinin (HA)mRNA, partial cds linear mRNA GI: 32140357 Influenza A virus(A/Pusan/24/2002(H1N1)) 1,449 bp AY297145.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31871998 Influenza A virus(A/Pusan/24/2002(H1N1)) 1,128 bp AY299494.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140376 Influenza A virus(A/Pusan/44/2002(H1N1)) 1,431 bp AY297148.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872004 Influenza A virus(A/Pusan/44/2002(H1N1)) 1,167 bp AY299504.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140396 Influenza A virus(A/Pusan/45/2002(H1N1)) 1,434 bp AY297146.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872000 Influenza A virus(A/Pusan/45/2002(H1N1)) 1,167 bp AY299496.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140380 Influenza A virus(A/Pusan/46/2002(H1N1)) 1,422 bp AY310408.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872385 Influenza A virus(A/Pusan/46/2002(H1N1)) 1,176 bp AY299497.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140382 Influenza A virus(A/Pusan/47/2002(H1N1)) 1,437 bp AY297149.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872008 Influenza A virus(A/Pusan/47/2002(H1N1)) 1,170 bp AY299505.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140398 Influenza A virus (A/Saudi 789 bpAJ519463.1 Arabia/7971/2000(H1N1)) partial NS1 gene for linear mRNA GI:31096450 non structural protein 1 and partial NS2 gene for nonstructural protein 2, genomic RNA Influenza A virus(A/Seoul/11/2002(H1N1)) 1,452 bp AY297142.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31871992 Influenza A virus(A/Seoul/11/2002(H1N1)) 1,176 bp AY297155.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140349 Influenza A virus(A/Seoul/13/2002(H1N1)) 1,452 bp AY310409.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872387 Influenza A virus(A/Seoul/13/2002(H1N1)) 1,167 bp AY299500.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140388 Influenza A virus(A/Seoul/15/2002(H1N1)) 1,449 bp AY297140.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31871988 Influenza A virus(A/Seoul/15/2002(H1N1)) 1,149 bp AY299501.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140390 Influenza A virus(A/Seoul/33/2002(H1N1)) 1,437 bp AY310407.1 neuraminidase (NA) mRNA,complete cds linear mRNA GI: 31872383 Influenza A virus(A/Seoul/33/2002(H1N1)) 1,167 bp AY299495.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32140378 Influenza A virus 1,050 bp Z46437.1(A/swine/Arnsberg/6554/1979(H1N1)) mRNA for linear mRNA GI: 565609hemagglutinin HA1 Influenza A virus 1,595 bp U46783.1(A/swine/Beijing/47/1991(H1N1)) hemagglutinin linear mRNA GI: 1912330precursor (HA) mRNA, partial cds Influenza A virus 1,565 bp U49091.1(A/swine/Beijing/94/1991(H1N1)) nucleoprotein linear mRNA GI: 1912380(NP) mRNA, complete cds Influenza A virus 1,778 bp AF091316.1(A/swine/Belgium/1/83(H1N1)) segment 4 linear mRNA GI: 4585174hemagglutinin precursor (HA) mRNA, complete cds Influenza A virus(A/swine/Cotes 1,116 bp AM490219.1 d'Armor/0118/2006(H1N1)) partial mRNAfor linear mRNA GI: 222062898 haemagglutinin precursor (HA1 gene)Influenza A virus (A/swine/Cotes 1,043 bp AM490223.1d'Armor/013618/2006(H1N1)) partial mRNA for linear mRNA GI: 222062906haemagglutinin precursor (HA1 gene) Influenza A virus (A/swine/Cotes1,089 bp AM490220.1 d'Armor/0184/2006(H1N1)) partial mRNA for linearmRNA GI: 222062900 haemagglutinin precursor (HA1 gene) Influenza A virus(A/swine/Cotes 1,068 bp AM490221.1 d'Armor/0227/2005(H1N1)) partial mRNAfor linear mRNA GI: 222062902 haemagglutinin precursor (HA1 gene)Influenza A virus (A/swine/Cotes 1,024 bp AM490222.1d'Armor/0250/2006(H1N1)) partial mRNA for linear mRNA GI: 222062904haemagglutinin precursor (HA1 gene) Influenza A virus (A/swine/Cotes1,011 bp AJ517820.1 d'Armor/736/2001(H1N1)) partial HA gene for linearmRNA GI: 38422533 Haemagglutinin, genomic RNA Influenza A virus(A/Swine/England/195852/92 1,410 bp AF250366.2 (H1N1)) neuraminidase(NA) gene, complete cds linear mRNA GI: 13260593 Influenza A virus PB2gene for Polymerase 2 2,268 bp AJ311457.1 protein, genomic RNA, strainlinear mRNA GI: 13661037 A/Swine/Finistere/2899/82 Influenza A virus PB1gene for Polymerase 1 2,341 bp AJ311462.1 protein, genomic RNA, strainlinear mRNA GI: 13661047 A/Swine/Finistere/2899/82 Influenza A virus PAgene for Polymerase A 2,233 bp AJ311463.1 protein, genomic RNA, strainlinear mRNA GI: 13661049 A/Swine/Finistere/2899/82 Influenza A virus1,002 bp AJ316059.1 (A/swine/Finistere/2899/82(H1N1) M1 gene for linearmRNA GI: 20068128 matrix protein 1 and M2 gene for matrix protein 2,genomic RNA Influenza A virus 864 bp AJ344037.1(A/swine/Finistere/2899/82(H1N1)) NS1 gene linear mRNA GI: 20068185 fornon structural protein 1 and NS2 gene for non structural protein 2,genomic RNA Influenza A virus 838 bp X75786.1(A/swine/Germany/2/1981(H1N1)) mRNA for PA linear mRNA GI: 438106polymerase Influenza A virus 305 bp Z30277.1(A/swine/Germany/2/1981(H1N1)) mRNA for linear mRNA GI: 530399neuraminidase (partial) Influenza A virus 1,730 bp Z30276.1(A/swine/Germany/2/1981(H1N1)) mRNA for linear mRNA GI: 563490hemagglutinin 165. Influenza A virus 1,730 bp Z46434.1(A/swine/Germany/8533/1991(H1N1)) mRNA for linear mRNA GI: 565611hemagglutinin precursor Influenza A virus 1,690 bp AY852271.1(A/swine/Guangdong/711/2001(H1N1)) linear mRNA GI: 60327789nonfunctional hemagglutinin (HA) mRNA, partial sequence Influenza Avirus 1,809 bp EU163946.1 (A/swine/Haseluenne/IDT2617/03(H1N1)) linearmRNA GI: 157679548 hemagglutinin mRNA, complete cds Influenza A virus(A/swine/Hokkaido/2/81 981 bp U47306.1 (H1N1)) hemagglutinin precursor(HA) mRNA, linear mRNA GI: 1912342 partial cds Influenza A virus(A/swine/Hokkaido/2/81 1,778 bp AF091306.1 (H1N1)) segment 4hemagglutinin precursor linear mRNA GI: 4585154 (HA) mRNA, complete cdsInfluenza A virus (A/swine/Hong 1,113 bp U44482.1 Kong/168/1993(H1N1))hemagglutinin precursor linear mRNA GI: 1912318 (HA) mRNA, partial cdsInfluenza A virus (A/swine/Hong 416 bp U47817.1 Kong/168/1993(H1N1))neuraminidase (NA) mRNA, linear mRNA GI: 1912354 partial cds Influenza Avirus (A/swine/Hong 286 bp U48286.1 Kong/168/1993(H1N1)) polymerase(PB2) mRNA, linear mRNA GI: 1912358 partial cds Influenza A virus(A/swine/Hong 379 bp U48283.1 Kong/168/1993(H1N1)) polymerase (PB1)mRNA, linear mRNA GI: 1912370 partial cds Influenza A virus(A/swine/Hong 308 bp U48850.1 Kong/168/1993(H1N1)) polymerase (PA) mRNA,linear mRNA GI: 1912376 partial cds Influenza A virus (A/swine/Hong1,397 bp U49096.1 Kong/168/1993(H1N1)) nucleoprotein (NP) mRNA, linearmRNA GI: 1912390 partial cds Influenza A virus (A/swine/Hong 1,315 bpU46020.1 Kong/172/1993(H1N1)) hemagglutinin precursor linear mRNA GI:1912324 (HA) mRNA, partial cds Influenza A virus (A/swine/Hong 1,113 bpU45451.1 Kong/176/1993(H1N1)) hemagglutinin precursor linear mRNA GI:1912320 (HA) mRNA, partial cds Influenza A virus (A/swine/Hong 1,330 bpU45452.1 Kong/273/1994(H1N1)) hemagglutinin precursor linear mRNA GI:1912322 (HA) mRNA, partial cds Influenza A virus (A/swine/Hong 241 bpU47818.1 Kong/273/1994(H1N1)) neuraminidase (NA) mRNA, linear mRNA GI:1912356 partial cds Influenza A virus (A/swine/Hong 328 bp U48287.1Kong/273/1994(H1N1)) polymerase (PB2) mRNA, linear mRNA GI: 1912360partial cds Influenza A virus (A/swine/Hong 240 bp U48282.1Kong/273/1994(H1N1)) polymerase (PB1) mRNA, linear mRNA GI: 1912368partial cds Influenza A virus (A/swine/Hong 336 bp U48851.1Kong/273/1994(H1N1)) polymerase (PA) mRNA, linear mRNA GI: 1912378partial cds Influenza A virus (A/swine/Hong 1,422 bp U49092.1Kong/273/1994(H1N1)) nucleoprotein (NP) mRNA, linear mRNA GI: 1912382partial cds Influenza A virus 1,761 bp EU163947.1(A/swine/IDT/Re230/92hp(H1N1)) hemagglutinin linear mRNA GI: 157679550mRNA, complete cds Influenza A virus 1,550 bp L46849.1(A/swine/IN/1726/1988(H1N1)) nucleoprotein linear mRNA GI: 954755(segment 5) mRNA, complete cds Influenza A virus(A/swine/Iowa/15/30(H1N1)) 981 bp U47305.1 hemagglutinin precursor (HA)mRNA, partial linear mRNA GI: 1912340 cds Influenza A virus(A/swine/Iowa/15/30 (H1N1)) 1,778 bp AF091308.1 segment 4 hemagglutininprecursor (HA) mRNA, linear mRNA GI: 4585158 complete cds Influenza Avirus (A/Swine/Iowa/30 (H1N1)) 1,410 bp AF250364.2 neuraminidase (NA)gene, complete cds linear mRNA GI: 13260586 Influenza A virus(A/swine/Iowa/17672/88 981 bp U47304.1 (H1N1)) hemagglutinin precursor(HA) mRNA, linear mRNA GI: 1912338 partial cds Influenza A virus 864 bpAJ519462.1 (A/swine/Italy/3364/00(H1N1)) partial NS1 linear mRNA GI:31096447 gene for non structural protein 1 and partial NS2 gene for nonstructural protein 2, genomic RNA Influenza A virus (A/swine/Italy-1,777 bp AF091315.1 Virus/671/87(H1N1)) segment 4 hemagglutinin linearmRNA GI: 4585172 precursor (HA) mRNA, complete cds Influenza A Virus1,028 bp Z46436.1 (A/swine/Italy/v.147/1981(H1N1)) mRNA for linear mRNAGI: 854214 hemagglutinin HA1 Influenza A virus 1,118 bp AM490218.1(A/swine/Morbihan/0070/2005(H1N1)) partial linear mRNA GI: 222062896mRNA for haemagglutinin precursor (HA1 gene) Influenza A virus 1,770 bpL09063.1 (A/swine/Nebraska/1/92(H1N1)) HA protein linear mRNA GI: 290722mRNA, complete cds Influenza A virus 1,550 bp L11164.1(A/swine/Nebraska/1/1992(H1N1)) segment 5 linear mRNA GI: 290724nucleoprotein (NP) mRNA, complete cds Influenza A virus 981 bp U46943.1(A/swine/Netherlands/12/1985(H1N1)) linear mRNA GI: 1912336hemagglutinin (HA) mRNA, partial cds Influenza A virus 1,776 bpAF091317.1 (A/swine/Netherlands/12/85(H1N1)) segment 4 linear mRNA GI:4585176 hemagglutinin precursor (HA) mRNA, complete cds Influenza Avirus 539 bp X75791.1 (A/swine/Netherlands/25/1980(H1N1)) mRNA forlinear mRNA GI: 438105 nucleoprotein Influenza A virus 981 bp U46942.1(A/swine/Netherlands/3/1980(H1N1)) linear mRNA GI: 1912334 hemagglutinin(HA) mRNA, partial cds Influenza A virus 1,778 bp AF091314.1(A/swine/Netherlands/3/80(H1N1)) segment 4 linear mRNA GI: 4585170hemagglutinin precursor (HA) mRNA, complete cds Influenza A virus(A/NJ/11/76 (H1N1)) 1,410 bp AF250363.2 neuraminidase (NA) gene,complete cds linear mRNA GI: 13260583 Influenza A virus(A/Swine/Quebec/192/81 1,438 bp U86144.1 (SwQc81)) neuraminidase mRNA,complete cds linear mRNA GI: 4099318 Influenza A virus(A/Swine/Quebec/5393/91 1,438 bp U86145.1 (SwQc91)) neuraminidase mRNA,complete cds linear mRNA GI: 4099320 Influenza A virus(A/swine/Schleswig- 1,730 bp Z46435.1 Holstein/1/1992(H1N1)) mRNA forhemagglutinin linear mRNA GI: 854216 precursor Influenza A Virus(A/swine/Schleswig- 1,554 bp Z46438.1 Holstein/1/1993(H1N1)) mRNA fornucleoprotein linear mRNA GI: 854222 Influenza A virus 1,778 bpAF091307.1 (A/swine/Wisconsin/1/61(H1N1)) segment 4 linear mRNA GI:4585156 hemagglutinin precursor (HA) mRNA, complete cds 212. Influenza Avirus 1,565 bp M76607.1 (A/swine/Wisconsin/1/1967(H1N1)) linear mRNA GI:325086 nucleoprotein mRNA, complete cds Influenza A virus 1,565 bpM76608.1 (A/swine/Wisconsin/1915/1988(H1N1)) linear mRNA GI: 325088nucleoprotein mRNA, complete cds Influenza A virus 1,550 bp L46850.1(A/swine/WI/1915/1988(H1N1)) nucleoprotein linear mRNA GI: 954757(segment 5) mRNA, complete cds Influenza A virus 729 bp AJ532568.1(A/Switzerland/8808/2002(H1N1)) partial m1 linear mRNA GI: 31096461 genefor matrix protein 1 and partial m2 gene for matrix protein 2, genomicRNA Influenza A virus 561 bp AF362803.1 (A/human/Taiwan/0012/00(H1N1))hemagglutinin linear mRNA GI: 14571975 (HA) mRNA, partial cds InfluenzaA virus 561 bp AF362779.1 (A/human/Taiwan/0016/00(H1N1)) hemagglutininlinear mRNA GI: 14571927 (HA) mRNA, partial cds Influenza A virus(A/Taiwan/0016/2000 (H1N1)) 303 bp AY303752.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330993 partial cds Influenza A virus 561bp AF362780.1 (A/human/Taiwan/0030/00(H1N1)) hemagglutinin linear mRNAGI: 14571929 (HA) mRNA, partial cds Influenza A virus(A/Taiwan/0030/2000 (H1N1)) 303 bp AY303704.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330897 partial cds Influenza A virus(A/Taiwan/0032/2002(H1N1)) 494 bp AY604804.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727488 Influenza A virus(A/Taiwan/0061/2002(H1N1)) 494 bp AY604795.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727470 Influenza A virus(A/Taiwan/0069/2002(H1N1)) 494 bp AY604803.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727486 Influenza A virus(A/Taiwan/0078/2002(H1N1)) 494 bp AY604805.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727490 Influenza A virus(A/Taiwan/0094/2002(H1N1)) 494 bp AY604797.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727474 Influenza A virus(A/Taiwan/0116/2002(H1N1)) 494 bp AY604796.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727472 Influenza A virus 564 bp AF362781.1(A/human/Taiwan/0130/96(H1N1)) hemagglutinin linear mRNA GI: 14571931(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0130/96 (H1N1)) 303bp AY303707.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330903 partial cds Influenza A virus 564 bp AF362782.1(A/human/Taiwan/0132/96(H1N1)) hemagglutinin linear mRNA GI: 14571933(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0132/96 (H1N1)) 303bp AY303708.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330905 partial cds Influenza A virus 564 bp AF362783.1(A/human/Taiwan/0211/96(H1N1)) hemagglutinin linear mRNA GI: 14571935(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0211/96 (H1N1)) 303bp AY303709.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330907 partial cds Influenza A virus 564 bp AF362784.1(A/human/Taiwan/0235/96(H1N1)) hemagglutinin linear mRNA GI: 14571937(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0235/96 (H1N1)) 303bp AY303710.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330909 partial cds Influenza A virus 564 bp AF362785.1(A/human/Taiwan/0255/96(H1N1)) hemagglutinin linear mRNA GI: 14571939(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0255/96 (H1N1)) 303bp AY303711.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330911 partial cds Influenza A virus 564 bp AF362786.1(A/human/Taiwan/0337/96(H1N1)) hemagglutinin linear mRNA GI: 14571941(HA) mRNA, partial cds Influenza A virus 564 bp AF362787.1(A/human/Taiwan/0342/96(H1N1)) hemagglutinin linear mRNA GI: 14571943(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0342/96 (H1N1)) 303bp AY303714.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330917 partial cds Influenza A virus 561 bp AF362788.1(A/human/Taiwan/0464/99(H1N1)) hemagglutinin linear mRNA GI: 14571945(HA) mRNA, partial cds Influenza A virus 564 bp AF362789.1(A/human/Taiwan/0562/95(H1N1)) hemagglutinin linear mRNA GI: 14571947(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0562/95 (H1N1)) 303bp AY303720.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330929 partial cds Influenza A virus 564 bp AF362790.1(A/human/Taiwan/0563/95(H1N1)) hemagglutinin linear mRNA GI: 14571949(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0563/95 (H1N1)) 303bp AY303721.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330931 partial cds Influenza A virus 564 bp AF362791.1(A/human/Taiwan/0657/95(H1N1)) hemagglutinin linear mRNA GI: 14571951(HA) mRNA, partial cds Influenza A virus (A/Taiwan/0657/95 (H1N1)) 303bp AY303724.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330937 partial cds Influenza A virus (A/Taiwan/0859/2002(H1N1)) 494 bpAY604801.1 hemagglutinin mRNA, partial cds linear mRNA GI: 50727482Influenza A virus 561 bp AF362792.1 (A/human/Taiwan/0892/99(H1N1))hemagglutinin linear mRNA GI: 14571953 (HA) mRNA, partial cds InfluenzaA virus (A/Taiwan/0983/2002(H1N1)) 494 bp AY604800.1 hemagglutinin mRNA,partial cds linear mRNA GI: 50727480 Influenza A virus(A/Taiwan/1007/2006(H1N1)) 507 bp EU068163.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452199 Influenza A virus(A/Taiwan/1015/2006(H1N1)) 507 bp EU068171.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452215 Influenza A virus(A/Taiwan/112/1996-1(H1N1)) 1,176 bp AF026153.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554950 Influenza A virus(A/Taiwan/112/1996-2(H1N1)) 1,176 bp AF026154.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554952 Influenza A virus(A/Taiwan/117/1996-1(H1N1)) 1,176 bp AF026155.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554954 Influenza A virus(A/Taiwan/117/1996-2(H1N1)) 1,176 bp AF026156.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554956 Influenza A virus(A/Taiwan/117/1996-3(H1N1)) 1,176 bp AF026157.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554958 Influenza A virus(A/Taiwan/118/1996-1(H1N1)) 1,176 bp AF026158.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554960 Influenza A virus(A/Taiwan/118/1996-2(H1N1)) 1,176 bp AF026159.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554962 Influenza A virus(A/Taiwan/118/1996-3(H1N1)) 1,176 bp AF026160.1 haemagglutinin (HA)mRNA, partial cds linear mRNA GI: 2554964 Influenza A virus 561 bpAF362793.1 (A/human/Taiwan/1184/99(HIN1)) hemagglutinin linear mRNA GI:14571955 (HA) mRNA, partial cds Influenza A virus (A/Taiwan/1184/99(H1N1)) 303 bp AY303726.1 polymerase basic protein 1 (PB1) mRNA, linearmRNA GI: 32330941 partial cds Influenza A virus 564 bp AF362794.1(A/human/Taiwan/1190/95(H1N1)) hemagglutinin linear mRNA GI: 14571957(HA) mRNA, partial cds Influenza A virus (A/Taiwan/1190/95 (H1N1)) 303bp AY303727.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330943 partial cds Influenza A virus (A/Taiwan/1523/2003(H1N1)) 494 bpAY604808.1 hemagglutinin mRNA, partial cds linear mRNA GI: 50727496Influenza A virus (A/Taiwan/1566/2003(H1N1)) 494 bp AY604806.1hemagglutinin mRNA, partial cds linear mRNA GI: 50727492 Influenza Avirus (A/Taiwan/1769/96(H1N1)) 875 bp AF138710.2 matrix protein M1 (M)mRNA, partial cds linear mRNA GI: 4996871 Influenza A virus(A/Taiwan/1906/2002(H1N1)) 494 bp AY604799.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727478 Influenza A virus(A/Taiwan/1922/2002(H1N1)) 494 bp AY604802.1 hemagglutinin mRNA, partialcds linear mRNA GI: 50727484 Influenza A virus(A/Taiwan/2069/2006(H1N1)) 507 bp EU068168.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452209 Influenza A virus(A/Taiwan/2157/2001 (H1N1)) 303 bp AY303733.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330955 partial cds Influenza A virus(A/Taiwan/2175/2001 (H1N1)) 561 bp AY303734.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32330957 Influenza A virus 564 bp AF362795.1(A/human/Taiwan/2200/95(H1N1)) hemagglutinin linear mRNA GI: 14571959(HA) mRNA, partial cds Influenza A virus (A/Taiwan/2200/95 (H1N1)) 303bp AY303737.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330963 partial cds Influenza A virus (A/Taiwan/2966/2006(H1N1)) 507 bpEU068170.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:158452213 Influenza A virus (A/Taiwan/3168/2005(H1N1)) 507 bp EU068174.1hemagglutinin (HA) mRNA, partial cds linear mRNA GI: 158452221 InfluenzaA virus 561 bp AF362796.1 (A/human/Taiwan/3355/97(H1N1)) hemagglutininlinear mRNA GI: 14571961 (HA) mRNA, partial cds Influenza A virus(A/Taiwan/3355/97 (H1N1)) 303 bp AY303739.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330967 partial cds Influenza A virus(A/Taiwan/3361/2001 (H1N1)) 303 bp AY303740.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330969 partial cds Influenza A virus(A/Taiwan/3361/2001 (H1N1)) 561 bp AY303741.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32330971 Influenza A virus(A/Taiwan/3518/2006(H1N1)) 507 bp EU068169.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452211 Influenza A virus 581 bpAF362797.1 (A/human/Taiwan/3825/00(H1N1)) hemagglutinin linear mRNA GI:14571963 (HA) mRNA, partial cds Influenza A virus (A/Taiwan/3896/2001(H1N1)) 303 bp AY303746.1 polymerase basic protein 1 (PB1) mRNA, linearmRNA GI: 32330981 partial cds Influenza A virus (A/Taiwan/3896/2001(H1N1)) 561 bp AY303747.1 hemagglutinin (HA) mRNA, partial cds linearmRNA GI: 32330983 Influenza A virus (A/Taiwan/4050/2003(H1N1)) 494 bpAY604807.1 hemagglutinin mRNA, partial cds linear mRNA GI: 50727494Influenza A virus (A/Taiwan/4054/2006(H1N1)) 507 bp EU068160.1hemagglutinin (HA) mRNA, partial cds linear mRNA GI: 158452193 InfluenzaA virus 561 bp AF362798.1 (A/human/Taiwan/4360/99(H1N1)) hemagglutininlinear mRNA GI: 14571965 (HA) mRNA, partial cds Influenza A virus(A/Taiwan/4360/99 (H1N1)) 303 bp AY303748.1 polymerase basic protein 1(PB1) mRNA, linear mRNA GI: 32330985 partial cds Influenza A virus 561bp AF362799.1 (A/human/Taiwan/4415/99(H1N1)) hemagglutinin linear mRNAGI: 14571967 (HA) mRNA, partial cds Influenza A virus (A/Taiwan/4415/99(H1N1)) 303 bp AY303749.1 polymerase basic protein 1 (PB1) mRNA, linearmRNA GI: 32330987 partial cds Influenza A virus(A/Taiwan/4509/2006(H1N1)) 507 bp EU068165.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452203 Influenza A virus 561 bpAF362800.1 (A/human/Taiwan/4845/99(H1N1)) hemagglutinin linear mRNA GI:14571969 (HA) mRNA, partial cds Influenza A virus (A/Taiwan/4845/99(H1N1)) 303 bp AY303750.1 polymerase basic protein 1 (PB1) mRNA, linearmRNA GI: 32330989 partial cds Influenza A virus 561 bp AF362801.1(A/human/Taiwan/4943/99(H1N1)) hemagglutinin linear mRNA GI: 14571971(HA) mRNA, partial cds Influenza A virus (A/Taiwan/5010/2006(H1N1)) 507bp EU068167.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:158452207 Influenza A virus 561 bp AF362802.1(A/human/Taiwan/5063/99(H1N1)) hemagglutinin linear mRNA GI: 14571973(HA) mRNA, partial cds Influenza A virus (A/Taiwan/5063/99 (H1N1)) 303bp AY303751.1 polymerase basic protein 1 (PB1) mRNA, linear mRNA GI:32330991 partial cds Influenza A virus (A/Taiwan/5084/2006(H1N1)) 507 bpEU068166.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:158452205 Influenza A virus (A/Taiwan/511/96(H1N1)) 875 bp AF138708.2matrix protein M1 (M) mRNA, partial cds linear mRNA GI: 4996867Influenza A virus (A/Taiwan/557/2006(H1N1)) 507 bp EU068156.1hemagglutinin (HA) mRNA, partial cds linear mRNA GI: 158452185 InfluenzaA virus (A/Taiwan/562/2006(H1N1)) 507 bp EU068159.1 hemagglutinin (HA)mRNA, partial cds linear mRNA GI: 158452191 Influenza A virus 561 bpAF362778.1 (A/human/Taiwan/5779/98(H1N1)) hemagglutinin linear mRNA GI:14571925 (HA) mRNA, partial cds Influenza A virus (A/Taiwan/5779/98(H1N1)) 303 bp AY303702.1 polymerase basic protein 1 (PB1) mRNA, linearmRNA GI: 32330893 partial cds Influenza A virus(A/Taiwan/6025/2005(H1N1)) 507 bp EU068172.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452217 Influenza A virus(A/Taiwan/607/2006(H1N1)) 507 bp EU068157.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452187 Influenza A virus(A/Taiwan/615/2006(H1N1)) 507 bp EU068162.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452197 Influenza A virus(A/Taiwan/645/2006(H1N1)) 507 bp EU068164.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452201 Influenza A virus(A/Taiwan/680/2005(H1N1)) 507 bp EU068173.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452219 Influenza A virus(A/Taiwan/719/2006(H1N1)) 507 bp EU068158.1 hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 158452189 Influenza A virus 1,410 bpEU021285.1 (A/Thailand/CU124/2006(H3N2)) neuraminidase linear mRNA GI:154224724 (NA) mRNA, complete cds Influenza A virus 1,413 bp EU021265.1(A/Thailand/CU32/2006(H1N1)) neuraminidase linear mRNA GI: 154224704(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021264.1(A/Thailand/CU32/2006(H1N1)) hemagglutinin linear mRNA GI: 154224775(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021247.1(A/Thailand/CU41/2006(H1N1)) neuraminidase linear mRNA GI: 154224686(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021246.1(A/Thailand/CU41/2006(H1N1)) hemagglutinin linear mRNA GI: 154224757(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021259.1(A/Thailand/CU44/2006(H1N1)) neuraminidase linear mRNA GI: 154224698(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021258.1(A/Thailand/CU44/2006(H1N1)) hemagglutinin linear mRNA GI: 154224769(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021255.1(A/Thailand/CU51/2006(H1N1)) neuraminidase linear mRNA GI: 154224694(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021254.1(A/Thailand/CU51/2006(H1N1)) hemagglutinin linear mRNA GI: 154224765(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021249.1(A/Thailand/CU53/2006(H1N1)) neuraminidase linear mRNA GI: 154224688(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021248.1(A/Thailand/CU53/2006(H1N1)) hemagglutinin linear mRNA GI: 154224759(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021257.1(A/Thailand/CU57/2006(H1N1)) neuraminidase linear mRNA GI: 154224696(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021256.1(A/Thailand/CU57/2006(H1N1)) hemagglutinin linear mRNA GI: 154224767(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021251.1(A/Thailand/CU67/2006(H1N1)) neuraminidase linear mRNA GI: 154224690(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021250.1(A/Thailand/CU67/2006(H1N1)) hemagglutinin linear mRNA GI: 154224761(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021261.1(A/Thailand/CU68/2006(H1N1)) neuraminidase linear mRNA GI: 154224700(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021260.1(A/Thailand/CU68/2006(H1N1)) hemagglutinin linear mRNA GI: 154224771(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021263.1(A/Thailand/CU75/2006(H1N1)) neuraminidase linear mRNA GI: 154224702(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021262.1(A/Thailand/CU75/2006(H1N1)) hemagglutinin linear mRNA GI: 154224773(HA) mRNA, complete cds Influenza A virus 1,413 bp EU021253.1(A/Thailand/CU88/2006(H1N1)) neuraminidase linear mRNA GI: 154224692(NA) mRNA, complete cds Influenza A virus 1,698 bp EU021252.1(A/Thailand/CU88/2006(H1N1)) hemagglutinin linear mRNA GI: 154224763(HA) mRNA, complete cds Influenza A virus 1,565 bp M76603.1(A/turkey/England/647/1977(H1N1)) linear mRNA GI: 325094 nucleoproteinmRNA, complete cds Influenza A virus 1,445 bp AJ416626.1(A/turkey/France/87075/87(H1N1)) N1 gene for linear mRNA GI: 39840719neuraminidase, genomic RNA Influenza A virus 394 bp Z30272.1(A/turkey/Germany/3/91(H1N1)) mRNA for PB2 linear mRNA GI: 456652polymerase (partial) Influenza A virus 97 bp Z30275.1(A/turkey/Germany/3/91(H1N1)) mRNA for linear mRNA GI: 530398neuraminidase (UTR) Influenza A virus 264 bp Z30274.1(A/turkey/Germany/3/91(H1N1)) mRNA for PA linear mRNA GI: 530401polymerase Influenza A virus 247 bp Z30273.1(A/turkey/Germany/3/91(H1N1)) mRNA for PBI linear mRNA GI: 530403polymerase (partial) Influenza A virus 1,038 bp Z46441.1(A/turkey/Germany/3/91(H1N1)) mRNA for linear mRNA GI: 854218hemagglutinin HA1 Influenza A virus 981 bp U46941.1(A/turkey/Minnesota/1661/1981(H1N1)) linear mRNA GI: 1912332hemagglutinin (HA) mRNA, partial cds Influenza A virus 1,777 bpAF091310.1 (A/turkey/Minnesota/1661/81(H1N1)) segment 4 linear mRNA GI:4585162 hemagglutinin precursor (HA) mRNA, complete cds Influenza Avirus (A/turkey/North 1,565 bp M7 6609.1 Carolina/1790/1988(H1N1))nucleoprotein mRNA, linear mRNA GI: 325096 complete cds Influenza Avirus (A/Weiss/43 (H1N1)) 1,410 bp AF250365.2 neuraminidase (NA) gene,complete cds linear mRNA GI: 13260589 Influenza A virus(A/Wilson-Smith/1933(H1N1)) 1,497 bp EU330203.1 nucleocapsid protein(NP) mRNA, complete cds linear mRNA GI: 167989512 Influenza A virus 241bp U47816.1 (A/Wisconsin/3523/1988(H1N1)) neuraminidase linear mRNA GI:1912352 (NA) mRNA, partial cds Influenza A virus 1,565 bp M7 6610.1(A/Wisconsin/3623/1988(H1N1)) nucleoprotein linear mRNA GI: 325103 mRNA,complete cds Influenza A virus (A/WI/4754/1994(H1N1)) PB1 235 bpU53156.1 (PB1) mRNA, partial cds linear mRNA GI: 1399590 Influenza Avirus (A/WI/4754/1994(H1N1)) PB2 168 bp U53158.1 (PB2) mRNA, partial cdslinear mRNA GI: 1399594 Influenza A virus (A/WI/4754/1994(H1N1)) PA 621bp U53160.1 (PA) mRNA, partial cds linear mRNA GI: 1399598 Influenza Avirus (A/WI/4754/1994(H1N1)) 1,778 bp U53162.1 hemagglutinin (HA) mRNA,complete cds linear mRNA GI: 1399602 Influenza A virus(A/WI/4754/1994(H1N1)) NP 200 bp U53164.1 (NP) mRNA, partial cds linearmRNA GI: 1399606 Influenza A virus (A/WI/4754/1994(H1N1)) 1,458 bpU53166.1 neuraminidase (NA) mRNA, complete cds linear mRNA GI: 1399610Influenza A virus (A/WI/4754/1994(H1N1)) M 1,027 bp U53168.1 (M) mRNA,complete cds linear mRNA GI: 1399614 Influenza A virus(A/WI/4754/1994(H1N1)) NS 890 bp U53170.1 (NS) mRNA, complete cds linearmRNA GI: 1399618 Influenza A virus (A/WI/4755/1994(H1N1)) PB1 203 bpU53157.1 (PB1) mRNA, partial cds linear mRNA GI: 1399592 Influenza Avirus (A/WI/4755/1994(H1N1)) PB2 173 bp U53159.1 (PB2) mRNA, partial cdslinear mRNA GI: 1399596 Influenza A virus (A/WI/4755/1994(H1N1)) PA 621bp U53161.1 (PA) mRNA, partial cds linear mRNA GI: 1399600 Influenza Avirus (A/WI/4755/1994(H1N1)) 1,778 bp U53163.1 hemagglutinin (HA) mRNA,complete cds linear mRNA GI: 1399604 Influenza A virus(A/WI/4755/1994(H1N1)) NP 215 bp U53165.1 (NP) mRNA, partial cds linearmRNA GI: 1399608 Influenza A virus (A/WI/4755/1994(H1N1)) 209 bpU53167.1 neuraminidase (NA) mRNA, partial cds linear mRNA GI: 1399612Influenza A virus (A/WI/4755/1994(H1N1)) M 1,027 bp U53169.1 (M) mRNA,complete cds linear mRNA GI: 1399616 Influenza A virus(A/WI/4755/1994(H1N1)) NS 890 bp U53171.1 (NS) mRNA, complete cds linearmRNA GI: 1399620 Influenza A virus (A/WSN/33) segment 5 543 bpAF306656.1 nucleocapsid protein (NP) mRNA, partial cds linear mRNA GI:11935089

TABLE 8 Influenza H3N2 Antigens GenBank/GI Strain/Protein LengthAccession No. 1. Influenza A virus (A/Aichi/2/1968(H3N2)) 1,704 bpEF614248.1 hemagglutinin (HA) mRNA, complete cds linear mRNA GI:148910819 2. Influenza A virus (A/Aichi/2/1968(H3N2)) 1,698 bpEF614249.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:148910821 3. Influenza A virus (A/Aichi/2/1968(H3N2)) 1,698 bpEF614250.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:148910823 4. Influenza A virus (A/Aichi/2/1968(H3N2)) 1,698 bpEF614251.1 hemagglutinin (HA) mRNA, partial cds linear mRNA GI:148910825 5. Influenza A virus (A/Akita/1/1995(H3N2)) 1,032 bp U48444.1haemagglutinin mRNA, partial cds linear mRNA GI: 1574989 6. Influenza Avirus 1,041 bp Z46392.1 (A/Beijing/32/1992(H3N2)) mRNA for linear mRNAGI: 609020 haemagglutinin 7. Influenza A virus 987 bp AF501516.1(A/Canada/33312/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 21314288mRNA, partial cds 8. Influenza A virus 987 bp AF297094.1(A/Charlottesville/10/99 (H3N2)) linear mRNA GI: 11228917 hemagglutininmRNA, partial cds 9. Influenza A virus 987 bp AF297096.1(A/Charlottesville/49/99 (H3N2)) linear mRNA GI: 11228921 hemagglutininmRNA, partial cds 10. Influenza A virus 987 bp AF297097.1(A/Charlottesville/69/99 (H3N2)) linear mRNA GI: 11228923 hemagglutininmRNA, partial cds 11. Influenza A virus 987 bp AF297095.1(A/Charlottesville/73/99 (H3N2)) linear mRNA GI: 11228919 hemagglutininmRNA, partial cds 12. Influenza A virus 1,041 bp Z46393.1(A/England/1/1993(H3N2)) mRNA for linear mRNA GI: 609024 haemagglutinin13. Influenza A virus 1,041 bp Z46394.1 (A/England/247/1993(H3N2)) mRNAfor linear mRNA GI: 609025 haemagglutinin 14. Influenza A virus 1,041 bpZ46395.1 (A/England/269/93(H3N2)) mRNA for linear mRNA GI: 609027haemagglutinin 15. Influenza A virus 1,041 bp Z46396.1(A/England/284/1993(H3N2)) mRNA for linear mRNA GI: 609029haemagglutinin 16. Influenza A virus 1,041 bp Z46397.1(A/England/286/1993(H3N2)) mRNA for linear mRNA GI: 609031haemagglutinin 17. Influenza A virus 1,041 bp Z46398.1(A/England/289/1993(H3N2)) mRNA for linear mRNA GI: 609033haemagglutinin 18. Influenza A virus 1,041 bp Z46399.1(A/England/328/1993(H3N2)) mRNA for linear mRNA GI: 609035haemagglutinin 19. Influenza A virus 1,041 bp Z46400.1(A/England/346/1993(H3N2)) mRNA for linear mRNA GI: 609037haemagglutinin 20. Influenza A virus 1,041 bp Z46401.1(A/England/347/1993(H3N2)) mRNA for linear mRNA GI: 609039haemagglutinin 21. Influenza A virus 1,091 bp AF201875.1(A/England/42/72(H3N2)) hemagglutinin mRNA, linear mRNA GI: 6470274partial cds 22. Influenza A virus 1,041 bp Z46402.1(A/England/471/1993(H3N2)) mRNA for linear mRNA GI: 609041haemagglutinin 23. Influenza A virus 1,041 bp Z46403.1(A/England/67/1994(H3N2)) mRNA for linear mRNA GI: 609043 haemagglutinin24. Influenza A virus 1,041 bp Z46404.1 (A/England/68/1994(H3N2)) mRNAfor linear mRNA GI: 609045 haemagglutinin 25. Influenza A virus 1,041 bpZ46405.1 (A/England/7/1994(H3N2)) mRNA for linear mRNA GI: 609047haemagglutinin 28. Influenza A virus 1,041 bp Z46406.1(A/Guangdong/25/1993(H3N2)) mRNA for linear mRNA GI: 609049haemagglutinin 29. Influenza A virus (A/Hong 1,091 bp AF201874.1Kong/1/68(H3N2)) hemagglutinin mRNA, partial linear mRNA GI: 6470272 cds30. Influenza A virus (A/Hong 1,041 bp Z46407.1 Kong/1/1994(H3N2)) mRNAfor haemagglutinin linear mRNA GI: 609051 31. Influenza A virus (A/Hong1,762 bp AF382319.1 Kong/1143/99(H3N2)) hemagglutinin mRNA, linear mRNAGI: 14487957 complete cds 32. Influenza A virus (A/Hong 1,762 bpAF382320.1 Kong/1143/99(H3N2)) hemagglutinin mRNA, linear mRNA GI:14487959 complete cds 33. Influenza A virus (A/Hong 1,466 bp AF382329.1Kong/1143/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487977complete cds 34. Influenza A virus (A/Hong 1,466 bp AF382330.1Kong/1143/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487979complete cds 35. Influenza A virus (A/Hong 1,762 bp AY035589.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486403complete cds 36. Influenza A virus (A/Hong 1,762 bp AF382321.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487961complete cds 37. Influenza A virus (A/Hong 1,762 bp AF382322.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487963complete cds 38. Influenza A virus (A/Hong 1,466 bp AF382331.1Kong/1144/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487981complete cds 39. Influenza A virus (A/Hong 1,466 bp AF382332.1Kong/1144/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487983complete cds 40. Influenza A virus (A/Hong 1,762 bp AY035590.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486405complete cds 41. Influenza A virus (A/Hong 1,762 bp AF382323.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487965complete cds 42. Influenza A virus (A/Hong 1,762 bp AF382324.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487967complete cds 43. Influenza A virus (A/Hong 1,762 bp AY035591.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486407complete cds 44. Influenza A virus (A/Hong 1,762 bp AF382325.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487969complete cds 45. Influenza A virus (A/Hong 1,762 bp AF382326.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487971complete cds 46. Influenza A virus (A/Hong 1,762 bp AF382327.1Kong/1182/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487973complete cds 47. Influenza A virus (A/Hong 1,762 bp AF382328.1Kong/1182/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487975complete cds 48. Influenza A virus (A/Hong 1,041 bp Z46408.1Kong/2/1994(H3N2)) mRNA for haemagglutinin linear mRNA GI: 609055 49.Influenza A virus (A/Hong 1,041 bp Z46410.1 Kong/23/1992(H3N2)) mRNA forhaemagglutinin linear mRNA GI: 609053 50. Influenza A virus (A/Hong1,041 bp Z46409.1 Kong/34/1990(H3N2)) mRNA for haemagglutinin linearmRNA GI: 609057 51. Influenza A virus 1,041 bp Z46397.1(A/England/286/1993(H3N2)) mRNA for linear mRNA GI: 609031haemagglutinin 52. Influenza A virus 1,041 bp Z46398.1(A/England/289/1993(H3N2)) mRNA for linear mRNA GI: 609033haemagglutinin 53. Influenza A virus 1,041 bp Z46399.1(A/England/328/1993(H3N2)) mRNA for linear mRNA GI: 609035haemagglutinin 54. Influenza A virus 1,041 bp Z46400.1(A/England/346/1993(H3N2)) mRNA for linear mRNA GI: 609037haemagglutinin 55. Influenza A virus 1,041 bp Z46401.1(A/England/347/1993(H3N2)) mRNA for linear mRNA GI: 609039haemagglutinin 56. Influenza A virus 1,091 bp AF201875.1(A/England/42/72(H3N2)) hemagglutinin mRNA, linear mRNA GI: 6470274partial cds 57. Influenza A virus 1,041 bp Z46402.1(A/England/471/1993(H3N2)) mRNA for linear mRNA GI: 609041haemagglutinin 58. Influenza A virus 1,041 bp Z46403.1(A/England/67/1994(H3N2)) mRNA for linear mRNA GI: 609043 haemagglutinin59. Influenza A virus 1,041 bp Z46404.1 (A/England/68/1994(H3N2)) mRNAfor linear mRNA GI: 609045 haemagglutinin 60. Influenza A virus 1,041 bpZ46405.1 (A/England/7/1994(H3N2)) mRNA for linear mRNA GI: 609047haemagglutinin 63. Influenza A virus 1,032 bp U48442.1(A/Guandong/28/1994(H3N2)) haemagglutinin linear mRNA GI: 1574985 mRNA,partial cds 64. Influenza A virus 1,041 bp Z46406.1(A/Guangdong/25/1993(H3N2)) mRNA for linear mRNA GI: 609049haemagglutinin 65. Influenza A virus 1,032 bp U48447.1(A/Hebei/19/1995(H3N2)) haemagglutinin mRNA, linear mRNA GI: 1574995partial cds 66. Influenza A virus 1,032 bp U48441.1(A/Hebei/41/1994(H3N2)) haemagglutinin mRNA, linear mRNA GI: 1574983partial cds 67. Influenza A virus (A/Hong 1,091 bp AF201874.1Kong/1/68(H3N2)) hemagglutinin mRNA, partial linear mRNA GI: 6470272 cds68. Influenza A virus (A/Hong 1,041 bp Z46407.1 Kong/1/1994(H3N2)) mRNAfor haemagglutinin linear mRNA GI: 609051 69. Influenza A virus (A/Hong1,762 bp AY035588.1 Kong/1143/99(H3N2)) hemagglutinin mRNA, linear mRNAGI: 14486401 complete cds 70. Influenza A virus (A/Hong 1,762 bpAF382319.1 Kong/1143/99(H3N2)) hemagglutinin mRNA, linear mRNA GI:14487957 complete cds 71. Influenza A virus (A/Hong 1,762 bp AF382320.1Kong/1143/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487959complete cds 72. Influenza A virus (A/Hong 1,466 bp AF382329.1Kong/1143/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487977complete cds 73. Influenza A virus (A/Hong 1,466 bp AF382330.1Kong/1143/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487979complete cds 74. Influenza A virus (A/Hong 1,762 bp AY035589.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486403complete cds 75. Influenza A virus (A/Hong 1,762 bp AF382321.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487961complete cds 76. Influenza A virus (A/Hong 1,762 bp AF382322.1Kong/1144/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487963complete cds 77. Influenza A virus (A/Hong 1,466 bp AF382331.1Kong/1144/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487981complete cds 78. Influenza A virus (A/Hong 1,466 bp AF382332.1Kong/1144/99(H3N2)) neuraminidase mRNA, linear mRNA GI: 14487983complete cds 79. Influenza A virus (A/Hong 1,762 bp AY035590.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486405complete cds 80. Influenza A virus (A/Hong 1,762 bp AF382323.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487965complete cds 81. Influenza A virus (A/Hong 1,762 bp AF382324.1Kong/1179/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487967complete cds 82. Influenza A virus (A/Hong 1,762 bp AY035591.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486407complete cds 83. Influenza A virus (A/Hong 1,762 bp AF382325.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487969complete cds 84. Influenza A virus (A/Hong 1,762 bp AF382326.1Kong/1180/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487971complete cds 85. Influenza A virus (A/Hong 1,762 bp AY035592.1Kong/1182/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14486409complete cds 86. Influenza A virus (A/Hong 1,762 bp AF382327.1Kong/1182/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487973complete cds 87. Influenza A virus (A/Hong 1,762 bp AF382328.1Kong/1182/99(H3N2)) hemagglutinin mRNA, linear mRNA GI: 14487975complete cds 88. Influenza A virus (A/Hong 1,041 bp Z46408.1Kong/2/1994(H3N2)) mRNA for haemagglutinin linear mRNA GI: 609055 89.Influenza A virus (A/Hong 1,041 bp Z46410.1 Kong/23/1992(H3N2)) mRNA forhaemagglutinin linear mRNA GI: 609053 90. Influenza A virus (A/Hong1,041 bp Z46409.1 Kong/34/1990(H3N2)) mRNA for haemagglutinin linearmRNA GI: 609057 91. Influenza A virus 987 bp AF501534.1(A/Indiana/28170/99(H3N2)) hemagglutinin linear mRNA GI: 21314324 (HA)mRNA, partial cds 92. Influenza A virus 529 bp AY961997.1(A/Kinmen/618/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138151mRNA, partial cds 93. Influenza A virus 383 bp AY973325.1(A/Kinmen/618/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673206mRNA, partial cds 94. Influenza A virus 882 bp AY986986.1(A/Kinmen/618/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728099mRNA, partial cds 95. Influenza A virus 545 bp AY962017.1(A/Kinmen/621/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138191mRNA, partial cds 96. Influenza A virus 386 bp AY973326.1(A/Kinmen/621/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673208mRNA, partial cds 97. Influenza A virus 882 bp AY986987.1(A/Kinmen/621/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728101mRNA, partial cds 98. Influenza A virus 786 bp AY962008.1(A/Kinmen/639/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138173mRNA, partial cds 99. Influenza A virus 381 bp AY973327.1(A/Kinmen/639/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673210mRNA, partial cds 100. Influenza A virus 882 bp AY986988.1(A/Kinmen/639/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728103mRNA, partial cds 101. Influenza A virus 596 bp AY962004.1(A/Kinmen/641/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138165mRNA, partial cds 102. Influenza A virus 785 bp AY973328.1(A/Kinmen/641/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673212mRNA, partial cds 103. Influenza A virus 576 bp AY962001.1(A/Kinmen/642/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138159mRNA, partial cds 104. Influenza A virus 580 bp AY973329.1(A/Kinmen/642/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673214mRNA, partial cds 105. Influenza A virus 882 bp AY986989.1(A/Kinmen/642/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728105mRNA, partial cds 106. Influenza A virus 789 bp AY962009.1(A/Kinmen/645/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138175mRNA, partial cds 107. Influenza A virus 581 bp AY973330.1(A/Kinmen/645/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673216mRNA, partial cds 108. Influenza A virus 981 bp AY986990.1(A/Kinmen/645/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728107mRNA, partial cds 109. Influenza A virus 2,341 bp U62543.1(A/LosAngeles/2/1987(H3N2)) polymerase linear mRNA GI: 1480737 proteinbasic 2 (PB2) mRNA, complete cds 110. Influenza A virus 1,041 bpZ46411.1 (A/Madrid/252/1993(H3N2)) mRNA for linear mRNA GI: 609067haemagglutinin 111. Influenza A virus 987 bp AF501531.1(A/Michigan/22568/99(H3N2)) hemagglutinin linear mRNA GI: 21314318 (HA)mRNA, partial cds 112. Influenza A virus 987 bp AF501518.1(A/Michigan/22692/99(H3N2)) hemagglutinin linear mRNA GI: 21314292 (HA)mRNA, partial cds 113. Influenza A virus 754 bp AJ519454.1(A/Moscow/10/99(H3N2)) partial NS1 gene for linear mRNA GI: 31096423 nonstructural protein 1 and partial NS2 gene for non structural protein 2,genomic RNA 114. Influenza A virus 987 bp AY138518.1(A/ningbo/17/2002(H3N2)) hemagglutinin (HA) linear mRNA GI: 24895178mRNA, partial cds 115. Influenza A virus 987 bp AY138517.1(A/ningbo/25/2002(H3N2)) hemagglutinin (HA) linear mRNA GI: 24895169mRNA, partial cds 116. Influenza A virus 1,765 bp V01103.1(A/NT/60/68/29C(H3N2)) mRNA for linear mRNA GI: 60800 haemagglutinin(HA1 and HA2 genes) 117. Influenza A virus 1,701 bp DQ059385.1(A/Oklahoma/323/03(H3N2)) hemagglutinin linear mRNA GI: 66933143 mRNA,complete cds 118. Influenza A virus 1,410 bp DQ059384.2(A/Oklahoma/323/03(H3N2)) neuraminidase linear mRNA GI: 75859981 mRNA,complete cds 119. Influenza A virus 766 bp AJ519458.1(A/Panama/2007/99(H3N2)) partial NS1 gene linear mRNA GI: 31096435 fornon structural protein 1 and partial NS2 gene for non structural protein2, genomic RNA 120. Influenza A virus 987 bp AF501526.1(A/Pennsylvania/20109/99(H3N2)) linear mRNA GI: 21314308 hemagglutinin(HA) mRNA, partial cds 121. Influenza A virus 1,091 bp AF233691.1(A/Philippines/2/82(H3N2)) hemagglutinin linear mRNA GI: 7331124 mRNA,partial cds 122. Influenza A virus 767 bp AY962000.1(A/Pingtung/303/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138157mRNA, partial cds 123. Influenza A virus 783 bp AY973331.1(A/Pingtung/303/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673218mRNA, partial cds 124. Influenza A virus 928 bp AY986991.1(A/Pingtung/303/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728109mRNA, partial cds 125. Influenza A virus 788 bp AY961999.1(A/Pingtung/313/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138155mRNA, partial cds 126. Influenza A virus 787 bp AY973332.1(A/Pingtung/313/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673220mRNA, partial cds 127. Influenza A virus 882 bp AY986992.1(A/Pingtung/313/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728111mRNA, partial cds 128. Influenza A virus (A/ruddy 927 bp AY664458.1turnstone/Delaware/142/99 (H3N2)) linear mRNA GI: 51011862 nonfunctionalmatrix protein mRNA, partial sequence 129. Influenza A virus 1,041 bpZ46413.1 (A/Scotland/142/1993(H3N2)) mRNA for linear mRNA GI: 609059haemagglutinin 130. Influenza A virus 1,041 bp Z46414.1(A/Scotland/160/1993(H3N2)) mRNA for linear mRNA GI: 609061haemagglutinin 131. Influenza A virus 1,041 bp Z46416.1(A/Scotland/173/1993(H3N2)) mRNA for linear mRNA GI: 609063haemagglutinin 132. Influenza A virus 1,041 bp Z46415.1(A/Scotland/174/1993(H3N2)) mRNA for linear mRNA GI: 609065haemagglutinin 133. Influenza A virus 1,041 bp Z46412.1(A/Scotland/2/1993(H3N2)) mRNA for linear mRNA GI: 609069 haemagglutinin134. Influenza A virus 1,032 bp U48439.1 (A/Sendai/C182/1994(H3N2))haemagglutinin linear mRNA GI: 1574979 mRNA, partial cds 135. InfluenzaA virus 1,032 bp U48445.1 (A/Sendai/c373/1995(H3N2)) haemagglutininlinear mRNA GI: 1574991 mRNA, partial cds 136. Influenza A virus 1,032bp U48440.1 (A/Sendai/c384/1994(H3N2)) haemagglutinin linear mRNA GI:1574981 mRNA, partial cds 137. Influenza A virus 1,041 bp Z46417.1(A/Shangdong/9/1993(H3N2)) mRNA for linear mRNA GI: 609071haemagglutinin 138. Influenza A virus 987 bp L19416.1(A/Shanghai/11/1987/X99aE high yield linear mRNA GI: 348117reassortant(H3N2)) hemagglutinin (HA) mRNA, partial cds 139. Influenza Avirus 2,280 bp AF225514.1 (A/sw/Shizuoka/110/97(H3N2)) polymerase linearmRNA GI: 27462098 basic 2 (PB2) mRNA, complete cds 140. Influenza Avirus 2,274 bp AF225518.1 (A/sw/Shizuoka/110/97(H3N2)) polymerase linearmRNA GI: 27462106 basic 1 (PB1) mRNA, complete cds 141. Influenza Avirus 2,151 bp AF225522.1 (A/sw/Shizuoka/110/97(H3N2)) polymerase linearmRNA GI: 27462114 acidic (PA) mRNA, complete cds 142. Influenza A virus1,497 bp AF225534.1 (A/sw/Shizuoka/110/97(H3N2)) nucleoprotein linearmRNA GI: 27462146 (NP) mRNA, complete cds 143. Influenza A virus 1,410bp AF225538.1 (A/sw/Shizuoka/110/97(H3N2)) neuraminidase linear mRNA GI:27462154 (NA) mRNA, complete cds 144. Influenza A virus 984 bpAF225542.1 (A/sw/Shizuoka/110/97(H3N2)) hemagglutinin linear mRNA GI:27462162 (HA1) mRNA, partial cds 145. Influenza A virus 2,280 bpAF225515.1 (A/sw/Shizuoka/115/97(H3N2)) polymerase linear mRNA GI:27462100 basic 2 (PB2) mRNA, complete cds 146. Influenza A virus 2,274bp AF225519.1 (A/sw/Shizuoka/115/97(H3N2)) polymerase linear mRNA GI:27462108 basic 1 (PB1) mRNA, complete cds 147. Influenza A virus 2,151bp AF225523.1 (A/sw/Shizuoka/115/97(H3N2)) polymerase linear mRNA GI:27462116 acidic (PA) mRNA, complete cds 148. Influenza A virus 1,497 bpAF225535.1 (A/sw/Shizuoka/115/97(H3N2)) nucleoprotein linear mRNA GI:27462148 (NP) mRNA, complete cds 149. Influenza A virus 1,410 bpAF225539.1 (A/sw/Shizuoka/115/97(H3N2)) neuraminidase linear mRNA GI:27462156 (NA) mRNA, complete cds 150. Influenza A virus 984 bpAF225543.1 (A/sw/Shizuoka/115/97(H3N2)) hemagglutinin linear mRNA GI:27462164 (HA1) mRNA, partial cds 151. Influenza A virus 2,280 bpAF225516.1 (A/sw/Shizuoka/119/97(H3N2)) polymerase linear mRNA GI:27462102 basic 2 (PB2) mRNA, complete cds 152. Influenza A virus 2,274bp AF225520.1 (A/sw/Shizuoka/119/97(H3N2)) polymerase linear mRNA GI:27462110 basic 1 (PB1) mRNA, complete cds 153. Influenza A virus 2,151bp AF225524.1 (A/sw/Shizuoka/119/97(H3N2)) polymerase linear mRNA GI:27462118 acidic (PA) mRNA, complete cds 154. Influenza A virus 1,497 bpAF225536.1 (A/sw/Shizuoka/119/97(H3N2)) nucleoprotein linear mRNA GI:27462150 (NP) mRNA, complete cds 155. Influenza A virus 1,410 bpAF225540.1 (A/sw/Shizuoka/119/97(H3N2)) neuraminidase linear mRNA GI:27462158 (NA) mRNA, complete cds 156. Influenza A virus 984 bpAF225544.1 (A/sw/Shizuoka/119/97(H3N2)) hemagglutinin linear mRNA GI:27462166 (HA1) mRNA, partial cds 159. Influenza A virus 1,410 bpEU163948.1 (A/swine/Bakum/1DTI769/2003(H3N2)) linear mRNA GI: 157679552neuraminidase mRNA, complete cds 163. Influenza A virus 1,738 bpAY857957.1 (A/swine/Fujian/668/01(H3N2)) nonfunctional linear mRNA GI:58042507 hemagglutinin mRNA, complete sequence 164. Influenza A virusPB2 gene for 2,280 bp AJ311459.1 Polymerase 2 protein, genomic RNA,strain linear mRNA GI: 13661041 A/Swine/Italy/1523/98 165. Influenza Avirus PB1 gene for 2,274 bp AJ311460.1 Polymerase 1 protein, genomicRNA, strain linear mRNA GI: 13661043 A/Swine/Italy/1523/98 166.Influenza A virus 821 bp AJ344024.1 (A/swine/Italy/1523/98(H3N2)) NS1gene for linear mRNA GI: 20068146 non structural protein 1 and NS2 genefor non structural protein 2, genomic RNA 167. Influenza A virus 1,465bp EU163949.1 (A/swine/Re220/92hp(H3N2)) neuraminidase linear mRNA GI:157679554 mRNA, complete cds 168. Influenza A virus 2,280 bp AF225517.1(A/sw/Shizuoka/120/97(H3N2)) polymerase linear mRNA GI: 27462104 basic 2(PB2) mRNA, complete cds 169. Influenza A virus 2,274 bp AF225521.1(A/sw/Shizuoka/120/97(H3N2)) polymerase linear mRNA GI: 27462112 basic 1(PB1) mRNA, complete cds 170. Influenza A virus 2,151 bp AF225525.1(A/sw/Shizuoka/120/97(H3N2)) polymerase linear mRNA GI: 27462120 acidic(PA) mRNA, complete cds 171. Influenza A virus 1,497 bp AF225537.1(A/sw/Shizuoka/120/97(H3N2)) nucleoprotein linear mRNA GI: 27462152 (NP)mRNA, complete cds 172. Influenza A virus 1,410 bp AF225541.1(A/sw/Shizuoka/120/97(H3N2)) neuraminidase linear mRNA GI: 27462160 (NA)mRNA, complete cds 173. Influenza A virus 984 bp AF225545.1(A/sw/Shizuoka/120/97(H3N2)) hemagglutinin linear mRNA GI: 27462168(HA1) mRNA, partial cds 174. Influenza A virus 1,762 bp AY032978.1(A/Switzerland/7729/98(H3N2)) hemagglutinin linear mRNA GI: 14161723mRNA, complete cds 175. Influenza A virus 1,762 bp AF382318.1(A/Switzerland/7729/98(H3N2)) hemagglutinin linear mRNA GI: 14487955mRNA, complete cds 176. Influenza A virus 528 bp AY962011.1(A/Tainan/704/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138179mRNA, partial cds 177. Influenza A virus 384 bp AY973333.1(A/Tainan/704/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673222mRNA, partial cds 178. Influenza A virus 882 bp AY986993.1(A/Tainan/704/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728113mRNA, partial cds 179. Influenza A virus 519 bp AY962012.1(A/Tainan/712/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138181mRNA, partial cds 180. Influenza A virus 383 bp AY973334.1(A/Tainan/712/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673224mRNA, partial cds 181. Influenza A virus 882 bp AY986994.1(A/Tainan/712/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728115mRNA, partial cds 182. Influenza A virus 784 bp AY962005.1(A/Tainan/722/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138167mRNA, partial cds 183. Influenza A virus 592 bp AY973335.1(A/Tainan/722/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673226mRNA, partial cds 184. Influenza A virus 936 bp AY986995.1(A/Tainan/722/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728117mRNA, partial cds 185. Influenza A virus 788 bp AY961998.1(A/Taipei/407/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138153mRNA, partial cds 186. Influenza A virus 787 bp AY973336.1(A/Taipei/407/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673228mRNA, partial cds 187. Influenza A virus 882 bp AY986996.1(A/Taipei/407/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728119mRNA, partial cds 188. Influenza A virus 787 bp AY962007.1(A/Taipei/416/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138171mRNA, partial cds 189. Influenza A virus 782 bp AY973337.1(A/Taipei/416/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673230mRNA, partial cds 190. Influenza A virus 882 bp AY986997.1(A/Taipei/416/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728121mRNA, partial cds 191. Influenza A virus (A/Taiwan/0020/98 297 bpAY303703.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330895 mRNA, partial cds 192. Influenza A virus 791 bp AY604817.1(A/Taiwan/0040/2003(H3N2)) hemagglutinin linear mRNA GI: 50727514 mRNA,partial cds 193. Influenza A virus (A/Taiwan/0045/98 297 bp AY303705.1(H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI: 32330899 mRNA,partial cds 194. Influenza A virus 844 bp AF362820.1(A/human/Taiwan/0095/96(H3N2)) hemagglutinin linear mRNA GI: 15055140(HA) mRNA, partial cds 195. Influenza A virus 791 bp AY604828.1(A/Taiwan/0097/2003(H3N2)) hemagglutinin linear mRNA GI: 50727536 mRNA,partial cds 196. Influenza A virus (A/Taiwan/0104/2001 297 bp AY303706.1(H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI: 32330901 mRNA,partial cds 197. Influenza A virus 844 bp AF362805.1(A/human/Taiwan/0118/98(H3N2)) hemagglutinin linear mRNA GI: 15055110(HA) mRNA, partial cds 198. Influenza A virus 791 bp AY604823.1(A/Taiwan/0122/2003(H3N2)) hemagglutinin linear mRNA GI: 50727526 mRNA,partial cds 199. Influenza A virus 844 bp AF362806.1(A/human/Taiwan/0149/00(H3N2)) hemagglutinin linear mRNA GI: 15055112(HA) mRNA, partial cds 200. Influenza A virus (A/Taiwan/0275/2000 297 bpAY303712.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330913 mRNA, partial cds 201. Influenza A virus (A/Taiwan/0275/2000844 bp AY303713.1 (H3N2)) hemagglutinin (HA) mRNA, partial cds linearmRNA GI: 32330915 202. Influenza A virus 844 bp AF362807.1(A/human/Taiwan/0293/98(H3N2)) hemagglutinin linear mRNA GI: 15055114(HA) mRNA, partial cds 203. Influenza A virus (A/Taiwan/0346/98 297 bpAY303715.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330919 mRNA, partial cds 204. Influenza A virus (A/Taiwan/0379/2000297 bp AY303716.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNAGI: 32330921 mRNA, partial cds 205. Influenza A virus(A/Taiwan/0379/2000 844 bp AY303717.1 (H3N2)) hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32330923 206. Influenza A virus 791 bpAY625729.1 (A/Taiwan/0388/2001(H3N2)) hemagglutinin linear mRNA GI:50604415 (HA) mRNA, partial cds 207. Influenza A virus 844 bp AF362808.1(A/human/Taiwan/0389/99(H3N2)) hemagglutinin linear mRNA GI: 15055116(HA) mRNA, partial cds 208. Influenza A virus 844 bp AF362809.1(A/human/Taiwan/0423/98(H3N2)) hemagglutinin linear mRNA GI: 15055118(HA) mRNA, partial cds 209. Influenza A virus (A/Taiwan/0423/98 297 bpAY303718.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330925 mRNA, partial cds 210. Influenza A virus 844 bp AF362810.1(A/human/Taiwan/0464/98(H3N2)) hemagglutinin linear mRNA GI: 15055120(HA) mRNA, partial cds 211. Influenza A virus (A/Taiwan/0464/98 297 bpAY303719.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330927 mRNA, partial cds 212. Influenza A virus 791 bp AY625730.1(A/Taiwan/0568/2001(H3N2)) hemagglutinin linear mRNA GI: 50604440 (HA)mRNA, partial cds 213. Influenza A virus 791 bp AY604822.1(A/Taiwan/0570/2003(H3N2)) hemagglutinin linear mRNA GI: 50727524 mRNA,partial cds 214. Influenza A virus 791 bp AY604827.1(A/Taiwan/0572/2003(H3N2)) hemagglutinin linear mRNA GI: 50727534 mRNA,partial cds 215. Influenza A virus 791 bp AY604821.1(A/Taiwan/0578/2003(H3N2)) hemagglutinin linear mRNA GI: 50727522 mRNA,partial cds 216. Influenza A virus 791 bp AY604820.1(A/Taiwan/0583/2003(H3N2)) hemagglutinin linear mRNA GI: 50727520 mRNA,partial cds 217. Influenza A virus (A/Taiwan/0646/2000 297 bp AY303722.1(H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI: 32330933 mRNA,partial cds 218. Influenza A virus (A/Taiwan/0646/2000 844 bp AY303723.1(H3N2)) hemagglutinin (HA) mRNA, partial cds linear mRNA GI: 32330935219. Influenza A virus 844 bp AF362811.1 (A/human/Taiwan/0830/99(H3N2))hemagglutinin linear mRNA GI: 15055122 (HA) mRNA, partial cds 220.Influenza A virus 791 bp AY625731.1 (A/Taiwan/0964/2001(H3N2))hemagglutinin linear mRNA GI: 50604469 (HA) mRNA, partial cds 221.Influenza A virus 844 bp AF362812.1 (A/human/Taiwan/1008/99(H3N2))hemagglutinin linear mRNA GI: 15055124 (HA) mRNA, partial cds 222.Influenza A virus (A/Taiwan/1008/99 297 bp AY303725.1 (H3N2)) polymerasebasic protein 1 (PB1) linear mRNA GI: 32330939 mRNA, partial cds 223.Influenza A virus 750 bp EU068138.1 (A/Taiwan/1219/2004(H3N2))hemagglutinin linear mRNA GI: 158452149 (HA) mRNA, partial cds 224.Influenza A virus 750 bp EU068125.1 (A/Taiwan/1315/2005(H3N2))hemagglutinin linear mRNA GI: 158452123 (HA) mRNA, partial cds 225.Influenza A virus 750 bp EU068153.1 (A/Taiwan/1511/2004(H3N2))hemagglutinin linear mRNA GI: 158452179 (HA) mRNA, partial cds 226.Influenza A virus 750 bp EU068119.1 (A/Taiwan/1533/2003(H3N2))hemagglutinin linear mRNA GI: 158452111 (HA) mRNA, partial cds 227.Influenza A virus 844 bp AF362813.1 (A/human/Taiwan/1537/99(H3N2))hemagglutinin linear mRNA GI: 15055126 (HA) mRNA, partial cds 228.Influenza A virus (A/Taiwan/1537/99 297 bp AY303728.1 (H3N2)) polymerasebasic protein 1 (PB1) linear mRNA GI: 32330945 mRNA, partial cds 229.Influenza A virus 791 bp AY604826.1 (A/Taiwan/1566/2003(H3N2))hemagglutinin linear mRNA GI: 50727532 mRNA, partial cds 230. InfluenzaA virus 791 bp AY604819.1 (A/Taiwan/1568/2003(H3N2)) hemagglutininlinear mRNA GI: 50727518 mRNA, partial cds 231. Influenza A virus 750 bpEU068116.1 (A/Taiwan/158/2003(H3N2)) hemagglutinin (HA) linear mRNA GI:158452105 mRNA, partial cds 232. Influenza A virus 875 bp AF138709.2(A/Taiwan/1600/96(H3N2)) matrix protein M1 linear mRNA GI: 4996869 (M)mRNA, partial cds 233. Influenza A virus 750 bp EU068117.1(A/Taiwan/1613/2003(H3N2)) hemagglutinin linear mRNA GI: 158452107 (HA)mRNA, partial cds 234. Influenza A virus 750 bp EU068148.1(A/Taiwan/1651/2004(H3N2)) hemagglutinin linear mRNA GI: 158452169 (HA)mRNA, partial cds 235. Influenza A virus 844 bp AF362814.1(A/human/Taiwan/1748/97(H3N2)) hemagglutinin linear mRNA GI: 15055128(HA) mRNA, partial cds 236. Influenza A virus (A/Taiwan/1748/97 297 bpAY303729.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330947 mRNA, partial cds 237. Influenza A virus 872 bp AF138707.2(A/Taiwan/179/96(H3N2)) matrix protein M1 linear mRNA GI: 4996865 (M)mRNA, partial cds 238. Influenza A virus 750 bp EU068139.1(A/Taiwan/1817/2004(H3N2)) hemagglutinin linear mRNA GI: 158452151 (HA)mRNA, partial cds 239. Influenza A virus 750 bp EU068154.1(A/Taiwan/1904/2003(H3N2)) hemagglutinin linear mRNA GI: 158452181 (HA)mRNA, partial cds 240. Influenza A virus 750 bp EU068155.1(A/Taiwan/1921/2003(H3N2)) hemagglutinin linear mRNA GI: 158452183 (HA)mRNA, partial cds 241. Influenza A virus 844 bp AF362815.1(A/human/Taiwan/1986/96(H3N2)) hemagglutinin linear mRNA GI: 15055130(HA) mRNA, partial cds 242. Influenza A virus (A/Taiwan/1990/96 297 bpAY303730.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330949 mRNA, partial cds 243. Influenza A virus (A/Taiwan/1990/96 844bp AY303731.1 (H3N2)) hemagglutinin (HA) mRNA, partial cds linear mRNAGI: 32330951 244. Influenza A virus 861 bp AF139938.1(A/Taiwan/20/98(H3N2)) H3 hemagglutinin (HA) linear mRNA GI: 4972940mRNA, partial cds 245. Influenza A virus 392 bp AF140627.1(A/Taiwan/20/98(H3N2)) N2 neuraminidase (NA) linear mRNA GI: 4972988mRNA, partial cds 246. Influenza A virus 875 bp AF138715.2(A/Taiwan/20/98(H3N2)) matrix protein M1 (M) linear mRNA GI: 4996879mRNA, partial cds 247. Influenza A virus 844 bp AF362816.1(A/human/Taiwan/2031/97(H3N2)) hemagglutinin linear mRNA GI: 15055132(HA) mRNA, partial cds 248. Influenza A virus 861 bp AF139937.1(A/Taiwan/2034/96(H3N2)) H3 hemagglutinin linear mRNA GI: 4972938 (HA)mRNA, partial cds 249. Influenza A virus 392 bp AF140620.1(A/Taiwan/2034/96(H3N2)) N2 neuraminidase linear mRNA GI: 4972974 (NA)mRNA, partial cds 250. Influenza A virus 297 bp AY303732.1(A/Taiwan/2034/96(H3N2)) polymerase basic linear mRNA GI: 32330953protein 1 (PB1) mRNA, partial cds 251. Influenza A virus 791 bpAY604818.1 (A/Taiwan/2040/2003(H3N2)) hemagglutinin linear mRNA GI:50727516 mRNA, partial cds 252. Influenza A virus 750 bp EU068131.1(A/Taiwan/2072/2006(H3N2)) hemagglutinin linear mRNA GI: 158452135 (HA)mRNA, partial cds 253. Influenza A virus 861 bp AF139934.1(A/Taiwan/21/98(H3N2)) H3 hemagglutinin (HA) linear mRNA GI: 4972932mRNA, partial cds 254. Influenza A virus 392 bp AF140624.1(A/Taiwan/21/98(H3N2)) N2 neuraminidase (NA) linear mRNA GI: 4972982mRNA, partial cds 255. Influenza A virus 875 bp AF138716.2(A/Taiwan/21/98(H3N2)) matrix protein M1 (M) linear mRNA GI: 4996881mRNA, partial cds 256. Influenza A virus 861 bp AF139932.1(A/Taiwan/2191/96(H3N2)) H3 hemagglutinin linear mRNA GI: 4972928 (HA)mRNA, partial cds 257. Influenza A virus 392 bp AF140622.1(A/Taiwan/2191/96(H3N2)) N2 neuraminidase linear mRNA GI: 4972978 (NA)mRNA, partial cds 258. Influenza A virus 875 bp AF138711.3(A/Taiwan/2191/96(H3N2)) matrix protein M1 linear mRNA GI: 156147502 (M)mRNA, partial cds 259. Influenza A virus 861 bp AF139936.1(A/Taiwan/2192/96(H3N2)) H3 hemagglutinin linear mRNA GI: 4972936 (HA)mRNA, partial cds 260. Influenza A virus 392 bp AF140626.1(A/Taiwan/2192/96(H3N2)) N2 neuraminidase linear mRNA GI: 4972986 (NA)mRNA, partial cds 261. Influenza A virus (A/Taiwan/2195/96 297 bpAY303735.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330959 mRNA, partial cds 262. Influenza A virus (A/Taiwan/2195/96 844bp AY303736.1 (H3N2)) hemagglutinin (HA) mRNA, partial cds linear mRNAGI: 32330961 263. Influenza A virus 875 bp AF138718.2(A/Taiwan/224/98(H3N2)) matrix protein M1 linear mRNA GI: 4996885 (M)mRNA, partial cds 264. Influenza A virus 844 bp AF362817.1(A/human/Taiwan/2548/99(H3N2)) hemagglutinin linear mRNA GI: 15055134(HA) mRNA, partial cds 265. Influenza A virus 750 bp EU068120.1(A/Taiwan/268/2005(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452113mRNA, partial cds 266. Influenza A virus 750 bp EU068149.1(A/Taiwan/3008/2004(H3N2)) hemagglutinin linear mRNA GI: 158452171 (HA)mRNA, partial cds 267. Influenza A virus 750 bp EU068152.1(A/Taiwan/3075/2003(H3N2)) hemagglutinin linear mRNA GI: 158452177 (HA)mRNA, partial cds 268. Influenza A virus 940 bp AF362818.1(A/human/Taiwan/3083/00(H3N2)) hemagglutinin linear mRNA GI: 15055136(HA) mRNA, partial cds 269. Influenza A virus 791 bp AY604811.1(A/Taiwan/3131/2002(H3N2)) hemagglutinin linear mRNA GI: 50727502 mRNA,partial cds 270. Influenza A virus 750 bp EU068145.1(A/Taiwan/3154/2004(H3N2)) hemagglutinin linear mRNA GI: 158452163 (HA)mRNA, partial cds 271. Influenza A virus 750 bp EU068141.1(A/Taiwan/3187/2004(H3N2)) hemagglutinin linear mRNA GI: 158452155 (HA)mRNA, partial cds 272. Influenza A virus 750 bp EU068134.1(A/Taiwan/3245/2004(H3N2)) hemagglutinin linear mRNA GI: 158452141 (HA)mRNA, partial cds 273. Influenza A virus 750 bp EU068133.1(A/Taiwan/3294/2005(H3N2)) hemagglutinin linear mRNA GI: 158452139 (HA)mRNA, partial cds 274. Influenza A virus 861 bp AF139935.1(A/Taiwan/3351/97(H3N2)) H3 hemagglutinin linear mRNA GI: 4972934 (HA)mRNA, partial cds 275. Influenza A virus 392 bp AF140625.1(A/Taiwan/3351/97(H3N2)) N2 neuraminidase linear mRNA GI: 4972984 (NA)mRNA, partial cds 276. Influenza A virus 875 bp AF138713.2(A/Taiwan/3351/97(H3N2)) matrix protein M1 linear mRNA GI: 4996875 (M)mRNA, partial cds 277. Influenza A virus 297 bp AY303738.1(A/Taiwan/3351/97(H3N2)) polymerase basic linear mRNA GI: 32330965protein 1 (PB1) mRNA, partial cds 278. Influenza A virus 750 bpEU068132.1 (A/Taiwan/3387/2005(H3N2)) hemagglutinin linear mRNA GI:158452137 (HA) mRNA, partial cds 279. Influenza A virus(A/Taiwan/3396/97 297 bp AY303742.1 (H3N2)) polymerase basic protein 1(PB1) linear mRNA GI: 32330973 mRNA, partial cds 280. Influenza A virus(A/Taiwan/3396/97 844 bp AY303743.1 (H3N2)) hemagglutinin (HA) mRNA,partial cds linear mRNA GI: 32330975 281. Influenza A virus 861 bpAF139930.1 (A/Taiwan/3427/97(H3N2)) H3 hemagglutinin linear mRNA GI:4972924 (HA) mRNA, partial cds 282. Influenza A virus 392 bp AF140619.1(A/Taiwan/3427/97(H3N2)) N2 neuraminidase linear mRNA GI: 4972972 (NA)mRNA, partial cds 283. Influenza A virus 861 bp AF139940.1(A/Taiwan/346/98(H3N2)) H3 hemagglutinin linear mRNA GI: 4972944 (HA)mRNA, partial cds 284. Influenza A virus 392 bp AF140787.1(A/Taiwan/346/98(H3N2)) N2 neuraminidase linear mRNA GI: 4972992 (NA)mRNA, partial cds 285. Influenza A virus 875 bp AF138719.2(A/Taiwan/346/98(H3N2)) matrix protein M1 linear mRNA GI: 4996887 (M)mRNA, partial cds 286. Influenza A virus 942 bp AF362819.1(A/human/Taiwan/3460/00(H3N2)) truncated linear mRNA GI: 15055138hemagglutinin (HA) mRNA, partial cds 287. Influenza A virus 861 bpAF139933.1 (A/Taiwan/3469/97(H3N2)) H3 hemagglutinin linear mRNA GI:4972930 (HA) mRNA, partial cds 288. Influenza A virus 392 bp AF140623.1(A/Taiwan/3469/97(H3N2)) N2 neuraminidase linear mRNA GI: 4972980 (NA)mRNA, partial cds 289. Influenza A virus 875 bp AF138714.2(A/Taiwan/3469/97(H3N2)) matrix protein M1 linear mRNA GI: 4996877 (M)mRNA, partial cds 290. Influenza A virus (A/Taiwan/3503/97 297 bpAY303744.1 (H3N2)) polymerase basic protein 1 (PB1) linear mRNA GI:32330977 mRNA, partial cds 291. Influenza A virus (A/Taiwan/3503/97 844bp AY303745.1 (H3N2)) hemagglutinin (HA) mRNA, partial cds linear mRNAGI: 32330979 292. Influenza A virus 919 bp AF138712.1(A/Taiwan/3513/96(H3N2)) matrix protein M1 linear mRNA GI: 4928900 (M)mRNA, partial cds 293. Influenza A virus 861 bp AF139931.1(A/Taiwan/3513/97(H3N2)) H3 hemagglutinin linear mRNA GI: 4972926 (HA)mRNA, partial cds 294. Influenza A virus 392 bp AF140621.1(A/Taiwan/3513/97(H3N2)) N2 neuraminidase linear mRNA GI: 4972976 (NA)mRNA, partial cds 295. Influenza A virus 791 bp AY604814.1(A/Taiwan/3744/2002(H3N2)) hemagglutinin linear mRNA GI: 50727508 mRNA,partial cds 296. Influenza A virus 940 bp AF362804.1(A/human/Taiwan/3760/00(H3N2)) hemagglutinin linear mRNA GI: 15055108(HA) mRNA, partial cds 297. Influenza A virus (A/Taiwan/3896/2001 561 bpAY303747.1 (H1N1)) hemagglutinin (HA) mRNA, partial cds linear mRNA GI:32330983 298. Influenza A virus 791 bp AY604825.1(A/Taiwan/4050/2003(H3N2)) hemagglutinin linear mRNA GI: 50727530 mRNA,partial cds 299. Influenza A virus 791 bp AY604824.1(A/Taiwan/4063/2003(H3N2)) hemagglutinin linear mRNA GI: 50727528 mRNA,partial cds 300. Influenza A virus 750 bp EU068137.1(A/Taiwan/41/2004(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452147mRNA, partial cds 301. Influenza A virus 861 bp AF139939.1(A/Taiwan/45/98(H3N2)) H3 hemagglutinin (HA) linear mRNA GI: 4972942mRNA, partial cds 302. Influenza A virus 392 bp AF140628.1(A/Taiwan/45/98(H3N2)) N2 neuraminidase (NA) linear mRNA GI: 4972990mRNA, partial cds 303. Influenza A virus 875 bp AF138717.2(A/Taiwan/45/98(H3N2)) matrix protein M1 (M) linear mRNA GI: 4996883mRNA, partial cds 304. Influenza A virus 750 bp EU068114.1(A/Taiwan/4548/2003(H3N2)) hemagglutinin linear mRNA GI: 158452101 (HA)mRNA, partial cds 305. Influenza A virus 791 bp AY604813.1(A/Taiwan/4673/2002(H3N2)) hemagglutinin linear mRNA GI: 50727506 mRNA,partial cds 306. Influenza A virus 791 bp AY604812.1(A/Taiwan/4680/2002(H3N2)) hemagglutinin linear mRNA GI: 50727504 mRNA,partial cds 307. Influenza A virus 750 bp EU068136.1(A/Taiwan/4735/2004(H3N2)) hemagglutinin linear mRNA GI: 158452145 (HA)mRNA, partial cds 308. Influenza A virus 750 bp EU068142.1(A/Taiwan/4829/2005(H3N2)) hemagglutinin linear mRNA GI: 158452157 (HA)mRNA, partial cds 309. Influenza A virus 750 bp EU068130.1(A/Taiwan/4836/2005(H3N2)) hemagglutinin linear mRNA GI: 158452133 (HA)mRNA, partial cds 310. Influenza A virus 750 bp EU068143.1(A/Taiwan/4865/2005(H3N2)) hemagglutinin linear mRNA GI: 158452159 (HA)mRNA, partial cds 311. Influenza A virus 750 bp EU068121.1(A/Taiwan/4883/2005(H3N2)) hemagglutinin linear mRNA GI: 158452115 (HA)mRNA, partial cds 312. Influenza A virus 791 bp AY604809.1(A/Taiwan/4938/2002(H3N2)) hemagglutinin linear mRNA GI: 50727498 mRNA,partial cds 313. Influenza A virus 791 bp AY604815.1(A/Taiwan/4954/2002(H3N2)) hemagglutinin linear mRNA GI: 50727510 mRNA,partial cds 314. Influenza A virus 791 bp AY604810.1(A/Taiwan/4963/2002(H3N2)) hemagglutinin linear mRNA GI: 50727500 mRNA,partial cds 315. Influenza A virus 750 bp EU068122.1(A/Taiwan/4987/2005(H3N2)) hemagglutinin linear mRNA GI: 158452117 (HA)mRNA, partial cds 316. Influenza A virus 750 bp EU068127.1(A/Taiwan/4990/2005(H3N2)) hemagglutinin linear mRNA GI: 158452127 (HA)mRNA, partial cds 317. Influenza A virus 750 bp EU068118.1(A/Taiwan/5/2003(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452109mRNA, partial cds 318. Influenza A virus 791 bp AY604816.1(A/Taiwan/5153/2002(H3N2)) hemagglutinin linear mRNA GI: 50727512 mRNA,partial cds 319. Influenza A virus 750 bp EU068128.1(A/Taiwan/5267/2005(H3N2)) hemagglutinin linear mRNA GI: 158452129 (HA)mRNA, partial cds 320. Influenza A virus 750 bp EU068146.1(A/Taiwan/556/2004(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452165mRNA, partial cds 321. Influenza A virus 750 bp EU068126.1(A/Taiwan/5694/2005(H3N2)) hemagglutinin linear mRNA GI: 158452125 (HA)mRNA, partial cds 322. Influenza A virus 750 bp EU068147.1(A/Taiwan/587/2004(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452167mRNA, partial cds 323. Influenza A virus 750 bp EU068151.1(A/Taiwan/592/2004(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452175mRNA, partial cds 324. Influenza A virus 791 bp AY604829.1(A/Taiwan/7099/2003(H3N2)) hemagglutinin linear mRNA GI: 50727538 mRNA,partial cds 325. Influenza A virus 791 bp AY604830.1(A/Taiwan/7100/2003(H3N2)) hemagglutinin linear mRNA GI: 50727540 mRNA,partial cds 326. Influenza A virus 750 bp EU068150.1(A/Taiwan/7196/2003(H3N2)) hemagglutinin linear mRNA GI: 158452173 (HA)mRNA, partial cds 327. Influenza A virus 750 bp EU068135.1(A/Taiwan/7568/2004(H3N2)) hemagglutinin linear mRNA GI: 158452143 (HA)mRNA, partial cds 328. Influenza A virus 750 bp EU068144.1(A/Taiwan/7601/2005(H3N2)) hemagglutinin linear mRNA GI: 158452161 (HA)mRNA, partial cds 329. Influenza A virus 750 bp EU068124.1(A/Taiwan/7681/2005(H3N2)) hemagglutinin linear mRNA GI: 158452121 (HA)mRNA, partial cds 330. Influenza A virus 750 bp EU068123.1(A/Taiwan/7702/2005(H3N2)) hemagglutinin linear mRNA GI: 158452119 (HA)mRNA, partial cds 331. Influenza A virus 750 bp EU068129.1(A/Taiwan/7873/2005(H3N2)) hemagglutinin linear mRNA GI: 158452131 (HA)mRNA, partial cds 332. Influenza A virus 750 bp EU068115.1(A/Taiwan/8/2003(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452103mRNA, partial cds 333. Influenza A virus 750 bp EU068140.1(A/Taiwan/93/2004(H3N2)) hemagglutinin (HA) linear mRNA GI: 158452153mRNA, partial cds 334. Influenza A virus 528 bp AY962016.1(A/Taoyuan/108/02(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138189mRNA, partial cds 335. Influenza A virus 754 bp AY973338.1(A/Taoyuan/108/02(H3N2)) neuraminidase (NA) linear mRNA GI: 70673232mRNA, partial cds 336. Influenza A virus 882 bp AY986998.1(A/Taoyuan/108/02(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728123mRNA, partial cds 337. Influenza A virus 1,410 bp EU021285.1(A/Thailand/CU124/2006(H3N2)) neuraminidase linear mRNA GI: 154224724(NA) mRNA, complete cds 338. Influenza A virus 1,701 bp EU021284.1(A/Thailand/CU124/2006(H3N2)) hemagglutinin linear mRNA GI: 154224795(HA) mRNA, complete cds 339. Influenza A virus 1,410 bp EU021275.1(A/Thailand/CU228/2006(H3N2)) neuraminidase linear mRNA GI: 154224714(NA) mRNA, complete cds 340. Influenza A virus 1,701 bp EU021274.1(A/Thailand/CU228/2006(H3N2)) hemagglutinin linear mRNA GI: 154224785(HA) mRNA, complete cds 341. Influenza A virus 1,347 bp EU021267.1(A/Thailand/CU23/2006(H3N2)) neuraminidase linear mRNA GI: 154224706(NA) mRNA, partial cds 342. Influenza A virus 1,701 bp EU021266.1(A/Thailand/CU23/2006(H3N2)) hemagglutinin linear mRNA GI: 154224777(HA) mRNA, complete cds 343. Influenza A virus 1,410 bp EU021283.1(A/Thailand/CU231/2006(H3N2)) neuraminidase linear mRNA GI: 154224722(NA) mRNA, complete cds 344. Influenza A virus 1,701 bp EU021282.1(A/Thailand/CU231/2006(H3N2)) hemagglutinin linear mRNA GI: 154224793(HA) mRNA, complete cds 345. Influenza A virus 1,410 bp EU021279.1(A/Thailand/CU259/2006(H3N2)) neuraminidase linear mRNA GI: 154224718(NA) mRNA, complete cds 346. Influenza A virus 1,701 bp EU021278.1(A/Thailand/CU259/2006(H3N2)) hemagglutinin linear mRNA GI: 154224789(HA) mRNA, complete cds 347. Influenza A virus 1,410 bp EU021281.1(A/Thailand/CU260/2006(H3N2)) neuraminidase linear mRNA GI: 154224720(NA) mRNA, complete cds 348. Influenza A virus 1,129 bp EU021280.1(A/Thailand/CU260/2006(H3N2)) hemagglutinin linear mRNA GI: 154224791(HA) mRNA, partial cds 349. Influenza A virus 1,410 bp EU021271.1(A/Thailand/CU272/2007(H3N2)) neuraminidase linear mRNA GI: 154224710(NA) mRNA, complete cds 350. Influenza A virus 1,701 bp EU021270.1(A/Thailand/CU272/2007(H3N2)) hemagglutinin linear mRNA GI: 154224781(HA) mRNA, complete cds 351. Influenza A virus 1,410 bp EU021273.1(A/Thailand/CU280/2007(H3N2)) neuraminidase linear mRNA GI: 154224712(NA) mRNA, complete cds 352. Influenza A virus 1,701 bp EU021272.1(A/Thailand/CU280/2007(H3N2)) hemagglutinin linear mRNA GI: 154224783(HA) mRNA, complete cds 353. Influenza A virus 1,410 bp EU021277.1(A/Thailand/CU282/2007(H3N2)) neuraminidase linear mRNA GI: 154224716(NA) mRNA, complete cds 354. Influenza A virus 1,701 bp EU021276.1(A/Thailand/CU282/2007(H3N2)) hemagglutinin linear mRNA GI: 154224787(HA) mRNA, complete cds 355. Influenza A virus 1,413 bp EU021265.1(A/Thailand/CU32/2006(H1N1)) neuraminidase linear mRNA GI: 154224704(NA) mRNA, complete cds 361. Influenza A virus 1,410 bp EU021269.1(A/Thailand/CU46/2006(H3N2)) neuraminidase linear mRNA GI: 154224708(NA) mRNA, complete cds 362. Influenza A virus 1,701 bp EU021268.1(A/Thailand/CU46/2006(H3N2)) hemagglutinin linear mRNA GI: 154224779(HA) mRNA, complete cds 377. Influenza A virus 987 bp U77837.1(A/Tottori/849AM1AL3/1994(H3N2)) linear mRNA GI: 2992515 hemagglutinin(HA) mRNA, partial cds 378. Influenza A virus 987 bp U77833.1(A/Tottori/849AM2/1994(H3N2)) hemagglutinin linear mRNA GI: 2992507 (HA)mRNA, partial cds 379. Influenza A virus 987 bp U77839.1(A/Tottori/849AM2AL3/1994(H3N2)) linear mRNA GI: 2992519 hemagglutinin(HA) mRNA, partial cds 380. Influenza A virus 987 bp U77835.1(A/Tottori/849AM4/1994(H3N2)) hemagglutinin linear mRNA GI: 2992511 (HA)mRNA, partial cds 382. Influenza A virus 987 bp U77834.1(A/Tottori/872AM2/1994(H3N2)) hemagglutinin linear mRNA GI: 2992509 (HA)mRNA, partial cds 383. Influenza A virus 987 bp U77840.1(A/Tottori/872AM2AL3/1994(H3N2)) linear mRNA GI: 2992521 hemagglutinin(HA) mRNA, partial cds 384. Influenza A virus 987 bp U77836.1(A/Tottori/872AM4/1994(H3N2)) hemagglutinin linear mRNA GI: 2992513 (HA)mRNA, partial cds 385. Influenza A virus 987 bp U77832.1(A/Tottori/872K4/1994(H3N2)) hemagglutinin linear mRNA GI: 2992505 (HA)mRNA, partial cds 386. Influenza A virus (A/United 987 bp AF501529.1Kingdom/26554/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 21314314mRNA, partial cds 387. Influenza A virus (A/United 987 bp AF501527.1Kingdom/34300/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 21314310mRNA, partial cds 388. Influenza A virus 987 bp AF501533.1(A/Utah/20997/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 21314322mRNA, partial cds 389. Influenza A virus (A/Victoria/3/75) 1,565 bpAF072545.1 segment 5 nucleoprotein mRNA, complete cds linear mRNA GI:4218933 390. Influenza A virus 1,762 bp AF017270.2(A/Vienna/47/96M(H3N2)) hemagglutinin (HA) linear mRNA GI: 14286338mRNA, complete cds 391. Influenza A virus 1,762 bp AF017272.2(A/Vienna/47/96V(H3N2)) hemagglutinin (HA) linear mRNA GI: 15004991mRNA, complete cds 392. Influenza A virus 1,069 bp AF017271.1(A/Vienna/81/96V(H3N2)) hemagglutinin (HA) linear mRNA GI: 2407251 mRNA,partial cds 393. Influenza A virus 987 bp AF501532.1(A/Virginia/21712/99(H3N2)) hemagglutinin linear mRNA GI: 21314320 (HA)mRNA, partial cds 394. Influenza A virus 987 bp AF501515.1(A/Virginia/21716/99(H3N2)) hemagglutinin linear mRNA GI: 21314286 (HA)mRNA, partial cds 395. Influenza A virus 987 bp AF501530.1(A/Virginia/21735/99(H3N2)) hemagglutinin linear mRNA GI: 21314316 (HA)mRNA, partial cds 396. Influenza A virus 987 bp AF501524.1(A/Virginia/21743/99(H3N2)) hemagglutinin linear mRNA GI: 21314304 (HA)mRNA, partial cds 397. Influenza A virus 987 bp AF501519.1(A/Virginia/21754/99(H3N2)) hemagglutinin linear mRNA GI: 21314294 (HA)mRNA, partial cds 398. Influenza A virus 987 bp AF501523.1(A/Virginia/21799/99(H3N2)) hemagglutinin linear mRNA GI: 21314302 (HA)mRNA, partial cds 399. Influenza A virus 987 bp AF501525.1(A/Virginia/21817/99(H3N2)) hemagglutinin linear mRNA GI: 21314306 (HA)mRNA, partial cds 400. Influenza A virus 987 bp AF501520.1(A/Virginia/21822/99(H3N2)) hemagglutinin linear mRNA GI: 21314296 (HA)mRNA, partial cds 401. Influenza A virus 987 bp AF501528.1(A/Virginia/21828/99(H3N2)) hemagglutinin linear mRNA GI: 21314312 (HA)mRNA, partial cds 402. Influenza A virus 987 bp AF501517.1(A/Virginia/21833/99(H3N2)) hemagglutinin linear mRNA GI: 21314290 (HA)mRNA, partial cds 403. Influenza A virus 987 bp AF501522.1(A/Virginia/21845/99(H3N2)) hemagglutinin linear mRNA GI: 21314300 (HA)mRNA, partial cds 404. Influenza A virus 987 bp AF501535.1(A/Virginia/21847/99(H3N2)) hemagglutinin linear mRNA GI: 21314326 (HA)mRNA, partial cds 405. Influenza A virus 987 bp AF501521.1(A/Virginia/G1/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 21314298mRNA, partial cds 406. Influenza A virus 755 bp AY973339.1(A/Yilan/508/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673234 mRNA,partial cds 407. Influenza A virus 882 bp AY986999.1(A/Yilan/508/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728125 mRNA,partial cds 408. Influenza A virus 740 bp AY962015.1(A/Yilan/513/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138187 mRNA,partial cds 409. Influenza A virus 396 bp AY973340.1(A/Yilan/513/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673236 mRNA,partial cds 410. Influenza A virus 882 bp AY987000.1(A/Yilan/513/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728127 mRNA,partial cds 411. Influenza A virus 511 bp AY962010.1(A/Yilan/515/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138177 mRNA,partial cds 412. Influenza A virus 394 bp AY973341.1(A/Yilan/515/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673238 mRNA,partial cds 413. Influenza A virus 882 bp AY987001.1(A/Yilan/516/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728129 mRNA,partial cds 414. Influenza A virus 530 bp AY962006.1(A/Yilan/518/03(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138169 mRNA,partial cds 415. Influenza A virus 397 bp AY973342.1(A/Yilan/518/03(H3N2)) neuraminidase (NA) linear mRNA GI: 70673240 mRNA,partial cds 416. Influenza A virus 882 bp AY987002.1(A/Yilan/518/03(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728131 mRNA,partial cds 417. Influenza A virus 777 bp AY962002.1(A/Yilan/538/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138161 mRNA,partial cds 418. Influenza A virus 783 bp AY973343.1(A/Yilan/538/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673242 mRNA,partial cds 419. Influenza A virus 882 bp AY987003.1(A/Yilan/538/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728133 mRNA,partial cds 420. Influenza A virus 788 bp AY962003.1(A/Yilan/549/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138163 mRNA,partial cds 421. Influenza A virus 779 bp AY973344.1(A/Yilan/549/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673244 mRNA,partial cds 422. Influenza A virus 882 bp AY987004.1(A/Yilan/549/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728135 mRNA,partial cds 423. Influenza A virus 776 bp AY962013.1(A/Yilan/557/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138183 mRNA,partial cds 424. Influenza A virus 796 bp AY973345.1(A/Yilan/557/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673246 mRNA,partial cds 425. Influenza A virus 882 bp AY987005.1(A/Yilan/557/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728137 mRNA,partial cds 426. Influenza A virus 753 bp AY962014.1(A/Yilan/566/04(H3N2)) hemagglutinin (HA) linear mRNA GI: 68138185 mRNA,partial cds 427. Influenza A virus 808 bp AY973346.1(A/Yilan/566/04(H3N2)) neuraminidase (NA) linear mRNA GI: 70673248 mRNA,partial cds 428. Influenza A virus 882 bp AY987006.1(A/Yilan/566/04(H3N2)) nucleoprotein (NP) linear mRNA GI: 70728139 mRNA,partial cds 429. Influenza A virus 987 bp AY138513.1(A/zhejiang/06/99(H3N2)) hemagglutinin (HA) linear mRNA GI: 24895131mRNA, partial cds 430. Influenza A virus 987 bp AY138515.1(A/zhejiang/10/98(H3N2)) hemagglutinin (HA) linear mRNA GI: 24895149mRNA, partial cds 431. Influenza A virus 987 bp AY138516.1(A/zhejiang/11/2002(H3N2)) hemagglutinin linear mRNA GI: 24895159 (HA)mRNA, partial cds 432. Influenza A virus 987 bp AY138514.1(A/zhejiang/12/99(H3N2)) hemagglutinin-like linear mRNA GI: 24895141(HA) mRNA, partial sequence 433. Influenza A virus 987 bp AY138519.1(A/zhejiang/8/2002(H3N2)) hemagglutinin (HA) linear mRNA GI: 24895188mRNA, partial cds 434. Influenza A virus H3N2 strain 840 bp U65670.1A/Akita/1/94 nonstructural protein 1 and linear mRNA GI: 3929405nonstructural protein 2 mRNAs, complete cds 435. Influenza A virus H3N2strain 840 bp U65671.1 A/Akita/1/95 nonstructural protein 1 and linearmRNA GI: 3929408 nonstructural protein 2 mRNAs, complete cds 436.Influenza A virus H3N2 strain 840 bp U65673.1 A/Shiga/20/95nonstructural protein 1 and linear mRNA GI: 3929411 nonstructuralprotein 2 mRNAs, complete cds 437. Influenza A virus H3N2 strain 840 bpU65674.1 A/Miyagi/69/95 nonstructural protein 1 and linear mRNA GI:3929414 nonstructural protein 2 mRNAs, complete cds 438. Influenza Avirus H3N2 strain 840 bp U65672.1 A/Hebei/19/95 nonstructural protein 1and linear mRNA GI: 6468319 nonstructural protein 2 mRNAs, complete cdsA/Aichi/69/1994(H3N2) haemagglutinin U48446.1 A/Bangkok/1/1979 (H3N2)hemagglutinin (HA) AF201843.1 A/Beijing/353/89(H3) hemagglutinin (HA)U97740.1 A/Beijing/353/1989(H3N2) haemagglutinin Z46391.1A/chicken/Singapore/2002(H3N2) M2 protein EU014143.1 A/ChristHospital/231/82(H3N2)) U77830.1 hemagglutinin (HA) A/duck/EasternChina/36/2002(H3N2) segment 6 EU429701.1 neuraminidase (NA)A/duck/Eastern China/160/2003(H3N2) segment EU429732.1 6 neuraminidase(NA) A/duck/Eastern China/848/2003(H3N2) segment EU429721.1 6neuraminidase (NA) A/duck/Eastern China/770/2003(H3N2) segmentEU429736.1 6 neuraminidase (NA) A/duck/Eastern China/855/2003(H3N2)segment EU429737.1 6 neuraminidase (NA) A/duck/EasternChina/875/2003(H3N2) segment EU429738.1 6 neuraminidase (NA)A/duck/Eastern China/901/2003(H3N2) segment EU429739.1 6 neuraminidase(NA) A/duck/Eastern China/866/2003(H3N2) segment EU429756.1 6neuraminidase (NA) A/duck/Eastern China/857/2003(H3N2) segmentEU429761.1 6 neuraminidase (NA) A/duck/Eastern China/852/2003(H3N2)segment EU429767.1 6 neuraminidase (NA) A/duck/EasternChina/838/2003(H3N2) segment EU429720.1 6 neuraminidase (NA)A/duck/Eastern China/6/2004(H3N2) segment 6 EU429745.1 neuraminidase(NA) A/duck/Eastern China/03/2005(H3N2) segment 6 EU429781.1neuraminidase (NA) A/duck/Eastern China/02/2006(H3N2) segment 6EU429769.1 neuraminidase (NA) A/duck/Eastern China/04/2006(H3N2) segment6 EU429770.1 neuraminidase (NA) A/duck/Eastern China/21/2006(H3N2)segment 6 EU429771.1 neuraminidase (NA) A/duck/EasternChina/23/2006(H3N2) segment 6 EU429772.1 neuraminidase (NA)A/duck/Eastern China/31/2006(H3N2) segment 6 EU429773.1 neuraminidase(NA) A/duck/Eastern China/35/2006(H3N2) segment 6 EU429768.1neuraminidase (NA) A/duck/Eastern China/42/2006(H3N2) segment 6EU429774.1 neuraminidase (NA) A/duck/Eastern China/53/2006(H3N2) segment6 EU429775.1 neuraminidase (NA) A/duck/Eastern China/60/2006(H3N2)segment 6 EU429776.1 neuraminidase (NA) A/duck/EasternChina/62/2006(H3N2) segment 6 EU429784.1 neuraminidase (NA)A/duck/Eastern China/63/2006(H3N2) segment 6 EU429777.1 neuraminidase(NA) A/duck/Eastern China/142/2006(H3N2) segment EU429742.1 6neuraminidase (NA) A/Dunedin/4/1973 (H3N2) hemagglutinin (HA) AF201842.1

TABLE 9 Influenza H5N1 Antigens GenBank/GI Strain/Protein LengthAccession No. 1. Influenza A virus (A/chicken/Burkina 827 bp AM503036.1Faso/01.03/2006(H5N1)) mRNA for non- linear mRNA GI:147846308 structuralprotein (ns gene) 2. Influenza A virus (A/chicken/Burkina 990 bpAM503007.1 Faso/13.1/2006(H5N1)) partial mRNA for linear mRNAGI:147846250 matrix protein 1 (m1 gene) 3. Influenza A virus(A/chicken/Burkina 1,529 bp AM503029.1 Faso/13.1/2006(H5N1)) mRNA fornucleoprotein linear mRNA GI:147846294 (np gene) 4. Influenza A virus(A/chicken/Burkina 827 bp AM503037.1 Faso/13.1/2006(H5N1)) mRNA for non-linear mRNA GI:147846310 structural protein (ns gene) 5. Influenza Avirus (A/chicken/Burkina 2,169 bp AM503046.1 Faso/13.1/2006(H5N1))partial mRNA for linear mRNA GI:147846328 polymerase (pa gene) 6.Influenza A virus (A/chicken/Burkina 2,259 bp AM503056.1Faso/13.1/2006(H5N1)) partial mRNA for linear mRNA GI:147846348polymerase basic protein 1 (pb1 gene) 7. Influenza A virus(A/chicken/Burkina 2,315 bp AM503067.1 Faso/13.1/2006(H5N1)) partialmRNA for linear mRNA GI:147846859 polymerase basic protein 2 (pb2 gene)8. Influenza A virus 1,736 bp DQ023145.1 (A/chicken/China/1/02(H5N1))hemagglutinin linear mRNA GI:66775624 (HA) mRNA, complete cds 9.Influenza A virus 1,509 bp DQ023146.1 (A/chicken/China/1/02(H5N1))nucleoprotein linear mRNA GI:66775626 (NP) mRNA, complete cds 10.Influenza A virus 1,379 bp DQ023147.1 (A/chicken/China/1/02(H5N1))neuraminidase linear mRNA GI:66775628 (NA) mRNA, complete cds 11.Influenza A virus 999 bp DQ650660.1 (A/chicken/Crimea/04/2005(H5N1))matrix linear mRNA GI:109692767 protein (M) mRNA, complete cds 12.Influenza A virus 850 bp DQ650662.1 (A/chicken/Crimea/04/2005(H5N1))linear mRNA GI:109692771 nonstructural protein (NS) mRNA, complete cds13. Influenza A virus 994 bp DQ650664.1 (A/chicken/Crimea/08/2005(H5N1))matrix linear mRNA GI:109692775 protein (M) mRNA, complete cds 14.Influenza A virus 1,532 bp DQ650666.1 (A/chicken/Crimea/08/2005(H5N1))linear mRNA GI:109692779 nucleoprotein (NP) mRNA, complete cds 15.Influenza A virus 850 bp DQ65066 7.1 (A/chicken/Crimea/08/2005(H5N1))linear mRNA GI:109692781 nonstructural protein (NS) mRNA, complete cds16. Influenza A virus 2,208 bp DQ650668.1(A/chicken/Crimea/08/2005(H5N1)) polymerase linear mRNA GI:109692783acidic protein (PA) mRNA, complete cds 17. Influenza A virus 2,305 bpDQ650670.1 (A/chicken/Crimea/08/2005(H5N1)) polymerase linear mRNAGI:109692787 basic protein 2 (PB2) mRNA, complete cds 18. Influenza Avirus 1,015 bp DQ676838.1 (A/chicken/Dovolnoe/03/2005(H5N1)) linear mRNAGI:108782527 hemagglutinin (HA) mRNA, partial cds 20. Influenza A virus2,341 bp DQ366327.1 (A/chicken/Guangxi/12/2004(H5N1)) polymerase linearmRNA GI:86753731 PB2 mRNA, complete cds 21. Influenza A virus 2,341 bpDQ366328.1 (A/chicken/Guangxi/12/2004(H5N1)) polymerase linear mRNAGI:86753741 PB1 mRNA, complete cds 22. Influenza A virus 2,233 bpDQ366329.1 (A/chicken/Guangxi/12/2004(H5N1)) PA protein linear mRNAGI:86753751 mRNA, complete cds 23. Influenza A virus 1,565 bp DQ366331.1(A/chicken/Guangxi/12/2004(H5N1)) linear mRNA GI:86753771 nucleocapsidmRNA, complete cds 24. Influenza A virus 1,027 bp DQ366333.1(A/chicken/Guangxi/12/2004(H5N1)) matrix linear mRNA GI:86753791 proteinmRNA, complete cds 25. Influenza A virus (A/chicken/Hong 1,718 bpAF057291.1 Kong/258/97(H5N1)) hemagglutinin mRNA, linear mRNA GI:3068720complete cds 26. Influenza A virus (A/chicken/Hong 1,318 bp AF057292.1Kong/258/97(H5N1)) neuraminidase mRNA, linear mRNA GI:3068722 partialcds 27. Influenza A virus (A/chicken/Hong 1,508 bp AF057293.1Kong/258/97(H5N1)) nucleoprotein mRNA, linear mRNA GI:3068724 completecds 28. Influenza A virus (A/Chicken/Hong 1,726 bp AF082034.1Kong/728/97 (H5N1)) hemagglutinin H5 mRNA, linear mRNA GI:4240435complete cds 29. Influenza A virus (A/Chicken/Hong 1,726 bp AF082035.1Kong/786/97 (H5N1)) hemagglutinin H5 mRNA, linear mRNA GI:4240437complete cds 30. Influenza A virus (A/chicken/Hong 1,726 bp AF082036.1Kong/915/97(H5N1)) hemagglutinin H5 mRNA, linear mRNA GI:4240439complete cds 31. Influenza A virus (A/chicken/Hong 1,091 bp AF082037.1Kong/990/97 (H5N1)) hemagglutinin H5 mRNA, linear mRNA GI:4240441partial cds 32. Influenza A virus 1,002 bp DQ676835.1(A/chicken/Krasnodar/01/2006(H5N1)) matrix linear mRNA GI:108782521protein 1 (M) mRNA, complete cds 33. Influenza A virus 850 bp DQ676837.1(A/chicken/Krasnodar/01/2006(H5N1)) linear mRNA GI:108782525nonstructural protein (NS) mRNA, complete cds 34. Influenza A virus1,754 bp DQ449632.1 (A/chicken/Kurgan/05/2005(H5N1)) linear mRNAGI:90289625 hemagglutinin (HA) mRNA, complete cds 35. Influenza A virus1,002 bp DQ449633.1 (A/chicken/Kurgan/05/2005(H5N1)) matrix linear mRNAGI:90289627 protein 1 (M) mRNA, complete cds 36. Influenza A virus 1,373bp DQ449634.1 (A/chicken/Kurgan/05/2005(H5N1)) linear mRNA GI:90289629neuraminidase (NA) mRNA, complete cds 37. Influenza A virus 1,540 bpDQ449635.1 (A/chicken/Kurgan/05/2005(H5N1)) linear mRNA GI:90289631nucleoprotein (NP) mRNA, complete cds 38. Influenza A virus 850 bpDQ449636.1 (A/chicken/Kurgan/05/2005(H5N1)) linear mRNA GI:90289633nonstructural protein (NS) mRNA, complete cds 39. Influenza A virus2,208 bp DQ449637.1 (A/chicken/Kurgan/05/2005(H5N1)) polymerase linearmRNA GI:90289635 acidic protein (PA) mRNA, complete cds 40. Influenza Avirus 2,316 bp DQ449638.1 (A/chicken/Kurgan/05/2005(H5N1)) polymeraselinear mRNA GI:90289637 basic protein 1 (PB1) mRNA, complete cds 41.Influenza A virus 2,316 bp DQ449639.1 (A/chicken/Kurgan/05/2005(H5N1))polymerase linear mRNA GI:90289646 basic protein 2 (PB2) mRNA, completecds 42. Influenza A virus 184 bp EU447276.1(A/chicken/Lobzenko/01/2008(H5N1)) linear mRNA GI:168998217hemagglutinin (HA) mRNA, partial cds 43. Influenza A virus 1,002 bpDQ676831.1 (A/chicken/Mahachkala/05/2006(H5N1)) matrix linear mRNAGI:108782513 protein 1 (M) mRNA, complete cds 44. Influenza A virus 850bp DQ676833.1 (A/chicken/Mahachkala/05/2006(H5N1)) linear mRNAGI:108782517 nonstructural protein (NS) mRNA, complete cds 45. InfluenzaA virus 1,531 bp AM503030.1 (A/chicken/Nigeria/AB13/2006(H5N1)) mRNA forlinear mRNA GI:147846296 nucleoprotein (np gene) 46. Influenza A virus827 bp AM503040.1 (A/chicken/Nigeria/AB13/2006(H5N1)) mRNA for linearmRNA GI:147846316 non-structural protein (ns gene) 47. Influenza A virus2,169 bp AM503051.1 (A/chicken/Nigeria/AB13/2006(H5N1)) partial linearmRNA GI:147846338 mRNA for polymerase (pa gene) 48. Influenza A virus2,259 bp AM503060.1 (A/chicken/Nigeria/AB13/2006(H5N1)) partial linearmRNA GI:147846845 mRNA for polymerase basic protein 1 (pb1 gene) 49.Influenza A virus 2,315 bp AM503071.1(A/chicken/Nigeria/AB13/2006(H5N1)) partial linear mRNA GI:147846867mRNA for polymerase basic protein 2 (pb2 gene) 70. Influenza A virus(A/chicken/Hong 1,055 bp DQ250158.1 Kong/3123.1/2002(H5N1))neuraminidase (NA) linear mRNA GI:82412012 mRNA, partial cds 75.Influenza A virus 1,754 bp DQ676834.1(A/chicken/Krasnodar/01/2006(H5N1)) linear mRNA GI:108782519hemagglutinin (HA) mRNA, complete cds 78. Influenza A virus 1,373 bpDQ676836.2 (A/chicken/Krasnodar/01/2006(H5N1)) linear mRNA GI:115520953neuraminidase (NA) mRNA, complete cds 91. Influenza A virus 184 bpEU447276.1 (A/chicken/Lobzenko/01/2008(H5N1)) linear mRNA GI:168998217hemagglutinin (HA) mRNA, partial cds 92. Influenza A virus 1,683 bpDQ676830.1 (A/chicken/Mahachkala/05/2006(H5N1)) linear mRNA GI:108782511hemagglutinin (HA) mRNA, complete cds 94. Influenza A virus 1,373 bpDQ676832.1 (A/chicken/Mahachkala/05/2006(H5N1)) linear mRNA GI:108782515neuraminidase (NA) mRNA, complete cds 96. Influenza A virus 433 bpDQ096567.1 (A/chicken/Malaysia/01/2004(H5N1)) linear mRNA GI:69145364neuramidase (NA) mRNA, partial cds 97. Influenza A virus 1,722 bpAM503002.1 (A/chicken/Nigeria/AB13/2006(H5N1)) partial linear mRNAGI:147846240 mRNA for hemagglutinin (ha gene) 98. Influenza A virus1,329 bp AM503020.1 (A/chicken/Nigeria/AB13/2006(H5N1)) partial linearmRNA GI:147846276 mRNA for neuraminidase (na gene) 105. Influenza Avirus 1,719 bp AM503003.1 (A/chicken/Nigeria/AB14/2006(H5N1)) partiallinear mRNA GI:147846242 mRNA for hemagglutinin (ha gene) 106. InfluenzaA virus 953 bp AM503011.1 (A/chicken/Nigeria/AB14/2006(H5N1)) partiallinear mRNA GI:147846258 mRNA for matrix protein 1 (m1 gene) 107.Influenza A virus 1,343 bp AM503025.1(A/chicken/Nigeria/AB14/2006(H5N1)) partial linear mRNA GI:147846286mRNA for neuraminidase (na gene) 108. Influenza A virus 827 bpAM503041.1 (A/chicken/Nigeria/AB14/2006(H5N1)) mRNA for linear mRNAGI:147846318 non-structural protein (ns gene) 109. Influenza A virus2,169 bp AM503054.1 (A/chicken/Nigeria/AB14/2006(H5N1)) partial linearmRNA GI:147846344 mRNA for polymerase (pa gene) 110. Influenza A virus2,259 bp AM503061.1 (A/chicken/Nigeria/AB14/2006(H5N1)) partial linearmRNA GI:147846847 mRNA for polymerase basic protein 1 (pb1 gene) 111.Influenza A virus 2,315 bp AM503072.1(A/chicken/Nigeria/AB14/2006(H5N1)) partial linear mRNA GI:147846869mRNA for polymerase basic protein 2 (pb2 gene) 112. Influenza A virus1,548 bp AM503034.2 (A/chicken/Nigeria/AB14/2006(H5N1)) mRNA for linearmRNA GI:149773117 nucleoprotein (np gene) 113. Influenza A virus 1,342bp AM503022.1 (A/chicken/Nigeria/BA210/2006(H5N1)) partial linear mRNAGI:147846280 mRNA for neuraminidase (na gene) 114. Influenza A virus1,321 bp AM503021.1 (A/chicken/Nigeria/BA211/2006(H5N1)) partial linearmRNA GI:147846278 mRNA for neuraminidase (na gene) 115. Influenza Avirus 2,315 bp AM503073.1 (A/chicken/Nigeria/BA211/2006(H5N1)) partiallinear mRNA GI:147846871 mRNA for polymerase basic protein 2 (pb2 gene)116. Influenza A virus 1,717 bp AM503004.1(A/chicken/Nigeria/FA4/2006(H5N1)) partial linear mRNA GI:147846244raRNA for hemagglutinin (ha gene) 117. Influenza A virus 989 bpAM503013.1 (A/chicken/Nigeria/FA4/2006(H5N1)) partial linear mRNAGI:147846262 mRNA for matrix protein 1 (m1 gene) 118. Influenza A virus1,321 bp AM503026.1 (A/chicken/Nigeria/FA4/2006(H5N1)) partial linearmRNA GI:147846288 mRNA for neuraminidase (na gene) 119. Influenza Avirus 827 bp AM503045.1 (A/chicken/Nigeria/FA4/2006(H5N1)) mRNA forlinear mRNA GI:147846326 non-structural protein (ns gene) 120. InfluenzaA virus 2,169 bp AM503055.1 (A/chicken/Nigeria/FA4/2006(H5N1)) partiallinear mRNA GI:147846346 mRNA for polymerase (pa gene) 121. Influenza Avirus 2,259 bp AM503064.1 (A/chicken/Nigeria/FA4/2006(H5N1)) partiallinear mRNA GI:147846853 mRNA for polymerase basic protein 1 (pb1 gene)122. Influenza A virus 2,224 bp AM503074.1(A/chicken/Nigeria/FA4/2006(H5N1)) partial linear mRNA GI:147846873 mRNAfor polymerase basic protein 2 (pb2 gene) 123. Influenza A virus 1,717bp AM502998.1 (A/chicken/Nigeria/FA6/2006(H5N1)) partial linear mRNAGI:147846232 mRNA for hemagglutinin (ha gene) 124. Influenza A virus 965bp AM503012.1 (A/chicken/Nigeria/FA6/2006(H5N1)) partial linear mRNAGI:147846260 mRNA for matrix protein 1 (m1 gene) 125. Influenza A virus1,327 bp AM503023.1 (A/chicken/Nigeria/FA6/2006(H5N1)) partial linearmRNA GI:147846282 mRNA for neuraminidase (na gene) 126. Influenza Avirus 1,543 bp AM503031.1 (A/chicken/Nigeria/FA6/2006(H5N1)) mRNA forlinear mRNA GI:147846298 nucleoprotein (np gene) 127. Influenza A virus2,169 bp AM503052.1 (A/chicken/Nigeria/FA6/2006(H5N1)) partial linearmRNA GI:147846340 mRNA for polymerase (pa gene) 128. Influenza A virus2,259 bp AM503063.1 (A/chicken/Nigeria/FA6/2006(H5N1)) partial linearmRNA GI:147846851 mRNA for polymerase basic protein 1 (pb1 gene) 129.Influenza A virus 1,710 bp AM502999.1 (A/chicken/Nigeria/FA7/2006(H5N1))partial linear mRNA GI:147846234 mRNA for hemagglutinin (ha gene) 130.Influenza A virus 1,001 bp AM503009.1 (A/chicken/Nigeria/FA7/2006(H5N1))partial linear mRNA GI:147846254 mRNA for matrix protein 1 (m1 gene)131. Influenza A virus 1,331 bp AM503018.1(A/chicken/Nigeria/FA7/2006(H5N1)) partial linear mRNA GI:147846272 mRNAfor neuraminidase (na gene) 132. Influenza A virus 1,531 bp AM503035.1(A/chicken/Nigeria/FA7/2006(H5N1)) mRNA for linear mRNA GI:147846306nucleoprotein (np gene) 133. Influenza A virus 827 bp AM503042.1(A/chicken/Nigeria/FA7/2006(H5N1)) mRNA for linear mRNA GI:147846320non-structural protein (ns gene) 134. Influenza A virus 2,169 bpAM503049.1 (A/chicken/Nigeria/FA7/2006(H5N1)) partial linear mRNAGI:147846334 mRNA for polymerase (pa gene) 135. Influenza A virus 2,259bp AM503057.1 (A/chicken/Nigeria/FA7/2006(H5N1)) partial linear mRNAGI:147846350 raRNA for polymerase basic protein 1 (pb1 gene) 136.Influenza A virus 2,315 bp AM503068.1 (A/chicken/Nigeria/FA7/2006(H5N1))partial linear mRNA GI:147846861 mRNA for polymerase basic protein 2(pb2 gene) 137. Influenza A virus 1,714 bp AM503001.1(A/chicken/Nigeria/IF10/2006(H5N1)) partial linear mRNA GI:147846238mRNA for hemagglutinin (ha gene) 138. Influenza A virus 990 bpAM503010.1 (A/chicken/Nigeria/IF10/2006(H5N1)) partial linear mRNAGI:147846256 mRNA for matrix protein 1 (m1 gene) 139. Influenza A virus1,332 bp AM503024.1 (A/chicken/Nigeria/IF10/2006(H5N1)) partial linearmRNA GI:147846284 mRNA for neuraminidase (na gene) 140. Influenza Avirus 827 bp AM503044.1 (A/chicken/Nigeria/IF10/2006(H5N1)) mRNA forlinear mRNA GI:147846324 non-structural protein (ns gene) 141. InfluenzaA virus 2,169 bp AM503053.1 (A/chicken/Nigeria/IF10/2006(H5N1)) partiallinear mRNA GI:147846342 mRNA for polymerase (pa gene) 142. Influenza Avirus 2,259 bp AM503059.1 (A/chicken/Nigeria/IF10/2006(H5N1)) partiallinear mRNA GI:147846843 mRNA for polymerase basic protein 1 (pb1 gene)143. Influenza A virus 2,315 bp AM503069.1(A/chicken/Nigeria/IF10/2006(H5N1)) partial linear mRNA GI:147846863mRNA for polymerase basic protein 2 (pb2 gene) 144. Influenza A virus1,550 bp AM503033.2 (A/chicken/Nigeria/IF10/2006(H5N1)) mRNA for linearmRNA GI:149773115 nucleoprotein (np gene) 145. Influenza A virus 1,719bp AM503005.1 (A/chicken/Nigeria/OD8/2006(H5N1)) partial linear mRNAGI:147846246 mRNA for hemagglutinin (ha gene) 146. Influenza A virus 989bp AM503014.1 (A/chicken/Nigeria/OD8/2006(H5N1)) partial linear mRNAGI:147846264 mRNA for matrix protein 1 (m1 gene) 147. Influenza A virus1,720 bp AM503000.1 (A/chicken/Nigeria/OD9/2006(H5N1)) partial linearmRNA GI:147846236 mRNA for hemagglutinin (ha gene) 148. Influenza Avirus 988 bp AM503015.1 (A/chicken/Nigeria/OD9/2006(H5N1)) partiallinear mRNA GI:147846266 mRNA for matrix protein 1 (m1 gene) 149.Influenza A virus 1,330 bp AM503019.1 (A/chicken/Nigeria/OD9/2006(H5N1))partial linear mRNA GI:147846274 mRNA for neuraminidase (na gene) 150.Influenza A virus 1,531 bp AM503032.1 (A/chicken/Nigeria/OD9/2006(H5N1))mRNA for linear mRNA GI:147846300 nucleoprotein (np gene) 151. InfluenzaA virus 827 bp AM503043.1 (A/chicken/Nigeria/OD9/2006(H5N1)) mRNA forlinear mRNA GI:147846322 non-structural protein (ns gene) 152. InfluenzaA virus 2,169 bp AM503050.1 (A/chicken/Nigeria/OD9/2006(H5N1)) partiallinear mRNA GI:147846336 mRNA for polymerase (pa gene) 153. Influenza Avirus 2,259 bp AM503058.1 (A/chicken/Nigeria/OD9/2006(H5N1)) partiallinear mRNA GI:147846841 raRNA for polymerase basic protein 1 (pb1 gene)154. Influenza A virus 2,315 bp AM503070.1(A/chicken/Nigeria/OD9/2006(H5N1)) partial linear mRNA GI:147846865 mRNAfor polymerase basic protein 2 (pb2 gene) 155. Influenza A virus 1,768bp X07869.1 (A/chicken/Scotland/59(H5N1)) mRNA for linear mRNA GI:60482haemaggiutinin precursor 156. Influenza A virus 1,445 bp AJ416625.1(A/chicken/Scotland/59(H5N1)) N1 gene for linear mRNA GI:39840717neuraminidase, genomic RNA 161. Influenza A virus 1,497 bp DQ208502.1(A/chicken/zz/02/2004(H5N1)) nucleoprotein linear mRNA GI:77158587 mRNA,complete cds 162. Influenza A virus (A/common 1,707 bp EF110519.1coot/Switzerland/V544/2006(H5N1)) linear mRNA GI:119394676 hemagglutinin(HA) gene, complete cds 163. Influenza A virus (A/domestic 1,735 bpEU190482.1 goose/Pavlodar/1/2005(H5N1)) hemagglutinin linear mRNAGI:158516739 (HA) mRNA, complete cds 164. Influenza A virus(A/duck/Eastern 1,401 bp EU429750.1 China/145/2003(H5N1)) segment 6linear mRNA GI:167859465 neuraminidase (NA) mRNA, complete cds 165.Influenza A virus (A/duck/Eastern 1,407 bp EU429731.1China/150/2003(H5N1)) segment 6 linear mRNA GI:167859427 neuraminidase(NA) mRNA, complete cds 166. Influenza A virus (A/duck/Eastern 1,398 bpEU429783.1 China/22/2005(H5N1)) segment 6 neuraminidase linear mRNAGI:167859531 (NA) mRNA, complete cds 167. Influenza A virus(A/duck/Eastern 1,398 bp EU429747.1 China/304/2002(H5N1)) segment 6linear mRNA GI:167859459 neuraminidase (NA) mRNA, complete cds 168.Influenza A virus (A/duck/Eastern 1,401 bp EU429727.1China/318/2002(H5N1)) segment 6 linear mRNA GI:167859419 neuraminidase(NA) mRNA, complete cds 169. Influenza A virus (A/duck/Eastern 1,399 bpEU429778.1 China/37/2006(H5N1)) segment 6 neuraminidase linear mRNAGI:167859521 (NA) mRNA, complete cds 170. Influenza A virus(A/duck/Eastern 1,398 bp EU429757.1 China/40/2005(H5N1)) segment 6neuraminidase linear mRNA GI:167859479 (NA) mRNA, complete cds 171.Influenza A virus (A/duck/Eastern 1,398 bp EU429779.1China/48/2006(H5N1)) segment 6 neuraminidase linear mRNA GI:167859523(NA) mRNA, complete cds 172. Influenza A virus (A/duck/Eastern 1,398 bpEU429763.1 China/51/2005(H5N1)) segment 6 neuraminidase linear mRNAGI:167859491 (NA) mRNA, complete cds 173. Influenza A virus(A/duck/Eastern 1,398 bp EU429758.1 China/54/2005(H5N1)) segment 6neuraminidase linear mRNA GI:167859481 (NA) mRNA, complete cds 174.Influenza A virus (A/duck/Eastern 1,398 bp EU429764.1China/58/2005(H5N1)) segment 6 neuraminidase linear mRNA GI:167859493(NA) mRNA, complete cds 175. Influenza A virus (A/duck/Eastern 1,398 bpEU429759.1 China/59/2005(H5N1)) segment 6 neuraminidase linear mRNAGI:167859483 (NA) mRNA, complete cds 176. Influenza A virus(A/duck/Eastern 1,398 bp EU429765.1 China/89/2005(H5N1)) segment 6neuraminidase linear mRNA GI:167859495 (NA) mRNA, complete cds 177.Influenza A virus (A/duck/Eastern 1,399 bp EU429785.1China/89/2006(H5N1)) segment 6 neuraminidase linear mRNA GI:167859535(NA) mRNA, complete cds 178. Influenza A virus (A/duck/Eastern 1,398 bpEU429717.1 China/97/2001(H5N1)) segment 6 neuraminidase linear mRNAGI:167859399 (NA) mRNA, complete cds 179. Influenza A virus 2,281 bpAY585504.1 (A/duck/Fujian/01/2002(H5N1)) polymerase linear mRNAGI:47156226 basic protein 2 (PB2) mRNA, complete cds 180. Influenza Avirus 760 bp AY585378.1 (A/duck/Fujian/01/2002(H5N1)) matrix proteinlinear mRNA GI:47156310 mRNA, complete cds 181. Influenza A virus 1,357bp AY585399.1 (A/duck/Fujian/01/2002(H5N1)) neuraminidase linear mRNAGI:47156352 (NA) mRNA, complete cds 182. Influenza A virus 1,497 bpAY585420.1 (A/duck/Fujian/01/2002(H5N1)) nucleoprotein linear mRNAGI:47156394 (NP) mRNA, complete cds 183. Influenza A virus 686 bpAY585441.1 (A/duck/Fujian/01/2002(H5N1)) nonstructural linear mRNAGI:47156436 protein 1 (NS1) mRNA, partial cds 184. Influenza A virus2,281 bp AY585505.1 (A/duck/Fujian/13/2002(H5N1)) polymerase linear mRNAGI:47156228 basic protein 2 (PB2) mRNA, complete cds 185. Influenza Avirus 761 bp AY585379.1 (A/duck/Fujian/13/2002(H5N1)) matrix proteinlinear mRNA GI:47156312 mRNA, complete cds 186. Influenza A virus 1,357bp AY585400.1 (A/duck/Fujian/13/2002(H5N1)) neuraminidase linear mRNAGI:47156354 (NA) mRNA, complete cds 187. Influenza A virus 1,499 bpAY585421.1 (A/duck/Fujian/13/2002(H5N1)) nucleoprotein linear mRNAGI:47156396 (NP) mRNA, complete cds 188. Influenza A virus 685 bpAY585442.1 (A/duck/Fujian/13/2002(H5N1)) nonstructural linear mRNAGI:47156438 protein 1 (NS1) mRNA, partial cds 189. Influenza A virus2,281 bp AY585506.1 (A/duck/Fujian/17/2001(H5N1)) polymerase linear mRNAGI:47156230 basic protein 2 (PB2) mRNA, complete cds 190. Influenza Avirus 759 bp AY585380.1 (A/duck/Fujian/17/2001(H5N1)) matrix proteinlinear mRNA GI:47156314 mRNA, complete cds 191. Influenza A virus 1,418bp AY585401.1 (A/duck/Fujian/17/2001(H5N1)) neuraminidase linear mRNAGI:47156356 (NA) mRNA, complete cds 192. Influenza A virus 1,498 bpAY585422.1 (A/duck/Fujian/17/2001(H5N1)) nucleoprotein linear mRNAGI:47156398 (NP) mRNA, complete cds 193. Influenza A virus 686 bpAY585443.1 (A/duck/Fujian/17/2001(H5N1)) nonstructural linear mRNAGI:47156440 protein 1 (NS1) mRNA, complete cds 194. Influenza A virus2,281 bp AY585507.1 (A/duck/Fujian/19/2000(H5N1)) polymerase linear mRNAGI:47156232 basic protein 2 (PB2) mRNA, complete cds 195. Influenza Avirus 760 bp AY585381.1 (A/duck/Fujian/19/2000(H5N1)) matrix proteinlinear mRNA GI:47156316 mRNA, complete cds 196. Influenza A virus 1,355bp AY585402.1 (A/duck/Fujian/19/2000(H5N1)) neuraminidase linear mRNAGI:47156358 (NA) mRNA, complete cds 197. Influenza A virus 1,498 bpAY585423.1 (A/duck/Fujian/19/2000(H5N1)) nucleoprotein linear mRNAGI:47156400 (NP) mRNA, complete cds 198. Influenza A virus 687 bpAY585444.1 (A/duck/Fujian/19/2000(H5N1)) nonstructural linear mRNAGI:47156442 protein 1 (NS1) mRNA, complete cds 199. Influenza A virus2,281 bp AY585508.1 (A/duck/Guangdong/01/2001(H5N1)) polymerase linearmRNA GI:47156234 basic protein 2 (PB2) mRNA, complete cds 200. InfluenzaA virus 760 bp AY585382.1 (A/duck/Guangdong/01/2001(H5N1)) matrix linearmRNA GI:47156318 protein mRNA, complete cds 201. Influenza A virus 1,414bp AY585403.1 (A/duck/Guangdong/01/2001(H5N1)) linear mRNA GI:47156360neuraminidase (NA) mRNA, complete cds 202. Influenza A virus 1,497 bpAY585424.1 (A/duck/Guangdong/01/2001(H5N1)) linear mRNA GI:47156402nucleoprotein (NP) mRNA, complete cds 203. Influenza A virus 687 bpAY585445.1 (A/duck/Guangdong/01/2001(H5N1)) linear mRNA GI:47156444nonstructural protein 1 (NS1) mRNA, complete cds 204. Influenza A virus2,280 bp AY585509.1 (A/duck/Guangdong/07/2000(H5N1)) polymerase linearmRNA GI:47156236 basic protein 2 (PB2) mRNA, complete cds 205. InfluenzaA virus 759 bp AY585383.1 (A/duck/Guangdong/07/2000(H5N1)) matrix linearmRNA GI:47156320 protein mRNA, complete cds 206. Influenza A virus 1,417bp AY585404.1 (A/duck/Guangdong/07/2000(H5N1)) linear mRNA GI:47156362neuraminidase (NA) mRNA, complete cds 207. Influenza A virus 1,497 bpAY585425.1 (A/duck/Guangdong/07/2000(H5N1)) linear mRNA GI:47156404nucleoprotein (NP) mRNA, complete cds 208. Influenza A virus 690 bpAY585446.1 (A/duck/Guangdong/07/2000(H5N1)) linear mRNA GI:47156446nonstructural protein 1 (NS1) mRNA, partial cds 209. Influenza A virus2,281 bp AY585510.1 (A/duck/Guangdong/12/2000(H5N1)) polymerase linearmRNA GI:47156238 basic protein 2 (PB2) mRNA, complete cds 210. InfluenzaA virus 760 bp AY585384.1 (A/duck/Guangdong/12/2000(H5N1)) matrix linearmRNA GI:47156322 protein mRNA, complete cds 211. Influenza A virus 1,359bp AY585405.1 (A/duck/Guangdong/12/2000(H5N1)) linear mRNA GI:47156364neuraminidase (NA) mRNA, complete cds 212. Influenza A virus 1,498 bpAY585426.1 (A/duck/Guangdong/12/2000(H5N1)) linear mRNA GI:47156406nucleoprotein (NP) mRNA, complete cds 213. Influenza A virus 685 bpAY585447.1 (A/duck/Guangdong/12/2000(H5N1)) linear mRNA GI:47156448nonstructural protein 1 (NS1) mRNA, partial cds 214. Influenza A virus2,281 bp AY585511.1 (A/duck/Guangdong/22/2002(H5N1)) polymerase linearmRNA GI:47156240 basic protein 2 (PB2) mRNA, complete cds 215. InfluenzaA virus 760 bp AY585385.1 (A/duck/Guangdong/22/2002(H5N1)) matrix linearmRNA GI:47156324 protein mRNA, complete cds 216. Influenza A virus 1,412bp AY585406.1 (A/duck/Guangdong/22/2002(H5N1)) linear mRNA GI:47156366neuraminidase (NA) mRNA, complete cds 217. Influenza A virus 1,499 bpAY585427.1 (A/duck/Guangdong/22/2002(H5N1)) linear mRNA GI:47156408nucleoprotein (NP) mRNA, complete cds 218. Influenza A virus 682 bpAY585448.1 (A/duck/Guangdong/22/2002(H5N1)) linear mRNA GI:47156450nonstructural protein 1 (NS1) mRNA, complete cds 219. Influenza A virus2,281 bp AY585512.1 (A/duck/Guangdong/40/2000(H5N1)) polymerase linearmRNA GI:47156242 basic protein 2 (PB2) mRNA, complete cds 220. InfluenzaA virus 760 bp AY585386.1 (A/duck/Guangdong/40/2000(H5N1)) matrix linearmRNA GI:47156326 protein mRNA, complete cds 221. Influenza A virus 1,401bp AY585407.1 (A/duck/Guangdong/40/2000(H5N1)) linear mRNA GI:47156368neuraminidase (NA) mRNA, partial cds 222. Influenza A virus 1,499 bpAY585428.1 (A/duck/Guangdong/40/2000(H5N1)) linear mRNA GI:47156410nucleoprotein (NP) mRNA, complete cds 223. Influenza A virus 689 bpAY585449.1 (A/duck/Guangdong/40/2000(H5N1)) linear mRNA GI:47156452nonstructural protein 1 (NS1) mRNA, partial cds 224. Influenza A virus2,281 bp AY585513.1 (A/duck/Guangxi/07/1999(H5N1)) polymerase linearmRNA GI:47156244 basic protein 2 (PB2) mRNA, complete cds 225. InfluenzaA virus 760 bp AY585387.1 (A/duck/Guangxi/07/1999(H5N1)) matrix linearmRNA GI:47156328 protein mRNA, complete cds 226. Influenza A virus 1,421bp AY585408.1 (A/duck/Guangxi/07/1999(H5N1)) neuraminidase linear mRNAGI:47156370 (NA) mRNA, complete cds 227. Influenza A virus 1,501 bpAY585429.1 (A/duck/Guangxi/07/1999(H5N1)) nucleoprotein linear mRNAGI:47156412 (NP) mRNA, complete cds 228. Influenza A virus 687 bpAY585450.1 (A/duck/Guangxi/07/1999(H5N1)) nonstructural linear mRNAGI:47156454 protein 1 (NS1) mRNA, partial cds 229. Influenza A virus 875bp DQ366342.1 (A/duck/Guangxi/13/2004(H5N1)) nonstructural linear mRNAGI:86753723 protein 1 mRNA, complete cds 230. Influenza A virus 2,341 bpDQ366335.1 (A/duck/Guangxi/13/2004(H5N1)) polymerase linear mRNAGI:86753733 PB2 mRNA, complete cds 231. Influenza A virus 2,341 bpDQ366336.1 (A/duck/Guangxi/13/2004(H5N1)) polymerase linear mRNAGI:86753743 PB1 mRNA, complete cds 232. Influenza A virus 2,233 bpDQ366337.1 (A/duck/Guangxi/13/2004(H5N1)) PA protein linear mRNAGI:86753753 mRNA, complete cds 233. Influenza A virus 1,776 bpDQ366338.1 (A/duck/Guangxi/13/2004(H5N1)) hemagglutinin linear mRNAGI:86753763 mRNA, complete cds 234. Influenza A virus 1,565 bpDQ366339.1 (A/duck/Guangxi/13/2004(H5N1)) nucleocapsid linear mRNAGI:86753773 mRNA, complete cds 235. Influenza A virus 1,378 bpDQ366340.1 (A/duck/Guangxi/13/2004(H5N1)) neuraminidase linear mRNAGI:86753783 mRNA, complete cds 236. Influenza A virus 1,027 bpDQ366341.1 (A/duck/Guangxi/13/2004(H5N1)) matrix linear mRNA GI:86753793protein mRNA, complete cds 237. Influenza A virus 2,281 bp AY585514.1(A/duck/Guangxi/22/2001(H5N1)) polymerase linear mRNA GI:47156246 basicprotein 2 (PB2) mRNA, complete cds 238. Influenza A virus 757 bpAY585388.1 (A/duck/Guangxi/22/2001(H5N1)) matrix linear mRNA GI:47156330protein mRNA, partial cds 239. Influenza A virus 1,414 bp AY585409.1(A/duck/Guangxi/22/2001(H5N1)) neuraminidase linear mRNA GI:47156372(NA) mRNA, complete cds 240. Influenza A virus 1,498 bp AY585430.1(A/duck/Guangxi/22/2001(H5N1)) nucleoprotein linear mRNA GI:47156414(NP) mRNA, complete cds 241. Influenza A virus 687 bp AY585451.1(A/duck/Guangxi/22/2001(H5N1)) nonstructural linear mRNA GI:47156456protein 1 (NS1) mRNA, complete cds 242. Influenza A virus 2,281 bpAY585515.1 (A/duck/Guangxi/35/2001(H5N1)) polymerase linear mRNAGI:47156248 basic protein 2 (PB2) mRNA, complete cds 243. Influenza Avirus 760 bp AY585389.1 (A/duck/Guangxi/35/2001(H5N1)) matrix linearmRNA GI:47156332 protein mRNA, complete cds 244. Influenza A virus 1,414bp AY585410.1 (A/duck/Guangxi/35/2001(H5N1)) neuraminidase linear mRNAGI:47156374 (NA) mRNA, complete cds 245. Influenza A virus 1,498 bpAY585431.1 (A/duck/Guangxi/35/2001(H5N1)) nucleoprotein linear mRNAGI:47156416 (NP) mRNA, complete cds 246. Influenza A virus 685 bpAY585452.1 (A/duck/Guangxi/35/2001(H5N1)) nonstructural linear mRNAGI:47156458 protein 1 (NS1) mRNA, complete cds 247. Influenza A virus2,281 bp AY585516.1 (A/duck/Guangxi/50/2001(H5N1)) polymerase linearmRNA GI:47156250 basic protein 2 (PB2) mRNA, complete cds 248. InfluenzaA virus 760 bp AY585398.1 (A/duck/Guangxi/50/2001(H5N1)) matrix linearmRNA GI:47156350 protein mRNA, complete cds 249. Influenza A virus 1,354bp AY585411.1 (A/duck/Guangxi/50/2001(H5N1)) neuraminidase linear mRNAGI:47156376 (NA) mRNA, complete cds 250. Influenza A virus 1,498 bpAY585432.1 (A/duck/Guangxi/50/2001(H5N1)) nucleoprotein linear mRNAGI:47156418 (NP) mRNA, complete cds 251. Influenza A virus 686 bpAY585453.1 (A/duck/Guangxi/50/2001(H5N1)) nonstructural linear mRNAGI:47156460 protein 1 (NS1) mRNA, complete cds 252. Influenza A virus2,281 bp AY585517.1 (A/duck/Guangxi/53/2002(H5N1)) polymerase linearmRNA GI:47156252 basic protein 2 (PB2) mRNA, complete cds 253. InfluenzaA virus 760 bp AY585390.1 (A/duck/Guangxi/53/2002(H5N1)) matrix linearmRNA GI:47156334 protein mRNA, complete cds 254. Influenza A virus 1,361bp AY585412.1 (A/duck/Guangxi/53/2002(H5N1)) neuraminidase linear mRNAGI:47156378 (NA) mRNA, complete cds 255. Influenza A virus 1,498 bpAY585433.1 (A/duck/Guangxi/53/2002(H5N1)) nucleoprotein linear mRNAGI:47156420 (NP) mRNA, complete cds 256. Influenza A virus 687 bpAY585454.1 (A/duck/Guangxi/53/2002(H5N1)) nonstructural linear mRNAGI:47156462 protein 1 (NS1) mRNA, partial cds 257. Influenza A virus1,754 bp DQ449640.1 (A/duck/Kurgan/08/2005(H5N1)) hemagglutinin linearmRNA GI:90289674 (HA) mRNA, complete cds 258. Influenza A virus 1,002 bpDQ449641.1 (A/duck/Kurgan/08/2005(H5N1)) matrix protein linear mRNAGI:90289689 1 (M) mRNA, complete cds 259. Influenza A virus 1,373 bpDQ449642.1 (A/duck/Kurgan/08/2005(H5N1)) neuraminidase linear mRNAGI:90289708 (NA) mRNA, complete cds 260. Influenza A virus 1,540 bpDQ449643.1 (A/duck/Kurgan/08/2005(H5N1)) nucleoprotein linear mRNAGI:90289731 (NP) mRNA, complete cds 261. Influenza A virus 850 bpDQ449644.1 (A/duck/Kurgan/08/2005(H5N1)) nonstructural linear mRNAGI:90289739 protein (NS) mRNA, complete cds 262. Influenza A virus 2,208bp DQ449645.1 (A/duck/Kurgan/08/2005(H5N1)) polymerase linear mRNAGI:90289756 acidic protein (PA) mRNA, complete cds 263. Influenza Avirus 2,316 bp DQ449646.1 (A/duck/Kurgan/08/2005(H5N1)) polymeraselinear mRNA GI:90289774 basic protein 1 (PB1) mRNA, complete cds 264.Influenza A virus 2,316 bp DQ449647.1 (A/duck/Kurgan/08/2005(H5N1))polymerase linear mRNA GI:90289783 basic protein 2 (PB2) mRNA, completecds 266. Influenza A virus 2,281 bp AY585518.1(A/duck/Shanghai/08/2001(H5N1)) polymerase linear mRNA GI:47156254 basicprotein 2 (PB2) mRNA, complete cds 267. Influenza A virus 760 bpAY585391.1 (A/duck/Shanghai/08/2001(H5N1)) matrix linear mRNAGI:47156336 protein mRNA, complete cds 268. Influenza A virus 1,357 bpAY585413.1 (A/duck/Shanghai/08/2001(H5N1)) linear mRNA GI:47156380neuraminidase (NA) mRNA, complete cds 269. Influenza A virus 1,498 bpAY585434.1 (A/duck/Shanghai/08/2001(H5N1)) linear mRNA GI:47156422nucleoprotein (NP) mRNA, complete cds 270. Influenza A virus 685 bpAY585455.1 (A/duck/Shanghai/08/2001(H5N1)) linear mRNA GI:47156464nonstructural protein 1 (NS1) mRNA, partial cds 271. Influenza A virus2,281 bp AY585519.1 (A/duck/Shanghai/13/2001(H5N1)) polymerase linearmRNA GI:47156256 basic protein 2 (PB2) mRNA, complete cds 272. InfluenzaA virus 760 bp AY585392.1 (A/duck/Shanghai/13/2001(H5N1)) matrix linearmRNA GI:47156338 protein mRNA, complete cds 273. Influenza A virus 1,417bp AY585414.1 (A/duck/Shanghai/13/2001(H5N1)) linear mRNA GI:47156382neuraminidase (NA) mRNA, complete cds 274. Influenza A virus 1,499 bpAY585435.1 (A/duck/Shanghai/13/2001(H5N1)) linear mRNA GI:47156424nucleoprotein (NP) mRNA, complete cds 275. Influenza A virus 685 bpAY585456.1 (A/duck/Shanghai/13/2001(H5N1)) linear mRNA GI:47156466nonstructural protein 1 (NS1) mRNA, complete cds 276. Influenza A virus2,281 bp AY585520.1 (A/duck/Shanghai/35/2002(H5N1)) polymerase linearmRNA GI:47156258 basic protein 2 (PB2) mRNA, complete cds 277. InfluenzaA virus 760 bp AY585393.1 (A/duck/Shanghai/35/2002(H5N1)) matrix linearmRNA GI:47156340 protein mRNA, complete cds 278. Influenza A virus 1,363bp AY585415.1 (A/duck/Shanghai/35/2002(H5N1)) linear mRNA GI:47156384neuraminidase (NA) mRNA, complete cds 279. Influenza A virus 1,498 bpAY585436.1 (A/duck/Shanghai/35/2002(H5N1)) linear mRNA GI:47156426nucleoprotein (NP) mRNA, complete cds 280. Influenza A virus 685 bpAY585457.1 (A/duck/Shanghai/35/2002(H5N1)) linear mRNA GI:47156468nonstructural protein 1 (NS1) mRNA, partial cds 281. Influenza A virus2,281 bp AY585521.1 (A/duck/Shanghai/37/2002(H5N1)) polymerase linearmRNA GI:47156260 basic protein 2 (PB2) mRNA, complete cds 282. InfluenzaA virus 760 bp AY585394.1 (A/duck/Shanghai/37/2002(H5N1)) matrix linearmRNA GI:47156342 protein mRNA, complete cds 283. Influenza A virus 1,361bp AY585416.1 (A/duck/Shanghai/37/2002(H5N1)) linear mRNA GI:47156386neuraminidase (NA) mRNA, complete cds 284. Influenza A virus 1,497 bpAY585437.1 (A/duck/Shanghai/37/2002(H5N1)) linear mRNA GI:47156428nucleoprotein (NP) mRNA, complete cds 285. Influenza A virus 685 bpAY585458.1 (A/duck/Shanghai/37/2002(H5N1)) linear mRNA GI:47156470nonstructural protein 1 (NS1) mRNA, partial cds 286. Influenza A virus2,282 bp AY585522.1 (A/duck/Shanghai/38/2001(H5N1)) polymerase linearmRNA GI:47156262 basic protein 2 (PB2) mRNA, complete cds 287. InfluenzaA virus 760 bp AY585395.1 (A/duck/Shanghai/38/2001(H5N1)) matrix linearmRNA GI:47156344 protein mRNA, complete cds 288. Influenza A virus 1,355bp AY585417.1 (A/duck/Shanghai/38/2001(H5N1)) linear mRNA GI:47156388neuraminidase (NA) mRNA, complete cds 289. Influenza A virus 1,499 bpAY585438.1 (A/duck/Shanghai/38/2001(H5N1)) linear mRNA GI:47156430nucleoprotein (NP) mRNA, complete cds 290. Influenza A virus 692 bpAY585459.1 (A/duck/Shanghai/38/2001(H5N1)) linear mRNA GI:47156472nonstructural protein 1 (NS1) mRNA, partial cds 291. Influenza A virus875 bp DQ354059.1 (A/duck/Sheyang/1/2005(H5N1)) nonstructural linearmRNA GI:87128643 protein (NS) mRNA, complete cds 292. Influenza A virus1,748 bp DQ861291.1 (A/duck/Tuva/01/2006(H5N1)) hemagglutinin linearmRNA GI:112820195 (HA) mRNA, complete cds 293. Influenza A virus 991 bpDQ861292.1 (A/duck/Tuva/01/2006(H5N1)) matrix protein 1 linear mRNAGI:112820197 (Ml) mRNA, complete cds 294. Influenza A virus 1,364 bpDQ861293.1 (A/duck/Tuva/01/2006(H5N1)) neuraminidase linear mRNAGI:112820199 (NA) mRNA, complete cds 295. Influenza A virus 1,531 bpDQ861294.1 (A/duck/Tuva/01/2006(H5N1)) nucleoprotein linear mRNAGI:112820201 (NP) mRNA, complete cds 296. Influenza A virus 842 bpDQ861295.1 (A/duck/Tuva/01/2006(H5N1)) nonstructural linear mRNAGI:112820203 protein (NS) mRNA, complete cds 297. Influenza A virus 890bp DQ366310.1 (A/duck/Vietnam/1/2005(H5N1)) nonstructural linear mRNAGI:86753715 protein 1 mRNA, complete cds 298. Influenza A virus 2,341 bpDQ366303.1 (A/duck/Vietnam/1/2005(H5N1)) polymerase PB2 linear mRNAGI:86753725 mRNA, complete cds 299. Influenza A virus 2,341 bpDQ366304.1 (A/duck/Vietnam/1/2005(H5N1)) polymerase PB1 linear mRNAGI:86753735 mRNA, complete cds 300. Influenza A virus 2,233 bpDQ366305.1 (A/duck/Vietnam/1/2005(H5N1)) PA protein linear mRNAGI:86753745 mRNA, complete cds 301. Influenza A virus 1,779 bpDQ366306.1 (A/duck/Vietnam/1/2005(H5N1)) hemagglutinin linear mRNAGI:86753755 mRNA, complete cds 302. Influenza A virus 1,565 bpDQ366307.1 (A/duck/Vietnam/1/2005(H5N1)) nucleocapsid linear mRNAGI:86753765 mRNA, complete cds 303. Influenza A virus 1,401 bpDQ366308.1 (A/duck/Vietnam/1/2005(H5N1)) neuraminidase linear mRNAGI:86753775 mRNA, complete cds 304. Influenza A virus 1,027 bpDQ366309.1 (A/duck/Vietnam/1/2005(H5N1)) matrix protein linear mRNAGI:86753785 mRNA, complete cds 305. Influenza A virus 890 bp DQ366326.1(A/duck/Vietnam/8/05(H5N1)) nonstructural linear mRNA GI:86753719protein 1 mRNA, complete cds 306. Influenza A virus 2,341 bp DQ366319.1(A/duck/Vietnam/8/05(H5N1)) polymerase PB2 linear mRNA GI:86753729 mRNA,complete cds 307. Influenza A virus 2,341 bp DQ366320.1(A/duck/Vietnam/8/05(H5N1)) polymerase PB1 linear mRNA GI:86753739 mRNA,complete cds 308. Influenza A virus 2,233 bp DQ366321.1(A/duck/Vietnam/8/05(H5N1)) PA protein mRNA, linear mRNA GI:86753749complete cds 309. Influenza A virus 1,779 bp DQ366322.1(A/duck/Vietnam/8/05(H5N1)) hemagglutinin linear mRNA GI:86753759 mRNA,complete cds 310. Influenza A virus 1,565 bp DQ366323.1(A/duck/Vietnam/8/05(H5N1)) nucleocapsid linear mRNA GI:86753769 mRNA,complete cds 311. Influenza A virus 1,401 bp DQ366324.1(A/duck/Vietnam/8/05(H5N1)) neuraminidase linear mRNA GI:86753779 mRNA,complete cds 312. Influenza A virus 1,027 bp DQ366325.1(A/duck/Vietnam/8/05(H5N1)) matrix protein linear mRNA GI:86753789 mRNA,complete cds 313. Influenza A virus 876 bp DQ354060.1(A/duck/Yangzhou/232/2004(H5N1)) linear mRNA GI:87128645 nonfunctionalnonstructural protein (NS) mRNA, complete sequence 314. Influenza Avirus 2,281 bp AY585523.1 (A/duck/Zhejiang/11/2000(H5N1)) polymeraselinear mRNA GI:47156264 basic protein 2 (PB2) mRNA, complete cds 315.Influenza A virus 760 bp AY585396.1 (A/duck/Zhejiang/11/2000(H5N1))matrix linear mRNA GI:47156346 protein mRNA, complete cds 316. InfluenzaA virus 1,352 bp AY585418.1 (A/duck/Zhejiang/11/2000(H5N1)) linear mRNAGI:47156390 neuraminidase (NA) mRNA, complete cds 317. Influenza A virus1,498 bp AY585439.1 (A/duck/Zhejiang/11/2000(H5N1)) linear mRNAGI:47156432 nucleoprotein (NP) mRNA, complete cds 318. Influenza A virus687 bp AY585460.1 (A/duck/Zhejiang/11/2000(H5N1)) linear mRNAGI:47156474 nonstructural protein 1 (NS1) mRNA, partial cds 319.Influenza A virus 2,281 bp AY585524.1 (A/duck/Zhejiang/52/2000(H5N1))polymerase linear mRNA GI:47156266 basic protein 2 (PB2) mRNA, completecds 320. Influenza A virus 760 bp AY585397.1(A/duck/Zhejiang/52/2000(H5N1)) matrix linear mRNA GI:47156348 proteinmRNA, complete cds 321. Influenza A virus 1,423 bp AY585419.1(A/duck/Zhejiang/52/2000(H5N1)) linear mRNA GI:47156392 neuraminidase(NA) mRNA, complete cds 322. Influenza A virus 1,499 bp AY585440.1(A/duck/Zhejiang/52/2000(H5N1)) linear mRNA GI:47156434 nucleoprotein(NP) mRNA, complete cds 323. Influenza A virus 686 bp AY585461.1(A/duck/Zhejiang/52/2000(H5N1)) linear mRNA GI:47156476 nonstructuralprotein 1 (NS1) mRNA, complete cds 324. Influenza A virus (A/Egypt/0636-1,749 bp EF382359.1 NAMRU3/2007(H5N1)) hemagglutinin (HA) mRNA, linearmRNA GI:124244205 complete cds 325. Influenza A virus 1,707 bpEF110518.1 (A/goosander/Switzerland/V82/06 (H5N1)) linear mRNAGI:119394674 hemagglutinin (HA) gene, complete cds 326. Influenza Avirus 1,707 bp AF148678.1 (A/goose/Guangdong/1/96/(H5N1)) linear mRNAGI:5007022 hemagglutinin mRNA, complete cds 327. Influenza A virus 1,779bp DQ201829.1 (A/Goose/Huadong/1/2000(H5N1)) hemagglutinin linear mRNAGI:76786306 (HA) mRNA, complete cds 328. Influenza A virus 1,458 bpDQ201830.1 (A/Goose/Huadong/1/2000(H5N1)) neuraminidase linear mRNAGI:76786308 (NA) mRNA, complete cds 329. Influenza A virus 2,287 bpEF446768.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNA GI:126428373polymerase PB1 (PB1) mRNA, partial cds 330. Influenza A virus 2,274 bpEF446769.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNA GI:126428375polymerase PB2 (PB2) mRNA, partial cds 331. Influenza A virus 2,175 bpEF446770.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNA GI:126428377polymerase PA (PA) mRNA, complete cds 332. Influenza A virus 1,735 bpEF446771.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNA GI:126428379hemagglutinin (HA) mRNA, complete cds 333. Influenza A virus 1,473 bpEF446772.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNA GI:126428381nucleocapsid protein (NP) mRNA, partial cds 334. Influenza A virus 1,311bp EF446773.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNAGI:126428383 neuraminidase (NA) mRNA, partial cds 335. Influenza A virus971 bp EF446774.1 (A/goose/Hungary/2823/2/2007(H5N1)) matrix linear mRNAGI:126428385 protein 1 (M1) mRNA, partial cds 336. Influenza A virus 795bp EF446775.1 (A/goose/Hungary/2823/2/2007(H5N1)) linear mRNAGI:126428387 nonstructural protein 1 (NS1) mRNA, partial cds 337.Influenza A virus 2,277 bp EF446776.1 (A/goose/Hungary/3413/2007(H5N1))polymerase linear mRNA GI:126428389 PB1 (PB1) mRNA, partial cds 338.Influenza A virus 2,274 bp EF446777.1 (A/goose/Hungary/3413/2007(H5N1))polymerase linear mRNA GI:126428391 PB2 (PB2) mRNA, partial cds 339.Influenza A virus 2,163 bp EF446778.1 (A/goose/Hungary/3413/2007 (H5N1))polymerase linear mRNA GI:126428393 PA (PA) mRNA, partial cds 340.Influenza A virus 1,722 bp EF446779.1 (A/goose/Hungary/3413/2007 (H5N1))linear mRNA GI:126428395 hemagglutinin (HA) mRNA, complete cds 341.Influenza A virus 1,463 bp EF446780.1 (A/goose/Hungary/3413/2007 (H5N1))linear mRNA GI:126428397 nucleocapsid protein (NP) mRNA, partial cds342. Influenza A virus 1,289 bp EF446781.1(A/goose/Hungary/3413/2007(H5N1)) linear mRNA GI:126428399 neuraminidase(NA) mRNA, partial cds 343. Influenza A virus 955 bp EF446782.1(A/goose/Hungary/3413/2007(H5N1)) matrix linear mRNA GI:126428401protein 1 (M1) mRNA, partial cds 344. Influenza A virus 805 bpEF446783.1 (A/goose/Hungary/3413/2007(H5N1)) linear mRNA GI:126428403nonstructural protein 1 (NS1) mRNA, complete cds 345. Influenza A virus877 bp DQ354061.1 (A/goose/jiangsu/131/2002(H5N1)) linear mRNAGI:87128646 nonfunctional nonstructural protein (NS) mRNA, completesequence 346. Influenza A virus 875 bp DQ354062.1(A/goose/Jiangsu/220/2003(H5N1)) linear mRNA GI:87128647 nonstructuralprotein (NS) mRNA, complete cds 347. Influenza A virus 1,754 bpDQ676840.1 (A/goose/Krasnoozerka/627/2005(H5N1)) linear mRNAGI:108782531 hemagglutinin (HA) mRNA, complete cds 348. Influenza Avirus 1,530 bp DQ676841.1 (A/goose/Krasnoozerka/627/2005(H5N1)) linearmRNA GI:108782533 nucleoprotein (NP) mRNA, complete cds 349. Influenza Avirus 850 bp DQ676842.1 (A/goose/Krasnoozerka/627/2005(H5N1)) linearmRNA GI:108782535 nonstructural protein (NS) mRNA, complete cds 350.Influenza A virus 890 bp DQ366318.1 (A/goose/Vietnam/3/05(H5N1))nonstructural linear mRNA GI:86753717 protein 1 mRNA, complete cds 351.Influenza A virus 2,341 bp DQ366311.1 (A/goose/Vietnam/3/05(H5N1))polymerase PB2 linear mRNA GI:86753727 mRNA, complete cds 352. InfluenzaA virus 2,341 bp DQ366312.1 (A/goose/Vietnam/3/05(H5N1)) polymerase PB1linear mRNA GI:86753737 mRNA, complete cds 353. Influenza A virus 2,233bp DQ366313.1 (A/goose/Vietnam/3/05(H5N1)) PA protein linear mRNAGI:86753747 mRNA, complete cds 354. Influenza A virus 1,779 bpDQ366314.1 (A/goose/Vietnam/3/05(H5N1)) hemagglutinin linear mRNAGI:86753757 mRNA, complete cds 355. Influenza A virus 1,565 bpDQ366315.1 (A/goose/Vietnam/3/05(H5N1)) nucleocapsid linear mRNAGI:86753767 mRNA, complete cds 356. Influenza A virus 1,401 bpDQ366316.1 (A/goose/Vietnam/3/05(H5N1)) neuraminidase linear mRNAGI:86753777 mRNA, complete cds 357. Influenza A virus 1,027 bpDQ366317.1 (A/goose/Vietnam/3/05(H5N1)) matrix protein linear mRNAGI:86753787 mRNA, complete cds 358. Influenza A virus 1,700 bpAF082043.1 (A/gull/Pennsylvania/4175/83(H5N1)) linear mRNA GI:4240453hemagglutinin H5 mRNA, partial cds 360. Influenza A virus 1,388 bpAF028708.1 (A/HongKong/156/97(H5N1)) neuraminidase linear mRNAGI:2865377 mRNA, complete cds 361. Influenza A virus 1,741 bp AF028709.1(A/HongKong/156/97(H5N1)) hemagglutinin linear mRNA GI:2865379 mRNA,complete cds 362. Influenza A virus 1,549 bp AF028710.1(A/HongKong/156/97(H5N1)) nucleoprotein linear mRNA GI:2865381 mRNA,complete cds 363. Influenza A virus (A/hooded 1,451 bp AM503028.1vulture/Burkina Faso/1/2006(H5N1)) partial linear mRNA GI:147846292 mRNAfor nucleoprotein (np gene) 364. Influenza A virus (A/hooded 827 bpAM503038.1 vulture/Burkina Faso/1/2006(H5N1)) mRNA for linear mRNAGI:147846312 non-structural protein (ns gene) 365. Influenza A virus(A/hooded 2,169 bp AM503047.1 vulture/Burkina Faso/1/2006(H5N1)) partiallinear mRNA GI:147846330 mRNA for polymerase (pa gene) 366. Influenza Avirus (A/hooded 1,686 bp AM503065.1 vulture/Burkina Faso/1/2006(H5N1))partial linear mRNA GI:147846855 mRNA for polymerase basic protein 1(pb1 gene) 367. Influenza A virus (A/hooded 977 bp AM503006.1vulture/Burkina Faso/2/2006(H5N1)) partial linear mRNA GI:147846248 mRNAfor matrix protein 1 (m1 gene) 368. Influenza A virus (A/hooded 1,336 bpAM503017.1 vulture/Burkina Faso/2/2006(H5N1)) partial linear mRNAGI:147846270 mRNA for neuraminidase (na gene) 369. Influenza A virus(A/hooded 1,499 bp AM503027.1 vulture/Burkina Faso/2/2006(H5N1)) partiallinear mRNA GI:147846290 mRNA for nucleoprotein (np gene) 370. InfluenzaA virus (A/hooded 827 bp AM503039.1 vulture/Burkina Faso/2/2006(H5N1))mRNA for linear mRNA GI:147846314 non-structural protein (ns gene) 371.Influenza A virus (A/hooded 2,169 bp AM503048.1 vulture/BurkinaFaso/2/2006(H5N1)) partial linear mRNA GI:147846332 mRNA for polymerase(pa gene) 372. Influenza A virus (A/hooded 2,259 bp AM503062.1vulture/Burkina Faso/2/2006(H5N1)) partial linear mRNA GI:147846849 mRNAfor polymerase basic protein 1 (pb1 gene) 373. Influenza A virus(A/hooded 2,315 bp AM503066.1 vulture/Burkina Faso/2/2006(H5N1)) partiallinear mRNA GI:147846857 mRNA for polymerase basic protein 2 (pb2 gene)374. Influenza A virus 294 bp EU014135.1 (A/Indonesia/CDC177/2005(H5N1))M2 protein linear mRNA GI:151336850 mRNA, complete cds 375. Influenza Avirus 294 bp EU014138.1 (A/Indonesia/CDC298/2005(H5N1)) M2 proteinlinear mRNA GI:151336856 mRNA, complete cds 376. Influenza A virus 294bp EU014136.1 (A/Indonesia/CDC485/2006(H5N1)) M2 protein linear mRNAGI:151336852 mRNA, complete cds 377. Influenza A virus 294 bp EU014134.1(A/Indonesia/CDC530/2006(H5N1)) M2 protein linear mRNA GI:151336848mRNA, complete cds 378. Influenza A virus 294 bp EU014133.1(A/Indonesia/CDC535/2006(H5N1)) M2 protein linear mRNA GI:151336846mRNA, complete cds 379. Influenza A virus 294 bp EU014132.1(A/Indonesia/CDC540/2006(H5N1)) M2 protein linear mRNA GI:151336844mRNA, complete cds 380. Influenza A virus 294 bp EU014137.1(A/Indonesia/CDC561/2006(H5N1)) M2 protein linear mRNA GI:151336854mRNA, complete cds 381. Influenza A virus 294 bp EU014139.1(A/Indonesia/CDC60/2005(H5N1)) M2 protein linear mRNA GI:151336858 mRNA,complete cds 382. Influenza A virus 996 bp U79453.1(A/mallard/Wisconsin/428/75(H5N1)) linear mRNA GI:1840071 hemagglutininmRNA, partial cds 383. Influenza A virus 441 bp JN157759.1(A/ostrich/VRLCU/Egypt/2011(H5N1)) segment 4 linear mRNA GI:338223304hemagglutinin (HA) mRNA, partial cds 384. Influenza A virus 875 bpDQ354063.1 (A/quail/yunnan/092/2002(H5N1)) linear mRNA GI:87128649nonstructural protein (NS) mRNA, complete cds 385. Influenza A virus1,472 bp AB241613.1 (A/R(Turkey/Ontario/7732/66- linear mRNA GI:82581222Bellamy/42)(H5N1)) HA mRNA for hemagglutinin, partial cds 386. InfluenzaA virus (A/Thailand/LFPN- 1,350 bp AY679513.1 2004/2004(H5N1))neuraminidase mRNA, linear mRNA GI:50843945 complete cds 387. InfluenzaA virus (A/Thailand/LFPN- 1,704 bp AY679514.1 2004/2004(H5N1))hemagglutinin mRNA, linear mRNA GI:50843949 complete cds 388. InfluenzaA virus (A/tiger/Thailand/CU- 534 bp DQ017251.1 T4/04(H5N1)) polymerasebasic protein 2 linear mRNA GI:65329524 (PB2) mRNA, partial cds 389.Influenza A virus (A/tiger/Thailand/CU- 582 bp DQ017252.1 T5/04(H5N1))polymerase basic protein 2 linear mRNA GI:65329536 (PB2) mRNA, partialcds 390. Influenza A virus (A/tiger/Thailand/CU- 564 bp DQ017253.1T6/04(H5N1)) polymerase basic protein 2 linear mRNA GI:65329553 (PB2)mRNA, partial cds 391. Influenza A virus (A/tiger/Thailand/CU- 582 bpDQ017254.1 T8/04(H5N1)) polymerase basic protein 2 linear mRNAGI:65329568 (PB2) mRNA, partial cds 392. Influenza A virus 1,695 bpEF441263.1 (A/turkey/England/250/2007(H5N1)) linear mRNA GI:129307104hemagglutinin (HA) mRNA, partial cds 393. Influenza A virus 943 bpEF441264.1 (A/turkey/England/250/2007(H5N1)) matrix linear mRNAGI:129307106 protein (M) mRNA, partial cds 394. Influenza A virus 812 bpEF441265.1 (A/turkey/England/250/2007(H5N1)) linear mRNA GI:129307109nonstructural protein 1 (NS1) mRNA, complete cds 395. Influenza A virus2,185 bp EF441266.1 (A/turkey/England/250/2007(H5N1)) polymerase linearmRNA GI:129307111 PA (PA) mRNA, complete cds 396. Influenza A virus2,272 bp EF441267.1 (A/turkey/England/250/2007(H5N1)) polymerase linearmRNA GI:129307113 PB2 (PB2) mRNA, partial cds 397. Influenza A virus1,396 bp EF441268.1 (A/turkey/England/250/2007(H5N1)) linear mRNAGI:129307115 nucleocapsid (NP) mRNA, partial cds 398. Influenza A virus2,288 bp EF441269.1 (A/turkey/England/250/2007(H5N1)) polymerase linearmRNA GI:129307117 PB1 (PB1) mRNA, partial cds 399. Influenza A virus1,276 bp EF441270.1 (A/turkey/England/250/2007(H5N1)) linear mRNAGI:129307119 neuraminidase (NA) mRNA, partial cds A/chicken/BurkinaFaso/13.1/2006(H5N1) AM503016.1 neuraminidase (NA)A/chicken/Crimea/04/2005(H5N1) neuraminidase DQ650661.1 (NA)A/chicken/Crimea/04/2005(H5N1) hemagglutinin DQ650659.1A/chicken/Crimea/08/2005(H5N1) polymerase DQ650669.1 basic protein 1(PB1) A/chicken/Crimea/08/2005(H5N1) neuraminidase DQ650665.1 (NA)A/chicken/Crimea/08/2005(H5N1) hemagglutinin DQ650663.1 (HA)A/chicken/Guangxi/12/2004(H5N1) DQ366334.1 nonstructural protein 1A/chicken/Guangxi/12/2004(H5N1) DQ366332.1 neuraminidaseA/chicken/Guangxi/12/2004(H5N1) DQ366330.1 hemagglutininA/duck/Kurgan/08/2005(H5N1) nucleoprotein DQ449643.1 (NP)

TABLE 10 Other Influenza A Antigens (H1N*, H2N*, H3N*) GenBank/GIStrain/Protein Length Accession Nos. H1N* Influenza A virus (A/duck/Hong1,402 bp U49097.1 Kong/193/1977(H1N2)) nucleoprotein (NP) linear mRNAGI:1912392 mRNA, partial cds Influenza A virus (A/duck/Hong 258 bpU48285.1 Kong/193/1977(H1N2)) polymerase (PB1) mRNA, linear mRNAGI:1912374 partial cds Influenza A virus (A/England/2/2002(H1N2)) 795 bpAJ519455.1 partial NS1 gene for non structural protein linear mRNAGI:31096426 1 and partial NS2 gene for non structural protein 2, genomicRNA Influenza A virus (A/England/3/02(H1N2)) 384 bp AJ489497.1 partialmRNA for nucleoprotein (np gene) linear mRNA GI:27526856 Influenza Avirus (A/England/3/02(H1N2)) 442 bp AJ489488.1 partial mRNA forpolymerase subunit 2 (pb2 linear mRNA GI:27526838 gene) Influenza Avirus (A/England/5/02(H1N2)) 384 bp AJ489498.1 partial mRNA fornucleoprotein (np gene) linear mRNA GI:27526858 Influenza A virus(A/England/5/02(H1N2)) 442 bp AJ489489.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526840 gene) Influenza A virus(A/England/57/02(H1N2)) 384 bp AJ489499.1 partial mRNA for nucleoprotein(np gene) linear mRNA GI:27526860 Influenza A virus(A/England/57/02(H1N2)) 442 bp AJ489492.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526846 gene) Influenza A virus(A/England/691/01(H1N2)) 384 bp AJ489496.1 partial mRNA fornucleoprotein (np gene) linear mRNA GI:27526854 Influenza A virus(A/England/73/02(H1N2)) 384 bp AJ489500.1 partial mRNA for nucleoprotein(np gene) linear mRNA GI:27526862 Influenza A virus(A/England/73/02(H1N2)) 442 bp AJ489493.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526848 gene) Influenza A virus(A/England/90/02(H1N2)) 384 bp AJ489501.1 partial mRNA for nucleoprotein(np gene) linear mRNA GI:27526864 Influenza A virus(A/England/90/02(H1N2)) 442 bp AJ489490.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526842 gene) Influenza A virus(A/England/97/02(H1N2)) 384 bp AJ489502.1 partial mRNA for nucleoprotein(np gene) linear mRNA GI:27526866 Influenza A virus(A/England/97/02(H1N2)) 442 bp AJ489491.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526844 gene) Influenza A virus(A/England/627/01(H1N2)) 384 bp AJ489494.1 partial mRNA fornucleoprotein (np gene) linear mRNA GI:27526850 Influenza A virus(A/England/627/01(H1N2)) 442 bp AJ489485.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526832 gene) Influenza A virus(A/England/691/01(H1N2)) 442 bp AJ489487.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526836 gene) Influenza A virus(A/Egypt/96/2002(H1N2)) 747 bp AJ519457.1 partial NS1 gene for nonstructural protein linear mRNA GI:31096432 1 and partial NS2 gene fornon structural protein 2, genomic RNA Influenza A virus(A/Israel/6/2002(H1N2)) 773 bp AJ519456.1 partial NS1 gene for nonstructural protein linear mRNA GI:31096429 1 and partial NS2 gene fornon structural protein 2, genomic RNA Influenza A virus (A/Saudi 772 bpAJ519453.1 Arabia/2231/2001(H1N2)) partial NS1 gene for linear mRNAGI:31096420 non structural protein 1 and partial NS2 gene for nonstructural protein 2, genomic RNA Influenza A virus(A/Scotland/122/01(H1N2)) 384 bp AJ489495.1 partial mRNA fornucleoprotein (np gene) linear mRNA GI:27526852 Influenza A virus(A/Scotland/122/01(H1N2)) 442 bp AJ489486.1 partial mRNA for polymerasesubunit 2 (pb2 linear mRNA GI:27526834 gene) Influenza A virus 832 bpAY861443.1 (A/swine/Bakum/1832/2000(H1N2)) linear mRNA GI:57791765hemagglutinin (HA) mRNA, partial cds Influenza A virus 467 bp AY870645.1(A/swine/Bakum/1832/2000(H1N2)) linear mRNA GI:58042754 neuraminidasemRNA, partial cds Influenza A virus (A/swine/Cotes 1,039 bp AM503547.1d'Armor/0040/2007(H1N2)) segment 4 partial linear mRNA GI:225578611 mRNAInfluenza A virus (A/swine/Cotes 1,136 bp AM490224.3d'Armor/0136_17/2006(H1N2)) partial mRNA for linear mRNA GI:222062921haemagglutinin precursor (HA1 gene) Influenza A virus 1,778 bpAF085417.1 (A/swine/England/72685/96(H1N2)) linear mRNA GI:3831770haemagglutinin precursor, mRNA, complete cds Influenza A virus 1,778 bpAF085416.1 (A/swine/England/17394/96(H1N2)) linear mRNA GI:3831768haemagglutinin precursor, mRNA, complete cds Influenza A virus 1,778 bpAF085415.1 (A/swine/England/690421/95(H1N2)) linear mRNA GI:3831766haemagglutinin precursor, mRNA, complete cds Influenza A virus 1,778 bpAF085414.1 (A/swine/England/438207/94(H1N2)) linear mRNA GI:3831764haemagglutinin precursor, mRNA, complete cds Influenza A virus 1,427 bpAY129157.1 (A/Swine/Korea/CY02/02(H1N2)) neuraminidase linear mRNAGI:24286064 (NA) mRNA, complete cds Influenza A virus 952 bp AY129158.1(A/Swine/Korea/CY02/02(H1N2)) matrix protein linear mRNA GI:24286066 (M)mRNA, complete cds Influenza A virus 1,542 bp AY129159.1(A/Swine/Korea/CY02/02(H1N2)) nucleoprotein linear mRNA GI:24286069 (NP)mRNA, complete cds Influenza A virus 842 bp AY129160.1(A/Swine/Korea/CY02/02(H1N2)) nonstructural linear mRNA GI:24286081protein (NS) mRNA, complete cds Influenza A virus 2,165 bp AY129161.1(A/Swine/Korea/CY02/02(H1N2)) polymerase linear mRNA GI:24286087 acidicprotein 2 (PA) mRNA, complete cds Influenza A virus 2,274 bp AY129162.1(A/Swine/Korea/CY02/02(H1N2)) polymerase linear mRNA GI:24286096 subunit1 (PB1) mRNA, complete cds Influenza A virus 2,334 bp AY129163.1(A/Swine/Korea/CY02/02(H1N2)) polymerase linear mRNA GI:24286100 subunit2 (PB2) mRNA, complete cds Influenza A virus 1,778 bp AF085413.1(A/swine/Scotland/410440/94(H1N2)) linear mRNA GI:3831762 haemagglutininprecursor, mRNA, complete cds Influenza A virus (A/swine/Spain/80598-291 bp EU305436.1 LP4/2007(H1N2)) matrix protein 2 (M2) mRNA, linearmRNA GI:168830657 partial cds Influenza A virus 975 bp AJ517813.1(A/Switzerland/3100/2002(H1N2)) partial HA linear mRNA GI:38422519 genefor Haemagglutinin, genomic RNA Influenza A virus (A/duck/Hong 1,387 bpU49095.1 Kong/717/1979(H1N3)) nucleoprotein (NP) linear mRNA GI:1912388mRNA, partial cds Influenza A virus (A/duck/Hong 265 bp U48281.1Kong/717/1979(H1N3)) polymerase (PB1) mRNA, linear mRNA GI:1912366partial cds Influenza A virus (A/herring gull/New 971 bp AY664422.1Jersey/780/86 (H1N3)) nonfunctional matrix linear mRNA GI:51011826protein mRNA, partial sequence Influenza A virus 997 bp AY664426.1(A/mallard/Alberta/42/77(H1N6)) linear mRNA GI:51011830 nonfunctionalmatrix protein mRNA, partial sequence Influenza A virus 1,020 bpU85985.1 (A/swine/England/191973/92(H1N7)) matrix linear mRNA GI:1835733protein Ml mRNA, complete cds Influenza A virus 1,524 bp U85987.1(A/swine/England/191973/92(H1N7)) linear mRNA GI:1835737 nucleoproteinmRNA, complete cds Influenza A virus 1,458 bp U85988.1(A/swine/England/191973/92(H1N7)) linear mRNA GI:1835739 neuraminidasemRNA, complete cds Influenza A virus 1,698 bp U85986.1(A/swine/England/191973/92 (H1N7) ) linear mRNA GI:1835735haemagglutinin HA mRNA, partial cds H2N* Influenza A virus (A/ruddy 917bp AY664465.1 turnstone/Delaware/81/93 (H2N1)) linear mRNA GI:51011869nonfunctional matrix protein mRNA, partial sequence Influenza A virus(A/ruddy 968 bp AY664429.1 turnstone/Delaware/34/93 (H2N1)) linear mRNAGI:51011833 nonfunctional matrix protein mRNA, partial sequenceInfluenza A virus 925 bp AY 66 4 466.1(A/Shorebird/Delaware/122/97(H2N1)) linear mRNA GI:51011870nonfunctional matrix protein mRNA, partial sequence Influenza A virus958 bp AY664454.1 (A/shorebird/Delaware/138/97 (H2N1)) linear mRNAGI:51011858 nonfunctional matrix protein mRNA, partial sequenceInfluenza A virus 958 bp AY664457.1 (A/shorebird/Delaware/111/97 (H2N1))linear mRNA GI:51011861 nonfunctional matrix protein mRNA, partialsequence Influenza A virus 979 bp AY664442.1 (A/shorebird/Delaware/24/98(H2N1)) linear mRNA GI:51011846 nonfunctional matrix protein mRNA,partial sequence Influenza virus type A/Leningrad/134/17/57 2,233 bpM81579.1 (H2N2) PA RNA, complete cds linear mRNA GI:324935 Influenza Avirus (STRAIN A/MALLARD/NEW 2,151 bp AJ243994.1 YORK/6750/78) partialmRNA for PA protein linear mRNA GI:5918195 Influenza A virus(A/X-7(F1)/(H2N2)) 1,467 bp M11205.1 neuraminidase mRNA, complete cdslinear mRNA GI:323969 Influenza A virus (A/mallard/Alberta/77/77 1,009bp AY664425.1 (H2N3)) nonfunctional matrix protein mRNA, linear mRNAGI:51011829 partial sequence Influenza A virus 968 bp AY664447.1(A/mallard/Alberta/226/98(H2N3)) linear mRNA GI:51011851 nonfunctionalmatrix protein mRNA, partial sequence Influenza A virus(A/sanderling/New 846 bp AY664477.1 Jersey/766/86 (H2N7)) nonfunctionalmatrix linear mRNA GI:51011881 protein mRNA, partial sequence InfluenzaA virus (A/laughing gull/New 907 bp AY664471.1 Jersey/798/86 (H2N7))nonfunctional matrix linear mRNA GI:51011875 protein mRNA, partialsequence Influenza A virus (A/herring 960 bp AY664440.1gull/Delaware/471/1986(H2N7)) nonfunctional linear mRNA GI:51011844matrix protein mRNA, partial sequence Influenza A virus (A/ruddy 1,011bp AY664423.1 turnstone/Delaware/142/98 (H2N8)) linear mRNA GI:51011827nonfunctional matrix protein mRNA, partial sequence Influenza A virus(A/pintail/Alberta/293/77 906 bp AY664473.1 (H2N9)) nonfunctional matrixprotein mRNA, linear mRNA GI:51011877 partial sequence Influenza A virus(A/blue-winged 961 bp AY664449.1 teal/Alberta/16/97 (H2N9))nonfunctional linear mRNA GI:51011853 matrix protein mRNA, partialsequence Influenza A virus (A/Laughing gull/New 952 bp AY664437.1Jersey/75/85 (H2N9)) nonfunctional matrix linear mRNA GI:51011841protein mRNA, partial sequence Influenza A virus(A/mallard/Alberta/205/98 959 bp AY664450.1 (H2N9)) nonfunctional matrixprotein mRNA, linear mRNA GI:51011854 partial sequence H3N* Influenza Avirus (A/duck/Eastern 1,458 bp EU429755.1 China/267/2003(H3N1)) segment6 linear mRNA GI:167859475 neuraminidase (NA) mRNA, complete cdsInfluenza A virus (A/duck/Eastern 1,458 bp EU429754.1China/253/2003(H3N1)) segment 6 linear mRNA GI:167859473 neuraminidase(NA) mRNA, complete cds Influenza A virus (A/duck/Eastern 1,458 bpEU429753.1 China/252/2003(H3N1)) segment 6 linear mRNA GI:167859471neuraminidase (NA) mRNA, complete cds Influenza A virus (A/duck/Eastern1,458 bp EU429752.1 China/243/2003(H3N1)) segment 6 linear mRNAGI:167859469 neuraminidase (NA) mRNA, complete cds Influenza A virus(A/duck/Eastern 1,458 bp EU429734.1 China/262/2003(H3N1)) segment 6linear mRNA GI:167859433 neuraminidase (NA) mRNA, complete cds InfluenzaA virus (A/duck/Eastern 1,459 bp EU429733.1 China/233/2003(H3N1))segment 6 linear mRNA GI:167859431 neuraminidase (NA) mRNA, complete cdsInfluenza A virus (A/duck/Eastern 1,458 bp EU429723.1China/213/2003(H3N1)) segment 6 linear mRNA GI:167859411 neuraminidase(NA) mRNA, complete cds Influenza A virus (A/duck/Eastern 1,458 bpEU429719.1 China/341/2003(H3N1)) segment 6 linear mRNA GI:167859403neuraminidase (NA) mRNA, complete cds Influenza A virus (A/duck/Eastern1,458 bp EU429718.1 China/01/2002(H3N1)) segment 6 neuraminidase linearmRNA GI:167859401 (NA) mRNA, complete cds Influenza A virus(A/mallard/Alberta/22/76 1,013 bp AY664434.1 (H3N6)) nonfunctionalmatrix protein mRNA, linear mRNA GI:51011838 partial sequence InfluenzaA virus 970 bp AY664443.1 (A/mallard/Alberta/199/99(H3N6)) linear mRNAGI:51011847 nonfunctional matrix protein mRNA, partial sequenceInfluenza A virus 922 bp AY664461.1 (A/shorebird/Delaware/222/97 (H3N6))linear mRNA GI:51011865 nonfunctional matrix protein mRNA, partialsequence Influenza A virus (A/Duck/Hokkaido/8/80 984 bp AF079570.1(H3N8)) hemagglutinin precursor, mRNA, linear mRNA GI:3414978 partialcds Influenza A virus (A/Duck/Hokkaido/8/80 1,497 bp AF079571.1 (H3N8))nucleoprotein mRNA, complete cds linear mRNA GI:3414980 Influenza Avirus 1,461 bp EU429797.1 (A/duck/Ukraine/1/1963(H3N8)) segment 6 linearmRNA GI:167859559 neuraminidase (NA) mRNA, complete cds Influenza Avirus (A/duck/Eastern 1,460 bp EU429698.1 China/19/2004(H3N8)) segment 6neuraminidase linear mRNA GI:167859361 (NA) mRNA, complete cds InfluenzaA virus (A/duck/Eastern 1,460 bp EU429700.1 China/90/2004(H3N8)) segment6 neuraminidase linear mRNA GI:167859365 (NA) mRNA, complete cdsInfluenza A virus (A/duck/Eastern 1,460 bp EU429787.1China/18/2005(H3N8)) segment 6 neuraminidase linear mRNA GI:167859539(NA) mRNA, complete cds Influenza A virus (A/duck/Eastern 1,460 bpEU429788.1 China/119/2005(H3N8)) segment 6 linear mRNA GI:167859541neuraminidase (NA) mRNA, complete cds Influenza A virus 1,061 bpAF197246.1 (A/equine/Argentina/1/96(H3N8)) linear mRNA GI:6651512hemagglutinin precursor (HA1) mRNA, partial cds Influenza A virus 1,061bp AF197245.1 (A/equine/Argentina/2/94(H3N8)) linear mRNA GI:6651510hemagglutinin precursor (HA1) mRNA, partial cds Influenza A virus 1,061bp AF197244.1 (A/equine/Argentina/1/95(H3N8)) linear mRNA GI:6651508hemagglutinin precursor (HA1) mRNA, partial cds Influenza A virus HApartial gene for 1,026 bp AJ223194.1 haemagglutinin, genomic RNA, strainlinear mRNA GI:2780201 A/equine/Berlin/3/89(H3N8) Influenza A virus HApartial gene for 1,006 bp AJ223195.1 haemagglutinin, genomic RNA, strainlinear mRNA GI:2780203 A/equine/Berlin/4/89(H3N8) Influenza A virus1,061 bp AF197242.1 (A/equine/Florida/1/94(H3N8)) hemagglutinin linearmRNA GI:6651504 precursor (HA1) mRNA, partial cds Influenza A virus 695bp AY328471.1 (A/equine/Grobois/1/98(H3N8)) nonstructural linear mRNAGI:32966577 protein NS1 mRNA, complete cds Influenza A virus (A/equi 473bp AY919314.1 2/Gotland/01(H3N8)) hemagglutinin HA1 linear mRNAGI:60250543 subunit mRNA, partial cds Influenza A virus(A/eq/Kentucky/81(H3N8)) 1,763 bp U58195.1 hemagglutinin mRNA, completecds linear mRNA GI:1377873 Influenza A virus 1,061 bp AF197247.1(A/equine/Kentucky/9/95(H3N8)) hemagglutinin linear mRNA GI:6651514precursor (HA1) mRNA, partial cds Influenza A virus 1,061 bp AF197248.1(A/equine/Kentucky/1/96(H3N8)) hemagglutinin linear mRNA GI:6651516precursor (HA1) mRNA, partial cds Influenza A virus 1,061 bp AF197249.1(A/equine/Kentucky/1/97(H3N8)) hemagglutinin linear mRNA GI:6651518precursor (HA1) mRNA, partial cds Influenza A virus 1,061 bp AF197241.1(A/equine/Kentucky/1/98(H3N8)) hemagglutinin linear mRNA GI:6651502precursor (HA1) mRNA, partial cds Influenza A virus 1,497 bp AY383753.1(A/equine/Santiago/85(H3N8)) nucleoprotein linear mRNA GI:37223511 mRNA,complete cds Influenza A virus 1,698 bp AY383755.1(A/equine/Santiago/85(H3N8)) hemagglutinin linear mRNA GI:37223515 mRNA,complete cds Influenza A virus 1,413 bp AY383754.1(A/equine/Santiago/85(H3N8)) neuraminidase linear mRNA GI:37223513 mRNA,complete cds Influenza A virus 1,061 bp AF197243.1(A/equine/Saskatoon/1/90(H3N8)) linear mRNA GI:6651506 hemagglutininprecursor (HA1) mRNA, partial cds Influenza A virus(A/mallard/Alberta/114/97 1,010 bp AY664432.1 (H3N8)) nonfunctionalmatrix protein mRNA, linear mRNA GI:51011836 partial sequence InfluenzaA virus (A/mallard/Alberta/167/98 961 bp AY664489.1 (H3N8))nonfunctional matrix protein mRNA, linear mRNA GI:51011893 partialsequence Influenza A virus 970 bp AY664445.1(A/pintail/Alberta/37/99(H3N8)) linear mRNA GI:51011849 nonfunctionalmatrix protein mRNA, partial sequence Influenza A virus 922 bpAY664455.1 (A/sanderling/Delaware/65/99 (H3N8)) linear mRNA GI:51011859nonfunctional matrix protein mRNA, partial sequence

TABLE 11 Other Influenza A Antigens (H4N*-H13N*) GenBank Strain/ProteinAccess No. A/chicken/Singapore/1992(H4N1) M2 protein EU014144.1A/mallard/Alberta/47/98(H4N1) nonfunctional matrix protein AY664488.1A/duck/Hong Kong/412/1978(H4N2) polymerase (PB1) U48279.1A/mallard/Alberta/300/77 (H4N3) nonfunctional matrix protein AY664480.1A/Duck/Czechoslovakia/56(H4N6) segment 4 hemagglutinin AF290436.1A/duck/Eastern China/376/2004(H4N6) segment 6neuraminidase (NA)EU429792.1 A/duck/Eastern China/01/2007(H4N6) segment 6 neuraminidase(NA) EU429790.1 A/duck/Eastern China/216/2007(H4N6) segment 6neuraminidase EU429789.1 (NA) A/duck/Eastern China/166/2004(H4N6)segment 6 neuraminidase EU429746.1 (NA) A/duck/EasternChina/02/2003(H4N6) segment 6 neuraminidase (NA) EU429713.1A/duck/Eastern China/160/2002(H4N6) segment 6 neuraminidase EU429706.1(NA) A/mallard/Alberta/111/99(H4N6) nonfunctional matrix proteinAY664482.1 A/mallard/Alberta/213/99 (H4N6) nonfunctional matrix proteinAY664460.1 A/mallard/Alberta/30/98 (H4N6) nonfunctional matrix proteinAY664484.1 A/blue-winged teal/Alberta/96/76 (H4N8) nonfunctional matrixAY664420.1 protein A/chicken/Florida/25717/1993(H5N2) hemagglutininU05332.1 A/chicken/Hidalgo/26654-1368/1994(H5N2) hemagglutinin (HA)U37172.1 A/chicken/Jalisco/14585-660/1994(H5N2) hemagglutinin (HA)U37181.1 A/chicken/Mexico/26654-1374/1994(H5N2) hemagglutinin (HA)U37173.1 A/chicken/Mexico/31381-3/1994(H5N2) hemagglutinin (HA) U37176.1A/chicken/Mexico/31381-6/1994(H5N2) hemagglutinin (HA) U37175.1A/chicken/Mexico/31381-4/1994(H5N2) hemagglutinin (HA) U37174.1A/chicken/Mexico/31381-5/1994(H5N2) hemagglutinin (HA) U37169.1A/chicken/Mexico/31381-8/1994(H5N2) hemagglutinin (HA) U37170.1A/Chicken/Mexico/31381-Avilab/94(H5N2)hemagglutinin (HA) L46585.1A/chicken/Mexico/31382-1/1994(H5N2)hemagglutinin (HA) U37168.1A/chicken/Mexico/31381-2/1994(H5N2) hemagglutinin (HA) U37167.1A/chicken/Mexico/31381-1/1994(H5N2) hemagglutinin (HA) U37166.1A/chicken/Mexico/31381-7/1994(H5N2) hemagglutinin (HA) U37165.1A/chicken/Pennsylvania/13609/1993(H5N2) hemagglutinin U05331.1A/chicken/Pennsylvania/1/1983(H5N2) hemagglutinin esterase M18001.1precursor A/chicken/Pennsylvania/1370/1983(H5N2) hemagglutinin esteraseM10243.1 precursor A/Chicken/Puebla/8623-607/94(H5N2) hemagglutinin (HA)L46586.1 A/chicken/Puebla/14586-654/1994(H5N2) hemagglutinin (HA)U37180.1 A/chicken/Puebla/14585-622/1994(H5N2) hemagglutinin (HA)U37179.1 A/chicken/Puebla/8623-607/1994(H5N2)hemagglutinin (HA) U37178.1A/chicken/Puebla/8624-604/1994(H5N2) hemagglutinin (HA) U37177.1A/Chicken/Queretaro/14588-19/95(H5N2) hemagglutinin (HA) L46587.1A/chicken/Queretaro/7653-20/95(H5N2) hemagglutinin (HA) U79448.1A/chicken/Queretaro/26654-1373/1994(H5N2) hemagglutinin (HA) U37171.1A/chicken/Queretaro/14588-19/1994(H5N2)hemagglutinin (HA) U37182.1A/chicken/Singapore/98(H5N2) matrix protein 2 (M2) EF682127.1A/chicken/Taiwan/1209/03(H5N2) hemagglutinin protein (HA) AY573917.1A/chicken/Taiwan/1209/03(H5N2) neuraminidase AY573918.1 A/duck/EasternChina/64/2004(H5N2) segment 6 neuraminidase (NA) EU429791.1A/duck/Eastern China/264/2002(H5N2) segment 6 neuraminidase EU429744.1(NA) A/duck/Eastern China/01/2001(H5N2) segment 6 neuraminidase (NA)EU429728.1 A/duck/Eastern China/06/2000(H5N2) segment 6 neuraminidaseEU429722.1 (NA) A/duck/Hong Kong/342/78(H5N2) matrix protein 1 (M) andmatrix DQ107452.1 protein 2 (M) A/duck/Hong Kong/342/78(H5N2)hemagglutinin precursor U20475.1 A/duck/Michigan/80(H5N2) hemagglutinin1 chain U20474.1 A/duck/Michigan/80(H5N2) hemagglutinin U79449.1A/duck/MN/1564/81(H5N2) matrix protein 1 (M) and matrix proteinDQ107467.1 2 (M) A/duck/Mongolia/54/2001(H5N2) hemagglutinin (HA)AB241614.2 A/duck/Primorie/2621/01(H5N2) hemagglutinin (HA) AJ621811.3A/duck/Primorie/2621/01(H5N2)nucleoprotein (NP ) AJ621812.1A/duck/Primorie/2621/01(H5N2) nonstructural protein (NS) AJ621813.1A/duck/Pennsylvania/84(H5N2) hemagglutinin 1chain U20473.1A/duck/Potsdam/1402-6/86(H5N2) hemagglutinin H5 AF082042.1A/emu/Texas/39442/93(H5N2) hemaglutinin U28920.1A/emu/Texas/39442/93(H5N2) hemaglutinin U28919.1A/mallard/Alberta/645/80(H5N2) matrix protein 1 (M) and matrixDQ107471.1 protein 2 (M) A/mallard/AR/1C/2001(H5N2) matrix protein 1 (M)and matrix DQ107463.1 protein 2 (M) A/mallard/NY/189/82(H5N2) matrixprotein 1 (M) and matrix DQ107465.1 protein 2 (M)A/mallard/MN/25/80(H5N2) matrix protein 1 (M) and matrix DQ107473.1protein 2 (M) A/mallard/MI/18/80(H5N2) matrix protein 1 (M) and matrixDQ107470.1 protein 2 (M) A/mallard/Ohio/345/88(H5N2) hemagglutininU79450.1 A/parrot/CA/6032/04(H5N2) polymerase basic protein 2 (PB2)DQ256390.1 A/parrot/CA/6032/04(H5N2) polymerase basic protein 1 (PB1)DQ256389.1 A/parrot/CA/6032/04(H5N2) matrix protein (M) DQ256384.2A/parrot/CA/6032/04(H5N2) hemagglutinin (HA) DQ256383.1A/parrot/CA/6032/04(H5N2) neuraminidase (NA) DQ256385.1A/parrot/CA/6032/04(H5N2) polymerase basic protein 2 (PB2) DQ256390.1A/parrot/CA/6032/04(H5N2) nucleoprotein (NP) DQ256386.1A/parrot/CA/6032/04(H5N2)) polymerase (PA) DQ256388.1 A/ruddyturnstone/Delaware/244/91 (H5N2) nonfunctional matrix AY664474.1 proteinA/ruddy turnstone/Delaware/244/91 (H5N2) U05330.1A/turkey/Colorado/72(H5N2) hemagglutinin 1 chain (HA) U20472.1A/turkey/England/N28/73 (H5N2) hemagglutinin AY500365.1A/turkey/TX/14082/81(H5N2) matrix protein 1 (M) and matrix DQ107464.1protein 2 (M) A/turkey/MN/1704/82(H5N2)) matrix protein 1 (M) and matrixDQ107472.1 protein 2 (M) A/turkey/Minnesota/10734/95(H5N2))hemagglutinin U79455.1 A/turkey/Minnesota/3689-1551/81(H5N2)hemagglutinin U79454.1 A/chicken/Singapore/1997(H5N3) M2 proteinEU014141.1 A/duck/Hokkaido/299/04(H5N3) hemagglutinin (HA) AB241626.1A/duck/Hokkaido/193/04(H5N3) hemagglutinin (HA) AB241625.1A/duck/Hokkaido/101/04(H5N3) hemagglutinin (HA) AB241624.1A/duck/Hokkaido/447/00(H5N3) hemagglutinin (HA) AB241620.1A/duck/Hokkaido/69/00(H5N3) hemagglutinin (HA) AB241619.1 A/duck/HongKong/205/77(H5N3) hemagglutinin H5 AF082038.1 A/duck/HongKong/698/79(H5N3) hemagglutinin H5 AF082039.1 A/duck/HongKong/308/78(H5N3) matrix protein 1 (M) and matrix DQ107457.1 protein 2(M) A/duck/Hong Kong/825/80(H5N3) matrix protein 1 (M) and matrixDQ107455.1 protein 2 (M) A/duck/Hong Kong/820/80(H5N3) matrix protein 1(M) and matrix DQ107453.1 protein 2 (M) A/duck/Hong Kong/205/77(H5N3)matrix protein 1 (M) and matrix DQ107456.1 protein 2 (M) A/Duck/Ho ChiMinh/014/78(H5N3) segment 4 hemagglutinin AF290443.1A/duck/Jiangxi/6151/2003(H5N3) matrix protein 1 (M) and matrixDQ107451.1 protein 2 (M) A/duck/Malaysia/F119-3/97(H5N3) hemagglutininAF303057.1 A/duck/Miyagi/54/76(H5N3)hemagglutinin (HA) AB241615.1A/duck/Mongolia/596/01(H5N3) hemagglutinin HA) AB241622.1A/duck/Mongolia/500/01(H5N3)hemagglutinin (HA) AB241621.1A/duck/Primorie/2633/01(H5N3) matrix protein (M1) AJ621810.1A/duck/Primorie/2633/01(H5N3)nucleoprotein (NP) AJ621808.1A/duck/Primorie/2633/01(H5N3)hemagglutinin (HA) AJ621807.1A/duck/Primorie/2633/01(H5N3)nucleoprotein (NP) AJ621809.1 A/goose/HongKong/23/78(H5N3) matrix protein 1 (M) and matrix DQ107454.1 protein 2(M) A/mallard/Wisconsin/169/75(H5N3) hemagglutinin U79452.1A/swan/Hokkaido/51/96(H5N3)hemagglutinin (HA) AB241617.1A/swan/Hokkaido/4/96(H5N3) hemagglutinin (HA) AB241616.1A/turkey/CA/6878/79(H5N3) matrix protein 1 (M) and matrix DQ107469.1protein 2 (M) A/tern/South Africa/61(H5N3) hemagglutinin precursor (HA)U20460.1 A/gull/Delaware/5/2000(H5N4) matrix protein 1 (M) and matrixDQ107459.1 protein 2 (M) A/gull/Delaware/4/2000(H5N4) matrix protein 1(M) and matrix DQ107458.1 protein 2 (M)A/shorebird/Delaware/109/2000(H5N4) matrix protein 1 (M) DQ107460.1A/shorebird/Delaware/243/2000(H5N4) matrix protein 1 (M) and DQ107462.1matrix protein 2 (M) A/shorebird/Delaware/230/2000(H5N4) matrix protein1 (M) and DQ107461.1 matrix protein 2 (M)A/mallard/Wisconsin/34/75(H5N6) hemagglutinin U79451.1A/duck/Potsdam/2216-4/1984(H5N6) hemagglutinin H5 AF082041.1A/shorebird/Delaware/207/98 (H5N8) nonfunctional matrix proteinAY664456.1 A/shorebird/Delaware/27/98 (H5N8) nonfunctional matrixprotein AY664453.1 A/herring gull/Delaware/281/98 (H5N8) nonfunctionalmatrix AY664452.1 protein A/mallard/Ohio/556/1987(H5N9) hemagglutinin(HA) U67783.2 A/turkey/Wisconsin/68(H5N9) hemagglutinin U79456.1A/blue-winged teal/Alberta/685/82(H6N1) matrix protein 1 (M) DQ107448.1and matrix protein 2 (M) A/chicken/Taiwan/7-5/99(H6N1) nucleocapsidprotein (NP) AF261750.1 A/chicken/Taiwan/7-5/99(H6N1) matrix proteinAF262213.1 A/chicken/Taiwan/7-5/99(H6N1) nonstructural proteinAF262212.1 A/chicken/Taiwan/7-5/99(H6N1) polymerase (PA) AF262211.1A/chicken/Taiwan/7-5/99(H6N1) polymerase subunit PB1 AF262210.1A/chicken/Taiwan/7-5/99(H6N1) nucleocapsid protein (NP) AF261750.1A/chicken/Taiwan/ns2/99(H6N1) segment 4 hemagglutinin (HA1) AF310985.1A/chicken/Taiwan/na3/98(H6N1) segment 4 hemagglutinin (HA1) AF310984.1A/chicken/Taiwan/7-5/99(H6N1) segment 4 hemagglutinin (HA1) AF310983.1A/duck/Hong Kong/D73/76(H6N1) matrix protein 1 (M) and matrix DQ107432.1protein 2 (M) A/duck/Taiwan/9/23-3/2000(H6N1) matrix protein 1 (M) andmatrix DQ107407.1 protein 2 (M) A/pheasant/Hong Kong/FY479/2000(H6N1)matrix protein 1 (M) and DQ107409.1 matrix protein 2 (M) A/pheasant/HongKong/SSP44/2002(H6N1) matrix protein 1 (M) and DQ107412.1 matrix protein2 (M) A/quail/Hong Kong/YU421/2002(H6N1) matrix protein 1 (M) andDQ107414.1 matrix protein 2 (M) A/avian/NY/17150-7/2000(H6N2) matrixprotein 1 (M) and matrix DQ107423.1 protein 2 (M)A/chicken/CA/285/2003(H6N2) matrix protein 1 (M) and matrix DQ107429.1protein 2 (M) A/chicken/CA/375TR/2002(H6N2) matrix protein 1 (M) andmatrix DQ107428.1 protein 2 (M) A/chicken/CA/203/2003(H6N2) matrixprotein 1 (M) and matrix DQ107426.1 protein 2 (M)A/chicken/NY/101250-7/2001(H6N2) matrix protein 1 (M) and DQ107419.1matrix protein 2 (M) A/chicken/CA/625/2002(H6N2) matrix protein 1 (M)and matrix DQ107418.1 protein 2 (M)A/Chicken/California/0139/2001(H6N2)nucleoprotein (NP) AF474070.1A/Chicken/California/650/2000(H6N2) nucleoprotein (NP) AF474069.1A/Chicken/California/9420/2001(H6N2) neuraminidase N2 (N2) AF474048.1A/Chicken/California/9174/2001(H6N2) neuraminidase N2 (N2) AF474047.1A/Chicken/California/8892/2001(H6N2)neuraminidase N2 (N2) AF474046.1A/Chicken/California/6643/2001(H6N2) neuraminidase N2 (N2) AF474045.1A/Chicken/California/1316/2001(H6N2)neuraminidase N2 (N2) AF474044.1A/Chicken/California/0139/2001(H6N2) neuraminidase N2 (N2) AF474043.1A/Chicken/California/1002/2000(H6N2) neuraminidase N2 (N2) AF474042.1A/Chicken/California/650/2000(H6N2) neuraminidase N2 (N2) AF474041.1A/Chicken/California/465/2000(H6N2) neuraminidase N2 (N2) AF474040.1A/Chicken/California/431/2000(H6N2) neuraminidase N2 (N2) AF474039.1A/Chicken/California/6643/2001(H6N2) hemagglutinin H6 (H6) AF474035.1A/Chicken/California/431/2000(H6N2) hemagglutinin H6 (H6) AF474029.1A/Chicken/California/9420/2001(H6N2) hemagglutinin H6 (H6) AF474038.1A/Chicken/California/9174/2001(H6N2) hemagglutinin H6 (H6) AF474037.1A/Chicken/California/8892/2001(H6N2) hemagglutinin H6 (H6) AF474036.1A/Chicken/California/1316/2001(H6N2) hemagglutinin H6 (H6) AF474034.1A/Chicken/California/0139/2001(H6N2) hemagglutinin H6 (H6) AF474033.1A/Chicken/California/1002/2000(H6N2) hemagglutinin H6 (H6) AF474032.1A/Chicken/California/650/2000(H6N2) hemagglutinin H6 (H6) AF474031.1A/Chicken/California/465/2000(H6N2) hemagglutinin H6 (H6) AF474030.1A/cornish cross/CA/139/2001(H6N2) matrix protein 1 (M) and DQ107424.1matrix protein 2 (M) A/duck/Eastern China/164/2002(H6N2) segment 6neuraminidase EU429762.1 (NA) A/duck/Eastern China/729/2003(H6N2)segment 6 neuraminidase EU429760.1 (NA) A/duck/EasternChina/262/2002(H6N2) segment 6 neuraminidase EU429743.1 (NA)A/duck/Eastern China/74/2006(H6N2) segment 6 neuraminidase EU429741.1(NA) A/duck/Eastern China/161/2002(H6N2) segment 6 neuraminidaseEU429740.1 (NA) A/duck/Hong Kong/960/80(H6N2)) matrix protein 1 (M) andmatrix DQ107435.1 protein 2 (M) A/duck/Hong Kong/D134/77(H6N2)) matrixprotein 1 (M) and matrix DQ107433.1 protein 2 (M)A/duck/CA/10221/2002(H6N2) matrix protein 1 (M) and matrix DQ107421.1protein 2 (M) A/duck/Shantou/5540/2001(H6N2) matrix protein 1 (M) andmatrix DQ107431.1 protein 2 (M) A/guinea fowl/Hong Kong/SSP99/2002(H6N2)matrix protein 1 (M) DQ107413.1 and matrix protein 2 (M)A/mallard/NY/016/83(H6N2) matrix protein 1 (M) and matrix DQ107449.1protein 2 (M) A/mallard/NY/046/83(H6N2) matrix protein 1 (M) and matrixDQ107450.1 protein 2 (M) A/pintail/Alberta/644/81(H6N2) matrix protein 1(M) and matrix DQ107445.1 protein 2 (M) A/quail/HongKong/SF792/2000(H6N2) matrix protein 1 (M) and DQ107410.1 matrix protein2 (M) A/ruddy turnstone/Delaware/106/98 (H6N2) nonfunctional matrixAY664439.1 protein A/Shorebird/Delaware/127/97(H6N2) nonfunctionalmatrix protein AY664467.1 A/shorebird/Delaware/124/2001(H6N2) matrixprotein 1 (M) and DQ107417.1 matrix protein 2 (M)A/shorebird/Delaware/208/2001(H6N2) matrix protein 1 (M) and DQ107427.1matrix protein 2 (M) A/turkey/CA/527/2002(H6N2) matrix protein 1 (M) andmatrix DQ107420.1 protein 2 (M) A/turkey/CA/1623CT/2002(H6N2) matrixprotein 1 (M) and matrix DQ107425.1 protein 2 (M)A/turkey/MN/836/80(H6N2) matrix protein 1 (M) and matrix DQ107440.1protein 2 (M) A/turkey/MN/735/79(H6N2) matrix protein 1 (M) and matrixDQ107437.1 protein 2 (M) A/chicken/Hong Kong/17/77(H6N4)) matrix protein1 (M) and DQ107436.1 matrix protein 2 (M) A/chicken/HongKong/CSW106/2001(H6N4) matrix protein 1 (M) and DQ107406.1 matrixprotein 2 (M) A/gull/Delaware/18/2000(H6N4) matrix protein 1 (M) andmatrix DQ107415.1 protein 2 (M) A/pheasant/Hong Kong/CSW2573/2001(H6N4)matrix protein 1 (M) DQ107411.1 and matrix protein 2 (M) A/quail/HongKong/CSW106/2001(H6N4) matrix protein 1 (M) and DQ107430.1 matrixprotein 2 (M) A/Shorebird/Delaware/194/98(H6N4) nonfunctional matrixprotein AY664424.1 A/shorebird/Delaware/259/2000(H6N4) matrix protein 1(M) and DQ107416.1 matrix protein 2 (M)A/shearwater/Australia/1/1972(H6N5) segment 6 neuraminidase EU429794.1(NA) A/shearwater/Australia/1/1972(H6N5) polymerase A (PA) L25832.1A/pintail/Alberta/1040/79(H6N5) matrix protein 1 (M) and matrixDQ107439.1 protein 2 (M) A/blue-winged teal/MN/993/80(H6N6)) matrixprotein 1 (M) and DQ107441.1 matrix protein 2 (M)A/duck/NY/83779/2002(H6N6) matrix protein 1 (M) and matrix DQ107422.1protein 2 (M) A/duck/MN/1414/81(H6N6) matrix protein 1 (M) and matrixDQ107444.1 protein 2 (M) A/mallard/Alberta/289/82(H6N6) matrix protein 1(M) and matrix DQ107447.1 protein 2 (M) A/mallard duck/MN/1041/80(H6N6)matrix protein 1 (M) and matrix DQ107442.1 protein 2 (M)A/pintail/Alberta/189/82(H6N6) matrix protein 1 (M) and matrixDQ107446.1 protein 2 (M) A/sanderling/Delaware/1258/86(H6N6)nonfunctional matrix AY664436.1 protein A/blue-wingedteal/Alberta/368/78(H6N8)) matrix protein 1 (M) DQ107438.1 and matrixprotein 2 (M) A/ruddy turnstone/Delaware/105/98 (H6N8) nonfunctionalmatrix AY664428.1 protein A/domestic duck/NY/81(H6N8)) matrix protein(M) DQ107443.1 A/duck/Eastern China/163/2002(H6N8) segment 6neuraminidase EU429786.1 (NA) A/duck/Hong Kong/D182/77(H6N9) matrixprotein 1 (M) and matrix DQ107434.1 protein 2 (M) A/chicken/HongKong/SF3/2001(H6) matrix protein 1 (M) and DQ107408.1 matrix protein 2(M) A/African starling/England/983/79(H7N1) neuraminidase (N1)AJ416629.1 A/Afri.Star./Eng-Q/938/79(H7N1) hemagglutinin precurosrAF149295.1 A/chicken/Italy/1067/99(H7N1) matrix protein 1 (M1)AJ416630.1 A/chicken/Italy/1067/99(H7N1) neuraminidase (N1) AJ416627.1A/chicken/Italy/4575/99 (H7N1) hemagglutinin (HA) AJ493469.1A/chicken/Italy/13474/99(H7N1) haemagglutinin (HA) AJ491720.1A/chicken/Italy/445/1999(H7N1) AX537385.1 A/Chicken/Italy/267/00(H7N1)hemagglutinin (HA) AJ493215.1 A/Chicken/Italy/13489/99(H7N1)hemagglutinin (HA) AJ493214.1 A/Chicken/Italy/13307/99(H7N1)hemagglutinin (HA) AJ493212.1 A/chicken/Singapore/1994(H7N1) M2 proteinEU014140.1 A/duck/Hong Kong/301/78(H7N1) matrix protein 1 (M) and matrixDQ107475.1 protein 2 (M) A/Hong Kong/301/78(H7N1) hemagglutinin (HA)AY672090.1 A/fowl plaguq virus/Rostock/34 (H7N1) NP protein AJ243993.1A/fowl plaguq virus/Rostock/34 (H7N1) PA protein AJ243992.1 A/fowlplaguq virus/Rostock/34 (H7N1) PB2 protein AJ243991.1 A/fowl plaguqvirus/Rostock/34 (H7N1) PB1 protein AJ243990.1 A/ostrich/SouthAfrica/5352/92(H7N1) hemagglutinin precursor U20458.1 (HA) A/rhea/NorthCarolina/39482/93(H7N1) hemagglutinin precursor U20468.1 (HA)A/turkey/Italy/3775/99 (H7N1) hemagglutinin (HA) AJ493472.1A/turkey/Italy/4603/99 (H7N1) hemagglutinin (HA) AJ493471.1A/turkey/Italy/4602/99 (H7N1) hemagglutinin (HA) AJ493470.1A/turkey/Italy/4169/99 (H7N1) hemagglutinin (HA) AJ493468.1A/turkey/Italy/4073/99 (H7N1) hemagglutinin (HA) AJ493467.1A/turkey/Italy/3889/99 (H7N1) hemagglutinin (HA) AJ493466.1A/turkey/Italy/12598/99(H7N1) haemagglutinin (HA) AJ489520.1A/turkey/Italy/4580/99(H7N1) haemagglutinin (HA) AJ416628.1A/Turkey/Italy/335/00(H7N1) haemagglutinin (HA) AJ493217.1A/Turkey/Italy/13468/99(H7N1) haemagglutinin (HA) AJ493216.1A/Turkey/Italy/13467/99(H7N1) haemagglutinin (HA) AJ493213.1A/chicken/CT/9407/2003(H7N2) matrix protein 1 (M) and matrix DQ107478.1protein 2 (M) A/chicken/NY/116124/2003(H7N2) matrix protein 1 (M) andmatrix DQ107479.1 protein 2 (M) A/chicken/PA/143586/2002(H7N2) matrixprotein 1 (M) and matrix DQ107477.1 protein 2 (M) A/duck/HongKong/293/78(H7N2) matrix protein 1 (M) and matrix DQ107474.1 protein 2(M) A/duck/Hong Kong/293/78(H7N2) hemagglutinin precursor (HA) U20461.1A/laughing gull/Delaware/2838/87 (H7N2) nonfunctional matrix AY664427.1protein A/pheasant/NJ/30739-9/2000(H7N2) matrix protein 1 (M) andDQ107481.1 matrix protein 2 (M) A/ruddy turnstone/Delaware/130/99 (H7N2)onfunctional matrix AY664451.1 protein A/unknown/149717-12/2002(H7N2)matrix protein 1 (M) and matrix DQ107480.1 protein 2 (M)A/unknown/NY/74211-5/2001(H7N2) matrix protein 1 (M) and matrixDQ107476.1 protein 2 (M) A/unknown/149717-12/2002(H7N2) matrix protein 1(M) and matrix DQ107480.1 protein 2(M) A/unknown/NY/74211-5/2001(H7N2)matrix protein 1(M) and matrix DQ107476.1 protein 2 (M)A/chicken/British Columbia/CN7-3/04 (H7N3) hemagglutinin (HA) AY644402.1A/chicken/British Columbia/CN7-3/04 (H7N3) matrix protein (M1)AY677732.1 A/chicken/Italy/270638/02(H7N3) hemagglutinin (HA) EU158111.1A/gadwall/MD/3495/83(H7N3) matrix protein 1 (M) and matrix DQ107488.1protein 2 (M) A/mallard/Alberta/22/2001(H7N3) matrix protein 1 (M) andmatrix DQ107482.1 protein 2 (M) A/mallard/Alberta/699/81(H7N3) matrixprotein 1 (M) and matrix DQ107487.1 protein 2 (M)A/pintail/Alberta/25/2001(H7N3) matrix protein 1 (M) and matrixDQ107483.1 protein 2 (M) A/Quail/Arkansas/16309-7/94 (H7N3)hemagglutinin protein AF072401.1 subunit 1 precursor (HA1) A/ruddyturnstone/New Jersey/65/85(H7N3) nonfunctional matrix AY664433.1 proteinA/turkey/England/63(H7N3) hemagglutinin precursor (HA) U20462.1A/Turkey/Colorado/13356/91 (H7N3) hemagglutinin protein subunitAF072400.1 1 precursor (HA1) A/turkey/MN/1200/80(H7N3)) matrix protein 1(M) and matrix DQ107486.1 protein 2 (M) A/turkey/MN/1818/82(H7N3) matrixprotein 1 (M) and matrix DQ107489.1 protein 2 (M)A/turkey/Minnesota/1237/80(H7N3) hemagglutinin precursor (HA) U20466.1A/turkey/TX/1/79(H7N3) matrix protein 1 (M) and matrix proteinDQ107484.1 2 (M) A/Turkey/0regon/71(H7N3) hemagglutinin AF497557.1A/Turkey/Utah/24721-10/95 (H7N3) hemagglutinin protein subunitAF072402.1 1 precursor (HA1) A/softbill/South Africa/142/92(H7N4)hemagglutinin precursor U20464.1 (HA) A/ruddy turnstone/Delaware/2770/87(H7N5) nonfunctional matrix AY664476.1 proteinA/chicken/Brescia/1902(H7N7) hemagglutinin 1 chain (HA) U20471.1A/chicken/Jena/1816/87(H7N7) hemagglutinin precursor (HA) U20469.1A/chicken/Leipzig/79(H7N7) hemagglutinin precursor (HA) U20459.1A/duck/Heinersdorf/S495/6/86(H7N7) hemagglutinin precursor (HA) U20465.1A/equine/Prague/1/56 (H7N7) neuraminidase U85989.1A/equine/Santiago/77(H7N7) nucleoprotein AY383752.1A/equine/Santiago/77(H7N7) neuraminidase AY383757.1A/equine/Santiago/77(H7N7) hemagglutinin AY383756.1A/FPV/Weybridge(H7N7) matrix protein M38299.1A/goose/Leipzig/187/7/1979(H7N7) hemagglutinin L43914.1A/goose/Leipzig/192/7/1979(H7N7) hemagglutinin L43915.1A/goose/Leipzig/137/8/1979(H7N7) hemagglutinin L43913.1 A/ruddyturnstone/Delaware/134/99 (H7N7) nonfunctional matrix AY664468.1 proteinA/seal/Mass/1/80 H7N7 recombinant S73497.1 A/swan/Potsdam/63/6/81(H7N7)hemagglutinin precursor (HA) U20467.1 A/tern/Potsdam/342/6/79(H7N7)hemagglutinin precursor (HA) U20470.1 A/pintail/Alberta/121/79(H7N8)matrix protein 1 (M) and matrix DQ107485.1 protein 2 (M)A/Turkey/Minnesota/38429/88(H7N9) hemagglutinin AF497551.1A/turkey/Ontario/6118/1968(H8N4) segment 6 neuraminidase (NA) EU429793.1A/Mallard Duck/Alberta/357/84(H8N4) segment 4 hemagglutinin AF310988.1(HA1) A/Pintail Duck/Alberta/114/79(H8N4) segment 4 hemagglutininAF310987.1 (HA1) A/duck/Eastern China/01/2005(H8N4) segment 6neuraminidase (NA) EU429780.1 A/Red Kont/Delaware/254/94(H8N4) segment 4hemagglutinin (HA1) AF310989.1 A/chicken/Amioz/1527/03(H9N2)nucleoprotein DQ116511.1 A/chicken/Amioz/1527/03(H9N2) neuraminidaseDQ116081.1 A/chicken/Amioz/1527/03(H9N2) hemagglutinin DQ108911.1A/chicken/Alonim/1953/104(H9N2) hemagglutinin DQ108928.1A/chicken/Alonim/1552/03(H9N2) hemagglutinin DQ108914.1A/chicken/Alonim/1552/03(H9N2) nucleoprotein DQ116514.1A/chicken/Alonim/1965/04(H9N2) hemagglutinin DQ108929.1A/Chicken/Anhui/1/98(H9N2) hemagglutinin (HA) AF461511.1A/Chicken/Beijing/1/95(H9N2) nonfunctional matrix protein AF536719.1A/Chicken/Beijing/1/95(H9N2) nucleoprotein (NP) AF536699.1A/Chicken/Beijing/1/95(H9N2) nonfunctional nonstructural AF536729.1protein A/Chicken/Beijing/1/95(H9N2) segment 6 neuraminidase (NA)AF536709.1 A/Chicken/Beijing/2/97(H9N2) nucleoprotein (NP) AF536700.1A/Chicken/Beijing/2/97(H9N2) nonfunctional matrix protein AF536720.1A/Chicken/Beijing/2/97(H9N2) nonfunctional nonstructural AF536730.1protein A/Chicken/Beijing/2/97(H9N2) segment 6 neuraminidase (NA)AF536710.1 A/Chicken/Beijing/1/97(H9N2) hemagglutinin (HA) AF461530.1A/Chicken/Beijing/3/99(H9N2) nonfunctional matrix protein AF536721.1A/Chicken/Beijing/3/99(H9N2) nucleoprotein (NP) AF536701.1A/Chicken/Beijing/3/99(H9N2) nonfunctional nonstructural AF536731.1protein A/Chicken/Beijing/3/99(H9N2) segment 6 neuraminidase (NA)AF536711.1 A/chicken/Beit Alfa/1282/03(H9N2)hemagglutinin DQ104476.1A/chicken/Beit-Aran/29/05(H9N2) hemagglutinin DQ108931.1 A/chicken/BneiDarom/1557/03(H9N2) hemagglutinin DQ108915.1 A/chicken/EinHabsor/1808/04(H9N2) hemagglutinin DQ108925.1A/Chicken/Gangxi/2/00(H9N2) hemagglutinin (HA) AF461514.1A/Chicken/Gangxi/1/00(H9N2) hemagglutinin (HA) AF461513.1 A/chicken/GanShomron/1465/03(H9N2) hemagglutinin DQ104480.1 A/chicken/GanShomron/1292/03(H9N2) hemagglutinin DQ104478.1A/chicken/Gan_Shomron/1465/03(H9N2) nucleoprotein DQ116506.1A/chicken/Gan_Shomron/1465/03(H9N2) neuraminidase DQ116077.1A/chicken/Gan Shomron/1543/04(H9N2) nucleoprotein DQ116512.1A/chicken/Gan Shomron/1543/04(H9N2) hemagglutinin DQ108912.1A/Chicken/Guangdong/97(H9N2) nonfunctional matrix protein AF536722.1A/Chicken/Guangdong/97(H9N2) nucleoprotein (NP) AF536702.1A/Chicken/Guangdong/97(H9N2) nonfunctional nonstructural AF536732.1protein A/Chicken/Guangdong/97(H9N2) segment 6 neuraminidase (NA)AF536712.1 A/Chicken/Gansu/1/99(H9N2) hemagglutinin (HA) AF461512.1A/chicken/Gujrat/India/3697/2004(H9N2) polymerase basic 2 DQ979865.1(PB2) A/chicken/Haryana/India/2424/2004(H9N2) polymerase basic 2DQ979862.1 (PB2) A/Chicken/Henan/98(H9N2) nonfunctional matrix proteinAF536726.1 A/Chicken/Henan/98(H9N2) nucleoprotein (NP) AF536706.1A/Chicken/Henan/98(H9N2) nonfunctional nonstructural protein AF536736.1A/Chicken/Henan/2/98(H9N2) hemagglutinin (HA) AF461517.1A/Chicken/Henan/1/99(H9N2) hemagglutinin (HA) AF461516.1A/Chicken/Henan/98(H9N2) segment 6 neuraminidase (NA) AF536716.1A/Chicken/Hebei/1/96(H9N2) nonfunctional matrix protein AF536723.1A/Chicken/Hebei/1/96(H9N2) segment 6 nonfunctional AF536713.1neuraminidase protein A/Chicken/Hebei/1/96(H9N2) nucleoprotein (NP)AF536703.1 A/Chicken/Hebei/1/96(H9N2) nonfunctional nonstructuralprotein AF536733.1 A/Chicken/Hebei/1/96(H9N2) segment 6 nonfunctionalAF536713.1 neuraminidase protein A/Chicken/Hebei/2/00(H9N2)hemagglutinin (HA) AF461531.1 A/Chicken/Hebei/2/98(H9N2) nonfunctionalmatrix protein AF536724.1 A/Chicken/Hebei/2/98(H9N2) nucleoprotein (NP)AF536704.1 A/Chicken/Hebei/2/98(H9N2) nonfunctional nonstructuralprotein AF536734.1 A/Chicken/Hebei/2/98(H9N2) segment 6 neuraminidase(NA) AF536714.1 A/Chicken/Hebei/1/00(H9N2) hemagglutinin (HA) AF461515.1A/Chicken/Hebei/3/98(H9N2) nucleoprotein (NP) AF536705.1A/Chicken/Hebei/3/98(H9N2) nonfunctional matrix protein AF536725.1A/Chicken/Hebei/3/98(H9N2) nonfunctional onstructural protein AF536735.1A/Chicken/Hebei/3/98(H9N)) segment 6 neuraminidase (NA) AF536715.1A/chicken/Hong Kong/FY313/2000(H9N2) matrix protein 1 (M) and DQ107508.1matrix protein 2 (M) A/chicken/Hong Kong/WF208/2001(H9N2) matrix protein1 (M) and DQ107513.1 matrix protein 2 (M) A/chicken/HongKong/NT471/2002(H9N2) matrix protein 1 (M) and DQ107514.1 matrix protein2 (M) A/chicken/Hong Kong/WF2/99(H9N2) hemagglutinin AY206677.1A/chicken/Iarah/1376/03(H9N2) nucleoprotein DQ116504.1A/chicken/Iarah/1376/03(H9N2) neuraminidase DQ116075.1A/chicken/Iarah/1376/03(H9N2) hemagglutinin DQ108910.1A/chicken/India/2793/2003(H9N2) hemagglutinin (HA) AY336597.1A/chicken/Iran/101/1998(H9N2) matrix protein 2 (M2) EU477375.1A/Chicken/Jiangsu/1/99(H9N)) hemagglutinin (HA) AF461509.1A/Chicken/Jiangsu/2/98(H9N2) hemagglutinin (HA) AF461510.1A/chicken/Kfar Monash/636/02(H9N2) hemagglutinin DQ104464.1A/chicken/Kalanit/1966/06.12.04(H9N2) hemagglutinin DQ108930.1A/chicken/Kaianit/1946/04(H9N2) hemagglutinin DQ108927.1A/chicken/Korea/S4/2003(H9N2) matrix protein 1 (M) and matrix DQ107517.1protein 2 (M) A/Chicken/Korea/MS96/96(H9N2) matrix protein 1 and 2 (M)AF203788.1 A/Chicken/Korea/MS96/96(H9N2) neuraminidase subtype 2AF203786.1 A/Chicken/Korea/MS96/96(H9N2) nucleoprotein AF203787.1A/Chicken/Liaoning/99(H9N2) nonfunctional matrix protein AF536727.1A/Chicken/Liaoning/1/00(H9N2) hemagglutinin (HA) AF461518.1A/Chicken/Liaoning/99(H9N2) nucleoprotein (NP) AF536707.1A/Chicken/Liaoning/99(H9N2) nonfunctional matrix protein AF536727.1A/Chicken/Liaoning/99(H9N2) nonfunctional onstructural proteinAF536737.1 A/Chicken/Liaoning/2/00(H9N2) hemagglutinin (HA) AF461519.1A/chicken/Liaoning/99(H9N2) segment 6 neuraminidase (NA) AF536717.1A/chicken/Mudanjiang/0823/2000(H9N2) nucleoprotein (NP) AY496851.1A/Chicken/Mudanjiang/0823/2000 (H9N2) nonstructural protein AY631868.1A/Chicken/Mudanjiang/0823/00 (H9N2) hemagglutinin (HA) AY513715.1A/chicken/Mudanjiang/0823/2000(H9N2) matrix protein (M1) AY496852.1A/chicken/Mudanjiang/0823/2000(H9N2) nucleoprotein (np) AY496851.1A/chicken/Maale HaHamisha/90658/00(H9N2) hemagglutinin DQ104472.1A/chicken/Maanit/1477/03(H9N2) hemagglutinin DQ104483.1A/chicken/Maanit/1291/03(H9N2) hemagglutinin DQ104477.1A/chicken/Maanit/1275/03(H9N2) hemagglutinin DQ104457.1A/chicken/Maanit/1477/03(H9N2) nucleoprotein DQ116508.1A/chicken/Netohah/1373/03 (H9N2) nucleoprotein DQ116503.1A/chicken/Netohah/1373/03 (H9N2) neuraminidase DQ116074.1A/chicken/Netohah/1373/03 (H9N2) hemagglutinin DQ108909.1 A/chicken/NeveIlan/1504/03(H9N2) hemagglutinin DQ104484.1A/chicken/Neve_Ilan/1504/03(H9N2) nucleoprotein DQ116509.1A/chicken/Neve_Ilan/1504/03(H9N2) neuraminidase DQ116079.1A/chicken/Orissa/India/2317/2004(H9N2) polymerase basic 2 (PB2)DQ979861.1 A/chicken/Pardes-Hana-Carcur/1475/03(H9N2) hemagglutininDQ104482.1 A/chicken/Pardes-Hana-Carcur/1475/03(H9N2) neuraminidaseDQ116078.1 A/chicken/Saar/1456/03(H9N2) hemagglutinin DQ104479.1A/chicken/Sde_Uziahu/1747/04(H9N2) neuraminidase DQ116068.1A/chicken/Sede Uzziyyahu/1651/04(H9N2) hemagglutinin DQ108923.1A/chicken/Sde Uziahu/1747/04(H9N2) DQ108905.1A/chicken/Singapore/1998(H9N2) M2 protein EU014142.1A/chicken/Singapore/1998(H9N2) M2 protein EU014142.1A/Chicken/Shandong/98(H9N2) nonfunctional matrix protein AF536728.1A/Chicken/Shandong/1/98(H9N2) hemagglutinin (HA) AF461520.1A/Chicken/Shandong/98(H9N2) nucleoprotein (NP) AF536708.1A/Chicken/Shandong/98(H9N2) nonfunctional nonstructural proteinAF536738.1 A/Chicken/Shandong/98(H9N2) segment 6 neuraminidase (NA)AF536718.1 A/Chicken/Shandong/2/99(H9N2) hemagglutinin (HA) AF461521.1A/chicken/Shandong/1/02(H9N2) neuraminidase (NA) AY295761.1A/Chicken/Shanghai/F/98(H9N2) hemagglutinin AF461532.1A/Chicken/Shanghai/1/02(H9N2) hemagglutinin AY281745.1A/Chicken/Shanghai/2/99(H9N2)) hemagglutinin (HA) AF461522.1A/Chicken/Shanghai/3/00(H9N2)) hemagglutinin (HA) AF461523.1A/Chicken/Shanghai/F/98(H9N2) hemagglutinin (HA) AY743216.1A/Chicken/Shanghai/4-2/01(H9N2) hemagglutinin (HA) AF461525.1A/Chicken/Shanghai/4-1/01(H9N2) hemagglutinin (HA) AF461524.1A/Chicken/Shanghai/4/01(H9N2) hemagglutinin (HA) AY083841.1A/Chicken/Shanghai/3/01(H9N2) hemagglutinin HA) AY083840.1A/chicken/Talmei_Elazar/1304/03(H9N2)nucleoprotein DQ116530.1A/chicken/Talmei_Elazar/1304/03(H9N2) neuraminidase DQ116072.1A/Chicken/Tianjing/2/96(H9N2) hemagglutinin AF461527.1A/Chicken/Tianjing/1/96(H9N2) hemagglutinin (HA) AF461526.1A/chicken/Tel Adashim/811/01 (H9N2) hemagglutinin DQ104467.1A/chicken/Tel Adashim/811/01 (H9N2) nucleoprotein DQ116527.1A/ck/Tel_Adashim/811/01(H9N2) neuraminidase DQ116064.1 A/chicken/TelAdashim/812/01 (H9N2) nucleoprotein DQ116528.1 A/chicken/TelAdashim/812/01 (H9N2) hemagglutinin DQ104468.1A/ck/Tel_Adashim/812/01(H9N2) neuraminidase DQ116065.1 A/chicken/TelAdashim/786/01 (H9N2) nucleoprotein DQ116524.1 A/chicken/TelAdashim/809/01 (H9N2) hemagglutinin DQ104465.1 A/chicken/TelAdashim/809/01 (H9N2) nucleoprotein DQ116525.1 A/chicken/TelAdashim/1469/03 (H9N2) nucleoprotein DQ116507.1 A/chicken/TelAdashim/1469/303(H9N2) hemagglutinin DQ104481.1 A/chicken/TelAdashim/1506/03 (H9N2) neuraminidase DQ116080.1 A/chicken/TelAdashim/1506/03(H9N2) hemagglutinin DQ104474.1 A/chicken/TelAdashim/1506/03 (H9N2) nucleoprotein DQ116510.1 A/chicken/TelAdashim/1332/03(H9N2) nucleoprotein DQ116501.1 A/chicken/TelAdashim/1321/03(H9N2) nucleoprotein DQ116500.1 A/chicken/TelAdashim/1332/03(H9N2) hemagglutinin DQ108907.1 A/chicken/TelAdashim/1321/03(H9N2) hemagglutinin DQ108906.1A/chicken/Telmond/1308/03(H9N2) nucleoprotein DQ116499.1A/chicken/Telmond/1308/03(H9N2) neuraminidase DQ116073.1A/chicken/Telmond/1308/03(H9N2) hemagglutinin DQ108921.1A/chicken/Tzrofa/1568/04(H9N2) nucleoprotein DQ116519.1A/chicken/Tzrofa/1568/04(H9N2) hemagglutinin DQ108919.1A/chicken/UP/India/2544/2004(H9N2) polymerase basic 2 (PB2) DQ979864.1A/chicken/UP/India/2543/2004(H9N2) polymerase basic 2 (PB2) DQ979863.1A/chicken/Wangcheng/4/2001(H9N2) nucleoprotein AY268949.1A/chicken/Ysodot/1362/03(H9N2) nucleoprotein DQ116502.1A/chicken/Ysodot/1362/03(H9N2) hemagglutinin DQ108908.1A/Chicken/Yunnan/2/00(H9N2) hemagglutinin (HA) AF461529.1A/Chicken/Yunnan/1/99(H9N2) hemagglutinin (HA) AF461528.1 A/duck/EasternChina/01/2000(H9N2) segment 6 neuraminidase (NA) EU429725.1A/duck/Eastern China/48/2001(H9N2) segment 6 neuraminidase (NA)EU429707.1 A/duck/Eastern China/66/2003(H9N2) segment 6 neuraminidase(NA) EU429699.1 A/duck/Eastern China/80/2004(H9N2) segment 6neuraminidase (NA) EU429726.1 A/duck/Hong Kong/448/78(H9N2) matrixprotein 1 (M) and matrix DQ107494.1 protein 2 (M) A/duck/HongKong/448/78(H9N2) hemagglutinin precursor AY206673.1 A/duck/HongKong/366/78(H9N2) hemagglutinin precursor AY206674.1 A/duck/HongKong/784/79(H9N2)) matrix protein 1(M) and matrix DQ107496.1 protein 2(M) A/duck/Hong Kong/702/79(H9N2) matrix protein 1 (M) and matrixDQ107495.1 protein 2 (M) /duck/Hong Kong/702/79(H9N2) hemagglutininprecursor AY206672.1 A/duck/Hong Kong/610/79(H9N2) hemagglutininprecursor AY206680.1 A/duck/Hong Kong/552/79(H9N2) hemagglutininprecursor AY206679.1 A/duck/Hong Kong/644/79(H9N2) hemagglutininprecursor AY206678.1 A/duck/Korea/S13/2003(H9N2) matrix protein 1 (M)and matrix DQ107518.1 protein 2 (M) A/duck/Nanchang/4-361/2001(H9N2)matrix protein 1 (M) and DQ107511.1 matrix protein 2 (M)A/duck/NY/83793/2002(H9N2) matrix protein 1 (M) and matrix DQ107499.1protein 2 (M) A/goose/MN/5733-1243/80(H9N2) matrix protein 1 (M) andmatrix DQ107492.1 protein 2 (M) A/geese/Tel Adashim/829/01(H9N2)hemagglutinin DQ104469.1 A/geese/Tel Adashim/830/01(H9N2 hemagglutininDQ104470.1 A/ostrich/Eshkol/1436/03(H9N2) neuraminidase DQ116076.1A/ostrich/Eshkol/1436/03(H9N2) nucleoprotein DQ116505.1 A/pigeon/HongKong/WF286/2000(H9N2) matrix protein 1 (M) and DQ107509.1 matrix protein2 (M) A/quail/Hong Kong/YU415/2002(H9N2) matrix protein 1 (M) andDQ107516.1 matrix protein 2 (M) A/quail/Hong Kong/SSP225/2001(H9) matrixprotein 1 (M) and DQ107512.1 matrix protein 2 (M) A/quail/HongKong/YU1495/2000(H9N2) matrix protein 1 (M) and DQ107510.1 matrixprotein 2 (M) A/quail/Hong Kong/A28945/88(H9N2) hemagglutinin precursorAY206675.1 A/shorebird/Delaware/276/99 (H9N2) nonfunctional matrixprotein AY664464.1 A/shorebird/Delaware/113/2001(H9N2) matrix protein 1(M) and DQ107505.1 matrix protein 2 (M) A/silky chicken/HongKong/WF266/2002(H9N2) matrix protein 2 (M) DQ107515.1 and matrix protein1 (M) A/shorebird/Delaware/77/2001(H9N2) matrix protein 1 (M) andDQ107497.1 matrix protein 2 (M) A/guinea fowl/Hong Kong/WF10/99(H9N2)hemagglutinin precursor AY206676.1 A/swine/Hangzhou/1/2006(H9N2)nucleocapsid protein (NP) DQ907704.1 A/swine/Hangzhou/1/2006(H9N2))matrix protein 1 (M1) EF055887.1 A/swine/Hangzhou/1/2006(H9N2))nonstructural protein 1 (NS1) DQ823385.1 A/Sw/ShanDong/1/2003(H9N2)hemagglutinin (HA) AY294658.1 A/turkey/CA/6889/80(H9N2) matrix protein 1(M) and matrix DQ107491.1 protein 2 (M) A/turkey/TX/28737/81(H9N2)matrix protein 1 (M) and matrix DQ107493.1 protein 2 (M)A/turkey/MN/511/78(H9N2) matrix protein 1 (M) and matrix DQ107490.1protein 2 (M) A/turkey/Beit Herut/1267/03(H9N2) hemagglutinin DQ104485.1A/turkey/Beit HaLevi/1009/02(H9N2) hemagglutinin DQ104473.1A/turkey/Beit Herut/1265/03(H9N2) hemagglutinin DQ104456.1A/turkey/Beit_HaLevi/1562/03(H9N2) nucleoprotein DQ116515.1A/turkey/Beit_HaLevi/1566/04(H9N2) nucleoprotein DQ116517.1A/turkey/Beit_HaLevi/1562/03(H9N2) neuraminidase DQ116083.1A/turkey/Beit_HaLevi/1566/04(H9N2) neuraminidase DQ116084.1A/turkey/Beit_Herut/1267/03(H9N2) neuraminidase DQ116070.1A/turkey/Beit_Herut/1265/03(H9N2) neuraminidase DQ116069.1 A/turkey/BeitHaLevi/1566/04(H9N2) hemagglutinin DQ108917.1 A/turkey/Bezat/89/05(H9N2)hemagglutinin DQ108922.1 A/turkey/Brosh/1276/03(H9N2) hemagglutininDQ104458.1 A/turkey/Brosh/1276/03(H9N2) neuraminidase DQ116071.1A/turkey/Emek Hefer/1272/03(H9N2) hemagglutinin DQ104475.1 A/turkey/EinHabsor/1804/04(H9N2) hemagglutinin DQ108924.1 A/turkey/EinTzurim/1172/02(H9N2) hemagglutinin DQ104451.1 A/turkey/EinTzurim/1738/04(H9N2) hemagglutinin DQ108920.1A/turkey/Ein_Tzurim/1738/04(H9N2) neuraminidase DQ116085.1A/turkey/Gyvat Haim Ehud/1544/03(H9N2)hemagglutinin DQ108913.1A/turkey/Givat Haim/810/01 (H9N2) hemagglutinin DQ104466.1A/turkey/Givat Haim/810/01 (H9N2) nucleoprotein DQ116526.1A/turkey/Givat Haim/868/02(H9N2) hemagglutinin DQ104471.1 A/turkey/GivatHaim/622/02(H9N2) hemagglutinin DQ104462.1A/turkey/Givat_Haim/965/02(H9N2) nucleoprotein DQ116498.1A/turkey/Gyvat_Haim_Ehud/1544/03(H9N2) nucleoprotein DQ116513.1A/turkey/Gyvat_Haim_Ehud/1544/03(H9N2) neuraminidase DQ116082.1A/tk/Givat_Haim/810/25.12.01(H9N2) neuraminidase DQ116063.1A/turkey/Givat_Haim/622/02(H9N2)) neuraminidase DQ116060.1A/turkey/Givat_Haim/965/02(H9N2) neuraminidase DQ116057.1A/turkey/Hod_Ezyon/699/02(H9N2) neuraminidase DQ116062.1A/turkey/Mishmar Hasharon/619/02 (H9N2) hemagglutinin DQ104461.1A/turkey/Mishmar_Hasharon/619/02(H9N2) neuraminidase DQ116059.1A/turkey/Kfar_Vitkin/616/02(H9N2) neuraminidase DQ116058.1 A/turkey/KfarVitkin/616/02 (H9N2) hemagglutinin DQ104460.1 A/turkey/KfarVitkin/615/02 (H9N2)hemagglutinin DQ104459.1 A/turkey/Kfar Vitkin/615/02(H9N2) nucleoprotein DQ116520.1 A/turkey/Kfar_Vitkin/616/02(H9N2))nucleoprotein DQ116521.1 A/turkey/Kfar Warburg/1224/03(H9N2)hemagglutinin DQ104455.1 A/tk/Kfar_Vitkin/615/02(H9N)) neuraminidaseDQ116067.1 A/turkey/Mishmar_Hasharon/619/02(H9N2) nucleoproteinDQ116522.1 A/turkey/Naharia/1013/02(H9N2) hemagglutinin DQ104449.1A/turkey/Nahalal/1547/04(H9N2) hemagglutinin DQ108932.1 A/turkey/NeveIlan/90710/00 (H9N2) nucleoprotein DQ116529.1A/tk/Neve_Ilan/90710/00(H9N2) neuraminidase DQ116066.1A/turkey/Qevuzat_Yavne/1242/03(H9N2) neuraminidase DQ116086.1A/turkey/Sapir/1199/02(H9N2) hemagglutinin DQ104452.1 A/turkey/ShadmotDvorah/1567/04(H9N2) nucleoprotein DQ116518.1 A/turkey/ShadmotDvorah/1567/04(H9N2) hemagglutinin DQ108918.1 A/turkey/TzurMoshe/1565/04(H9N2) nucleoprotein DQ116516.1 A/turkey/TzurMoshe/1565/04(H9N2) hemagglutinin DQ108916.1 A/turkey/Yedidia/625/02(H9N2) hemagglutinin DQ104463.1 A/turkey/Yedidia/625/02 (H9N2)nucleoprotein DQ116523.1 A/turkey/Yedidia/625/02 (H9N2) neuraminidaseDQ116061.1 A/turkey/Yedidia/911/02(H9N2) hemagglutinin DQ104448.1A/turkey/Avigdor/1215/03(H9N2) hemagglutinin DQ104454.1A/turkey/Avigdor/1209/03(H9N2) hemagglutinin DQ104453.1A/turkey/Avichail/1075/02(H9N2) hemagglutinin DQ104450.1A/turkey/Avigdor/1920/04(H9N2) hemagglutinin DQ108926.1A/pintail/Alberta/49/2003(H9N5) matrix protein 1 (M) and matrixDQ107498.1 protein 2 (M) A/red knot/Delaware/2552/87 (H9N5)nonfunctional matrix protein AY664472.1 A/duck/Hong Kong/147/77(H9N6)hemagglutinin precursor AY206671.1 A/shorebird/Delaware/270/2001(H9N7)matrix protein 1 (M) and DQ107504.1 matrix protein 2 (M)A/shorebird/Delaware/277/2000(H9N7) matrix protein 1 (M) and DQ107507.1matrix protein 2 (M) A/shorebird/Delaware/275/2001(H9N7)) matrix protein2 (M) and DQ107506.1 matrix protein 1 (M) A/ruddyturnstone/Delaware/116/98 (H9N8) nonfunctional matrix AY664435.1 proteinA/shorebird/Delaware/141/2002(H9N9) matrix protein 1 (M) and DQ107503.1matrix protein 2 (M) A/ruddy turnstone/Delaware/103/2002(H9N9) matrixprotein 1 (M) DQ107502.1 and matrix protein 2 (M)A/shorebird/Delaware/29/2002(H9N9) matrix protein 1 (M) and DQ107501.1matrix protein 2 (M) A/shorebird/Delaware/18/2002(H9N9) matrix protein 1(M) and DQ107500.1 matrix protein 2 (M) A/ruddyturnstone/Delaware/259/98 (H9N9) nonfunctional matrix AY664469.1 proteinA/duck/Eastern China/527/2003(H10N3) segment 6 neuraminidase EU429716.1(NA) A/duck/Eastern China/495/2003(H10N3) segment 6 neuraminidaseEU429715.1 (NA) A/duck/Eastern China/372/2003(H10N3) segment 6neuraminidase EU429714.1 (NA) A/duck/Eastern China/488/2003(H10N3)segment 6 neuraminidase EU429712.1 (NA) A/duck/EasternChina/453/2002(H10N3) segment 6 neuraminidase EU429711.1 (NA)A/duck/Eastern China/412/2003(H10N3) segment 6 neuraminidase EU429710.1(NA) A/duck/Eastern China/404/2003(H10N3) segment 6 neuraminidaseEU429709.1 (NA) A/duck/Eastern China/397/2003(H10N3) segment 6neuraminidase EU429708.1 (NA) A/duck/Eastern China/502/2003(H10N3)segment 6 neuraminidase EU429705.1 (NA) A/duck/EasternChina/395/2003(H10N3) segment 6 neuraminidase EU429704.1 (NA)A/duck/Eastern China/356/2003(H10N3) segment 6 neuraminidase EU429703.1(NA) A/duck/Eastern China/368/2003(H10N3) segment 6 neuraminidaseEU429702.1 (NA) A/chicken/Singapore/1993(H10N5) M2 protein EU014145.1A/red knot/Delaware/2561/87 (H10N5) nonfunctional matrix AY664441.1protein A/chicken/Germany/N/1949(H10N7) segment 6 neuraminidase (NA)EU429796.1 A/ruddy turnstone/Delaware/2764/87 (H10N7) nonfunctionalmatrix AY664462.1 protein A/mallard/Alberta/71/98 (H10N7) nonfunctionalmatrix protein AY664485.1 A/mallard/Alberta/90/97 (H10N7) nonfunctionalmatrix protein AY664446.1 A/mallard/Alberta/110/99(Hl0N7) nonfunctionalmatrix protein AY664481.1 A/mallard/Alberta/297/77 (H10N7) nonfunctionalmatrix protein AY664430.1 A/mallard/Alberta/223/98 (H10N8) nonfunctionalmatrix protein AY664486.1 A/ruddy turnstone/New Jersey/51/85 (H11N1)nonfunctional matrix AY664479.1 protein A/duck/Nanchang/1749/1992(H11N2)nucleoprotein (NP) U49094.1 A/duck/Hong Kong/62/1976(H11N2) polymerase(PB1) U48280.1 A/duck/Yangzhou/906/2002(H11N2) hemagglutinin DQ080993.1A/shorebird/Delaware/86/99 (H11N2) nonfunctional matrix proteinAY664463.1 A/ruddy turnstone/Delaware Bay/2762/1987(H11N2)polymerase PB2CY126279.1 (PB2) A/ruddy turnstone/Delaware/2762/87 (H11N2)nonfunctional AY664459.1 matrix protein A/ruddy turnstone/DelawareBay/2762/1987(H11N2) polymerase PB1 CY126278.1 (PB1) and PB1-F2 protein(PB1-F2) A/ruddy turnstone/Delaware/2589/87 (H11N4) nonfunctional matrixAY664478.1 protein A/duck/England/1/1956(H11N6) segment 6 neuraminidase(NA) EU429795.1 A/mallard/Alberta/125/99 (H11N6) nonfunctional matrixprotein AY664483.1 A/duck/Memphis/546/1974(H11N9) segment 6neuraminidase (NA) EU429798.1 A/mallard/Alberta/122/99 (H11N9)nonfunctional matrix protein AY664444.1 A/MallardDuck/Alberta/342/83(H12N1) segment 4 hemagglutinin AF310991.1 (HA1)A/ruddy turnstone/Delaware/67/98(H12N4) nonfunctional matrix AY664470.1protein A/Ruddy Turnstone/Delaware/67/98(H12N4) segment 4 hemagglutininAF310990.1 (HA1) A/mallard/Alberta/52/97 (H12N5) nonfunctional matrixprotein AY664448.1 A/mallard/Alberta/223/77 (H12N5) nonfunctional matrixprotein AY664431.1 A/Laughing Gull/New Jersey/171/92(H12N5) segment 4AF310992.1 hemagglutinin (HA1) A/ruddy turnstone/Delaware/265/98 (H12N8)nonfunctional matrix AY664438.1 protein A/herring gull/New Jersey/782/86(H13N2) nonfunctional matrix AY664475.1 proteinA/shorebird/Delaware/224/97 (H13N6) nonfunctional matrix AY664421.1protein A/PR/8/34 (H1N1) × A/England/939/69 (H3N2) PB1 proteinAJ564806.1 A/PR/8/34 (H1N1) × A/England/939/69 (H3N2)PB2 proteinAJ564804.1 A/duck/Czechslovakia/56(H4N6) × A/USSR/90/77(H1N1))EU643639.1 neuraminidase (NA) A/duck/Czechslovakia/56(H4N6) ×A/USSR/90/77(H1N1)) EU643638.1 neuraminidase (NA)A/duck/Ukraine/63(H3N8) × A/USSR/90/77(H1N1)) neuraminidase EU643637.1(NA) A/duck/Ukraine/63(H3N8) × A/USSR/90/77(H1N1)) neuraminidaseEU643636.1 (NA) RCB1-XXI: A/USSR/90/77(H1N1) × A/Duck/Czechoslov 56(H4N6) AF290438.1 segment 4 hemagglutinin RCB1: A/USSR/90/77(H1N1) ×A/Duck/Czechoslov 56 (H4N6) AF290437.1 hemagglutinin PX14-XIII(A/USSR/90/77(H1N1) × A/Pintail AF290442.1 Duck/Primorie/695/76(H2N3))segment 4 hemagglutinin PX14(A/USSR/90/77(H1N1) × A/PintailDuck/Primorie/695/76(H2N3)) AF290441.1 segment 4 hemagglutininPX8-XIII(A/USSR/90/77(H1N1) × A/Pintail Duck/Primorie/695/76(H2N3))segment 4 hemagglutinin PX8(A/USSR/90/77(H1N1) × A/PintailDuck/Primorie/695/76(H2N3)) AF290439.1 segment 4 hemagglutininA/swine/Schleswig-Holstein/1/93 hemagglutinin (HA) U72669.1A/swine/England/283902/93 hemagglutinin (HA) U72668.1A/swine/England/195852/92 hemagglutinin (HA) U72667.1A/swine/England/117316/86 hemagglutinin (HA) U72666.1A/turkey/Germany/2482/90) hemagglutinin (HA) U96766.1

TABLE 12 Influenza B Antigens GenBank Strain/Protein Access No.B/Daeku/47/97 hemagglutinin AF521237.1 B/Daeku/45/97 hemagglutininAF521236.1 B/Daeku/10/97 hemagglutinin AF521221.1 B/Daeku/9/97hemagglutinin AF521220.1 B/Gyeonggi/592/2005 neuraminidase DQ231543.1B/Gyeonggi/592/2005 hemagglutinin DQ231538.1 B/Hong Kong/5/72neuraminidase AF305220.1 B/Hong Kong/5/72 hemagglutinin AF305219.1B/Hong Kong/157/99 hemagglutinin AF387503.1 B/Hong Kong/157/99hemagglutinin AF387502.1 B/Hong Kong/156/99 hemagglutinin AF387501.1B/Hong Kong/156/99 hemagglutinin AF387500.1 B/Hong Kong/147/99hemagglutinin AF387499.1 B/Hong Kong/147/99 hemagglutinin AF387498.1B/Hong Kong/110/99 hemagglutinin AF387497.1 B/Hong Kong/110/99hemagglutinin AF387496.1 B/Incheon/297/2005 hemagglutinin DQ231539.1B/Incheon/297/2005 neuraminidase DQ231542.1 B/Lee/40 polymerase protein(PB1) D00004.1 B/Michigan/22572/99 hemagglutinin AY129961.1B/Michigan/22723/99 hemagglutinin (HA) AY112992.1 B/Michigan/22631/99hemagglutinin (HA) AY112991.1 B/Michigan/22587/99 hemagglutinin (HA)AY112990.1 B/New York/20139/99 hemagglutinin AY129960.1 B/Panama/45/90nucleoprotein AF005739.1 B/Panama/45/90 polymerase (PA) AF005738.1B/Panama/45/90 polymerase (PB2) AF005737.1 B/Panama/45/90 polymerase(PB1) AF005736.1 B/Pusan/250/99 hemagglutinin AF521218.1 B/Pusan/255/99hemagglutinin AF521226.1 B/Pusan/270/99 hemagglutinin AF521219.1B/Pusan/285/99 hemagglutinin AF521217.1 B/Riyadh/01/2007 segment 8nuclear export protein (NEP) GU135839.1 and non structural protein 1(NS1) B/Seoul/6/88 hemagglutinin AF521238.1 B/Seoul/12/88 hemagglutininAF521239.1 B/Seoul/1/89 hemagglutinin AF521230.1 B/Seoul/37/91hemagglutinin AF521229.1 B/Seoul/38/91 hemagglutinin AF521227.1B/Seoul/40/91 hemagglutinin AF521235.1 B/Seoul/41/91 hemagglutininAF521228.1 B/Seoul/13/95 hemagglutinin AF521225.1 B/Seoul/12/95hemagglutinin AF521223.1 B/Seoul/17/95 hemagglutinin AF521222.1B/Seoul/21/95 hemagglutinin AF521224.1 B/Seoul/16/97 hemagglutininAF521233.1 B/Seoul/19/97 hemagglutinin AF521231.1 B/Seoul/28/97hemagglutinin AF521234.1 B/Seoul/31/97 hemagglutinin AF521232.1B/Seoul/232/2004 neuraminidase DQ231541.1 B/Seoul/1163/2004neuraminidase DQ231540.1 B/Seoul/1163/2004 hemagglutinin DQ231537.1B/Sichuan/379/99 hemagglutinin (HA) AF319590.1 B/Sichuan/38/2000hemagglutinin (HA) AF319589.1 B/South Carolina/25723/99 hemagglutininAY129962.1 B/Switzerland/4291/97 hemagglutinin AF387505.1B/Switzerland/4291/97 hemagglutinin AF387504.1 B/Taiwan/21706/97nonstructural protein 1 (NS1) AF492479.1 B/Taiwan/21706/97 hemagglutinin(HA) AF026162.1 B/Taiwan/3143/97 nonstructural protein 1 (NS1)AF492478.1 B/Taiwan/3143/97 haemagglutinin (HA) AF026161.1B/Taiwan/2026/99 nonstructural protein 1 (NS1) AF492481.1B/Taiwan/2026/99 hemagglutinin AY604741.1 B/Taiwan/2027/99 nonstructuralprotein 1 (NS1) AF492480.1 B/Taiwan/2027/99 hemagglutinin AY604742.1B/Taiwan/1243/99 nonstructural protein NS1(NS1) AF380504.1B/Taiwan/1243/99 hemagglutinin AY604740.1 B/Taiwan/2195/99 hemagglutininAY604743.1 B/Taiwan/2195/99 nonstructural protein 1 (NS1) AF492482.1B/Taiwan/1293/2000 nonstructural protein NS1(NS1) AF380509.1B/Taiwan/1293/00 hemagglutinin AY604746.1 B/Taiwan/1293/2000hemagglutinin (HA) AF492477.1 B/Taiwan/1265/2000 nonstructural proteinNS1 (NS1) AF380508.1 B/Taiwan/1265/00 hemagglutinin AY604745.1B/Taiwan/4184/2000 nonstructural protein NS1 (NS1) AF380507.1B/Taiwan/4184/00 hemagglutinin (HA) AY604750.1 B/Taiwan/31511/2000nonstructural protein NS1 (NS1) AF380505.1 B/Taiwan/31511/00hemagglutinin (HA) AY604748.1 B/Taiwan/12192/2000 hemagglutininAY604747.1 B/Taiwan/41010/00 hemagglutinin (HA) AY604749.1B/Taiwan/41010/2000 nonstructural protein NS1 (NS1) AF380506.1B/Taiwan/0409/00 hemagglutinin (HA) AY604744.1 B/Taiwan/202/2001nonstructural protein 1 (NS1) AF380512.1 B/Taiwan/202/2001 hemagglutinin(HA) AF366076.1 B/Taiwan/11515/2001 nonstructural protein 1 (NS1)AF380511.1 B/Taiwan/11515/01 hemagglutinin AY604754.1B/Taiwan/11515/2001 hemagglutinin (HA) AF366075.1 B/Taiwan/1103/2001nonstructural protein NS1 (NS1) AF380510.1 B/Taiwan/1103/01hemagglutinin AY604755.1 B/Taiwan/114/2001 hemagglutinin (HA), HA-4allele AF492476.1 B/Taiwan/2805/2001 hemagglutinin (HA) AF400581.1B/Taiwan/2805/01 hemagglutinin (HA) AY604752.1 B/Taiwan/0114/01hemagglutinin (HA) AY604753.1 B/Taiwan/0202/01 hemagglutinin (HA)AY604751.1 B/Taiwan/4119/02 hemagglutinin (HA) AY604778.1B/Taiwan/4602/02 hemagglutinin (HA) AY604777.1 B/Taiwan/1950/02hemagglutinin (HA) AY604776.1 B/Taiwan/1949/02 hemagglutinin (HA)AY604775.1 B/Taiwan/1584/02 hemagglutinin (HA) AY604774.1B/Taiwan/1561/02 hemagglutinin (HA) AY604773.1 B/Taiwan/1536/02hemagglutinin (HA) AY604772.1 B/Taiwan/1534/02 hemagglutinin (HA)AY604771.1 B/Taiwan/1503/02 hemagglutinin (HA) AY604770.1B/Taiwan/1502/02 hemagglutinin (HA) AY604769.1 B/Taiwan/1013/02hemagglutinin (HA) AY604768.1 B/Taiwan/0993/02 hemagglutinin (HA)AY604766.1 B/Taiwan/0932/02 hemagglutinin (HA) AY604765.1B/Taiwan/0927/02 hemagglutinin (HA) AY604764.1 B/Taiwan/0880/02hemagglutinin (HA) AY604763.1 B/Taiwan/0874/02 hemagglutinin (HA)AY604762.1 B/Taiwan/0730/02 hemagglutinin (HA) AY604761.1B/Taiwan/0722/02 hemagglutinin (HA) AY604760.1 B/Taiwan/0702/02hemagglutinin (HA) AY604759.1 B/Taiwan/0654/02 hemagglutinin (HA)AY604758.1 B/Taiwan/0600/02 hemagglutinin (HA) AY604757.1B/Taiwan/0409/02 hemagglutinin (HA) AY604756.1 B/Taiwan/0879/02nonfunctional hemagglutinin AY604767.1 B/Taiwan/3532/03 hemagglutinin(HA) AY604794.1 B/Taiwan/2551/03 hemagglutinin (HA) AY604793.1B/Taiwan/1618/03 hemagglutinin (HA) AY604792.1 B/Taiwan/1574/03hemagglutinin (HA) AY604791.1 B/Taiwan/1013/03 hemagglutinin (HA)AY604790.1 B/Taiwan/0833/03 hemagglutinin (HA) AY604789.1B/Taiwan/0735/03 hemagglutinin (HA) AY604788.1 B/Taiwan/0699/03hemagglutinin (HA) AY604787.1 B/Taiwan/0684/03 hemagglutinin (HA)AY604786.1 B/Taiwan/0616/03 hemagglutinin (HA) AY604785.1B/Taiwan/0615/03 hemagglutinin (HA) AY604784.1 B/Taiwan/0610/03hemagglutinin (HA) AY604783.1 B/Taiwan/0576/03 hemagglutinin (HA)AY604782.1 B/Taiwan/0569/03 hemagglutinin (HA) AY604781.1B/Taiwan/0562/03 hemagglutinin (HA) AY604780.1 B/Taiwan/0002/03hemagglutinin (HA) AY604779.1 B/Taiwan/773/2004 hemagglutinin (HA)EU068195.1 B/Taiwan/187/2004 hemagglutinin (HA) EU068194.1B/Taiwan/3892/2004 hemagglutinin (HA) EU068193.1 B/Taiwan/562/2004hemagglutinin (HA) EU068191.1 B/Taiwan/234/2004 hemagglutinin (HA)EU068188.1 B/Taiwan/4897/2004 hemagglutinin (HA) EU068186.1B/Taiwan/8579/2004 hemagglutinin (HA) EU068184.1 B/Taiwan/184/2004hemagglutinin (HA) EU068183.1 B/Taiwan/647/2005 hemagglutinin (HA)EU068196.1 B/Taiwan/877/2005 hemagglutinin (HA) EU068198.1B/Taiwan/521/2005 hemagglutinin (HA) EU068189.1 B/Taiwan/1064/2005hemagglutinin (HA) EU068192.1 B/Taiwan/3722/2005 hemagglutinin (HA)EU068197.1 B/Taiwan/5049/2005 hemagglutinin (HA) EU068190.1B/Taiwan/5011/2005 hemagglutinin (HA) EU068187.1 B/Taiwan/4659/2005hemagglutinin (HA) EU068185.1 B/Taiwan/25/2005 hemagglutinin (HA)EU068182.1 B/Taiwan/1037/2005 hemagglutinin (HA) EU068181.1B/Taiwan/62/2005 hemagglutinin (HA) EU068180.1 B/Taiwan/591/2005hemagglutinin (HA) EU068179.1 B/Taiwan/649/2005 hemagglutinin (HA)EU068178.1 B/Taiwan/4554/2005 hemagglutinin (HA) EU068177.1B/Taiwan/987/2005 hemagglutinin (HA) EU068176.1 B/Taiwan/2607/2006hemagglutinin (HA) EU068175.1 B/Vienna/1/99 hemagglutinin AF387495.1B/Vienna/1/99 hemagglutinin AF387494.1 B/Vienna/1/99 hemagglutininAF387493.1 B/Vienna/1/99 hemagglutinin AF387492.1

TABLE 13 Influenza C Antigens GenBank Strain/Protein Access No.C/JHB/1/66) hemagglutinin-esterase-fusion AY880247.1 protein (HEF) mRNA,complete cds. STRAIN C/ANN ARBOR/1/50) persistent variant AF102027.1segment 7 non-structural protein 1 (NS1) mRNA, complete cds (STRAINC/ANN ARBOR/1/50) wild type segment 7 AF102026.1 non-structural protein1 (NS1) mRNA, complete cds (C/JHB/1/66) hemagglutinin-esterase-fusionprotein AY880247.1 (HEF) mRNA, complete cds (STRAIN C/BERLIN/1/85) mRNAfor basic polymerase X55992.1 2 precursor

TABLE 14 H7 Hemagglutinin Amino Acid Sequences Accession No/ SEQStrain/Protein Amino Acid Sequence ID NO: AAM19228ACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVVNATETVETA 1 A/turkey/NIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFESDLIIERR Minnesota/EGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGIITNGAT 38429/1988SACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIVW 1988// HAGIHHSGSTTEQTKLYGSGNKLITVESSKYQQSFTPSPGARPQVNG 20335017ESGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIEKDGGSHYG AAY46211MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 2 A/mallard/NATETVERTNVPRICSRGKRTVDLGQCGLLGTITGPPQCDQFLEF Sweden/91/2002SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 2002// HASGIRTNGAPSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 66394828RNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFMCVKNGNMRCTICIABI84694 MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVV 3 A/turkey/NATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/ESDLIIERREGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 1/1988SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 1988/07/13 HARNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPS 115278573PGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHAQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIABS89409 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 4 A/blue-wingedNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF teal/Ohio/566/DTDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 2006 2006// HASGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 155016324RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVRLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIACD03594 MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTLTEKGIEVV 5 A/ruddyNATETVESANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF turnstone/DE/DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 1538/2000SGIRTNGATSACRRLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 2000// HARNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTPS 187384848PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLIFICIKNGNMRCTICIBAH22785 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 6A/duck/Mongolia/ NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 119/2008SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIGKETMGFTY 2008// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 223717820RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICICAY39406 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 7 A/Anascrecca/NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Spain/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 1460/2008SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2008/01/26 HARKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS 254674376PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIACX53683 MNIQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 8 A/goose/CzechNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Republic/1848-SADLIIERRGGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY K9/2009SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2009/02/04 HARKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS 260907763PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIACZ48625 MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVV 9 A/turkey/NATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/ESDLIIERREGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 38429/1988SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 1988// HARNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPS 269826341PGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEL ADC29485STQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWT 10 A/mallard/Spain/RDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLREN 08.00991.3/AEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQID 2005 2005/11/PVKLSSGYKDVILWFSFGASCFILL HA 284927336 ADK71137MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 11 A/blue-wingedNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF teal/Guatemala/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY CIP049-SGIRTNGATSACRRSGSSSYAEMKWLLSNSDNAAFPQMTKSYRNP 01/2008RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS 2008/02/07 HAPGIRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLR 301333785GKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQHFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIADK71148 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 12 A/blue-wingedNXTETVETANIKKICTHGKRPTDLGQCGLLGTLIGPPQCDRFLEF teal/Guatemala/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY CIP049-SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 02/2008RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS 2008/03/05 HAPGIRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLR 301333804GKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIADN34727 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 13 A/goose/CzechNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Republic/1848-SADLIIERRGGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY T14/2009SGIRTNGXTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2009/02/04 HARKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS 307141869PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAEK84760 PAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLP 14 A/wildFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAG bird/Korea/A14/FIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLN 2011 2011/02/RLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAEL HA 341610308LVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTICI AEK84761ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERGVEVFNATE 15 A/wildTVERTNVPRICSKGKKTVDLGQCGLRGTITGPPQCDQFLKFSPDL bird/Korea/A3/IIERQKGSDVCYPGKFVNEKPLRQILRESGGIDKETMGFAYNGIK 2011 2011/02/TNGPPIACRKSGSSFYAKMKWLLSNTDKAAFPQMTKSYKNTRRNP HA 341610310ALIVWGIHHSGSTTKQTKLYGIGSNLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIPPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGKGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGL VFICVKNGNMRCTICI AEK84763ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERGVEFFNATE 16 A/wildTVEPINVPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEFSADL bird/Korea/A9/IIERREGSDVCYPGKFVNEKALRQILRESGGIDKETMGFAYSGIK 2011 2011/02/TNGPPIACRKSGSSFYAKMKWLLSNTDKAAFPQMTKSYKNTRRDP HA 341610314ALIVWGIHHSGSTIKQINLYGIGSNLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVIFIENGAFIAPDRASFLIGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGL VFICVKNGNMRCTICI AEK84765LVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATET 17 A/spot-billedVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLI duck/Korea/447/IERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGIRT 2011 2011/04/NGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 341610318LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMARIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLV FICVKNGNMRCTICI AEM98291SILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNAT 18 A/wildETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSAD duck/Mongolia/LIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGI 1-241/2008RTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKD 2008/04/ HAPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGA 344196120RPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGSIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMG LVFICVKNGNMRCTI AFM09439QILAFIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVVNAT 19 A/emperorETVETVNIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFDAD goose/Alaska/LIIERRKGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGI 44063-061/2006RTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNK 2006/05/23 HAPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFVPSPGA 390535062RPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPERASFERGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQINPVKLSSGYKDIILWFSFGASCFLLLAIAMG LVFICIKNGNMRCTICI AFV33945MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERRIEVV 20 A/guineaNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF fowl/Nebraska/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 17096-1/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2011/04/05 HARNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS 409676820PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAFV33947 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 21 A/goose/NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Nebraska/17097-DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 4/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 2011/04/05 HARNKPALIVWGVHHSASATEQTKLYGSGSKLITVGSSKYQQSFTPS 409676827PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAFX85260 MNTQILAFIACMLIGINGDKICLGHHAVANGTKVNTLTERGIEVV 22 A/ruddyNATETVETANIKRICTQGKRPIDLGQCGLLGTLIGPPQCDQFLEF turnstone/DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY DelawareSGIRTNGATSACIRLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP Bay/220/1995RNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTPS 1995/05/21 HAPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR 423514912GESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGRCPRYVKQTSLLLATGMKNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAGE08098 MNTQILTLIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 23 A/northernNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF shoverl/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY Mississippi/SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 11OS145/2011RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS 2011/01/08 HAPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR 444344488GESLGVQSDVPLDSGCEGDCFHNGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAGI60301 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 24 A/Hangzhou/1/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/03/24SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 475662454SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGISGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGI60292 MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTLTERGVEVV 25 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 4664T/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/03/05 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 476403560RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCHHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGJ72861 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVV 26 A/chicken/NATETVERTNIPRICSKGKKTVDLGQGGPRGTITGPPQCDQFLEF Zhejiang/DTID-SADLIMERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY ZJU01/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS HA 479280294PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGJ73503 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 27 A/Nanjing/1/NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/03/28SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 479285761SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIBAN16711 MNIQVLVFALMAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 28 A/duck/Gunma/NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 466/2011 2011//SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY HA 482661571SGIRTNGITSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPALIAWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDDTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGK84857 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 29 A/Hangzhou/2/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/01SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 485649824SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQIIKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGL44438 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 30 A/Shanghai/02/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/03/05 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 496493389RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGL33692 GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTN 31 A/Shanghai/QQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ 4655T/2013HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA 2013/02/26 HASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASC 491874175FILLAIAMGLVFICVKNGNMRCTICI AGL33693GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTN 32 A/Shanghai/QQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ 4659T/2013HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA 2013/02/27 HASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASC 491874186FILLAIVMGLVFICVKNGNMRCTICI AGL95088VFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETV 33 A/Taiwan/ERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLII S02076/2013ERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTN 2013/04/22 HAGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAL 501485301IVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF ICVKNGNMR AGL95098LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATET 34 A/Taiwan/VERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLI T02081/2013IERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRT 2013/04/22 HANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 501485319LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV FICVKNGNMRCT AGM53883GFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELID 35 A/Shanghai/NEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLAD 5083T/2013SEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTY 2013/04/20 HADHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIV 507593986 MGLVFICVKNGNMRCTAGM53884 AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEV 36 A/Shanghai/EKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKL 5180T/2013YERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR 2013/04/23 HAEEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFI 507593988 CVKNGNMRCTICIAGM53885 QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFN 37 A/Shanghai/EVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMD 5240T/2013KLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSK 2013/04/25 HAYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV 507593990 FICVKNGNMRCTAGM53886 NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNE 38 A/Shanghai/VEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDK 4842T/2013LYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKY 2013/04/13 HAREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF 507593992 ICVKNGNMRCTAGM53887 NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNE 39 A/Shanghai/VEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDK 4701T/2013LYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKY 2013/04/06 HAREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF 507593994 ICVKNGNMRCTICAGN69462 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 40 A/Wuxi/2/2013NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013/03/31 HASADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 511105778SGIRTNGSTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGN69474 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 41 A/Wuxi/1/2013NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013/03/31 HASADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 511105798SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLINGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGO51387 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 42 A/Jiangsu/2/NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/20SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 514390990SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRKEAMKBXIQIDPVKLSSGYKDVXJWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIBAN59726 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 43A/duck/Mongolia/ NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 147/2008SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIGKETMGFTY 2008/08/29 HASGIRTNGATSACRRSRSSFYAEMKWLLSNTDNAAFPQMIRSYKNT 519661951RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIBAN59727 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 44A/duck/Mongolia/ NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 129/2010SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 2010// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 519661954RKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGQ80952 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 45A/duck/Jiangxi/ NATETVERTSIPRICSKGKRAVDLGQCGLLGTITGPPQCDQFLEF 3096/2009SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 2009// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQTIKSYKNT 523788794RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGQ80989 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 46A/duck/Jiangxi/ NATETVERTSIPRICSKGKRAVDLGQCGLLGTITGPPQCDQFLEF 3257/2009SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 2009// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQTIKSYKNT 523788868RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGXSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGQ81043 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 47 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Rizhao/515/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEEMGFTY 2013// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 523788976RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR33894 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 48 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Rizhao/719b/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 524845213RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDRSKYREEAMQNRXXXXXXXXXXXXKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49399 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 49 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY SD001/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/05/03 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 525338528PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49495 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 50 A/chicken/NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF Shanghai/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY S1358/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/03RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS HA 525338689PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIKNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49506 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 51 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Shanghai/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY S1410/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/03RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS HA 525338708PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49554 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 52 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Zhejiang/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY SD033/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/11RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS HA 525338789PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49566 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 53 A/duck/Anhui/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF SC702/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/04/16 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 525338809RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49722 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 54 A/homingNATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF pigeon/Jiangsu/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY SD184/2013SEIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/20 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 525339071PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49734 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 55 A/pigeon/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Shanghai/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY S1069/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/02 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 525339091PGARPQVNGLSGRIDFHWLMLNPNDTITFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR49770 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 56 A/wildNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF pigeon/Jiangsu/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY SD001/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/04/17 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 525339151PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGY41893 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 57 A/Huizhou/01/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/08/08SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 552049496SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGY42258 FALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETVE 58 A/mallard/RTNVPRICSRGKRTVDLGQCGLLGTIXGPPQCDQFLEFSADLIIE Sweden/91/2002RREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGIRTNG 2002/12/12 HAAXSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPALI 552052155IWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFM CVKNGNMRCTICI AHA11441MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 59 A/guineaNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF fowl/Nebraska/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 17096/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2011/04/10 HARNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS 557478572PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHIQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHA11452 MNTQILALIACMLVGIKGDKICLGHHAVANGTKVNTLTERGIEVV 60 A/turkey/NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEEPLRQILRGSGGIDKESMGFTY 32710/2011SGIRTNGATSTCRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2011/07/12RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS HA 557478591PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEMIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHIQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHA11461 MNTQILALIACMLVGIKGDKICLGHHAVANGTKVNTLTERGIEVV 61 A/turkey/NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEEPLRQILRGSGGIDKESMGFTY 31900/2011SGIRTNGATSTCRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2011/07/05RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS HA 557478606PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHIQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHK10585 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 62 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Guangdong/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY G1/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/05/05 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 587680636PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGG53366 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 63 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGLTY CSM42-34/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2011/03/RRDPALIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459252887PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGG53377 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 64 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGLTY CSM42-1/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2011/03/RRDPALIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459252925PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCT AGG53399MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 65 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY MHC39-26/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2011/03/RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459253005PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGG53432 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 66 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY MHC35-41/2011SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2011/03/RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459253136PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCT AGG53476MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 67 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY SH19-27/2010SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2010/12/RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459253257PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTIAGG53487 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 68 A/wildNATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF duck/Korea/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY SH19-50/2010SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2010/01/RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS HA 459253278PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAGG53520 QILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNAT 69 A/wildETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQLLEFSAD duck/Korea/LIIERREGTDVCYPGKFVNEEALRQILRESGGIEKETMGFTYSGI SH20-27/2008RTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKD 2008/12/PALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGA HA 459253409RPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMG LVFICVKNGNMR AGL43637MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 70 A/Taiwan/1/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013// HASADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 496297389SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGPSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIINNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGL97639 IACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVVNATETVET 71 A/mallard/ANIKKLCTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFDADLIIER Minnesota/AI09-REGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGIRTNGA 3770/2009TSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALII 2009/09/12 HAWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVN 505555371GQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGIGCFEIFHKCDDQCMESIRNNTYDHIQYRT ESLQNRIQIDPVKLS AGO02477MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 72 A/Xuzhou/1/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/25SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 512403688SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKSRNMRCTICIAGR84942 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 73 A/Suzhou/5/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/12SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 526304561SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAGR84954 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 74 A/Nanjing/6/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/11SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 526304594SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNRNMRCTICIAGR84978 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 75 A/Wuxi/4/2013NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF 2013/04/07 HASADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 526304656SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKSRNMRCTICIAGR84990 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 76 A/Wuxi/3/2013NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2013/04/07 HASADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 526304688SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKSRNMRCTICIAGR85002 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 77 A/Zhenjiang/1/NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF 2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/04/07 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 526304708RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKSRNKRCTICIAGR85026 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 78 A/Nanjing/2/NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF 2013 2013/04/05SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 526304762SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKSRNMRCTICIAGU02230 LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVVNATET 79 A/Zhejiang/VERTNIPRICSKGKRTVDLGQCGLRGTITGPPQCDQFLEFSADLI DTID-ZJU05/2013IERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRT 2013/04/NGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA HA 532808765LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV FICVKNGNMRCT AGU02233FALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVVNATETVE 80 A/Zhejiang/RINFPRICSKGKRTVDLGQCGLRGTITGPPQCDQFLEFSADLIIE DTID-ZJU08/2013RREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTNG 2013/04/ATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNIRKSPALI HA 532808788VWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFI CVKNGNMRCT AGW82588MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 81 A/treeNATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF sparrow/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY Shanghai/01/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/05/09 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 546235348PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTIGIAGW82600 ALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETVER 82 A/Shanghai/TNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLIIER CN01/2013REGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTNGA 2013/04/11 HATSACRRSRSSFYAEMKWLLSNTDNAAFPQMTKSYKNIRKSPALIV 546235368WGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFIC VKNGNMRCTICI AGW82612MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 83 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF JS01/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/04/03 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 546235388RKNPALIVWGIHHSGSTAEQTKLYGSGNKLVTVGSSNYQQSFAPSPGARTQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFICVKNGNMRCTICIAHA11472 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 84 A/turkey/NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 31676/2009SGIRTNGETSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2009/12/08RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS HA 557478625PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITNKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHA11483 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 85 A/turkey/NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 14135-2/2009SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2009/08/07 HARDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS 557478644PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHA11500 TQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNA 86 A/Zhejiang/TETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSA DTID-ZJU10/2013DLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSG 2013/10/14 HAIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNIRK 557478676SPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVM GLVFICVKN AHA57050MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 87 A/turkey/NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 14659/2009SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP 2009/08/12RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS HA 558484427PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHNCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHA57072 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV 88 A/turkey/NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY 18421/2009SGIRTNGATSACRRSGSSFYAEMKWLLSNSNDAAFPQMTKSYRNP 2009/09/09RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS HA 558484465PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHD25003 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 89A/Guangdong/02/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF2013 2013/10/ SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY HA 568260567SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNM AHF20528MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 90 A/HongNATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Kong/470129/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/11/30SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT HA 570933555RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHF20568 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 91 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF CN02/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/04/02 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 570933626RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHH25185 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 92 A/Guangdong/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF 04/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY 2013/12/16 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 576106234RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHJ57411 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 93 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF PD-01/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/17 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 585478041RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVSSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCKGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHJ57418 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 94 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF PD-02/2014SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/17 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 585478256RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHK10800 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 95 A/Shanghai/01/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/03 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 587681014RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHM24224 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 96A/Beijing/3/2013 NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF2013/04/16 SADLIIERREGSDVCYPGKEVKEEALRQILRESGGIDKEAMGFTY HA 594704802SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHN96472 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 97 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shanghai/PD-CN-SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 02/2014SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/01/21 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 602701641PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHZ39686 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 98A/Anhui/DEWH72- NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 01/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNT 632807036RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHZ39710 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 99A/Anhui/DEWH72- NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 03/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013// HASGIRTDGATSACRRSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNT 632807076RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHZ39746 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 100A/Anhui/DEWH72- NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 06/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013// HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 632807136RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGERPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAHZ41929 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 101 A/mallard/NATETVERTNVPRICSRGKRTVDLGQCGLLGTITGPPQCDQFLEF Sweden/1621/2002SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY 2002/12/12 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 632810949RNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI AMGLVFMCVKNGNMRCTICIAHZ42537 MNTQILAFIACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVV 102 A/mallard/NATETVETANIKKLCTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF Minnesota/DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY AI09-3770/2009SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP 2009/09/12 HARNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS 632811964PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI AMGLVFICIKNGNMRCTICIAHZ42549 MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTLTEKGIEVV 103 A/ruddyNATETVESANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF turnstone/DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY Delaware/AI00-SGIRTNGATSACRRLGSSSFYAEMKWLLSNSDNAAFPQMTKSYRN 1538/2000PRNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTP 2000/05/20 HASPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFF 632811984RGESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLA IAMGLIFICIKNGNMRCTICIAID70634 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 104 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Mix1/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/03 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 660304650RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQISNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAIN76383 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 105 A/Zhejiang/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF LS01/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/08 HASGIRTNGITSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 684694637RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAIU46619 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 106 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Zhejiang/DTID-SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY ZJU06/2013SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS HA 699978931PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVEVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAIU47013 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 107 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Suzhou/040201H/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013 2013/04/SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT HA 699979673RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDMILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90490 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 108 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/742/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/10 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755178094RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90526 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 109 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/898/2013SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/09 HASGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755178154RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90538 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 110 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY Shenzhen/918/2013SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/09 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755178174PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90576 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 111 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/1665/2013SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/12 HASGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755178238RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90588 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 112 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/2110/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/13 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755178258RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90661 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 113 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/2912/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/18 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755178380RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90673 MNTQILVFALTAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 114 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY Dongguan/3049/2013SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/18 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755178400PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90795 MNTQILVFALIAIIPTNADKICLGHHAVPNGTKVNTLTERGVEVV 115 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY Dongguan/3281/2013SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/18 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755178604PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90891 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 116 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY Dongguan/3520/2013SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/19 HARKXPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755178764PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ90951 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 117 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/3544/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/19 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYRNT 755178864RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91035 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 118 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/3780/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/19 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755179004RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91155 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 119 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/4037/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/19 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755179204RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ92005 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 120 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/801/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/09 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180629RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94254 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 121 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1374/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184382RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94606 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 122 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/191/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/02/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184968RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96552 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 123 A/chicken/NATETVERTNIPRICSKGKKTIDLGQCGLLGTITGPPQCDQFLEF Jiangxi/12206/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/03/16 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188219RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96684 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKINTLTERGVEVV 124 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13207/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/03/30 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188439RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96732 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 125 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13223/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/03/30 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188519RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJK00354 MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 126A/duck/Zhejiang/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF LS02/2014SADLIVERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/12 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755194469RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPLVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQVIGKLNRLIEKTNQQFELIDHEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91264 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 127 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 4129/2013SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2013/12/19 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755179386PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLMEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91314 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 128 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Shaoxing/2417/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/10/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755179470RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91402 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 129 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Huzhou/4045/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/10/24 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755179618RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKEVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91476 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 130 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Huzhou/4076/2013SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2013/10/24 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755179743RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91725 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 131 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Shaoxing/5201/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/10/28 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180161RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91885 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 132A/Shenzhen/SP4/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF 2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/16 HASGIRANGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180429RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91909 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 133 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP26/2014SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/20 HASGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180469RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDGCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91945 MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 134 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP38/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/22 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180529RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIGGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91957 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 135 A/Shenzhen/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF SP44/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/23 HASGIRANGTTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180549RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91969 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 136 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP48/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/23 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180569RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ91993 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 137 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/4119/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/19 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180609RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLLGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFTLLAI VMGLVFICVKNGNMRCTICIAJJ92031 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 138 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/4064/2013SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2013/12/19 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755180672RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVESSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ92967 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 139 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Jiangxi/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 9469/2014SGIRTNGVISACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/16 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755182232PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93027 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 140A/chicken/Jiangxi/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF9558/2014 SADLIIERREGSDVCYPGKEVKEEALRQILRESGGIDKEAMGFTY 2014/02/16 HASGIRTNGVISACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755182332RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93051 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 141A/chicken/Jiangxi/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF10573/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/18 HASGIRTNGVISACRRSGSSFYAEMKWLLSNIDDAAFPQMTKSYKNT 755182372RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93845 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 142 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 157/2014SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/20 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755183695PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93857 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 143 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/169/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/02/20 HASGIRTNGATSACMRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183715RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93869 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 144 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF Dongguan/173/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183735RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93881 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 145 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF Dongguan/189/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183755RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPKYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93907 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 146 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/449/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183799RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93931 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 147 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/536/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/02/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183839RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISKLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93943 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 148 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/568/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755183859RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ93979 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 149 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 656/2014SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/20 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755183919PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFGLIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94134 MNTQILVLALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 150 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1051/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184182RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVXLSXGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94158 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 151 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1075/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184222RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94182 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 152 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1177/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184262RKSPALIVWGIHHSVSIAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94194 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 153 A/silkieNATETVERTNIPRICSKGKKTIDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 1264/2014SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/21 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755184282PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQVIGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI VMGLVFICVKNGNMRCTICIAJJ94206 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 154 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 1268/2014SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/21 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755184302PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISDLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94344 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 155 A/silkieNSTETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 1451/2014SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/21 HARKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755184532PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRTVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94356 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 156 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1456/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184552RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94396 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 157 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1494/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755184618RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94754 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 158 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/748/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185215RKSPALIVWGIHHSVSNAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94838 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 159 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/835/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185356RKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFGFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94862 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 160 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/843/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY 2014/02/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185396RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94886 MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 161 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/851/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185436RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94910 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 162 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/874/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/20 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185476RKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ94959 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 163 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 967/2014SGIRANGATSACXRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/21 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755185558PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95048 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 164 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1009/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185708RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95171 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 165 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1314/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755185913RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVIFNFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95227 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 166 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1382/2014SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186006RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95251 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 167 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1401/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186046RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95346 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 168 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1548/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186206RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95382 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 167 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1690/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/02/21 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186266RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95464 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 170 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shenzhen/138/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/19 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186404RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI VMGLVFICVKNGNMRCTICIAJJ95572 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 171 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Dongguan/1100/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY 2014/02/21 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186584RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95584 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 172 A/silkieNATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF chicken/Dongguan/SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 1519/2014SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/02/21 HARKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755186604PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI VMGLVFICVKNGNMRCTICIAJJ95596 MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 173 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP58/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/01/25 HASGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186624RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ95620 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 174 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP75/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/15 HASGIRTNGSTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755186664RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAV VMGLVFICVKNGNMRCTICIAJJ95632 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 175 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP62/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/05 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNATFPQMTKSYKNT 755186684RKSPALIIWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96720 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 176A/chicken/Jiangxi/ NATETVERTTIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF13220/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/03/30 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188499RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96817 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 177A/chicken/Jiangxi/ NATEIVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF9513/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/02/16 HASGIRTNGVISACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188661RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96841 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 178 A/Shenzhen/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF SP139/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/04/02 HASGIRTNGATSTCRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188701RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRACFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVERQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96889 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 179 A/chicken/NATETVERIXIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13496/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKXAMGFTY 2014/04/11 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188781RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96901 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 180 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13502/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/11 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188801RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ96925 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 181 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13513/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/11 HANGIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755188841RKSPAIIVWGIHHTVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDLHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97267 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 182 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13252/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/03/30 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189411RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97291 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 183 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13493/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/06 HANGIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189451RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97331 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 184 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13512/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/06 HANGIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189517RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97373 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 185 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13521/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/06 HANGIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189587RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPXRASFLRGKSXGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97443 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 186 A/chicken/NATETVERTTIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/13530/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/06 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189702RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97582 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 187 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/14023/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/13 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755189933RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97697 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 188 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/14517/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190125RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCDGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97709 MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTLTERGVEVV 189 A/chicken/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/14518/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/20 HANGIRINGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190145RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGNCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97745 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 190 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Jiangxi/14554/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/20 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190205RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELMDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97757 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 191 A/chicken/NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF Shantou/2537/2014SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/04/16 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190225RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97841 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 192A/duck/Jiangxi/ NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF 15044/2014SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/04/27 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190365RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97899 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 193A/chicken/Jiangxi/ NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF15524/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/05/05 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190462RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKINQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFMCVKNGNMRCTICIAJJ97925 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 194 A/silkieNATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF chicken/Shantou/SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2050/2014SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 2014/03/25 HARKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS 755190506PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97973 MNTQILVFALISIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 195A/chicken/Shantou/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF4325/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY 2014/07/01 HASGIRTNGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190586RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICIAJJ97998 MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV 196A/chicken/Shantou/ NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF4816/2014 SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY 2014/07/22 HASGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT 755190628RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELVDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI VMGLVFICVKNGNMRCTICI

TABLE 15 H10 Hemagglutinin Amino Acid Sequences SEQ Accession No/ SEQID NO: Strain/Protein Amino Acid Sequence ID NO: AAM19228ACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVVN 197 A/turkey/ATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQ Minnesota/CDQFLEFESDLIIERREGNDVCYPGKFTNEESLRQIL 38429/1988 RGSGGIDKESMGFTYSGIITNGATSACRRSGSSFYAE 1988// HAMKWLLSNSDNAAFPQMTKSYRNPRNKPALIVWGIHHS 20335017GSTTEQTKLYGSGNKLITVESSKYQQSFTPSPGARPQVNGESGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLF GAIAGFIEKDGGSHYG AAY46211MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 198 A/mallard/TERGVEVVNATETVERTNVPRICSRGKRTVDLGQCGL Sweden/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 91/2002NEEALRQILRESGGIDKETMGFTYSGIRTNGAPSACR 2002// HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPA 66394828LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFMCVKNGNMR CTICI ABI84694MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTL 199 A/turkey/TEKGIEVVNATETVETANIGKICTQGKRPTDLGQCGL Minnesota/1/1988LGTLIGPPQCDQFLEFESDLIIERREGNDVCYPGKFT 1988/07/13 HANEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 115278573RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHAQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI ABS89409MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 200 A/blue-wingedTERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL teal/Ohio/566/LGTLIGPPQCDQFLEFDTDLIIERREGTDVCYPGKFT 2006 2006// HANEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 155016324RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVRLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI ACD03594MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTL 201 A/ruddyTEKGIEVVNATETVESANIKKICTQGKRPTDLGQCGL turnstone/DE/LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT 1538/2000NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2000// HARLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 187384848LIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFERGESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLIFICIKNGNMR CTICI BAH22785MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 202 A/duck/Mongolia/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 119/2008LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2008// HANEEALRQILRESGGIGKETMGFTYSGIRTNGATSACR 223717820RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI CAY39406MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 203 A/Anas crecca/TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL Spain/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 1460/2008NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2008/01/26 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA 254674376LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI ACX53683MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 204 A/goose/CzechTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL Republic/1848-LGTITGPPQCDQFLEFSADLIIERRGGSDVCYPGKFV K9/2009NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2009/02/04 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA 260907763LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI ACZ48625MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTL 205 A/turkey/TEKGIEVVNATETVETANIGKICTQGKRPTDLGQCGL Minnesota/38429/LGTLIGPPQCDQFLEFESDLIIERREGNDVCYPGKFT 1988 1988// HANEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 269826341RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELADC29485 STQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQ 206 A/mallard/Spain/IGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADS 08.00991.3/EMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA 2005 2005/11/SIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVIL HA 284927336 WFSFGASCFILL ADK71137MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 207 A/blue-wingedTERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL teal/Guatemala/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT CIP049-NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 01/2008RSGSSSYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 2008/02/07 HALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF 301333785TPSPGIRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLRGKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQHFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI ADK71148MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 208 A/blue-wingedTERGIEVVNXTETVETANIKKICTHGKRPTDLGQCGL teal/Guatemala/LGTLIGPPQCDRFLEFDADLIIERREGTDVCYPGKFT CIP049-NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 02/2008RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 2008/03/05 HALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF 301333804TPSPGIRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLRGKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI ADN34727MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 209 A/goose/CzechTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL Republic/1848-LGTITGPPQCDQFLEFSADLIIERRGGSDVCYPGKFV T14/2009NEEALRQILRESGGIDKETMGFTYSGIRINGXTSACR 2009/02/04 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA 307141869LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AEK84760PAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSG 210 A/wildGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKN bird/Korea/A14/VPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNA 2011 2011/02/QGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI HA 341610308DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGN MRCTICI AEK84761ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERG 211 A/wildVEVFNATETVERTNVPRICSKGKKTVDLGQCGLRGTI bird/Korea/A3/TGPPQCDQFLKFSPDLIIERQKGSDVCYPGKFVNEKP 2011 2011/02/LRQILRESGGIDKETMGFAYNGIKTNGPPIACRKSGS HA 341610310SFYAKMKWLLSNTDKAAFPQMTKSYKNTRRNPALIVWGIHHSGSTTKQTKLYGIGSNLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIPPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGKGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTIC I AEK84763ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERG 212 A/wildVEFFNATETVEPINVPRICSKGKKTVDLGQCGLLGTI bird/Korea/A9/TGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEKA 2011 2011/02/LRQILRESGGIDKETMGFAYSGIKTNGPPIACRKSGS HA 341610314SFYAKMKWLLSNTDKAAFPQMTKSYKNTRRDPALIVWGIHHSGSTIKQINLYGIGSNLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFIFNGAFIAPDRASFLIGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTIC I AEK84765LVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGV 213 A/spot-billedEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGTIT duck/Korea/447/GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL 2011 2011/04/RQILRESGGIDKETMGFTYSGIRTNGATSACRRSGSS HA 341610318FYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMARIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTICI AEM98291SILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTER 214 A/wildGVEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGT duck/Mongolia/ITGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEE 1-241/2008ALRQILRESGGIDKETMGFTYSGIRTNGATSACRRSG 2008/04/ HASSFYAEMKWLLSNTDNAAFPQMTKSYKNIRKDPALII 344196120WGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGSIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTI AFM09439QILAFIACMLIGAKGDKICLGHHAVANGTKVNTLTER 215 A/emperorGIEVVNATETVETVNIKKICTQGKRPTDLGQCGLLGT goose/Alaska/LIGPPQCDQFLEFDADLIIERRKGTDVCYPGKFTNEE 44063-061/2006SLRQILRGSGGIDKESMGFTYSGIRTNGATSACRRSG 2006/05/23 HASSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALII 390535062WGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFVPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPERASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQINPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMRCTI CI AFV33945MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 216 A/guineaTERRIEVVNATETVETANIKKICTQGKRPTDLGQCGL fowl/Nebraska/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 17096-1/2011NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2011/04/05 HARSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA 409676820LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AFV33947MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 217 A/goose/TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL Nebraska/17097-LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 4/2011NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2011/04/05 HARSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 409676827LIVWGVHHSASATEQTKLYGSGSKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AFX85260MNTQILAFIACMLIGINGDKICLGHHAVANGTKVNTL 218 A/ruddyTERGIEVVNATETVETANIKRICTQGKRPIDLGQCGL turnstone/LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT DelawareNEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACI Bay/220/1995RLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 1995/05/21 HALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSF 423514912TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGRCPRYVKQTSLLLATGMKNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AGE08098MNTQILTLIACMLIGAKGDKICLGHHAVANGTKVNTL 219 A/northernTERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL shoverl/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT Mississippi/NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 11OS145/2011RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 2011/01/08 HALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF 444344488TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHNGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AGI60301MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 220 A/Hangzhou/1/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/03/24LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 475662454NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGISGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGI60292MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTL 221 A/Shanghai/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 4664T/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/03/05 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 476403560RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCHHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGJ72861MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 222 A/chicken/TERGGEVVNATETVERTNIPRICSKGKKTVDLGQGGP Zhejiang/DTID-RGTITGPPQCDQFLEFSADLIMERREGSDVCYPGKFV ZJU01/2013NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2013/04/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA HA 479280294LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGJ73503MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 223 A/Nanjing/1/TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL 2013 2013/03/28LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 479285761NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI BAN16711MNIQVLVFALMAIIPTNADKICLGHHAVSNGTKVNTL 224 A/duck/Gunma/TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL 466/2011 2011//LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 482661571NEEALRQILRESGGIDKETMGFTYSGIRINGITSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPALIAWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDDTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGK84857MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 225 A/Hangzhou/2/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/04/01LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 485649824NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQIIKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGL44438MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 226 A/Shanghai/02/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/03/05 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 496493389RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGL33692GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL 227 A/Shanghai/NRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSIT 4655T/2013EVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQL 2013/02/26 HARENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR 491874175EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLA IAMGLVFICVKNGNMRCTICI AGL33693GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL 228 A/Shanghai/NRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSIT 4659T/2013EVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQL 2013/02/27 HA RENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR 491874186EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLA IVMGLVFICVKNGNMRCTICI AGL95088VFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVE 229 A/Taiwan/VVNATETVERTNIPRICSKGKRTVDLGQCGLLGTITG S02076/2013PPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALR 2013/04/22 HAQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSF 501485301YAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDV ILWFSFGASCFILLAIVMGLVFICVKNGNMRAGL95098 LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGV 230 A/Taiwan/EVVNATETVERTNIPRICSKGKRTVDLGQCGLLGTIT T02081/2013GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL 2013/04/22 HARQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSS 501485319FYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKD VILWFSFGASCFILLAIVMGLVFICVKNGNMRCTAGM53883 GFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKT 231 A/Shanghai/NQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNA 5083T/2013ELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEED 2013/04/20 HAGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNR 507593986IQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF ICVKNGNMRCT AGM53884AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFEL 232 A/Shanghai/IDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAM 5180T/2013ENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFE 2013/04/23 HAIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPV 507593988KLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNG NMRCTICI AGM53885QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQF 233 A/Shanghai/ELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLV 5240T/2013AMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGC 2013/04/25 HAFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQID 507593990PVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVK NGNMRCT AGM53886NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFE 234 A/Shanghai/LIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVA 4842T/2013MENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCF 2013/04/13 HAEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDP 507593992VKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKN GNMRCT AGM53887NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFE 235 A/Shanghai/LIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVA 4701T/2013MENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCF 2013/04/06 HAEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDP 507593994VKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKN GNMRCTIC AGN69462MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 236 A/Wuxi/2/2013TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013/03/31 HALGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 511105778NEEALRQILRESGGIDKEAMGFTYSGIRTNGSTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGN69474MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 236 A/Wuxi/1/2013TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013/03/31 HALGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 511105798NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLINGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGO51387MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 238 A/Jiangsu/2/TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL 2013 2013/04/20LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 514390990NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRXEAMXBXIQIDPVKLSSGYKDVXJWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI BAN59726MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 239 A/duck/Mongolia/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 147/2008LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2008/08/29 HANEEALRQILRESGGIGKETMGFTYSGIRTNGATSACR 519661951RSRSSFYAEMKWLLSNTDNAAFPQMTRSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI BAN59727MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 240 A/duck/Mongolia/TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL 129/2010LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2010// HANEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 519661954RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGQ80952MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 241 A/duck/Jiangxi/TERGVEVVNATETVERTSIPRICSKGKRAVDLGQCGL 3096/2009LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2009// HANEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 523788794RSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGQ80989MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 242 A/duck/Jiangxi/TERGVEVVNATETVERTSIPRICSKGKRAVDLGQCGL 3257/2009LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2009// HANEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 523788868RSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGXSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGQ81043MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 243 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Rizhao/515/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013// HANEEALRQILRESGGIDKEEMGFTYSGIRTNGATSACR 523788976RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR33894MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 244 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Rizhao/719b/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013// HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 524845213RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDRSKYREEAMQNRXXXXXXXXXXXXKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49399MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 245 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Jiangxi/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV SD001/2013NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 2013/05/03 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 525338528LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49495MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 246 A/chicken/TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL Shanghai/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV S1358/2013NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2013/04/03RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA HA 525338689LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIKNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49506MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 247 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Shanghai/S1410/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013 2013/04/03NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR HA 525338708RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49554MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 248 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Zhejiang/SD033/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013 2013/04/11NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR HA 525338789RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49566MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 249 A/duck/Anhui/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL SC702/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/16 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 525338809RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49722MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 250 A/homingTERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL pigeon/Jiangsu/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV SD184/2013NEEALRQILRESGGIDKEAMGFTYSEIRTNGATSACR 2013/04/20 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 525339071LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49734MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 251 A/pigeon/Shanghai/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL S1069/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/02 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 525339091RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTITFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR49770MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 252 A/wildTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL pigeon/Jiangsu/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV SD001/2013NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2013/04/17 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 525339151LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGY41893MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 253 A/Huizhou/01/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 2013 2013/08/08LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 552049496NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGY42258FALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEV 254 A/mallard/VNATETVERTNVPRICSRGKRTVDLGQCGLLGTIXGP Sweden/91/2002PQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQ 2002/12/12 HAILRESGGIDKETMGFTYSGIRTNGAXSACRRSGSSFY 552052155AEMKWLLSNTDNAAFPQMTKSYKNTRNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFMCVKNGNMRCTICI AHA11441MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 255 A/guineaTERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL fowl/Nebraska/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 17096/2011NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2011/04/10 HARSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA 557478572LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHA11452MNTQILALIACMLVGIKGDKICLGHHAVANGTKVNTL 256 A/turkey/Minnesota/TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL 32710/2011LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2011/07/12NEEPLRQILRGSGGIDKESMGFTYSGIRTNGATSTCR HA 557478591RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEMIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHA11461MNTQILALIACMLVGIKGDKICLGHHAVANGTKVNTL 257 A/turkey/Minnesota/TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL 31900/2011LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2011/07/05NEEPLRQILRGSGGIDKESMGFTYSGIRTNGATSTCR HA 557478606RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHK10585MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 258 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Guangdong/G1/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/05/05 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 587680636RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGG53366MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 259 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV CSM42-34/2011NEEALRQILRESGGIDKETMGLTYSGIRTNGATSACR 2011/03/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459252887LIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGG53377MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 260 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV CSM42-1/2011NEEALRQILRESGGIDKETMGLTYSGIRTNGATSACR 2011/03/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459252925LIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CT AGG53399MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 261 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV MHC39-26/2011NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2011/03/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459253005LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGG53432MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 262 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV MHC35-41/2011NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2011/03/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459253136LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CT AGG53476MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 263 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV SH19-27/2010NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2010/12/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459253257LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTI AGG53487MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 264 A/wildTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL duck/Korea/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV SH19-50/2010NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 2010/01/RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA HA 459253278LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AGG53520QILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTER 265 A/wildGVEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGT duck/Korea/ITGPPQCDQLLEFSADLIIERREGTDVCYPGKEVNEE SH20-27/2008ALRQILRESGGIEKETMGFTYSGIRTNGATSACRRSG 2008/12/SSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALII HA 459253409WGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGY KDVILWFSFGASCFILLAIAMGLVFICVKNGNMRAGL43637 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 266 A/Taiwan/1/2013TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013// HALGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 496297389NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGPSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIINNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGL97639IACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVV 267 A/mallard/NATETVETANIKKLCTQGKRPTDLGQCGLLGTLIGPP Minnesota/AI09-QCDQFLEFDADLIIERREGTDVCYPGKFTNEESLRQI 3770/2009LRGSGGIDKESMGFTYSGIRTNGATSACRRSGSSFYA 2009/09/12 HAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIIWGVHH 505555371SGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVIFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCME SIRNNTYDHTQYRTESLQNRIQIDPVKLSAGO02477 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 268 A/Xuzhou/1/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/04/25LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 512403688NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR CTICI AGR84942MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 269 A/Suzhou/5/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/04/12LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 526304561NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AGR84954MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 270 A/Nanjing/6/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/04/11LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 526304594NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNRNMR CTICI AGR84978MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 271 A/Wuxi/4/2013TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 2013/04/07 HALGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 526304656NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR CTICI AGR84990MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 272 A/Wuxi/3/2013TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013/04/07 HALGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 526304688NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR CTICI AGR85002MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 273 A/Zhenjiang/1/TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL 2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/07 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 526304708RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNKR CTICI AGR85026MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 274 A/Nanjing/2/TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL 2013 2013/04/05LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 526304762NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR CTICI AGU02230LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGG 275 A/Zhejiang/EVVNATETVERTNIPRICSKGKRTVDLGQCGLRGTIT DTID-ZJU05/2013GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL 2013/04/RQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSS HA 532808765FYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKD VILWFSFGASCFILLAIVMGLVFICVKNGNMRCTAGU02233 FALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEV 276 A/Zhejiang/VNATETVERTNFPRICSKGKRTVDLGQCGLRGTITGP DTID-ZJU08/2013PQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQ 2013/04/ILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFY HA 532808788AEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVI LWFSFGASCFILLAIVMGLVFICVKNGNMRCTAGW82588 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 277 A/treeTERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL sparrow/Shanghai/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 01/2013NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2013/05/09 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 546235348LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTIGI AGW82600ALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV 278 A/Shanghai/NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPP CN01/2013QCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQI 2013/04/11 HALRESGGIDKEAMGFTYSGIRTNGATSACRRSRSSFYA 546235368EMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVIL WFSFGASCFILLAIVMGLVFICVKNGNMRCTICIAGW82612 MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 280 A/Shanghai/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL JS01/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/03 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 546235388RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKNPALIVWGIHHSGSTAEQTKLYGSGNKLVTVGSSNYQQSFAPSPGARTQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR CTICI AHA11472MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 281 A/turkey/TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL Minnesota/31676/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2009 2009/12/08NEESLRQILRGSGGIDKESMGFTYSGIRTNGETSACR HA 557478625RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITNKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHA11483MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 282 A/turkey/TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL Minnesota/14135-LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2/2009NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2009/08/07 HARSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPA 557478644LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHA11500TQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTE 283 A/Zhejiang/RGVEVVNATETVERTNIPRICSKGKRTVDLGQCGLLG DTID-ZJU10/2013TITGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNE 2013/10/14 HAEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRS 557478676GSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSG YKDVILWFSFGASCFILLAIVMGLVFICVKNAHA57050 MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 284 A/turkey/TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL Minnesota/14659/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2009 2009/08/12NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR HA 558484427RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHNCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHA57072MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL 285 A/turkey/TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL Minnesota/18421/LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 2009 2009/09/09NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR HA 558484465RSGSSFYAEMKWLLSNSNDAAFPQMTKSYRNPRDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHD25003MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 286 A/Guangdong/02/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 2013 2013/10/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 568260567NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNM AHF20528MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 287 A/HongTERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Kong/470129/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013 2013/11/30NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR HA 570933555RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHF20568MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 288 A/Shanghai/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL CN02/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/02 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 570933626RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHH25185MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 289 A/Guangdong/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 04/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/16 HANEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR 576106234RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHJ57411MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 290 A/Shanghai/PD-TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 01/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/17 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 585478041RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVSSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCKGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHJ57418MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 291 A/Shanghai/PD-TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 02/2014LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV 2014/01/17 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 585478256RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHK10800MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 292 A/Shanghai/01/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/03 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 587681014RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHM24224MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 293 A/Beijing/3/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2013 2013/04/16LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV HA 594704802KEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHN96472MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 294 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shanghai/PD-CN-LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 02/2014NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2014/01/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 602701641LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHZ39686MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 295 A/Anhui/DEWH72-TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 01/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013// HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 632807036RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHZ39710MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 296 A/Anhui/DEWH72-TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 03/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013// HANEEALRQILRESGGIDKEAMGFTYSGIRTDGATSACR 632807076RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHZ39746MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 297 A/Anhui/DEWH72-TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 06/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013// HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 632807136RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGERPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AHZ41929MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 298 A/mallard/Sweden/TERGVEVVNATETVERTNVPRICSRGKRTVDLGQCGL 1621/2002LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2002/12/12 HANEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR 632810949RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFMCVKNGNMR CTICI AHZ42537MNTQILAFIACMLVGAKGDKICLGHHAVANGTKVNTL 299 A/mallard/TERGIEVVNATETVETANIKKLCTQGKRPTDLGQCGL Minnesota/AI09-LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT 3770/2009NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 2009/09/12 HARSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA 632811964LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR CTICI AHZ42549MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTL 300 A/ruddyTEKGIEVVNATETVESANIKKICTQGKRPTDLGQCGL turnstone/LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT Delaware/AI00-NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR 1538/2000RLGSSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKP 2000/05/20 HAALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQS 632811984FTPSPGARPQVNGQSGRIDFHWLLLDPNDTVIFTENGAFIAPDRASFFRGESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAIAMGLIFICIKNGNM RCTICI AID70634MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 301 A/Shanghai/Mix1/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/03 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 660304650RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDNEFNEVEKQISNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AIN76383MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 302 A/Zhejiang/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL LS01/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/08 HANEEALRQILRESGGIDKEAMGFTYSGIRINGITSACR 684694637RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AIU46619MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 303 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Zhejiang/DTID-LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV ZJU06/2013NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2013/12/ HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 699978931LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVEVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AIU47013MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 304 A/chicken/Suzhou/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 040201H/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/04/NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR HA 699979673RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDMILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90490MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 305 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/742/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/10 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755178094RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90526MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 306 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/898/2013LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV 2013/12/09 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK 755178154RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90538MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 307 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Shenzhen/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 918/2013NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2013/12/09 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755178174LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90576MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 308 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/1665/2013LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV 2013/12/12 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK 755178238RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90588MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 309 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/2110/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/13 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755178258RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90661MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 310 A/chicken/Dongguan/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 2912/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/18 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755178380RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90673MNTQILVFALTAIIPTNADKICLGHHAVSNGTKVNTL 311 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 3049/2013NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2013/12/18 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755178400LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90795MNTQILVFALIAIIPTNADKICLGHHAVPNGTKVNTL 312 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 3281/2013NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2013/12/18 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755178604LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90891MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 313 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 3520/2013NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2013/12/19 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKXPA 755178764LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ90951MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 314 A/chicken/Dongguan/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 3544/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/19 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755178864RSGSSFYAEMKWLLSNTDNAAFPQMTKSYRNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91035MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 315 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/3780/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/19 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755179004RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91155MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 316 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/4037/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/19 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755179204RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ92005MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 317 A/chicken/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 801/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/09 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755180629RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94254MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 318 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1374/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755184382RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94606MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 319 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/191/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755184968RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96552MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 320 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTIDLGQCGL Jiangxi/12206/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/03/16 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755188219RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96684MNTQILVFALIAIIPTNADKICLGHHAVSNGTKINTL 321 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Jiangxi/13207/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/03/30 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755188439RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96732MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 322 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 13223/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/03/30 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755188519RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJK00354MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL 323 A/duck/Zhejiang/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL LS02/2014LGTITGPPQCDQFLEFSADLIVERREGSDVCYPGKFV 2014/01/12 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755194469RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPLVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQVIGKLNRLIEKTNQQFELIDHEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91264MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 324 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 4129/2013NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2013/12/19 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755179386LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLMEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91314MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 325 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Shaoxing/2417/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/10/20 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755179470RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91402MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 326 A/chicken/Huzhou/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 4045/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/10/24 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755179618RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKEVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91476MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 327 A/chicken/Huzhou/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 4076/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/10/24 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755179743RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91725MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 328 A/chicken/Shaoxing/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 5201/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/10/28 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755180161RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91885MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 329 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP4/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/16 HANEEALRQILRESGGIDKEAMGFTYSGIRANGVISACR 755180429RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91909MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 330 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP26/2014LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV 2014/01/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK 755180469RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDGCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91945MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL 331 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP38/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/22 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755180529RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIGGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91957MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 332 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL SP44/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/23 HANEEALRQILRESGGIDKEAMGFTYSGIRANGTTSACR 755180549RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91969MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 333 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP48/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/23 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755180569RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ91993MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 334 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/4119/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/19 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755180609RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLLGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFTLLAIVMGLVFICVKNGNMR CTICI AJJ92031MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 335 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/4064/2013LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2013/12/19 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755180672RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVESSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ92967MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 336 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Jiangxi/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 9469/2014NEEALRQILRESGGIDKEAMGFTYSGIRINGVISACR 2014/02/16 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755182232LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93027MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 337 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Jiangxi/9558/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/16 HAKEEALRQILRESGGIDKEAMGFTYSGIRINGVISACR 755182332RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93051MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 338 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Jiangxi/10573/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/18 HANEEALRQILRESGGIDKEAMGFTYSGIRINGVISACR 755182372RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93845MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 339 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 157/2014NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2014/02/20 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755183695LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93857MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 340 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/169/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACM 755183715RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93869MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 341 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/173/2014LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755183735RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93881MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 342 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/189/2014LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755183755RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPKYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93907MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 343 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/449/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755183799RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93931MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 344 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/536/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755183839RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISKLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93943MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 345 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/568/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR 755183859RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ93979MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 346 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 656/2014NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2014/02/20 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755183919LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFGLIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94134MNTQILVLALIAIIPTNADKICLGHHAVSNGTKVNTL 347 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1051/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755184182RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVXLSXGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94158MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 348 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1075/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755184222RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94182MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 349 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1177/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACK 755184262RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSIAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94194MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 350 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTIDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 1264/2014NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2014/02/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755184282LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQVIGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR CTICI AJJ94206MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 351 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 1268/2014NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 2014/02/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755184302LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISDLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94344MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 352 A/silkieTERGVEVVNSTETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 1451/2014NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 2014/02/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755184532IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRTVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94356MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 353 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1456/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755184552RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94396MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 354 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1494/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755184618RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94754MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 355 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/748/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR 755185215RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSNAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94838MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 356 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/835/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755185356RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFGFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94862MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 357 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/843/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIEKEAMGFTYSGIRTNGATSACR 755185396RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94886MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL 358 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/851/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755185436RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94910MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 359 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/874/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/20 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755185476RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ94959MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 360 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 967/2014NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACX 2014/02/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755185558LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95048MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 361 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Dongguan/1009/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755185708RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95171MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 362 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1314/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755185913RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVIFNFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95227MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 363 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1382/2014LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755186006RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95251MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 364 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1401/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755186046RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95346MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 365 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1548/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755186206RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95382MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 366 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Dongguan/1690/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755186266RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95464MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 367 A/chicken/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL Shenzhen/138/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/19 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755186404RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR CTICI AJJ95572MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 368 A/chicken/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL Dongguan/1100/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/21 HANEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR 755186584RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95584MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 369 A/silkieTERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL chicken/Dongguan/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 1519/2014NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 2014/02/21 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755186604LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR CTICI AJJ95596MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL 370 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP58/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/01/25 HANEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR 755186624RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ95620MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 371 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP75/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/15 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGSTSACR 755186664RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAVVMGLVFICVKNGNMR CTICI AJJ95632MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 372 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP62/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/05 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755186684RSGSSFYAEMKWLLSNTDNATFPQMTKSYKNTRKSPALIIWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96720MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 373 A/chicken/TERGVEVVNATETVERTTIPRICSKGKKTVDLGQCGL Jiangxi/13220/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/03/30 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755188499RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96817MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 374 A/chicken/TERGVEVVNATEIVERTNIPRICSKGKKTVDLGQCGL Jiangxi/9513/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/02/16 HANEEALRQILRESGGIDKEAMGFTYSGIRINGVISACR 755188661RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96841MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 375 A/Shenzhen/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL SP139/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/02 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSTCR 755188701RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRACFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVERQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96889MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 376 A/chicken/Jiangxi/TERGVEVVNATETVERTXIPRICSKGKKTVDLGQCGL 13496/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/11 HANEEALRQILRESGGIDKXAMGFTYSGIRTNGATSACR 755188781RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96901MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 377 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 13502/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/11 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755188801RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ96925MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 378 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 13513/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/11 HANEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR 755188841RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHTVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDLHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97267MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 379 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 13252/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/03/30 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755189411RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97291MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 380 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 13493/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/06 HANEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR 755189451RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97331MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 381 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 13512/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/06 HANEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR 755189517RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97373MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 382 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 13521/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/06 HANEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR 755189587RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPXRASFLRGKSXGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97443MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 383 A/chicken/Jiangxi/TERGVEVVNATETVERTTIPRICSKGKRTVDLGQCGL 13530/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/06 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755189702RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97582MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 384 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 14023/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/13 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755189933RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97697MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 385 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 14517/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/20 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755190125RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCDGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97709MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTL 386 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 14518/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/20 HANEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR 755190145RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGNCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97745MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 387 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 14554/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/20 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755190205RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELMDNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97757MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 388 A/chicken/Shantou/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 2537/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/16 HANEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 755190225RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97841MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 389 A/duck/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 15044/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/04/27 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755190365RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97899MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 390 A/chicken/Jiangxi/TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL 15524/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/05/05 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755190462RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFMCVKNGNMR CTICI AJJ97925MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL 391 A/silkieTERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL chicken/Shantou/LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2050/2014NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR 2014/03/25 HARSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA 755190506IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97973MNTQILVFALISIIPTNADKICLGHHAVSNGTKVNTL 392 A/chicken/Shantou/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 4325/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/07/01 HANEEALRQILRKSGGIDKEAMGFTYSGIRINGVISACR 755190586RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI AJJ97998MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL 393 A/chicken/Shantou/TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL 4816/2014LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV 2014/07/22 HANEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR 755190628RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELVDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR CTICI

TABLE 16 Exemplary Influenza HA Stem Antigens SEQ ID SEQ ID StrainFoldon version NO: AA seq NO: H1N1 DTVDTVLEKNVTVTHSVNL 394METPAQLLFLLLLWLPDTTGDT 403 A/Puerto LEDSHGSANSSLPYQNTHPVDTVLEKNVTVTHSVNLLEDSH Rico/8/ TTNGESPKYVRSAKLRMVTGSANSSLPYQNTHPTTNGESPK 1934 GLRNGSAGSATQNAINGIT YVRSAKLRMVTGLRNGSAGSATNKVNTVIEKMNIQDTATGK QNAINGITNKVNTVIEKMNIQD EFNKDEKRMENLNKKVDDGTATGKEFNKDEKRMENLNKKVD FLDIWTYNAELLVLLENER DGFLDIWTYNAELLVLLENERTTLDAHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQ rdgqayvrkdgewvllstfAYVRKDGEWVLLSTFL l H1N1 DTVDTVLEKNVTVTHSVNL 395 METPAQLLFLLLLWLPDTTGDT404 A/VietNam/ LEDKHGSANTSLPFQNTHP VDTVLEKNVTVTHSVNLLEDKH 850/2009TTNGKCPKYVKSTKLRLAT GSANTSLPFQNTHPTTNGKCPK GLRNGSAGSATQNAIDEITYVKSTKLRLATGLRNGSAGSAT NKVNSVIEKMNTQDTATGK QNAIDEITNKVNSVIEKMNTQDEFNHDEKRIENLNKKVDDG TATGKEFNHDEKRIENLNKKVD FLDIWTYNAELLVLLENERDGFLDIWTYNAELLVLLENERT TLDAHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQrdgqayvrkdgewvllstf AYVRKDGEWVLLSTFL l H1N1 DTVDTVLEKNVTVTHSVNL 396METPAQLLFLLLLWLPDTTGDT 405 A/New LEDSHGSANSSLPFQNTHPVDTVLEKNVTVTHSVNLLEDSH Caledonia/ TTNGESPKYVRSAKLRMVTGSANSSLPFQNTHPTTNGESPK 20/99 GLRNGSAGSATQNAINGIT YVRSAKLRMVTGLRNGSAGSATNKVNSVIEKMNTQDTAVGK QNAINGITNKVNSVIEKMNTQD EFNKDERRMENLNKKVDDGTAVGKEFNKDERRMENLNKKVD FLDIWTYNAELLVLLENER DGFLDIWTYNAELLVLLENERTTLDAHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQ rdgqayvrkdgewvllstfAYVRKDGEWVLLSTFL l H1N1 DTVDTVLEKNVTVTHSVNL 397 METPAQLLFLLLLWLPDTTGDT406 A/ LEDKHGSANTSLPFQNTHP VDTVLEKNVTVTHSVNLLEDKH California/TTNGKSPKYVKSTKLRLAT GSANTSLPFQNTHPTTNGKSPK 04/2009 GLRNGSAGSATQNAIDEITYVKSTKLRLATGLRNGSAGSAT NKVNSVIEKMNTQDTAVGK QNAIDEITNKVNSVIEKMNTQDEFNHDEKRIENLNKKVDDG TAVGKEFNHDEKRIENLNKKVD FLDIWTYNAELLVLLENERDGFLDIWTYNAELLVLLENERT TLDAHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQrdgqayvrkdgewvllstf AYVRKDGEWVLLSTFL l H3N2 HAVPNGTIVKTITNDQIEV 398METPAQLLFLLLLWLPDTTGHA 407 A/ TNATEgsaPNDKPFQNtNR VPNGTIVKTITNDQIEVTNATEWisconsin/ tTtGACPRYVKQNTLKLAT GSAPNDKPFQNTNRTTTGACPR 67/2005GMRNgsagsaTQAAINQIN YVKQNTLKLATGMRNGSAGSAT GKLNRLIGKTNEKdHQdEKQAAINQINGKLNRLIGKTNEKD EFSEdEGRIQDLEKYVEDT HQDEKEFSEDEGRIQDLEKYVEKIDLWSYNAELLVALENQH DTKIDLWSYNAELLVALENQHT TIDaTDSQGTgggyipeapIDATDSQGTGGGYIPEAPRDGQ rdgqayvrkdgewvllstf AYVRKDGEWVLLSTFL l H5N1EQVDTIMEKNVTVTHAQDI 399 METPAQLLFLLLLWLPDTTGEQ 408 A/Vietnam/LEKTHGSANSSMPFHNTHP VDTIMEKNVTVTHAQDILEKTH 1203/2004 NTTGESPKYVKSNRLVLATGSANSSMPFHNTHPNTTGESPK GLRNGSAGSATQKAIDGVT YVKSNRLVLATGLRNGSAGSATNKVNSIIDKMNTQFEADGR QKAIDGVTNKVNSIIDKMNTQF EFNNDERRIENLNKKMEDGEADGREFNNDERRIENLNKKME FLDVWTYNAELLVLMENER DGFLDVWTYNAELLVLMENERTTLDAHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQ rdgqayvrkdgewvllstfAYVRKDGEWVLLSTFL l H7N9 TKVNTLTERGVEVVNATET 400 METPAQLLFLLLLWLPDTTGTK409 (A/Anhui/ VERTgsaISNLPFQNtDSt VNTLTERGVEVVNATETVERTG 1/2013)AnGKCPRYVKQRSLLLATG SAISNLPFQNTDSTANGKCPRY MKNgsagsaTQSAIDQITGVKQRSLLLATGMKNGSAGSATQ KLNRLIEKTNQQdELtDNE SAIDQITGKLNRLIEKTNQQDEFNEdEKQIGNVINWTRDSI LTDNEFNEDEKQIGNVINWTRD TEVWSYNAELLVAMENQHTSITEVWSYNAELLVAMENQHTI IDaADSQGTgggyipeapr DAADSQGTGGGYIPEAPRDGQAdgqayvrkdgewvllstfl YVRKDGEWVLLSTFL H9N2 ETVDTLTETNVPVTHAKEL 401METPAQLLFLLLLWLPDTTGET 410 A/Hong LHTEHgsaNSTLPFHNtSKVDTLTETNVPVTHAKELLHTEH Kong/1073/ tAnGTCPKYVRVNSLKLAVGSANSTLPFHNTSKTANGTCPK 99 GLRNgsagsaTQKAIDKIT YVRVNSLKLAVGLRNGSAGSATSKVNNIVDKMNKQdEItDH QKAIDKITSKVNNIVDKMNKQD EFSEdETRLNMINNKIDDQEITDHEFSEDETRLNMINNKID IQDVWAYNAELLVLLENQK DQIQDVWAYNAELLVLLENQKTTLDaHDSQGTgggyipeap LDAHDSQGTGGGYIPEAPRDGQ rdgqayvrkdgewvllstfAYVRKDGEWVLLSTFL l H10N8 TIVKTLTNEQEEVTNATET 402 METPAQLLFLLLLWLPDTTGTI411 A/JX346/ VESTGgsaNTRLPFQNtSP VKTLTNEQEEVTNATETVESTG 2013tTnGQCPKYVNRRSLMLAT GSANTRLPFQNTSPTTNGQCPK GMRNgsagsaTQAAIDQITYVNRRSLMLATGMRNGSAGSAT GKLNRLVEKTNTEdSItSE QAAIDQITGKLNRLVEKTNTEDFSEIEHQIGNVINWTKDSI SITSEFSEIEHQIGNVINWTKD TDIWTYQAELLVAMENQHTSITDIWTYQAELLVAMENQHTI IDaADSQGTgggyipeapr DAADSQGTGGGYIPEAPRDGQAdgqayvrkdgewvllstfl YVRKDGEWVLLSTFL H3N2 METPAQLLFLLLLWLPDTTGAS 412A/Hong PNGTLVKTITDDQIEVTNATEL Kong/1/ VQSSGSAGSANDKPFQNTNKRT 1968 stemSGASPKYVKQNTLKLATGQRGS RNA AGSAATDQINGKLNRVIEKTNE KDHQIEKEFSEDEGRIQDLEKYVEDTKIDLWSYNAELLVALENQ HTIDLTDSQGTGGGYIPEAPRD GQAYVRKDGEWVLLSTFLThe first underlined sequence for each of the amino acid sequenceslisted in Table 16, indicates a signal or secretory sequence, which maybe substituted by an alternative sequence that achieves the same orsimilar function, or the signal or secretory sequence may be deleted.The second underlined sequence for the amino acid sequences listed inTable 16, indicates a foldon sequence, which is a heterologous sequencethat naturally trimerizes, to bring 3 HA stems together in a trimer.Such foldon sequence may be substituted by an alternative sequence,which achieves the same or similar function.

TABLE 17 Exemplary Influenza Constructs Construct SEQ Description ORFID NO: Influenza METPAQLLFLLLLWLPDTTGGLFGAIAGFIENGWEGMIDGWYGFRH 413H3HA6 QNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKDHQIEKEFSEDEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEEMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQGSAGSAGDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSSGSAGSANDKPFQNTNKETTGATPKYVKQNTLKLATGM R InfluenzaMETPAQLLFLLLLWLPDTTGGLFGAIAGFIEGGWTGMIDGWYGYHH 414 H1HA6QNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKGSAGSAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHGSANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRN IP InfluenzaMETPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS 415 H1HA10-ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGGAGSATQNAI Foldon_ΔNgly1NGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDAHDSQGTGGGYIPEAPRDGQAYVRKDGE WVLLSTFL InfluenzaMETPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV 416 eH1HATHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPNLKNSYVNKKGKEVLVLWGIHHPSNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKD GEWVLLSTFL InfluenzaMKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHS 417 eH1HA_NativeVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRS SSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPNLKNSYVNKKGKEVLVLWGIHHPSNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEW VLLSTFL H1HA10TM-METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS 418 PR8 (H1ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI A/PuertoNGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI Rico/8/34 HA),WTYNAELLVLLENERTLDAHDSQGTGGILAIYSTVASSLVLLVSLG with TMAISFWMCSNGSLQCRICI domain, without foldon (with IgG Kappa leader)H1HA10-PR8- METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVTHSVNLLEDSHGS 419 DS (H1ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI A/PuertoNCITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI Rico/8/34 HA),WTYNAELLVLLENERTLDAHDS ds bond, without foldon (with IgG Kappa leader)pH1HA10- METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVTHSVNLLEDKHGS 420 Cal04-DS (H1ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI A/California/04/DCITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI 2009 HA), dsWTYNAELLVLLENERTLDAHDS bond, without foldon (with IgG Kappa leader)Nucleoprotein MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCTE 421from H3N2 (no LKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKKT IgG KappaGGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDDATAGLTHMMI leader)WHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGRKTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRGSVAHKSCLPACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTVMAAFTGNTEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN HA10 versionMETPAQLLFLLLLWLPDTTGHVVKTATQGEVNVTGVIPLTTTPTGS 422 for Influenza BANKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYGSAGSATQEAI strainNKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAYVRKDGEW VLLSTFL B/Yamagata/16/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 423 1988 mHALTTTPTKSHFANLKGTKTRGKLCPNCLNCTDLDVALGRPMCMGTIPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSTHNVINAERAPGGPYRLGTSGSCPNVTSRNGFFATMAWAVPRDNKTATNPLTVEVPYICTKGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGDFPNQTEDGGLPQSGRIVVDYMVQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSLAVTLMIAIFIVYMVSRDNVSCSICL B/Yamagata/16/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 424 1988 sHALTTTPTKSHFANLKGTKTRGKLCPNCLNCTDLDVALGRPMCMGTIPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSTHNVINAERAPGGPYRLGTSGSCPNVTSRNGFFATMAWAVPRDNKTATNPLTVEVPYICTKGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSANGVTTHYVSQIGDFPNQTEDGGLPQSGRIVVDYMVQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHT B/Victoria/02/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 425 1987 mHALTTTPTKSHFANLKGTKTRGKLCPKCLNCTDLDVALGRPKCTGTIPSAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAETAPGGPYKVGTSGSCPNVTNGNGFFATMAWAVPKNDNNKTATNPLTVEVPYICTEGEDQITVWGFHSDNEAQMVKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQAEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKEKGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNKILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSLAVTLMIAIFIVYMVSRDNVSCSICl B/Victoria/02/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 426 1987 sHALTTTPTKSHFANLKGTKTRGKLCPKCLNCTDLDVALGRPKCTGTIPSAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAETAPGGPYKVGTSGSCPNVTNGNGFFATMAWAVPKNDNNKTATNPLTVEVPYICTEGEDQITVWGFHSDNEAQMVKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQAEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKEKGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNKILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHT B/Brisbane/60/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 427 2008 mHALTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSLAVTLMIAIFVVYMVSRDNVSCSICL B/Brisbane/60/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 428 2008 sHALTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHNVINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHT B/Phuket/3073/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 429 2013 mHALTTTPTKSYFANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVWGFHSDNKTQMKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSLAVTLMLAIFIVYMVSRDNVSCSICL B/Phuket/3073/MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP 430 2013 sHALTTTPTKSYFANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVWGFHSDNKTQMKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHT PandemicMETPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS 431 H1HA10 fromANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI California 04DEITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI strain, withoutWTYNAELLVLLENERTLDAHDSQGTGGDIIKLLNEQVNKEMQSSNL foldon and withYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQ ferritin fusionLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHA for particleTFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGI formation AKSRKSGen6 HA SS METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV 432construct with THSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVDGW ferritinYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSGGSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDSGGDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGL YLADQYVKGIAKSRKSGen6 HA SS METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV 433construct with THSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVDGW foldonYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSGGSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDPGSGYIPEAPRD GQAYVRKDGEWVLLSTFL#4900 construct METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV 434without THSVNLLENGGGGKYVCSAKLRMVTGLRNKPSKQSQGLFGAIAGFT cleavage siteEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI and tagEKMNTQYTAIGCEYNKSERCMKQIEDKIEEIESKIWCYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQ PandemicMETPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS 435 H1HA10 fromANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI California 04DEITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI strain, withoutWTDLAELLVLLENERTLDAHDS foldon and with Y94D/N95L mutation fortrimerization Pandemic METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS436 H1HA10 from ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAICalifornia 04 DEITNKVNSVIEKMNTQDTAVGCEFNHDEKCIENLNKKVDDGFLDIstrain, without WTYNAELLVLLENERTLDAHDS foldon and with K68C/R76Cmutation for trimerization H1HA10 fromMETPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS 437 A/PuertoANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI Rico/8/34NGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI strain, withoutWTDLAELLVLLENERTLDAHDS foldon and with Y94D/N95L mutation fortrimerization H1HA10 from METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS438 A/Puerto ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI Rico/8/34NGITNKVNTVIEKMNIQDTATGCEFNKDEKCMENLNKKVDDGFLDI strain, withoutWTYNAELLVLLENERTLDAHDS foldon and with K68C/R76C mutation fortrimerization >sp|P06821|M2_MSLLTEVETPIRNEWGCRCNGSSDPLAIAANIIGILHLILWILDRL 439 I34A1 MatrixFFKCIYRRFKYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFV protein 2 SIELEOS = Influenza A virus (strain A/Puerto Rico/8/1934 H1N1) GN = MPE = 3 SV = 1 A Matrix 1 MSLLTEVETYVLSIIPSGPLKAEIAQRLESVFAGKNTDLEALMEWL440 (A/California/ KTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNN04/2009 (H1N1), MDRAVKLYKKLKREITFHGAKEVSLSYSTGALASCMGLIYNRMGTV ACP44152)TTEAAFGLVCATCEQIADSQHRSHRQMATTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVANQTRQMVHAMRTIGTHPSSSAGLK DDLLENLQAYQKRMGVQMQRFKBHA10-2 METPAQLLFLLLLWLPDTTG HVVKTATQGEVNVTGVIPLTTTPTGS 441ANKSKPYYTGEHAKATGNCPIWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQRLSGASDETHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAYVRKDGEW VLLSTFL BHA10-2*HVVKTATQGEVNVTGVIPLTTTPTGSANKSKPYYTGEHAKATGNCP 442IWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQRLSGASDETHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAYVRKDGEWVLLSTFL BHA10-3 METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVTGVIPLTTTPTGS 443ANKSKPYYTGEHAKATGNCPIWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQRLSCASDETHNCILELDEKVDDLRADT ISSLIELAVLLSNEGIINSEDEBHA10-3* HVVKTATQGEVNVTGVIPLTTTPTGSANKSKPYYTGEHAKATGNCP 444IWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQRLSCASDETHNCILELDEKVDDLRADTISSLIELAVLLSNEGIINSE DE 5′UTR for eachconstruct:TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ ID NO: 445) 3′UTR for each construct:TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC (SEQ ID NO: 446)The first underlined sequence for each of the amino acid sequenceslisted in Table 17, indicates a signal or secretory sequence, which maybe substituted by an alternative sequence that achieves the same orsimilar function, or the signal or secretory sequence may be deleted.

TABLE 18 Influenza Nucleic Acids Construct SEQ Description ORF ID NO:B/Yamagata/16/ ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAACGCAG 4471988 mHA ATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGTCAAAACAGCTACTCAAGGGGAAGTTAATGTGACTGGTGTGATACCACTGACAACAACACCAACAAAATCTCATTTTGCAAATCTCAAAGGAACAAAGACCAGAGGGAAACTATGCCCAAACTGTCTCAACTGCACAGATCTGGATGTGGCCTTGGGCAGACCAATGTGTATGGGGACCATACCTTCGGCAAAAGCTTCAATACTCCACGAAGTCAGACCTGTTACATCCGGGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGACAGCTACCCAATCTTCTCAGAGGATATGAAAATATCAGATTATCAACCCATAACGTTATCAACGCAGAAAGGGCACCAGGAGGACCCTACAGACTTGGAACCTCAGGATCTTGCCCTAACGTTACCAGTAGAAACGGATTCTTCGCAACAATGGCTTGGGCTGTCCCAAGGGACAACAAAACAGCAACGAATCCACTAACAGTAGAAGTACCATACATTTGCACAAAAGGAGAAGACCAAATTACTGTTTGGGGGTTCCATTCTGATGACAAAACCCAAATGAAAAACCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCTGCCAATGGAGTAACCACACATTATGTTTCTCAGATTGGTGACTTCCCAAATCAAACAGAAGACGGAGGGCTACCACAAAGCGGCAGAATTGTTGTTGATTACATGGTGCAAAAACCTGGGAAAACAGGAACAATTGTCTATCAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGTGAAGCAGATTGCCTTCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGGTGAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAGGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCTCATGGAGCACATGGAGTGGCAGTGGCAGCAGACCTTAAGAGCACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCTTTGAGTGAGCTAGAAGTAAAGAATCTTCAAAGACTAAGTGGTGCCATGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGTGGATGATCTCAGAGCTGACACAATAAGCTCGCAAATAGAGCTTGCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTATTGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGCTGTAGACATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAGACCTGCTTAGACAGGATAGCTGCTGGCACCTTTAATGCAGGAGAATTTTCTCTTCCCACTTTTGATTCACTGAATATTACTGCTGCATCTTTAAATGATGATGGATTGGATAATCATACTATACTGCTCTACTACTCAACTGCTGCTTCTAGTTTGGCCGTAACATTGATGATAGCTATTTTTATTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCATCTGTCT A B/Yamagata/16/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAACGCAG 448 1988 sHAATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGTCAAAACAGCTACTCAAGGGGAAGTTAATGTGACTGGTGTGATACCACTGACAACAACACCAACAAAATCTCATTTTGCAAATCTCAAAGGAACAAAGACCAGAGGGAAACTATGCCCAAACTGTCTCAACTGCACAGATCTGGATGTGGCCTTGGGCAGACCAATGTGTATGGGGACCATACCTTCGGCAAAAGCTTCAATACTCCACGAAGTCAGACCTGTTACATCCGGGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGACAGCTACCCAATCTTCTCAGAGGATATGAAAATATCAGATTATCAACCCATAACGTTATCAACGCAGAAAGGGCACCAGGAGGACCCTACAGACTTGGAACCTCAGGATCTTGCCCTAACGTTACCAGTAGAAACGGATTCTTCGCAACAATGGCTTGGGCTGTCCCAAGGGACAACAAAACAGCAACGAATCCACTAACAGTAGAAGTACCATACATTTGCACAAAAGGAGAAGACCAAATTACTGTTTGGGGGTTCCATTCTGATGACAAAACCCAAATGAAAAACCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCTGCCAATGGAGTAACCACACATTATGTTTCTCAGATTGGTGACTTCCCAAATCAAACAGAAGACGGAGGGCTACCACAAAGCGGCAGAATTGTTGTTGATTACATGGTGCAAAAACCTGGGAAAACAGGAACAATTGTCTATCAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGTGAAGCAGATTGCCTTCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGGTGAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAGGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCTCATGGAGCACATGGAGTGGCAGTGGCAGCAGACCTTAAGAGCACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCTTTGAGTGAGCTAGAAGTAAAGAATCTTCAAAGACTAAGTGGTGCCATGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGTGGATGATCTCAGAGCTGACACAATAAGCTCGCAAATAGAGCTTGCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTATTGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGCTGTAGACATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAGACCTGCTTAGACAGGATAGCTGCTGGCACCTTTAATGCAGGAGAATTTTCTCTTCCCACTTTTGATTCACTGAATATTACTGCTGCATCTTTAAATGATGATGGATTGGATAATCATACT B/Victoria/02/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG 449 1987 mHAATCGAATCTGCACTGGGATAACATCGTCAAACTCACCCCATGTGGTCAAAACTGCTACTCAAGGGGAAGTCAATGTGACTGGTGTGATACCACTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAACAAAAACCAGAGGGAAACTATGCCCAAAGTGTCTCAACTGCACAGATCTGGACGTGGCCTTGGGCAGACCAAAGTGCACGGGGACCATACCTTCGGCAAAAGCTTCAATACTCCACGAAGTCAAACCTGTTACATCTGGGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTACCCAATCTTCTCAGAGGATACGAACATATCAGGTTATCAACCCATAACGTTATCAACGCAGAAACGGCACCAGGAGGACCCTACAAAGTTGGAACCTCAGGGTCTTGCCCTAACGTTACCAATGGAAACGGATTCTTCGCAACAATGGCTTGGGCTGTCCCAAAAAACGACAACAACAAAACAGCAACAAATCCATTAACAGTAGAAGTACCATACATTTGTACAGAAGGAGAAGACCAAATTACTGTTTGGGGGTTCCACTCTGATAACGAAGCCCAAATGGTAAAACTCTATGGAGACTCAAAGCCTCAGAAGTTCACCTCATCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCTTCCCAAATCAAGCAGAAGACGGAGGGCTACCACAAAGCGGTAGAATTGTTGTTGATTACATGGTGCAAAAATCTGGAAAAACAGGAACAATTACCTACCAAAGAGGTATTTTATTGCCTCAAAAAGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGCGAAGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGGGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAAGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCCCATGGAGCACATGGAGTAGCAGTGGCAGCAGACCTTAAGAGTACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCGGTGCCATGGATGAACTCCACAACAAAATACTCGAACTGGATGAGAAAGTGGATGATCTCAGAGCTGATACAATAAGCTCGCAAATAGAGCTCGCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTCTTGGCGCTTGAAAGAAAACTGAAGAAAATGCTGGGCCCCTCTGCTGTAGAGATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAGACCTGCCTCGACAGAATAGCTGCTGGCACCTTTAATGCAGGAGAATTTTCTCTCCCCACCTTTGATTCACTAAATATTACTGCTGCATCTTTAAATGATGATGGATTGGATAATCATACTATACTGCTTTACTACTCAACTGCTGCTTCCAGTTTGGCTGTAACATTGATGATAGCTATCTTTATTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCAT CTGTCTA B/Victoria/02/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG 450 1987 sHAATCGAATCTGCACTGGGATAACATCGTCAAACTCACCCCATGTGGTCAAAACTGCTACTCAAGGGGAAGTCAATGTGACTGGTGTGATACCACTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAACAAAAACCAGAGGGAAACTATGCCCAAAGTGTCTCAACTGCACAGATCTGGACGTGGCCTTGGGCAGACCAAAGTGCACGGGGACCATACCTTCGGCAAAAGCTTCAATACTCCACGAAGTCAAACCTGTTACATCTGGGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTACCCAATCTTCTCAGAGGATACGAACATATCAGGTTATCAACCCATAACGTTATCAACGCAGAAACGGCACCAGGAGGACCCTACAAAGTTGGAACCTCAGGGTCTTGCCCTAACGTTACCAATGGAAACGGATTCTTCGCAACAATGGCTTGGGCTGTCCCAAAAAACGACAACAACAAAACAGCAACAAATCCATTAACAGTAGAAGTACCATACATTTGTACAGAAGGAGAAGACCAAATTACTGTTTGGGGGTTCCACTCTGATAACGAAGCCCAAATGGTAAAACTCTATGGAGACTCAAAGCCTCAGAAGTTCACCTCATCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCTTCCCAAATCAAGCAGAAGACGGAGGGCTACCACAAAGCGGTAGAATTGTTGTTGATTACATGGTGCAAAAATCTGGAAAAAGAGGAACAATTACCTACCAAAGAGGTATTTTATTGCCTCAAAAAGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGCGAAGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGGGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAAGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCCCATGGAGCACATGGAGTAGCAGTGGCAGCAGACCTTAAGAGTACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCGGTGCCATGGATGAACTCCACAACAAAATACTCGAACTGGATGAGAAAGTGGATGATCTCAGAGCTGATACAATAAGCTCGCAAATAGAGCTCGCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTCTTGGCGCTTGAAAGAAAACTGAAGAAAATGCTGGGCCCCTCTGCTGTAGAGATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAGACCTGCCTCGACAGAATAGCTGCTGGCACCTTTAATGCAGGAGAATTTTCTCTCCCCACCTTTGATTCACTAAATATTACTGCTGCATCTTTAAATGATGATGGATTGGATAATCATACT B/Brisbane/60/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG 451 2008 mHAATCGAATCTGCACTGGGATAACATCGTCAAACTCACCACATGTCGTCAAAACTGCTACTCAAGGGGAGGTCAATGTGACTGGTGTAATACCACTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAACAGAAACCAGGGGGAAACTATGCCCAAAATGCCTCAACTGCACAGATCTGGACGTAGCCTTGGGCAGACCAAAATGCACGGGGAAAATACCCTCGGCAAGAGTTTCAATACTCCATGAAGTCAGACCTGTTACATCTGGGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTGCCTAACCTTCTCCGAGGATACGAACATATCAGGTTATCAACCCATAACGTTATCAATGCAGAAAATGCACCAGGAGGACCCTACAAAATTGGAACCTCAGGGTCTTGCCCTAACATTACCAATGGAAACGGATTTTTCGCAACAATGGCTTGGGCCGTCCCAAAAAACGACAAAAACAAAACAGCAACAAATCCATTAACAATAGAAGTACCATACATTTGTACAGAAGGAGAAGACCAAATTACCGTTTGGGGGTTCCACTCTGACGACGAGACCCAAATGGCAAAGCTCTATGGGGACTCAAAGCCCCAGAAGTTCACCTCATCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCTTCCCAAATCAAACAGAAGACGGAGGACTACCACAAAGTGGTAGAATTGTTGTTGATTACATGGTGCAAAAATCTGGGAAAACAGGAACAATTACCTATCAAAGGGGTATTTTATTGCCTCAAAAGGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGATCCTTGCCTTTAATTGGAGAAGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGGGAACATGCAAAGGCCATAGGAAATTGCCCAATATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCCCATGGGGCACATGGAGTAGCGGTGGCAGCAGACCTTAAGAGCACTCAAGAGGCCATAAACAAGATAACAAAAAATCTCAACTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCGGTGCCATGGATGAACTCCACAACGAAATACTAGAACTAGATGAGAAAGTGGATGATCTCAGAGCTGATACAATAAGCTCACAAATAGAACTCGCAGTCCTGCTTTCCAATGAAGGAATAATAAACAGTGAAGATGAACATCTCTTGGCGCTTGAAAGAAAGCTGAAGAAAATGCTGGGCCCCTCTGCTGTAGAGATAGGGAATGGATGCTTTGAAACCAAACACAAGTGCAACCAGACCTGTCTCGACAGAATAGCTGCTGGTACCTTTGATGCAGGAGAATTTTCTCTCCCCACCTTTGATTCACTGAATATTACTGCTGCATCTTTAAATGACGATGGATTGGATAATCATACTATACTGCTTTACTACTCAACTGCTGCCTCCAGTTTGGCTGTAACACTGATGATAGCTATCTTTGTTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCAT CTGTCTA B/Brisbane/60/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG 452 2008 sHAATCGAATCTGCACTGGGATAACATCGTCAAACTCACCACATGTCGTCAAAACTGCTACTCAAGGGGAGGTCAATGTGACTGGTGTAATACCACTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAACAGAAACCAGGGGGAAACTATGCCCAAAATGCCTCAACTGCACAGATCTGGACGTAGCCTTGGGCAGACCAAAATGCACGGGGAAAATACCCTCGGCAAGAGTTTCAATACTCCATGAAGTCAGACCTGTTACATCTGGGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTGCCTAACCTTCTCCGAGGATACGAACATATCAGGTTATCAACCCATAACGTTATCAATGCAGAAAATGCACCAGGAGGACCCTACAAAATTGGAACCTCAGGGTCTTGCCCTAACATTACCAATGGAAACGGATTTTTCGCAACAATGGCTTGGGCCGTCCCAAAAAACGACAAAAACAAAACAGCAACAAATCCATTAACAATAGAAGTACCATACATTTGTACAGAAGGAGAAGACCAAATTACCGTTTGGGGGTTCCACTCTGACGACGAGACCCAAATGGCAAAGCTCTATGGGGACTCAAAGCCCCAGAAGTTCACCTCATCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCTTCCCAAATCAAACAGAAGACGGAGGACTACCACAAAGTGGTAGAATTGTTGTTGATTACATGGTGCAAAAATCTGGGAAAACAGGAACAATTACCTATCAAAGGGGTATTTTATTGCCTCAAAAGGTGTGGTGCGCAAGTGGCAGGAGCAAGGTAATAAAAGGATCCTTGCCTTTAATTGGAGAAGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGGGAACATGCAAAGGCCATAGGAAATTGCCCAATATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCCCATGGGGCACATGGAGTAGCGGTGGCAGCAGACCTTAAGAGCACTCAAGAGGCCATAAACAAGATAACAAAAAATCTCAACTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCGGTGCCATGGATGAACTCCACAACGAAATACTAGAACTAGATGAGAAAGTGGATGATCTCAGAGCTGATACAATAAGCTCACAAATAGAACTCGCAGTCCTGCTTTCCAATGAAGGAATAATAAACAGTGAAGATGAACATCTCTTGGCGCTTGAAAGAAAGCTGAAGAAAATGCTGGGCCCCTCTGCTGTAGAGATAGGGAATGGATGCTTTGAAACCAAACACAAGTGCAACCAGACCTGTCTCGACAGAATAGCTGCTGGTACCTTTGATGCAGGAGAATTTTCTCTCCCCACCTTTGATTCACTGAATATTACTGCTGCATCTTTAAATGACGATGGATTGGATAATCATACT B/Phuket/3073/ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG 453 2013 mHAATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGTCAAAACAGCTACTCAAGGGGAGGTCAATGTGACTGGCGTGATACCACTGACAACAACACCAACAAAATCTTATTTTGCAAATCTCAAAGGAACAAGGACCAGAGGGAAACTATGCCCGGACTGTCTCAACTGTACAGATCTGGATGTGGCCTTGGGCAGGCCAATGTGTGTGGGGACCACACCTTCTGCTAAAGCTTCAATACTCCACGAGGTCAGACCTGTTACATCCGGGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGGCAACTACCCAATCTTCTCAGAGGATATGAAAAGATCAGGTTATCAACCCAAAACGTTATCGATGCAGAAAAAGCACCAGGAGGACCCTACAGACTTGGAACCTCAGGATCTTGCCCTAACGCTACCAGTAAAATCGGATTTTTCGCAACAATGGCTTGGGCTGTCCCAAAGGACAACTACAAAAATGCAACGAACCCACTAACAGTAGAAGTACCATACATTTGTACAGAAGGGGAAGACCAAATTACTGTTTGGGGGTTCCATTCAGACAACAAAACCCAAATGAAGAGCCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCTGCTAATGGAGTAACCACACATTATGTTTCTCAGATTGGCGACTTCCCAGATCAAACAGAAGACGGAGGACTACCACAAAGCGGCAGAATTGTTGTTGATTACATGATGCAAAAACCTGGGAAAACAGGAACAATTGTCTATCAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCGAGTGGCAGGAGCAAAGTAATAAAAGGGTCATTGCCTTTAATTGGTGAAGCAGATTGCCTTCATGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTACTACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGGTAAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACCTCCTGCAAAACTATTGAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGTTTCCTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGATACACATCTCACGGAGCACATGGAGTGGCAGTGGCGGCAGACCTTAAGAGTACACAAGAAGCTATAAATAAGATAACAAAAAATCTCAATTCTTTGAGTGAGCTAGAAGTAAAGAACCTTCAAAGACTAAGTGGTGCCATGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGTGGATGATCTCAGAGCTGACACTATAAGCTCACAAATAGAACTTGCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGACGAGCATCTATTGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGCTGTAGACATAGGAAACGGATGCTTCGAAACCAAACACAAATGCAACCAGACCTGCTTAGACAGGATAGCTGCTGGCACCTTTGATGCAGGAGAATTTTCTCTCCCCACTTTTGATTCATTGAACATTACTGCTGCATCTTTAAATGATGATGGATTGGATAACCATACTATACTGCTCTATTACTCAACTGCTGCTTCTAGTTTGGCTGTAACATTAATGCTAGCTATTTTTATTGTTTATATGGTCTCCAGAGACAACGTTTCATGCTCCATCTG TCTA 5′UTR for eachconstruct:TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ ID NO: 445) 3′UTR for each construct:TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC (SEQ ID NO: 446)It should be understood that the 5′ and/or 3′ UTR for each construct maybe omitted, modified or substituted for a different UTR sequences in anyone of the vaccines as provided herein.

TABLE 19 Examples of Wild Type Hemagglutinin Antigens Protein/ SEQStrain Nucleic Acid Sequence ID NO: H1AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCAAACCTACTG 454GTCCTGTTATGTGCACTTGCAGCTGCAGATGCAGACACAATATGTATAGGCTACCATGCGAACAATTCAACCGACACTGTTGACACAGTGCTCGAGAAGAATGTGACAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGAAAACTATGTAGATTAAAAGGAATAGCCCCACTACAATTGGGGAAATGTAACATCGCCGGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGTCCTACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAGGAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTGTCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAACCACAACACAACCAAAGGAGTAACGGCAGCATGCTCCCATGCGGGGAAAAGCAGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCAAAGCTGAAAAATTCTTATGTGAACAAGAAAGGGAAAGAAGTCCTTGTACTGTGGGGTATTCATCACCCGTCTAACAGTAAGGATCAACAGAATATCTATCAGAATGAAAATGCTTATGTCTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAATAGCAGAAAGACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGACACAATAATATTTGAGGCAAATGGAAATCTAATAGCACCAAGGTATGCTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCACCTCAAACGCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCTATAAACAGCAGTCTCCCTTTCCAGAATATACACCCAGTCACAATAGGAGAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGACTAAGGAACATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCCATTGCCGGTTTTATTGAAGGGGGATGGACTGGAATGATAGATGGATGGTACGGTTATCATCATCAGAATGAACAGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAAAATGCCATTAACGGGATTACAAACAAGGTGAACTCTGTTATCGAGAAAATGAACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTAGAAAAAAGGATGGAAAATTTAAATAAAAAAGTTGATGATGGATTTCTGGACATTTGGACATATAATGCAGAATTGTTAGTTCTACTGGAAAATGAAAGGACTCTGGATTTCCATGACTCAAATGTGAAGAATCTGTATGAGAAAGTAAAAAGCCAATTAAAGAATAATGCCAAAGAAATCGGAAATGGATGTTTTGAGTTCTACCACAAGTGTGACAATGAATGCATGGAAAGTGTAAGAAATGGGACTTATGATTATCCCAAATATTCAGAAGAGTCAAAGTTGAACAGGGAAAAGGTAGATGGAGTGAAATTGGAATCAATGGGGATCTATCAGATTCTGGCGATCTACTCAACTGTCGCCAGTTCACTGGTGCTTTTGGTCTCCCTGGGGGCAATCAGTTTCTGGATGTGTTCTAATGGATCTTTGCAGTGCAGAATATGCATCTGAGATTAGAATTTCAGAAATATGAGGAAAAACACCCTTGTTTCTACT H7AGCGAAAGCAGGGGATACAAAATGAACACTCAAATCCTGGTATTCGCTCT 455GATTGCGATCATTCCAACAAATGCAGACAAAATCTGCCTCGGACATCATGCCGTGTCAAACGGAACCAAAGTAAACACATTAACTGAAAGAGGAGTGGAAGTCGTCAATGCAACTGAAACAGTGGAACGAACAAACATCCCCAGGATCTGCTCAAAAGGGAAAAGGACAGTTGACCTCGGTCAATGTGGACTCCTGGGGACAATCACTGGACCACCTCAATGTGACCAATTCCTAGAATTTTCAGCCGATTTAATTATTGAGAGGCGAGAAGGAAGTGATGTCTGTTATCCTGGGAAATTCGTGAATGAAGAAGCTCTGAGGCAAATTCTCAGAGAATCAGGCGGAATTGACAAGGAAGCAATGGGATTCACATACAGTGGAATAAGAACTAATGGAGCAACCAGTGCATGTAGGAGATCAGGATCTTCATTCTATGCAGAAATGAAATGGCTCCTGTCAAACACAGATGATGCTGCATTCCCGCAGATGACTAAGTCATATAAAAATACAAGAAAAAGCCCAGCTCTAATAGTATGGGGGATCCATCATTCCGTATCAACTGCAGAGCAAACCAAGCTATATGGGAGTGGAAACAAACTGGTGACAGTTGGGAGTTCTAATTATCAACAATCTTTTGTACCGAGTCCAGGAGCGAGACCACAAGTTAATGGTCTATCTGGAAGAATTGACTTTCATTGGCTAATGCTAAATCCCAATGATACAGTCACTTTCAGTTTCAATGGGGCTTTCATAGCTCCAGACCGTGCAAGCTTCCTGAGAGGAAAATCTATGGGAATCCAGAGTGGAGTACAGGTTGATGCCAATTGTGAAGGGGACTGCTATCATAGTGGAGGGACAATAATAAGTAACTTGCCATTTCAGAACATAGATAGCAGGGCAGTTGGAAAATGTCCGAGATATGTTAAGCAAAGGAGTCTGCTGCTAGCAACAGGGATGAAGAATGTTCCTGAGATTCCAAAGGGAAGAGGCCTATTTGGTGCTATAGCGGGTTTCATTGAAAATGGATGGGAAGGCCTAATTGATGGTTGGTATGGTTTCAGACACCAGAATGCACAGGGAGAGGGAACTGCTGCAGATTACAAAAGCACTCAATCGGCAATTGATCAAATAACAGGAAAATTAAACCGGCTTATAGAAAAAACCAACCAACAATTTGAGTTGATAGACAATGAATTCAATGAGGTAGAGAAGCAAATCGGTAATGTGATAAATTGGACCAGAGATTCTATAACAGAAGTGTGGTCATACAATGCTGAACTCTTGGTAGCAATGGAGAACCAGCATACAATTGATCTGGCTGATTCAGAAATGGACAAACTGTACGAACGAGTGAAAAGACAGCTGAGAGAGAATGCTGAAGAAGATGGCACTGGTTGCTTTGAAATATTTCACAAGTGTGATGATGACTGTATGGCCAGTATTAGAAATAACACCTATGATCACAGCAAATACAGGGAAGAGGCAATGCAAAATAGAATACAGATTGACCCAGTCAAACTAAGCAGCGGCTACAAAGATGTGATACTTTGGTTTAGCTTCGGGGCATCATGTTTCATACTTCTAGCCATTGTAATGGGCCTTGTCTTCATATGTGTAAAGAATGGAAACATGCGGTGCACTATTTGTATATAAGTTTGGAAAAAAACACCCTTGTTTCTAC H10ATGTACAAAATAGTAGTGATAATCGCGCTCCTTGGAGCTGTGAAAGGTCT 456TGATAAAATCTGTCTAGGACATCATGCAGTGGCTAATGGGACCATCGTAAAGACTCTCACAAACGAACAGGAAGAGGTAACCAACGCTACTGAAACAGTGGAGAGTACAGGCATAAACAGATTATGTATGAAAGGAAGAAAACATAAAGACCTGGGCAACTGCCATCCAATAGGGATGCTAATAGGGACTCCAGCTTGTGATCTGCACCTTACAGGGATGTGGGACACTCTCATTGAACGAGAGAATGCTATTGCTTACTGCTACCCTGGAGCTACTGTAAATGTAGAAGCACTAAGGCAGAAGATAATGGAGAGTGGAGGGATCAACAAGATAAGCACTGGCTTCACTTATGGATCTTCCATAAACTCGGCCGGGACCACTAGAGCGTGCATGAGGAATGGAGGGAATAGCTTTTATGCAGAGCTTAAGTGGCTGGTATCAAAGAGCAAAGGACAAAACTTCCCTCAGACCACGAACACTTACAGAAATACAGACACGGCTGAACACCTCATAATGTGGGGAATTCATCACCCTTCTAGCACTCAAGAGAAGAATGATCTATATGGAACACAATCACTGTCCATATCAGTCGGGAGTTCCACTTACCGGAACAATTTTGTTCCGGTTGTTGGAGCAAGACCTCAGGTCAATGGACAAAGTGGCAGAATTGATTTTCACTGGACACTAGTACAGCCAGGTGACAACATCACCTTCTCACACAATGGGGGCCTGATAGCACCGAGCCGAGTTAGCAAATTAATTGGGAGGGGATTGGGAATCCAATCAGACGCACCAATAGACAATAATTGTGAGTCCAAATGTTTTTGGAGAGGGGGTTCTATAAATACAAGGCTTCCCTTTCAAAATTTGTCACCAAGAACAGTGGGTCAGTGTCCTAAATATGTGAACAGAAGAAGCTTGATGCTTGCAACAGGAATGAGAAACGTACCAGAACTAATACAAGGGAGAGGTCTATTTGGTGCAATAGCAGGGTTTTTAGAGAATGGGTGGGAAGGAATGGTAGATGGCTGGTATGGTTTCAGACATCAAAATGCTCAGGGCACAGGCCAGGCCGCTGATTACAAGAGTACTCAGGCAGCTATTGATCAAATCACTGGGAAACTGAATAGACTTGTTGAAAAAACCAATACTGAGTTCGAGTCAATAGAATCTGAGTTCAGTGAGATCGAACACCAAATCGGTAACGTCATCAATTGGACTAAGGATTCAATAACCGACATTTGGACTTATCAGGCTGAGCTGTTGGTGGCAATGGAGAACCAGCATACAATCGACATGGCTGACTCAGAGATGTTGAATCTATATGAAAGAGTGAGGAAACAACTAAGGCAGAATGCAGAAGAAGATGGGAAAGGATGTTTTGAGATATATCATGCTTGTGATGATTCATGCATGGAGAGCATAAGAAACAACACCTATGACCATTCACAGTACAGAGAGGAAGCTCTTTTGAACAGATTGAATATCAACCCAGTGACACTCTCTTCTGGATATAAAGACATCATTCTCTGGTTTAGCTTCGGGGCATCATGTTTTGTTCTTCTAGCCGTTGTCATGGGTCTTTTCTTTTTCTGTCTGAAGAATGGAAACATGCGATGCACAATCTGTATTTAG

TABLE 20 Additional Flu Constructs SEQ Name Sequence ID NO: MRK_LZ_ATGGCCAGCCAGGGCACCAAGAGAAGCTACGAGCAGATGGAG 457 NP-H3N2ACCGACGGCGAGAGACAGAACGCCACCGAGATCAGAGCCAGC SQ-031687GTGGGCAAGATGATCGACGGCATCGGCAGATTCTACATCCAGA CX-003145TGTGCACCGAGCTCAAGCTGAGCGACTACGAGGGCAGACTGATCCAGAACAGCCTGACCATCGAAAGAATGGTTCTGAGCGCCTTCGACGAGAGAAGAAACAGATACCTGGAGGAGCACCCCAGCGCCGGCAAGGACCCCAAGAAGACCGGCGGCCCCATCTACAAGAGAGTGGACGGCAGATGGATGAGAGAGCTGGTGCTGTACGACAAGGAGGAGATCAGAAGAATCTGGAGACAGGCCAACAACGGCGACGACGCCACCGCCGGCCTGACCCACATGATGATCTGGCACAGCAACCTGAACGACACCACCTACCAGAGAACCAGAGCCCTGGTGAGAACCGGCATGGACCCCAGAATGTGCAGCTTAATGCAGGGCAGCACCCTGCCCAGAAGATCCGGCGCCGCTGGTGCCGCCGTCAAGGGCATCGGCACCATGGTGATGGAGCTGATCCGCATGATCAAGCGCGGCATCAACGACAGAAACTTCTGGAGAGGCGAAAACGGCAGAAAGACCAGAAGCGCCTACGAGAGAATGTGCAACATCCTGAAGGGCAAGTTCCAGACCGCCGCCCAAAGAGCCATGATGGACCAGGTGAGAGAGAGCAGAAACCCCGGCAACGCCGAGATCGAAGACCTGATCTTCAGCGCCAGATCGGCCCTGATCCTGAGAGGCAGCGTGGCCCACAAGAGCTGCCTGCCCGCCTGCGTGTATGGCCCCGCCGTGAGCAGCGGCTACAACTTCGAGAAGGAGGGCTACAGCCTGGTGGGCATCGACCCCTTCAAGCTGCTGCAGAACTCTCAGGTGTATAGCCTGATCAGACCCAACGAGAACCCCGCCCACAAGAGCCAGCTGGTGTGGATGGCCTGCCACAGCGCCGCCTTCGAGGACCTGAGACTGCTGAGCTTCATCAGAGGTACCAAGGTGTCCCCCAGAGGCAAGCTGAGCACCAGAGGTGTGCAGATCGCCAGCAATGAGAACATGGACAATATGGAGAGCAGCACCCTGGAGCTAAGAAGCAGGTACTGGGCCATCCGGACCAGAAGCGGCGGCAATACCAACCAGCAGAGAGCCAGCGCCGGCCAGATCAGCGTGCAGCCCACCTTCAGCGTGCAGAGAAACCTGCCCTTTGAGAAGAGCACCGTGATGGCCGCCTTCACCGGCAACACCGAGGGCAGAACCAGCGACATGAGAGCCGAGATCATCAGAATGATGGAGGGCGCCAAGCCCGAGGAGGTGAGCTTTAGAGGCAGAGGCGTGTTCGAGCTGAGCGACGAGAAGGCCACCAACCCAATTGTGCCCAGCTTCGACATGTCGAACGAGGGCAGCTACTTCTTCGGCGACAACGCCGAGGAGTACGACAAC MRK_LZ_MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCT 458 NP-H3N2ELKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKK SQ-031687TGGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDDATAGLTH CX-003145MMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGRKTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRGSVAHKSCLPACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTVMAAFTGNTEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEY DN MRK_LZ_ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGCT 459 NIHGen6HGCCCGACACCACCGGCGACACCATCTGCATCGGCTACCACGCC ASS-TM2AACAACAGCACCGACACCGTGGACACCGTGCTGGAGAAGAAC SQ-034074GTGACCGTGACCCACAGCGTGAACCTGGGCAGCGGCCTGAGGA CX-000553TGGTGACCGGCCTGAGGAACATCCCCCAGAGGGAGACCAGGGGCCTGTTCGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACCGGCATGGTGGACGGCTGGTACGGCTACCACCACCAGAACGAGCAGGGCAGCGGCTACGCCGCCGACCAGAAGAGCACCCAGAACGCCATCAACGGCATCACCAACATGGTGAACAGCGTGATCGAGAAGATGGGCAGCGGCGGCAGCGGCACCGACCTGGCCGAGCTGCTGGTGCTGCTGCTGAACGAGAGGACCCTGGACTTCCACGACAGCAACGTGAAGAACCTGTACGAGAAGGTGAAGAGCCAGCTGAAGAACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAGTGCAACAACGAGTGCATGGAGAGCGTGAAGAACGGCACCTACGACTACCCCAAGTACAGCGAGGAGAGCAAGCTGAACAGGGAGAAGATCGACGGAGTGAAATTGGAATCAATGGGGGTCTATCAGATCCTGGCCATCTACAGCACCGTGGCCAGCAGCCTGGTGCTGCTGGTGAGCCTGGGCGCCATCAGCTTCTGGATGTGCAGCAAC GGCAGCCTGCAGTGCAGAATCTGCATCMRK_LZ_ METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVT 460 NIHGen6HVTHSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVD ASS-TM2GWYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSG SQ-034074GSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIG CX-000553NGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI MRK_LZ_ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGCT 461 NIHGen6HGCCCGACACCACCGGCGACACCATCTGCATCGGCTACCACGCC ASS-foldonAACAACAGCACCGACACCGTGGACACCGTGCTGGAGAAGAAC SQ-032106GTGACCGTGACCCACAGCGTGAACCTGGGCAGCGGCCTGAGGA CX-000596TGGTGACCGGCCTGAGGAACATCCCCCAGAGGGAGACCAGGGGCCTGTTCGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACCGGCATGGTGGACGGCTGGTACGGCTACCACCACCAGAACGAGCAGGGCAGCGGCTACGCCGCCGACCAGAAGAGCACCCAGAACGCCATCAACGGCATCACCAACATGGTGAACAGCGTGATCGAGAAGATGGGCAGCGGCGGCAGCGGCACCGACCTGGCCGAGCTGCTGGTGCTGCTGCTGAACGAGAGGACCCTGGACTTCCACGACAGCAACGTGAAGAACCTGTACGAGAAGGTGAAGAGCCAGCTGAAGAACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAGTGCAACAACGAGTGCATGGAGAGCGTGAAGAACGGCACCTACGACTACCCCAAGTACAGCGAGGAGAGCAAGCTGAACAGGGAGAAGATCGACCCCGGCAGCGGCTACATCCCCGAGGCCCCCAGGGACGGCCAGGCCTACGTGAGGAAGGACGGCGAGTGGGTGC TGCTGAGCACCTTCCTG MRK_LZ_METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVT 462 NIHGen6HVTHSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVD ASS-foldonGWYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSG SQ-032106GSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIG CX-000596NGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDPGSGY IPEAPRDGQAYVRKDGEWVLLSTFLThe underlined sequence for each of the amino acid sequences listed inTable 20, indicates a signal or secretory sequence, which may besubstituted by an alternative sequence that achieves the same or similarfunction, or the signal or secretory sequence may be deleted.

TABLE 21 Additional Flu Sequences SEQ Name Sequence ID NO:BHA10-2: HA10 version for METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVT 463Influenza B strain, with GVIPLTTTPTGSANKSKPYYTGEHAKATGNCPIWVexposed hydrophobic KTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELresidues mutated EVKNLQRLSGASDETHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAY VRKDGEWVLLSTFLBHA10-3: HA10 version for METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVT 464Influenza B strain, with GVIPLTTTPTGSANKSKPYYTGEHAKATGNCPIWVexposed hydrophobic KTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELresidues mutated, with EVKNLQRLSCASDETHNCILELDEKVDDLRADTISSK68C/R76C/N95L LIELAVLLSNEGIINSEDE mutations for trimerizationNIHGen6HASS-TM: Gen6 METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDT 465HA SS construct without VDTVLEKNVTVTHSVNLGSGLRMVTGLRNIPQRETfoldon or ferritin, with RGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGStransmembrane domain, GYAADQKSTQNAINGITNMVNSVIEKMGSGGSGT version 1DLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLK NNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDQGTGGILAIYSTVASSLVLLVSL GAISFWMCSNGSLQCRICINIHGen6HASS-TM2: Gen6 METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDT 466HA SS construct without VDTVLEKNVTVTHSVNLGSGLRMVTGLRNIPQRETfoldon or ferritin, with RGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGStransmembrane domain, GYAADQKSTQNAINGITNMVNSVIEKMGSGGSGT version 2DLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLK NNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSL VLLVSLGAISFWMCSNGSLQCRICIH1HA10-PR8-DS-ferritin: METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVT 467H1HA10 from PR8 strain, HSVNLLEDSHGSANSSLPYQNTHPTTNGESPKYVRwith additional disulfide SAKLRMVTGLRNGSAGSATQNAINCITNKVNTVIEmutation, without foldon KMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDIand with ferritin fusion for WTYNAELLVLLENERTLDAHDSQGTGGDIIKLLNEparticle formation QVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATF NFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS ConH1: consensus HA MKAKLLVLLCAFTATDADTICIGYHANNSTDTVDT468 sequence for subtype H1 VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLGKCNIAGWILGNPECESLISKRSWSYIVETPNSENGTCYPGDFADYEELREQLSSVSSFERFEIFPKESSWPN HNVTKGVTAACSHAGKSSFYRNLLWLTEKNGSYPKLSKSYVNNKEKEVLVLWGVHHPSNITDQRTLYQ NENAYVSVVSSHYNRRFTPEIAKRPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNAPMHECDTKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLEKRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN NECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS LQCRICI ConH3: consensus HAMKTIIALSYIFCLVFAQKLPGNDNSTATLCLGHHAV 469 sequence for subtype H3PNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPH RILDGTNCTLIDALLGDPHCDGFQNKEWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNEGFN WTGVTQNGGSSACKRGSDKSFFSRLNWLHKLKYKYPALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSL YVQASGRVTVSTKRSQQTVIPNIGSRPWVRGLSSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGTCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE NGWEGMVDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRLIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEM NKLFERTRKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYK DWILWISFAISCFLLCVVLLGFIMWACQKGNIRCNICI MRK_pH1_Con: consensus MKAILVVLLYTFATANADTLCIGYHANNSTDTVDT 470HA sequence for pandemic VLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHL H1 strainsGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPN HDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQN ADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFI EGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIE NLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDN TCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQ CRICI MRK_sH1_Con: consensusMKVKLLVLLCTFTATYADTICIGYHANNSTDTVDT 471 HA sequence for seasonalVLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPLQLG H1 strainsNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN HTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHT ENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIITSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTIG ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLES MGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI Cobra_P1: consensus HA MKARLLVLLCALAATDADTICIGYHANNSTDTVDT 472sequence P1 for H1 subtype VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLGKCNIAGWLLGNPECESLLSARSWSYIVETPNSENGTCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPN HNTTKGVTAACSHAGKSSFYRNLLWLTKKGGSYPKLSKSYVNNKGKEVLVLWGVHHPSTSTDQQSLYQ NENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRMNYYWTLLEPGDTIIFEATGNLIAPWYAFALSRGSGSGIITSNASMHECNTKCQTPQGAINSSLPFQNIHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNNLEKRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLRNNAKEIGNGCFEFYHKCD NECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS LQCRICI Cobra_X3: consensus HAMEARLLVLLCAFAATNADTICIGYHANNSTDTVDT 473 sequence X3 for H1 subtypeVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLG NCSVAGWILGNPECESLFSKESWSYIAETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN HTVTKGVTASCSHNGKSSFYRNLLWLTEKNGLYPNLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYH TENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN NECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS LQCRICI ConH1_ferritin: consensusMKAKLLVLLCAFTATDADTICIGYHANNSTDTVDT 474 HA sequence for subtypeVLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG H1, with ferritin forKCNIAGWILGNPECESLISKRSWSYIVETPNSENGT particle formationCYPGDFADYEELREQLSSVSSFERFEIFPKESSWPN HNVTKGVTAACSHAGKSSFYRNLLWLTEKNGSYPKLSKSYVNNKEKEVLVLWGVHHPSNITDQRTLYQ NENAYVSVVSSHYNRRFTPEIAKRPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNAPMHECDTKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLEKRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN NECMESVKNGTYDYPKYSEESKLNREKIDSGGDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS ConH3_ferritin: consensusMKTIIALSYIFCLVFAQKLPGNDNSTATLCLGHHAV 475 HA sequence for subtypePNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPH H3, with ferritin forRILDGTNCTLIDALLGDPHCDGFQNKEWDLFVERS particle formationKAYSNCYPYDVPDYASLRSLVASSGTLEFNNEGFN WTGVTQNGGSSACKRGSDKSFFSRLNWLHKLKYKYPALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSL YVQASGRVTVSTKRSQQTVIPNIGSRPWVRGLSSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGTCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE NGWEGMVDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRLIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEM NKLFERTRKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKSGGDIIKLLNE QVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATF NFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS Merck_pH1_Con_ferritin:MKAILVVLLYTFATANADTLCIGYHANNSTDTVDT 476 consensus HA sequence forVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHL pandemic H1 strains, withGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNG ferritin for particleTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPN formationHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYP KLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNY YWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFI EGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIE NLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDN TCMESVKNGTYDYPKYSEEAKLNREEIDSGGDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLF LFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDH ATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS Merck_sH1_Con_ferritin:MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDT 477 consensus HA sequence forVLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPLQLG seasonal H1 strains, withNCSVAGWILGNPECELLISKESWSYIVETPNPENGT ferritin for particleCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN formationHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPN LSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIITSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTIG ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDSGGDII KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS Cobra_P1_ferritin:MKARLLVLLCALAATDADTICIGYHANNSTDTVDT 478 consensus HA sequence P1VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG for H1 subtype, with ferritinKCNIAGWLLGNPECESLLSARSWSYIVETPNSENG for particle formationTCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPN HNTTKGVTAACSHAGKSSFYRNLLWLTKKGGSYPKLSKSYVNNKGKEVLVLWGVHHPSTSTDQQSLYQ NENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRMNYYWTLLEPGDTIIFEATGNLIAPWYAFALSRGSGSGIITSNASMHECNTKCQTPQGAINSSLPFQNIHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNNLEKRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLRNNAKEIGNGCFEFYHKCD NECMESVKNGTYDYPKYSEESKLNREKIDSGGDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS Cobra_X3_ferritin:MEARLLVLLCAFAATNADTICIGYHANNSTDTVDT 479 consensus HA sequence X3VLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLG for H1 subtype, with ferritinNCSVAGWILGNPECESLFSKESWSYIAETPNPENGT for particle formationCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN HTVTKGVTASCSHNGKSSFYRNLLWLTEKNGLYPNLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYH TENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSGIITSNASMDECDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN NECMESVKNGTYDYPKYSEESKLNREKIDSGGDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

TABLE 22 Signal Peptides SEQ Description Sequence ID NO:HuIgG_(k) signal METPAQLLFLLLLWLPDTTG 480 peptide IgE heavy chainMDWTWILFLVAAATRVHS 481 epsilon -1 signal peptide JapaneseMLGSNSGQRVVFTILLLLVA 482 encephalitis PRM PAYS signal sequenceVSVg protein MKCLLYLAFLFIGVNCA 483 signal sequence JapaneseMWLVSLAIVTACAGA 484 encephalitis JEV signal sequence

TABLE 23 Flagellin Nucleic Acid Sequences SEQ Name Sequence ID NO:NT (5′ TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCA 485 UTR, ORF,CTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAA 3′ UTR)ATATAAGAGCCACCATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCCCAGTCCGCACTGGGCACTGCTATCGAGCGTTTGTCTTCCGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGACAGGCGATTGCTAACCGTTTTACCGCGAACATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGTATCTCCATTGCGCAGACCACTGAAGGCGCGCTGAACGAAATCAACAACAACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGTCTGCGAATGGTACTAACTCCCAGTCTGACCTCGACTCCATCCAGGCTGAAATCACCCAGCGCCTGAACGAAATCGACCGTGTATCCGGCCAGACTCAGTTCAACGGCGTGAAAGTCCTGGCGCAGGACAACACCCTGACCATCCAGGTTGGTGCCAACGACGGTGAAACTATCGATATTGATTTAAAAGAAATCAGCTCTAAAACACTGGGACTTGATAAGCTTAATGTCCAAGATGCCTACACCCCGAAAGAAACTGCTGTAACCGTTGATAAAACTACCTATAAAAATGGTACAGATCCTATTACAGCCCAGAGCAATACTGATATCCAAACTGCAATTGGCGGTGGTGCAACGGGGGTTACTGGGGCTGATATCAAATTTAAAGATGGTCAATACTATTTAGATGTTAAAGGCGGTGCTTCTGCTGGTGTTTATAAAGCCACTTATGATGAAACTACAAAGAAAGTTAATATTGATACGACTGATAAAACTCCGTTGGCAACTGCGGAAGCTACAGCTATTCGGGGAACGGCCACTATAACCCACAACCAAATTGCTGAAGTAACAAAAGAGGGTGTTGATACGACCACAGTTGCGGCTCAACTTGCTGCAGCAGGGGTTACTGGCGCCGATAAGGACAATACTAGCCTTGTAAAACTATCGTTTGAGGATAAAAACGGTAAGGTTATTGATGGTGGCTATGCAGTGAAAATGGGCGACGATTTCTATGCCGCTACATATGATGAGAAAACAGGTGCAATTACTGCTAAAACCACTACTTATACAGATGGTACTGGCGTTGCTCAAACTGGAGCTGTGAAATTTGGTGGCGCAAATGGTAAATCTGAAGTTGTTACTGCTACCGATGGTAAGACTTACTTAGCAAGCGACCTTGACAAACATAACTTCAGAACAGGCGGTGAGCTTAAAGAGGTTAATACAGATAAGACTGAAAACCCACTGCAGAAAATTGATGCTGCCTTGGCACAGGTTGATACACTTCGTTCTGACCTGGGTGCGGTTCAGAACCGTTTCAACTCCGCTATCACCAACCTGGGCAATACCGTAAATAACCTGTCTTCTGCCCGTAGCCGTATCGAAGATTCCGACTACGCAACCGAAGTCTCCAACATGTCTCGCGCGCAGATTCTGCAGCAGGCCGGTACCTCCGTTCTGGCGCAGGCGAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCG GC ORFATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTG 486 Sequence,ACCCAGAATAACCTGAACAAATCCCAGTCCGCACTGGGC NTACTGCTATCGAGCGTTTGTCTTCCGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGACAGGCGATTGCTAACCGTTTTACCGCGAACATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGTATCTCCATTGCGCAGACCACTGAAGGCGCGCTGAACGAAATCAACAACAACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGTCTGCGAATGGTACTAACTCCCAGTCTGACCTCGACTCCATCCAGGCTGAAATCACCCAGCGCCTGAACGAAATCGACCGTGTATCCGGCCAGACTCAGTTCAACGGCGTGAAAGTCCTGGCGCAGGACAACACCCTGACCATCCAGGTTGGTGCCAACGACGGTGAAACTATCGATATTGATTTAAAAGAAATCAGCTCTAAAACACTGGGACTTGATAAGCTTAATGTCCAAGATGCCTACACCCCGAAAGAAACTGCTGTAACCGTTGATAAAACTACCTATAAAAATGGTACAGATCCTATTACAGCCCAGAGCAATACTGATATCCAAACTGCAATTGGCGGTGGTGCAACGGGGGTTACTGGGGCTGATATCAAATTTAAAGATGGTCAATACTATTTAGATGTTAAAGGCGGTGCTTCTGCTGGTGTTTATAAAGCCACTTATGATGAAACTACAAAGAAAGTTAATATTGATACGACTGATAAAACTCCGTTGGCAACTGCGGAAGCTACAGCTATTCGGGGAACGGCCACTATAACCCACAACCAAATTGCTGAAGTAACAAAAGAGGGTGTTGATACGACCACAGTTGCGGCTCAACTTGCTGCAGCAGGGGTTACTGGCGCCGATAAGGACAATACTAGCCTTGTAAAACTATCGTTTGAGGATAAAAACGGTAAGGTTATTGATGGTGGCTATGCAGTGAAAATGGGCGACGATTTCTATGCCGCTACATATGATGAGAAAACAGGTGCAATTACTGCTAAAACCACTACTTATACAGATGGTACTGGCGTTGCTCAAACTGGAGCTGTGAAATTTGGTGGCGCAAATGGTAAATCTGAAGTTGTTACTGCTACCGATGGTAAGACTTACTTAGCAAGCGACCTTGACAAACATAACTTCAGAACAGGCGGTGAGCTTAAAGAGGTTAATACAGATAAGACTGAAAACCCACTGCAGAAAATTGATGCTGCCTTGGCACAGGTTGATACACTTCGTTCTGACCTGGGTGCGGTTCAGAACCGTTTCAACTCCGCTATCACCAACCTGGGCAATACCGTAAATAACCTGTCTTCTGCCCGTAGCCGTATCGAAGATTCCGACTACGCAACCGAAGTCTCCAACATGTCTCGCGCGCAGATTCTGCAGCAGGCCGGTACCTCCGTTCTGGCGCAGGCGAACCAGGT TCCGCAAAACGTCCTCTCTTTACTGCGTmRNA G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAU 487 SequenceAUAAGAGCCACCAUGGCACAAGUCAUUAAUACAAACAG (assumesCCUGUCGCUGUUGACCCAGAAUAACCUGAACAAAUCCC T100 tail)AGUCCGCACUGGGCACUGCUAUCGAGCGUUUGUCUUCCGGUCUGCGUAUCAACAGCGCGAAAGACGAUGCGGCAGGACAGGCGAUUGCUAACCGUUUUACCGCGAACAUCAAAGGUCUGACUCAGGCUUCCCGUAACGCUAACGACGGUAUCUCCAUUGCGCAGACCACUGAAGGCGCGCUGAACGAAAUCAACAACAACCUGCAGCGUGUGCGUGAACUGGCGGUUCAGUCUGCGAAUGGUACUAACUCCCAGUCUGACCUCGACUCCAUCCAGGCUGAAAUCACCCAGCGCCUGAACGAAAUCGACCGUGUAUCCGGCCAGACUCAGUUCAACGGCGUGAAAGUCCUGGCGCAGGACAACACCCUGACCAUCCAGGUUGGUGCCAACGACGGUGAAACUAUCGAUAUUGAUUUAAAAGAAAUCAGCUCUAAAACACUGGGACUUGAUAAGCUUAAUGUCCAAGAUGCCUACACCCCGAAAGAAACUGCUGUAACCGUUGAUAAAACUACCUAUAAAAAUGGUACAGAUCCUAUUACAGCCCAGAGCAAUACUGAUAUCCAAACUGCAAUUGGCGGUGGUGCAACGGGGGUUACUGGGGCUGAUAUCAAAUUUAAAGAUGGUCAAUACUAUUUAGAUGUUAAAGGCGGUGCUUCUGCUGGUGUUUAUAAAGCCACUUAUGAUGAAACUACAAAGAAAGUUAAUAUUGAUACGACUGAUAAAACUCCGUUGGCAACUGCGGAAGCUACAGCUAUUCGGGGAACGGCCACUAUAACCCACAACCAAAUUGCUGAAGUAACAAAAGAGGGUGUUGAUACGACCACAGUUGCGGCUCAACUUGCUGCAGCAGGGGUUACUGGCGCCGAUAAGGACAAUACUAGCCUUGUAAAACUAUCGUUUGAGGAUAAAAACGGUAAGGUUAUUGAUGGUGGCUAUGCAGUGAAAAUGGGCGACGAUUUCUAUGCCGCUACAUAUGAUGAGAAAACAGGUGCAAUUACUGCUAAAACCACUACUUAUACAGAUGGUACUGGCGUUGCUCAAACUGGAGCUGUGAAAUUUGGUGGCGCAAAUGGUAAAUCUGAAGUUGUUACUGCUACCGAUGGUAAGACUUACUUAGCAAGCGACCUUGACAAACAUAACUUCAGAACAGGCGGUGAGCUUAAAGAGGUUAAUACAGAUAAGACUGAAAACCCACUGCAGAAAAUUGAUGCUGCCUUGGCACAGGUUGAUACACUUCGUUCUGACCUGGGUGCGGUUCAGAACCGUUUCAACUCCGCUAUCACCAACCUGGGCAAUACCGUAAAUAACCUGUCUUCUGCCCGUAGCCGUAUCGAAGAUUCCGACUACGCAACCGAAGUCUCCAACAUGUCUCGCGCGCAGAUUCUGCAGCAGGCCGGUACCUCCGUUCUGGCGCAGGCGAACCAGGUUCCGCAAAACGUCCUCUCUUUACUGCGUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAUCUAG

The first underlined sequence is representative of the 5′ UTR, which maybe included in or omitted from any of the constructs listed in Table 1,or it may be modified or substituted with another 5′ UTR comprising adifferent sequence. The second underlined sequence is representative ofthe 3′ UTR, which may be included in or omitted from any of theconstructs listed in Table 1, or it may be modified or substituted withanother 3′ UTR comprising a different sequence.

TABLE 24 Flagellin Amino Acid Sequences SEQ Name Sequence ID NO: ORFMAQVINTNSLSLLTQNNLNKSQSAL 488 Sequence, GTAIERLSSGLRINSAKDDAAGQAI AAANRFTANIKGLTQASRNANDGISIA QTTEGALNEINNNLQRVRELAVQSANGTNSQSDLDSIQAEITQRLNEIDR VSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKEISSKTLGLDKLNV QDAYTPKETAVTVDKTTYKNGTDPITAQSNTDIQTAIGGGATGVTGADIK FKDGQYYLDVKGGASAGVYKATYDETTKKVNIDTTDKTPLATAEATAIRG TATITHNQIAEVTKEGVDTTTVAAQLAAAGVTGADKDNTSLVKLSFEDKN GKVIDGGYAVKMGDDFYAATYDEKTGAITAKTTTYTDGTGVAQTGAVKFG GANGKSEVVTATDGKTYLASDLDKHNFRTGGELKEVNTDKTENPLQKIDA ALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLSSARSRIEDSDYATEVS NMSRAQILQQAGTSVLAQANQVPQN VLSLLR Flagellin-MAQVINTNSLSLLTQNNLNKSQSAL 489 GS linker- GTAIERLSSGLRINSAKDDAAGQAIcircumspor- ANRFTANIKGLTQASRNANDGISIA ozoite QTTEGALNEINNNLQRVRELAVQSAprotein NSTNSQSDLDSIQAEITQRLNEIDR (CSP) VSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDTLNV QQKYKVSDTAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDD TTGKYYAKVTVTGGTGKDGYYEVSVDKTNGEVTLAGGATSPLTGGLPATA TEDVKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDGGLA VKVGDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVS IGGKTYAASKAEGHNFKAQPDLAEAAATTTENPLQKIDAALAQVDTLRSD LGAVQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQILQQA GTSVLAQANQVPQNVLSLLRGGGGSGGGGSMMAPDPNANPNANPNANPNA NPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANP NANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEE PSDKHIEQYLKKIKNSISTEWSPCSVTCGNGIQVRIKPGSANKPKDELDY ENDIEKKICKMEKCSSVFNVVNS Flagellin-MMAPDPNANPNANPNANPNANPNAN 490 RPVT PNANPNANPNANPNANPNANPNANP linker-NANPNANPNANPNANPNANPNANPN circumspor- ANPNANPNKNNQGNGQGHNMPNDPN ozoiteRNVDENANANNAVKNNNNEEPSDKH protein IEQYLKKIKNSISTEWSPCSVTCGN (CSP)GIQVRIKPGSANKPKDELDYENDIE KKICKMEKCSSVFNVVNSRPVT MAQVINTNSLSLLTQNNLNKSQSALGTA IERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNANDGISIAQTT EGALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAEITQRLNEIDRVSG QTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGLDTLNVQQK YKVSDTAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDDTTG KYYAKVTVTGGTGKDGYYEVSVDKTNGEVTLAGGATSPLTGGLPATATED VKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDGGLAVKV GDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVSIGG KTYAASKAEGHNFKAQPDLAEAAATTTENPLQKIDAALAQVDTLRSDLGA VQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQILQQAGTS VLAQANQVPQNVLSLLR

TABLE 25 Influenza mRNA Constructs Influenza mRNA Sequences ConstructSEQ Description ORF ID NO: B/Yamagata/16/AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 491 1988 mHACAACGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAAACUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAAGUUAAUGUGACUGGUGUGAUACCACUGACAACAACACCAACAAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAGACCAGAGGGAAACUAUGCCCAAACUGUCUCAACUGCACAGAUCUGGAUGUGGCCUUGGGCAGACCAAUGUGUAUGGGGACCAUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAGACCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUCAGACAGCUACCCAAUCUUCUCAGAGGAUAUGAAAAUAUCAGAUUAUCAACCCAUAACGUUAUCAACGCAGAAAGGGCACCAGGAGGACCCUACAGACUUGGAACCUCAGGAUCUUGCCCUAACGUUACCAGUAGAAACGGAUUCUUCGCAACAAUGGCUUGGGCUGUCCCAAGGGACAACAAAACAGCAACGAAUCCACUAACAGUAGAAGUACCAUACAUUUGCACAAAAGGAGAAGACCAAAUUACUGUUUGGGGGUUCCAUUCUGAUGACAAAACCCAAAUGAAAAACCUCUAUGGAGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCCAAUGGAGUAACCACACAUUAUGUUUCUCAGAUUGGUGACUUCCCAAAUCAAACAGAAGACGGAGGGCUACCACAAAGCGGCAGAAUUGUUGUUGAUUACAUGGUGCAAAAACCUGGGAAAACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGGUCCUUGCCUUUAAUUGGUGAAGCAGAUUGCCUUCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGAGAACAUGCAAAAGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCUUUGAAGCUUGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAGGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCUCAUGGAGCACAUGGAGUGGCAGUGGCAGCAGACCUUAAGAGCACGCAAGAAGCCAUAAACAAGAUAACAAAAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGAAUCUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACAACGAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUCAGAGCUGACACAAUAAGCUCGCAAAUAGAGCUUGCAGUCUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAGCAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUGCUGGGUCCCUCUGCUGUAGACAUAGGGAAUGGAUGCUUCGAAACCAAACACAAGUGCAACCAGACCUGCUUAGACAGGAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUUCCCACUUUUGAUUCACUGAAUAUUACUGCUGCAUCUUUAAAUGAUGAUGGAUUGGAUAAUCAUACUAUACUGCUCUACUACUCAACUGCUGCUUCUAGUUUGGCCGUAACAUUGAUGAUAGCUAUUUUUAUUGUUUAUAUGGUCUCCAGAGACA AUGUUUCUUGCUCCAUCUGUCUAB/Yamagata/16/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 492 1988 sHACAACGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAAACUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAAGUUAAUGUGACUGGUGUGAUACCACUGACAACAACACCAACAAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAGACCAGAGGGAAACUAUGCCCAAACUGUCUCAACUGCACAGAUCUGGAUGUGGCCUUGGGCAGACCAAUGUGUAUGGGGACCAUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAGACCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUCAGACAGCUACCCAAUCUUCUCAGAGGAUAUGAAAAUAUCAGAUUAUCAACCCAUAACGUUAUCAACGCAGAAAGGGCACCAGGAGGACCCUACAGACUUGGAACCUCAGGAUCUUGCCCUAACGUUACCAGUAGAAACGGAUUCUUCGCAACAAUGGCUUGGGCUGUCCCAAGGGACAACAAAACAGCAACGAAUCCACUAACAGUAGAAGUACCAUACAUUUGCACAAAAGGAGAAGACCAAAUUACUGUUUGGGGGUUCCAUUCUGAUGACAAAACCCAAAUGAAAAACCUCUAUGGAGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCCAAUGGAGUAACCACACAUUAUGUUUCUCAGAUUGGUGACUUCCCAAAUCAAACAGAAGACGGAGGGCUACCACAAAGCGGCAGAAUUGUUGUUGAUUACAUGGUGCAAAAACCUGGGAAAACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGGUCCUUGCCUUUAAUUGGUGAAGCAGAUUGCCUUCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGAGAACAUGCAAAAGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCUUUGAAGCUUGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAGGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCUCAUGGAGCACAUGGAGUGGCAGUGGCAGCAGACCUUAAGAGCACGCAAGAAGCCAUAAACAAGAUAACAAAAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGAAUCUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACAACGAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUCAGAGCUGACACAAUAAGCUCGCAAAUAGAGCUUGCAGUCUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAGCAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUGCUGGGUCCCUCUGCUGUAGACAUAGGGAAUGGAUGCUUCGAAACCAAACACAAGUGCAACCAGACCUGCUUAGACAGGAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUUCCCACUUUUGAUUCACUGAAUAUUACUGCUGCAUCUUUA AAUGAUGAUGGAUUGGAUAAUCAUACUB/Victoria/02/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 493 1987 mHACAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAAACUCACCCCAUGUGGUCAAAACUGCUACUCAAGGGGAAGUCAAUGUGACUGGUGUGAUACCACUGACAACAACACCCACCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAAACCAGAGGGAAACUAUGCCCAAAGUGUCUCAACUGCACAGAUCUGGACGUGGCCUUGGGCAGACCAAAGUGCACGGGGACCAUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAAACCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUUAGACAGCUACCCAAUCUUCUCAGAGGAUACGAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAACGCAGAAACGGCACCAGGAGGACCCUACAAAGUUGGAACCUCAGGGUCUUGCCCUAACGUUACCAAUGGAAACGGAUUCUUCGCAACAAUGGCUUGGGCUGUCCCAAAAAACGACAACAACAAAACAGCAACAAAUCCAUUAACAGUAGAAGUACCAUACAUUUGUACAGAAGGAGAAGACCAAAUUACUGUUUGGGGGUUCCACUCUGAUAACGAAGCCCAAAUGGUAAAACUCUAUGGAGACUCAAAGCCUCAGAAGUUCACCUCAUCUGCCAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGCUUCCCAAAUCAAGCAGAAGACGGAGGGCUACCACAAAGCGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGGAAAAACAGGAACAAUUACCUACCAAAGAGGUAUUUUAUUGCCUCAAAAAGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGGUCCUUGCCUUUAAUUGGCGAAGCAGAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGGGAACAUGCAAAAGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAAGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCCCAUGGAGCACAUGGAGUAGCAGUGGCAGCAGACCUUAAGAGUACGCAAGAAGCCAUAAACAAGAUAACAAAAAAUCUCAAUUCUUUGAGUGAGCUGGAAGUAAAGAAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACAACAAAAUACUCGAACUGGAUGAGAAAGUGGAUGAUCUCAGAGCUGAUACAAUAAGCUCGCAAAUAGAGCUCGCAGUCUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAGCAUCUCUUGGCGCUUGAAAGAAAACUGAAGAAAAUGCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUUCGAAACCAAACACAAGUGCAACCAGACCUGCCUCGACAGAAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUCCCCACCUUUGAUUCACUAAAUAUUACUGCUGCAUCUUUAAAUGAUGAUGGAUUGGAUAAUCAUACUAUACUGCUUUACUACUCAACUGCUGCUUCCAGUUUGGCUGUAACAUUGAUGAUAGCUAUCUUUAUUGUUUAUAUGGUCUCCAGAGA CAAUGUUUCUUGCUCCAUCUGUCUAB/Victoria/02/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 494 1987 sHACAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAAACUCACCCCAUGUGGUCAAAACUGCUACUCAAGGGGAAGUCAAUGUGACUGGUGUGAUACCACUGACAACAACACCCACCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAAACCAGAGGGAAACUAUGCCCAAAGUGUCUCAACUGCACAGAUCUGGACGUGGCCUUGGGCAGACCAAAGUGCACGGGGACCAUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAAACCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUUAGACAGCUACCCAAUCUUCUCAGAGGAUACGAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAACGCAGAAACGGCACCAGGAGGACCCUACAAAGUUGGAACCUCAGGGUCUUGCCCUAACGUUACCAAUGGAAACGGAUUCUUCGCAACAAUGGCUUGGGCUGUCCCAAAAAACGACAACAACAAAACAGCAACAAAUCCAUUAACAGUAGAAGUACCAUACAUUUGUACAGAAGGAGAAGACCAAAUUACUGUUUGGGGGUUCCACUCUGAUAACGAAGCCCAAAUGGUAAAACUCUAUGGAGACUCAAAGCCUCAGAAGUUCACCUCAUCUGCCAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGCUUCCCAAAUCAAGCAGAAGACGGAGGGCUACCACAAAGCGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGGAAAAACAGGAACAAUUACCUACCAAAGAGGUAUUUUAUUGCCUCAAAAAGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGGUCCUUGCCUUUAAUUGGCGAAGCAGAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGGGAACAUGCAAAAGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAAGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCCCAUGGAGCACAUGGAGUAGCAGUGGCAGCAGACCUUAAGAGUACGCAAGAAGCCAUAAACAAGAUAACAAAAAAUCUCAAUUCUUUGAGUGAGCUGGAAGUAAAGAAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACAACAAAAUACUCGAACUGGAUGAGAAAGUGGAUGAUCUCAGAGCUGAUACAAUAAGCUCGCAAAUAGAGCUCGCAGUCUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAGCAUCUCUUGGCGCUUGAAAGAAAACUGAAGAAAAUGCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUUCGAAACCAAACACAAGUGCAACCAGACCUGCCUCGACAGAAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUCCCCACCUUUGAUUCACUAAAUAUUACUGCUGCAUCUU UAAAUGAUGAUGGAUUGGAUAAUCAUACUB/Brisbane/60/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 495 2008 mHACAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAAACUCACCACAUGUCGUCAAAACUGCUACUCAAGGGGAGGUCAAUGUGACUGGUGUAAUACCACUGACAACAACACCCACCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAGAAACCAGGGGGAAACUAUGCCCAAAAUGCCUCAACUGCACAGAUCUGGACGUAGCCUUGGGCAGACCAAAAUGCACGGGGAAAAUACCCUCGGCAAGAGUUUCAAUACUCCAUGAAGUCAGACCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUUAGACAGCUGCCUAACCUUCUCCGAGGAUACGAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAAUGCAGAAAAUGCACCAGGAGGACCCUACAAAAUUGGAACCUCAGGGUCUUGCCCUAACAUUACCAAUGGAAACGGAUUUUUCGCAACAAUGGCUUGGGCCGUCCCAAAAAACGACAAAAACAAAACAGCAACAAAUCCAUUAACAAUAGAAGUACCAUACAUUUGUACAGAAGGAGAAGACCAAAUUACCGUUUGGGGGUUCCACUCUGACGACGAGACCCAAAUGGCAAAGCUCUAUGGGGACUCAAAGCCCCAGAAGUUCACCUCAUCUGCCAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGCUUCCCAAAUCAAACAGAAGACGGAGGACUACCACAAAGUGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGGGAAAACAGGAACAAUUACCUAUCAAAGGGGUAUUUUAUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGAUCCUUGCCUUUAAUUGGAGAAGCAGAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGGGAACAUGCAAAGGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCCCAUGGGGCACAUGGAGUAGCGGUGGCAGCAGACCUUAAGAGCACUCAAGAGGCCAUAAACAAGAUAACAAAAAAUCUCAACUCUUUGAGUGAGCUGGAAGUAAAGAAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACAACGAAAUACUAGAACUAGAUGAGAAAGUGGAUGAUCUCAGAGCUGAUACAAUAAGCUCACAAAUAGAACUCGCAGUCCUGCUUUCCAAUGAAGGAAUAAUAAACAGUGAAGAUGAACAUCUCUUGGCGCUUGAAAGAAAGCUGAAGAAAAUGCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUUUGAAACCAAACACAAGUGCAACCAGACCUGUCUCGACAGAAUAGCUGCUGGUACCUUUGAUGCAGGAGAAUUUUCUCUCCCCACCUUUGAUUCACUGAAUAUUACUGCUGCAUCUUUAAAUGACGAUGGAUUGGAUAAUCAUACUAUACUGCUUUACUACUCAACUGCUGCCUCCAGUUUGGCUGUAACACUGAUGAUAGCUAUCUUUGUUGUUUAUAUGGUCUCCAGAG ACAAUGUUUCUUGCUCCAUCUGUCUAB/Brisbane/60/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 496 2008 sHACAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAAACUCACCACAUGUCGUCAAAACUGCUACUCAAGGGGAGGUCAAUGUGACUGGUGUAAUACCACUGACAACAACACCCACCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAGAAACCAGGGGGAAACUAUGCCCAAAAUGCCUCAACUGCACAGAUCUGGACGUAGCCUUGGGCAGACCAAAAUGCACGGGGAAAAUACCCUCGGCAAGAGUUUCAAUACUCCAUGAAGUCAGACCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUUAGACAGCUGCCUAACCUUCUCCGAGGAUACGAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAAUGCAGAAAAUGCACCAGGAGGACCCUACAAAAUUGGAACCUCAGGGUCUUGCCCUAACAUUACCAAUGGAAACGGAUUUUUCGCAACAAUGGCUUGGGCCGUCCCAAAAAACGACAAAAACAAAACAGCAACAAAUCCAUUAACAAUAGAAGUACCAUACAUUUGUACAGAAGGAGAAGACCAAAUUACCGUUUGGGGGUUCCACUCUGACGACGAGACCCAAAUGGCAAAGCUCUAUGGGGACUCAAAGCCCCAGAAGUUCACCUCAUCUGCCAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGCUUCCCAAAUCAAACAGAAGACGGAGGACUACCACAAAGUGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGGGAAAACAGGAACAAUUACCUAUCAAAGGGGUAUUUUAUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAAUAAAAGGAUCCUUGCCUUUAAUUGGAGAAGCAGAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGGGAACAUGCAAAGGCCAUAGGAAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCCCAUGGGGCACAUGGAGUAGCGGUGGCAGCAGACCUUAAGAGCACUCAAGAGGCCAUAAACAAGAUAACAAAAAAUCUCAACUCUUUGAGUGAGCUGGAAGUAAAGAAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACAACGAAAUACUAGAACUAGAUGAGAAAGUGGAUGAUCUCAGAGCUGAUACAAUAAGCUCACAAAUAGAACUCGCAGUCCUGCUUUCCAAUGAAGGAAUAAUAAACAGUGAAGAUGAACAUCUCUUGGCGCUUGAAAGAAAGCUGAAGAAAAUGCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUUUGAAACCAAACACAAGUGCAACCAGACCUGUCUCGACAGAAUAGCUGCUGGUACCUUUGAUGCAGGAGAAUUUUCUCUCCCCACCUUUGAUUCACUGAAUAUUACUGCUGCAUCU UUAAAUGACGAUGGAUUGGAUAAUCAUACUB/Phuket/3073/ AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC 497 2013 mHACAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAAACUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAGGUCAAUGUGACUGGCGUGAUACCACUGACAACAACACCAACAAAAUCUUAUUUUGCAAAUCUCAAAGGAACAAGGACCAGAGGGAAACUAUGCCCGGACUGUCUCAACUGUACAGAUCUGGAUGUGGCCUUGGGCAGGCCAAUGUGUGUGGGGACCACACCUUCUGCUAAAGCUUCAAUACUCCACGAGGUCAGACCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACAGAACAAAAAUCAGGCAACUACCCAAUCUUCUCAGAGGAUAUGAAAAGAUCAGGUUAUCAACCCAAAACGUUAUCGAUGCAGAAAAAGCACCAGGAGGACCCUACAGACUUGGAACCUCAGGAUCUUGCCCUAACGCUACCAGUAAAAUCGGAUUUUUCGCAACAAUGGCUUGGGCUGUCCCAAAGGACAACUACAAAAAUGCAACGAACCCACUAACAGUAGAAGUACCAUACAUUUGUACAGAAGGGGAAGACCAAAUUACUGUUUGGGGGUUCCAUUCAGACAACAAAACCCAAAUGAAGAGCCUCUAUGGAGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCUAAUGGAGUAACCACACAUUAUGUUUCUCAGAUUGGCGACUUCCCAGAUCAAACAGAAGACGGAGGACUACCACAAAGCGGCAGAAUUGUUGUUGAUUACAUGAUGCAAAAACCUGGGAAAACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUUGCCUCAAAAGGUGUGGUGCGCGAGUGGCAGGAGCAAAGUAAUAAAAGGGUCAUUGCCUUUAAUUGGUGAAGCAGAUUGCCUUCAUGAAAAAUACGGUGGAUUAAACAAAAGCAAGCCUUACUACACAGGAGAACAUGCAAAAGCCAUAGGAAAUUGCCCAAUAUGGGUAAAAACACCUUUGAAGCUUGCCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUGAAGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCCUAGAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUACACAUCUCACGGAGCACAUGGAGUGGCAGUGGCGGCAGACCUUAAGAGUACACAAGAAGCUAUAAAUAAGAUAACAAAAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGAACCUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACAACGAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUCAGAGCUGACACUAUAAGCUCACAAAUAGAACUUGCAGUCUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGACGAGCAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUGCUGGGUCCCUCUGCUGUAGACAUAGGAAACGGAUGCUUCGAAACCAAACACAAAUGCAACCAGACCUGCUUAGACAGGAUAGCUGCUGGCACCUUUGAUGCAGGAGAAUUUUCUCUCCCCACUUUUGAUUCAUUGAACAUUACUGCUGCAUCUUUAAAUGAUGAUGGAUUGGAUAACCAUACUAUACUGCUCUAUUACUCAACUGCUGCUUCUAGUUUGGCUGUAACAUUAAUGCUAGCUAUUUUUAUUGUUUAUAUGGUCUCCAGAGA CAACGUUUCAUGCUCCAUCUGUCUA H1AGCAAAAGCAGGGGAAAAUAAAAACAACCAAAAUGAAG 498GCAAACCUACUGGUCCUGUUAUGUGCACUUGCAGCUGCAGAUGCAGACACAAUAUGUAUAGGCUACCAUGCGAACAAUUCAACCGACACUGUUGACACAGUGCUCGAGAAGAAUGUGACAGUGACACACUCUGUUAACCUGCUCGAAGACAGCCACAACGGAAAACUAUGUAGAUUAAAAGGAAUAGCCCCACUACAAUUGGGGAAAUGUAACAUCGCCGGAUGGCUCUUGGGAAACCCAGAAUGCGACCCACUGCUUCCAGUGAGAUCAUGGUCCUACAUUGUAGAAACACCAAACUCUGAGAAUGGAAUAUGUUAUCCAGGAGAUUUCAUCGACUAUGAGGAGCUGAGGGAGCAAUUGAGCUCAGUGUCAUCAUUCGAAAGAUUCGAAAUAUUUCCCAAAGAAAGCUCAUGGCCCAACCACAACACAACCAAAGGAGUAACGGCAGCAUGCUCCCAUGCGGGGAAAAGCAGUUUUUACAGAAAUUUGCUAUGGCUGACGGAGAAGGAGGGCUCAUACCCAAAGCUGAAAAAUUCUUAUGUGAACAAGAAAGGGAAAGAAGUCCUUGUACUGUGGGGUAUUCAUCACCCGUCUAACAGUAAGGAUCAACAGAAUAUCUAUCAGAAUGAAAAUGCUUAUGUCUCUGUAGUGACUUCAAAUUAUAACAGGAGAUUUACCCCGGAAAUAGCAGAAAGACCCAAAGUAAGAGAUCAAGCUGGGAGGAUGAACUAUUACUGGACCUUGCUAAAACCCGGAGACACAAUAAUAUUUGAGGCAAAUGGAAAUCUAAUAGCACCAAGGUAUGCUUUCGCACUGAGUAGAGGCUUUGGGUCCGGCAUCAUCACCUCAAACGCAUCAAUGCAUGAGUGUAACACGAAGUGUCAAACACCCCUGGGAGCUAUAAACAGCAGUCUCCCUUUCCAGAAUAUACACCCAGUCACAAUAGGAGAGUGCCCAAAAUACGUCAGGAGUGCCAAAUUGAGGAUGGUUACAGGACUAAGGAACAUUCCGUCCAUUCAAUCCAGAGGUCUAUUUGGAGCCAUUGCCGGUUUUAUUGAAGGGGGAUGGACUGGAAUGAUAGAUGGAUGGUACGGUUAUCAUCAUCAGAAUGAACAGGGAUCAGGCUAUGCAGCGGAUCAAAAAAGCACACAAAAUGCCAUUAACGGGAUUACAAACAAGGUGAACUCUGUUAUCGAGAAAAUGAACAUUCAAUUCACAGCUGUGGGUAAAGAAUUCAACAAAUUAGAAAAAAGGAUGGAAAAUUUAAAUAAAAAAGUUGAUGAUGGAUUUCUGGACAUUUGGACAUAUAAUGCAGAAUUGUUAGUUCUACUGGAAAAUGAAAGGACUCUGGAUUUCCAUGACUCAAAUGUGAAGAAUCUGUAUGAGAAAGUAAAAAGCCAAUUAAAGAAUAAUGCCAAAGAAAUCGGAAAUGGAUGUUUUGAGUUCUACCACAAGUGUGACAAUGAAUGCAUGGAAAGUGUAAGAAAUGGGACUUAUGAUUAUCCCAAAUAUUCAGAAGAGUCAAAGUUGAACAGGGAAAAGGUAGAUGGAGUGAAAUUGGAAUCAAUGGGGAUCUAUCAGAUUCUGGCGAUCUACUCAACUGUCGCCAGUUCACUGGUGCUUUUGGUCUCCCUGGGGGCAAUCAGUUUCUGGAUGUGUUCUAAUGGAUCUUUGCAGUGCAGAAUAUGCAUCUGAGAUUAGAAUUUCAGAAAUAUGAGG AAAAACACCCUUGUUUCUACU H7AGCGAAAGCAGGGGAUACAAAAUGAACACUCAAAUCCU 499GGUAUUCGCUCUGAUUGCGAUCAUUCCAACAAAUGCAGACAAAAUCUGCCUCGGACAUCAUGCCGUGUCAAACGGAACCAAAGUAAACACAUUAACUGAAAGAGGAGUGGAAGUCGUCAAUGCAACUGAAACAGUGGAACGAACAAACAUCCCCAGGAUCUGCUCAAAAGGGAAAAGGACAGUUGACCUCGGUCAAUGUGGACUCCUGGGGACAAUCACUGGACCACCUCAAUGUGACCAAUUCCUAGAAUUUUCAGCCGAUUUAAUUAUUGAGAGGCGAGAAGGAAGUGAUGUCUGUUAUCCUGGGAAAUUCGUGAAUGAAGAAGCUCUGAGGCAAAUUCUCAGAGAAUCAGGCGGAAUUGACAAGGAAGCAAUGGGAUUCACAUACAGUGGAAUAAGAACUAAUGGAGCAACCAGUGCAUGUAGGAGAUCAGGAUCUUCAUUCUAUGCAGAAAUGAAAUGGCUCCUGUCAAACACAGAUGAUGCUGCAUUCCCGCAGAUGACUAAGUCAUAUAAAAAUACAAGAAAAAGCCCAGCUCUAAUAGUAUGGGGGAUCCAUCAUUCCGUAUCAACUGCAGAGCAAACCAAGCUAUAUGGGAGUGGAAACAAACUGGUGACAGUUGGGAGUUCUAAUUAUCAACAAUCUUUUGUACCGAGUCCAGGAGCGAGACCACAAGUUAAUGGUCUAUCUGGAAGAAUUGACUUUCAUUGGCUAAUGCUAAAUCCCAAUGAUACAGUCACUUUCAGUUUCAAUGGGGCUUUCAUAGCUCCAGACCGUGCAAGCUUCCUGAGAGGAAAAUCUAUGGGAAUCCAGAGUGGAGUACAGGUUGAUGCCAAUUGUGAAGGGGACUGCUAUCAUAGUGGAGGGACAAUAAUAAGUAACUUGCCAUUUCAGAACAUAGAUAGCAGGGCAGUUGGAAAAUGUCCGAGAUAUGUUAAGCAAAGGAGUCUGCUGCUAGCAACAGGGAUGAAGAAUGUUCCUGAGAUUCCAAAGGGAAGAGGCCUAUUUGGUGCUAUAGCGGGUUUCAUUGAAAAUGGAUGGGAAGGCCUAAUUGAUGGUUGGUAUGGUUUCAGACACCAGAAUGCACAGGGAGAGGGAACUGCUGCAGAUUACAAAAGCACUCAAUCGGCAAUUGAUCAAAUAACAGGAAAAUUAAACCGGCUUAUAGAAAAAACCAACCAACAAUUUGAGUUGAUAGACAAUGAAUUCAAUGAGGUAGAGAAGCAAAUCGGUAAUGUGAUAAAUUGGACCAGAGAUUCUAUAACAGAAGUGUGGUCAUACAAUGCUGAACUCUUGGUAGCAAUGGAGAACCAGCAUACAAUUGAUCUGGCUGAUUCAGAAAUGGACAAACUGUACGAACGAGUGAAAAGACAGCUGAGAGAGAAUGCUGAAGAAGAUGGCACUGGUUGCUUUGAAAUAUUUCACAAGUGUGAUGAUGACUGUAUGGCCAGUAUUAGAAAUAACACCUAUGAUCACAGCAAAUACAGGGAAGAGGCAAUGCAAAAUAGAAUACAGAUUGACCCAGUCAAACUAAGCAGCGGCUACAAAGAUGUGAUACUUUGGUUUAGCUUCGGGGCAUCAUGUUUCAUACUUCUAGCCAUUGUAAUGGGCCUUGUCUUCAUAUGUGUAAAGAAUGGAAACAUGCGGUGCACUAUUUGUAUAUAAGUUUGGAAAAA AACACCCUUGUUUCUAC H10AUGUACAAAAUAGUAGUGAUAAUCGCGCUCCUUGGAGC 500UGUGAAAGGUCUUGAUAAAAUCUGUCUAGGACAUCAUGCAGUGGCUAAUGGGACCAUCGUAAAGACUCUCACAAACGAACAGGAAGAGGUAACCAACGCUACUGAAACAGUGGAGAGUACAGGCAUAAACAGAUUAUGUAUGAAAGGAAGAAAACAUAAAGACCUGGGCAACUGCCAUCCAAUAGGGAUGCUAAUAGGGACUCCAGCUUGUGAUCUGCACCUUACAGGGAUGUGGGACACUCUCAUUGAACGAGAGAAUGCUAUUGCUUACUGCUACCCUGGAGCUACUGUAAAUGUAGAAGCACUAAGGCAGAAGAUAAUGGAGAGUGGAGGGAUCAACAAGAUAAGCACUGGCUUCACUUAUGGAUCUUCCAUAAACUCGGCCGGGACCACUAGAGCGUGCAUGAGGAAUGGAGGGAAUAGCUUUUAUGCAGAGCUUAAGUGGCUGGUAUCAAAGAGCAAAGGACAAAACUUCCCUCAGACCACGAACACUUACAGAAAUACAGACACGGCUGAACACCUCAUAAUGUGGGGAAUUCAUCACCCUUCUAGCACUCAAGAGAAGAAUGAUCUAUAUGGAACACAAUCACUGUCCAUAUCAGUCGGGAGUUCCACUUACCGGAACAAUUUUGUUCCGGUUGUUGGAGCAAGACCUCAGGUCAAUGGACAAAGUGGCAGAAUUGAUUUUCACUGGACACUAGUACAGCCAGGUGACAACAUCACCUUCUCACACAAUGGGGGCCUGAUAGCACCGAGCCGAGUUAGCAAAUUAAUUGGGAGGGGAUUGGGAAUCCAAUCAGACGCACCAAUAGACAAUAAUUGUGAGUCCAAAUGUUUUUGGAGAGGGGGUUCUAUAAAUACAAGGCUUCCCUUUCAAAAUUUGUCACCAAGAACAGUGGGUCAGUGUCCUAAAUAUGUGAACAGAAGAAGCUUGAUGCUUGCAACAGGAAUGAGAAACGUACCAGAACUAAUACAAGGGAGAGGUCUAUUUGGUGCAAUAGCAGGGUUUUUAGAGAAUGGGUGGGAAGGAAUGGUAGAUGGCUGGUAUGGUUUCAGACAUCAAAAUGCUCAGGGCACAGGCCAGGCCGCUGAUUACAAGAGUACUCAGGCAGCUAUUGAUCAAAUCACUGGGAAACUGAAUAGACUUGUUGAAAAAACCAAUACUGAGUUCGAGUCAAUAGAAUCUGAGUUCAGUGAGAUCGAACACCAAAUCGGUAACGUCAUCAAUUGGACUAAGGAUUCAAUAACCGACAUUUGGACUUAUCAGGCUGAGCUGUUGGUGGCAAUGGAGAACCAGCAUACAAUCGACAUGGCUGACUCAGAGAUGUUGAAUCUAUAUGAAAGAGUGAGGAAACAACUAAGGCAGAAUGCAGAAGAAGAUGGGAAAGGAUGUUUUGAGAUAUAUCAUGCUUGUGAUGAUUCAUGCAUGGAGAGCAUAAGAAACAACACCUAUGACCAUUCACAGUACAGAGAGGAAGCUCUUUUGAACAGAUUGAAUAUCAACCCAGUGACACUCUCUUCUGGAUAUAAAGACAUCAUUCUCUGGUUUAGCUUCGGGGCAUCAUGUUUUGUUCUUCUAGCCGUUGUCAUGGGUCUUUUCUUUUUCUGUCUGAAGAAUGGAAACAUGCGAUGCACAAUCUGUA UUUAG MRK_LZ_NP-AUGGCCAGCCAGGGCACCAAGAGAAGCUACGAGCAGAUG 501 H3N2GAGACCGACGGCGAGAGACAGAACGCCACCGAGAUCAGA SQ-031687GCCAGCGUGGGCAAGAUGAUCGACGGCAUCGGCAGAUUC CX-003145UACAUCCAGAUGUGCACCGAGCUCAAGCUGAGCGACUACGAGGGCAGACUGAUCCAGAACAGCCUGACCAUCGAAAGAAUGGUUCUGAGCGCCUUCGACGAGAGAAGAAACAGAUACCUGGAGGAGCACCCCAGCGCCGGCAAGGACCCCAAGAAGACCGGCGGCCCCAUCUACAAGAGAGUGGACGGCAGAUGGAUGAGAGAGCUGGUGCUGUACGACAAGGAGGAGAUCAGAAGAAUCUGGAGACAGGCCAACAACGGCGACGACGCCACCGCCGGCCUGACCCACAUGAUGAUCUGGCACAGCAACCUGAACGACACCACCUACCAGAGAACCAGAGCCCUGGUGAGAACCGGCAUGGACCCCAGAAUGUGCAGCUUAAUGCAGGGCAGCACCCUGCCCAGAAGAUCCGGCGCCGCUGGUGCCGCCGUCAAGGGCAUCGGCACCAUGGUGAUGGAGCUGAUCCGCAUGAUCAAGCGCGGCAUCAACGACAGAAACUUCUGGAGAGGCGAAAACGGCAGAAAGACCAGAAGCGCCUACGAGAGAAUGUGCAACAUCCUGAAGGGCAAGUUCCAGACCGCCGCCCAAAGAGCCAUGAUGGACCAGGUGAGAGAGAGCAGAAACCCCGGCAACGCCGAGAUCGAAGACCUGAUCUUCAGCGCCAGAUCGGCCCUGAUCCUGAGAGGCAGCGUGGCCCACAAGAGCUGCCUGCCCGCCUGCGUGUAUGGCCCCGCCGUGAGCAGCGGCUACAACUUCGAGAAGGAGGGCUACAGCCUGGUGGGCAUCGACCCCUUCAAGCUGCUGCAGAACUCUCAGGUGUAUAGCCUGAUCAGACCCAACGAGAACCCCGCCCACAAGAGCCAGCUGGUGUGGAUGGCCUGCCACAGCGCCGCCUUCGAGGACCUGAGACUGCUGAGCUUCAUCAGAGGUACCAAGGUGUCCCCCAGAGGCAAGCUGAGCACCAGAGGUGUGCAGAUCGCCAGCAAUGAGAACAUGGACAAUAUGGAGAGCAGCACCCUGGAGCUAAGAAGCAGGUACUGGGCCAUCCGGACCAGAAGCGGCGGCAAUACCAACCAGCAGAGAGCCAGCGCCGGCCAGAUCAGCGUGCAGCCCACCUUCAGCGUGCAGAGAAACCUGCCCUUUGAGAAGAGCACCGUGAUGGCCGCCUUCACCGGCAACACCGAGGGCAGAACCAGCGACAUGAGAGCCGAGAUCAUCAGAAUGAUGGAGGGCGCCAAGCCCGAGGAGGUGAGCUUUAGAGGCAGAGGCGUGUUCGAGCUGAGCGACGAGAAGGCCACCAACCCAAUUGUGCCCAGCUUCGACAUGUCGAACGAGGGCAGCUACUUCUUCGGCGACAAC GCCGAGGAGUACGACAAC MRK_LZ_NIHGAUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCUG 502 en6HASS-TM2UGGCUGCCCGACACCACCGGCGACACCAUCUGCAUCGGC SQ-034074UACCACGCCAACAACAGCACCGACACCGUGGACACCGUG CX-000553CUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUGGGCAGCGGCCUGAGGAUGGUGACCGGCCUGAGGAACAUCCCCCAGAGGGAGACCAGGGGCCUGUUCGGCGCCAUCGCCGGCUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGCUGGUACGGCUACCACCACCAGAACGAGCAGGGCAGCGGCUACGCCGCCGACCAGAAGAGCACCCAGAACGCCAUCAACGGCAUCACCAACAUGGUGAACAGCGUGAUCGAGAAGAUGGGCAGCGGCGGCAGCGGCACCGACCUGGCCGAGCUGCUGGUGCUGCUGCUGAACGAGAGGACCCUGGACUUCCACGACAGCAACGUGAAGAACCUGUACGAGAAGGUGAAGAGCCAGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCUUCGAGUUCUACCACAAGUGCAACAACGAGUGCAUGGAGAGCGUGAAGAACGGCACCUACGACUACCCCAAGUACAGCGAGGAGAGCAAGCUGAACAGGGAGAAGAUCGACGGAGUGAAAUUGGAAUCAAUGGGGGUCUAUCAGAUCCUGGCCAUCUACAGCACCGUGGCCAGCAGCCUGGUGCUGCUGGUGAGCCUGGGCGCCAUCAGCUUCUGGAUGUGCAGCAACGGCA GCCUGCAGUGCAGAAUCUGCAUCMRK_LZ_NIHG AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCUG 503 en6HASS-foldonUGGCUGCCCGACACCACCGGCGACACCAUCUGCAUCGGC SQ-032106UACCACGCCAACAACAGCACCGACACCGUGGACACCGUG CX-000596CUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUGGGCAGCGGCCUGAGGAUGGUGACCGGCCUGAGGAACAUCCCCCAGAGGGAGACCAGGGGCCUGUUCGGCGCCAUCGCCGGCUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGCUGGUACGGCUACCACCACCAGAACGAGCAGGGCAGCGGCUACGCCGCCGACCAGAAGAGCACCCAGAACGCCAUCAACGGCAUCACCAACAUGGUGAACAGCGUGAUCGAGAAGAUGGGCAGCGGCGGCAGCGGCACCGACCUGGCCGAGCUGCUGGUGCUGCUGCUGAACGAGAGGACCCUGGACUUCCACGACAGCAACGUGAAGAACCUGUACGAGAAGGUGAAGAGCCAGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCUUCGAGUUCUACCACAAGUGCAACAACGAGUGCAUGGAGAGCGUGAAGAACGGCACCUACGACUACCCCAAGUACAGCGAGGAGAGCAAGCUGAACAGGGAGAAGAUCGACCCCGGCAGCGGCUACAUCCCCGAGGCCCCCAGGGACGGCCAGGCCUACGUGAGGAAGGACGGCGAGUGGGUGCUGCUGAGCA CCUUCCUG

It should be understood that each of the ORF sequences provided hereinmay be combined with a 5′ and/or 3′ UTR, such as those described herein.

TABLE 26 Additional Influenza mRNA Vaccine Constructs Name of SEQantigen Open Reading Frame (ORF) Sequences ID NO MRK_pH1_ DNAATGAAGGTGAAGCTGCTGGTGCTGCTGTGCACCTTCACCGCC 505 Con_RBDACCTACGCCGGCGTGGCCCCTCTGCACCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGCAACCCTGAGTGCGAGAGCCTTAGCACAGCCTCCTCCTGGAGCTACATCGTGGAGACGAGCAGCAGCGATAACGGGACCTGCTACCCTGGCGACTTCATCGACTACGAGGAGCTGAGAGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGAGATTCGAGATCTTCCCTAAGACCAGCAGCTGGCCTAACCACGACAGCAACAAGGGCGTGACCGCCGCCTGCCCACACGCCGGGGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCTAAACTGAGCAAGTCCTACATCAACGACAAAGGCAAGGAGGTCCTCGTGCTCTGGGGCATCCACCACCCTAGCACCAGCGCCGATCAGCAGAGCCTGTACCAGAACGCCGACGCGTACGTGTTCGTGGGCACCAGCAGATACAGCAAGAAGTTCAAGCCTGAGATCGCCATCAGACCTAAGGTGAGGGACCAGGAGGGCAGAATGAACTACTACTGGACCCTGGTGGAGCCCGGAGATAAGATCACATTTGAGGCCACCGGCAACCTGGTGGTGCCTAGATACGCCTTCGCCATGGAGAGAAACGCC mRNAAUGAAGGUGAAGCUGCUGGUGCUGCUGUGCACCUUCACCGC 524CACCUACGCCGGCGUGGCCCCUCUGCACCUGGGCAAGUGCAACAUCGCCGGCUGGAUCCUGGGCAACCCUGAGUGCGAGAGCCUUAGCACAGCCUCCUCCUGGAGCUACAUCGUGGAGACGAGCAGCAGCGAUAACGGGACCUGCUACCCUGGCGACUUCAUCGACUACGAGGAGCUGAGAGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGACCAGCAGCUGGCCUAACCACGACAGCAACAAGGGCGUGACCGCCGCCUGCCCACACGCCGGGGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCUAAACUGAGCAAGUCCUACAUCAACGACAAAGGCAAGGAGGUCCUCGUGCUCUGGGGCAUCCACCACCCUAGCACCAGCGCCGAUCAGCAGAGCCUGUACCAGAACGCCGACGCGUACGUGUUCGUGGGCACCAGCAGAUACAGCAAGAAGUUCAAGCCUGAGAUCGCCAUCAGACCUAAGGUGAGGGACCAGGAGGGCAGAAUGAACUACUACUGGACCCUGGUGGAGCCCGGAGAUAAGAUCACAUUUGAGGCCACCGGCAACCUGGUGGUGCCUAGAUACGCCUUCGCCAUGGAGAGAAA CGCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESLST 543ASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLV VPRYAFAMERNA MRK_pH1_ DNAATGAAGGCCATCCTCGTGGTGCTGCTGTACACCTTTGCCACCG 506 Con_ectoCCAACGCCGATACCCTGTGTATCGGCTACCACGCCAACAACAGCACCGACACCGTGGATACTGTCCTGGAGAAGAACGTGACCGTGACCCACAGCGTGAACCTGCTGGAGGACAAGCACAACGGCAAGCTGTGCAAGCTGAGAGGCGTGGCCCCTCTGCACCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGCAACCCTGAGTGCGAGAGCCTTAGCACAGCCTCCTCCTGGAGCTACATCGTGGAGACGAGCAGCAGCGATAACGGGACCTGCTACCCTGGCGACTTCATCGACTACGAGGAGCTGAGAGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGAGATTCGAGATCTTCCCTAAGACCAGCAGCTGGCCTAACCACGACAGCAACAAGGGCGTGACCGCCGCCTGCCCACACGCCGGGGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCTAAACTGAGCAAGTCCTACATCAACGACAAAGGCAAGGAGGTCCTCGTGCTCTGGGGCATCCACCACCCTAGCACCAGCGCCGATCAGCAGAGCCTGTACCAGAACGCCGACGCGTACGTGTTCGTGGGCACCAGCAGATACAGCAAGAAGTTCAAGCCTGAGATCGCCATCAGACCTAAGGTGAGGGACCAGGAGGGCAGAATGAACTACTACTGGACCCTGGTGGAGCCCGGAGATAAGATCACATTTGAGGCCACCGGCAACCTGGTGGTGCCTAGATACGCCTTCGCCATGGAGAGAAACGCCGGCAGCGGCATCATCATCAGCGACACCCCTGTGCACGACTGCAACACCACCTGCCAGACCCCTAAGGGCGCCATCAACACGAGCCTGCCTTTCCAGAACATCCACCCTATCACCATCGGCAAGTGCCCTAAGTACGTGAAGTCAACCAAACTGAGACTCGCCACCGGCCTCAGAAACGTGCCTAGCATCCAGAGCAGAGGCCTCTTCGGCGCCATCGCGGGATTCATCGAGGGCGGCTGGACCGGCATGGTGGACGGCTGGTACGGCTACCACCATCAGAACGAGCAGGGCAGCGGGTACGCGGCCGACCTCAAGAGCACCCAGAACGCCATCGACAAGATCACCAACAAGGTGAACAGCGTGATCGAGAAGATGAACACCCAGTTCACCGCCGTGGGCAAGGAGTTCAACCACCTGGAGAAGAGAATCGAGAACCTGAACAAGAAGGTGGACGACGGCTTCCTGGACATCTGGACCTACAACGCAGAACTGCTCGTGCTTCTGGAGAACGAGAGAACCCTGGACTACCACGACTCCAACGTGAAGAACCTGTACGAGAAGGTGAGAAGCCAGCTGAAGAACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAGTGCGACAACACCTGCATGGAGAGCGTGAAGAACGGCACCTACGACTACCCTAAGTACAGCGAGGAGGCCAAGCTGAACAGAGAGGAGATCGACGGCGTGAAGCTGGAGAGCACCAGAATCGGCTCAGCCGGGAGCGCCGGCTACATCCCTGAGGCCCCTAGAGACGGCCAGGCCTACGTGAGAAAGGACGGCGAGTGGGTGCTGCTG AGCACCTTCCTG mRNAAUGAAGGCCAUCCUCGUGGUGCUGCUGUACACCUUUGCCAC 525CGCCAACGCCGAUACCCUGUGUAUCGGCUACCACGCCAACAACAGCACCGACACCGUGGAUACUGUCCUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUGCUGGAGGACAAGCACAACGGCAAGCUGUGCAAGCUGAGAGGCGUGGCCCCUCUGCACCUGGGCAAGUGCAACAUCGCCGGCUGGAUCCUGGGCAACCCUGAGUGCGAGAGCCUUAGCACAGCCUCCUCCUGGAGCUACAUCGUGGAGACGAGCAGCAGCGAUAACGGGACCUGCUACCCUGGCGACUUCAUCGACUACGAGGAGCUGAGAGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGACCAGCAGCUGGCCUAACCACGACAGCAACAAGGGCGUGACCGCCGCCUGCCCACACGCCGGGGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCUAAACUGAGCAAGUCCUACAUCAACGACAAAGGCAAGGAGGUCCUCGUGCUCUGGGGCAUCCACCACCCUAGCACCAGCGCCGAUCAGCAGAGCCUGUACCAGAACGCCGACGCGUACGUGUUCGUGGGCACCAGCAGAUACAGCAAGAAGUUCAAGCCUGAGAUCGCCAUCAGACCUAAGGUGAGGGACCAGGAGGGCAGAAUGAACUACUACUGGACCCUGGUGGAGCCCGGAGAUAAGAUCACAUUUGAGGCCACCGGCAACCUGGUGGUGCCUAGAUACGCCUUCGCCAUGGAGAGAAACGCCGGCAGCGGCAUCAUCAUCAGCGACACCCCUGUGCACGACUGCAACACCACCUGCCAGACCCCUAAGGGCGCCAUCAACACGAGCCUGCCUUUCCAGAACAUCCACCCUAUCACCAUCGGCAAGUGCCCUAAGUACGUGAAGUCAACCAAACUGAGACUCGCCACCGGCCUCAGAAACGUGCCUAGCAUCCAGAGCAGAGGCCUCUUCGGCGCCAUCGCGGGAUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGCUGGUACGGCUACCACCAUCAGAACGAGCAGGGCAGCGGGUACGCGGCCGACCUCAAGAGCACCCAGAACGCCAUCGACAAGAUCACCAACAAGGUGAACAGCGUGAUCGAGAAGAUGAACACCCAGUUCACCGCCGUGGGCAAGGAGUUCAACCACCUGGAGAAGAGAAUCGAGAACCUGAACAAGAAGGUGGACGACGGCUUCCUGGACAUCUGGACCUACAACGCAGAACUGCUCGUGCUUCUGGAGAACGAGAGAACCCUGGACUACCACGACUCCAACGUGAAGAACCUGUACGAGAAGGUGAGAAGCCAGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCUUCGAGUUCUACCACAAGUGCGACAACACCUGCAUGGAGAGCGUGAAGAACGGCACCUACGACUACCCUAAGUACAGCGAGGAGGCCAAGCUGAACAGAGAGGAGAUCGACGGCGUGAAGCUGGAGAGCACCAGAAUCGGCUCAGCCGGGAGCGCCGGCUACAUCCCUGAGGCCCCUAGAGACGGCCAGGCCUACGUGAGAAAGGACGGCGAGUGGGUGCUGCUGAGCACCUU CCUG ProteinMKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTV 544THSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL MRK_sH1_ DNAATGAAGGTGAAGCTGCTGGTGCTGCTGTGCACCTTCACCGCC 507 Con_RBDACCTACGCCGGAATCGCTCCCCTGCAGCTCGGCAACTGCAGCGTGGCCGGCTGGATTCTGGGCAACCCCGAGTGCGAACTGCTGATTAGCAAAGAGTCCTGGAGCTACATCGTGGAAACCCCGAATCCCGAGAACGGCACCTGCTACCCCGGCTACTTCGCCGACTACGAGGAGCTAAGAGAGCAGCTGAGTAGCGTGAGCTCATTCGAGAGATTCGAGATCTTTCCCAAGGAGTCTAGCTGGCCCAATCACACCGTCACCGGCGTGTCCGCCAGCTGTAGCCACAACGGCAAGAGCAGCTTCTACAGAAACCTGCTGTGGCTGACCGGCAAGAACGGACTGTACCCTAACCTGAGCAAGAGCTACGCGAACAATAAGGAGAAGGAGGTGCTAGTGCTGTGGGGCGTGCACCATCCGCCCAACATCGGCGACCAGAGAGCCCTGTACCACACCGAGAACGCCTACGTGAGCGTGGTGAGCAGCCACTATAGCAGAAGATTCACCCCTGAGATCGCCAAGAGGCCAAAGGTGAGAGATCAGGAAGGAAGAATAAACTACTACTGGACCCTCCTGGAGCCCGGCGACACCATCATCTTCGAGGCTAACGGCAACCTGATCGCCCCTAGA TACGCCTTCGCCCTGAGCAGAGGC mRNAAUGAAGGUGAAGCUGCUGGUGCUGCUGUGCACCUUCACCGC 526CACCUACGCCGGAAUCGCUCCCCUGCAGCUCGGCAACUGCAGCGUGGCCGGCUGGAUUCUGGGCAACCCCGAGUGCGAACUGCUGAUUAGCAAAGAGUCCUGGAGCUACAUCGUGGAAACCCCGAAUCCCGAGAACGGCACCUGCUACCCCGGCUACUUCGCCGACUACGAGGAGCUAAGAGAGCAGCUGAGUAGCGUGAGCUCAUUCGAGAGAUUCGAGAUCUUUCCCAAGGAGUCUAGCUGGCCCAAUCACACCGUCACCGGCGUGUCCGCCAGCUGUAGCCACAACGGCAAGAGCAGCUUCUACAGAAACCUGCUGUGGCUGACCGGCAAGAACGGACUGUACCCUAACCUGAGCAAGAGCUACGCGAACAAUAAGGAGAAGGAGGUGCUAGUGCUGUGGGGCGUGCACCAUCCGCCCAACAUCGGCGACCAGAGAGCCCUGUACCACACCGAGAACGCCUACGUGAGCGUGGUGAGCAGCCACUAUAGCAGAAGAUUCACCCCUGAGAUCGCCAAGAGGCCAAAGGUGAGAGAUCAGGAAGGAAGAAUAAACUACUACUGGACCCUCCUGGAGCCCGGCGACACCAUCAUCUUCGAGGCUAACGGCAACCUGAUCGCCCCUAGAUACGCCUUCGCCCUGAGCAGAGGC ProteinMKVKLLVLLCTFTATYAGIAPLQLGNCSVAGWILGNPECELLIS 545KESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAP RYAFALSRG MRK_sH1_ DNAATGAAGGTGAAGCTGCTGGTGCTGCTGTGTACCTTCACTGCC 508 Con_ectoACTTACGCCGACACCATTTGCATCGGCTACCACGCCAACAACAGCACCGATACCGTGGACACCGTGCTGGAGAAGAACGTCACCGTGACCCACAGCGTGAACCTGCTGGAGGATAGCCATAACGGCAAGCTGTGCCTGCTGAAGGGAATCGCTCCCCTGCAGCTCGGCAACTGCAGCGTGGCCGGCTGGATTCTGGGCAACCCCGAGTGCGAACTGCTGATTAGCAAAGAGTCCTGGAGCTACATCGTGGAAACCCCGAATCCCGAGAACGGCACCTGCTACCCCGGCTACTTCGCCGACTACGAGGAGCTAAGAGAGCAGCTGAGTAGCGTGAGCTCATTCGAGAGATTCGAGATCTTTCCCAAGGAGTCTAGCTGGCCCAATCACACCGTCACCGGCGTGTCCGCCAGCTGTAGCCACAACGGCAAGAGCAGCTTCTACAGAAACCTGCTGTGGCTGACCGGCAAGAACGGACTGTACCCTAACCTGAGCAAGAGCTACGCGAACAATAAGGAGAAGGAGGTGCTAGTGCTGTGGGGCGTGCACCATCCGCCCAACATCGGCGACCAGAGAGCCCTGTACCACACCGAGAACGCCTACGTGAGCGTGGTGAGCAGCCACTATAGCAGAAGATTCACCCCTGAGATCGCCAAGAGGCCAAAGGTGAGAGATCAGGAAGGAAGAATAAACTACTACTGGACCCTCCTGGAGCCCGGCGACACCATCATCTTCGAGGCTAACGGCAACCTGATCGCCCCTAGATACGCCTTCGCCCTGAGCAGAGGCTTCGGCAGCGGCATCATCACCAGCAACGCTCCCATGGACGAGTGCGACGCCAAGTGCCAGACCCCGCAGGGCGCCATCAACTCGAGCCTGCCCTTCCAGAACGTGCACCCCGTGACCATCGGCGAGTGCCCCAAGTACGTGAGAAGCGCCAAGCTGAGAATGGTGACCGGCCTGAGAAACATCCCAAGCATCCAGAGCAGAGGGCTGTTCGGCGCCATCGCTGGCTTCATCGAGGGCGGCTGGACCGGCATGGTGGACGGCTGGTACGGTTATCACCACCAGAACGAGCAGGGCAGCGGCTACGCCGCCGACCAGAAGTCCACCCAGAACGCCATCAACGGCATTACAAACAAGGTGAACAGCGTTATCGAGAAGATGAACACCCAATTCACCGCCGTGGGCAAGGAGTTCAACAAGCTGGAGAGAAGAATGGAGAACCTGAACAAGAAGGTGGACGACGGCTTCCTGGACATCTGGACCTACAACGCCGAACTGCTGGTCCTGCTGGAGAACGAGAGAACCCTGGACTTCCACGACTCCAACGTGAAGAACTTATACGAGAAGGTCAAATCCCAGCTGAAGAACAACGCCAAAGAAATCGGAAACGGCTGCTTCGAATTCTACCACAAGTGCAACGACGAGTGCATGGAGAGCGTGAAGAACGGAACCTACGACTACCCCAAGTACAGCGAGGAAAGCAAACTGAACAGAGAGAAGATCGACGGCGTGAAGTTAGAGAGCATGGGCGTGGGCAGCGCCGGCTCTGCTGGATACATCCCTGAGGCCCCTAGAGACGGCCAGGCCTACGTGAGAAAGGACGGCGAGTGGGTGCTGCTGAGC ACCTTCCTG mRNAAUGAAGGUGAAGCUGCUGGUGCUGCUGUGUACCUUCACUG 527CCACUUACGCCGACACCAUUUGCAUCGGCUACCACGCCAACAACAGCACCGAUACCGUGGACACCGUGCUGGAGAAGAACGUCACCGUGACCCACAGCGUGAACCUGCUGGAGGAUAGCCAUAACGGCAAGCUGUGCCUGCUGAAGGGAAUCGCUCCCCUGCAGCUCGGCAACUGCAGCGUGGCCGGCUGGAUUCUGGGCAACCCCGAGUGCGAACUGCUGAUUAGCAAAGAGUCCUGGAGCUACAUCGUGGAAACCCCGAAUCCCGAGAACGGCACCUGCUACCCCGGCUACUUCGCCGACUACGAGGAGCUAAGAGAGCAGCUGAGUAGCGUGAGCUCAUUCGAGAGAUUCGAGAUCUUUCCCAAGGAGUCUAGCUGGCCCAAUCACACCGUCACCGGCGUGUCCGCCAGCUGUAGCCACAACGGCAAGAGCAGCUUCUACAGAAACCUGCUGUGGCUGACCGGCAAGAACGGACUGUACCCUAACCUGAGCAAGAGCUACGCGAACAAUAAGGAGAAGGAGGUGCUAGUGCUGUGGGGCGUGCACCAUCCGCCCAACAUCGGCGACCAGAGAGCCCUGUACCACACCGAGAACGCCUACGUGAGCGUGGUGAGCAGCCACUAUAGCAGAAGAUUCACCCCUGAGAUCGCCAAGAGGCCAAAGGUGAGAGAUCAGGAAGGAAGAAUAAACUACUACUGGACCCUCCUGGAGCCCGGCGACACCAUCAUCUUCGAGGCUAACGGCAACCUGAUCGCCCCUAGAUACGCCUUCGCCCUGAGCAGAGGCUUCGGCAGCGGCAUCAUCACCAGCAACGCUCCCAUGGACGAGUGCGACGCCAAGUGCCAGACCCCGCAGGGCGCCAUCAACUCGAGCCUGCCCUUCCAGAACGUGCACCCCGUGACCAUCGGCGAGUGCCCCAAGUACGUGAGAAGCGCCAAGCUGAGAAUGGUGACCGGCCUGAGAAACAUCCCAAGCAUCCAGAGCAGAGGGCUGUUCGGCGCCAUCGCUGGCUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGCUGGUACGGUUAUCACCACCAGAACGAGCAGGGCAGCGGCUACGCCGCCGACCAGAAGUCCACCCAGAACGCCAUCAACGGCAUUACAAACAAGGUGAACAGCGUUAUCGAGAAGAUGAACACCCAAUUCACCGCCGUGGGCAAGGAGUUCAACAAGCUGGAGAGAAGAAUGGAGAACCUGAACAAGAAGGUGGACGACGGCUUCCUGGACAUCUGGACCUACAACGCCGAACUGCUGGUCCUGCUGGAGAACGAGAGAACCCUGGACUUCCACGACUCCAACGUGAAGAACUUAUACGAGAAGGUCAAAUCCCAGCUGAAGAACAACGCCAAAGAAAUCGGAAACGGCUGCUUCGAAUUCUACCACAAGUGCAACGACGAGUGCAUGGAGAGCGUGAAGAACGGAACCUACGACUACCCCAAGUACAGCGAGGAAAGCAAACUGAACAGAGAGAAGAUCGACGGCGUGAAGUUAGAGAGCAUGGGCGUGGGCAGCGCCGGCUCUGCUGGAUACAUCCCUGAGGCCCCUAGAGACGGCCAGGCCUACGUGAGAAAGGACGGCGAGUGGGUGCUGCUGAGCACC UUCCUG ProteinMKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVT 546HSVNLLEDSHNGKLCLLKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHTENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIITSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL MRK_sH1_ DNAATGAAGGTGAAACTCCTCGTCCTGCTGTGCACCTTCACCGCC 509 Con_v2ACCTACGCCGATACCATCTGTATTGGCTACCACGCCAACAACTCCACCGACACCGTGGATACCGTGCTCGAGAAGAACGTGACCGTGACCCACAGCGTGAACCTGCTGGAGAACAGCCACAACGGCAAGCTGTGCCTGCTGAAGGGCATCGCGCCCCTGCAGTTGGGTAACTGCTCCGTGGCCGGCTGGATCCTGGGCAACCCTGAGTGCGAGCTGCTGATCAGCAAGGAGAGCTGGAGCTACATCGTGGAGAAGCCTAACCCCGAGAACGGCACCTGCTACCCTGGCCACTTCGCCGACTACGAGGAGCTGAGAGAGCAACTCAGCAGCGTGAGCAGCTTCGAGAGATTCGAGATCTTCCCTAAGGAGAGCAGCTGGCCCAATCACACTGTGACCGGCGTGTCCGCTTCTTGCAGCCATAACGGGGAAAGCTCCTTCTACAGAAATCTCCTTTGGCTGACGGGGAAGAACGGCCTGTACCCTAACCTGAGCAAGAGCTACGCCAACAACAAGGAGAAGGAGGTGCTGGTGCTGTGGGGCGTGCACCACCCTCCTAACATCGGCGACCAGAAGGCCCTGTACCACACCGAGAACGCCTACGTCAGCGTGGTGTCCAGCCACTACAGCAGAAAGTTCACCCCTGAGATCGCCAAGAGGCCTAAGGTGCGGGACCAGGAGGGCAGAATCAACTACTACTGGACCCTGCTGGAGCCTGGCGACACCATCATCTTCGAGGCCAACGGCAACCTGATCGCCCCTAGATACGCCTTCGCCCTGAGCAGAGGCTTCGGCAGCGGCATCATCAACAGCAACGCCCCTATGGACAAGTGCGACGCCAAGTGCCAGACTCCGCAGGGCGCTATCAACAGCTCCCTGCCTTTCCAGAACGTGCACCCTGTGACCATCGGCGAGTGCCCTAAGTACGTGAGAAGCGCCAAGCTGAGAATGGTGACCGGCCTGAGAAACATCCCTAGCATCCAGAGCAGAGGCCTGTTCGGCGCCATCGCCGGGTTTATCGAGGGCGGCTGGACCGGCATGGTGGACGGCTGGTACGGCTACCACCACCAGAACGAGCAGGGCTCCGGCTACGCCGCCGACCAGAAATCCACCCAGAACGCCATCAACGGCATCACCAACAAGGTGAACAGCGTCATCGAGAAGATGAACACCCAGTTCACCGCCGTGGGCAAGGAGTTCAACAAGCTGGAGAGAAGAATGGAGAACCTGAACAAGAAGGTGGACGACGGCTTCATCGACATCTGGACCTACAACGCCGAGCTTCTGGTGCTCCTGGAGAACGAGAGAACCCTGGACTTCCACGACAGCAACGTGAAGAACCTGTACGAGAAGGTGAAGTCCCAGCTGAAGAACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAGTGCAACGACGAGTGCATGGAGAGCGTGAAGAACGGCACCTACGATTACCCCAAGTACAGCGAGGAGAGCAAGCTGAACAGAGAGAAGATCGACGGCGTGAAGCTGGAGAGCATGGGCGTGTACCAGATCCTGGCCATCTACTCCACCGTGGCCAGTAGCCTGGTGCTGCTGGTGAGCCTGGGCGCAATCAGCTTCTGGATGTGCAGCAA CGGCAGCCTGCAGTGCAGAATCTGCATCmRNA AUGAAGGUGAAACUCCUCGUCCUGCUGUGCACCUUCACCGC 528CACCUACGCCGAUACCAUCUGUAUUGGCUACCACGCCAACAACUCCACCGACACCGUGGAUACCGUGCUCGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUGCUGGAGAACAGCCACAACGGCAAGCUGUGCCUGCUGAAGGGCAUCGCGCCCCUGCAGUUGGGUAACUGCUCCGUGGCCGGCUGGAUCCUGGGCAACCCUGAGUGCGAGCUGCUGAUCAGCAAGGAGAGCUGGAGCUACAUCGUGGAGAAGCCUAACCCCGAGAACGGCACCUGCUACCCUGGCCACUUCGCCGACUACGAGGAGCUGAGAGAGCAACUCAGCAGCGUGAGCAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGGAGAGCAGCUGGCCCAAUCACACUGUGACCGGCGUGUCCGCUUCUUGCAGCCAUAACGGGGAAAGCUCCUUCUACAGAAAUCUCCUUUGGCUGACGGGGAAGAACGGCCUGUACCCUAACCUGAGCAAGAGCUACGCCAACAACAAGGAGAAGGAGGUGCUGGUGCUGUGGGGCGUGCACCACCCUCCUAACAUCGGCGACCAGAAGGCCCUGUACCACACCGAGAACGCCUACGUCAGCGUGGUGUCCAGCCACUACAGCAGAAAGUUCACCCCUGAGAUCGCCAAGAGGCCUAAGGUGCGGGACCAGGAGGGCAGAAUCAACUACUACUGGACCCUGCUGGAGCCUGGCGACACCAUCAUCUUCGAGGCCAACGGCAACCUGAUCGCCCCUAGAUACGCCUUCGCCCUGAGCAGAGGCUUCGGCAGCGGCAUCAUCAACAGCAACGCCCCUAUGGACAAGUGCGACGCCAAGUGCCAGACUCCGCAGGGCGCUAUCAACAGCUCCCUGCCUUUCCAGAACGUGCACCCUGUGACCAUCGGCGAGUGCCCUAAGUACGUGAGAAGCGCCAAGCUGAGAAUGGUGACCGGCCUGAGAAACAUCCCUAGCAUCCAGAGCAGAGGCCUGUUCGGCGCCAUCGCCGGGUUUAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGCUGGUACGGCUACCACCACCAGAACGAGCAGGGCUCCGGCUACGCCGCCGACCAGAAAUCCACCCAGAACGCCAUCAACGGCAUCACCAACAAGGUGAACAGCGUCAUCGAGAAGAUGAACACCCAGUUCACCGCCGUGGGCAAGGAGUUCAACAAGCUGGAGAGAAGAAUGGAGAACCUGAACAAGAAGGUGGACGACGGCUUCAUCGACAUCUGGACCUACAACGCCGAGCUUCUGGUGCUCCUGGAGAACGAGAGAACCCUGGACUUCCACGACAGCAACGUGAAGAACCUGUACGAGAAGGUGAAGUCCCAGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCUUCGAGUUCUACCACAAGUGCAACGACGAGUGCAUGGAGAGCGUGAAGAACGGCACCUACGAUUACCCCAAGUACAGCGAGGAGAGCAAGCUGAACAGAGAGAAGAUCGACGGCGUGAAGCUGGAGAGCAUGGGCGUGUACCAGAUCCUGGCCAUCUACUCCACCGUGGCCAGUAGCCUGGUGCUGCUGGUGAGCCUGGGCGCAAUCAGCUUCUGGAUGUGCAGCAACGGCAGCCU GCAGUGCAGAAUCUGCAUC ProteinMKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVT 547HSVNLLENSHNGKLCLLKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI MRK_RBS- DNAATGAAGGTCAAACTTCTCGTGCTCCTGTGCACCTTCACCGCCA 510 HA129CCTACGCGGGCGTGGCTCCGCTTCACCTGGGCAAGTGCAACATCGCCGGTTGGCTGCTGGGTAACCCAGAGTGCGAGCTACTGCTGACCGTGAGCAGCTGGAGCTACATCGTGGAAACCAGCAACAGCGACAACGGCACCTGCTACCCTGGCGACTTCATCAACTACGAGGAGCTGAGAGAGCAGCTCAGCAGCGTGTCCAGCTTCGAGAGATTCGAGATCTTCCCTAAGACTAGCAGCTGGCCCGACCACGAAACAAACAGAGGCGTGACCGCCGCTTGTCCATACGCCGGCGCCAACAGCTTCTACAGAAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCTAAGCTGAGCAAGAGCTACGTGAACAACAAGGGCAAGGAGGTGCTTGTGCTGTGGGGCATCCACCACCCTCCTACCAGCACCGACCAGCAGAGCCTGTACCAGAACGCCGACGCCTACGTGTTCGTGGGCAGCAGCAGATACAGCAAGAAGTTCAAGCCTGAGATCGCCATCAGACCTAAGGTGAGGGACCAGGAGGGCAGAATGAACTACTACTGGACTCTGGTGGAGCCCGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCTA GATACGCCTTCGCCATGGAGAGAAACGCCmRNA AUGAAGGUCAAACUUCUCGUGCUCCUGUGCACCUUCACCGC 529CACCUACGCGGGCGUGGCUCCGCUUCACCUGGGCAAGUGCAACAUCGCCGGUUGGCUGCUGGGUAACCCAGAGUGCGAGCUACUGCUGACCGUGAGCAGCUGGAGCUACAUCGUGGAAACCAGCAACAGCGACAACGGCACCUGCUACCCUGGCGACUUCAUCAACUACGAGGAGCUGAGAGAGCAGCUCAGCAGCGUGUCCAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGACUAGCAGCUGGCCCGACCACGAAACAAACAGAGGCGUGACCGCCGCUUGUCCAUACGCCGGCGCCAACAGCUUCUACAGAAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCUAAGCUGAGCAAGAGCUACGUGAACAACAAGGGCAAGGAGGUGCUUGUGCUGUGGGGCAUCCACCACCCUCCUACCAGCACCGACCAGCAGAGCCUGUACCAGAACGCCGACGCCUACGUGUUCGUGGGCAGCAGCAGAUACAGCAAGAAGUUCAAGCCUGAGAUCGCCAUCAGACCUAAGGUGAGGGACCAGGAGGGCAGAAUGAACUACUACUGGACUCUGGUGGAGCCCGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCUAGAUACGCCUUCGCCAUGGAGAGAA ACGCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWLLGNPECELLL 548TVSSWSYIVETSNSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPDHETNRGVTAACPYAGANSFYRNLIWLVKKGNSYPKLSKSYVNNKGKEVLVLWGIHHPPTSTDQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGN LVVPRYAFAMERNA MRK_H1_ DNAATGAAGGCCATCCTGGTCGTGCTGCTCTACACATTCGCCACC 511 cot_allGCCAACGCAGACACTCTGTGCATCGGCTACCACGCCAACAACAGCACCGACACCGTGGATACCGTGCTGGAGAAGAACGTGACCGTGACCCACAGCGTGAACCTGCTGGAGGACAAGCACAACGGCAAGCTGTGCAAGCTGAGAGGCGTGGCCCCTCTGCACCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGAAACCCCGAGTGCGAGAGCCTGTCAACCGCCTCGAGCTGGTCCTACATCGTGGAAACCAGCAGCAGCGATAACGGGACGTGCTACCCGGGCGACTTCATCAACTACGAGGAGCTGAGAGAACAGCTGAGCAGCGTCAGTAGCTTCGAGAGATTCGAGATCTTCCCTAAGACCAGCAGCTGGCCTAACCACGACAGCAACAAGGGCGTGACCGCCGCTTGCCCGCACGCAGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCTAAGCTGAGCAAGAGCTACATCAACGACAAGGGGAAGGAGGTGCTAGTCCTGTGGGGCATCCATCACCCTAGCACCACAGCCGACCAGCAAAGCCTGTACCAGAACGCGGACGCCTACGTGTTCGTCGGCACCAGCAGATACAGCAAGAAGTTCAAGCCTGAGATCGCCATCAGACCTAAGGTGCGAGATCAGGAGGGCAGAATGAACTACTACTGGACCCTGGTGGAGCCCGGAGACAAGATTACTTTCGAAGCGACCGGCAACCTGGTGGTGCCTAGATACGCCTTCGCCATGGAGAGAAACGCCGGCAGCGGCATCATCATCAGCGACACCCCTGTGCACGACTGCAACACCACCTGCCAGACCCCTAAAGGCGCCATCAACACAAGCCTGCCTTTTCAGAACATCCACCCTATCACCATCGGCAAGTGCCCTAAGTACGTGAAGTCCACCAAGCTCCGCCTGGCAACCGGCCTCAGGAACGTGCCTAGCATCCAGAGCAGAGGCCTGTTCGGGGCCATAGCCGGCTTCATAGAGGGTGGCTGGACCGGCATGGTTGACGGGTGGTACGGATACCATCACCAGAACGAGCAAGGCAGCGGCTACGCCGCAGACCTGAAGTCAACCCAGAACGCCATCGACAAGATCACCAACAAGGTGAACAGCGTGATCGAGAAGATGAACACCCAGTTCACCGCCGTGGGCAAGGAGTTCAACCACCTAGAGAAGAGGATCGAGAACCTGAATAAGAAGGTGGACGACGGCTTCCTGGACATCTGGACCTACAACGCCGAGCTGCTCGTCCTCCTGGAGAACGAGAGAACCCTGGACTACCACGATAGCAACGTGAAGAACCTGTACGAGAAGGTGAGAAACCAGCTGAAGAATAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCACAAGTGCGACAACACCTGCATGGAGAGCGTGAAGAACGGCACCTACGACTACCCTAAGTACAGCGAGGAGGCCAAGCTGAACAGAGAGAAGATCGACGGCGTGAAGCTGGAGAGCACCAGAATCTACCAGATCCTGGCCATCTACAGCACCGTGGCCAGCAGCCTCGTGCTCGTGGTGAGCCTGGGCGCCATCTCCTTCTGGATGTGCAGCAACGGCAGCCTGCAGTGCAGAATCTGCATC mRNAAUGAAGGCCAUCCUGGUCGUGCUGCUCUACACAUUCGCCAC 530CGCCAACGCAGACACUCUGUGCAUCGGCUACCACGCCAACAACAGCACCGACACCGUGGAUACCGUGCUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUGCUGGAGGACAAGCACAACGGCAAGCUGUGCAAGCUGAGAGGCGUGGCCCCUCUGCACCUGGGCAAGUGCAACAUCGCCGGCUGGAUCCUGGGAAACCCCGAGUGCGAGAGCCUGUCAACCGCCUCGAGCUGGUCCUACAUCGUGGAAACCAGCAGCAGCGAUAACGGGACGUGCUACCCGGGCGACUUCAUCAACUACGAGGAGCUGAGAGAACAGCUGAGCAGCGUCAGUAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGACCAGCAGCUGGCCUAACCACGACAGCAACAAGGGCGUGACCGCCGCUUGCCCGCACGCAGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCUAAGCUGAGCAAGAGCUACAUCAACGACAAGGGGAAGGAGGUGCUAGUCCUGUGGGGCAUCCAUCACCCUAGCACCACAGCCGACCAGCAAAGCCUGUACCAGAACGCGGACGCCUACGUGUUCGUCGGCACCAGCAGAUACAGCAAGAAGUUCAAGCCUGAGAUCGCCAUCAGACCUAAGGUGCGAGAUCAGGAGGGCAGAAUGAACUACUACUGGACCCUGGUGGAGCCCGGAGACAAGAUUACUUUCGAAGCGACCGGCAACCUGGUGGUGCCUAGAUACGCCUUCGCCAUGGAGAGAAACGCCGGCAGCGGCAUCAUCAUCAGCGACACCCCUGUGCACGACUGCAACACCACCUGCCAGACCCCUAAAGGCGCCAUCAACACAAGCCUGCCUUUUCAGAACAUCCACCCUAUCACCAUCGGCAAGUGCCCUAAGUACGUGAAGUCCACCAAGCUCCGCCUGGCAACCGGCCUCAGGAACGUGCCUAGCAUCCAGAGCAGAGGCCUGUUCGGGGCCAUAGCCGGCUUCAUAGAGGGUGGCUGGACCGGCAUGGUUGACGGGUGGUACGGAUACCAUCACCAGAACGAGCAAGGCAGCGGCUACGCCGCAGACCUGAAGUCAACCCAGAACGCCAUCGACAAGAUCACCAACAAGGUGAACAGCGUGAUCGAGAAGAUGAACACCCAGUUCACCGCCGUGGGCAAGGAGUUCAACCACCUAGAGAAGAGGAUCGAGAACCUGAAUAAGAAGGUGGACGACGGCUUCCUGGACAUCUGGACCUACAACGCCGAGCUGCUCGUCCUCCUGGAGAACGAGAGAACCCUGGACUACCACGAUAGCAACGUGAAGAACCUGUACGAGAAGGUGAGAAACCAGCUGAAGAAUAACGCCAAGGAGAUCGGCAACGGCUGCUUCGAGUUCUACCACAAGUGCGACAACACCUGCAUGGAGAGCGUGAAGAACGGCACCUACGACUACCCUAAGUACAGCGAGGAGGCCAAGCUGAACAGAGAGAAGAUCGACGGCGUGAAGCUGGAGAGCACCAGAAUCUACCAGAUCCUGGCCAUCUACAGCACCGUGGCCAGCAGCCUCGUGCUCGUGGUGAGCCUGGGCGCCAUCUCCUUCUGGAUGUGCAGCAACGGC AGCCUGCAGUGCAGAAUCUGCAUCProtein MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTV 549THSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTTADQQSLYQNADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI MRK_H3_ DNAATGAAGACCATCATCGCCCTGAGCTACATCCTGTGCCTGGTG 512 ConATTCGCGCAGAAACTCCCCGGCAACGACAATAGCACTGCCACCCTGTGTCTGGGCCATCACGCCGTGCCTAACGGAACCCTCGTGAAGACGATCACCAACGACCAGATCGAGGTGACCAACGCCACCGAGCTGGTCCAGAGTTCGAGCACCGGCAGAATCTGCGACAGCCCTCACCGGATCCTGGACGGCGAGAACTGCACCCTGATTGACGCACTGCTAGGCGACCCACACTGTGACGGCTTCCAGAACAAGGAGTGGGACCTGTTCGTGGAGAGAAGCAAGGCCTACAGCAACTGCTACCCTTACGACGTGCCTGACTACGCCAGCCTGAGATCCCTCGTGGCCTCCAGCGGCACCCTCGAGTTCAATAACGAGAGCTTCAACTGGACCGGAGTCGCCCAGAACGGGACATCCTACGCCTGCAAGAGAGGAAGCGTCAAGAGCTTCTTCAGCAGACTGAACTGGCTGCACCAGCTGAAGTACAAGTACCCTGCCCTGAACGTGACCATGCCTAACAACGACAAGTTCGACAAGCTGTACATCTGGGGCGTGCACCATCCCAGCACCGACAGCGACCAGACCTCCCTGTACGTCCAGGCATCCGGCAGGGTCACCGTGAGCACCAAGAGAAGCCAGCAGACCGTGATCCCTAACATCGGCAGCAGACCTTGGGTCAGAGGCGTCTCTAGCAGAATCAGCATCTACTGGACCATAGTGAAGCCCGGCGACATCCTGCTGATCAACTCGACCGGCAACCTGATCGCTCCTAGGGGCTACTTCAAGATCAGAAGCGGCAAGAGCAGCATCATGAGAAGCGACGCGCCCATCGGGAAGTGCAACTCCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCTTTCCAGAACGTGAACAGAATCACCTACGGCGCCTGCCCTAGATACGTGAAGCAGAACACACTGAAGCTGGCCACCGGCATGAGGAACGTGCCTGAGAAGCAGACCAGAGGCATCTTCGGGGCTATTGCCGGCTTCATCGAGAACGGTTGGGAGGGAATGGTCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAAGGCACGGGACAGGCCGCCGACCTCAAGTCCACCCAGGCTGCCATCAATCAGATCAACGGGAAGCTGAACAGACTGATCGAGAAGACCAACGAGAAGTTCCACCAGATCGAGAAGGAGTTCAGCGAGGTGGAGGGCAGAATCCAGGACCTGGAGAAGTACGTGGAGGACACGAAGATCGACCTGTGGAGCTACAACGCAGAGCTGTTGGTGGCACTGGAGAACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAGGACCAGGAAGCAGTTACGAGAGAACGCCGAGGACATGGGAAACGGCTGTTTTAAGATCTACCACAAGTGCGACAACGCCTGCATCGGGAGCATCAGGAACGGGACCTACGACCACGACGTGTACAGAGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGCGTGGAGCTGAAGTCCGGCTACAAGGACTGGATCCTGTGGATCAGCTTCGCCATCAGCTGCTTCCTGCTGTGCGTGGTCCTCCTGGGCTTTATAATGTGGGCCTGCCAGAA GGGCAACATCAGGTGCAACATCTGCATCmRNA AUGAAGACCAUCAUCGCCCUGAGCUACAUCCUGUGCCUGGU 531GUUCGCGCAGAAACUCCCCGGCAACGACAAUAGCACUGCCACCCUGUGUCUGGGCCAUCACGCCGUGCCUAACGGAACCCUCGUGAAGACGAUCACCAACGACCAGAUCGAGGUGACCAACGCCACCGAGCUGGUCCAGAGUUCGAGCACCGGCAGAAUCUGCGACAGCCCUCACCGGAUCCUGGACGGCGAGAACUGCACCCUGAUUGACGCACUGCUAGGCGACCCACACUGUGACGGCUUCCAGAACAAGGAGUGGGACCUGUUCGUGGAGAGAAGCAAGGCCUACAGCAACUGCUACCCUUACGACGUGCCUGACUACGCCAGCCUGAGAUCCCUCGUGGCCUCCAGCGGCACCCUCGAGUUCAAUAACGAGAGCUUCAACUGGACCGGAGUCGCCCAGAACGGGACAUCCUACGCCUGCAAGAGAGGAAGCGUCAAGAGCUUCUUCAGCAGACUGAACUGGCUGCACCAGCUGAAGUACAAGUACCCUGCCCUGAACGUGACCAUGCCUAACAACGACAAGUUCGACAAGCUGUACAUCUGGGGCGUGCACCAUCCCAGCACCGACAGCGACCAGACCUCCCUGUACGUCCAGGCAUCCGGCAGGGUCACCGUGAGCACCAAGAGAAGCCAGCAGACCGUGAUCCCUAACAUCGGCAGCAGACCUUGGGUCAGAGGCGUCUCUAGCAGAAUCAGCAUCUACUGGACCAUAGUGAAGCCCGGCGACAUCCUGCUGAUCAACUCGACCGGCAACCUGAUCGCUCCUAGGGGCUACUUCAAGAUCAGAAGCGGCAAGAGCAGCAUCAUGAGAAGCGACGCGCCCAUCGGGAAGUGCAACUCCGAGUGCAUCACCCCUAACGGCAGCAUCCCCAACGACAAGCCUUUCCAGAACGUGAACAGAAUCACCUACGGCGCCUGCCCUAGAUACGUGAAGCAGAACACACUGAAGCUGGCCACCGGCAUGAGGAACGUGCCUGAGAAGCAGACCAGAGGCAUCUUCGGGGCUAUUGCCGGCUUCAUCGAGAACGGUUGGGAGGGAAUGGUCGACGGGUGGUACGGCUUCAGACACCAGAACAGCGAAGGCACGGGACAGGCCGCCGACCUCAAGUCCACCCAGGCUGCCAUCAAUCAGAUCAACGGGAAGCUGAACAGACUGAUCGAGAAGACCAACGAGAAGUUCCACCAGAUCGAGAAGGAGUUCAGCGAGGUGGAGGGCAGAAUCCAGGACCUGGAGAAGUACGUGGAGGACACGAAGAUCGACCUGUGGAGCUACAACGCAGAGCUGUUGGUGGCACUGGAGAACCAGCACACCAUCGACCUGACCGACAGCGAGAUGAACAAGCUGUUCGAGAGGACCAGGAAGCAGUUACGAGAGAACGCCGAGGACAUGGGAAACGGCUGUUUUAAGAUCUACCACAAGUGCGACAACGCCUGCAUCGGGAGCAUCAGGAACGGGACCUACGACCACGACGUGUACAGAGACGAGGCCCUGAACAACAGAUUCCAGAUCAAGGGCGUGGAGCUGAAGUCCGGCUACAAGGACUGGAUCCUGUGGAUCAGCUUCGCCAUCAGCUGCUUCCUGCUGUGCGUGGUCCUCCUGGGCUUUAUAAUGUGGGCCUGCCAGAAGG GCAACAUCAGGUGCAACAUCUGCAUCProtein MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTLVKTI 550TNDQIEVTNATELVQSSSTGRICDSPHRILDGENCTLIDALLGDPHCDGFQNKEWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVAQNGTSYACKRGSVKSFFSRLNWLHQLKYKYPALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSLYVQASGRVTVSTKRSQQTVIPNIGSRPWVRGVSSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGTGQAADLKSTQAAINQINGKLNRLIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFERTRKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIRCNICI MRK_H3_ DNAATGAAGACCATCATCGCCCTGAGCTACATCCTGTGCCTGGTG 513 ConBTTCGCGCAGAAACTCCCCGGCAACGACAATAGCACTGCCACCCTGTGTCTGGGCCATCACGCCGTGCCTAACGGAACCATCGTGAAGACGATCACCAACGACCAGATCGAGGTGACCAACGCCACCGAGCTGGTCCAGAATTCGAGCACCGGCGAAATCTGCGACAGCCCTCACCAGATCCTGGACGGCGAGAACTGCACCCTGATTGACGCACTGCTAGGCGACCCACAGTGTGACGGCTTCCAGAACAAGAAGTGGGACCTGTTCGTGGAGAGAAGCAAGGCCTACAGCAACTGCTACCCTTACGACGTGCCTGACTACGCCAGCCTGAGATCCCTCGTGGCCTCCAGCGGCACCCTCGAGTTCAATAACGAGAGCTTCAACTGGACCGGAGTCACCCAGAACGGGACATCCAGCGCCTGCATCAGAAGAAGCAACAGCAGCTTCTTCAGCAGACTGAACTGGCTGACCCACCTGAACTTCAAGTACCCTGCCCTGAACGTGACCATGCCTAACAACGAGCAGTTCGACAAGCTGTACATCTGGGGCGTGCACCATCCCGGCACCGACAAGGACCAGATCTTCCTGTACGCCCAGAGCTCCGGCAGGATCACCGTGAGCACCAAGAGAAGCCAGCAGGCCGTGATCCCTAACATCGGCAGCAGACCTAGAATCAGAAACATCCCTAGCAGAATCAGCATCTACTGGACCATAGTGAAGCCCGGCGACATCCTGCTGATCAACTCGACCGGCAACCTGATCGCTCCTAGGGGCTACTTCAAGATCAGAAGCGGCAAGAGCAGCATCATGAGAAGCGACGCGCCCATCGGGAAGTGCAACTCCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCTTTCCAGAACGTGAACAGAATCACCTACGGCGCCTGCCCTAGATACGTGAAGCAGAGCACACTGAAGCTGGCCACCGGCATGAGGAACGTGCCTGAGAAGCAGACCAGAGGCATCTTCGGGGCTATTGCCGGCTTCATCGAGAACGGTTGGGAGGGAATGGTCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCTCAAGTCCACCCAGGCTGCCATCGATCAGATCAACGGGAAGCTGAACAGACTGATCGGCAAGACCAACGAGAAGTTCCACCAGATCGAGAAGGAGTTCAGCGAGGTGGAGGGCAGAATCCAGGACCTGGAGAAGTACGTGGAGGACACGAAGATCGACCTGTGGAGCTACAACGCAGAGCTGTTGGTGGCACTGGAGAACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAGACCAAGAAGCAGTTACGAGAGAACGCCGAGGACATGGGAAACGGCTGTTTTAAGATCTACCACAAGTGCGACAACGCCTGCATCGGGAGCATCAGGAACGGGACCTACGACCACGACGTGTACAGAGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGCGTGGAGCTGAAGTCCGGCTACAAGGACTGGATCCTGTGGATCAGCTTCGCCATCAGCTGCTTCCTGCTGTGCGTGGCCCTCCTGGGCTTTATAATGTGGGCCTGCCAGA AGGGCAACATCAGGTGCAACATCTGCATCmRNA AUGAAGACCAUCAUCGCCCUGAGCUACAUCCUGUGCCUGGU 532GUUCGCGCAGAAACUCCCCGGCAACGACAAUAGCACUGCCACCCUGUGUCUGGGCCAUCACGCCGUGCCUAACGGAACCAUCGUGAAGACGAUCACCAACGACCAGAUCGAGGUGACCAACGCCACCGAGCUGGUCCAGAAUUCGAGCACCGGCGAAAUCUGCGACAGCCCUCACCAGAUCCUGGACGGCGAGAACUGCACCCUGAUUGACGCACUGCUAGGCGACCCACAGUGUGACGGCUUCCAGAACAAGAAGUGGGACCUGUUCGUGGAGAGAAGCAAGGCCUACAGCAACUGCUACCCUUACGACGUGCCUGACUACGCCAGCCUGAGAUCCCUCGUGGCCUCCAGCGGCACCCUCGAGUUCAAUAACGAGAGCUUCAACUGGACCGGAGUCACCCAGAACGGGACAUCCAGCGCCUGCAUCAGAAGAAGCAACAGCAGCUUCUUCAGCAGACUGAACUGGCUGACCCACCUGAACUUCAAGUACCCUGCCCUGAACGUGACCAUGCCUAACAACGAGCAGUUCGACAAGCUGUACAUCUGGGGCGUGCACCAUCCCGGCACCGACAAGGACCAGAUCUUCCUGUACGCCCAGAGCUCCGGCAGGAUCACCGUGAGCACCAAGAGAAGCCAGCAGGCCGUGAUCCCUAACAUCGGCAGCAGACCUAGAAUCAGAAACAUCCCUAGCAGAAUCAGCAUCUACUGGACCAUAGUGAAGCCCGGCGACAUCCUGCUGAUCAACUCGACCGGCAACCUGAUCGCUCCUAGGGGCUACUUCAAGAUCAGAAGCGGCAAGAGCAGCAUCAUGAGAAGCGACGCGCCCAUCGGGAAGUGCAACUCCGAGUGCAUCACCCCUAACGGCAGCAUCCCCAACGACAAGCCUUUCCAGAACGUGAACAGAAUCACCUACGGCGCCUGCCCUAGAUACGUGAAGCAGAGCACACUGAAGCUGGCCACCGGCAUGAGGAACGUGCCUGAGAAGCAGACCAGAGGCAUCUUCGGGGCUAUUGCCGGCUUCAUCGAGAACGGUUGGGAGGGAAUGGUCGACGGGUGGUACGGCUUCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCUCAAGUCCACCCAGGCUGCCAUCGAUCAGAUCAACGGGAAGCUGAACAGACUGAUCGGCAAGACCAACGAGAAGUUCCACCAGAUCGAGAAGGAGUUCAGCGAGGUGGAGGGCAGAAUCCAGGACCUGGAGAAGUACGUGGAGGACACGAAGAUCGACCUGUGGAGCUACAACGCAGAGCUGUUGGUGGCACUGGAGAACCAGCACACCAUCGACCUGACCGACAGCGAGAUGAACAAGCUGUUCGAGAAGACCAAGAAGCAGUUACGAGAGAACGCCGAGGACAUGGGAAACGGCUGUUUUAAGAUCUACCACAAGUGCGACAACGCCUGCAUCGGGAGCAUCAGGAACGGGACCUACGACCACGACGUGUACAGAGACGAGGCCCUGAACAACAGAUUCCAGAUCAAGGGCGUGGAGCUGAAGUCCGGCUACAAGGACUGGAUCCUGUGGAUCAGCUUCGCCAUCAGCUGCUUCCUGCUGUGCGUGGCCCUCCUGGGCUUUAUAAUGUGGGCCUGCCAGAAGG GCAACAUCAGGUGCAACAUCUGCAUCProtein MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTI 551TNDQIEVTNATELVQNSSTGEICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACIRRSNSSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQSSGRITVSTKRSQQAVIPNIGSRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVALLGFIMWACQKGNIRCNICI MRK_H3_ DNAATGAAGACCATCATCGCCCTGAGCTACATCCTGTGCCTGGTG 514 con_allTTCGCGCAGAAACTCCCCGGCAACGACAATAGCACTGCCACCCTGTGTCTGGGCCATCACGCCGTGCCTAACGGAACCATCGTGAAGACGATCACCAACGACCAGATCGAGGTGACCAACGCCACCGAGCTGGTCCAGAGTTCGAGCACCGGCGAAATCTGCGACAGCCCTCACCAGATCCTGGACGGCGAGAACTGCACCCTGATTGACGCACTGCTAGGCGACCCACAGTGTGACGGCTTCCAGAACAAGAAGTGGGACCTGTTCGTGGAGAGAAGCAAGGCCTACAGCAACTGCTACCCTTACGACGTGCCTGACTACGCCAGCCTGAGATCCCTCGTGGCCTCCAGCGGCACCCTCGAGTTCAATAACGAGAGCTTCAACTGGACCGGAGTCACCCAGAACGGGACATCCAGCGCCTGCATCAGAAGAAGCAACAGCAGCTTCTTCAGCAGACTGAACTGGCTGACCCACCTGAACTTCAAGTACCCTGCCCTGAACGTGACCATGCCTAACAACGAGCAGTTCGACAAGCTGTACATCTGGGGCGTGCACCATCCCGGCACCGACAAGGACCAGATCTTCCTGTACGCCCAGGCATCCGGCAGGATCACCGTGAGCACCAAGAGAAGCCAGCAGGCCGTGATCCCTAACATCGGCAGCAGACCTAGAGTCAGAAACATCCCTAGCAGAATCAGCATCTACTGGACCATAGTGAAGCCCGGCGACATCCTGCTGATCAACTCGACCGGCAACCTGATCGCTCCTAGGGGCTACTTCAAGATCAGAAGCGGCAAGAGCAGCATCATGAGAAGCGACGCGCCCATCGGGAAGTGCAACTCCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCTTTCCAGAACGTGAACAGAATCACCTACGGCGCCTGCCCTAGATACGTGAAGCAGAACACACTGAAGCTGGCCACCGGCATGAGGAACGTGCCTGAGAAGCAGACCAGAGGCATCTTCGGGGCTATTGCCGGCTTCATCGAGAACGGTTGGGAGGGAATGGTCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCTCAAGTCCACCCAGGCTGCCATCGATCAGATCAACGGGAAGCTGAACAGACTGATCGGCAAGACCAACGAGAAGTTCCACCAGATCGAGAAGGAGTTCAGCGAGGTGGAGGGCAGAATCCAGGACCTGGAGAAGTACGTGGAGGACACGAAGATCGACCTGTGGAGCTACAACGCAGAGCTGTTGGTGGCACTGGAGAACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAGACCAAGAAGCAGTTACGAGAGAACGCCGAGGACATGGGAAACGGCTGTTTTAAGATCTACCACAAGTGCGACAACGCCTGCATCGGGAGCATCAGGAACGGGACCTACGACCACGACGTGTACAGAGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGCGTGGAGCTGAAGTCCGGCTACAAGGACTGGATCCTGTGGATCAGCTTCGCCATCAGCTGCTTCCTGCTGTGCGTGGCCCTCCTGGGCTTTATAATGTGGGCCTGCCAGA AGGGCAACATCAGGTGCAACATCTGCATCmRNA AUGAAGACCAUCAUCGCCCUGAGCUACAUCCUGUGCCUGGU 533GUUCGCGCAGAAACUCCCCGGCAACGACAAUAGCACUGCCACCCUGUGUCUGGGCCAUCACGCCGUGCCUAACGGAACCAUCGUGAAGACGAUCACCAACGACCAGAUCGAGGUGACCAACGCCACCGAGCUGGUCCAGAGUUCGAGCACCGGCGAAAUCUGCGACAGCCCUCACCAGAUCCUGGACGGCGAGAACUGCACCCUGAUUGACGCACUGCUAGGCGACCCACAGUGUGACGGCUUCCAGAACAAGAAGUGGGACCUGUUCGUGGAGAGAAGCAAGGCCUACAGCAACUGCUACCCUUACGACGUGCCUGACUACGCCAGCCUGAGAUCCCUCGUGGCCUCCAGCGGCACCCUCGAGUUCAAUAACGAGAGCUUCAACUGGACCGGAGUCACCCAGAACGGGACAUCCAGCGCCUGCAUCAGAAGAAGCAACAGCAGCUUCUUCAGCAGACUGAACUGGCUGACCCACCUGAACUUCAAGUACCCUGCCCUGAACGUGACCAUGCCUAACAACGAGCAGUUCGACAAGCUGUACAUCUGGGGCGUGCACCAUCCCGGCACCGACAAGGACCAGAUCUUCCUGUACGCCCAGGCAUCCGGCAGGAUCACCGUGAGCACCAAGAGAAGCCAGCAGGCCGUGAUCCCUAACAUCGGCAGCAGACCUAGAGUCAGAAACAUCCCUAGCAGAAUCAGCAUCUACUGGACCAUAGUGAAGCCCGGCGACAUCCUGCUGAUCAACUCGACCGGCAACCUGAUCGCUCCUAGGGGCUACUUCAAGAUCAGAAGCGGCAAGAGCAGCAUCAUGAGAAGCGACGCGCCCAUCGGGAAGUGCAACUCCGAGUGCAUCACCCCUAACGGCAGCAUCCCCAACGACAAGCCUUUCCAGAACGUGAACAGAAUCACCUACGGCGCCUGCCCUAGAUACGUGAAGCAGAACACACUGAAGCUGGCCACCGGCAUGAGGAACGUGCCUGAGAAGCAGACCAGAGGCAUCUUCGGGGCUAUUGCCGGCUUCAUCGAGAACGGUUGGGAGGGAAUGGUCGACGGGUGGUACGGCUUCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCUCAAGUCCACCCAGGCUGCCAUCGAUCAGAUCAACGGGAAGCUGAACAGACUGAUCGGCAAGACCAACGAGAAGUUCCACCAGAUCGAGAAGGAGUUCAGCGAGGUGGAGGGCAGAAUCCAGGACCUGGAGAAGUACGUGGAGGACACGAAGAUCGACCUGUGGAGCUACAACGCAGAGCUGUUGGUGGCACUGGAGAACCAGCACACCAUCGACCUGACCGACAGCGAGAUGAACAAGCUGUUCGAGAAGACCAAGAAGCAGUUACGAGAGAACGCCGAGGACAUGGGAAACGGCUGUUUUAAGAUCUACCACAAGUGCGACAACGCCUGCAUCGGGAGCAUCAGGAACGGGACCUACGACCACGACGUGUACAGAGACGAGGCCCUGAACAACAGAUUCCAGAUCAAGGGCGUGGAGCUGAAGUCCGGCUACAAGGACUGGAUCCUGUGGAUCAGCUUCGCCAUCAGCUGCUUCCUGCUGUGCGUGGCCCUCCUGGGCUUUAUAAUGUGGGCCUGCCAGAAGG GCAACAUCAGGUGCAACAUCUGCAUCProtein MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTI 552TNDQIEVTNATELVQSSSTGEICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACIRRSNSSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQASGRITVSTKRSQQAVIPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVALLGFIMWACQKGNIRCNICI MRK_H3_ DNAATGAAGACCATCATCGCCCTGAGCTACATCCTGTGCCTGGTG 515 cot_allTTCGCGCAGAAACTCCCCGGCAACGACAATAGCACTGCCACCCTGTGTCTGGGCCATCACGCCGTGCCTAACGGAACCATCGTGAAGACGATCACCAACGACAGAATCGAGGTGACCAACGCCACCGAGCTGGTCCAGAATTCGAGCATCGGCGAAATCTGCGACAGCCCTCACCAGATCCTGGACGGCGAGAACTGCACCCTGATTGACGCACTGCTAGGCGACCCACAGTGTGACGGCTTCCAGAACAAGAAGTGGGACCTGTTCGTGGAGAGAAGCAAGGCCTACAGCAACTGCTACCCTTACGACGTGCCTGACTACGCCAGCCTGAGATCCCTCGTGGCCTCCAGCGGCACCCTCGAGTTCAATAACGAGAGCTTCAACTGGACCGGAGTCACCCAGAACGGGACATCCAGCGCCTGCATCAGAAGAAGCAACAGCAGCTTCTTCAGCAGACTGAACTGGCTGACCCACCTGAACTTCAAGTACCCTGCCCTGAACGTGACCATGCCTAACAACGAGCAGTTCGACAAGCTGTACATCTGGGGCGTGCACCATCCCGGCACCGACAAGGACCAGATCTTCCTGTACGCCCAGAGCTCCGGCAGGATCACCGTGAGCACCAAGAGAAGCCAGCAGGCCGTGATCCCTAACATCGGCAGCAGACCTAGAATCAGAAACATCCCTAGCAGAATCAGCATCTACTGGACCATAGTGAAGCCCGGCGACATCCTGCTGATCAACTCGACCGGCAACCTGATCGCTCCTAGGGGCTACTTCAAGATCAGAAGCGGCAAGAGCAGCATCATGAGAAGCGACGCGCCCATCGGGAAGTGCAAGTCCGAGTGCATCACCCCTAACGGCAGCATCCCCAACGACAAGCCTTTCCAGAACGTGAACAGAATCACCTACGGCGCCTGCCCTAGATACGTGAAGCAGAGCACACTGAAGCTGGCCACCGGCATGAGGAACGTGCCTGAGAAGCAGACCAGAGGCATCTTCGGGGCTATTGCCGGCTTCATCGAGAACGGTTGGGAGGGAATGGTCGACGGGTGGTACGGCTTCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCTCAAGTCCACCCAGGCTGCCATCGATCAGATCAACGGGAAGCTGAACAGACTGATCGGCAAGACCAACGAGAAGTTCCACCAGATCGAGAAGGAGTTCAGCGAGGTGGAGGGCAGAATCCAGGACCTGGAGAAGTACGTGGAGGACACGAAGATCGACCTGTGGAGCTACAACGCAGAGCTGTTGGTGGCACTGGAGAACCAGCACACCATCGACCTGACCGACAGCGAGATGAACAAGCTGTTCGAGAAGACCAAGAAGCAGTTACGAGAGAACGCCGAGGACATGGGAAACGGCTGTTTTAAGATCTACCACAAGTGCGACAACGCCTGCATCGGGAGCATCAGGAACGGGACCTACGACCACGACGTGTACAGAGACGAGGCCCTGAACAACAGATTCCAGATCAAGGGCGTGGAGCTGAAGTCCGGCTACAAGGACTGGATCCTGTGGATCAGCTTCGCCATCAGCTGCTTCCTGCTGTGCGTGGCCCTCCTGGGCTTTATAATGTGGGCCTGCCAGA AGGGCAACATCAGGTGCAACATCTGCATCmRNA AUGAAGACCAUCAUCGCCCUGAGCUACAUCCUGUGCCUGGU 534GUUCGCGCAGAAACUCCCCGGCAACGACAAUAGCACUGCCACCCUGUGUCUGGGCCAUCACGCCGUGCCUAACGGAACCAUCGUGAAGACGAUCACCAACGACAGAAUCGAGGUGACCAACGCCACCGAGCUGGUCCAGAAUUCGAGCAUCGGCGAAAUCUGCGACAGCCCUCACCAGAUCCUGGACGGCGAGAACUGCACCCUGAUUGACGCACUGCUAGGCGACCCACAGUGUGACGGCUUCCAGAACAAGAAGUGGGACCUGUUCGUGGAGAGAAGCAAGGCCUACAGCAACUGCUACCCUUACGACGUGCCUGACUACGCCAGCCUGAGAUCCCUCGUGGCCUCCAGCGGCACCCUCGAGUUCAAUAACGAGAGCUUCAACUGGACCGGAGUCACCCAGAACGGGACAUCCAGCGCCUGCAUCAGAAGAAGCAACAGCAGCUUCUUCAGCAGACUGAACUGGCUGACCCACCUGAACUUCAAGUACCCUGCCCUGAACGUGACCAUGCCUAACAACGAGCAGUUCGACAAGCUGUACAUCUGGGGCGUGCACCAUCCCGGCACCGACAAGGACCAGAUCUUCCUGUACGCCCAGAGCUCCGGCAGGAUCACCGUGAGCACCAAGAGAAGCCAGCAGGCCGUGAUCCCUAACAUCGGCAGCAGACCUAGAAUCAGAAACAUCCCUAGCAGAAUCAGCAUCUACUGGACCAUAGUGAAGCCCGGCGACAUCCUGCUGAUCAACUCGACCGGCAACCUGAUCGCUCCUAGGGGCUACUUCAAGAUCAGAAGCGGCAAGAGCAGCAUCAUGAGAAGCGACGCGCCCAUCGGGAAGUGCAAGUCCGAGUGCAUCACCCCUAACGGCAGCAUCCCCAACGACAAGCCUUUCCAGAACGUGAACAGAAUCACCUACGGCGCCUGCCCUAGAUACGUGAAGCAGAGCACACUGAAGCUGGCCACCGGCAUGAGGAACGUGCCUGAGAAGCAGACCAGAGGCAUCUUCGGGGCUAUUGCCGGCUUCAUCGAGAACGGUUGGGAGGGAAUGGUCGACGGGUGGUACGGCUUCAGACACCAGAACAGCGAAGGCAGGGGACAGGCCGCCGACCUCAAGUCCACCCAGGCUGCCAUCGAUCAGAUCAACGGGAAGCUGAACAGACUGAUCGGCAAGACCAACGAGAAGUUCCACCAGAUCGAGAAGGAGUUCAGCGAGGUGGAGGGCAGAAUCCAGGACCUGGAGAAGUACGUGGAGGACACGAAGAUCGACCUGUGGAGCUACAACGCAGAGCUGUUGGUGGCACUGGAGAACCAGCACACCAUCGACCUGACCGACAGCGAGAUGAACAAGCUGUUCGAGAAGACCAAGAAGCAGUUACGAGAGAACGCCGAGGACAUGGGAAACGGCUGUUUUAAGAUCUACCACAAGUGCGACAACGCCUGCAUCGGGAGCAUCAGGAACGGGACCUACGACCACGACGUGUACAGAGACGAGGCCCUGAACAACAGAUUCCAGAUCAAGGGCGUGGAGCUGAAGUCCGGCUACAAGGACUGGAUCCUGUGGAUCAGCUUCGCCAUCAGCUGCUUCCUGCUGUGCGUGGCCCUCCUGGGCUUUAUAAUGUGGGCCUGCCAGAAGG GCAACAUCAGGUGCAACAUCUGCAUCProtein MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTI 553TNDRIEVTNATELVQNSSIGEICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACIRRSNSSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQSSGRITVSTKRSQQAVIPNIGSRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISCFLLCVALLGFIMWACQKGNIRCNICI RBD1- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 516 Cal09-PC-CCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACA CbTCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCTTGAGCACCGCCAGCAGCTGGAGCAACATCACGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACAGCAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGAACGGCAGCTACCCCAAGCTGAACAAGTCTTACATTAACGACTCAGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCAACAGCACCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCAACTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 535CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCUUGAGCACCGCCAGCAGCUGGAGCAACAUCACGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACAGCAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGAACGGCAGCUACCCCAAGCUGAACAAGUCUUACAUUAACGACUCAGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCAACAGCACCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCAACUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESLST 554ASSWSNITETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHSSNKGVTAACPHAGAKSFYKNLIWLVKKNGSYPKLNKSYINDSGKEVLVLWGIHHPSNSTDQQSLYQNADTYVFVGSSNYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVV PRYAFAMERNA RBD1- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 517 Cal09-PCCCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACATCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCAACAGCACCGCCAGCAGCTGGAGCAACATCACGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACAGCAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGAACGGCAGCTACCCCAAGCTGAACAAGTCTTACATTAACGACTCAGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCAACAGCACCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCAACTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 536CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCAACAGCACCGCCAGCAGCUGGAGCAACAUCACGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACAGCAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGAACGGCAGCUACCCCAAGCUGAACAAGUCUUACAUUAACGACUCAGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCAACAGCACCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCAACUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESNST 555ASSWSNITETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHSSNKGVTAACPHAGAKSFYKNLIWLVKKNGSYPKLNKSYINDSGKEVLVLWGIHHPSNSTDQQSLYQNADTYVFVGSSNYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVV PRYAFAMERNA RBD1- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 518 Cal09CCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACATCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCTTGAGCACCGCCAGCAGCTGGAGCAACATCACGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACGACAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCCAAGCTGTCCAAGTCTTACATTAACGACAAGGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCACCAGCGCCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCCGGTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 537CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCUUGAGCACCGCCAGCAGCUGGAGCAACAUCACGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACGACAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCCAAGCUGUCCAAGUCUUACAUUAACGACAAGGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCACCAGCGCCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCCGGUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESLST 556ASSWSNITETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLV VPRYAFAMERNA MRK_RBD- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 519 Cal09-PC-CCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACA CbTCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCTTGAGCACCGCCAGCAGCTGGAGCTACATCGTGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACAGCAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGAACGGCAGCTACCCCAAGCTGAACAAGTCTTACATTAACGACTCAGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCAACAGCACCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCAACTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 538CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCUUGAGCACCGCCAGCAGCUGGAGCUACAUCGUGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACAGCAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGAACGGCAGCUACCCCAAGCUGAACAAGUCUUACAUUAACGACUCAGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCAACAGCACCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCAACUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESLST 557ASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHSSNKGVTAACPHAGAKSFYKNLIWLVKKNGSYPKLNKSYINDSGKEVLVLWGIHHPSNSTDQQSLYQNADTYVFVGSSNYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVV PRYAFAMERNA MRK_RBD- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 520 Cal09-PCCCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACATCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCAACAGCACCGCCAGCAGCTGGAGCTACATCGTGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACAGCAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGAACGGCAGCTACCCCAAGCTGAACAAGTCTTACATTAACGACTCAGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCAACAGCACCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCAACTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 539CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCAACAGCACCGCCAGCAGCUGGAGCUACAUCGUGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACAGCAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGAACGGCAGCUACCCCAAGCUGAACAAGUCUUACAUUAACGACUCAGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCAACAGCACCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCAACUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESNST 558ASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHSSNKGVTAACPHAGAKSFYKNLIWLVKKNGSYPKLNKSYINDSGKEVLVLWGIHHPSNSTDQQSLYQNADTYVFVGSSNYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVV PRYAFAMERNA MRK_RBD- DNAATGAAGGTGAAGCTTCTCGTGCTCTTATGCACCTTCACCGCCA 521 Cal09CCTACGCCGGCGTGGCTCCGCTTCACCTTGGCAAGTGCAACATCGCCGGCTGGATCTTGGGAAACCCCGAGTGCGAGAGCTTGAGCACCGCCAGCAGCTGGAGCTACATCGTGGAAACCCCTAGCAGCGACAACGGCACCTGCTACCCCGGCGACTTCATCGACTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTGAGCAGCTTCGAGCGGTTCGAGATCTTCCCCAAGACCAGCTCTTGGCCCAACCACGACAGCAACAAGGGCGTGACCGCCGCCTGCCCTCACGCTGGCGCCAAGAGCTTCTACAAGAACCTGATCTGGCTGGTGAAGAAGGGCAACAGCTACCCCAAGCTGTCCAAGTCTTACATTAACGACAAGGGCAAGGAGGTGCTGGTCCTGTGGGGCATCCACCACCCCAGCACCAGCGCCGACCAACAGAGCCTGTACCAGAACGCCGACACCTACGTGTTCGTGGGCAGCAGCCGGTACAGCAAGAAGTTCAAGCCCGAGATCGCCATCCGGCCCAAGGTGCGGGACCAGGAGGGCCGGATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAGATCACCTTCGAGGCCACCGGCAACCTGGTGGTGCCCC GGTACGCCTTCGCCATGGAGCGGAACGCCmRNA AUGAAGGUGAAGCUUCUCGUGCUCUUAUGCACCUUCACCGC 540CACCUACGCCGGCGUGGCUCCGCUUCACCUUGGCAAGUGCAACAUCGCCGGCUGGAUCUUGGGAAACCCCGAGUGCGAGAGCUUGAGCACCGCCAGCAGCUGGAGCUACAUCGUGGAAACCCCUAGCAGCGACAACGGCACCUGCUACCCCGGCGACUUCAUCGACUACGAGGAGCUGCGGGAGCAGCUGAGCAGCGUGAGCAGCUUCGAGCGGUUCGAGAUCUUCCCCAAGACCAGCUCUUGGCCCAACCACGACAGCAACAAGGGCGUGACCGCCGCCUGCCCUCACGCUGGCGCCAAGAGCUUCUACAAGAACCUGAUCUGGCUGGUGAAGAAGGGCAACAGCUACCCCAAGCUGUCCAAGUCUUACAUUAACGACAAGGGCAAGGAGGUGCUGGUCCUGUGGGGCAUCCACCACCCCAGCACCAGCGCCGACCAACAGAGCCUGUACCAGAACGCCGACACCUACGUGUUCGUGGGCAGCAGCCGGUACAGCAAGAAGUUCAAGCCCGAGAUCGCCAUCCGGCCCAAGGUGCGGGACCAGGAGGGCCGGAUGAACUACUACUGGACCCUGGUGGAGCCUGGCGACAAGAUCACCUUCGAGGCCACCGGCAACCUGGUGGUGCCCCGGUACGCCUUCGCCAUGGAGCGGAAC GCC ProteinMKVKLLVLLCTFTATYAGVAPLHLGKCNIAGWILGNPECESLST 559ASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLV VPRYAFAMERNA FLHA_PR8 DNAATGAAGGCCAATTTGTTGGTCCTTCTATGTGCCCTAGCCGCCG 522CCGACGCCGACACAATCTGCATCGGATATCACGCAAACAACAGCACCGACACCGTGGATACGGTCTTGGAGAAGAACGTGACCGTGACCCATTCCGTGAACCTTCTCGAGGATAGCCACAATGGCAAGCTGTGTAGACTCAAGGGCATTGCCCCGCTGCAGCTGGGAAAGTGCAATATTGCTGGCTGGCTGTTGGGCAACCCTGAGTGTGACCCTCTGTTACCAGTGAGATCTTGGAGCTATATCGTCGAAACCCCTAACAGCGAGAACGGCATATGCTACCCAGGCGACTTCATCGACTACGAGGAACTGCGCGAGCAGCTGAGCTCTGTGTCGAGCTTCGAGCGGTTCGAGATCTTCCCTAAGGAATCTAGCTGGCCTAATCATAACACAAATGGCGTTACTGCTGCCTGTAGCCACGAGGGAAAGAGCAGTTTCTACCGGAATCTGCTGTGGCTGACAGAGAAGGAGGGCTCCTACCCTAAGCTGAAGAATAGCTATGTGAACAAGAAGGGCAAGGAGGTGCTGGTGCTGTGGGGAATACACCACCCACCTAACTCGAAGGAGCAGCAGAATCTGTACCAGAATGAGAATGCCTACGTGTCCGTCGTGACCTCCAACTACAACCGGCGGTTCACGCCTGAGATCGCCGAGAGGCCTAAGGTGAGGGACCAGGCCGGACGCATGAACTACTACTGGACCCTGCTGAAGCCTGGCGATACAATCATCTTCGAGGCTAATGGAAACCTGATCGCGCCAATGTACGCCTTCGCCCTGTCCAGAGGATTCGGCAGCGGCATCATCACATCCAACGCCTCCATGCACGAATGCAACACCAAGTGCCAGACGCCTCTGGGAGCTATCAATAGCAGCTTGCCTTACCAGAATATCCACCCTGTGACCATTGGAGAGTGTCCAAAGTACGTGCGCAGCGCAAAGCTGCGGATGGTCACAGGCCTGCGGAATATACCTTCTATCCAGAGCCGAGGCCTGTTCGGTGCCATTGCCGGCTTCATCGAGGGTGGCTGGACCGGAATGATCGACGGCTGGTATGGATACCACCACCAGAATGAACAGGGCAGCGGCTACGCCGCCGATCAGAAGTCCACCCAGAACGCAATCAATGGTATCACAAACAAGGTGAACACTGTAATCGAGAAGATGAACATCCAATTCACAGCCGTGGGCAAGGAGTTCAATAAGCTGGAGAAGCGGATGGAGAACCTCAACAAGAAGGTGGACGACGGCTTCCTGGATATCTGGACCTACAACGCAGAGCTGCTGGTGTTGCTGGAGAACGAGAGAACCCTCGACTTCCATGATAGCAACGTTAAGAACCTATACGAGAAGGTGAAGTCACAGCTGAAGAATAACGCCAAGGAGATTGGCAACGGCTGCTTCGAATTCTACCACAAGTGCGACAACGAGTGTATGGAGAGCGTCCGGAATGGCACCTACGACTATCCTAAGTATAGCGAGGAGAGCAAGCTTAATAGAGAGAAGGTCGATGGCGTGAAGCTGGAGTCAATGGGAATCTACCAGATCCTGGCTATTTATTCAACCGTGGCATCAAGTCTGGTGCTTCTGGTCAGCCTGGGCGCCATCAGCTTCTGGATGTGCTCCAATGGCAGCCTGC AATGCCGCATCTGCATA mRNAAUGAAGGCCAAUUUGUUGGUCCUUCUAUGUGCCCUAGCCGC 541CGCCGACGCCGACACAAUCUGCAUCGGAUAUCACGCAAACAACAGCACCGACACCGUGGAUACGGUCUUGGAGAAGAACGUGACCGUGACCCAUUCCGUGAACCUUCUCGAGGAUAGCCACAAUGGCAAGCUGUGUAGACUCAAGGGCAUUGCCCCGCUGCAGCUGGGAAAGUGCAAUAUUGCUGGCUGGCUGUUGGGCAACCCUGAGUGUGACCCUCUGUUACCAGUGAGAUCUUGGAGCUAUAUCGUCGAAACCCCUAACAGCGAGAACGGCAUAUGCUACCCAGGCGACUUCAUCGACUACGAGGAACUGCGCGAGCAGCUGAGCUCUGUGUCGAGCUUCGAGCGGUUCGAGAUCUUCCCUAAGGAAUCUAGCUGGCCUAAUCAUAACACAAAUGGCGUUACUGCUGCCUGUAGCCACGAGGGAAAGAGCAGUUUCUACCGGAAUCUGCUGUGGCUGACAGAGAAGGAGGGCUCCUACCCUAAGCUGAAGAAUAGCUAUGUGAACAAGAAGGGCAAGGAGGUGCUGGUGCUGUGGGGAAUACACCACCCACCUAACUCGAAGGAGCAGCAGAAUCUGUACCAGAAUGAGAAUGCCUACGUGUCCGUCGUGACCUCCAACUACAACCGGCGGUUCACGCCUGAGAUCGCCGAGAGGCCUAAGGUGAGGGACCAGGCCGGACGCAUGAACUACUACUGGACCCUGCUGAAGCCUGGCGAUACAAUCAUCUUCGAGGCUAAUGGAAACCUGAUCGCGCCAAUGUACGCCUUCGCCCUGUCCAGAGGAUUCGGCAGCGGCAUCAUCACAUCCAACGCCUCCAUGCACGAAUGCAACACCAAGUGCCAGACGCCUCUGGGAGCUAUCAAUAGCAGCUUGCCUUACCAGAAUAUCCACCCUGUGACCAUUGGAGAGUGUCCAAAGUACGUGCGCAGCGCAAAGCUGCGGAUGGUCACAGGCCUGCGGAAUAUACCUUCUAUCCAGAGCCGAGGCCUGUUCGGUGCCAUUGCCGGCUUCAUCGAGGGUGGCUGGACCGGAAUGAUCGACGGCUGGUAUGGAUACCACCACCAGAAUGAACAGGGCAGCGGCUACGCCGCCGAUCAGAAGUCCACCCAGAACGCAAUCAAUGGUAUCACAAACAAGGUGAACACUGUAAUCGAGAAGAUGAACAUCCAAUUCACAGCCGUGGGCAAGGAGUUCAAUAAGCUGGAGAAGCGGAUGGAGAACCUCAACAAGAAGGUGGACGACGGCUUCCUGGAUAUCUGGACCUACAACGCAGAGCUGCUGGUGUUGCUGGAGAACGAGAGAACCCUCGACUUCCAUGAUAGCAACGUUAAGAACCUAUACGAGAAGGUGAAGUCACAGCUGAAGAAUAACGCCAAGGAGAUUGGCAACGGCUGCUUCGAAUUCUACCACAAGUGCGACAACGAGUGUAUGGAGAGCGUCCGGAAUGGCACCUACGACUAUCCUAAGUAUAGCGAGGAGAGCAAGCUUAAUAGAGAGAAGGUCGAUGGCGUGAAGCUGGAGUCAAUGGGAAUCUACCAGAUCCUGGCUAUUUAUUCAACCGUGGCAUCAAGUCUGGUGCUUCUGGUCAGCCUGGGCGCCAUCAGCUUCUGGAUGUGCUCCAAUGG CAGCCUGCAAUGCCGCAUCUGCAUAProtein MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTV 560THSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI FLHA_Cal09 DNAATGAAGGCTATCTTGGTGGTGTTGTTGTACACATTCGCCACCG 523CCAACGCCGACACCCTCTGCATCGGCTACCACGCGAACAATTCAACCGACACCGTTGACACCGTCCTCGAGAAGAACGTGACCGTGACTCATAGCGTCAACCTCCTCGAGGACAAGCATAACGGCAAGCTCTGTAAGCTTAGAGGAGTGGCCCCTCTCCACCTGGGCAAGTGTAACATTGCAGGCTGGATCCTGGGCAACCCTGAGTGCGAGAGCCTGTCAACCGCTAGCAGCTGGAGCTACATCGTGGAAACCCCATCCAGCGATAACGGCACCTGCTACCCTGGCGATTTCATCGACTACGAGGAGCTGCGCGAGCAGTTGAGCAGCGTCTCCAGCTTCGAGAGATTCGAGATCTTCCCTAAGACTAGCAGCTGGCCTAATCATGACTCCAATAAGGGCGTGACGGCCGCCTGTCCTCACGCTGGAGCCAAGTCGTTCTACAAGAACCTGATCTGGCTGGTAAAGAAGGGCAACAGCTACCCAAAGCTGAGCAAGTCCTACATCAACGACAAGGGCAAGGAAGTGCTGGTGCTGTGGGGAATCCATCACCCAAGCACCTCTGCGGACCAGCAGTCTCTGTATCAGAACGCCGACACCTATGTGTTCGTAGGCTCCTCCAGATACTCCAAGAAGTTCAAGCCAGAGATTGCTATCCGCCCAAAGGTGCGGGATCAAGAGGGTCGCATGAATTATTACTGGACCCTGGTCGAGCCAGGCGATAAGATCACATTCGAAGCCACGGGAAATCTGGTGGTGCCTAGATACGCTTTCGCCATGGAGAGAAACGCCGGCAGCGGCATCATCATATCCGACACACCTGTGCACGACTGCAACACAACATGCCAGACGCCAAAGGGAGCCATCAACACATCTCTTCCATTCCAGAACATTCACCCAATCACAATCGGCAAGTGTCCAAAGTACGTGAAGTCCACCAAGCTTAGACTGGCCACCGGCCTGCGTAACATCCCTAGCATCCAGTCGAGAGGCCTCTTCGGCGCCATCGCCGGATTCATTGAAGGTGGCTGGACCGGCATGGTGGACGGTTGGTATGGCTACCACCACCAGAACGAGCAGGGCAGCGGCTACGCCGCGGACCTGAAGTCCACCCAGAACGCTATTGACGAGATCACCAACAAGGTGAACAGCGTGATCGAGAAGATGAATACCCAGTTCACCGCCGTCGGCAAGGAGTTCAACCATCTGGAGAAGAGAATCGAGAACCTCAACAAGAAGGTCGACGACGGCTTCCTGGACATTTGGACTTACAACGCTGAGTTGTTGGTGCTTCTTGAGAATGAGCGGACCCTGGACTATCACGACTCAAATGTGAAGAACCTGTACGAGAAGGTGAGATCCCAGCTGAAGAACAATGCTAAGGAAATCGGCAACGGCTGCTTCGAGTTCTATCATAAGTGTGACAACACCTGCATGGAGTCTGTTAAGAACGGCACATACGACTACCCGAAGTACTCTGAGGAGGCCAAGCTGAACCGAGAGGAGATAGACGGCGTTAAGCTAGAAAGTACAAGGATCTACCAGATCCTTGCCATCTACTCCACCGTGGCCTCCAGCCTGGTGTTGGTGGTGAGCCTGGGCGCCATCAGCTTCTGGATGTGCAGTAACGGAAGCC TACAGTGCCGAATCTGCATC mRNAAUGAAGGCUAUCUUGGUGGUGUUGUUGUACACAUUCGCCA 542CCGCCAACGCCGACACCCUCUGCAUCGGCUACCACGCGAACAAUUCAACCGACACCGUUGACACCGUCCUCGAGAAGAACGUGACCGUGACUCAUAGCGUCAACCUCCUCGAGGACAAGCAUAACGGCAAGCUCUGUAAGCUUAGAGGAGUGGCCCCUCUCCACCUGGGCAAGUGUAACAUUGCAGGCUGGAUCCUGGGCAACCCUGAGUGCGAGAGCCUGUCAACCGCUAGCAGCUGGAGCUACAUCGUGGAAACCCCAUCCAGCGAUAACGGCACCUGCUACCCUGGCGAUUUCAUCGACUACGAGGAGCUGCGCGAGCAGUUGAGCAGCGUCUCCAGCUUCGAGAGAUUCGAGAUCUUCCCUAAGACUAGCAGCUGGCCUAAUCAUGACUCCAAUAAGGGCGUGACGGCCGCCUGUCCUCACGCUGGAGCCAAGUCGUUCUACAAGAACCUGAUCUGGCUGGUAAAGAAGGGCAACAGCUACCCAAAGCUGAGCAAGUCCUACAUCAACGACAAGGGCAAGGAAGUGCUGGUGCUGUGGGGAAUCCAUCACCCAAGCACCUCUGCGGACCAGCAGUCUCUGUAUCAGAACGCCGACACCUAUGUGUUCGUAGGCUCCUCCAGAUACUCCAAGAAGUUCAAGCCAGAGAUUGCUAUCCGCCCAAAGGUGCGGGAUCAAGAGGGUCGCAUGAAUUAUUACUGGACCCUGGUCGAGCCAGGCGAUAAGAUCACAUUCGAAGCCACGGGAAAUCUGGUGGUGCCUAGAUACGCUUUCGCCAUGGAGAGAAACGCCGGCAGCGGCAUCAUCAUAUCCGACACACCUGUGCACGACUGCAACACAACAUGCCAGACGCCAAAGGGAGCCAUCAACACAUCUCUUCCAUUCCAGAACAUUCACCCAAUCACAAUCGGCAAGUGUCCAAAGUACGUGAAGUCCACCAAGCUUAGACUGGCCACCGGCCUGCGUAACAUCCCUAGCAUCCAGUCGAGAGGCCUCUUCGGCGCCAUCGCCGGAUUCAUUGAAGGUGGCUGGACCGGCAUGGUGGACGGUUGGUAUGGCUACCACCACCAGAACGAGCAGGGCAGCGGCUACGCCGCGGACCUGAAGUCCACCCAGAACGCUAUUGACGAGAUCACCAACAAGGUGAACAGCGUGAUCGAGAAGAUGAAUACCCAGUUCACCGCCGUCGGCAAGGAGUUCAACCAUCUGGAGAAGAGAAUCGAGAACCUCAACAAGAAGGUCGACGACGGCUUCCUGGACAUUUGGACUUACAACGCUGAGUUGUUGGUGCUUCUUGAGAAUGAGCGGACCCUGGACUAUCACGACUCAAAUGUGAAGAACCUGUACGAGAAGGUGAGAUCCCAGCUGAAGAACAAUGCUAAGGAAAUCGGCAACGGCUGCUUCGAGUUCUAUCAUAAGUGUGACAACACCUGCAUGGAGUCUGUUAAGAACGGCACAUACGACUACCCGAAGUACUCUGAGGAGGCCAAGCUGAACCGAGAGGAGAUAGACGGCGUUAAGCUAGAAAGUACAAGGAUCUACCAGAUCCUUGCCAUCUACUCCACCGUGGCCUCCAGCCUGGUGUUGGUGGUGAGCCUGGGCGCCAUCAGCUUCUGGAUGUGCAGUAAC GGAAGCCUACAGUGCCGAAUCUGCAUCProtein MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTV 561THSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADTYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI eH1HA_d5 ProteinMETPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNV 562 v1TVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLPPMKSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKGSSWPNHNTNGVTAACSHEGKNSFYRNLLWLTKKEGLYPNLENSYVNKKEKEVLVLWGIHHPSNNKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL eH1HA_d5 ProteinMETPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNV 563 v2TVTHSVNLLEDSHNGKLCRLKG1APLQLGKCN1AGWLLGNPECDPLPPMKSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKGSSWPNHTTNGVTAACSHEGKNSFYRNLLWLTKKEGSYPNLKNSYVNKKEKEVLVLWGIHHPSNSKEQQNLYQNENAHVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEADGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL eH1HA_d5 ProteinMETPAQLLFLLLLWLPDTTGDTICIGYFIANNSTDTVDTVLEKNV 564 v3TVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLPPMKSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKGSSWPDHNTNGVTAACSHEGKNSFYRNLLWLTEKKGSYPNLKNPYVNKKEKEVLVLWGIHHPSNSKEQQNLYRNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL eH1HA_d5 ProteinMETPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNV 565 v4TVTHSVNLLEDSHNGKLCKLKGIAPLQLGKCNIAGWLLGNPGCDPLLPVGSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFKIFPKESSWPDHNTNGVTAACSHEGKNSFYRNLLWLTKKESSYPNLENSYVNKKRKEVLVLWGIHHPSNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVKGQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEWVLLSTFL eH1HA_d5 mRNAAUGGAGACGCCUGCUCAGCUGCUCUUUCUGCUGCUCCUGUG 566 v1GUUGCCCGAUACCACUGGGGACACUAUCUGUAUCGGAUACCACGCCAACAACUCAACCGAUACCGUGGAUACUGUCCUCGAAAAGAAUGUGACCGUUACACAUUCAGUAAAUUUGUUAGAGGAUUCUCACAAUGGGAAGCUGUGUCGACUGAAGGGGAUCGCUCCCCUGCAACUGGGGAAGUGCAACAUCGCUGGAUGGUUGCUCGGCAACCCGGAAUGCGAUCCGCUGCCACCCAUGAAGAGUUGGAGCUAUAUUGUCGAGACCCCUAACUCAGAGAACGGUAUAUGCUACCCUGGAGAUUUUAUCGAUUACGAAGAGCUGCGGGAACAGCUGAGCAGCGUCUCCAGUUUCGAACGGUUUGAAAUAUUCCCCAAGGGCAGUUCCUGGCCCAAUCACAACACUAAUGGCGUCACCGCCGCCUGCUCACACGAGGGUAAGAACUCUUUUUACCGCAAUCUGCUUUGGCUUACUAAGAAGGAAGGACUGUACCCGAAUCUGGAGAACAGUUACGUCAACAAGAAAGAGAAAGAGGUCCUGGUGCUGUGGGGAAUUCACCACCCUUCCAAUAACAAGGAACAGCAGAAUCUGUACCAAAACGAAAAUGCUUACGUGAGUGUGGUGACCUCGAACUAUAAUAGACGAUUCACACCUGAGAUUGCCGAGCGUCCCAAAGUUAGGGACCAAGCCGGUAGGAUGAACUACUACUGGACUCUCCUGAAGCCCGGUGACACCAUUAUCUUCGAGGCCAAUGGUAAUCUGAUCGCCCCUAUGUACGCUUUCGCACUGUCACGCGGGUUCGGAUCUGGGAUAAUUACUUCGAACGCUAGCAUGCAUGAGUGUAAUACCAAGUGCCAGACCCCACUUGGAGCAAUCAAUUCCAGCCUACCUUAUCAGAAUAUUCAUCCCGUGACCAUCGGAGAAUGCCCAAAGUACGUUAGGUCCGCUAAACUGAGGAUGGUGACUGGCUUGAGGAACAUACCAUCUAUCCAAUCUAGGGGCCUGUUUGGCGCUAUUGCCGGGUUCAUCGAGGGUGGCUGGACAGGCAUGAUUGACGGGUGGUACGGUUACCACCACCAGAACGAGCAGGGAUCCGGCUAUGCAGCUGACCAGAAGUCAACCCAGAACGCAAUCAACGGCAUCACAAAUAAGGUCAAUACUGUGAUCGAAAAGAUGAACAUCCAAUUCACUGCCGUGGGCAAGGAGUUUAAUAAGCUCGAGAAGCGCAUGGAAAAUCUGAACAAAAAAGUGGACGAUGGCUUCCUGGAUAUAUGGACUUACAACGCCGAGCUCCUUGUGCUUCUGGAGAACGAACGUACCUUGGACUUUCAUGAUAGUAACGUCAAGAAUUUGUACGAGAAGGUUAAAUCCCAGCUGAAGAACAAUGCCAAGGAAAUCGGCAACGGCUGUUUUGAAUUUUACCAUAAAUGCGACAAUGAGUGCAUGGAAUCCGUACGCAAUGGGACAUACGAUUACCCUAAAUACUCCGAGGAAAGCAAGCUCAACCGAGAAAAAGUGGACGGCGUCAAGCUCGAAUCAAUGGGUAUUGGCAGUGCCGGAUCCGCCGGGUAUAUCCCCGAGGCCCCUAGAGACGGCCAAGCCUAUGUGCGGAAAGACGGCGAA UGGGUUCUGCUAUCCACCUUCUUAeH1HA_d5 5′ UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAG 574 v1 AGCCACCeH1HA_d5 3′ UTR UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCC 575 v1UUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC eH1HA_d5 DNAATGGAGACGCCTGCTCAGCTGCTCTTTCTGCTGCTCCTGTGGT 570 v1TGCCCGATACCACTGGGGACACTATCTGTATCGGATACCACGCCAACAACTCAACCGATACCGTGGATACTGTCCTCGAAAAGAATGTGACCGTTACACATTCAGTAAATTTGTTAGAGGATTCTCACAATGGGAAGCTGTGTCGACTGAAGGGGATCGCTCCCCTGCAACTGGGGAAGTGCAACATCGCTGGATGGTTGCTCGGCAACCCGGAATGCGATCCGCTGCCACCCATGAAGAGTTGGAGCTATATTGTCGAGACCCCTAACTCAGAGAACGGTATATGCTACCCTGGAGATTTTATCGATTACGAAGAGCTGCGGGAACAGCTGAGCAGCGTCTCCAGTTTCGAACGGTTTGAAATATTCCCCAAGGGCAGTTCCTGGCCCAATCACAACACTAATGGCGTCACCGCCGCCTGCTCACACGAGGGTAAGAACTCTTTTTACCGCAATCTGCTTTGGCTTACTAAGAAGGAAGGACTGTACCCGAATCTGGAGAACAGTTACGTCAACAAGAAAGAGAAAGAGGTCCTGGTGCTGTGGGGAATTCACCACCCTTCCAATAACAAGGAACAGCAGAATCTGTACCAAAACGAAAATGCTTACGTGAGTGTGGTGACCTCGAACTATAATAGACGATTCACACCTGAGATTGCCGAGCGTCCCAAAGTTAGGGACCAAGCCGGTAGGATGAACTACTACTGGACTCTCCTGAAGCCCGGTGACACCATTATCTTCGAGGCCAATGGTAATCTGATCGCCCCTATGTACGCTTTCGCACTGTCACGCGGGTTCGGATCTGGGATAATTACTTCGAACGCTAGCATGCATGAGTGTAATACCAAGTGCCAGACCCCACTTGGAGCAATCAATTCCAGCCTACCTTATCAGAATATTCATCCCGTGACCATCGGAGAATGCCCAAAGTACGTTAGGTCCGCTAAACTGAGGATGGTGACTGGCTTGAGGAACATACCATCTATCCAATCTAGGGGCCTGTTTGGCGCTATTGCCGGGTTCATCGAGGGTGGCTGGACAGGCATGATTGACGGGTGGTACGGTTACCACCACCAGAACGAGCAGGGATCCGGCTATGCAGCTGACCAGAAGTCAACCCAGAACGCAATCAACGGCATCACAAATAAGGTCAATACTGTGATCGAAAAGATGAACATCCAATTCACTGCCGTGGGCAAGGAGTTTAATAAGCTCGAGAAGCGCATGGAAAATCTGAACAAAAAAGTGGACGATGGCTTCCTGGATATATGGACTTACAACGCCGAGCTCCTTGTGCTTCTGGAGAACGAACGTACCTTGGACTTTCATGATAGTAACGTCAAGAATTTGTACGAGAAGGTTAAATCCCAGCTGAAGAACAATGCCAAGGAAATCGGCAACGGCTGTTTTGAATTTTACCATAAATGCGACAATGAGTGCATGGAATCCGTACGCAATGGGACATACGATTACCCTAAATACTCCGAGGAAAGCAAGCTCAACCGAGAAAAAGTGGACGGCGTCAAGCTCGAATCAATGGGTATTGGCAGTGCCGGATCCGCCGGGTATATCCCCGAGGCCCCTAGAGACGGCCAAGCCTATGTGCGGAAAGACGGCGAATGGGTTCTGCTATCCACCT TCTTA eH1HA_d5 mRNAAUGGAGACGCCUGCUCAGCUGCUCUUUCUGCUGCUCCUGUG 567 v2GUUGCCCGAUACCACUGGGGACACUAUCUGUAUCGGAUACCACGCCAACAACUCAACCGAUACCGUGGAUACUGUCCUCGAAAAGAAUGUGACCGUUACACAUUCAGUAAAUUUGUUAGAGGAUUCUCACAAUGGGAAGCUGUGUCGACUGAAGGGGAUCGCUCCCCUGCAACUGGGGAAGUGCAACAUCGCUGGAUGGUUGCUCGGCAACCCGGAAUGCGAUCCGCUGCCACCCAUGAAGAGUUGGAGCUAUAUUGUCGAGACCCCUAACUCAGAGAACGGUAUAUGCUACCCUGGAGAUUUUAUCGAUUACGAAGAGCUGCGGGAACAGCUGAGCAGCGUCUCCAGUUUCGAACGGUUUGAAAUAUUCCCCAAGGGCAGUUCCUGGCCCAAUCACACCACUAAUGGCGUCACCGCCGCCUGCUCACACGAGGGUAAGAACUCUUUUUACCGCAAUCUGCUUUGGCUUACUAAGAAGGAAGGAAGUUACCCGAAUCUGAAAAACAGUUACGUCAACAAGAAAGAGAAAGAGGUCCUGGUGCUGUGGGGAAUUCACCACCCUUCCAAUUCGAAGGAACAGCAGAAUCUGUACCAAAACGAAAAUGCUCACGUGAGUGUGGUGACCUCGAACUAUAAUAGACGAUUCACACCUGAGAUUGCCGAGCGUCCCAAAGUUAGGGACCAAGCCGGUAGGAUGAACUACUACUGGACUCUCCUGAAGCCCGGUGACACCAUUAUCUUCGAGGCCGACGGUAAUCUGAUCGCCCCUAUGUACGCUUUCGCACUGUCACGCGGGUUCGGAUCUGGGAUAAUUACUUCGAACGCUAGCAUGCAUGAGUGUAAUACCAAGUGCCAGACCCCACUUGGAGCAAUCAAUUCCAGCCUACCUUAUCAGAAUAUUCAUCCCGUGACCAUCGGAGAAUGCCCAAAGUACGUUAGGUCCGCUAAACUGAGGAUGGUGACUGGCUUGAGGAACAUACCAUCUAUCCAAUCUAGGGGCCUGUUUGGCGCUAUUGCCGGGUUCAUCGAGGGUGGCUGGACAGGCAUGAUUGACGGGUGGUACGGUUACCACCACCAGAACGAGCAGGGAUCCGGCUAUGCAGCUGACCAGAAGUCAACCCAGAACGCAAUCAACGGCAUCACAAAUAAGGUCAAUACUGUGAUCGAAAAGAUGAACAUCCAAUUCACUGCCGUGGGCAAGGAGUUUAAUAAGCUCGAGAAGCGCAUGGAAAAUCUGAACAAAAAAGUGGACGAUGGCUUCCUGGAUAUAUGGACUUACAACGCCGAGCUCCUUGUGCUUCUGGAGAACGAACGUACCUUGGACUUUCAUGAUAGUAACGUCAAGAAUUUGUACGAGAAGGUUAAAUCCCAGCUGAAGAACAAUGCCAAGGAAAUCGGCAACGGCUGUUUUGAAUUUUACCAUAAAUGCGACAAUGAGUGCAUGGAAUCCGUACGCAAUGGGACAUACGAUUACCCUAAAUACUCCGAGGAAAGCAAGCUCAACCGAGAAAAAGUGGACGGCGUCAAGCUCGAAUCAAUGGGUAUUGGCAGUGCCGGAUCCGCCGGGUAUAUCCCCGAGGCCCCUAGAGACGGCCAAGCCUAUGUGCGGAAAGACGGCGAA UGGGUUCUGCUAUCCACCUUCUUAeH1HA_d5 5′ UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAG 574 v2 AGCCACCeH1HA_d5 3′ UTR UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCC 575 v2UUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC eH1HA_d5 DNAATGGAGACGCCTGCTCAGCTGCTCTTTCTGCTGCTCCTGTGGT 571 v2TGCCCGATACCACTGGGGACACTATCTGTATCGGATACCACGCCAACAACTCAACCGATACCGTGGATACTGTCCTCGAAAAGAATGTGACCGTTACACATTCAGTAAATTTGTTAGAGGATTCTCACAATGGGAAGCTGTGTCGACTGAAGGGGATCGCTCCCCTGCAACTGGGGAAGTGCAACATCGCTGGATGGTTGCTCGGCAACCCGGAATGCGATCCGCTGCCACCCATGAAGAGTTGGAGCTATATTGTCGAGACCCCTAACTCAGAGAACGGTATATGCTACCCTGGAGATTTTATCGATTACGAAGAGCTGCGGGAACAGCTGAGCAGCGTCTCCAGTTTCGAACGGTTTGAAATATTCCCCAAGGGCAGTTCCTGGCCCAATCACACCACTAATGGCGTCACCGCCGCCTGCTCACACGAGGGTAAGAACTCTTTTTACCGCAATCTGCTTTGGCTTACTAAGAAGGAAGGAAGTTACCCGAATCTGAAAAACAGTTACGTCAACAAGAAAGAGAAAGAGGTCCTGGTGCTGTGGGGAATTCACCACCCTTCCAATTCGAAGGAACAGCAGAATCTGTACCAAAACGAAAATGCTCACGTGAGTGTGGTGACCTCGAACTATAATAGACGATTCACACCTGAGATTGCCGAGCGTCCCAAAGTTAGGGACCAAGCCGGTAGGATGAACTACTACTGGACTCTCCTGAAGCCCGGTGACACCATTATCTTCGAGGCCGACGGTAATCTGATCGCCCCTATGTACGCTTTCGCACTGTCACGCGGGTTCGGATCTGGGATAATTACTTCGAACGCTAGCATGCATGAGTGTAATACCAAGTGCCAGACCCCACTTGGAGCAATCAATTCCAGCCTACCTTATCAGAATATTCATCCCGTGACCATCGGAGAATGCCCAAAGTACGTTAGGTCCGCTAAACTGAGGATGGTGACTGGCTTGAGGAACATACCATCTATCCAATCTAGGGGCCTGTTTGGCGCTATTGCCGGGTTCATCGAGGGTGGCTGGACAGGCATGATTGACGGGTGGTACGGTTACCACCACCAGAACGAGCAGGGATCCGGCTATGCAGCTGACCAGAAGTCAACCCAGAACGCAATCAACGGCATCACAAATAAGGTCAATACTGTGATCGAAAAGATGAACATCCAATTCACTGCCGTGGGCAAGGAGTTTAATAAGCTCGAGAAGCGCATGGAAAATCTGAACAAAAAAGTGGACGATGGCTTCCTGGATATATGGACTTACAACGCCGAGCTCCTTGTGCTTCTGGAGAACGAACGTACCTTGGACTTTCATGATAGTAACGTCAAGAATTTGTACGAGAAGGTTAAATCCCAGCTGAAGAACAATGCCAAGGAAATCGGCAACGGCTGTTTTGAATTTTACCATAAATGCGACAATGAGTGCATGGAATCCGTACGCAATGGGACATACGATTACCCTAAATACTCCGAGGAAAGCAAGCTCAACCGAGAAAAAGTGGACGGCGTCAAGCTCGAATCAATGGGTATTGGCAGTGCCGGATCCGCCGGGTATATCCCCGAGGCCCCTAGAGACGGCCAAGCCTATGTGCGGAAAGACGGCGAATGGGTTCTGCTATCCACCT TCTTA eH1HA_d5 mRNAAUGGAGACGCCUGCUCAGCUGCUCUUUCUGCUGCUCCUGUG 568 v3GUUGCCCGAUACCACUGGGGACACUAUCUGUAUCGGAUACCACGCCAACAACUCAACCGAUACCGUGGAUACUGUCCUCGAAAAGAAUGUGACCGUUACACAUUCAGUAAAUUUGUUAGAGGAUUCUCACAAUGGGAAGCUGUGUCGACUGAAGGGGAUCGCUCCCCUGCAACUGGGGAAGUGCAACAUCGCUGGAUGGUUGCUCGGCAACCCGGAAUGCGAUCCGCUGCCACCCAUGAAGAGUUGGAGCUAUAUUGUCGAGACCCCUAACUCAGAGAACGGUAUAUGCUACCCUGGAGAUUUUAUCGAUUACGAAGAGCUGCGGGAACAGCUGAGCAGCGUCUCCAGUUUCGAACGGUUUGAAAUAUUCCCCAAGGGCAGUUCCUGGCCCGACCACAACACUAAUGGCGUCACCGCCGCCUGCUCACACGAGGGUAAGAACUCUUUUUACCGCAAUCUGCUUUGGCUUACUGAGAAGAAGGGAAGUUACCCGAAUCUGAAAAACCCCUACGUCAACAAGAAAGAGAAAGAGGUCCUGGUGCUGUGGGGAAUUCACCACCCUUCCAAUUCGAAGGAACAGCAGAAUCUGUACAGAAACGAAAAUGCUUACGUGAGUGUGGUGACCUCGAACUAUAAUAGACGAUUCACACCUGAGAUUGCCGAGCGUCCCAAAGUUAGGGACCAAGCCGGUAGGAUGAACUACUACUGGACUCUCCUGAAGCCCGGUGACACCAUUAUCUUCGAGGCCAAUGGUAAUCUGAUCGCCCCUAUGUACGCUUUCGCACUGUCACGCGGGUUCGGAUCUGGGAUAAUUACUUCGAACGCUAGCAUGCAUGAGUGUAAUACCAAGUGCCAGACCCCACUUGGAGCAAUCAAUUCCAGCCUACCUUAUCAGAAUAUUCAUCCCGUGACCAUCGGAGAAUGCCCAAAGUACGUUAGGUCCGCUAAACUGAGGAUGGUGACUGGCUUGAGGAACAUACCAUCUAUCCAAUCUAGGGGCCUGUUUGGCGCUAUUGCCGGGUUCAUCGAGGGUGGCUGGACAGGCAUGAUUGACGGGUGGUACGGUUACCACCACCAGAACGAGCAGGGAUCCGGCUAUGCAGCUGACCAGAAGUCAACCCAGAACGCAAUCAACGGCAUCACAAAUAAGGUCAAUACUGUGAUCGAAAAGAUGAACAUCCAAUUCACUGCCGUGGGCAAGGAGUUUAAUAAGCUCGAGAAGCGCAUGGAAAAUCUGAACAAAAAAGUGGACGAUGGCUUCCUGGAUAUAUGGACUUACAACGCCGAGCUCCUUGUGCUUCUGGAGAACGAACGUACCUUGGACUUUCAUGAUAGUAACGUCAAGAAUUUGUACGAGAAGGUUAAAUCCCAGCUGAAGAACAAUGCCAAGGAAAUCGGCAACGGCUGUUUUGAAUUUUACCAUAAAUGCGACAAUGAGUGCAUGGAAUCCGUACGCAAUGGGACAUACGAUUACCCUAAAUACUCCGAGGAAAGCAAGCUCAACCGAGAAAAAGUGGACGGCGUCAAGCUCGAAUCAAUGGGUAUUGGCAGUGCCGGAUCCGCCGGGUAUAUCCCCGAGGCCCCUAGAGACGGCCAAGCCUAUGUGCGGAAAGACGGCGAA UGGGUUCUGCUAUCCACCUUCUUAeH1HA_d5 5′ UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAG 574 v3 AGCCACCeH1HA_d5 3′ UTR UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCC 575 v3UUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC eH1HA_d5 DNAATGGAGACGCCTGCTCAGCTGCTCTTTCTGCTGCTCCTGTGGT 572 v3TGCCCGATACCACTGGGGACACTATCTGTATCGGATACCACGCCAACAACTCAACCGATACCGTGGATACTGTCCTCGAAAAGAATGTGACCGTTACACATTCAGTAAATTTGTTAGAGGATTCTCACAATGGGAAGCTGTGTCGACTGAAGGGGATCGCTCCCCTGCAACTGGGGAAGTGCAACATCGCTGGATGGTTGCTCGGCAACCCGGAATGCGATCCGCTGCCACCCATGAAGAGTTGGAGCTATATTGTCGAGACCCCTAACTCAGAGAACGGTATATGCTACCCTGGAGATTTTATCGATTACGAAGAGCTGCGGGAACAGCTGAGCAGCGTCTCCAGTTTCGAACGGTTTGAAATATTCCCCAAGGGCAGTTCCTGGCCCGACCACAACACTAATGGCGTCACCGCCGCCTGCTCACACGAGGGTAAGAACTCTTTTTACCGCAATCTGCTTTGGCTTACTGAGAAGAAGGGAAGTTACCCGAATCTGAAAAACCCCTACGTCAACAAGAAAGAGAAAGAGGTCCTGGTGCTGTGGGGAATTCACCACCCTTCCAATTCGAAGGAACAGCAGAATCTGTACAGAAACGAAAATGCTTACGTGAGTGTGGTGACCTCGAACTATAATAGACGATTCACACCTGAGATTGCCGAGCGTCCCAAAGTTAGGGACCAAGCCGGTAGGATGAACTACTACTGGACTCTCCTGAAGCCCGGTGACACCATTATCTTCGAGGCCAATGGTAATCTGATCGCCCCTATGTACGCTTTCGCACTGTCACGCGGGTTCGGATCTGGGATAATTACTTCGAACGCTAGCATGCATGAGTGTAATACCAAGTGCCAGACCCCACTTGGAGCAATCAATTCCAGCCTACCTTATCAGAATATTCATCCCGTGACCATCGGAGAATGCCCAAAGTACGTTAGGTCCGCTAAACTGAGGATGGTGACTGGCTTGAGGAACATACCATCTATCCAATCTAGGGGCCTGTTTGGCGCTATTGCCGGGTTCATCGAGGGTGGCTGGACAGGCATGATTGACGGGTGGTACGGTTACCACCACCAGAACGAGCAGGGATCCGGCTATGCAGCTGACCAGAAGTCAACCCAGAACGCAATCAACGGCATCACAAATAAGGTCAATACTGTGATCGAAAAGATGAACATCCAATTCACTGCCGTGGGCAAGGAGTTTAATAAGCTCGAGAAGCGCATGGAAAATCTGAACAAAAAAGTGGACGATGGCTTCCTGGATATATGGACTTACAACGCCGAGCTCCTTGTGCTTCTGGAGAACGAACGTACCTTGGACTTTCATGATAGTAACGTCAAGAATTTGTACGAGAAGGTTAAATCCCAGCTGAAGAACAATGCCAAGGAAATCGGCAACGGCTGTTTTGAATTTTACCATAAATGCGACAATGAGTGCATGGAATCCGTACGCAATGGGACATACGATTACCCTAAATACTCCGAGGAAAGCAAGCTCAACCGAGAAAAAGTGGACGGCGTCAAGCTCGAATCAATGGGTATTGGCAGTGCCGGATCCGCCGGGTATATCCCCGAGGCCCCTAGAGACGGCCAAGCCTATGTGCGGAAAGACGGCGAATGGGTTCTGCTATCCACCT TCTTA eH1HA_d5 mRNAAUGGAGACGCCUGCUCAGCUGCUCUUUCUGCUGCUCCUGUG 569 v4GUUGCCCGAUACCACUGGGGACACUAUCUGUAUCGGAUACCACGCCAACAACUCAACCGAUACCGUGGAUACUGUCCUCGAAAAGAAUGUGACCGUUACACAUUCAGUAAAUUUGUUAGAGGAUUCUCACAAUGGGAAGCUGUGUAAGCUGAAGGGGAUCGCUCCCCUGCAACUGGGGAAGUGCAACAUCGCUGGAUGGUUGCUCGGCAACCCGGGCUGCGAUCCGCUGCUGCCCGUUGGCAGUUGGAGCUAUAUUGUCGAGACCCCUAACUCAGAGAACGGUAUAUGCUACCCUGGAGAUUUUAUCGAUUACGAAGAGCUGCGGGAACAGCUGAGCAGCGUCUCCAGUUUCGAACGGUUUAAGAUAUUCCCCAAGGAGAGUUCCUGGCCCGACCACAACACUAAUGGCGUCACCGCCGCCUGCUCACACGAGGGUAAGAACUCUUUUUACCGCAAUCUGCUUUGGCUUACUAAGAAGGAAAGCAGUUACCCGAAUCUGGAGAACAGUUACGUCAACAAGAAACGGAAAGAGGUCCUGGUGCUGUGGGGAAUUCACCACCCUUCCAAUUCGAAGGAACAGCAGAAUCUGUACCAAAACGAAAAUGCUUACGUGAGUGUGGUGACCUCGAACUAUAAUAGACGAUUCACACCUGAGAUUGCCGAGCGUCCCAAAGUUAAGGGCCAAGCCGGUAGGAUGAACUACUACUGGACUCUCCUGAAGCCCGGUGACACCAUUAUCUUCGAGGCCAAUGGUAAUCUGAUCGCCCCUAUGUACGCUUUCGCACUGUCACGCGGGUUCGGAUCUGGGAUAAUUACUUCGAACGCUAGCAUGCAUGAGUGUAAUACCAAGUGCCAGACCCCACUUGGAGCAAUCAAUUCCAGCCUACCUUAUCAGAAUAUUCAUCCCGUGACCAUCGGAGAAUGCCCAAAGUACGUUAGGUCCGCUAAACUGAGGAUGGUGACUGGCUUGAGGAACAUACCAUCUAUCCAAUCUAGGGGCCUGUUUGGCGCUAUUGCCGGGUUCAUCGAGGGUGGCUGGACAGGCAUGAUUGACGGGUGGUACGGUUACCACCACCAGAACGAGCAGGGAUCCGGCUAUGCAGCUGACCAGAAGUCAACCCAGAACGCAAUCAACGGCAUCACAAAUAAGGUCAAUACUGUGAUCGAAAAGAUGAACAUCCAAUUCACUGCCGUGGGCAAGGAGUUUAAUAAGCUCGAGAAGCGCAUGGAAAAUCUGAACAAAAAAGUGGACGAUGGCUUCCUGGAUAUAUGGACUUACAACGCCGAGCUCCUUGUGCUUCUGGAGAACGAACGUACCUUGGACUUUCAUGAUAGUAACGUCAAGAAUUUGUACGAGAAGGUUAAAUCCCAGCUGAAGAACAAUGCCAAGGAAAUCGGCAACGGCUGUUUUGAAUUUUACCAUAAAUGCGACAAUGAGUGCAUGGAAUCCGUACGCAAUGGGACAUACGAUUACCCUAAAUACUCCGAGGAAAGCAAGCUCAACCGAGAAAAAGUGGACGGCGUCAAGCUCGAAUCAAUGGGUAUUGGCAGUGCCGGAUCCGCCGGGUAUAUCCCCGAGGCCCCUAGAGACGGCCAAGCCUAUGUGCGGAAAGACGGCGAA UGGGUUCUGCUAUCCACCUUCUUAeH1HA_d5 5′ UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAG 574 v4 AGCCACCeH1HA_d5 3′ UTR UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCC 575 v4UUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC eH1HA_d5 DNAATGGAGACGCCTGCTCAGCTGCTCTTTCTGCTGCTCCTGTGGT 573 v4TGCCCGATACCACTGGGGACACTATCTGTATCGGATACCACGCCAACAACTCAACCGATACCGTGGATACTGTCCTCGAAAAGAATGTGACCGTTACACATTCAGTAAATTTGTTAGAGGATTCTCACAATGGGAAGCTGTGTAAGCTGAAGGGGATCGCTCCCCTGCAACTGGGGAAGTGCAACATCGCTGGATGGTTGCTCGGCAACCCGGGCTGCGATCCGCTGCTGCCCGTTGGCAGTTGGAGCTATATTGTCGAGACCCCTAACTCAGAGAACGGTATATGCTACCCTGGAGATTTTATCGATTACGAAGAGCTGCGGGAACAGCTGAGCAGCGTCTCCAGTTTCGAACGGTTTAAGATATTCCCCAAGGAGAGTTCCTGGCCCGACCACAACACTAATGGCGTCACCGCCGCCTGCTCACACGAGGGTAAGAACTCTTTTTACCGCAATCTGCTTTGGCTTACTAAGAAGGAAAGCAGTTACCCGAATCTGGAGAACAGTTACGTCAACAAGAAACGGAAAGAGGTCCTGGTGCTGTGGGGAATTCACCACCCTTCCAATTCGAAGGAACAGCAGAATCTGTACCAAAACGAAAATGCTTACGTGAGTGTGGTGACCTCGAACTATAATAGACGATTCACACCTGAGATTGCCGAGCGTCCCAAAGTTAAGGGCCAAGCCGGTAGGATGAACTACTACTGGACTCTCCTGAAGCCCGGTGACACCATTATCTTCGAGGCCAATGGTAATCTGATCGCCCCTATGTACGCTTTCGCACTGTCACGCGGGTTCGGATCTGGGATAATTACTTCGAACGCTAGCATGCATGAGTGTAATACCAAGTGCCAGACCCCACTTGGAGCAATCAATTCCAGCCTACCTTATCAGAATATTCATCCCGTGACCATCGGAGAATGCCCAAAGTACGTTAGGTCCGCTAAACTGAGGATGGTGACTGGCTTGAGGAACATACCATCTATCCAATCTAGGGGCCTGTTTGGCGCTATTGCCGGGTTCATCGAGGGTGGCTGGACAGGCATGATTGACGGGTGGTACGGTTACCACCACCAGAACGAGCAGGGATCCGGCTATGCAGCTGACCAGAAGTCAACCCAGAACGCAATCAACGGCATCACAAATAAGGTCAATACTGTGATCGAAAAGATGAACATCCAATTCACTGCCGTGGGCAAGGAGTTTAATAAGCTCGAGAAGCGCATGGAAAATCTGAACAAAAAAGTGGACGATGGCTTCCTGGATATATGGACTTACAACGCCGAGCTCCTTGTGCTTCTGGAGAACGAACGTACCTTGGACTTTCATGATAGTAACGTCAAGAATTTGTACGAGAAGGTTAAATCCCAGCTGAAGAACAATGCCAAGGAAATCGGCAACGGCTGTTTTGAATTTTACCATAAATGCGACAATGAGTGCATGGAATCCGTACGCAATGGGACATACGATTACCCTAAATACTCCGAGGAAAGCAAGCTCAACCGAGAAAAAGTGGACGGCGTCAAGCTCGAATCAATGGGTATTGGCAGTGCCGGATCCGCCGGGTATATCCCCGAGGCCCCTAGAGACGGCCAAGCCTATGTGCGGAAAGACGGCGAATGGGTTCTGCTATCCACCT TCTTA

It should be understood that the 5′ and/or 3′ UTR for each construct maybe omitted, modified or substituted for a different UTR sequences in anyone of the vaccines as provided herein.

Equivalents

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the disclosure described herein. Such equivalents areintended to be encompassed by the following claims.

All references, including patent documents, disclosed herein areincorporated by reference in their entirety.

What is claimed is:
 1. A vaccine comprising at least one ribonucleicacid (RNA) polynucleotide having an open reading frame encoding at leastone influenza virus antigenic polypeptide formulated in a lipidnanoparticle comprising compounds of Formula (I):

or a salt or isomer thereof, wherein: R₁ is selected from the groupconsisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂and R₃ are independently selected from the group consisting of H, C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle; R₄ is selected from the group consisting of a C₃₋₆carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, andunsubstituted C₁₋₆ alkyl, where Q is selected from a carbocycle,heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5; each R₅ is independently selected from the group consisting ofC₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independently selected fromthe group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ is selected fromthe group consisting of C₃₋₆ carbocycle and heterocycle; R₉ is selectedfrom the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R,—S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and
 13. 2. The vaccine of claim 1, wherein a subset ofcompounds of Formula (I) includes those in which when R₄ is —(CH₂)_(n)Q,—(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q is not —N(R)₂ when n is 1,2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl whenn is 1 or
 2. 3. The vaccine of claim 1, wherein a subset of compounds ofFormula (I) includes those in which R₁ is selected from the groupconsisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂and R₃ are independently selected from the group consisting of H, C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle; R₄ is selected from the group consisting of a C₃₋₆carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, andunsubstituted C₁₋₆ alkyl, where Q is selected from a C₃₋₆ carbocycle, a5- to 14-membered heteroaryl having one or more heteroatoms selectedfrom N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂,—C(═NR₉)R, —C(O)N(R)OR, and a 5- to 14-membered heterocycloalkyl havingone or more heteroatoms selected from N, O, and S which is substitutedwith one or more substituents selected from oxo (═O), OH, amino, mono-or di-alkylamino, and C₁₋₃ alkyl, and each n is independently selectedfrom 1, 2, 3, 4, and 5; each R₅ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; Mand M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group; R₇ is selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ isselected from the group consisting of C₃₋₆ carbocycle and heterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl; each R* is independently selected from thegroup consisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y isindependently a C₃₋₆ carbocycle; each X is independently selected fromthe group consisting of F, Cl, Br, and I; and m is selected from 5, 6,7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
 4. The vaccineof claim 1, wherein a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selectedfrom the group consisting of H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″,—YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle; R₄ is selected from thegroup consisting of a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, —CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from aC₃₋₆ carbocycle, a 5- to 14-membered heterocycle having one or moreheteroatoms selected from N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR,—OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,—C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selectedfrom 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycleand (i) R₄ is —(CH₂)_(n)Q in which n is 1 or 2, or (ii) R₄ is—(CH₂)_(n)CHQR in which n is 1, or (iii) R₄ is —CHQR, and —CQ(R)₂, thenQ is either a 5- to 14-membered heteroaryl or 8- to 14-memberedheterocycloalkyl; each R₅ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; Mand M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group; R₇ is selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ isselected from the group consisting of C₃₋₆ carbocycle and heterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl; each R* is independently selected from thegroup consisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y isindependently a C₃₋₆ carbocycle; each X is independently selected fromthe group consisting of F, Cl, Br, and I; and m is selected from 5, 6,7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
 5. The vaccineof claim 1, wherein a subset of compounds of Formula (I) includes thosein which R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selectedfrom the group consisting of H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″,—YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle; R₄ is selected from thegroup consisting of a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, —CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from aC₃₋₆ carbocycle, a 5- to 14-membered heteroaryl having one or moreheteroatoms selected from N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR,—OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈ —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,—C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selectedfrom 1, 2, 3, 4, and 5; each R₅ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; Mand M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group; R₇ is selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ isselected from the group consisting of C₃₋₆ carbocycle and heterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl; each R* is independently selected from thegroup consisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y isindependently a C₃₋₆ carbocycle; each X is independently selected fromthe group consisting of F, Cl, Br, and I; and m is selected from 5, 6,7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
 6. The vaccineof claim 1, wherein subset of compounds of Formula (I) includes those inwhich R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selectedfrom the group consisting of H, C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″,—YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle; R₄ is —(CH₂)_(n)Q or—(CH₂)_(n)CHQR, where Q is —N(R)₂, and n is selected from 3, 4, and 5;each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R₆ is independently selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₁₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and 13, or salts or isomers thereof.
 7. The vaccine of claim1, wherein a subset of compounds of Formula (I) includes those in whichR₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selected from thegroup consisting of C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and—R*OR″, or R₂ and R₃, together with the atom to which they are attached,form a heterocycle or carbocycle; R₄ is selected from the groupconsisting of —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, where Qis —N(R)₂, and n is selected from 1, 2, 3, 4, and 5; each R₅ isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R₆ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₁₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and 13, or salts or isomers thereof.
 8. The vaccine of claim1, wherein a subset of compounds of Formula (I) includes those ofFormula (IA):

or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄ isunsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,—NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroarylor heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and R₂ and R₃ are independently selected from thegroup consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.
 9. The vaccine ofany one of claims 1-8, wherein the at least one antigenic polypeptide isinfluenza hemagglutinin 1 (HA1) and/or hemagglutinin 2 (HA2).
 10. Thevaccine of any one of claims 1-8, wherein at least one antigenicpolypeptide is HA1, HA2, or a combination of HA1 and HA2, and at leastone antigenic polypeptide is selected from the group consisting ofneuraminidase (NA), nucleoprotein (NP), matrix protein 1 (M1), matrixprotein 2 (M2), non-structural protein 1 (NS1) and non-structuralprotein 2 (NS2).
 11. The vaccine of claim 10, wherein at least oneantigenic polypeptide is HA2 and at least one antigenic polypeptide isselected from the group consisting of NA, NP, M1, M2, NS1 and NS2. 12.The vaccine of claim 11, wherein at least one antigenic polypeptide isHA2 and at least one antigenic polypeptides is selected from the groupconsisting of NA, NP, M1, M2, NS1 and NS2.
 13. The vaccine of any one ofclaims 1-12, wherein the at least one antigenic polypeptide is frominfluenza virus strain H1/PuertoRico/8/1934, H1/New Caledonia/20/1999,H1/California/04/2009, H5/Vietnam/1194/2004, H2/Japan/305/1957, H9/HongKong/1073/99, H3/Aichi/2/1968, H3/Brisbane/10/2007, H7/Anhui/1/2013,H10/Jiangxi-Donghu/346/2013, H3/Wisconsin/67/2005, H1/Vietnam/850/2009,or a combination thereof.
 14. The vaccine of any one of claims 1-13,wherein the at least one antigenic polypeptide comprises an amino acidsequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479,or 543-565.
 15. The vaccine of any one of claims 1-14, wherein the atleast one RNA polypeptide is encoded by a nucleic acid sequenceidentified by any one of SEQ ID NO: 447-457, 459, 461, or 505-523,and/or wherein the at least one RNA polypeptide comprises a nucleic acidsequence identified by any one of SEQ ID NO: 491-503 or 524-542.
 16. Thevaccine of any one of claims 1-15, wherein the at least one antigenicpolypeptide has an amino acid sequence that has at least 95% identity toan amino acid sequence identified by any one of SEQ ID NO: 1-444, 458,460, 462-479, or 543-565.
 17. The vaccine of any one of claims 1-16,wherein the at least one antigenic polypeptide has an amino acidsequence that is 95%-99% identical to an amino acid sequence identifiedby any one of SEQ ID NO: 1-444, 458, 460, 462-479, or 543-565.
 18. Thevaccine of any one of claims 1-17, wherein the at least one antigenicpolypeptide has an amino acid sequence that has at least 90% identity toan amino acid sequence of SEQ ID NO: 1-444, 458, 460, 462-479, or543-565 and wherein the antigenic polypeptide has membrane fusionactivity, attaches to cell receptors, causes fusion of viral andcellular membranes, and/or is responsible for binding of the virus to acell being infected.
 19. The vaccine of any one of claims 1-18, whereinthe at least one antigenic polypeptide has an amino acid sequence thathas 90%-99% identity to an amino acid sequence of SEQ ID NO: 1-444, 458,460, 462-479, or 543-565 and wherein the antigenic polypeptide hasmembrane fusion activity, attaches to cell receptors, causes fusion ofviral and cellular membranes, and/or is responsible for binding of thevirus to a cell being infected.
 20. The vaccine of any one of claims1-19, wherein the open reading frame is codon-optimized.
 21. Aninfluenza virus vaccine, comprising: at least one ribonucleic acidpolynucleotide having an open reading frame encoding at least oneinfluenza virus antigenic polypeptide or an immunogenic fragmentthereof, formulated in a lipid nanoparticle, wherein (i) the at leastone RNA polypeptide is encoded by a nucleic acid sequence identified byany one of SEQ ID NO: 505-523 or 570-573, and/or (ii) the at least oneRNA polypeptide comprises a nucleic acid sequence identified by any oneof SEQ ID NO: 524-542 or 566-569, and/or (iii) the at least oneantigenic polypeptide comprises an amino acid sequence identified by anyone of SEQ ID NO: 543-565.
 22. The vaccine of any one of claims 1-21,wherein the vaccine is multivalent.
 23. The vaccine of any one of claims1-22 formulated in an effective amount to produce an antigen-specificimmune response.
 24. A multiple consensus subtype vaccine comprising atleast one ribonucleic acid (RNA) polynucleotide having an open readingframe encoding at least one influenza virus antigenic polypeptide,wherein the vaccine provides cross-reactivity against a variety ofinfluenza strains, the vaccine comprising at least one consensushemagglutinin antigen, formulated in a lipid nanoparticle comprisingcompounds of Formula (I):

or a salt or isomer thereof, wherein: R₁ is selected from the groupconsisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂and R₃ are independently selected from the group consisting of H, C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle; R₄ is selected from the group consisting of a C₃₋₆carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, andunsubstituted C₁₋₆ alkyl, where Q is selected from a carbocycle,heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5; each R₅ is independently selected from the group consisting ofC₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independently selected fromthe group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ is selected fromthe group consisting of C₃₋₆ carbocycle and heterocycle; R₉ is selectedfrom the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R,—S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and
 13. 25. The vaccine of claim 24, wherein a subset ofcompounds of Formula (I) includes those in which when R₄ is —(CH₂)_(n)Q,—(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then (i) Q is not —N(R)₂ when n is 1,2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl whenn is 1 or
 2. 26. The vaccine of claim 24, wherein a subset of compoundsof Formula (I) includes those in which R₁ is selected from the groupconsisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂and R₃ are independently selected from the group consisting of H, C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle; R₄ is selected from the group consisting of a C₃₋₆carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, andunsubstituted C₁₋₆ alkyl, where Q is selected from a C₃₋₆ carbocycle, a5- to 14-membered heteroaryl having one or more heteroatoms selectedfrom N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂,—C(═NR₉)R, —C(O)N(R)OR, and a 5- to 14-membered heterocycloalkyl havingone or more heteroatoms selected from N, O, and S which is substitutedwith one or more substituents selected from oxo (═O), OH, amino, mono-or di-alkylamino, and C₁₋₃ alkyl, and each n is independently selectedfrom 1, 2, 3, 4, and 5; each R₅ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; Mand M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group; R₇ is selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ isselected from the group consisting of C₃₋₆ carbocycle and heterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl; each R* is independently selected from thegroup consisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y isindependently a C₃₋₆ carbocycle; each X is independently selected fromthe group consisting of F, Cl, Br, and I; and m is selected from 5, 6,7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
 27. Thevaccine of claim 24, wherein a subset of compounds of Formula (I)includes those in which R₁ is selected from the group consisting ofC₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ areindependently selected from the group consisting of H, C₁₋₁₄ alkyl,C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with theatom to which they are attached, form a heterocycle or carbocycle; R₄ isselected from the group consisting of a C₃₋₆ carbocycle, —(CH₂)_(n)Q,—(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q isselected from a C₃₋₆ carbocycle, a 5- to 14-membered heterocycle havingone or more heteroatoms selected from N, O, and S, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR,—N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂,—OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR,—N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉) N(R)₂, andeach n is independently selected from 1, 2, 3, 4, and 5; and when Q is a5- to 14-membered heterocycle and (i) R₄ is —(CH₂)_(n)Q in which n is 1or 2, or (ii) R₄ is —(CH₂)_(n)CHQR in which n is 1, or (iii) R₄ is—CHQR, and —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or8- to 14-membered heterocycloalkyl; each R₅ is independently selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—,—CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroarylgroup; R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; R₈ is selected from the group consisting of C₃₋₆carbocycle and heterocycle; R₉ is selected from the group consisting ofH, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆carbocycle and heterocycle; each R is independently selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R′ isindependently selected from the group consisting of C₁₋₁₈ alkyl, C₂₋₁₈alkenyl, —R*YR″, —YR″, and H; each R″ is independently selected from thegroup consisting of C₃₋₁₄ alkyl and C₃₋₁₄ alkenyl; each R* isindependently selected from the group consisting of C₁₋₁₂ alkyl andC₂₋₁₂ alkenyl; each Y is independently a C₃₋₆ carbocycle; each X isindependently selected from the group consisting of F, Cl, Br, and I;and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orisomers thereof.
 28. The vaccine of claim 24, wherein a subset ofcompounds of Formula (I) includes those in which R₁ is selected from thegroup consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl, —R*YR″, —YR″, and—R″M′R′; R₂ and R₃ are independently selected from the group consistingof H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ andR₃, together with the atom to which they are attached, form aheterocycle or carbocycle; R₄ is selected from the group consisting of aC₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, andunsubstituted C₁₋₆ alkyl, where Q is selected from a C₃₋₆ carbocycle, a5- to 14-membered heteroaryl having one or more heteroatoms selectedfrom N, O, and S, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR,—N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR,—N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂,—N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R,—C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selectedfrom 1, 2, 3, 4, and 5; each R₅ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R₆ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; Mand M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group; R₇ is selectedfrom the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; R₈ isselected from the group consisting of C₃₋₆ carbocycle and heterocycle;R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl; each R* is independently selected from thegroup consisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y isindependently a C₃₋₆ carbocycle; each X is independently selected fromthe group consisting of F, Cl, Br, and I; and m is selected from 5, 6,7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
 29. Thevaccine of claim 24, wherein subset of compounds of Formula (I) includesthose in which R₁ is selected from the group consisting of C₅₋₃₀ alkyl,C₅₋₂₀ alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independentlyselected from the group consisting of H, C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl,—R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to whichthey are attached, form a heterocycle or carbocycle; R₄ is —(CH₂)_(n)Qor —(CH₂)_(n)CHQR, where Q is —N(R)₂, and n is selected from 3, 4, and5; each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R₆ is independently selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₁₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and 13, or salts or isomers thereof.
 30. The vaccine ofclaim 24, wherein a subset of compounds of Formula (I) includes those inwhich R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀alkenyl, —R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selectedfrom the group consisting of C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″,and —R*OR″, or R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle; R₄ is selected from thegroup consisting of —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂,where Q is —N(R)₂, and n is selected from 1, 2, 3, 4, and 5; each R₅ isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R₆ is independently selected from the groupconsisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—,—S—S—, an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₁₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and 13, or salts or isomers thereof.
 31. The vaccine ofclaim 24, wherein a subset of compounds of Formula (I) includes those ofFormula (IA):

or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄ isunsubstituted C₁₋₃ alkyl, or —(CH₂).Q, in which Q is OH, —NHC(S)N(R)₂,—NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂,—NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl orheterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and R₂ and R₃ are independently selected from thegroup consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.
 32. The vaccineof any one of claims 24-31, wherein the consensus hemagglutinin antigenis selected from the group consisting of influenza hemagglutinin 1 (HA1)and/or hemagglutinin 2 (HA2).
 33. The vaccine of any one of claims24-31, wherein at least one antigenic polypeptide is HA1, HA2, or acombination of HA1 and HA2, and at least one antigenic polypeptide isselected from the group consisting of neuraminidase (NA), nucleoprotein(NP), matrix protein 1 (M1), matrix protein 2 (M2), non-structuralprotein 1 (NS1) and non-structural protein 2 (NS2).
 34. The vaccine ofclaim 33, wherein at least one antigenic polypeptide is HA1 and at leastone antigenic polypeptide is selected from the group consisting of NA,NP, M1, M2, NS1 and NS2.
 35. The vaccine of claim 34, wherein at leastone antigenic polypeptide is HA2 and at least one antigenic polypeptidesis selected from the group consisting of NA, NP, M1, M2, NS1 and NS2.36. The vaccine of any one of claims 24-35, wherein the at least oneantigenic polypeptide is from influenza virus strainH1/PuertoRico/8/1934, H1/New Caledonia/20/1999, H1/California/04/2009,H5/Vietnam/1194/2004, H2/Japan/305/1957, H9/Hong Kong/1073/99,H3/Aichi/2/1968, H3/Brisbane/10/2007, H7/Anhui/1/2013,H10/Jiangxi-Donghu/346/2013, H3/Wisconsin/67/2005, H1/Vietnam/850/2009,or a combination thereof.
 37. The vaccine of any one of claims 1-36,wherein the nanoparticle has a mean diameter of 50-200 nm.
 38. Thevaccine of any one of claims 1-37 or any one of claims 1-15, wherein thelipid nanoparticle further comprises a PEG-modified lipid, a sterol, anda non-cationic lipid.
 39. The vaccine of claim 38, wherein the lipidnanoparticle comprises a molar ratio of about 20-60% cationic lipid,0.5-15% PEG-modified lipid, 25-55% sterol, and 5-25% non-cationic lipid.40. The vaccine of claim 39, wherein the non-cationic lipid is a neutrallipid and the sterol is a cholesterol.
 41. The vaccine of any one ofclaims 1-40, wherein the nanoparticle has a polydispersity value of lessthan 0.4.
 42. The vaccine of any one of claims 1-41, wherein thenanoparticle has a net neutral charge at a neutral pH value.
 43. Thevaccine of any one of claims 1-42, wherein the at least one RNApolynucleotide comprises at least one chemical modification.
 44. Thevaccine of claim 43, wherein the chemical modification is selected frompseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine,2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine,2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine,2-thio-5-aza-uridine , 2-thio-dihydropseudouridine,2-thio-dihydrouridine, 2-thio-pseudouridine,4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine,4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine,dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine.
 45. Amethod of inducing an immune response in a subject, the methodcomprising administering to the subject the vaccine of any one of claims1-44 in an amount effective to produce an antigen-specific immuneresponse in the subject.
 46. The method of claim 45, wherein the antigenspecific immune response comprises a T cell response or a B cellresponse.
 47. The method of claim 45 or 46, wherein the subject isadministered a single dose of the vaccine.
 48. The method of claim 45 or46, wherein the subject is administered a booster dose of the vaccine.49. The method of any one of claims 45-48, wherein the vaccine isadministered to the subject by intradermal injection or intramuscularinjection.
 50. The method of any one of claims 45-49, wherein ananti-antigenic polypeptide antibody titer produced in the subject isincreased by at least 1 log relative to a control.
 51. The method of anyone of claims 45-50, wherein an anti-antigenic polypeptide antibodytiter produced in the subject is increased by 1-3 log relative to acontrol.
 52. The method of any one of claims 45-51, wherein theanti-antigenic polypeptide antibody titer produced in the subject isincreased at least 2 times relative to a control.
 53. The method of anyone of claims 45-52, wherein the anti-antigenic polypeptide antibodytiter produced in the subject is increased 2-10 times relative to acontrol.
 54. The method of any one of claims 50-53, wherein the controlis an anti-antigenic polypeptide antibody titer produced in a subjectwho has not been administered a vaccine against the virus.
 55. Themethod of any one of claims 50-53, wherein the control is ananti-antigenic polypeptide antibody titer produced in a subject who hasbeen administered a live attenuated vaccine or an inactivated vaccineagainst the virus.
 56. The method of any one of claims 50-53, whereinthe control is an anti-antigenic polypeptide antibody titer produced ina subject who has been administered a recombinant protein vaccine orpurified protein vaccine against the virus.
 57. The method of any one ofclaims 50-53, wherein the control is an anti-antigenic polypeptideantibody titer produced in a subject who has been administered a VLPvaccine against the virus.
 58. The method of any one of claims 45-57,wherein the effective amount is a dose equivalent to an at least 2-foldreduction in the standard of care dose of a recombinant protein vaccineor a purified protein vaccine against the virus, and wherein ananti-antigenic polypeptide antibody titer produced in the subject isequivalent to an anti-antigenic polypeptide antibody titer produced in acontrol subject administered the standard of care dose of a recombinantprotein vaccine or a purified protein vaccine against the virus,respectively.
 59. The method of any one of claims 45-57, wherein theeffective amount is a dose equivalent to an at least 2-fold reduction inthe standard of care dose of a live attenuated vaccine or an inactivatedvaccine against the virus, and wherein an anti-antigenic polypeptideantibody titer produced in the subject is equivalent to ananti-antigenic polypeptide antibody titer produced in a control subjectadministered the standard of care dose of a live attenuated vaccine oran inactivated vaccine against the virus, respectively.
 60. The methodof any one of claims 45-57, wherein the effective amount is a doseequivalent to an at least 2-fold reduction in the standard of care doseof a VLP vaccine against the virus, and wherein an anti-antigenicpolypeptide antibody titer produced in the subject is equivalent to ananti-antigenic polypeptide antibody titer produced in a control subjectadministered the standard of care dose of a VLP vaccine against thevirus.
 61. The method of any one of claims 45-57, wherein the effectiveamount is a total dose of 50 μg-1000 μg.
 62. The method of claim 61,wherein the effective amount is a dose of 25 μg, 100 μg, 400 μg, or 500μg administered to the subject a total of two times.
 63. The method ofany one of claims 45-62, wherein the efficacy of the vaccine against thevirus is greater than 65%.
 64. The method of any one of claims 45-63,wherein the vaccine immunizes the subject against the virus for up to 2years.
 65. The method of any one of claims 45-63, wherein the vaccineimmunizes the subject against the virus for more than 2 years.
 66. Themethod of any one of claims 45-65, wherein the subject has been exposedto the virus, wherein the subject is infected with the virus, or whereinthe subject is at risk of infection by the virus.
 67. The method of anyone of claims 45-66, wherein the subject is immunocompromised.
 68. Thevaccine of any one of claims 1-44 for use in a method of inducing anantigen specific immune response in a subject, the method comprisingadministering to the subject the vaccine in an amount effective toproduce an antigen specific immune response in the subject.
 69. Use ofthe vaccine of any one of claims 1-44 in the manufacture of a medicamentfor use in a method of inducing an antigen specific immune response in asubject, the method comprising administering to the subject the vaccinein an amount effective to produce an antigen specific immune response inthe subject.
 70. A method of inducing cross-reactivity against a varietyof influenza strains in a mammal, the method comprising administering tothe mammal in need thereof the vaccine of any one of claims 1-44. 71.The method of claim 70, wherein at least two ribonucleic acid (RNA)polynucleotides having an open reading frame each encoding a consensushemagglutinin antigen are administered to the mammal separately.
 72. Themethod of claim 70, wherein at least two ribonucleic acid (RNA)polynucleotides having an open reading frame each encoding a consensushemagglutinin antigen are administered to the mammal simultaneously. 73.A pharmaceutical composition for use in vaccination of a subjectcomprising the vaccine of any one of claims 1-44, wherein the effectivedose is sufficient to produce detectable levels of antigen as measuredin serum of the subject at 1-72 hours post administration.
 74. Thecomposition of claim 73, wherein the cut off index of the antigen is1-2.
 75. A pharmaceutical composition for use in vaccination of asubject comprising an effective dose of the vaccine of any one of claims1-44, wherein the effective dose is sufficient to produce a 1,000-10,000neutralization titer produced by neutralizing antibody against saidantigen as measured in serum of the subject at 1-72 hours postadministration.